                                   Europace (2024) 26, 1–107                              EHRA DOCUMENT
                                   https://doi.org/10.1093/europace/euae043




2024 European Heart Rhythm Association/
Heart Rhythm Society/Asia Pacific Heart
Rhythm Society/Latin American Heart Rhythm
Society expert consensus statement on
catheter and surgical ablation of atrial
fibrillation
Stylianos Tzeis 1* (EHRA Chair), Edward P. Gerstenfeld2 (HRS Co-Chair),
Jonathan Kalman 3,4 (APHRS Co-Chair), Eduardo B. Saad 5,6 (LAHRS Co-Chair),
Alireza Sepehri Shamloo 7 (Writing Group Coordinator), Jason G. Andrade 8,
Chirag R. Barbhaiya 9, Tina Baykaner10, Serge Boveda 11,12, Hugh Calkins 13,
Ngai-Yin Chan 14, Minglong Chen 15, Shih-Ann Chen16, Nikolaos Dagres 17,
Ralph J. Damiano18, Tom De Potter 19, Isabel Deisenhofer 20, Nicolas Derval 21,
Luigi Di Biase 22, Mattias Duytschaever 23, Katia Dyrda 24,
Gerhard Hindricks 17, Meleze Hocini 21, Young-Hoon Kim25, Mark la Meir 26,
Jose Luis Merino 27,28, Gregory F. Michaud29, Andrea Natale 30,31,32,33,
Isabelle Nault 34, Santiago Nava 35, Takashi Nitta 36, Mark O’Neill 37,
Hui-Nam Pak 38, Jonathan P. Piccini 39, Helmut Pürerfellner 40,
Tobias Reichlin 41, Luis Carlos Saenz 42, Prashanthan Sanders 43,
Richard Schilling 44, Boris Schmidt 45, Gregory E. Supple 46,
Kevin L. Thomas 39, Claudio Tondo 47,48, Atul Verma 49, and Elaine Y. Wan 50
Document-Reviewers: Daniel Steven (Reviewer Coordinator), Michael-Joseph Agbayani, T. Jared Bunch,
Aman Chugh, Juan Carlos Díaz, James V. Freeman, Carina Abigail Hardy, Hein Heidbuchel, Sofian Johar,
Dominik Linz, Bart Maesen, Peter A. Noseworthy, Seil Oh, Andreu Porta-Sanchez, Tatjana Potpara,
Gerardo Rodriguez-Diez, Frederic Sacher, Piotr Suwalski, and Serge A. Trines
1
 Department of Cardiology, Mitera Hospital, 6, Erythrou Stavrou Str., Marousi, Athens, PC 151 23, Greece; 2Section of Cardiac Electrophysiology, University of California, San Francisco,
CA, USA; 3Department of Cardiology, Royal Melbourne Hospital, Melbourne, Australia; 4Department of Medicine, University of Melbourne and Baker Research Institute, Melbourne,
Australia; 5Electrophysiology and Pacing, Hospital Samaritano Botafogo, Rio de Janeiro, Brazil; 6Cardiac Arrhythmia Service, Beth Israel Deaconess Medical Center, Harvard Medical School,
Boston, MA, USA; 7Department of Electrophysiology, Heart Center at University of Leipzig, Leipzig, Germany; 8Department of Medicine, Vancouver General Hospital, Vancouver, British
Columbia, Canada; 9NYU Grossman School of Medicine, New York, NY, USA; 10Division of Cardiology and Cardiovascular Institute, Stanford University, Stanford, CA, USA; 11Heart
Rhythm Management Department, Clinique Pasteur, Toulouse, France; 12Universiteit Brussel (VUB), Brussels, Belgium; 13Division of Cardiology, Department of Medicine, Johns Hopkins
University, Baltimore, MD, USA; 14Department of Medicine and Geriatrics, Princess Margaret Hospital, Hong Kong Special Administrative Region, China; 15The First Affiliated Hospital of
Nanjing Medical University, Nanjing, China; 16Heart Rhythm Center, Taipei Veterans General Hospital, Taipei, and Cardiovascular Center, Taichung Veterans General Hospital, Taichung,
Taiwan; 17Deutsches Herzzentrum der Charité, Berlin, Germany; 18Division of Cardiothoracic Surgery, Department of Surgery, Washington University School of Medicine, Barnes-Jewish


* Corresponding author. Tel: +30 6973798970, E-mail address: stzeis@otenet.gr
Developed in partnership with and endorsed by the European Heart Rhythm Association (EHRA), a branch of the European Society of Cardiology (ESC), the Heart Rhythm Society (HRS), the
Asia Pacific Heart Rhythm Society (APHRS), and the Latin American Heart Rhythm Society (LAHRS).
The document was peer-reviewed (anonymous review) by official external reviewers representing EHRA, HRS, APHRS, and LAHRS.
This article has been co-published with permission in Europace, HeartRhythm, Journal of Arrhythmia and Journal of Interventional Cardiac Electrophysiology. © 2024 Heart Rhythm Society, the
European Society of Cardiology, the Asia Pacific Heart Rhythm Society, and the Latin American Heart Rhythm Society
The articles are identical except for minor stylistic and spelling differences in keeping with each journal’s style. Any citation can be used when citing this article.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which
permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited.
2                                                                                                                                                                                                                                                            S. Tzeis et al.


Hospital, St. Louis, MO, USA; 19Cardiovascular Center, OLV Hospital Aalst, Belgium; 20Department of Electrophysiology, German Heart Center Munich, Technical University of Munich
(TUM) School of Medicine and Health, Munich, Germany; 21IHU LIRYC, Electrophysiology and Heart Modeling Institute, Cardiac Electrophysiology and Stimulation Department, Fondation
Bordeaux Université and Bordeaux University Hospital (CHU), Pessac-Bordeaux, France; 22Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA; 23Department
of Cardiology, AZ Sint-Jan Hospital, Bruges, Belgium; 24Department of Medicine, Montreal Heart Institute, Université de Montréal, Montreal, Canada; 25Division of Cardiology, Korea
University College of Medicine and Korea University Medical Center, Seoul, Republic of Korea; 26Cardiac Surgery Department, Vrije Universiteit Brussel, Universitair Ziekenhuis Brussel,
Brussels, Belgium; 27La Paz University Hospital, Idipaz, Universidad Autonoma, Madrid, Spain; 28Hospital Viamed Santa Elena, Madrid, Spain; 29Massachusetts General Hospital and Harvard
Medical School, MA, USA; 30Texas Cardiac Arrhythmia Institute, St. David’s Medical Center, Austin, TX, USA; 31Case Western Reserve University, Cleveland, OH, USA; 32Interventional
Electrophysiology, Scripps Clinic, San Diego, CA, USA; 33Department of Biomedicine and Prevention, Division of Cardiology, University of Tor Vergata, Rome, Italy; 34Institut Universitaire
de Cardiologie et de Pneumologie de Quebec (IUCPQ), Quebec, Canada; 35Departamento de Electrocardiología, Instituto Nacional de Cardiología ‘Ignacio Chávez’, Ciudad de México,
México; 36Department of Cardiovascular Surgery, Nippon Medical School, Tokyo, Japan; 37Cardiovascular Directorate, St. Thomas’ Hospital and King’s College, London, UK; 38Division of
Cardiology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea; 39Duke University Medical Center, Durham, NC, USA; 40Ordensklinikum
Linz Elisabethinen, Linz, Austria; 41Department of Cardiology, Inselspital Bern, Bern University Hospital, University of Bern, Bern, Switzerland; 42International Arrhythmia Center,
Cardioinfantil Foundation, Bogota, Colombia; 43Centre for Heart Rhythm Disorders, University of Adelaide and Royal Adelaide Hospital, Adelaide, Australia; 44Barts Heart Centre and
Welbeck Heart Health, London, UK; 45Cardioangiologisches Centrum Bethanien, Medizinische Klinik III, Agaplesion Markuskrankenhaus, Frankfurt, Germany; 46Cardiac Electrophysiology
Section, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA; 47Department of Clinical Electrophysiology and Cardiac Pacing, Centro Cardiologico Monzino,
IRCCS, Milan, Italy; 48Department of Biomedical, Surgical and Dental Sciences, University of Milan, Milan, Italy; 49McGill University Health Centre, McGill University, Montreal, Canada; and
50
   Department of Medicine, Division of Cardiology, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA

Received 15 January 2024; accepted after revision 16 January 2024; online publish-ahead-of-print 8 April 2024




Abstract                In the last three decades, ablation of atrial fibrillation (AF) has become an evidence-based safe and efficacious treatment for
                        managing the most common cardiac arrhythmia. In 2007, the first joint expert consensus document was issued, guiding
                        healthcare professionals involved in catheter or surgical AF ablation. Mounting research evidence and technological advances
                        have resulted in a rapidly changing landscape in the field of catheter and surgical AF ablation, thus stressing the need for
                        regularly updated versions of this partnership which were issued in 2012 and 2017. Seven years after the last consensus,
                        an updated document was considered necessary to define a contemporary framework for selection and management of
                        patients considered for or undergoing catheter or surgical AF ablation. This consensus is a joint effort from collaborating
                        cardiac electrophysiology societies, namely the European Heart Rhythm Association, the Heart Rhythm Society, the Asia
                        Pacific Heart Rhythm Society, and the Latin American Heart Rhythm Society .
...................................................................................................................................................
Keywords                Atrial fibrillation • Catheter ablation • Surgical ablation



                                                                                                                                          3.3. Fossa ovalis—interatrial septum (implications for transseptal
Table of contents                                                                                                                         puncture) ....................................................................................................................        10
1. Introduction................................................................................................................. 4        3.4. Architecture of left atrial musculature..................................................                                        12
   1.1. Preamble .............................................................................................................. 4         3.5. Coronary sinus—vein of Marshall...........................................................                                       14
   1.2. Organization of the writing committee.................................................. 4                                         3.6. Superior vena cava.........................................................................................                      14
   1.3. Methods................................................................................................................ 4         3.7. Autonomic ganglionated plexi ..................................................................                                  14
   1.4. Document review and approval ................................................................ 5                                   3.8. Pericardial reflections ...................................................................................                      14
   1.5. Scope of the document ................................................................................. 5                         3.9. Phrenic nerves .................................................................................................                 15
2. Classification—atrial fibrillation pathophysiology........................................ 6                                           3.10. Esophagus........................................................................................................               15
   2.1. Definitions ........................................................................................................... 6      4. Indications for catheter ablation of atrial fibrillation................................                                              16
   2.2. Classifications ..................................................................................................... 6           4.1. Catheter ablation in patients with atrial fibrillation–related
   2.3. Natural history of atrial fibrillation and atrial fibrillation                                                                    symptoms ...................................................................................................................          16
   progression .................................................................................................................. 7       4.2. Catheter ablation in patients with atrial fibrillation and heart
   2.4. Pathophysiology of atrial fibrillation ......................................................... 7                                failure............................................................................................................................   19
      2.4.1. Genetics of atrial fibrillation ................................................................ 7                           4.3. Catheter ablation in patients without atrial fibrillation–related
      2.4.2. Molecular basis of atrial fibrillation................................................... 8                                  symptoms ...................................................................................................................          21
      2.4.3. Mechanisms of atrial fibrillation initiation and                                                                             4.4. Patients with atrial fibrillation and coexistent rhythm
      maintenance............................................................................................................ 8           disorders .....................................................................................................................       22
         2.4.3.1. Role of triggers and automaticity ............................................. 8                                           4.4.1. Atrial fibrillation and supraventricular tachycardia.................                                                      22
         2.4.3.2. Role of focal and rotational activity and spiral                                                                            4.4.2. Atrial fibrillation and sinus node dysfunction............................                                                 23
         waves.................................................................................................................... 8          4.4.3. Atrial fibrillation and atrial flutter ..................................................                                  23
         2.4.3.3. Role of multi-wavelet reentry.................................................... 8                                     4.5. Atrial fibrillation with other risk factors or diseases.......................                                                   23
         2.4.3.4. Role of endocardial–epicardial asynchrony.......................... 8                                                       4.5.1. Older patients with atrial fibrillation ............................................                                       23
      2.4.4. Structural and electrical remodelling in atrial fibrillation ........ 8                                                          4.5.2. Atrial fibrillation and hypertrophic cardiomyopathy .............                                                          23
         2.4.4.1. Structural remodelling................................................................... 8                                 4.5.3. Patients with atrial fibrillation and obesity—physical
         2.4.4.2. Electrical remodelling.................................................................. 10                                 inactivity—obstructive sleep apnoea........................................................                                       24
      2.4.5. Autonomic nervous system and its role in atrial                                                                           5. Atrial fibrillation risk factors and preprocedural management ...........                                                             24
      fibrillation pathophysiology ........................................................................... 10                         5.1. Atrial fibrillation risk factors ......................................................................                          25
3. Anatomical considerations—implications for catheter ablation......... 10                                                                   5.1.1. Hypertension ..........................................................................................                    25
   3.1. The pulmonary veins—typical anatomy and variants ..................... 10                                                             5.1.2. Obesity ......................................................................................................             25
   3.2. Pulmonary vein epicardial connections................................................. 10                                             5.1.3. Obstructive sleep apnoea .................................................................                                 26
Catheter and surgical ablation of atrial fibrillation                                                                                                                                                                                                                                3


      5.1.4. Alcohol consumption..........................................................................                               26            8.1.2.7. Inducibility of atrial fibrillation after pulmonary vein
      5.1.5. Physical inactivity...................................................................................                      26            isolation ............................................................................................................        43
      5.1.6. Diabetes mellitus...................................................................................                        27         8.1.3. Pulmonary vein isolation with cryoballoon ablation..............                                                          43
      5.1.7. Smoking.....................................................................................................                27      8.2. Adjunctive ablation targets beyond pulmonary vein
      5.1.8. Cardiovascular comorbidities ..........................................................                                     27      isolation .......................................................................................................................   44
   5.2. Preprocedural management.......................................................................                                  27         8.2.1. Cavotricuspid isthmus.........................................................................                            44
      5.2.1. Preprocedural predictors of atrial fibrillation                                                                                        8.2.2. Linear lesions ..........................................................................................                 44
      recurrences..........................................................................................................              27         8.2.3. Complex fractionated atrial electrogram ablation .................                                                        44
         5.2.1.1. Atrial fibrillation type and duration ......................................                                           27         8.2.4. Stepwise approach to atrial fibrillation ablation ......................                                                  44
         5.2.1.2. Left atrial size .................................................................................                     28         8.2.5. Left atrial posterior wall isolation..................................................                                    45
         5.2.1.3. Electrocardiographic predictors.............................................                                           28         8.2.6. Substrate ablation .................................................................................                      45
         5.2.1.4. Preprocedural imaging of atrial structure..........................                                                    28         8.2.7. Vein of Marshall ablation ...................................................................                             48
      5.2.2. Preprocedural pharmacological treatment................................                                                     28         8.2.8. Ablation of non-pulmonary vein triggers....................................                                               48
         5.2.2.1. Preprocedural anticoagulation................................................                                          28         8.2.9. Ganglionated plexi ablation ..............................................................                                49
         5.2.2.2. Preprocedural antiarrhythmic drug treatment................                                                            29   9. Postprocedural management .............................................................................                             49
      5.2.3. Imaging for exclusion of thrombus ...............................................                                           29      9.1. Sheath removal—hemostasis achievement.........................................                                                 50
         5.2.3.1. Candidates for thrombus screening prior to                                                                                     9.2. Duration of hospitalization—same-day discharge ...........................                                                     50
         ablation .............................................................................................................          29      9.3. Postprocedural pharmacological management..................................                                                    50
         5.2.3.2 Imaging modalities for thrombus exclusion .......................                                                       30         9.3.1. Anticoagulants ........................................................................................                   50
6. Mapping and ablation tools for atrial fibrillation catheter                                                                                         9.3.1.1. Early postprocedural (the first 2 months).........................                                                   50
ablation .............................................................................................................................   30            9.3.1.2. Late postprocedural (more than 2 months) ....................                                                        50
   6.1. Mapping tools...................................................................................................                 30            9.3.1.3. Candidates to discontinue anticoagulation .......................                                                    51
      6.1.1. Invasive mapping tools........................................................................                              30            9.3.1.4. Targeted anticoagulation (on demand)
         6.1.1.1. Electroanatomical contact mapping .....................................                                                30            postablation ....................................................................................................             51
         6.1.1.2. Non-contact mapping ................................................................                                   32         9.3.2. Antiarrhythmic drug treatment ......................................................                                      51
         6.1.1.3. Spatiotemporal dispersion mapping.....................................                                                 32         9.3.3. Proton pump inhibitors......................................................................                              51
      6.1.2. Non-invasive mapping tools.............................................................                                     32         9.3.4. Anti-inflammatory agents ..................................................................                               52
         6.1.2.1. Electrocardiographic imaging...................................................                                        32      9.4. Rhythm monitoring following catheter ablation ...............................                                                  52
         6.1.2.2. Magnetic resonance imaging fibrosis guidance ................                                                          33         9.4.1. Continuous postablation rhythm monitoring...........................                                                      52
   6.2. Ablation tools...................................................................................................                33         9.4.2. Intermittent postablation rhythm monitoring..........................                                                     52
      6.2.1. Radiofrequency ablation ....................................................................                                33         9.4.3. Practical considerations on postablation rhythm
      6.2.2. Cryoablation and ultra-low temperature cryoablation ........                                                                34         monitoring............................................................................................................           53
         6.2.2.1. Conventional cryoballoon technologies .............................                                                    34      9.5. Early recurrences after ablation—postablation blanking
         6.2.2.2. Ultra-low temperature cryoablation ...................................                                                 34      period...........................................................................................................................   53
      6.2.3. Pulsed field ablation .............................................................................                         34         9.5.1. Incidence and pathophysiology of early recurrence after
         6.2.3.1. Biophysics and mechanisms .....................................................                                        34         atrial fibrillation ablation.................................................................................                    53
         6.2.3.2. Efficiency and safety—key advantages ................................                                                  35         9.5.2. Duration of blanking period.............................................................                                  53
         6.2.3.3. Efficacy of pulsed field ablation ..............................................                                       35         9.5.3. Management of early recurrences after catheter
      6.2.4. Laser ablation..........................................................................................                    36         ablation ..................................................................................................................      54
   6.3. Robotic and magnetic catheter navigation ..........................................                                              36            9.5.3.1. Electrical cardioversion ..............................................................                              54
   6.4. Future developments....................................................................................                          36            9.5.3.2. Early reablation..............................................................................                       54
      6.4.1. Mapping tools .........................................................................................                     36      9.6. Patient follow-up following catheter ablation....................................                                              54
      6.4.2. Ablation tools .........................................................................................                    36      9.7. Atrial tachycardia following atrial fibrillation ablation.....................                                                 55
7. Procedural management and techniques......................................................                                            37         9.7.1. Incidence—underlying mechanisms ..............................................                                            55
   7.1. Anesthesia and ventilation during atrial fibrillation ablation ........                                                          37         9.7.2. Management............................................................................................                    55
      7.1.1. General anesthesia vs. sedation ......................................................                                      37   10. Ablation outcome and efficacy.......................................................................                               55
      7.1.2. Ventilation................................................................................................                 37      10.1. Acute procedural success ........................................................................                             55
   7.2. Vascular access ................................................................................................                 38      10.2. Atrial fibrillation recurrence endpoints ..............................................                                       55
   7.3. Continuous arterial blood pressure monitoring...............................                                                     38      10.3. Atrial fibrillation burden endpoints......................................................                                    55
   7.4. Anticoagulation during atrial fibrillation ablation ..............................                                               38      10.4. Atrial fibrillation progression endpoints ............................................                                        56
   7.5. Transseptal puncture ....................................................................................                        38      10.5. Atrial fibrillation–related symptoms ....................................................                                     56
   7.6. The use of intracardiac echocardiography ..........................................                                              39      10.6. Quality of life assessment.........................................................................                           56
   7.7. Fluoroless ablation .........................................................................................                    39   11. Complications ........................................................................................................             56
   7.8. Esophageal temperature management..................................................                                              40      11.1. General considerations..............................................................................                          56
8. Ablation strategies ..................................................................................................                41      11.2. Factors associated with procedural complication rate................                                                          57
   8.1. Pulmonary vein isolation .............................................................................                           41         11.2.1. Procedural volume.............................................................................                           57
      8.1.1. Endpoint of pulmonary vein isolation ..........................................                                             41         11.2.2. Type of energy source.....................................................................                               57
      8.1.2. Pulmonary vein isolation using radiofrequency energy ........                                                               42         11.2.3. Role of ablation protocols..............................................................                                 57
         8.1.2.1. Electrogram parameters and impedance change............                                                                42         11.2.4. Time course of complications and implications for
         8.1.2.2. Lesion quality indicators............................................................                                  42         discharge practice..............................................................................................                 57
         8.1.2.3. Waiting phase ................................................................................                         42      11.3. Presentation, treatment, and prevention of specific
         8.1.2.4. Adenosine testing.........................................................................                             43      complications ............................................................................................................          57
         8.1.2.5. First-pass isolation........................................................................                           43         11.3.1. Esophageal perforation ....................................................................                              57
         8.1.2.6. Loss of pace capture along pulmonary vein isolation                                                                               11.3.2. Periprocedural thromboembolic events ..................................                                                  59
         line ......................................................................................................................     43         11.3.3. Asymptomatic cerebral lesions ....................................................                                       60
4                                                                                                                                                                                                                                                               S. Tzeis et al.



      11.3.4. Cardiac tamponade ...........................................................................                              60   References.......................................................................................................................   76
      11.3.5. Pulmonary vein stenosis..................................................................                                  61
      11.3.6. Phrenic nerve palsy............................................................................                            62
      11.3.7. Vascular complications.....................................................................                                62   1. Introduction
      11.3.8. Other complications of AF ablation...........................................                                              63
        11.3.8.1. Air embolism ...............................................................................                           63   1.1. Preamble
        11.3.8.2. Acute coronary artery stenosis and occlusion .............                                                             64   In the last three decades, ablation of atrial fibrillation (AF) has become
        11.3.8.3. Mitral valve trauma and curvilinear catheter                                                                                an evidence-based safe and efficacious treatment for managing the
        entrapment .....................................................................................................                 64   most common cardiac arrhythmia. In 2007, the first joint expert con­
        11.3.8.4. Stiff left atrial syndrome..........................................................                                   64   sensus document was issued, guiding healthcare professionals involved
        11.3.8.5. Gastric hypomotility.................................................................                                  64   in catheter or surgical AF ablation.1 Mounting research evidence and
12. Surgical and hybrid atrial fibrillation ablation............................................                                         65   technological advances have resulted in a rapidly changing landscape
  12.1. Technology and techniques.....................................................................                                   65   in the field of catheter and surgical AF ablation, thus stressing the
      12.1.1. Energy sources ....................................................................................                        65   need for regularly updated versions of this partnership, which was is­
        12.1.1.1. Radiofrequency energy............................................................                                      65   sued in 2012 and 2017.2,3 Seven years after the last consensus, an up­
        12.1.1.2. Cryoenergy .................................................................................                           66   dated document was considered necessary to define a contemporary
      12.1.2. Specific ablation tools.......................................................................                             66   framework for selection and management of patients considered for
        12.1.2.1. Radiofrequency ablation tools .............................................                                            66   or undergoing catheter or surgical AF ablation. This consensus is a joint
        12.1.2.2. Cryoablation tools ....................................................................                                66   effort from collaborating cardiac electrophysiology societies, namely
      12.1.3. Procedural targets and lesion sets ..............................................                                          67   the European Heart Rhythm Association (EHRA), the Heart Rhythm
        12.1.3.1. Pulmonary vein isolation.........................................................                                      67   Society (HRS), the Asia Pacific Heart Rhythm Society (APHRS), and
        12.1.3.2. Isolation of the left atrial posterior wall ..........................                                                 67   the Latin American Heart Rhythm Society (LAHRS).
        12.1.3.3. Right and left atrial linear lesions ........................................                                          67
        12.1.3.4. Ganglionated plexi ablation ...................................................                                        67
        12.1.3.5. Ligament of Marshall ................................................................                                  67
                                                                                                                                              1.2. Organization of the writing committee
        12.1.3.6. Left atrial appendage exclusion ...........................................                                            67   The EHRA, as the leading society, nominated the chair of the document,
  12.2. Concomitant surgical ablation of atrial fibrillation.........................                                                    67   and each of the partner societies nominated a co-chair. The writing
      12.2.1. Efficacy of concomitant atrial fibrillation surgery .................                                                      67   group was defined based on a list of representatives put forward by
      12.2.2. Safety of concomitant atrial fibrillation surgery ....................                                                     68   each organization. The members were qualified in order of preference
      12.2.3. Optimal lesion set in patients undergoing left atrial open                                                                      provided that they did not meet any of the following: part-time employ­
      procedures...........................................................................................................              68   ment or salary from a related company, significant stock ownership,
      12.2.4. Optimal lesion set in patients undergoing non-left atrial                                                                       holding of a patent which generates significant revenues, and receipt
      open procedures...............................................................................................                     68   of significant royalties for intellectual property related to the topic of
  12.3. Stand-alone surgical ablation of atrial fibrillation............................                                                 68   the scientific paper. The entire group comprised 44 members and
      12.3.1. Stand-alone Cox maze procedure..............................................                                               68   was appointed to section writing teams based on preference and ex­
      12.3.2. Minimally invasive surgical—hybrid atrial fibrillation                                                                          pertise, aiming to cover specific content. All members provided disclos­
      ablation ..................................................................................................................        69   ure statements to assess potential conflicts of interest. Details are
        12.3.2.1. Thoracoscopic surgical approach .......................................                                                69   available in the Supplementary Material.
        12.3.2.2. Hybrid convergent procedure .............................................                                              69
      12.3.3. Clinical evidence—comparison of catheter and surgical                                                                           1.3. Methods
      ablation ..................................................................................................................        70   A detailed survey including 140 questions was sent to all members, aiming
        12.3.3.1. Paroxysmal atrial fibrillation..................................................                                       70   to capture common practice and preferences in the care of patients
        12.3.3.2. Persistent and long-standing persistent atrial                                                                              undergoing AF ablation. After a comprehensive literature search, evalu­
        fibrillation.........................................................................................................            71   ation of existing evidence, and consideration of the survey results, prac­
  12.4. Left atrial appendage exclusion ............................................................                                     72   tical advice was proposed by the writing group in five sections
13. Training and institutional requirements for atrial fibrillation                                                                           (indications, preprocedural management, ablation strategies, procedural,
ablation .............................................................................................................................   72   and postprocedural management). The writing group had face-to-face
  13.1. Training requirements ...............................................................................                            72   meetings and web-based conference calls discussing proposed guidance
      13.1.1. Appropriate selection of patients ...............................................                                          72   and pertinent supporting evidence, while consensus modifications were
      13.1.2. Technical knowledge required......................................................                                         73   made based on raised comments, thus compiling a final list of clinical ad­
      13.1.3. Training of non-medical team members ..................................                                                    73   vice for the voting process. During voting, each member had the option
      13.1.4. Completion of training.....................................................................                                73   to agree, disagree, or abstain. Every proposed advice was included only if
      13.1.5. Maintaining competence .................................................................                                   73   the voting results (excluding abstention) were at least 80% in support. In
  13.2. Institutional requirements ........................................................................                              73   total, the suggested clinical advice has been approved by an average of
      13.2.1. Staff...........................................................................................................           73   94% of the writing committee members.
      13.2.2. Equipments and facilities .................................................................                                73      It should be emphasized that the current document is not in­
      13.2.3. Follow-up and other requirements ............................................                                              74   tended as a guideline and aims to document the current expert con­
14. Areas for future research .................................................................................                          74   sensus in the dedicated narrow field of catheter and surgical AF
  14.1. Basic translational science ........................................................................                             74   ablation. Healthcare professionals should refer to the latest guide­
  14.2. Risk factor modification ............................................................................                            75   lines for overall structured management of AF patients.4,5 In this
  14.3. Patient selection—personalized management ................................                                                       75   consensus document, a colour-coded classification of proposed clin­
  14.4. Energy sources—ablation tools.............................................................                                       75   ical advice was used. Classification of different categories of advice
  14.5. Ablation strategies.......................................................................................                       75   and the respective definitions are presented in Table 1.
  14.6. Endpoints and outcomes after ablation .............................................                                              75   Furthermore, the evidence supporting each advice has been classi­
Supplementary material.............................................................................................                      76   fied in different categories based on the type, quality, and quantity
Data availability..............................................................................................................          76   of respective sources (Table 2).
Catheter and surgical ablation of atrial fibrillation                                                                                                        5



 Table 1 Colour-coded classification of different categories of                   Table 3 Abbreviations
 advice and respective definition
                                                                                  Term (abbreviation)                           Definition
  Definition                                                   Category of        ..................................................................
                                                                 advice           AAD                     Antiarrhythmic drug
  ..................................................................
                                                                                  ACC                     American College of Cardiology
  Evidence or general agreement that a given
                                                            Advice TO DO          AEF                     Atrioesophageal fistula
     measure is clinically useful and appropriate
                                                                                  AF                      Atrial fibrillation
  Evidence or general agreement that a given
                                                            May be appropriate    AFl                     Atrial flutter
     measure may be clinically useful and
                                                              TO DO               AHA                     American Heart Association
     appropriate
  No strong advice can be given, lack of data,                                    AI                      Ablation index
                                                            Area of uncertainty
   inconsistency of data                                                          ANS                     Autonomic nervous system

  Evidence or general agreement that a given                                      APD                     Action potential duration
                                                            Advice NOT TO DO
    measure is not appropriate or harmful                                         APHRS                   Asia Pacific Heart Rhythm Society
                                                                                  ASD                     Atrial septum defect
                                                                                  AT                      Atrial tachycardia
                                                                                  ATP                     Adenosine triphosphate
 Table 2 Classification of different types of evidence and                        AVNRT                   Atrioventricular nodal reentry tachycardia
 respective criteria
                                                                                  AVRT                    Atrioventricular reentry tachycardia
  Type of evidence—                                 Criteria                      BMI                     Body mass index
  abbreviation                                                                    BP                      Blood pressure
  ..................................................................
                                                                                  CABG                    Coronary artery bypass graft
  META                             • Evidence from >1 high-quality RCT            CCS                     Canadian Cardiovascular Society
                                   • Metaanalyses of high-quality RCTs
                                                                                  CCT                     Cardiac computed tomography
  RAND                             • Evidence from 1 high-quality RCT             CF                      Contact force
                                   • Evidence from >1 moderate-quality RCT        CFAE                    Complex fractionated atrial electrogram
                                   • Metaanalyses of moderate-quality RCTs        CMR                     Cardiac magnetic resonance
  OBS                              • Observational studies or registries          CNS                     Cardiac nervous system
                                   • Metaanalyses of such studies                 CPAP                    Continuous positive airway pressure
  OPN                              • Randomized, non-randomized,                  CRT-D                   Cardiac resynchronization therapy defibrillator
                                      observational or registry studies with
                                                                                  CS                      Coronary sinus
                                      limitations of design or execution, case
                                                                                  CSANZ                   Cardiac Society of Australia and New Zealand
                                      series
                                                                                  CTI                     Cavotricuspid isthmus
                                   • Metaanalyses of such studies                 DAT                     Diagnosis to ablation time
                                   • Physiological or mechanistic studies in      DOAC                    Direct oral anticoagulant
                                      human subjects
                                   • Consensus of expert opinion based on         EAM                     Electroanatomical mapping
                                      clinical experience                         ECG                     Electrocardiogram
                                                                                  ECGI                    Electrocardiographic imaging
 RCT, randomized clinical trial.
                                                                                  EHRA                    European Heart Rhythm Association
                                                                                  ERP                     Effective refractory period
                                                                                  ESC                     European Society of Cardiology
1.4. Document review and approval
The draft document was subjected to a peer review process by a re­                FTI                     Force time integral
view committee whose members were assigned by each of the partner                 GCV                     Great cardiac vein
societies. All peer reviewers were requested to complete a declaration            GP                      Ganglionated plexi
of interest and were not allowed to own stocks or stock options or any            HCM                     Hypertrophic cardiomyopathy
type of financial interest in a company marketing electrophysiologic
                                                                                  HF                      Heart failure
products. Each partnering organization has officially reviewed and en­
dorsed the final document.                                                        HFJV                    High-frequency jet ventilation
                                                                                  HFLTV                   High-frequency low tidal volume
1.5. Scope of the document                                                        HFpEF                   Heart failure with preserved ejection fraction
The objective of this consensus document is to provide practical                  HFrEF                   Heart failure with reduced ejection fraction
guidance and set standards in the selection and management                        HRS                     Heart Rhythm Society
(preprocedural, procedural, and postprocedural) of patients consid­
ered for or undergoing AF ablation. Specific sections are devoted to              ICD                     Implantable cardiac defibrillator
AF pathophysiology, anatomical considerations, evaluation and man­                                                                               Continued
agement of complications, training, and institutional requirements for
6                                                                                                                                             S. Tzeis et al.



                                                                            rhythm documentation with an electrocardiogram (ECG) tracing.
    Table 3 Continued                                                       Electrocardiographic characteristics of AF include:
    Term (abbreviation)                         Definition
    ..................................................................
                                                                            • absence   of distinct P waves on the surface ECG;
                                                                            • irregular  atrial activations with an atrial cycle length that is usually
                                                                              <200 ms; and
    ICE                     Intracardiac echocardiography
    ICM                     Implantable cardiac monitor                     • ‘absolutely’ irregular R–R intervals [when atrioventricular (AV) conduc­
                                                                              tion is not impaired].
    INR                     International normalized ratio
                                                                               By convention, an AF episode is defined as an arrhythmia that has the
    LA                      Left atrium
                                                                            ECG characteristics of AF and persists for at least 30 s in an ECG re­
    LAA                     Left atrial appendage                           cording (or the duration of a 12-lead ECG).5 While the 30 s duration
    LAHRS                   Latin American Heart Rhythm Society             has been employed in previous published consensus statements, it is im­
    LAPW                    Left atrial posterior wall                      portant to recognize that this duration of AF has not been associated
                                                                            with clinically meaningful outcomes or pathophysiological processes.
    LGE                     Late gadolinium enhancement
                                                                            While it has been proposed that 30 s of atrial tachyarrhythmia may
    LoE                     Level of evidence                               be a harbinger of more advanced or clinically relevant disease, recent
    LIPV                    Left inferior pulmonary vein                    evidence suggests that may not be the case.6 Moreover, the 30 s sus­
    LMWH                    Low molecular weight heparin                    tained AF episode duration was defined in the era of non-invasive inter­
                                                                            mittent rhythm monitoring, and its relevance is unknown when applied
    LSI                     Lesion size index
                                                                            to continuous rhythm monitoring [cardiac implantable electronic de­
    LSPV                    Left superior pulmonary vein                    vices, implantable cardiac monitors (ICMs), or wearable devices
    LVEF                    Left ventricular ejection fraction              (e.g. ECG-tracking smartwatches)].7
    MRI                     Magnetic resonance imaging
    OSA                     Obstructive sleep apnoea                        2.2. Classifications
    PFA                     Pulsed field ablation                           Although there are several classification systems for AF, for this consen­
    PFO                     Patent foramen ovale                            sus document, we have continued to endorse the duration-based AF
    PN                      Phrenic nerve                                   classification system employed by the American College of
    PPI                     Proton pump inhibitor
                                                                            Cardiology/American Heart Association (AHA)/HRS, the Canadian
                                                                            Cardiovascular Society, the Cardiac Society of Australia and New
    PV                      Pulmonary vein                                  Zealand, and ESC, with slight modifications (Table 4).5,8–11 This classifi­
    PVI                     Pulmonary vein isolation                        cation system broadly categorized AF into four clinical patterns, based
    PWI                     Posterior wall isolation                        on the clinical assessment of AF episode duration and persistence:
    QoL                     Quality of life                                 (i) paroxysmal AF, defined as a continuous AF episode lasting longer
                                                                            than 30 s but terminating spontaneously or with intervention within
    RA                      Right atrium
                                                                            7 days of onset; (ii) persistent AF, defined as a continuous AF episode
    RCT                     Randomized clinical trial                       lasting longer than 7 days but <1 year; (iii) long-standing persistent AF,
    RF                      Radiofrequency                                  defined as continuous AF ≥1 year in duration, in patients where rhythm
    RSPV                    Right superior pulmonary vein                   control management is being pursued; and (iv) permanent AF, defined as
                                                                            AF for which a therapeutic decision has been made not to pursue sinus
    SVC                     Superior vena cava
                                                                            rhythm (SR) restoration.
    SVT                     Supraventricular tachycardia                       It is important to recognize that permanent AF represents a thera­
    TEE                     Transesophageal echocardiography                peutic attitude on the part of a patient and the treating physician rather
    TIA                     Transient ischemic attack                       than on any inherent pathophysiological attribute of the AF. If a rhythm
    TTI                     Time to isolation
    UFH                     Unfractionated heparin                           Table 4 Proposed classification of atrial fibrillation
    VKA                     Vitamin K antagonist
                                                                              Duration-based classification
    VoM                     Vein of Marshall                                  ..................................................................
                                                                              Paroxysmal—continuous AF episode lasting longer than 30 s but
                                                                                 terminating spontaneously or with intervention within 7 days of onset
                                                                                 • Early paroxysmal—continuous AF episode lasting longer than 30 s but
AF ablation. The terms and abbreviations used in the consensus state­                 terminating spontaneously or with intervention within 24 h of onset
ment are summarized in Table 3.                                               Persistent—continuous AF episode lasting longer than 7 days but <1 year
                                                                                 • Early persistent—continuous AF episode lasting longer than 7 days
                                                                                      but <3 months
2. Classification—atrial fibrillation                                         Long-standing persistent—continuous AF episode lasting longer than
pathophysiology                                                                  1 year, in whom rhythm control management is being pursued
                                                                              Permanent—AF for which a therapeutic decision has been made not to
2.1. Definitions                                                                 pursue sinus rhythm restoration
Atrial fibrillation is the most common supraventricular arrhythmia
characterized by rapid, disorganized atrial electrical activation leading    AF, atrial fibrillation.
to ineffective atrial contraction. The diagnosis of clinical AF requires
Catheter and surgical ablation of atrial fibrillation                                                                                                       7


control strategy is recommended after re-evaluation, the AF should be             AF episode will remain free of further recurrence, particularly if they
redesignated as paroxysmal, persistent, or long-standing persistent AF.           are young and free of comorbidities at the time of index presenta­
Early paroxysmal AF is defined as a continuous AF episode lasting longer          tion.22,24–26 A metaanalysis of 47 studies reported that the incidence
than 30 s but terminating within 24 h of onset either spontaneously or            of progression from paroxysmal to non-paroxysmal AF was 7.1 per
with intervention. The 24 h duration was chosen based on the knowledge            100 patient-years of follow-up, with higher incidence in studies with
that important changes in AF-related electrical and structural remodelling        shorter follow-up duration.23 In a relatively young and healthy popula­
occur over time frames as short as 24 h,12,13 leading to reductions in car­       tion at low risk of AF progression, 7.4% of patients with symptomatic
dioversion14,15 and catheter ablation efficacy.16 Similarly, AF episodes          paroxysmal AF receiving first-line antiarrhythmic drug (AAD) therapy
>24 h have been associated with increased risk of ischemic stroke or sys­         experienced an episode of persistent AF over a 3 year follow-up as
temic embolism, as well as increased cardiovascular hospitalization, all-         documented by continuous rhythm monitoring with implantable car­
cause hospitalization, and all-cause mortality.17–19 Early persistent AF is de­   diac device.27 A recent loop recorder study of 417 paroxysmal AF pa­
fined as continuous AF of more than 7 days of duration but <3 months of           tients with 2.2 years of follow-up demonstrated progression to
duration. Within the context of AF ablation and clinical trials of AF abla­       persistent or permanent AF in 8.4% (∼3.8% annually).28 For longer dur­
tion, early persistent AF defines a population of patients in whom better         ation studies, the rate of progression has been reported to be 22–36%
outcomes of AF ablation are anticipated when compared with persistent             at 10 years.24,29,30 Importantly, while AF progression has been asso­
AF of more than 3 months of duration.                                             ciated with worse outcomes, it is unclear whether progression is re­
   A duration-based AF classification is a relatively straightforward             sponsible for or merely a marker of a worse underlying substrate.31,32
schema that can be employed to standardize reporting, characterize                   Predictors associated with progression from paroxysmal to persist­
the severity of disease, define patient populations in clinical trials of         ent AF include increasing age, the presence of structural cardiac path­
catheter and surgical ablation of AF, and form the basis of therapeutic           ology [left atrial (LA) dilatation], and an increasing burden of
recommendations regarding invasive arrhythmia management.                         modifiable risk factors and concomitant risk conditions such as hyper­
However, it is important to recognize that clinical assessment of AF epi­         tension, diabetes mellitus, obesity, heart failure (HF), coronary artery
sode duration often underestimates the temporal persistence of AF                 disease, chronic kidney disease, chronic obstructive pulmonary disease,
when compared with long-term ECG monitoring, often leading to mis­                prior transient ischemic attack (TIA) or stroke, and obstructive sleep
classification between paroxysmal and persistent AF.20,21 In addition,            apnoea (OSA).25,30,33–36 Several biomarkers have also been associated
AF is a chronic progressive disease, evolving often from short parox­             with AF progression.28,37
ysms of AF to more frequent exacerbations of longer-lasting persistent
AF. If both paroxysmal and persistent episodes are present, the classi­
fication should be defined based on the predominant AF pattern during             2.4. Pathophysiology of atrial fibrillation
the preceding 6 months.
                                                                                  2.4.1. Genetics of atrial fibrillation
                                                                                  Atrial fibrillation is a complex disease where both environmental and
2.3. Natural history of atrial fibrillation and                                   genetic factors contribute to disease pathogenesis. Studies have shown
                                                                                  familial aggregation and heritability of AF.38,39 After accounting for es­
atrial fibrillation progression                                                   tablished clinical risk factors, individuals with a first-degree relative
Atrial fibrillation is a chronic progressive disease characterized by ex­         with AF have a 40% increased risk for AF development.40
acerbations and remissions. Early in its course, AF is predominantly                  The first rare pathogenic variant linked to familial AF was found in the
an isolated electrical disorder, triggered by rapid discharges originating        Kv1.7 voltage-gated potassium channel.41 Since then, further variants
mainly from the pulmonary veins (PVs), either secondary to enhanced               have been identified in genes encoding potassium channels,42–48 sodium
automaticity or triggered activity from afterdepolarizations. These trig­         channel,49–51 and other non-channel proteins52,53 in patients and fam­
gered impulses initiate and maintain AF through sustained rapid firing            ilies with AF. In addition, genome-wide association studies comparing
with secondary disorganization into fibrillatory waves. Although re­              AF patients with the general population have associated a common
entry is not usually sustained in a normal atrium, the presence of a vul­         variant at the 4q25 locus, a non-coding region of the genome near
nerable substrate can perpetuate AF through electrical heterogeneity              the gene PITX2, with a 60% increased risk of developing AF.54
[e.g. regional differences in conduction velocity, action potential dur­          Further genome-wide association studies have associated single nucleo­
ation (APD), and refractory period], with functional conduction abnor­            tide polymorphisms at more than 140 loci with AF.55–58 Single nucleo­
malities promoting reentrant activity and stabilizing reentrant circuits.         tide polymorphisms identified by genome-wide association studies
Moreover, the cumulative effect of these intermittent AF episodes is              account for ∼22% of the risk of developing AF.59
electrical, contractile, and structural remodelling, with fibrosis promot­            Polygenic risk scores derived from these single nucleotide poly­
ing reentry through structural conduction abnormalities, and chamber              morphisms have been associated with stroke, outcomes after AF abla­
dilatation promoting reentry. This atrial structural remodelling and              tion or cardioversion, and response to certain rate and rhythm control
worsening of atrial cardiomyopathy promote sustained arrhythmia                   medications.60 Larger, prospective, multi-ethnic studies will be neces­
and underpin the progression from paroxysmal to persistent forms                  sary before clinical application of these scores can be considered.
of AF.22                                                                              It may be reasonable to refer patients with onset of AF earlier than
   While a wealth of experimental data exists regarding structural and            45 years old without any identifiable risk factors to an inherited arrhyth­
functional atrial changes that contribute to the development, mainten­            mia clinic for consideration of genetic testing and family screening.60
ance, and progression of AF, considerably less data exist regarding the           The 2022 EHRA/HRS/APHRS/LAHRS expert consensus statement
natural history of AF. The reported rate of AF progression to non-                on the state of genetic testing for cardiac diseases supports analysis
paroxysmal AF types varies substantially due to differences in patient            of specific genetic variants (SCN5A, KCNQ1, MYL4, and truncating
characteristics and comorbidities, study design (retrospective vs. pro­           TTN) in index patients in whom the diagnosis of familial AF is estab­
spective), follow-up duration (progression appears to be non-linear),             lished, based on examination of the patient’s clinical history, family his­
and arrhythmia monitoring technology (e.g. most used intermittent                 tory, and ECG characteristics.61 Currently, there is no role for routine
rhythm assessments, which underestimate progression).7,22,23 Within               clinical genetic testing in older patients presenting with AF in the ab­
these limitations, a proportion of patients presenting with their first           sence of familial disease.61
8                                                                                                                                                       S. Tzeis et al.



2.4.2. Molecular basis of atrial fibrillation                                          2.4.3.4. Role of endocardial–epicardial asynchrony
Atrial fibrillation triggers resulting from ectopic activity within the atria          Recent data have found that despite the relatively thin-walled atria, the
are linked to spontaneous diastolic Ca2+-release from the sarcoplasmic                 complex LA anatomy has a structure that, combined with the progres­
reticulum via leaky ryanodine receptor channels. Early afterdepolariza­                sion of intramural fibrosis, can contribute to AF maintenance by provid­
tions due to loss-of-function mutations in outward potassium channels,                 ing a larger three-dimensional (3D) substrate that increases the
or gain-of-function mutations in inward calcium channels leading to a                  probability of intramural reentry and AF maintenance. Preclinical and
reduced repolarization reserve, have also been linked to spontaneous                   clinical surgical high-density mapping studies have found that activation
ectopic activity.62,63 The canine PVs have been shown to have smaller                  is often asynchronous and dissociated during AF, likely exacerbated by
inward rectifier K+ current (IK1) and L-type Ca2+ current (ICa,L), as                  slow conduction and intramural conduction delay and block.74,83,84
well as larger delayed rectifier K+ currents, compared with the LA                     These findings have been confirmed in right atrium (RA) recordings
cells.63                                                                               in humans with AF undergoing cardiac surgical procedures85–88 and
   Conduction abnormalities have a role in AF pathophysiology, presum­                 in LA simultaneous endo-epicardial recordings of patients undergoing
ably by increasing susceptibility to reentry and maintenance of AF. The                catheter ablation of AF.89,90 Such findings further increase the complex
most important determinants of conduction are as follows: (i) structural               nature of AF and may explain why mapping from the endocardium or
integrity of atrial tissue, often disrupted by fibrosis; (ii) effective cell-to-cell   epicardium alone has failed to identify the true underlying mechanism of
coupling, principally determined by connexin hemichannels in interca­                  AF.
lated disks; and (iii) integrity of the rapid phase-0 Na+ current (INa),                  In summary, the presently available data suggest that both ectopic ac­
which provides the electrical energy for conduction.63,64                              tivity and reentry play important roles in AF initiation and maintenance
                                                                                       of fibrillatory conduction. Moreover, localized driver sites may have a
2.4.3. Mechanisms of atrial fibrillation initiation and                                role in AF maintenance independent of the initiating mechanism. The
maintenance                                                                            specific mechanisms and determinants remain to be elucidated, along
2.4.3.1. Role of triggers and automaticity                                             with their implications for therapy.
Atrial fibrillation is initiated by triggers and then sustained by distinct
mechanisms for longer durations. Ectopic activity, particularly occurring              2.4.4. Structural and electrical remodelling in atrial
in the PVs, has been shown to have a central role in initiation of AF.65               fibrillation
Variances in the ion channels and the structure of PV tissue predispose                2.4.4.1. Structural remodelling
to ectopic activity by (i) reducing APD leading to reentry and (ii) in­
                                                                                       The atria of patients with AF often show evidence of structural remod­
creasing delayed afterdepolarizations (DADs) due to aberrant
                                                                                       elling. The easiest type of structural change to recognize is LA enlarge­
Ca2+-release leading to spontaneous ectopy.63,66 Clinically, PVs are
                                                                                       ment, which is seen in many AF patients and correlates with disease
noted to have smaller electrogram voltages, slower conduction, shorter                 progression and outcomes.91,92 Atrial enlargement provides more at­
effective refractory period (ERP), and a greater vulnerability to AF in­               rial tissue to harbour disordered wavelets or drivers and also correlates
duction during programmed electrical stimulation.67 Embryologically,
                                                                                       with the presence of fibrosis.93 Atrial fibrosis can be a result of the elec­
the posterior wall of the LA has the same origin as the PVs and there­
                                                                                       trical remodelling of AF, AF-related risk factors, or a fibrotic atrial car­
fore is considered to have a similar arrhythmogenic role.68 Other sites
                                                                                       diomyopathy.64,93–96 The mechanisms of fibrosis and its consequences
of triggered activity include the superior vena cava (SVC), the ligament               comprise many phenomena at molecular, cellular, organelle, and tissue
of Marshall, and the LA appendage (LAA), although atrial sites beyond                  levels.97 At the molecular level, dynamic changes occur in the genome,
PVs are less clearly linked to AF initiation.69
                                                                                       the transcriptome, and the signalling pathways underlying the gener­
                                                                                       ation of profibrotic molecules.98 Cellular changes involve interactions
2.4.3.2. Role of focal and rotational activity and spiral waves                        among the various cardiac cells, including myocytes, fibroblasts or myo­
The concept of small rapidly rotating circuits postulates that fibrillatory            fibroblasts, and inflammatory cells such as macrophages and neutro­
conduction is maintained by AF-perpetuating drivers or localized re­                   phils.98,99 Tissue changes relate to the dynamics of scar, angiogenesis,
gions that activate faster compared with the surrounding atrial tis­                   electrical conduction, and contractility.100 Fibrosis may also increase
sue.70,71 Rotational and focal drivers of AF have been identified near                 the number of fibroblasts, promoting AF by altering the electrophysio­
regions of fibrosis by optical mapping of ex-vivo animal hearts, ex-vivo               logical behaviour of cardiomyocytes coupled to fibroblasts through car­
human atria, and in-vivo human atria.72–74                                             diomyocyte–fibroblast interactions99,101 (Figure 1).
   Unfortunately, the tools required to demonstrate rotational and fo­                     Atrial fibrosis results in heterogeneous electrical conduction and re­
cal drivers of AF are limited by the complexity of assessing intracardiac              polarization and may facilitate multiple wavelet reentry or anchor driver
electrograms during fibrillatory conduction, particularly in reference to              regions.102 Clinically, identification of atrial fibrosis has been challenging,
the accurate identification of local activation timings.75–77                          with promising techniques including detection of increased signal inten­
                                                                                       sity on gadolinium-enhanced magnetic resonance imaging (MRI)103 or
                                                                                       identification of low amplitude electrical signals at invasive electrophysi­
2.4.3.3. Role of multi-wavelet reentry                                                 ology study,104,105 although a mismatch between these techniques has
The multiple wavelet concept was initially proposed by Garrey,78 re­                   been suggested106 (Section 5.2.1.4.).
fined by Moe et al.79 with computer modelling studies, and later sup­                      Another potentially important factor in AF-related atrial remodelling
ported by Allessie and colleagues80 with mapping of AF in canine                       is fatty infiltration, which is known to increase in several pathophysio­
atria and human atria.81 The multiple wavelet theory proposes that                     logical conditions and is regarded as arrhythmogenic.107,108 Epicardial
multiple AF-perpetuating wavelets self-replenish by collision, facilitated             fatty infiltration occurs with obesity and has been associated with AF
by structural obstacles and conduction dissociation between the endo­                  via structural and electrical remodelling of the atria, via direct infiltration
cardial and epicardial surfaces of the atrial wall. This theory implies that           of adipose tissue into the atrial tissue, and via indirect mechanisms
extensive ablation is required to limit the surface area of conduction                 through paracrine modulators resulting in inflammation and oxidative
and resolve constant replenishment of fibrillatory wavelets. Recent                    stress109,110 (Section 5.2.1.4.).
mechanistic evidence from computational models also suggests that                          Myocardial infiltration by amyloid deposits may also disturb atrial
smaller areas for fibrillatory waves to propagate are associated with im­              conduction in cardiac amyloidosis.111 Patients with long-standing AF
proved long-term postablation outcomes in persistent AF.82                             and rheumatic heart disease have a very high prevalence of atrial
Catheter and surgical ablation of atrial fibrillation                                                                                                   9




                            Modifiable risk factors (e.g. hypertension, obesity, sleep apnoea, alcohol consumption, diabetes)




                                 Electrical remodelling                                   Structural remodelling         Autonomic remodelling




                      Ca2+                                Ion channel                              Atrial                  Cardiac autonomic
                  dysregulation                           dysfunction                            fibrosis                   nervous system


       T-tubule




                              RγR
                  Ca2+

                         SERCA

        Cytoplasm




                                                                                                      · ¯CV                         · Sympathovagal
                                                                    · ¯APD                            · Conduction                    activation
                                               · Hyper-                                                                 · EADs
                                                 polarization                                           heterogeneity
                                                                                     · Increased                                    · Heterogeneous
                     · DADs                                         · ¯RP                             · Paracrine
                                                                                       automaticity
                                                                                                        action                        refractoriness
                                               · EADs               · ¯CV                                               · DADs
                                                                                                      · Endo–epi
                                                                                                        asynchrony                  · ¯RP




                                                  Focal ectopic firing                     Reentry-prone substrate




                                                                         Atrial fibrillation


  Figure 1 Pathophysiological mechanisms of atrial fibrillation. APD, action potential duration; CV, conduction velocity; DADs, delayed afterdepolar­
  izations; EADs, early afterdepolarizations; RP, refractory period; RyR, ryanodine receptor; SERCA, sarcoplasmic/endoplasmic reticulum Ca2+-ATPase.
10                                                                                                                                           S. Tzeis et al.



amyloidosis.112 Isolated atrial amyloidosis is more prevalent than            emanating from the PVs. Since the ground-breaking publication of
amyloid light chain (AL) amyloidosis or wild-type (senile) transthyretin      Haïssaguerre et al.,65 multiple studies have shown that unique anatomic
cardiac amyloidosis, with a prevalence of >90% in the ninth decade.113        features of the PV myocardial sleeves or extensions enable focal auto­
Pathophysiologic association between amyloidosis and AF is still under        maticity.66,138 In addition to the enhanced focal activity of the PV them­
investigation but is considered to relate to structural abnormalities         selves, anisotropic, heterogeneous conduction in the PV antra creates
similar to atrial fibrosis.                                                   an environment prone to microreentrant activity, acting like a ‘repeater’
                                                                              augmenting single ectopics into a burst of fibrillatory activity or PV
                                                                              tachycardia139,140 (Section 2.4.3.).
2.4.4.2. Electrical remodelling
                                                                                 The entrance of the PVs to the LA is located on the superior–
Electrical remodelling in AF patients involves shortened atrial refractory    posterior part, with the inferior PVs entering the LA inferiorly but
periods from down-regulation of Ca2+ currents, shortened repolariza­          also posteriorly to the superior PVs. The typical PV branching pattern
tion and hyperpolarization of atrial cells from increased outward K+          comprises four separate PV ostia, with a pair of superior and inferior
currents, and conduction slowing from altered expression and localiza­        PVs on the left and right posterior aspect. Most common PV variants
tion of connexins between myocytes114 (Figure 1). Oxidative stress, at­       include a common trunk (either short or long) of the left-sided PVs
rial dilatation, microRNAs, inflammation, and myofibroblast activation        and an additional (middle) PV on the right side.141,142 Rarely, other
also have a role in electrical remodelling.64                                 atypical variations in PV anatomy may be encountered including an ac­
   Electrical remodelling, manifested as shortening of atrial refractori­     cessory PV draining at the LA roof, a common superior or inferior con­
ness, develops within the first few days of AF.100,115 Several ion channel    joined vein, and three or even all four PVs entering LA together with a
modifications underlying such electrical changes have been described in       common trunk141–143 (Figure 2).
animal models and humans.114,116–118 Dominant frequency of AF is                 Myocardial sleeves extend into the PVs ∼2–3 cm from the PV–LA
shown to increase gradually after AF onset, stabilizing within 2 weeks.       junction, often taking a spiralling course.144 Additionally, the thickness
These dominant frequency changes are associated with down-                    of the LA wall in the region of the PV antra varies from 2 mm (posterior
regulation of ICaL and INa and up-regulation of IK1, along with corre­        wall) up to 8 mm at the ridge separating the left superior PV (LSPV)
sponding mRNA or protein changes. Interstitial fibrosis develops at           from the LAA.68,141,145 This variance in target lesion depth is one of
6–12 months, highlighting increasing tendency of AF to persist over           the challenges in safely achieving transmural and durable PVI.146
time.119,120 Sustained AF shortens APD and ERP, decreasing the wave­
length and facilitating the acceleration and stabilization of sustained re­
entry. The primary determinants of APD shortening are the decrease in         3.2. Pulmonary vein epicardial connections
ICaL and increase in IK1.119 Rapid atrial rates can activate fibroblasts      Besides the knowledge of typical PV anatomy and related variants, it is
and increase collagen gene activity, promoting fibrosis and structural        also critical to understand the concept of epicardial connections be­
remodelling.121                                                               tween PVs and other adjacent atrial structures as it can strongly influ­
                                                                              ence short-term and long-term achievement of PVI. Although difficult
2.4.5. Autonomic nervous system and its role in atrial                        to evaluate, their overall prevalence appears to be as high as
fibrillation pathophysiology                                                  13.5%.147 The presence of underlying structural heart disease or a pa­
The electrophysiology of the heart is highly influenced by the auto­          tent foramen ovale (PFO) is associated with a higher prevalence of epi­
nomic nervous system (ANS; Section 3.7.). Initiation and termination          cardial connections, whereas a left common trunk is associated with
of AF episodes have been linked to changes and abnormalities in cardiac       absence of epicardial connections.147,148 Several studies have reported
autonomic tone.122–124 At the whole heart and cellular levels, both ex­       the anatomical distribution and functional impact of these epicardial
trinsic and intrinsic autonomic modulations have been shown to pro­           connections.147–151
duce early or DADs that trigger ectopic firing and contribute to AF              More than half of epicardial connections are located in the left PVs
maintenance.125–130                                                           and are mediated by the ligament of Marshall.147 As described here­
   Autonomic interventions have been shown to modulate AF occur­              after, the ligament of Marshall is an epicardial structure containing the
rence. A small randomized trial of vagal stimulation via the tragus re­       vein of Marshall (VoM), the Marshall myocardial bundle, and autonomic
duced AF burden over 6 months.131 This effect may be mediated by              nerves. Post-mortem studies have revealed that, unlike other atrial
up-regulation of small conductance calcium-activated potassium chan­          tracts, the ligament of Marshall is distinctly segregated and insulated
nels in the stellate ganglion.132 Spinal cord stimulation has also demon­     from the underlying LA myocardium and connects directly to the cor­
strated a protective effect on AF inducibility in a tachypacing model.133     onary sinus (CS) musculature and the LA free wall at the level of the left
   Due to the inter-relationship between the sympathetic and parasym­         inferior PV (LIPV).152,153
pathetic ANS components, it is not possible to perform selective                 Epicardial connections are also located in the right PVs connecting
modulation of the parasympathetic or the sympathetic nervous system           them with the RA or less frequently with distinct areas of the LA. In
alone with direct ablation at ganglionated plexi (GP) sites. However, ab­     the former, epicardial connections are supported by muscular strands
lation targeting GP sites has been shown to modulate cardiac auto­            that connect the muscular sleeves of the right PVs to the RA.153–155
nomic tone and AF inducibility.134–137 Due to their anatomic location         Epicardial connections between the right PV and the posterior wall of
in proximity to the PVs, these GP sites may actually be ablated during        the LA have also been described suggesting variants of the septopulmon­
a standard PV isolation (PVI) procedure.                                      ary bundle that link the right carina with the posterior wall.147,148,150,156


3. Anatomical considerations—                                                 3.3. Fossa ovalis—interatrial septum
                                                                              (implications for transseptal puncture)
implications for catheter ablation                                            During cardiac development, a complex advancement, growth, and mi­
                                                                              gration of atrial tissue forming the septum primum and then the septum
3.1. The pulmonary veins—typical                                              secundum allow the formation of the interatrial septum, which eventu­
anatomy and variants                                                          ally separates left from RA.145,157 During this process, the fossa ovalis is
Atrial fibrillation is regarded as a primarily LA arrhythmia, mainly be­      formed, which is where the septum primum overlies the septum secun­
cause AF episodes are initiated most commonly by atrial extrasystoles         dum. The fossa ovalis represents the thinnest part of the septum and
Catheter and surgical ablation of atrial fibrillation                                                                                                       11




       A             Typical PV anatomy                 B             Left common ostium                  C            Right middle PV




       D      Common ostium of inferior veins           E           PV draining at the roof               F             Miscellaneous




  Figure 2 Typical PV anatomy and common variants. PV, pulmonary vein.




                          A                                                      B
                                                            LSPV
                                          RSPV
                          SVC                           LIPV
                                               RIPV


                                         IVC




  Figure 3 (A) Anatomy of interatrial septum and optimal site of transseptal puncture (demarcated with a brace). Black arrow in the dotted area shows
  the infolded groove of the atrial wall between the SVC and the right PVs filled with extracardiac fat tissue. (B) Intracardiac echo view of typical tenting
  before transseptal crossing. Modified from Tzeis et al.159 IVC, inferior vena cava; LIVP, left inferior pulmonary vein; LSVP, left superior pulmonary vein;
  PV, pulmonary vein; RIVP, right inferior pulmonary vein; RSVP, right superior pulmonary vein; SVC, superior vena cava




thus is the ideal location for transseptal puncture.145,157,158 It has an            In ∼25–28% of patients, the two membranes that comprise the fossa
average vertical diameter of 18.5 ± 6.9 mm and an average horizontal              ovalis do not fuse, so that a PFO is present. This defect varies consid­
diameter of 10.0 ± 2.4 mm.159 The septal area located superiorly (cra­            erably in size, from a more slit like formation to defects of 19 mm
nially) to the fossa ovalis is formed by an infolded groove of the atrial         size, with a mean reported PFO diameter of 5 mm.161–163 Although
wall between the SVC and the right PVs and contains extracardiac adi­             the fossa ovalis is considered to be the optimal site for transseptal punc­
pose tissue.159 Inadvertent puncture of this area must be avoided since           ture, crossing the septum via a PFO during AF catheter ablation has sev­
it may result in interatrial septum dissection, atrial wall hematoma, or          eral limitations, since the PFO is located very cranially and anteriorly at
tamponade160 (Figure 3).                                                          the septum, thus impeding access to the caudal parts of the LA
12                                                                                                                                                S. Tzeis et al.




      A                                                B                                                 C


                                                                                                                                             LA
                                 LA                                          LA




      D                                                E                                                 F




                                  LA                                                LA                                                LA




  Figure 4 Anatomic variations of the interatrial septum that may be encountered during transseptal puncture. (A) Patent foramen ovale (white ar­
  row); (B) septal aneurysm with large excursion towards the right atrium (white arrow); (C ) tenting of floppy septum from transseptal needle close to
  the left atrial wall; (D) very small fossa ovalis (white arrow) in a patient with lipomatous septal hypertrophy (yellow arrow); (E) standard transseptal
  needle crossing a pericardial patch; (F) atrial septal closure device (yellow arrow) covering almost all of the interatrial septum. LA, left atrium.



(including the inferior PVs) and the right superior PV (RSPV), where a            closure devices can pose more of a challenge. Typically, there is a
steep turn is needed to enter. Hence, some operators prefer to per­               room inferior–posterior to most ASD closure devices for transseptal
form transseptal puncture inferior and posterior to a present PFO.                access through the native septum using the usual transseptal tools.169
Several observational studies have shown that use of a PFO to gain ac­            Occasionally (Figure 4F) an ASD device may cover the entire septum.
cess in the LA during AF catheter ablation does not adversely affect ab­          Crossing through an ASD closure device has been described but should
lation efficacy when compared with needle-assisted LA access.164,165              be reserved for highly experienced centers.170
However, the presence of a large and/or compliant PFO has been re­
ported as independent predictor of PVI failure and increased arrhyth­
mia recurrence rate following AF catheter ablation.166                            3.4. Architecture of left atrial musculature
   In contrast, ‘true’ atrial septum defects (ASDs) are usually located at        The orientation of the major atrial muscular bundles has been recognized
the site of a transseptal puncture and offer a very convenient access to          from anatomical dissections, with mostly circular bundles around the os­
the LA and the PV regions. However, an ASD with a relevant                        tia of the PVs, AV valves, and LAA.171 The body of the LA is comprised of
left-to-right shunt results in RA volume load with subsequent increased           the venous component located posteriorly, the septum, and the vestibu­
arrhythmogenic remodelling. The latter should be taken into account               lar portion, which forms the ‘LA outlet’.155 The vestibule partly forms the
when individualizing AF ablation approach, since in the presence of               mitral isthmus located between the orifice of the LIPV and the annular
an ASD, the RA is likely implicated in AF initiation and maintenance              attachment of the mitral valve.155,172 Several anatomical isthmuses can
and thus should be evaluated as potential ablation target.158,167                 be identified between these native obstacles, which have the potential
   The rare variant of an atrial septum aneurysm (∼1–2% of patients) can          for supporting reentry.173–175 The body of the LA has relatively smooth
complicate transseptal puncture. Most commonly, the aneurysm com­                 wall with a complex architecture of overlapping myofibres of different
prises a ‘floppy septum’, which means that true crossing of the septum            orientation. The most prominent interatrial muscular connection is the
requires pushing the transseptal needle almost to or even beyond the              Bachmann’s bundle comprised of atrial myocardial strands aligned in a
most left lateral boundaries of the LA, risking a perforation of the LA.          parallel fashion. It extends from the right of the SVC orifice, crosses
Available technologies that facilitate crossing of the septum in                  the interatrial groove, and courses along the anterior wall of the LA until
challenging anatomies are presented in Section 7.5.157,158,161,167,168            the LAA where it divides into two branches that encircle it.171 The super­
Anatomic variations of interatrial septum and clinical settings that may          ior part continues along the left lateral ridge and the inferior part towards
be encountered during transseptal puncture are presented in Figure 4.             the atrial vestibule and then merge into the musculature of the lateral and
   Some patients with AF may have had prior surgical or percutaneous              inferoposterior atrial wall176 (Figure 5).
ASD closure. Surgical closure of an ASD with a stitch typically does                 In 1920, Papez177 first described the septopulmonary bundle and the
not impede subsequent transseptal puncture. Use of a pericardial patch            septoatrial bundle. This terminology directly reflects their different
to close the ASD may impede crossing of the septum, but there is often            course through the LA components previously described. The two
room to cross above or below the patch. Direct puncture through the               bundles arise from the septum, but the septoatrial bundle preferentially
patch with a radiofrequency (RF) needle is also feasible. Percutaneous            covers the LA body (as well as the LAA and the vestibule), while the
Catheter and surgical ablation of atrial fibrillation                                                                                                     13




                                                                                                                          1


                        1                   9                                                                                    10
                                                                                                    9
                                8                    11

                                            7
                                                                                                                                 16            6
                                                                                               11
         6                                                                           15
                                                                                                    13

                                                4




                                        9



                                                11                                             12
                   10                                                                   11
                                                        7

                                                               5                                                     17
                                                                                                                          *
               2                                                                                         9
                                                                                                                                      18
                                    3                                                                          13
                                                                                          14




                                 1 Superior vena cava                             10 Precaval bundle
                                 2 Right atrial appendage                         11 Septoatrial bundle
                                 3 Ascending aorta                                12 Fat interposition
                                 4 Pulmonary artery                               13 Circumferiential band
                                 5 Left atrial appendage                          14 Coronary sinus and musculature
                                 6 Pectinate muscules                             15 Marshall vein and bundle
                                 7 Antero-superior interatrial bundle             16 Intercaval bundle
                                 (Bachmann’s bundle)
                                                                                  17 Postero-inferior interatrial bundle
                                 8 Postero-superior interatrial bundle
                                                                                  18 Terminal bundle
                                 9 Septopulmonary bundle
                                                                                   * Sites of main epicardial connections of the pulmonary veins

  Figure 5 Architecture of atrial musculature. Upper left: main atrial muscular bundles from anterior view. Lower left: transection of the Bachmann’s
  bundle, postero-superior interatrial bundle, and the septopulmonary bundle enables visualization of the septoatrial bundle. Upper right: main atrial mus­
  cular bundles from posterior view with slight rightward tilting—the stars denote epicardial connections of the right PVs with the right atrium and left
  atrium posterior wall. Lower right: transection of the septopulmonary bundle coursing epicardially enables visualization of the septoatrial bundle and
  neighbouring fat inter-position. PV, pulmonary vein.



septopulmonary bundle mainly encircles the PVs. Both bundles course              bundle has been described to be separated from the LA body by fat
along the dome and the posterior wall, where the septopulmonary bun­             inter-position. This intervening fat layer may act as an insulation prevent­
dle epicardially overlaps the septoatrial bundle to form a bilayer architec­     ing transmission of ablation energy to the epicardially situated
ture. Until recently, these bundles were not considered to be separated          septopulmonary bundle and thus impairing the achievement of durable
by a layer of insulating tissue.154,171,177,178 Recently, the septopulmonary     PVI, complete roof line, or posterior wall isolation (PWI).179
14                                                                                                                                              S. Tzeis et al.



3.5. Coronary sinus—vein of Marshall                                           appendage joining the SVC, and ablation should be interrupted if sinus
The coronary venous system, with the CS located at its most proximal           acceleration or deceleration is observed. Furthermore, collateral dam­
part, drains ∼85% of the venous flow into the RA. The great cardiac            age may occur to the neighbouring right phrenic nerve (PN), which
vein (GCV) ascends into the left AV groove, where it passes close to           should be clearly delineated with high-output pacing prior to abla­
the circumflex artery and under the cover of the LAA. The CS has               tion202 (Figure 6; Section 3.9.).
an individualized musculature separated from the LA myocardium by
fat, with sparse connections to the posterior wall via discrete muscular       3.7. Autonomic ganglionated plexi
tracts.180 The juncture between the GCV and the CS is marked by the            The cardiac nervous system (CNS) plays a crucial role in arrhythmogen­
entrance of the VoM.181                                                        esis and more specifically in the initiation and maintenance of AF. The
   The CS-VoM musculature has an arbourized layout. A primary bun­             CNS is divided into the extrinsic and the intrinsic CNSs.145,202–204
dle running epicardially along the vein displays secondary bundles insu­       The extrinsic CNS consists of sympathetic and parasympathetic com­
lated into fibro-fatty tissue. Following an epi-endocardial course, these      ponents and includes neurons in the brain and spinal cord and nerves
secondary bundles join at the bottom with the LA free wall myocar­             directed to the heart.205 The extrinsic parasympathetic fibres are car­
dium.180,182–184 A muscular continuum is observed from the CS to               ried almost entirely within the vagus nerve.206 The extrinsic sympathet­
the left PVs, using the VoM as a hub: its primary bundle is connected          ic fibres are largely derived from the autonomic ganglia along the
to the CS musculature near the Vieussens valve, while its secondary            cervical and thoracic spinal cord.204,206 The intrinsic ANS includes auto­
bundles are connected to the left PV sleeves at the ridge.                     nomic nerve fibres once they enter the pericardial sac, forming a com­
   The VoM is an embryological remnant of the left upper caval system          plex network composed of GPs, concentrated within epicardial fat
resulting from the involution of the left anterior cardinal vein.185 This      pads.207,208 These GPs function as integration centers between extrin­
vestigial structure is separated into two portions: (i) the extracardiac       sic and intrinsic cardiac ANSs and contain predominantly parasympa­
portion, named the ligament of Marshall, is contained in a fold of peri­       thetic, as well as sympathetic neurons.203,204,209
cardium, occluded in almost all cases and associated with branches of             Ganglionated plexi are most commonly located at the anterior–
extrinsic cardiac nerves and (ii) the intracardiac part that extends           superior LA (close to the SVC–RA junction and the anterior aspect of
from the left lateral ridge (between LAA and left PVs) to the CS, main­        the RSPV), at the inferior–posterior RA/LA junction (adjacent to the in­
taining patency at different distance from its connection with the CS,         teratrial groove), at the lateral-posterior (close to LIPV) and lateral-
forming the VoM (also known as oblique vein of the LA). The VoM                superior LA (between LAA and LSPV), and in proximity to the
has an epicardial myocardial sleeve (the Marshall bundle) and neigh­           VoM.202–204,209
bours with closely associated autonomic nerve fibres and                          Localization of GPs is feasible with nuclear imaging studies and intra­
fat.182,183,186 The Marshall bundle is an insulated muscular structure         procedurally with high-frequency stimulation to elicit a vagal re­
that connects to the LA myocardium at the level of the left PVs with           sponse.208,210–213 However, due to their common localization close
limited connections to the underlying myocardium along its epicardial          to the PVs, it is estimated that the GPs are ‘collaterally ablated’ in
course. Several studies have demonstrated that the muscular fibres             20–50% of AF patients undergoing wide antral circumferential PVI. In
of the VoM and adjacent structures have a multi-faceted proarrhythmic          line with this, a substantial proportion of patients display signs of auto­
potential, since they may be the source of focal activities, part of reentry   nomic modulation, e.g. changes in mean heart rate or heart rate variabil­
circuits and autonomic modulators.187–191 Being co-localized with ar­          ity, following PVI, a finding which has not been observed in pulsed field
rhythmogenic structures, the VoM may represent an ablation target be­          ablation (PFA)-treated patients.214,215 Some studies have shown that
yond PVI during AF catheter ablation (Section 8.2.7.).                         such an increase in resting heart rate after PVI is associated with a
   The VoM has close anatomical relationship with the mitral isthmus,          more favourable prognosis.216–218
located between the mitral annulus and the LIPV ostium155,192 with
practical implications during ablation attempts at the mitral isthmus ei­      3.8. Pericardial reflections
ther for LA substrate modification or for the treatment of perimitral
flutter.172,193 Achievement of mitral isthmus block may prove challen­         Although less frequent than in ventricular arrhythmia management,
ging not only due to mitral isthmus wall thickness but also due to its         pericardial access is sometimes required for the treatment of atrial ar­
complex anatomy including: (i) the thick left lateral atrial wall, rarely      rhythmias. Alternative to the conventional endocardial ablation, hybrid
exceeding 4 mm,152,194 (ii) the VoM,195,196 and (iii) the GCV with its         strategies have been proposed to improve the transmurality of lesions
musculature extending over 2–40 mm, either at the anchored or free             created during AF ablation with favourable impact on arrhythmia out­
wall of the vessel.197                                                         come219–221 (Section 12). In selected patients, epicardial approach might
                                                                               be an option for second or third ablation strategy to achieve transmural
                                                                               block in areas with protected epicardial connections.222–224 Therefore, it
3.6. Superior vena cava                                                        is important to familiarize with the anatomy of the pericardium and its
Apart from the PVs, the SVC also exhibits myocardial sleeves that ex­          anatomic characteristics that impair accessibility in specific areas of the
tend as much as 4–5 cm cranially into the vein.145,198 Increased length of     LA during epicardial mapping and ablation. The normal pericardium is a
SVC myocardial sleeves and increased SVC diameter are reported as              double-layered sac consisting of an outer fibrous envelope and an inner
independent predictors of SVC firing in AF patients undergoing cath­           serous sac (divided into a visceral layer and a parietal layer) that is invagi­
eter ablation.199 However, the SVC myocardium has different origin             nated by the heart. The visceral layer is reflected from the heart back onto
than the myocardial sleeves of the PVs, and hence, the arrhythmogenic          the parietal layer along the great vessels including the aorta, pulmonary ar­
potential of the SVC is not prominent. This seems to be especially true        tery, proximal PVs, and vena cavae. These reflections define recesses and
for the influent or antral region of the SVC, which is not known to have       sinuses that constrain catheter manipulation. Therefore, epicardial map­
such anisotropic or heterogenous conduction properties as the PV an­           ping of the anterior wall or the mitral annulus is unimpeded, whereas
tral region.200 Several studies have reported that the SVC acts as an          the network of pericardial sinuses at the posterior wall limits the catheter
extra-PV trigger in 2–6% of patients.198,201 In such settings, SVC isola­      from crossing the dome, roof, and carina on both sides.224,225
tion is usually attempted. Superior vena cava isolation can be compli­             There are three sinuses in the pericardial space. The superior sinus is
cated by sinus node dysfunction due to close vicinity of the sinus             situated along the right side of the ascending aorta. The transverse sinus
node to the lateral influx of the SVC into the RA. Delivery of RF energy       is located behind the great vessels and has the LA dome as an anterior
should be avoided in the sinus node region at the base of the right atrial     boundary. Its exploration allows access to the antero-superior aspect
Catheter and surgical ablation of atrial fibrillation                                                                                                      15




           A                                              B                                           C                                Trachea

                             SVC

                        RSPV
                                       Aorta


                                                                       LA                                                  LA


                   RIPV
                                  RA                                                    RA                                                   RA




                                                           Esophagus
                                                                                                          Esophagus
                            IVC                                                     IVC


  Figure 6 Course of the right phrenic nerve in relation to neighbouring structures in different projections (A: right anterior oblique; B: right lateral;
  C: right posterior oblique)—reconstruction from computed tomography scan. IVC, inferior vena cava; LA, left atrium; RA, right atrium; RIPV, right in­
  ferior pulmonary vein; RSPV, right superior pulmonary vein; SVC, superior vena cava.



of the LA. The oblique sinus extends behind the LA between the four             epicardium, so that the distance between the endocardial surface close
PVs. Its exploration allows access to most of the inferior part of the          to the PVs and the left PN is usually more than 7–10 mm. Localization
dome and the posterior wall. However, superiorly, the oblique sinus             and mapping of the left PN with high-output pacing is feasible and avoids
is separated from the transverse sinus by the pericardial reflection con­       its inadvertent injury during LAA isolation using RF or cryoballoon abla­
necting left and right PVs. Thus, the middle part of the dome remains           tion.229 During surgical/epicardial ablation, protective measures similar to
inaccessible for epicardial mapping.                                            those taken during endocardial PVI for the right PN are recommended.

3.9. Phrenic nerves                                                             3.10. Esophagus
Ablation-induced damage of the PNs (mainly the right one) is a possible         Thermal injury to the esophagus by ablation energy is one of the most
complication of AF catheter ablation (Section 11). The anatomical rela­         dangerous and frequently fatal complications of AF ablation230 (Section
tionship of the right PN to the right PVs is complex, due to the course         11). The anatomic course of the esophagus is variable but is more com­
of the PN in between the RA and LA: cranio-caudally, coming from                monly closer to the left PVs145,202,230–233 (Figure 6). However, it should
the lateral aspect of the SVC, it runs between both atria along the antero-     be kept in mind that the esophagus is a mobile structure, and its relative
septal portion of the RSPV and turns then via the posterior RA to the           position may change intraprocedurally especially when the patient re­
lateral RA, where it crosses very often the crista terminalis145,202            mains under conscious sedation, allowing esophageal peristalsis to oc­
(Figure 6). Thus, damage occurs most frequently while isolating the             cur.234 In 67% of patients undergoing AF catheter ablation, the
RSPV, especially while using balloon devices.226,227 There are several po­      esophagus shifts sideways by ≥2 cm, while in 4%, there is a lateral
tential reasons why a (transient or permanent) palsy of the right PN may        movement exceeding 4 cm.235 Furthermore, the location, size, and
occur significantly more often with balloon-shaped than point-by-point          shape of the esophagus may be affected by the presence of common
RF ablation. First, balloon devices are—by their shape and technical de­        esophageal abnormalities such as hiatal hernia.
sign—placed inside the PVs, and ablation energy is also delivered (in part)        Apart from the distance between the esophagus and the LA poster­
inside the PVs.226 Thus, the PN, which runs along the PV, is more often         ior wall (LAPW), another anatomical factor that influences the prob­
comprised within the most distal extensions of the ablation lesion.             ability of thermal esophageal injury is the presence of pericardial fat
Furthermore, the balloon is inflated in the PV with the purpose to obtain       pads around each PV that are located between the LA and the esopha­
maximum contact and occlusion of the PV by the balloon. Therefore, the          gus and may protect against esophageal lesions during abla­
PV tissue is circumferentially stretched and the PV diameter is enlarged,       tion.230,232,233 Most of the inferior PVs are not covered by fat pads.232
placing the PN closer to the ablation lesion. Proposed measures to pre­            Furthermore, the movement of the esophagus may be restricted by
vent the occurrence of PN palsy/paralysis are reported in Section               surrounding mediastinal structures, like the descending aorta or the
11.226,228 Larger diameter of the right PVs and a flat angle between the        spine. In these cases, if the LA wall is ‘tented’ by the ablation catheter pos­
right PV and the LA body are reported to predict PN damage during               teriorly towards the esophagus, the latter remains entrapped, so that the
PVI, whereas an enlarged LA is potentially protective.228                       full impact of the applied energy is absorbed by the esophageal wall. If the
   There is also an anatomic relationship between the left PN and the           ablation also damages the arterioles supplying the esophagus, impairing
LAA, but damage to the nerve is rare when using endocardial ablation            blood flow to the affected esophageal tissue, the resultant ulcerations
techniques. This is because the PN remains along the whole course on            may not heal and may progress to perforation and fistulaization to the
the pericardial surface and does not enter the pericardial space or the         pericardium and/or to the LA232,233 (Section 11).
16                                                                                                                                                       S. Tzeis et al.



4. Indications for catheter ablation of atrial fibrillation



  Indications for catheter ablation of atrial fibrillation                                                                       Category of           Type of
                                                                                                                                   advice              evidence
  ..............................................................................................................................................
  Patients with AF-related symptoms
     Catheter ablation of AF is beneficial in symptomatic patients with recurrent paroxysmal or persistent AF
                                                                                                                                 Advice TO DO         META236–242
       resistant or intolerant to previous treatment with at least one Class I or III antiarrhythmic drug
     Catheter ablation of AF is beneficial as first-line treatment in symptomatic patients with recurrent paroxysmal AF          Advice TO DO         META243–249
     Catheter ablation of AF may be reasonable as first-line treatment in symptomatic patients with persistent AF              Area of uncertainty       OPN
  Patients with AF and heart failure
     Catheter ablation is beneficial in patients with AF and left ventricular systolic dysfunction, suspected to be related
                                                                                                                                 Advice TO DO         META250–254
        to arrhythmia-mediated cardiomyopathy, to improve left ventricular function
     It is reasonable to perform catheter ablation in selected patients with AF and heart failure with reduced ejection
                                                                                                                              May be appropriate to
        fraction to reduce cardiovascular hospitalizations and prolong survival, regardless of previous antiarrhythmic                                META254–260
                                                                                                                                      DO
        drug failure or intolerance
  Patients without AF-related symptoms
     Catheter ablation of AF may be reasonable in selected asymptomatic patients with recurrent paroxysmal or
                                                                                                                               Area of uncertainty       OPN
        persistent AF following thorough discussion of potential risks and associated benefits
  Patients with AF and coexistent rhythm disorders
     Catheter ablation of supraventricular tachycardia alone is reasonable in patients with supraventricular                  May be appropriate to
                                                                                                                                                      OBS261–264
        tachycardia and AF when the former is considered the main trigger of the latter                                               DO
     Catheter ablation of AF is reasonable in patients with AF and symptomatic bradycardia or prolonged sinus pauses          May be appropriate to
                                                                                                                                                      OBS265,266
        upon AF termination to avoid pacemaker implantation                                                                           DO
     Cavotricuspid isthmus ablation with documentation of bidirectional block is reasonable in patients undergoing AF         May be appropriate to
                                                                                                                                                      OBS267–269
        ablation in case of prior history or intraprocedural induction of cavotricuspid isthmus-dependent flutter                     DO
  Patients with AF and other risk factors or diseases
     It is reasonable to use similar indications for AF ablation in older (>75 years of age) patients with AF as in younger   May be appropriate to
                                                                                                                                                      OBS270–272
        patients after taking into account comorbidities and patient preferences                                                      DO
     Catheter ablation of AF is reasonable in patients with hypertrophic cardiomyopathy after careful consideration of
                                                                                                                              May be appropriate to
        anticipated clinical benefit, associated risk of procedural complications, and potential need for more than one                               OBS273–279
                                                                                                                                      DO
        procedure




This section presents the consensus of the writing group on the indica­                  and the associated risk of complications. Finally, patient preferences
tions for catheter ablation of AF. Suggested advice has been formulated                  should be taken into consideration in a shared decision-making process.
based on the presence of AF-related symptoms and the duration-
dependent type of AF (Section 2) but also in specific patient groups.
Advice pertaining to the management of patients with persistent AF
is also applicable to those with long-standing persistent AF. The writing
                                                                                         4.1. Catheter ablation in patients with
group decided not to issue a separate set of advice for long-standing                    atrial fibrillation–related symptoms
persistent AF due to lack of specific evidence and a high degree of simi­                Patients with AF may experience different types of symptoms including
larity with the management of persistent AF patients.                                    palpitations, dyspnea, dizziness, fatigue, pre-syncope, and syncope. The
    The final decision regarding patient eligibility for catheter ablation               presence and intensity of AF symptoms may vary significantly even in
should be refined on an individualized basis, considering factors that                   the same patient. Several symptom scales [EHRA score, Canadian
influence rhythm outcome including among others age, duration of AF                      Cardiovascular Society Severity of Atrial Fibrillation (CCS-SAF) scale]
episodes, comorbidities, atrial dilatation, and presence of fibrosis.                    have been developed to assess AF-related symptoms in a more standar­
Furthermore, the selection of catheter ablation vs. AADs for rhythm con­                 dized approach.280,281 The documentation of correlation between
trol may also depend on the underlying clinical setting, which may limit the             symptoms and underlying rhythm in patients with intermittent AF is
use of several AADs and/or may reinforce the need for SR maintenance                     challenging, since patient symptomatology is not specific and may be at­
due to associated prognostic benefit. Therefore, the selection of optimal                tributed to coexistent cardiovascular conditions or AF risk factors.282
management strategy should be guided by a balanced analysis of the po­                   Symptom rhythm correlation is low in patients with persistent AF es­
tential clinical benefits of reducing AF burden, the likelihood of achieving it,         pecially in the presence of comorbidities such as HF and diabetes.283,284
Table 5 Randomized controlled clinical trials comparing catheter ablation vs. antiarrhythmic drugs as first-line treatment in patients with symptomatic AF

                                             RAAFT-1248                    MANTRA-PAF246                 RAAFT-2247                     STOP-AF243                     EARLY-AF244           CRYO-FIRST245
............................................................................................................................................................................................
Year of publication                2005                               2012                           2014                 2021                                     2021                  2021
Sample size (ablation vs. AADs)    32 vs. 35                          146 vs. 148                    66 vs. 61            104 vs. 99                               154 vs. 149           107 vs. 111
Mean age (SD), years (ablation     53 (8) vs. 54 (8)                  56 (9) vs. 54 (10)             56 (9) vs. 54 (12)   60 (11) vs. 62 (11)                      58 (12) vs. 60 (11)   51 (13) vs. 54 (13)
 vs. AADs)
Mean LA diameter (SD), mm          41 (8) vs. 42 (7)                  40 (6) vs. 40 (5)              40 (5) vs. 43 (5)    39 (6) vs. 38 (5)                        40 (5) vs. 38 (7)     37 (6) vs. 38 (5)
 (ablation vs. AAD)
Mean LVEF (SD), % (ablation vs.    53 (5) vs. 54 (6)                  LVEF >60% in 80 vs. 82%        61 (5) vs. 61 (7)    61 (6) vs. 61 (6)                        60 (7) vs. 60 (8)     63 (5.4) vs. 64 (5.4)
 AAD)
                                                                                                                                                                                                                        Catheter and surgical ablation of atrial fibrillation




Paroxysmal AF (%) (ablation vs.    97 vs. 95                          100 vs. 100                    99 vs. 97            100 vs. 100                              96 vs. 94             100 vs. 100
   AADs)
Ablation type                      Radiofrequency                     Radiofrequency                 Radiofrequency       Cryoballoon                              Cryoballoon           Cryoballoon
Ablation strategy                  PVI                                PV encirclement plus roof      PVI, additional      PVI                                      PVI                   PVI
                                                                        line, additional ablation      ablation lesions
                                                                          lesions allowed                allowed
Acute PVI rate (%)                 100                                                               87                   98                                       100                   100
Rhythm monitoring protocol         •     1 month event monitor at     •    7 day Holter monitor at   •    Biweekly        •     12-lead ECG at 1, 3, 6, and        •     Implantable     • 12-lead ECG and
                                         1 and 3 months and                3, 6, 12, 18, and              TTM                   12 months AND                            loop recorder         7 day Holter
                                         thereafter in case of             24 months                                      •     Patient-activated TTM weekly and                               monitor at 1, 3, 6, 9,
                                         symptom recurrence AND                                                                 in case of symptoms AND                                        and 12 month
                                   •     24 h Holter recording                                                            •     24 h ambulatory ECG monitoring                                 follow-up
                                         before discharge and at 3,                                                             at 6 and 12 months
                                         6, and 12 months
Primary endpoint—definition        First recurrence of AF >15 s       AF burden and cumulative       First recurrence     Initial failure of the procedure;        First recurrence of   Free from any AF/AFL/
                                                                          burden                          of AF/AFL/AT         subsequent AF surgery or LA             AF/AFL/AT             AT >30 s
                                                                                                          >30 s                ablation; AF/AFL/AT ≥30 s during        ≥30 s or AAD
                                                                                                                               ambulatory monitoring or ≥10 s on       initiation
                                                                                                                               a 12-lead ECG; cardioversion or
                                                                                                                               Class I or III AAD outside the
                                                                                                                               90 day blanking period (ablation
                                                                                                                               group only)
Follow-up (years)                  1                                  2                              2                    1                                        1                     1
Recurrence of any atrial           13 vs. 63a                         15 vs. 29b                     54.5 vs. 72.1        20.2 vs. 35.4                            42.9 vs. 67.8         17.8 vs. 32.4
   tachyarrhythmia (%) (ablation
   vs. AADs)

                                                                                                                                                                                                           Continued
                                                                                                                                                                                                                        17
18                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       S. Tzeis et al.



                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           These considerations need to be taken into account when assessing pa­




                                                                                                                                                                                                                                                                                                                                                                                 AAD, antiarrhythmic drug; AE, adverse event; AF, atrial fibrillation; AFL, atrial flutter; AT, atrial tachycardia; LA, left atrium; LVAD, left ventricular assist device; LVEF, left ventricular ejection fraction; NS, non-significant; PVI, pulmonary vein isolation;
                                   ............................................................................................................................................................................................
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           tients’ symptomatic status before tailoring management approach.
                         CRYO-FIRST245




                                                                                                                                                                                                                                                                                       Cryoballoon ablation
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Several multicenter randomized clinical trials (RCTs) have demon­




                                                                                                                                                                                                                                                                                         superior to AADs
                                                                                                                                                                                                                                                     24.3 vs. 33.3 (NS)
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           strated the superiority of catheter ablation over AADs in patients
                                                                                                                                                                                                                                  0.48 (0.26–0.86)                                                                                                                                                                                                                                                                                                                                                                                                         with paroxysmal or persistent AF resistant or intolerant to AADs, in
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           reducing AF recurrences and improving symptoms and quality of life
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           (QoL).236–242
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Implementation of an early rhythm control strategy in patients with AF
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           and concomitant cardiovascular conditions is associated with improved
                                                                                                                                                                                                                                                                                         ablation superior                                                                                                                                                                                                                                                                                                                                                 cardiovascular outcomes.285 Antiarrhythmic agents have a modest
                         EARLY-AF244




                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           efficacy in preventing AF recurrences with significant adverse event
                                                                                                                                                                                                                                  0.48 (0.35–0.66)
                                                                                                                                                                                                                                                     3.2 vs. 4.0 (N.S)




                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           rates.286,287 Observational data have shown that invasive intervention
                                                                                                                                                                                                                                                                                                                          to AADsd
                                                                                                                                                                                                                                                                                       Cryoballoon




                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           early in the natural course of AF results in favourable outcome, with
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           shorter ‘diagnosis-to-ablation’ time related to lower likelihood of
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           arrhythmia recurrence, repeat ablation, and cardiovascular hospitaliza­
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           tion.288–290 However, a recent RCT enrolling 100 symptomatic paroxys­
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           mal or persistent AF patients demonstrated that a strategy of AAD
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           therapy with 12 month delay in catheter ablation had no impact on
                                                                                                                                                                                                                                                                                       Cryoballoon ablation superior to




                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           arrhythmia-free survival or AF burden over 12 month postablation
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           follow-up when compared with an early ablation strategy (within
                         STOP-AF243




                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           1 month).291 This study provides reassurance that an initial approach
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           of medical therapy and risk factor management may be reasonable with­
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           out compromising ablation outcomes. This approach takes into consid­
                                                                                                                                                                                                                                  0.57 (0.36–0.91)
                                                                                                                                                                                                                                                     14 vs. 14 (NS)




                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           eration the highly variable natural history of paroxysmal AF (Section 2.3.).
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Several prospective multicenter RCTs have evaluated cryoballoon
                                                                                                                                                                                                                                                                                         AADs




                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           ablation as first-line treatment in symptomatic paroxysmal AF and de­
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           monstrated that it significantly reduces atrial tachyarrhythmia recur­
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           rences and improves patients’ QoL with similar risk of adverse events
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           when compared with AAD treatment243–245,292 (Table 5).
                                                                                                                                                                                                                                  0.56 (0.35–0.90)
                         RAAFT-2247




                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               The superiority of cryoballoon ablation over antiarrhythmic therapy
                                                                                                                                                                                                                                                                                         superior to




                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           in reducing arrhythmia burden was also verified in the 3 year follow-up
                                                                                                                                                                                                                                                                                       RF ablation
                                                                                                                                                                                                                                                     9.1 vs.4.9




                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           of patients enrolled in the EARLY-AF trial with a strict monitoring
                                                                                                                                                                                                                                                                                                                           AAD




                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           protocol with implantable loop recorder and scheduled follow-up vis­
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           its.27 A crucial question is whether the favourable impact of catheter
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           ablation as first-line treatment in paroxysmal AF patients is specific
                                                                                                                                                                                                                                                                                                                           AADs in the cumulative AF
                                                                                                                                                                                                                                                                                        between RF ablation and




                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           for cryoenergy ablation or represents a ‘class effect’ irrespective of
                                                                                                                                                                                                                                                                                                                                                       burden over a period of
                         MANTRA-PAF246




                                                                                                                                                                                                                                                                                       No significant difference




                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           the employed ablation technology. Prior trials of first-line RF catheter
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           ablation demonstrated modest efficacy in arrhythmia outcome but
                                                                                                                                                                                                                                                     13.7 vs. 10.8 (NS)




                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           were limited by high cross-over rates, inconsistent procedural end­
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           points, and lack of procedural standardization246–248 (Table 5). A
                                                                                                                                                                                                                                                                                                                                                       2 yearsc




                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           pooled analysis concluded that RF catheter ablation resulted in signifi­
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           cantly higher freedom from AF recurrence compared with AAD ther­
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           apy in AAD-naïve paroxysmal AF patients.249 Furthermore,
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           randomized comparison of cryoballoon ablation with RF ablation has
                                                                                                                                                                                                                                                                                                                                                                                 RF, radiofrequency; SD, standard deviation; TTM, transtelephonic monitoring.




                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           demonstrated similar safety and efficacy in arrhythmia outcome in
                                                                                                                                                                                                                                                                                       RF ablation superior to AAD




                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           drug-refractory paroxysmal AF patients.293,294
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Recent data have indicated that in addition to traditional physical
                         RAAFT-1248




                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           symptoms, AF may be associated with significant adverse impact on
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           mental health. An observational study found that over one-third of pa­
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           tients referred for AF management demonstrated severe psychological
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           distress.295 A recent randomized trial indicated significant improve­
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           ments in psychological distress maintained at 12 months associated
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           with catheter ablation but not with active medical therapy.296
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               In the real world, RF ablation has greater heterogeneity in procedural
                                                                                                                                                                                                                                                                                                                                                                                   Continuous cardiac rhythm monitoring.
                                                                                                                                                                                                                                                                                                                                                                                  Symptomatic AF recurrence, P < 0.001.
                                                                                                                                                                                                                                                     Serious AEs—no. of patients (%)




                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           results and is less reproducible than cryoablation in paroxysmal AF pa­
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           tients.297 Furthermore, the center’s annual AF ablation caseload is an
                                                                                                                                                                                                                                                                                                                                                                                   Recurrence of any AF, P = 0.004.




                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           independent predictor of procedural success only in RF-treated parox­
     Table 5 Continued




                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           ysmal AF patients.297 Despite variant needs in gaining experience and
                                                                                                                                                                                                                                                       (ablation vs. AADs)




                                                                                                                                                                                                                                                                                                                                                                                  No PVI documentation.




                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           maintaining skills, an annual operator volume of at least 25 AF ablation
                                                                                                                                                                                                                                                                                       Findings/comments
                                                                                                                                                                                                                                  Treatment effect




                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           procedures and an annual hospital volume of 50 AF ablation cases have
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           been associated with improved procedural outcome.298,299 Therefore,
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           procedural volumes should be taken into account when selecting the
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           type of ablation technology to perform first-line catheter ablation.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               The value of catheter ablation as first-line rhythm control therapy in
                                                                                                                                                                                                                                                                                                                                                                                 b


                                                                                                                                                                                                                                                                                                                                                                                 d
                                                                                                                                                                                                                                                                                                                                                                                 a


                                                                                                                                                                                                                                                                                                                                                                                 c




                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           persistent AF patients has not been specifically evaluated. Although the
Catheter and surgical ablation of atrial fibrillation                                                                                                 19




                                              Paroxysmal AF                                  Persistent AF




                            Symptomatic                               Asymptomatic                              Symptomatic




            Resistance or                      First-line                                        Resistance or                   First-line
        intolerance to AAD(s)                 treatment                                      intolerance to AAD(s)              treatment



                                                                  Catheter ablation may                                   Catheter ablation may
          Catheter ablation              Catheter ablation                                     Catheter ablation
                                                                    be reasonable in                                        be reasonable in
            is beneficial                  is beneficial                                         is beneficial
                                                                    selected patients                                       selected patients

                                                                                             Stand-alone surgical
                                                                                              or hybrid ablation
                                                                                                is reasonable*


        *In patients who prefer a surgical/hybrid approach after careful consideration of relative safety and efficacy of treatment options


  Figure 7 Suggested advice for catheter ablation in patients with paroxysmal or persistent AF in relation to the presence of AF-related symptoms.
  AAD, antiarrhythmic drug; AF, atrial fibrillation.




relative efficacy of catheter ablation in reducing AF burden and first AF      attributed to arrhythmia-mediated cardiomyopathy and could be re­
recurrence is similar in paroxysmal and persistent AF types, extrapola­        verted with SR maintenance achieved by catheter ablation. On the
tion of the beneficial impact of first-line catheter ablation from the         other hand, patients with more advanced HF are more likely to have
paroxysmal to the persistent patient group needs further verifica­             established myocardial dysfunction due to structural alterations, patho­
tion.240,300 Nevertheless, the discrimination between paroxysmal and           physiologically unrelated to AF, which is thus not reversible by catheter
persistent AF may be challenging, and some patients may present                ablation (Table 6).
with both paroxysmal and persistent AF episodes. In addition, some pa­            Catheter ablation in HF with reduced ejection fraction (HFrEF) pa­
tients may present with an early stage of persistent AF, which is asso­        tients may also have a beneficial impact on patient prognosis. A pooled
ciated with fewer arrhythmia relapses following ablation compared              analysis of randomized data concluded that rhythm control strategy re­
with longer-lasting persistent AF. Suggested advice for catheter ablation      duces hospitalizations and confers a survival benefit in HFrEF patients
in patients with paroxysmal or persistent AF in relation to the presence       when implemented with catheter ablation but not with antiarrhythmic
of AF-related symptoms is presented in Figure 7.                               medications.305 The CASTLE-AF study enrolled patients with paroxys­
                                                                               mal or persistent AF and HF [New York Heart Association (NYHA)
                                                                               Class II or above, and LVEF < 35%], and implantable cardiac defibrillator
4.2. Catheter ablation in patients with                                        (ICD), who were unresponsive, intolerant, or unwilling to take AAD.306
atrial fibrillation and heart failure                                          Patients were randomized to catheter ablation or medical treatment
Atrial fibrillation and HF frequently coexist and potentiate each other in     with rate or rhythm control. Fewer patients in the catheter ablation
a vicious circle (AF begets HF and HF begets AF). Several studies have         group had primary endpoint events (death from any cause or hospital­
evaluated potential benefits of AF catheter ablation in patients with HF       ization for worsening HF) at a follow-up of 3.2 years [28.5 vs 44.6%;
(Table 6). The favourable impact of catheter ablation in patients with AF      hazard ratio (HR), 0.62; P = 0.007]. Mortality was also significantly
and impaired left ventricular systolic function extends beyond rhythm          reduced in the catheter ablation group (13.4 vs. 25.0%; HR, 0.53; P =
outcome and may frequently result in left ventricular ejection fraction        0.01). Therefore, these results were strongly supportive that catheter
(LVEF) improvement. In the CAMERA-MRI trial, 68 patients with per­             ablation may favourably affect prognosis in this population, despite
sistent AF and non-ischemic cardiomyopathy were randomized to                  study limitations related to sample size, strict selection criteria, gener­
catheter ablation or medical rate control.250 All patients had cardiac         alizability of findings, lack of blinded randomization, and treatment allo­
magnetic resonance (CMR) before enrolment to assess LVEF and late              cation. In the AATAC prospective RCT, catheter ablation was also
gadolinium enhancement (LGE), indicative of underlying ventricular fi­         shown to significantly reduce all-cause mortality in ICD/CRT-D recipi­
brosis. Patients randomized to catheter ablation had significantly great­      ents with persistent AF and HFrEF (LVEF < 40%) when compared with
er LVEF improvement compared with the rate control group, while                amiodarone treatment.255 In the recent CASTLE HTx trial, catheter ab­
LVEF normalization was achieved in 58% of patients postablation.               lation plus optimal medical therapy in patients with symptomatic AF
These results were maintained during long-term follow-up.251 The               and end-stage HFrEF referred for heart transplantation evaluation sig­
study findings suggest that left ventricular dysfunction was at least partly   nificantly reduced the composite of death from any cause, implantation
                                                                                                                                                                                                                                                             20




Table 6 Randomized controlled clinical trials comparing catheter ablation vs. medical therapy in patients with atrial fibrillation and heart failure with reduced ejection fraction

                         PABA-CHF301 MacDonald                      ARC-HF303 CAMTAF252                    AATAC255                CAMERA-            AMICA304       CASTLE-AF256             CABANA RAFT-AF253                           CASTLE
                                      et al.302                                                                                     MRI250                                                  subanalysis257                                HTx260
............................................................................................................................................................................................
Year of publication      2008                   2011               2013              2014              2016                   2017                2019               2018                   2021                   2022                2023
Sample size              81                     41                 52                50                203                    66                  140                363                    778                    411                 194
Mean age (years)         60.5 ± 8               63 ± 7             63 ± 9            57 ± 11           61 ± 11                61 ± 10             65 ± 8             64 ± 5                 68 ± 8                 67 ± 8              64 ± 11
AF type                  Parox: 52%             Pers: 100%         Pers: 100%        Pers: 100%        Pers: 100%             Pers: 100%          Pers: 76.4%        Parox: 32.5%           Parox: 31.6%           Parox: 7.3%         Parox: 30%
                         Pers or LS-pers: 48%                                                                                                     LS-pers: 23.6%     Pers: 38.3%            Pers: 55.3%            Pers: 69.3%         Pers: 56%,
                                                                                                                                                                     LS-pers: 29.2%         LS-pers: 13.1%         LS-pers: 23.4%      LS-pers: 14%
NYHA                     NYHA II and III:       NYHA II: 10%       NYHA II: 52%      NYHA II: 46%      NYHA II and III:       Average NYHA:       NYHA II: 39%       NYHA I: 11%            NYHA II: 76.1%         NYHA II: 67%        NYHA II: 31%
                         100%                   NYHA III: 90%      NYHA III: 48%     NYHA III: 54%     100%                   2.5±0.6             NYHA III: 61%      NYHA II: 60%           NYHA III: 23.7%        NYHA III: 33%       NYHA III: 55%,
                                                                                                                                                                     NYHA III: 28%          NYHA IV: 0.3%                              NYHA IV: 14%
                                                                                                                                                                     NYHA IV: 1%
Baseline LVEF            28 ± 8%                39 ± 11%           24 ± 8%           33 ± 10%          29 ± 7%                33 ± 9%             26 ± 9%            32 ± 9%                55 ± 8%                41 ± 15%            27 ± 6%
                                                                                                                                                                                            LVEF ≤35%: 8%          LVEF ≤45%: 58%
Ischemic etiology        71%                    49%                33%               26%               64%                    0%                  50%                46%                    21.9%                  31.4%               39%
LA diameter (mm)         48 ± 6                                    48 ± 7            51 ± 10           47 ± 5                 48 ± 7              51 ± 6             49 ± 7                 –                      46 ± 6              49 ± 7
Follow-up (years)        0.5                    0.5                1                 0.5               2                      0.5                 1                  3.1 ± 1.6              5                      3.2 ± 1.8           1.5 ± 0.5
Control arm—therapy AV node ablation            Rate control       Rate control      Rate control      Rate control           Rate control        Best medical       Medical therapy (rate Medical therapy         Rate control        Guideline-directed
                         plus BiV pacing                                                               Amiodarone                                 therapy (rate or   or rhythm control)     (rate or rhythm                            medical therapy
                                                                                                                                                  rhythm control)                           control)
Primary outcome          Composite of LVEF, LVEF                   Change in peak O2 LVEF              Freedom from AF/       Change in LVEF at   Absolute increase Composite of            Composite of           Composite of        Composite of
                         6 min walk test                           consumption                         AFL/AT >30 s off       6 months            in LVEF            all-cause mortality    all-cause mortality,   all-cause           death from any
                         distance, and                                                                 AADs                                                          and HF hospitalization disabling stroke,      mortality, and HF cause, LVAD
                         MLWHF score                                                                                                                                                        serious bleeding, and events               implantation, or
                                                                                                                                                                                            cardiac arrest                             urgent heart
                                                                                                                                                                                                                                       transplantation
Mean change in LVEF      8 ± 8 vs. 1 ± 4%,      4.5 ± 11.1 vs.     10.9 ± 11.5 vs.   8.1 vs. −3.6%,    8.1 ± 4 vs. 6.2 ± 5,   18.3 vs. 4.4%,      8.8 vs. 7.3%       8.0 vs. 0.2%                                  10.1 ± 1.2 vs.      7.8 ± 7.6
(ablation vs. control)   P < 0.001              2.8 ± 6.7%, P = 0.6 5.4 ± 8.5%       P < 0.001         P = 0.02               P < 0.0001          P = 0.36           P = 0.005                                     3.8 ± 1.2%          vs. 1.4 ± 7.2
                                                                   P = 0.055                                                                                                                                       P = 0.017           (12 months)
                                                                                                                                                                                                                   (24 months)
Rhythm outcome           12 vs. 100% in AF      50 vs. 100% in AF 88 vs. 8% in SR    19 vs. 100% in AF 70 vs. 34% free        25 vs. 100% in      73.5 vs. 50% in    63.1 vs. 21.7% in      44 vs. 28% w/o         85.6 vs. 12.9% in   31.4 ± 33.3% vs
(ablation vs. control)                                                               (at 6 months)     from AF                AF (at 6 months)    SR (at 1 year)     SR (at 5 years)        AF recurrence (at      SR (at 2 years)     8.6 ± 26.3% AF
                                                                                                                                                                                            5 years)                                   burden reduction
                                                                                                                                                                                                                                       at 12 months

                                                                                                                                                                                                                                                 Continued
                                                                                                                                                                                                                                                             S. Tzeis et al.
Catheter and surgical ablation of atrial fibrillation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                21


                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             of a left ventricular assist device, or urgent heart transplantation than




                                                                                                                                                                                                                                                                                                                                                                         AAD, antiarrhythmic drug; AF, atrial fibrillation; AFl, atrial flutter; AT, atrial tachycardia; AV, atrioventricular; BiV, biventricular; HF, heart failure; LA, left atrium; LS-pers, long-standing persistent; LVAD, left ventricular assist device; LVEF, left
                                                       ............................................................................................................................................................................................
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             medical therapy alone after a median follow-up of 18 months (8 vs.


                                    CASTLE


                                                                                                                                                                                                                                                                                    Reduction in
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             30%; HR, 0.24; P < 0.001).260


                                    HTx260


                                                                                                                                                                                                                                                                                    the primary
                                                                                                                                                                                                                                                                       outcome (P = composite
                                                                                                                                                                                                                                                                                    endpoint
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Proper patient selection is crucial for maximizing benefit from AF
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             catheter ablation in HFrEF patients. Several indicators may help guide
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             this decision (Table 7).
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Higher NYHA class (III/IV), ischemic HF etiology, paroxysmal AF type,
                                   CABANA RAFT-AF253


                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             prolonged QRS duration (>120 ms), severe LA dilatation [left atrial vol­




                                                                                                                                                                                                                                                                                                                                 Increase in
                                                                                                                                                                                                                                                                       primary                                                                                                                                                                                                                                                                                                                                                               ume index (LAVI) >50 mL/m2], and atrial and ventricular fibrosis are pre­
                                                                                                                                                                                                                                                      Reduction in the Similar



                                                                                                                                                                                                                                                                       0.066)

                                                                                                                                                                                                                                                                                                                                 LVEF
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             dictors of lack of LVEF recovery following catheter ablation in patients
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             with impaired left ventricular systolic function.253,256,307,308,311,313
                                 subanalysis257




                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                It is also important to determine the relative chronologic sequence


                                                                                                                                                                                                                                                                                                                                                  improvement in
                                                                                                                                                                                                                                                                                                                                 mortality, and
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             of AF and HF presentation, since patients who develop HF first have
                                                                                                                                                                                                                                                      reduction in
                                                                                                                                                                                                                                                                             HF hospitalization composite,



                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             a worse prognosis, are less likely to present AF-mediated tachymyopa­
                                                                                                                                                                                                                                                                                                                                 all-cause
                                                                                                                                                                                                                                                                             all-cause death or primary




                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             thy and have a poorer outcome after AF ablation.252,312,314 The
                                                                                                                                                                                                                                                                                                                                                                   QoL


                                                                                                                                                                                                                                                                                                                                                                         ventricular ejection fraction; MLWHF, Minnesota Living with Heart Failure; NYHA, New York Heart Association; Parox, paroxysmal; Pers, persistent; QoL, quality of life; SR, sinus rhythm.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Antwerp score based on four simple parameters (wide QRS, known
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             HF etiology, severe atrial dilatation, and paroxysmal AF) has been
                                 CASTLE-AF256




                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             shown to predict left ventricular systolic function recovery after AF ab­
                                                                                                                                                                                                                                                      Reduction in




                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             lation in HF patients.307 Recently, this score was externally validated in a
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             large multicenter study yielding good discrimination and calibration.308
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Nevertheless, even in the presence of less favourable characteristics,
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             some patients with AF and HF may experience improvement in LV sys­
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             tolic function and clinical outcome following SR restoration.
                                 AMICA304




                                                                                                                                                                                                                                                                             improvement




                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Registry and observational data suggest that catheter ablation signifi­
                                                                                                                                                                                                                                                      No LVEF




                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             cantly reduces arrhythmia recurrences and the risk of cardiovascular
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             events compared with drug therapy in HF patients across all LVEF sub­
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             groups, even in HF patients with preserved ejection fraction
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             (HFpEF).313,315–321 In a prespecified subanalysis of the CABANA trial
                                    CAMERA-




                                                                                                                                                                                                                                                                             improvement




                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             in patients with baseline HF symptoms (NYHA Class ≥II, 79% with
                                     MRI250




                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             LVEF ≥50%), catheter ablation conferred significant improvement in
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             arrhythmia recurrence, QoL, and survival when compared with
                                                                                                                                                                                                                                                      Reduction in AF LVEF




                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             pharmacological therapy.257 In the subgroup of HFpEF patients
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             (LVEF ≥ 50%), ablation reduced mortality by 60% compared with
                                                                                                                                                                                                                                                                                                             hospitalizations,




                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             drug therapy.257 A small, randomized trial demonstrated that AF cath­
                                 AATAC255




                                                                                                                                                                                                                                                                                                                                 and mortality




                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             eter ablation significantly improved invasive hemodynamic parameters,
                                                                                                                                                                                                                                                                             improvement recurrence,
                                                                                                                                                                                                                                                                                         unplanned




                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             exercise capacity, and QoL outcomes when compared with medical
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             therapy in patients with HFpEF and concomitant AF.322 Adequately
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             powered prospective RCTs are needed to provide more robust clinical
                                 ARC-HF303 CAMTAF252




                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             data.

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             4.3. Catheter ablation in patients without
                                                                                                                                                                                                                                                      LVEF




                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             atrial fibrillation–related symptoms
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             The main objective of AF catheter ablation is symptom amelioration
                                                                                                                                                                                                                                                                                                             consumption




                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             and reduction in arrhythmia recurrences. Pertinent benefit, beyond
                                                                                                                                                                                                                                                                             increase in
                                                                                                                                                                                                                                                      Significant

                                                                                                                                                                                                                                                                             peak O2




                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             symptomatic control, might justify eligibility of truly asymptomatic AF
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             patients for catheter ablation.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                A key issue in the management of patients without symptoms while
                                 PABA-CHF301 MacDonald




                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             remaining in AF is the exclusion of a pseudo-asymptomatic status. Up
                                                                                                                                                                                                                                                                             improvement
                                              et al.302




                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             to 77% of these patients may experience subjective symptomatic ameli­
                                                                                                                                                                                                                                                      No LVEF




                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             oration,323 improvement in functional class, and decrease in brain
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             natriuretic peptide levels with SR restoration following electrical cardi­
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             oversion.324 Therefore, in asymptomatic patients, especially at younger
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             age, a cardioversion is worth attempting to assess potential symptom­
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             atic improvement that would enhance patient eligibility for catheter ab­
                                                                                                                                                                                                                                                                             composite
                                                                                                                                                                                                                                                      Improved

                                                                                                                                                                                                                                                                             endpoint




                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             lation due to reclassification in the symptomatic category.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Atrial fibrillation has significant hemodynamic consequences that
             Table 6 Continued




                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             may lead to HF and worsen patient prognosis, such as loss of atrial con­
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             tribution to cardiac output, rapid and irregular heart rate, and loss of
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             heart rate adaptation to metabolic demands. Heart rate irregularity re­
                                                                                                                                                                                                                                                      Main findings




                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             sults in inefficient cardiac cycles due to inadequate ventricular filling,
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             contributes to hemodynamic impairment, and worsens left ventricular
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             systolic and diastolic functions.325 An irregularly paced ventricular
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             rhythm following AV node ablation decreases cardiac output and in­
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             creases pulmonary wedge pressure when compared with a regular
22                                                                                                                                                                                     S. Tzeis et al.



 Table 7 Characteristics associated with LVEF recovery in response to AF catheter ablation in patients with impaired left ventricular systolic
 function

  Characteristics                                                                                                       Evidence
  ..............................................................................................................................................
  Lower NYHA class                                       Lower NYHA Class (I and II) at presentation is a predictor of significant LVEF recovery following AF ablation when
                                                           compared with higher NYHA Class (III and IV) in patients with HFrEF256
  Non-ischemic etiology                                  Non-ischemic HF etiology is a significant predictor of LVEF improvement after AF ablation in patients with HFrEF256
  Persistent AF                                          Persistent AF is an independent predictor of LVEF improvement and left ventricular reverse remodelling after AF
                                                            ablation in patients with impaired LVEF307–310
  Narrow QRS                                             Narrow QRS (≤120 ms) is an independent predictor of LVEF recovery after AF ablation in patients with impaired
                                                            LVEF307,308
  Absence of CMR-detected atrial fibrosis                Extent of atrial fibrosis is inversely correlated to LVEF response following AF catheter ablation in patients with
                                                            HFrEF311
  Absence of CMR-detected ventricular                    Absence of ventricular fibrosis is an independent predictor of LVEF normalization after AF catheter ablation in
     fibrosis                                               patients with non-ischemic cardiomyopathy and persistent AF250
  Post-cardioversion EF and NYHA                         Improvement in functional status and/or LVEF after cardioversion is indicative of underlying
     improvement                                            tachyarrhythmia-mediated cardiomyopathy and a favourable response to catheter ablation in HFrEF patients
  Absence of severe atrial dilatation                    Absence of severe atrial dilatation (LAVI ≤ 50 mL/m2) is an independent predictor of LVEF recovery after AF
                                                           ablation in patients with impaired LVEF307,308
  AF preceding HF or simultaneous AF and                 Patients with simultaneous AF and HF diagnosis or AF history preceding HF diagnosis are more likely to present
    HF diagnosis                                           normalization of LVEF and resolution of HF symptoms following catheter ablation252,312

 AF, atrial fibrillation; CMR, cardiovascular magnetic resonance; HF, heart failure; HFrEF, HF with reduced ejection fraction; LA, left atrial; LAVI, left atrial volume index; LVEF, left ventricular
 ejection fraction; NYHA, New York Heart Association.




rhythm at the same average cycle length.326 Therefore, SR maintenance                                  of catheter ablation (P = 0.046). In addition, the composite secondary
might confer benefit due to prevention of abovementioned                                               endpoint of death from any cause or cardiovascular hospitalization oc­
AF-mediated hemodynamic sequelae even in the absence of coexisting                                     curred significantly less frequently in the catheter ablation group than in
symptoms.                                                                                              the medical therapy group. Despite these considerations and caveats,
   Apart from symptomatic improvement, catheter ablation is also ef­                                   the study findings do not support the use of catheter ablation to im­
fective in delaying AF progression from paroxysmal to persistent type                                  prove prognosis in the general population of asymptomatic patients
(Section 2). Atrial fibrillation progression to longer-lasting types has                               with AF. However, in the CABANA trial, the clinical outcome of abla­
an impact on patient outcome since non-paroxysmal AF is associated                                     tion vs. AAD therapy demonstrated an age-based variation with the lar­
with significantly increased risk of thromboembolism, HF, hospital ad­                                 gest relative and absolute prognostic benefit seen in patients younger
missions, and mortality compared with paroxysmal AF.32,327,328 In the                                  than 65 years, suggesting that selected patient subgroups may have
ATTEST trial, catheter ablation significantly delayed AF progression                                   clinical outcome benefit from catheter ablation.331 Furthermore, a pre
compared with AADs in patients with drug-refractory paroxysmal                                         specified analysis of the EAST-AFNET 4 trial showed that an early sys­
AF.329 Furthermore, in the 3 year follow-up of the EARLY-AF trial,                                     tematic rhythm control strategy (mainly with AADs) confers a similar
first-line treatment of paroxysmal AF patients with cryoballoon abla­                                  degree of outcome benefit in symptomatic and asymptomatic AF
tion was associated with significantly lower incidence of persistent AF                                patients.332
[HR, 0.25; 95% confidence inetrval (CI), 0.09–0.70] when compared
with AAD therapy using continuous cardiac monitoring.27 Therefore,                                     4.4. Patients with atrial fibrillation and
beyond symptom control, catheter ablation may have a favourable im­
pact by limiting disease progression especially when implemented in                                    coexistent rhythm disorders
early stages of AF natural course.                                                                     4.4.1. Atrial fibrillation and supraventricular tachycardia
   The largest trial assessing potential prognostic benefits of catheter                               Paroxysms of AF are commonly triggered by ectopic beats from the
ablation is the CABANA trial that enrolled 2204 symptomatic patients                                   PVs.65 However, other types of supraventricular tachycardia (SVT),
with AF aged 65 years and older or younger than 65 years with 1 or                                     such as AV nodal reentry tachycardia (AVNRT), focal atrial tachycardia
more risk factors for stroke.330 Patients were randomized to catheter                                  (AT), or AV reentry tachycardia (AVRT) may trigger AF, especially in
ablation or AAD/rate control therapy. In the intention-to-treat analysis,                              younger patients.333 The incidence of AF in patients with paroxysmal
catheter ablation did not significantly reduce the primary composite                                   SVT is higher than in age-matched normal populations, while 12% of pa­
endpoint of death, disabling stroke, serious bleeding, or cardiac arrest                               tients with known SVT also experience AF episode within 12 months of
compared with medical therapy over a median follow-up of 48.5                                          follow-up.334 Furthermore, a small subgroup of patients who are re­
months. However, the study was limited by high crossover rates, while                                  ferred for AF catheter ablation, ranging from 7.6 to 10.1%, also have in­
the per-protocol analysis demonstrated significant differences in favour                               ducible SVT.261,262 Sciarra et al.261 reported that the role of SVT as AF
Catheter and surgical ablation of atrial fibrillation                                                                                               23


trigger could be verified in 42.3% of patients with AF and inducible SVT,    higher likelihood of flutter recurrence within 1 year (10 vs. 2%, P =
as evidenced by spontaneous conversion of SVT to AF. In these pa­            0.07).342
tients, elimination of the SVT only, without AF catheter ablation, may          In recent catheter ablation trials, recurrence rates are not negligible,
be sufficient for a favourable rhythm outcome with freedom from AF           and therefore, patients with both AF and typical AFl may still be prone
recurrences ranging from 70 to 92.3% during follow-up.261,263,264            to AFl recurrence following PVI since even short bursts of AF may trig­
Observational trials have demonstrated an age-related increase in the        ger AFl. In addition, CTI ablation reduces the likelihood of AFl recur­
risk of AF recurrence in patients with coexistent SVT and AF following       rence if AAD is administered following AF catheter ablation.
ablation of the SVT only, with age over 50 years indicative of high AF          Non–CTI-dependent AFl is also encountered following AF ablation
recurrence rate.264,335 Therefore, in patients with coexistent SVT           especially after extensive ablation lesion sets in the context of persist­
and AF, preferably in the younger age group, and only when the former        ent AF ablation.339,343 However, these types of macroreentrant ATs
is considered the main trigger of the latter, it is reasonable to simplify   may resolve spontaneously in some patients, and therefore, catheter
the ablation strategy to elimination of the SVT only. Atrial fibrillation    ablation should be deferred for several months and beyond the blanking
ablation would then be deferred depending upon AF recurrence fol­            period unless non–CTI-dependent AFl episodes are recurrent, highly
lowing SVT ablation.                                                         symptomatic and resistant to AADs and cardioversion (Section 9).

4.4.2. Atrial fibrillation and sinus node dysfunction
                                                                             4.5. Atrial fibrillation with other risk
Symptomatic prolonged sinus pauses are common upon AF termin­
ation and may be aggravated by AV node–blocking agents and AADs.             factors or diseases
This often leads to the indication for pacemaker implantation. Atrial fib­   4.5.1. Older patients with atrial fibrillation
rillation catheter ablation is effective in preventing both AF recurrences   Some centers may withhold ablation therapy in older patients.344 This
and sinus pauses upon AF termination, likely due to autonomic modu­          reluctance stems from a perceived less favourable risk to benefit ratio
lation.265 Chen et al.266 reported that 95.3% of patients with paroxys­      of catheter ablation in elderly patients. Two recent metaanalyses of ob­
mal, AF-related, symptomatic prolonged sinus pauses who underwent            servational studies demonstrated similar AF ablation success rates with
AF catheter ablation no longer needed a pacemaker and had significant­       a significantly higher risk of complications in patients >75 years when
ly higher freedom from AF recurrences and tachycardia-related hospi­         compared with younger ones.270,271 However, contradictory results
talizations compared with those treated with permanent pacemaker             have also been reported. Data from a Danish nationwide cohort study
implantation and AADs. Although sinus node dysfunction in the pres­          reported a similar incidence of periprocedural complications and AF re­
ence of paroxysmal AF is mainly attributed to electrical remodelling,336     lapse in patients ≥75 years subjected to catheter ablation when com­
underlying sinus node structural remodelling may also be present in a        pared with patients aged 65–74 years.272
few cases.337,338 A minority of patients with coexistent AF and sinus           At present, it is unclear whether a specific technology of AF catheter
node dysfunction will still require permanent pacemaker implantation         ablation should be preferred in elderly patients due to associated en­
following catheter ablation due to underlying structural alteration of       hanced safety profile. In a propensity-matched comparison of older pa­
the sinus node.339 However, the vagal denervation that occurs with           tients ≥75 years, cryoballoon ablation was associated with similar
catheter ablation results in a higher resting heart rate, which may also     efficacy and safety, but with shorter procedural time when compared
help a patient compensate for coexistent sinus node dysfunction,             with RF ablation.345 Furthermore, a subanalysis of the CABANA trial
even if AF recurs. Atrial fibrillation recurrence rate was significantly     found no prognostic benefit of catheter ablation (CA) in patients
higher in patients requiring pacemaker implantations after AF ablation       ≥75 years of age, with similar rates of complications and AF recur­
than those who did not.339,340                                               rences postablation.331

4.4.3. Atrial fibrillation and atrial flutter                                4.5.2. Atrial fibrillation and hypertrophic cardiomyopathy
Cavotricuspid isthmus (CTI)-dependent atrial flutter (AFl) is frequent in    Atrial fibrillation is highly prevalent in patients with hypertrophic car­
patients with AF, either spontaneously or during type Ic AAD or amio­        diomyopathy (HCM).346,347 These patients often have limited options
darone therapy.267 The two arrhythmias have mechanistic and patho­           for antiarrhythmic therapy, due to hypertrophy and underlying struc­
physiological linkage with short bursts of AF frequently preceding and       tural heart disease. However, AF is often poorly tolerated and impairs
triggering AFl development.341 Scharf et al.267 reported that spontan­       clinical outcome in HCM patients, thus stressing the need to pursue SR
eous or pacing induced AFl occurrence during AF ablation procedure           maintenance in many patients.348
is predictive of symptomatic AFl during post-PVI follow-up, with 24%            Several studies have evaluated the efficacy of catheter ablation in
of patients who did not undergo CTI ablation during the PVI procedure        HCM patients with AF. Three metaanalyses have reported significantly
experiencing symptomatic AFl recurrence during a mean follow-up of           lower freedom from AF/AT recurrences in patients with as compared
609 ± 252 days. These findings are supportive of CTI ablation in case        to those without HCM after single and multiple catheter abla­
of AFl occurrence during AF ablation procedure. Contradictory findings       tions.273,274,279 Recent studies have shown that catheter ablation has
have also been reported. Wazni et al.268 in a trial conducted at the be­     comparable efficacy in HCM patients as compared to the general patient
ginning of the AF ablation era advocated that PVI only, without CTI ab­      population when treating paroxysmal AF.275,276 However, results are
lation, suppressed both AF and typical AFl recurrences. However, in          poorer in patients with persistent AF.273,275,276 Therefore, early inva­
this patient series, CTI block reduced early AFl recurrences, since          sive intervention, before progression of AF and/or underlying atrial sub­
55% of patients not receiving CTI ablation experienced episodes of typ­      strate, is of primary importance in HCM patients to increase success
ical AFl within the first 8 weeks following catheter ablation and 20%        rates.
needed electrical cardioversion.268 Based on the concept that PV ecto­          Non-PV triggers are commonly involved in AF pathophysiology in
pics are main triggers of typical AFl, the CRAFT trial tested the hypoth­    HCM patients and are documented in many patients with arrhythmia
esis whether cryoballoon PVI was superior to CTI ablation as first-line      recurrence following catheter ablation, thus supporting the concept of
therapy in patients with typical AFl without prior AF documentation.         extensive ablation lesion sets to increase success rate.277 However, ad­
The primary efficacy outcome measure (time to first recurrence of sus­       junctive ablation beyond PVI was not associated with additional benefit
tained symptomatic atrial arrhythmia) was similar between the com­           in a large multicenter cohort of HCM patients undergoing AF catheter
pared groups, although patients subjected to PVI had a five-fold             ablation.276 The use of RF vs. cryoballoon ablation has no impact on
24                                                                                                                                                      S. Tzeis et al.



procedural outcome among HCM patients.276 Furthermore, the risk of                        complication rate and lower long-term freedom from AF.350–352
major procedural complications appears to be increased in HCM pa­                         Evaluation at a comprehensive weight loss clinic may be useful to deter­
tients when compared with the general AF population.276 Despite a tem­                    mine eligibility for medications or surgical approaches to facilitate weight
poral decline in the incidence of procedural complications in HCM                         loss (Section 5.1.2.).
patients, real-world data verify the still high periprocedural morbidity                     Obstructive sleep apnoea is associated with AF,355 and up to 45% of
and mortality.278                                                                         patients referred for AF ablation have OSA.356 Patients with OSA have
                                                                                          a significantly increased risk of AF recurrence following catheter abla­
                                                                                          tion compared with those without OSA.357–360 Treatment with con­
4.5.3. Patients with atrial fibrillation and obesity—physical                             tinuous positive airway pressure (CPAP) appears to significantly
inactivity—obstructive sleep apnoea                                                       reduce the risk of AF recurrence or progression in patients with AF
Obesity and physical inactivity are associated with increased risk of                     and OSA.361,362 Continuous positive airway pressure therapy also re­
AF349 and reduced efficacy of AF ablation350,351 (Section 5.1.2.).                        sults in reversal of atrial remodelling in AF patients.362 For these rea­
Obesity also increases the risk of complications of catheter ablation                     sons, some centers are reluctant to perform AF ablation before OSA
and increases radiation to both the patient and personnel352 (Section                     evaluation and potential initiation of CPAP treatment. The rate of AF
11). Comprehensive management of these modifiable risk factors                            recurrence following PVI is similar between CPAP-treated OSA pa­
improves the outcome of catheter ablation353–356 (Section 5.1.).                          tients and non-OSA patients.357 In addition, PVI considerably reduces
However, weight reduction and improvement in cardiorespiratory fit­                       the burden of paroxysmal AF in OSA patients, but the use of CPAP
ness requisites lengthy efforts with slow yielding results that may be dif­               following ablation has not been shown to further reduce the risk
ficult to sustain in long term. Furthermore, prolonged delays from AF                     of AF recurrence in a recent randomized study, which was though
diagnosis to catheter ablation adversely affect success rates.288–290                     lacking sufficient statistical power (Section 5.1.3.).363 Finally, there are
Therefore, catheter ablation of AF should not be deferred in obese or                     no controlled studies comparing AF ablation followed by OSA treat­
physical inactive patients who have initiated lifestyle interventions                     ment vs. OSA treatment followed by AF ablation if needed. At present
and are showing progress towards their pertinent lifestyle goals.                         time, there is no evidence supporting the concept that CPAP may com­
Individualized risk–benefit assessment is needed in patients with morbid                  pletely prevent AF recurrences and the need for catheter ablation at
obesity [body mass index (BMI) >40 kg/m2] due to a higher                                 follow-up.



5. Atrial fibrillation risk factors and preprocedural management


     Atrial fibrillation risk factors and preprocedural management                                                          Category of              Type of
                                                                                                                              advice                 evidence
     ..............................................................................................................................................
     Modifiable risk factors
       Comprehensive management of AF risk factors should be undertaken to improve the outcomes of catheter
                                                                                                                            Advice TO DO         OBS353,354,364–366
         ablation of AF
     Preablation anticoagulation strategy
       Patients with stroke risk factor(s) (CHA2DS2-VASc score ≥1 in males and ≥2 in females) or with increased risk
         of thrombusa should receive oral anticoagulation therapeutically for at least 3 weeks before AF catheter           Advice TO DO            OBS367–380
         ablation
       Catheter ablation of AF without interruption of anticoagulation is beneficial in patients who have been
                                                                                                                            Advice TO DO            META381–393
         therapeutically anticoagulated with either vitamin K antagonists or direct oral anticoagulants (DOACs)
       For patients anticoagulated with a DOAC prior to AF catheter ablation, it is reasonable to hold one dose prior     May be appropriate
                                                                                                                                                    META394–398
         to AF catheter ablation with early reinitiation postablation                                                          TO DO
     Imaging for exclusion of atrial thrombus
       Transesophageal echocardiography or cardiac computed tomography within 48 h prior to catheter ablation or
                                                                                                                          May be appropriate
         intraprocedural intracardiac echocardiography are reasonable imaging options for exclusion of atrial                                       OBS399–408
                                                                                                                               TO DO
         thrombus
       Imaging for exclusion of atrial thrombus is reasonable in patients with stroke risk factor(s) (CHA2DS2-VASc
                                                                                                                          May be appropriate
         score ≥1 in males and ≥2 in females) or with increased risk of thrombusa presenting for AF catheter                                        OBS367–380
                                                                                                                               TO DO
         ablation, who have not received anticoagulation therapeutically for 3 weeks or longer
       Imaging for exclusion of atrial thrombus may be reasonable in patients with increased risk of thrombusb even if
                                                                                                                          Area of uncertainty       OBS367–380
         therapeutically anticoagulated for 3 weeks or longer

 a
  Persistent AF, hypertrophic cardiomyopathy, rheumatic heart disease, or cardiac amyloidosis.
 b
  CHA2DS2-VASc score ≥3, persistent AF, hypertrophic cardiomyopathy, rheumatic heart disease, or cardiac amyloidosis.
Catheter and surgical ablation of atrial fibrillation                                                                                                        25


5.1. Atrial fibrillation risk factors                                                 management, had similar rhythm outcome after catheter ablation to
Several risk factors for AF development and recurrence following cath­                those without hypertension.438 In the SMAC-AF randomized trial,
eter ablation have been identified, many of which are modifiable. These               short-term aggressive blood pressure (BP) treatment (target systolic
include traditional modifiable risk factors such as hypertension409–412               BP ≤120 mmHg) for a median duration of 3.5 months before scheduled
and diabetes,364,413–417 but also emerging factors such as obes­                      AF catheter ablation in patients with hypertension did not reduce ar­
ity,109,351,418,419 metabolic syndrome,420–422 physical inactivity,423–427            rhythmia recurrence following ablation when compared with standard
OSA,358,359,428,429 alcohol consumption,365,430,431 and smoking.366,432               BP treatment (target systolic BP <140 mmHg).439 Although treating
There is compelling evidence to suggest that management of these                      modest hypertension in isolation has not proven to be of benefit,
risk factors has the potential to reduce AF burden and improve the out­               when undertaken in the setting of a comprehensive risk factor manage­
comes of ablation strategies to maintain SR. In practice, although there              ment programme in overweight and obese individuals, it has been asso­
have been variable results when targeting risk factors in isolation, com­             ciated with higher rate of SR maintenance after catheter ablation.353
prehensive management in specific risk factor management clinics has                     Renal artery denervation, a procedure developed for the treatment
been shown to be effective in conferring tangible clinical improve­                   of resistant hypertension, has also a potential antiarrhythmic role. In a
ments.353,354 In addition, there are cardiovascular comorbidities that                small, randomized study of 27 patients with drug-resistant hyperten­
warrant specific treatments and may have a role in improving the out­                 sion scheduled for AF catheter ablation, combined renal artery denerv­
comes of catheter ablation. The recently described HEAD2TOES sche­                    ation and PVI resulted in significant BP reduction and a higher freedom
ma with targets for secondary prevention of AF is presented in                        from AF recurrence at 12 months compared with PVI only.440 In the
Figure 8.433 Below we discuss the evidence pertaining to each of these                larger, multicenter ERADICATE-AF RCT, 302 patients with hyperten­
modifiable factors (see Supplementary material online, Table S1).                     sion resistant to at least one antihypertensive medication undergoing
                                                                                      paroxysmal AF ablation were randomized to catheter ablation alone
5.1.1. Hypertension                                                                   or ablation plus renal denervation.441 Addition of renal denervation
                                                                                      to catheter ablation significantly increased freedom from AF recur­
Hypertension is one of the most significant risk factors for AF develop­
                                                                                      rence at 12 months when compared with ablation alone. The under­
ment.434–436 It increases left ventricular wall thickness and diastolic dys­
                                                                                      lying mechanisms explaining the favourable impact of renal artery
function, which mediate adverse atrial remodelling associated with
                                                                                      denervation on AF burden have not been clarified. It has been postu­
increased LA pressure, wall thickness, fibrotic changes, and dilatation.
                                                                                      lated that this effect may be due to BP control itself or to direct antiar­
In addition, the increased activation of the renin-angiotensin-aldosterone
                                                                                      rhythmic actions of renal artery denervation including reduction in
system in hypertensive patients mediates atrial fibrosis and electro­
                                                                                      central sympathetic output and attenuation of atrial structural and elec­
physiological remodelling thus promoting AF.437
                                                                                      trophysiological remodelling.442
   Discrepant results have been reported regarding the impact of un­
controlled hypertension on AF ablation outcome. In an observational
study including 531 patients who underwent AF catheter ablation, un­                  5.1.2. Obesity
controlled hypertension was significantly associated with postablation                Obesity is a pandemic and contributes significantly to the increasing
arrhythmia recurrence after confounder adjustment.412 In contrast, a                  prevalence of AF worldwide. The correlation between obesity and
registry analysis showed that patients with a diagnosis of hypertension,              AF is well-recognized.443 A metaanalysis of 51 studies reported that
without information regarding the efficiency of antihypertensive                      for every 5-unit increase in BMI, there was a 29% greater excess risk




                                                        Optimization of AF risk factors

                                                        Optimize heart failure medications
                 H eart failure

                    E xercise                           ³ 210 min/week of moderate/vigorous exercise

                                                        < 130/80 mmHg (rest)
                    A rterial hypertension              < 200/100 mmHg (exercise)

                     D iabetes type 2                   Dietary changes | HbA1c < 7.0%


                     T obacco                           Complete cessation


                    O besity                            ³ 10% weight reduction | BMI < 27 Kg/m2


                    E thanol                            £ 3 standard drinks/week
                                                        (secondary AF prevention)

                  S leep apnoea                         AHI < 15 without CPAP |
                                                        CPAP for AHI ³ 30 or AHI ³ 20 with HTN


  Figure 8 Risk factors and respective targets for AF prevention in patients considered for or undergoing AF ablation—the HEAD2TOES schema
  (green light: established evidence; orange light: evolving evidence). AF, atrial fibrillation; AHI, apnoea–hypopnoea index; BMI, body mass index;
  CPAP, continuous positive airway pressure; HbA1c, glycated haemoglobin; HTN, hypertension.
26                                                                                                                                             S. Tzeis et al.



of incident AF and a 13% increased likelihood of AF recurrence follow­            electrical remodelling as documented by high-density RA mapping.362
ing ablation.444 Related mechanisms include structural and electrical at­         Randomized evidence on the impact of CPAP treatment on arrhythmia
rial remodelling.109,445,446 In addition, cardiac imaging studies have            outcome after ablation is sparse. In a recent study, 83 patients with par­
shown that obesity is associated with increased epicardial and pericar­           oxysmal AF and OSA undergoing PVI were randomized to either CPAP
dial fat depositions adjacent to the LA.447 Increased pericardial and epi­        or standard of care without any difference in postablation AF recur­
cardial fat is associated with AF, likely through direct fatty infiltration of    rence as documented by implantable loop recorders. Of note, this
the LA and/or paracrine effects attributable to released cytokines and            was a small study and probably without adequate statistical power to
chemokines.448                                                                    detect subtle treatment differences.363
   Based on the findings of the ESC-EHRA AF Ablation Long-Term                       Importantly, treatment of OSA in the context of a comprehensive
Registry, patients with BMI over 30 kg/m2 had 1.2-fold increased likeli­          risk factor management strategy has been associated with improved ab­
hood of AF recurrence following catheter ablation when compared                   lation outcomes.353,354 In the ARREST-AF study, patients were offered
with overweight patients.351 A single-center retrospective study enrol­           therapy if the apnoea–hypopnoea index (AHI) was ≥30/h or if it was
ling 2715 consecutive patients undergoing AF catheter ablation con­               >20/h with resistant hypertension or problematic daytime sleepi­
cluded that BMI over 35 kg/m2 was an independent predictor of                     ness.353 However, proponents of treating sleep apnoea are increasingly
worse postablation rhythm outcome.419 In an observational study                   utilizing therapy with an AHI ≥15/h in patients with AF.362 This latter
that categorized patients who underwent ablation by BMI, AF recur­                trigger for treatment is being prospectively evaluated in the
rence was higher in all high-BMI groups when compared with normal-                SNORE-AF study (ACTRN12621001213831).
weight controls.350
   The role of weight loss in patients undergoing AF ablation has also            5.1.4. Alcohol consumption
been examined in several studies. The ARREST-AF study evaluated                   Long-term alcohol intake is associated with incident AF in a dose-
the value of a comprehensive risk factor management approach in pa­               dependent manner.458 High quantities of alcohol consumption (more
tients undergoing AF ablation and showed that aggressive risk factor              than three standard drinks per day) increase the risk of AF development
management achieved significantly greater weight loss and increased               by almost 35%, with a more significant effect in males. However, there
freedom from AF.353 In contrast, a small non-randomized study in pa­              is limited association with incident AF in those who limit alcohol con­
tients with morbid obesity and long-standing persistent AF undergoing             sumption to less than one standard drink per day. Proposed mechan­
AF ablation reported that weight loss did not improve either AF symp­             isms underlying this association include pleiotropic effects of alcohol
tom severity or freedom from AF recurrence at 1-year follow-up.449                on atrial electrical properties: conduction slowing and shortening of
The prospective SORT-AF trial randomized patients with symptomatic                the atrial ERP,459 alterations in autonomic nervous control of the
AF and BMI 30–40 kg/m2 undergoing AF ablation to a supervised struc­              heart,460 and an increase in circulating plasma free fatty acids, which
tured weight management programme or to usual care on the day of                  have been shown to be arrhythmogenic.461 Structural LA remodelling
the procedure and evaluated potential impact on rhythm outcome as­                may also be implicated in the association of alcohol consumption
sessed by invasive monitoring.450 The primary endpoint of AF burden               with AF development, since chronic alcohol consumption has been
did not differ between compared groups probably due to a high rate                identified as a predictor of LA enlargement.462 Furthermore, chronic al­
of non-compliance in the intervention group, a modest weight loss                 cohol consumption is closely associated with other independent AF risk
achieved, and a rather short postablation follow-up.                              factors including hypertension, obesity, and OSA.
   Bariatric surgery may also have a positive impact on postablation AF               Several studies support a relationship between alcohol consumption
recurrence rate in patients with morbid obesity. In a retrospective co­           and AF recurrence following ablation. In a study of patients with parox­
hort study of 239 patients with morbid obesity, bariatric surgery prior           ysmal AF undergoing ablation, those consuming alcohol had higher AF
to AF ablation was associated with reduced risk of AF recurrence and              recurrence rates after first catheter ablation compared with those who
reduced rate of repeat AF ablation. Prospective RCTs are needed to                did not, though this difference was attenuated after repeat ablations.430
confirm the positive impact of surgical weight loss procedures.451                In an observational study of symptomatic patients with paroxysmal AF,
                                                                                  alcohol consumption was an independent predictor of low-voltage
5.1.3. Obstructive sleep apnoea                                                   zones assessed by LA voltage mapping and AF recurrence following
Obstructive sleep apnoea is a chronic condition characterized by recur­           catheter ablation.431 Contradictory results regarding potential associ­
rent pharyngeal collapse leading to repetitive interruption of ventilation        ation of alcohol consumption with substrate remodelling (atrial low
during sleep. It is increasingly recognized as a critical risk factor in a var­   voltage and conduction slowing) have been reported.459,463 The asso­
iety of cardiovascular conditions and has recently been shown to dou­             ciation of alcohol consumption with adverse postablation rhythm out­
ble the risk of incident AF.452 Both the acute effects of apnoeic episodes        come has also been validated in studies using objective markers of
and the chronic effects of long-term OSA contribute to the increased              alcohol use, such as ethyl glucuronide levels in hair, thus overcoming po­
risk of AF. The transient hypoxaemia associated with pharyngeal col­              tential bias in patient self-reporting.464
lapse is postulated to mediate changes in atrial ERP acutely and subse­               Several studies have evaluated the impact of alcohol abstinence on
quently to enhance susceptibility to AF induction and maintenance.453             clinical outcome after AF ablation either alone or in the context of a
In the long-term, OSA mediates significant hemodynamic changes re­                comprehensive risk factor management. Alcohol reduction of ≥1%
sulting in increased LA pressures and LA enlargement.454 Obstructive              from baseline to 1 year follow-up is independently associated with a
sleep apnoea is also known to induce a systemic inflammatory and pro-             lower risk of postablation arrhythmia recurrence.365 Therefore, it is
thrombotic state, which increase the likelihood of fibrotic changes and           reasonable to reduce alcohol consumption to fewer than 30 g/week
electrophysiological remodelling within the atria.455                             (three standard drinks) in individuals undergoing catheter ablation of
   Mounting evidence suggests that OSA is also associated with worse              AF as part of a comprehensive management of risk factors.353,354
outcomes following catheter ablation.358,359,428,429 Metaanalyses re­
port that patients with OSA have a significantly increased risk (ranging          5.1.5. Physical inactivity
from 25 to 70%) for AF recurrence following AF catheter abla­                     Physical activity and exercise are linked with cardiovascular health.
tion.359,428 Observational studies and metaanalyses concluded that                Increasing evidence supports that sedentary lifestyle increases the risk
the use of CPAP as a treatment strategy for OSA is associated with im­            of incident AF.465 Regular light-to-moderate exercise has been shown
proved patient outcome following ablation.456,457 A recent study in pa­           to reduce the risk of AF development.466 However, the relationship be­
tients with OSA and AF demonstrated that CPAP therapy reverses                    tween physical exercise and incident AF does not appear to be linear.
Catheter and surgical ablation of atrial fibrillation                                                                                                27


Several cohort studies have shown that exercise intensity has a              survival after ablation.364 Therefore, in the context of a multidisciplinary
U-shaped relationship with AF, with highly active subjects exhibiting in­    risk factor management approach, optimized glycaemic control should
creased risk of incident AF compared with moderately active indivi­          be set as a treatment objective in diabetic patients undergoing AF abla­
duals.466–468 Regular moderate-intensity exercise would, therefore,          tion to improve rhythm outcome.
appear to be the key in reducing the risk of AF.
   Physical activity is also important in secondary AF prevention. In the    5.1.7. Smoking
CARDIO-FIT study, cardiorespiratory fitness (a surrogate for physical ac­    Several long-term prospective observational cohort studies have iden­
tivity) measured by metabolic equivalents was associated with reduced        tified smoking as an independent predictor of incident AF.475–477 Most
AF burden and symptom severity in obese individuals with symptomatic         of these studies showed that the risk was higher in those who contin­
AF. Each unit increase in metabolic equivalent was associated with 13%       ued smoking compared with those who were able to quit. Proposed
decline in the risk of AF recurrence.469 In a recent prospective RCT         implicated mechanisms include increased sympathetic tone, oxidative
(ACTIVE-AF), implementation of a supervised exercise-based interven­         stress, inflammation, and atrial fibrosis. In the presence of AF, smoking
tion with progressively increased aerobic exercise up to 210 min per         increases the risk of thromboembolism and mortality, even after adjust­
week significantly reduced arrhythmia recurrence by 50% and improved         ing for well-recognized risk factors used in stroke risk stratification
symptom severity when compared with usual care.470                           schemes.478 In a matched case–control study including AF patients
   Several studies have evaluated the impact of physical activity and car­   with a low stroke risk (CHA2DS2-VASc score 0 in men or 1 in women),
diorespiratory fitness on clinical outcome following catheter ablation       smoking was the only independent predictor associated with ischemic
(see Supplementary material online, Table S1). Higher cardiorespiratory      stroke. These findings provide strong evidence that smoking cessation
fitness measured with the use of exercise stress test is associated with     should be an important part of AF risk factor management.479
reduced arrhythmia recurrence and mortality following ablation.423               There are limited data exploring the relationship between smoking
In the subgroup of highly trained athletes, several rather small observa­    and AF ablation. In a small study of 59 patients who underwent PVI,
tional studies have shown that catheter ablation is similarly effective as   smoking was associated with a three-fold relative risk of AF recur­
in the general population.424,426,471,472 The largest observational study    rence.432 In another retrospective study of persistent AF patients
in 144 athletes undergoing ablation found a similar arrhythmia recur­        undergoing ablation, smokers had a significantly higher incidence of
rence rate following PVI when compared with a matched cohort of              non-PV triggers compared with non-smokers without associated differ­
non-athletes.424 In a randomized study including persistent AF patients      ence in long-term ablation outcomes.366 Implementation of smoking
treated with AF ablation, participation of patients in an exercise-based     cessation in the context of a structured risk factor management pro­
cardiac rehabilitation programme improved exercise capacity after a          gramme significantly improves long-term outcome in symptomatic AF
6-month follow-up without associated reduction in AF recurrence              patients undergoing AF ablation.480
when compared with usual care.427 The latter finding may be due to in­
sufficient sample size and limited patient follow-up. Based on the exist­    5.1.8. Cardiovascular comorbidities
ing evidence, individuals undergoing catheter ablation of AF should          Cardiovascular disease contributes to the development of AF. There is
follow a training programme of at least moderate aerobic exercise            considerable evidence supporting the association of AF with HF and
for a minimum of 210 min per week to improve rhythm outcome.469              valvular heart disease. In patients with severe rheumatic mitral stenosis,
                                                                             reduction of chronic stretch after mitral commissurotomy results in
5.1.6. Diabetes mellitus                                                     reversal of atrial structural remodelling and associated conduction ab­
A number of studies have confirmed diabetes mellitus as an independ­         normalities.481 In HFrEF patients, HF-directed therapy reduces AF
ent risk factor for AF.473 Through increased production of reactive oxy­     recurrence, cardiovascular hospitalization, and mortality.482–484
gen species and advanced glycation end-products, diabetes has been           Although not specifically studied in the context of AF catheter ablation,
shown to result in fibrotic changes as well as ion channel and gap junc­     optimizing therapy directed at these underlying conditions, when
tion remodelling within the atria.474 These changes increase conduction      indicated, may improve AF ablation outcomes. Therefore, guideline-
heterogeneity, reduce conduction velocity, and prolong APD, promot­          recommended HF treatment should be undertaken in patients under­
ing an electrophysiological milieu that favours AF development.              going catheter ablation of AF.
   The association between diabetes mellitus and AF recurrence fol­
lowing ablation has been demonstrated in several studies. Metabolic          5.2. Preprocedural management
syndrome, which encompasses disorders of BP, fasting sugar state,            5.2.1. Preprocedural predictors of atrial fibrillation
body weight, and lipids, has been associated with poor AF catheter ab­       recurrences
lation outcomes.420–422 In a prospective study including 1496 patients
                                                                             Atrial fibrillation recurrence following catheter ablation is not uncom­
with non-paroxysmal AF undergoing catheter ablation, metabolic syn­
                                                                             mon and remains a notable problem.485 Several preprocedural factors
drome was associated with higher AF recurrence rates.422 In the
                                                                             are associated with increased risk of AF recurrences, including modifi­
German Ablation Registry, diabetic patients experienced a similar
                                                                             able comorbidities (Section 5.1.), AF type and duration, LA size, and ab­
rate of AF recurrence when compared with those without diabetes
                                                                             normal atrial substrate as detected by ECG and cardiac imaging.5
at 12 months of follow-up.414 In contrast, another observational study
                                                                             Consideration of these predictors of postablation rhythm outcome is
of 2504 patients undergoing AF ablation concluded, after propensity-
                                                                             important to drive patient selection for AF ablation.
matched analysis, that diabetes was an independent predictor of post­
ablation AF recurrence.415 Smaller observational studies have also
demonstrated the detrimental impact of diabetes mellitus on catheter         5.2.1.1. Atrial fibrillation type and duration
ablation outcome.416                                                         The association of AF type with postablation recurrence rates has been
   In addition, preablation glycaemic control has been shown to affect       widely investigated. Despite variation associated with the type and inten­
arrhythmia recurrences after ablation.364 Patients with glycated haemo­      sity of postablation rhythm monitoring, postablation arrhythmia recur­
globin (HbA1c) >9% were more than twice as likely to experience AF           rence rate is lower in patients with paroxysmal when compared with
recurrence following AF ablation compared with those with an HbA1c           those with persistent AF.243–245,366,486–490 Apart from AF type, the
< 7. In multivariate analysis, improved glycaemic control prior to abla­     time interval from AF diagnosis to ablation (DAT) is a predictor of post­
tion, defined as >10% reduction in HbA1c during the last 12 months           ablation AF recurrence.288,290,491–494 Each year increase in DAT in­
prior to ablation, was an independent predictor of arrhythmia-free           creases the risk of AF recurrence by 20% after adjustment for baseline
28                                                                                                                                            S. Tzeis et al.



comorbidities and medications.491 A metaanalysis of 6 observational                marker of local inflammation, was associated with increased risk of
studies with a total of 4950 patients demonstrated that DAT <1 year                AF recurrence in patients undergoing catheter ablation.521
was associated with a lower AF recurrence rate (relative risk: 0.73) com­             Preprocedural imaging may also be useful for anatomic modelling to
pared with DAT >1 year.288                                                         guide the ablation procedure. Though most patients have typical PV
                                                                                   anatomy (Section 3.1.), unusual PV variants (PV draining at the roof,
                                                                                   common trunk) occur and may influence choice of ablation approach
5.2.1.2. Left atrial size                                                          and modality (single shot vs. point-by-point ablation). While postabla­
Several studies showed that LA size is an independent preprocedural                tion imaging is no longer routinely performed to check for PV stenosis
predictor of AF recurrence following AF ablation.409,495–498 A linear re­          in the absence of symptoms, preprocedural imaging in patients who
lationship has been reported between the increase in LA anteroposterior            have undergone prior RF ablation may be reasonable to identify unrec­
diameter and the mean predicted proportion of patients with AF recur­              ognized significant stenosis and/or avoid ablation in areas of mild-
rence after AF ablation.409 Although linear LA measurements are widely             moderate PV narrowing.
used in everyday practice and clinical trials, they may underestimate LA
dilatation, since LA enlargement is asymmetric, mainly occurring in the            5.2.2. Preprocedural pharmacological treatment
medial-lateral and superior-inferior axes and to a lesser extent in the an­        5.2.2.1. Preprocedural anticoagulation
teroposterior axis, due to constrainment of the LA within the thoracic             Based on currently used stroke risk assessment that guides decision-
cavity. Left atrial volume is a more accurate indicator of LA size, and it         making on eligibility for antithrombotic treatment, patients with AF
has been shown to independently predict AF recurrence following cath­              and stroke risk factor(s) (CHA2DS2-VASc score ≥1 in males and ≥2
eter ablation in a metaanalysis of 13 studies.496 Left atrial dilatation is sug­   in females) who are scheduled for AF catheter ablation should receive
gestive of underlying atrial remodelling and correlates with AF                    oral anticoagulation therapeutically for at least 3 weeks prior to abla­
progression and presence of fibrosis (Section 2).91–93                             tion.9,522 This panel of experts shares the opinion that a minimum of
                                                                                   3-week therapeutic anticoagulation before AF catheter ablation is
                                                                                   also beneficial in patients with the lowest CHA2DS2-VASc score (0 in
5.2.1.3. Electrocardiographic predictors                                           males and 1 in females) if they are considered to have increased risk
Electrocardiography is a widely available and inexpensive tool for evalu­          of thrombus due to persistent AF type or specific underlying heart dis­
ation of atrial substrate.499,500 Several P-wave indices have been asso­           ease (HCM, rheumatic heart disease, and cardiac amyloidosis; Section
ciated with AF recurrences following catheter ablation.501–505 In a                5.2.3.1.).
recent metaanalysis of 14 studies with 1674 patients, maximal                         In the pre-DOAC era, several trials validated the superiority of per­
P-wave duration and P-wave dispersion were shown to predict posta­                 forming catheter ablation without warfarin interruption.381–383
blation AF recurrences.506 Prolonged P-wave duration on amplified                  COMPARE was a large, randomized trial that demonstrated that
12-lead surface ECG also correlates with the extent of LA low-voltage              undergoing AF ablation on uninterrupted vitamin K antagonist (VKA)
substrate, and a cutoff value ≥150 ms was shown to identify persistent             compared with VKA interruption and bridging with low molecular
AF patients at increased risk for arrhythmia recurrence following                  weight heparin (LMWH) resulted in a significantly lower incidence of
PVI.507,508 In addition, several signal-averaged P-wave parameters, in­            thromboembolic events and was associated with a lower minor bleed­
cluding total filtered P-wave duration, have been proposed to reflect              ing risk.384 Importantly, there was no increased incidence of major
the extent of underlying atrial remodelling and predict postablation               bleeding in the uninterrupted group. In the VENTURE-AF,
AF recurrences.499,500,509 However, signal-averaged ECG measure­                   RE-CIRCUIT, AXAFA-AFNET 5, and ELIMINATE-AF trials, patients
ments are rarely used in everyday practice.                                        undergoing AF ablation on uninterrupted rivaroxaban, dabigatran, apix­
                                                                                   aban, and edoxaban, respectively, were compared with patients under­
                                                                                   going AF ablation on uninterrupted warfarin.385–388 The primary
5.2.1.4. Preprocedural imaging of atrial structure                                 endpoint used in these studies varied slightly, as did the outcomes. In
Preprocedural documentation of atrial structural changes is useful to              the VENTURE-AF, the primary endpoint of major bleeding did not
identify patients with advanced atrial remodelling and AF progression,             differ between the rivaroxaban and warfarin groups385; in the
who are less likely to have a favourable response to catheter ablation.            RE-CIRCUIT, the primary endpoint of major bleeding occurred signifi­
Preprocedural imaging may provide relevant prognostic information                  cantly less frequently with dabigatran compared with warfarin386; in the
with implications for guiding selection of patients considered more suit­          AXAFA-AFNET 5 and the ELIMINATE-AF, the primary composite
able candidates for ablation. Atrial fibrosis is the primary structural            outcome of all-cause death, stroke, or major bleeding did not differ be­
change associated with atrial cardiomyopathy, AF progression, and per­             tween the DOAC (apixaban or edoxaban, respectively) and warfarin
sistence and can be detected and quantified by LGE-MRI.99,103,510–513 In           groups.387,388 Metaanalyses have documented a significant relative
the DECAAF study, the extent of preablation fibrosis as assessed by                risk reduction in major bleeding (50–55%) with uninterrupted
LGE-MRI was an independent predictor of arrhythmia recurrence fol­                 DOAC when compared with uninterrupted warfarin strategy at the
lowing AF catheter ablation.103 Implementation of this imaging modality            time of AF ablation.389,390 Taken together, these studies provide strong
requires experience in atrial LGE imaging and specific image sequences.            evidence in favour of the use of uninterrupted anticoagulation with ei­
Lack of reproducibility in atrial fibrosis assessment based on LGE meas­           ther DOACs or VKA during AF ablation procedures.
urement has limited its widespread adoption. Furthermore, discrepan­                  Several randomized trials have shown comparable efficacy and safety
cies have been reported in the extent and distribution of fibrotic areas           of a minimally interrupted DOAC anticoagulation strategy, skipping a
documented by LGE-MRI when compared with low-voltage areas iden­                   single dose at the day of the procedure, when compared with uninter­
tified during LA catheter-based mapping.106,514                                    rupted strategy.394–398 A recent metaanalysis including 2168 patients
    Cardiac computed tomography (CCT) may be used to quantify LA                   reported similar rate of adverse clinical events (major bleeding,
epicardial adipose tissue, which is related to AF recurrence after cath­           thromboembolic events) with minimally interrupted (holding morning
eter ablation. Several observational studies and a metaanalysis have               DOAC dose on the day of the procedure without any LMWH bridging)
shown that epicardial adipose tissue volume or thickness have a nega­              when compared with an uninterrupted DOAC strategy.523 However,
tive impact on AF ablation outcomes.515–519 Discrepant results have                there was no sign of lower bleeding rates with preprocedural DOAC
also been reported.520,521 In a retrospective observational study, en­             interruption.523 The randomized trials supporting the minimally (single
hanced attenuation of posterior LA adipose tissue, as an imaging                   dose) interrupted DOAC strategy had several limitations: most were
Catheter and surgical ablation of atrial fibrillation                                                                                                29


single-center, mainly performed in Asian populations, and the sample        anticoagulation for 3 weeks or longer prior to catheter ablation in
size was insufficient to document non-inferiority. It is though acknowl­    the presence of any of the following factors.
edged that conduction of an adequately powered randomized trial                High CHA2DS2-VASc score. In an early trial assessing the value of sys­
comparing the two preprocedural anticoagulation strategies based on         tematic screening with transesophageal echocardiography (TEE) before
standard sample size calculations is rather unrealistic due to a prohibi­   AF catheter ablation, the prevalence of thrombus or sludge was shown
tive sample size related to the very low event rate.                        to increase with increasing CHADS2 score.530 In a recent trial of con­
   A survey of the writing group showed that 47% of the members rou­        secutive DOAC-treated AF patients, higher CHA2DS2-VASc score sig­
tinely implement an uninterrupted anticoagulation strategy when per­        nificantly predicted the presence of TEE-detected LA thrombus before
forming AF catheter ablation, while 53% use a minimally interrupted         catheter ablation or scheduled electrical cardioversion.367 A recent
anticoagulation approach (single skipped DOAC dose).                        metaanalysis of 35 studies assessing the prevalence of LA thrombus in
                                                                            adequately anticoagulated patients with AF/AFl undergoing TEE before
                                                                            cardioversion or AF catheter ablation demonstrated a significantly high­
5.2.2.2. Preprocedural antiarrhythmic drug treatment                        er prevalence of LA thrombus in patients with CHA2DS2-VASc scores
Many patients undergoing AF ablation are already on prior AAD treat­        ≥3 when compared with those with scores ≤2 (6.3 vs. 1.1%, P <
ment when scheduled for AF ablation. Optimal handling of AAD before         0.001).368 Therefore, preprocedural imaging for thrombus exclusion
ablation has not been clarified. Observational data support that failure    may be a reasonable approach in patients with CHA2DS2-VASc score
of amiodarone to restore and maintain SR prior to AF ablation is not        ≥3 scheduled for AF catheter ablation even if adequately treated with
associated with poor procedural outcome.524 A retrospective observa­        therapeutic oral anticoagulation for at least 3 weeks.
tional study in 180 consecutive patients undergoing their first ablation       Persistent atrial fibrillation. Multiple anticoagulation trials have vali­
procedure demonstrated a similar rate of symptomatic AF recurrences         dated that persistent AF patients, even if adequately anticoagulated,
in patients undergoing ablation while taking AAD when compared with         are more likely to experience thromboembolic events when compared
those who were not on an AAD at the time of ablation, at 6 months and       with those with paroxysmal AF after adjustment for baseline vari­
at the end of follow-up (mean 24 months).525                                ables.328,369–371 In an older retrospective study of 1058 AF patients
   Prior trials of persistent AF ablation employing extensive substrate     undergoing systematic screening with TEE to rule out atrial thrombus
ablation evaluated the impact of AAD continuation on intraprocedural        before AF ablation, patients with persistent AF had a 3% incidence of
SR restoration and procedural outcome. In a retrospective study of          LAA thrombus when compared with 0.5% in patients with paroxysmal
persistent AF patients undergoing a stepwise AF ablation,                   AF presenting in normal SR.530 In a multicenter retrospective study of
preprocedural amiodarone prolonged AF cycle length during catheter          414 consecutive AF patients undergoing TEE before scheduled electric­
ablation and reduced substrate ablation needed to achieve SR without        al cardioversion or ablation, LAA thrombus was documented in 15 pa­
favourable impact on long-term outcome.526 A multicenter prospective        tients and 93.3% of those had persistent AF.367 In a recent prospective
randomized study of long-standing persistent AF patients on                 registry, 900 patients with at least 3 weeks of prior uninterrupted
amiodarone therapy undergoing PVI plus substrate ablation also de­          therapeutic anticoagulation underwent AF ablation without any type
monstrated that amiodarone continuation during ablation significantly       of imaging screening. In total, four (0.32%) thromboembolic complica­
reduced the procedure, RF, and fluoroscopy times.527 However, amio­         tions were documented, and all occurred in patients with persistent
darone continuation was associated with significantly increased late re­    AF.529 In a recent metaanalysis of 14 653 adequately anticoagulated pa­
currence rates, which was attributed to AAD-mediated masking of             tients with AF/AFl undergoing TEE before cardioversion or AF catheter
non-PV triggers.527 In the absence of definitive evidence suggesting an     ablation, non-paroxysmal AF was associated with a four-fold higher LA
impact of AAD continuation at the time of AF ablation on procedural         thrombus prevalence when compared with paroxysmal AF.368 Based
outcome, pertinent recommendations cannot be issued.                        on the abovementioned evidence, persistent AF patients have an in­
                                                                            creased risk of LA thrombus irrespective of their anticoagulation status.
5.2.3. Imaging for exclusion of thrombus                                       Hypertrophic cardiomyopathy—rheumatic heart disease—cardiac
5.2.3.1. Candidates for thrombus screening prior to ablation                amyloidosis. Atrial fibrillation patients with HCM have significantly
The presence of atrial thrombus is a contraindication for catheter          higher incidence of ischemic stroke compared with those without
ablation due to associated risk of procedural thromboembolic com­           HCM.372 Hypertrophic cardiomyopathy patients with AF categorized
plications. In this context, patients undergoing catheter ablation          as low risk based on their CHA2DS2-VASc score (0 in men or 1 in wo­
should be screened to rule out the presence of thrombus. A survey           men) have a significantly greater stroke risk than AF patients without
of the writing group showed that 59% of the members routinely               HCM and a CHA2DS2-VASc score of 2.372 In a large cohort of patients
employ imaging for thrombus exclusion in all patients undergoing            with AF undergoing TEE, HCM patients had a significantly higher risk of
AF ablation irrespective of presenting rhythm, AF type, and prior           LA thrombus than matched control subjects (8.8 vs. 4.1%; P < 0.001)
anticoagulation. However, the adoption of uninterrupted peri                despite high rates of anticoagulation at the time of TEE and continuous­
procedural anticoagulation strategy has reduced substantially the           ly for 1 month prior.380
rate of periprocedural stroke thus calling into question the need              Several small observational studies have shown that patients with
for routine screening of all patients undergoing AF ablation.399,528,529    rheumatic mitral stenosis have a substantially increased incidence of
Furthermore, several baseline factors increase the risk of thrombus         LA thrombus as documented by TEE even when in SR, varying from
detection and/or procedural thromboembolic event, supporting the            2.4 to 25%.373–375
adoption of a selective, individualized strategy of thrombus surveil­          Patients with cardiac amyloidosis have an increased incidence of in­
lance in patients undergoing AF ablation.                                   tracardiac thrombus, even in the absence of AF/AFl, due to the amyloid
   The writing group suggests that imaging for thrombus exclusion is        infiltration, which results in atrial enlargement, mechanical dysfunction,
reasonable in patients who are considered eligible for anticoagulation      and blood stasis.376,377 In a series of 116 autopsies, intracardiac throm­
before AF catheter ablation (CHA2DS2-VASc score ≥1 in males and             bus was identified in 33% of amyloidosis cases, with AL amyloidosis and
≥2 in females, persistent AF, HCM, cardiac amyloidosis, or rheumatic        AF being independently associated with thromboembolism.376 In a
heart disease—see below) but have not received anticoagulation thera­       single-center, retrospective analysis of patients referred for elective dir­
peutically for 3 weeks or longer.                                           ect cardioversion for atrial arrhythmias, patients with cardiac amyloid­
   In the context of maximizing procedural safety, screening for throm­     osis had 10 times higher rate of TEE-documented LA/LAA thrombus
bus may be reasonable even if patients have received therapeutic            when compared with a matched cohort (28.5 vs. 2.5%) even if
30                                                                                                                                         S. Tzeis et al.



anticoagulated for ≥3 weeks before TEE.378 In a more recent observa­             Intracardiac echocardiography. Intracardiac echocardiography (ICE) is
tional study, LA thrombus was present in 14% of patients with cardiac         increasingly used as an alternative to TEE for exclusion of LAA throm­
amyloidosis referred for electrical cardioversion, despite prior anticoa­     bus at the time of AF ablation.400 In an early study comparing ICE with
gulation, mainly with DOACs.379                                               TEE in patients undergoing AFl ablation, ICE showed very high correl­
   Based on the abovementioned evidence, patients with HCM, rheum­            ation with TEE for detection of LA stunning.401 Since then, several pro­
atic heart disease, or cardiac amyloidosis are considered as high risk for    spective studies comparing ICE with TEE for detection of LAA and/or
stroke, and therefore, routine preprocedural screening for thrombus           LA thrombus have indicated that ICE is as effective as TEE.402,403 The
exclusion may be reasonable irrespective of their CHA2DS2-VASc                ICE-CHIP study compared ICE with TEE and observed a non-significant
score or previous anticoagulation.                                            trend to increased thrombus detection with TEE.404 However, ICE im­
                                                                              aging was performed from the RA, and it is now well-established that
                                                                              optimal LAA views are obtained when the ICE catheter is positioned
5.2.3.2 Imaging modalities for thrombus exclusion                             in the right ventricle or the pulmonary artery.405 Intracardiac echocar­
Several imaging modalities may be used for exclusion of atrial thrombus       diography may also have a role for LA thrombus screening after a re­
in patients undergoing AF ablation. The selection of a particular imaging     cent equivocal or even negative TEE in patients undergoing AF
tool is based on patient’s characteristics, physician preference and ex­      ablation.405 In a prospective multicenter registry of 6186 patients
pertise, institutional availabilities, and cost. Available options are dis­   undergoing AF ablation on uninterrupted DOAC anticoagulation, ICE
cussed below.                                                                 was used to screen for LA/LAA thrombi. In this population with
   Transesophageal echocardiography. Transesophageal echocardiog­             mean CHAD2S2-VASc score of 2.9, no thrombi were observed and
raphy has long been used in the preablation setting since it enables re­      only one TIA occurred.399 In practices familiar with ICE, it is reasonable
liable exclusion of atrial thrombus and assessment of LA size, functional     to use ICE, with imaging from the RV inflow tract or pulmonary artery,
parameters, and valvular disorders. In an early large prospective intrao­     instead of TEE to screen for LA/LAA thrombi prior to ablation. Since
perative study, TEE had a sensitivity and specificity of 100 and 99%, re­     ICE may be used at some centers to guide transseptal puncture and
spectively, for identifying atrial thrombi when compared with direct          monitor for complications, use of ICE to screen for thrombi may
visual inspection of LA content.531 However, TEE is a semi-invasive pro­      save procedural time and cost (compared with additional TEE or
cedure requiring sedation and esophageal intubation, occasionally lim­        CCT performance).
ited by subjective estimates, and is not devoid of complications                 A survey of the writing group showed that 59% of the writing group
(0.18–2.8%), which may be associated with major morbidity (0.2%)              members mainly use TEE for exclusion of LA thrombus, 18% use ICE,
and rarely mortality (<0.01–0.02%).532,533 Transesophageal echocardi­         and 23% use cardiac CT.
ography prior to the ablation procedure may lengthen the procedure
and general anesthesia time, while it can prove helpful in guiding trans­
septal puncture.                                                              6. Mapping and ablation tools for
   Cardiac computed tomography. Delayed phase CCT is a useful and re­
liable imaging modality for exclusion of atrial thrombus. Incorporation
                                                                              atrial fibrillation catheter ablation
of late acquisition protocols reduces false-positive rates by providing a
time delay to allow enhanced LAA contrast opacification and differen­         6.1. Mapping tools
tiate whether a low attenuation region is due to thrombus or circula­         6.1.1. Invasive mapping tools
tory stasis and low blood flow. A metaanalysis of 22 studies                  6.1.1.1. Electroanatomical contact mapping
demonstrated that CCT had a sensitivity and specificity of 0.99 and           Mapping and ablation require precise navigation within the chamber of
0.94, respectively, vs. TEE.407 Delayed imaging CCT protocols signifi­        interest. Electroanatomical mapping (EAM) systems allow for 3D visu­
cantly improved specificity when compared with early imaging proto­           alization of the anatomy of any heart chamber, delineation of AT/AFL
cols.406,407 A recent prospective cohort analysis evaluating optimal          circuits, catheter positioning, and catheter manipulation without use
time delay for late phase CCT protocols demonstrated that even a              of fluoroscopy. Accurate anatomical reconstruction of the 3D shell
3-min delay may be associated with false-positive results, while a            of the chamber of interest is of the utmost importance. However, inac­
6-min delayed acquisition protocol is optimal due to associated 100%          curacies are caused by continuous motion of the heart, patient breath­
specificity.408 Related disadvantages include (i) the risk of                 ing, and body movement. All available EAM systems have a set of
contrast-induced nephropathy, which is low in patients with normal re­        algorithms to account for movement (including respiratory gating).
nal function and reversible in most cases, and (ii) the related radiation     Mapping can be performed either with point-by-point acquisition using
exposure, which is though relatively low (<3 mSv) with contemporary           the ablation catheter or more frequently using dedicated multi
technology computed tomography (CT) scans.406,534,535                         electrode catheters.
   Another prerequisite for recommending CCT for exclusion of atrial             In general, there are two types of EAM systems. Impedance-based
thrombus prior to AF ablation is its performance within 48 h prior to         systems utilize a transthoracic electrical field for catheter localization,
ablation to prevent the likelihood of de novo thrombus formation in           which is created by surface patch electrodes that emit high-frequency
the waiting period between screening and ablation.                            electrical signal in three orthogonal axes. Drawbacks include that the
   Cardiac magnetic resonance imaging. Cardiac MRI enables imaging of         field is non-linear, impedance is affected by changes in tissue properties,
atrial anatomical features and structural changes that are important          and the co-ordinate system (patches) can move. Magnetic field–based
for procedural planning (Section 5.2.1.4.). It also has a favourable diag­    systems, on the other hand, are not affected by tissue differences and
nostic performance for assessment of atrial thrombus.536–538 A recent         are inherently linear and stable over time. Magnetic sensors are needed
metaanalysis of four CMR studies reported a sensitivity and specificity       to visualize catheters, so map creation is only possible with sensor-
of 0.80 and 0.98, respectively, when compared with TEE.407 However,           enabled catheters. The co-ordinate system is often linked to the fluor­
the existing trials supporting the role of CMR for thrombus exclusion         oscopy unit under the patient and can be distorted by metal (bed, flat
are limited, single-center, rather small in number, heterogeneous in          detector, ICDs, etc.).
type of MRI sequence used, and with uncertain reproducibility.                   Several EAM systems are currently on the market. The CARTO 3
Large-scale studies with standardized and consistent CMR protocols            (Biosense Webster, Irvine, CA, USA) is a hybrid system, which uses
are needed to support the value of MRI as reasonable imaging option           magnetic technology for localization of dedicated mapping and ablation
for exclusion of atrial thrombus in the preablation setting.                  catheters and current-based technology for visualization of electrodes
Catheter and surgical ablation of atrial fibrillation                                                                                                   31




                            Advisor HD                                                                                                 Intellamap
          Catheter                            Reflexion HD         Lasso          Pentaray          Octaray            Optrell
                               Grid                                                                                                       Orion



                                                                  Biosense       Biosense          Biosense           Biosense           Boston
         Company              Abbott             Abbott
                                                                  Webster        Webster           Webster            Webster           Scientific




          Catheter
           figure




        Number of
                                 16                 20             10–20             22                48                48                64
        electrodes


                                                               4.5 mm (15 mm)
                                                               6.0 mm (20 mm)
                                                                                                 3–3–3–3–3 mm
         Electrode                                             8.0 mm (25 mm)    4–4–4 mm
                               3 mm            2–7–2 mm                                          2–2–2–2–2 mm         2.4 mm             2.5 mm
          spacing                                                 2–6–2 mm       2–6–2 mm        2–5–2–5–2 mm
                                                                   (variable
                                                                  15–25 mm)

                                                 1 mm
           Size of                                                                                                    0.46 mm
         electrodes
                               1 mm            (except tip          1 mm          0.76 mm           0.46 mm
                                                                                                                      0.9 mm2           0.4 mm2
                                             which is 2 mm)


  Figure 9 Multielectrode mapping catheters.




and shaft of other electrophysiology catheters. Integration of ICE into          Furthermore, mapping catheters now have multiple bipoles with smal­
the CARTO mapping system (CARTOSOUND, Biosense Webster)                          ler electrodes for signal recording, allowing faster acquisition of high-
enables the construction of the 3D shell of the chamber of interest              quality signals (Figure 9). Synthesizing all this information from multiple
from a series of ICE-acquired chamber contours with associated reduc­            electrograms requires mathematical algorithms, which automate elec­
tion in fluoroscopy time even to zero.539,540                                    trogram annotation and timing.
   The Ensite NavX (Precision) EAM system (Abbott, Chicago, IL, USA)                Newer modules are helping operators to delineate complex tachy­
uses both voltage and impedance data for localization of proprietary             cardias. A new module in the latest CARTO 3 platform provides an al­
and non-proprietary mapping and ablation catheters. In addition, the             gorithm, which computes conduction velocity based on collected
system integrates magnetic information for dynamic optimization of               electrograms and applies a global best-fit solution when displaying
3D models (field scaling) when sensor-enabled catheters are used.                wave propagation (Coherent Mapping).541 Activation direction map­
The latest generation of the Ensite NavX (Ensite X) EAM system                   ping in the latest generation EnSite X system uses ‘omnipolar’ EGMs
uses magnetic-based data from sensor-enabled catheters to create                 correcting for voltage differences caused by directionality of the elec­
3D maps, also maintaining the option to rely on impedance data for               trical wavefront in relation to the mapping electrodes. Using these cor­
map creation and catheter visualization.                                         rected electrograms, the system can compute a beat-by-beat vector
   The Rhythmia system (Boston Scientific, Marlborough, MA, USA)                 direction of the wavefront and present the information in a propagation
uses a combination of magnetic and impedance-based location technol­             map.542 The incremental value of both coherent and omnipolar map­
ogy and allows for automated high-density mapping using a dedicated              ping in the management of complex atrial tachyarrhythmias needs to
steerable 64-electrode mini basket catheter (Figure 9).                          be proven in prospective studies.
   Multimodality approaches allow for image integration of pre-                     Electroanatomical mapping systems have attempted to incorporate
acquired CCTs and MRIs with real-time 3D EAM maps or ICE imaging.                algorithms for mapping persistent AF. CARTOFINDER is an algorithm
Accuracy is critically dependent on fusion quality (including the use of         used to map focal and rotational sources during AF, with clinical trials
fiducial points in both images). In addition, 3D rotational angiography          pending.543–545 Both CARTO and Ensite include optional algorithms
images can be merged with live two-dimensional fluoroscopy and                   for automated detection of complex fractionated atrial electrograms
thus obviate the need for pre-interventional imaging. The quality of             (CFAE) during AF and tagging of respective areas on the 3D anatomical
EAM acquired with multielectrode catheters has generally reduced                 map. Other algorithms are in development (Section 6.4.).
the need for fusion with pre-acquired images due to the higher reso­                The evolution of ablation indicators (Section 8.1.2.2.) incorporating
lution of the former and errors associated with the latter.                      power, ablation duration, and contact force (CF) in one formula to assess
   The quality of electrogram acquisition is crucial for accurate annota­        lesion quality has further leveraged EAM systems. Radiofrequency-based
tion of signals, particularly in low-voltage areas and diseased atrial tissue.   ablation incorporating CF-sensing ablation catheters combined with
32                                                                                                                                              S. Tzeis et al.



quality lesion indicators allows for automated tagging of ablation points        Several studies have shown promising results regarding the efficacy and
to interactively review the position and quality of RF lesions.                  safety of AF ablation guided by spatiotemporal electrogram disper­
   Using EAM systems has proven to reduce fluoroscopic duration and              sion.567–569 Seitz et al. described an ablation approach where regions
dose.546–548 However, studies assessing the clinical benefit of safety and       displaying spatiotemporal ‘dispersion’ were targeted.567 Dispersion
efficacy in various arrhythmias have initially shown mixed results.549–553       areas were visually identified and defined as clusters of electrograms,
The implementation of the CLOSE protocol in RF-based AF catheter                 either fractionated or non-fractionated, that displayed interelectrode
ablation has proven both effective and safe554–559 and consequently              time and space dispersion at a minimum of three adjacent bipoles
standardized the PVI procedure using the CARTO mapping system                    such that activation spans the AF cycle length. These electrograms
(Section 8.1.2.2.).                                                              could be continuously fractionated, burst fractionated, or of very rapid
   The cost of the ablation procedure is inevitably increased when using         cycle length. Areas displaying spatiotemporal electrogram dispersion
EAM systems with high complexity (multipolar catheters, mapping sys­             can be identified either manually or automatically with the use of ma­
tem upgrades). This cost needs to be weighed against the benefits de­            chine and deep learning algorithms (VOLTA VX1) that perform real-
scribed above. However, the future role of 3D EAM systems in PVI                 time analysis of electrograms recorded by multipolar catheters
procedures using single-shot or large footprint ablation catheters is            and then annotate areas of interest on the 3D anatomical shell, which
at present unclear.                                                              represent potential ablation targets.570 The TAILORED AF trial
                                                                                 (NCT04702451) is comparing an ablation strategy targeting areas of
6.1.1.2. Non-contact mapping                                                     spatiotemporal dispersion identified with the use of this artificial intel­
                                                                                 ligence software algorithm in combination with PVI to PVI alone in pa­
Most EAM systems require contact between the mapping catheter and
                                                                                 tients with persistent AF and will provide further data on the efficacy of
cardiac tissue to accurately record cardiac potentials. It is difficult, how­
                                                                                 this approach. Stability and reproducibility of identified target sites dis­
ever, to achieve stable, complete contact of multipolar or even single
                                                                                 playing spatiotemporal dispersion needs to be documented.
point catheters on the cardiac surface, and therefore, interpolation al­
gorithms are required to smooth out the electrical data collected. This          6.1.2. Non-invasive mapping tools
limits both the spatial and temporal accuracy of such recordings and can         6.1.2.1. Electrocardiographic imaging
obscure finer, detailed patterns of activation. It is also difficult to obtain
                                                                                 In recent years, a drive towards better understanding of AF mechan­
a global, instantaneous, panoramic view of a chamber’s activation se­
                                                                                 isms has resulted in the emergence of new forms of AF mapping tech­
quence when recordings of the various chamber segments are col­
                                                                                 nology, which employ the principle of phase mapping, a mathematical
lected sequentially in a stepwise fashion.
                                                                                 approach for the assessment of spatial and temporal periodicity in
   Non-contact mapping utilizes a large, multipolar catheter positioned
                                                                                 tissue electrical activity and identification of periodic rotations or
within the chamber of interest to record global far-field and near-field
                                                                                 ‘rotors’.571 Optical mapping work in animal models provides compelling
unipolar electrograms. These electrograms are then typically fed into a
                                                                                 evidence for the existence of rotors and their role in AF perpetuation,
mathematical algorithm, which can interpolate and extrapolate global
                                                                                 and these insights served as the basis for clinical translation to AF
activation based on the ‘ground-truth’ of the recorded unipoles.560
                                                                                 mapping.572
The resulting activation patterns can then be projected onto a map
                                                                                     Electrocardiographic imaging or ECGI mapping is a non-invasive
surface.
                                                                                 phase-mapping approach, which utilizes a 252-body surface electrode ar­
   One system (AQMap, Acutus Medical) utilizes a multi-splined, 48
                                                                                 ray and patient-specific heart-torso geometries to display virtual cardiac
electrode catheter, equipped with ultrasound transducers for recon­
                                                                                 potentials on the epicardial surface. Activation mapping in AF allows iden­
struction of the anatomic surface, which records unipolar electrograms
                                                                                 tification of reentrant and focal activities generated from unipolar elec­
and then uses an inverse algorithm to calculate the ‘charge density’ on
                                                                                 trograms combined with phase-mapping analysis. Potential advantages
each point of the map surface.560 Charge density is calculated from the
                                                                                 over conventional invasive mapping systems include non-invasive, simul­
local unipolar voltage but filters out putative far-field effects to provide
                                                                                 taneous, global characterization of biatrial electrical activity, albeit at a
a higher resolution local electrical activation. Early results have sug­
                                                                                 lower mapping resolution.573 Three-dimensional imaging acquisition is
gested that complex atrial activations during AF can be identified, but
                                                                                 central to the technique for generation of individualized anatomical mod­
the additive effect of targeting these activations in the persistent AF ab­
                                                                                 els of the atria and torso volume conductor. Computed tomography im­
lation strategy is not well-established.561 Furthermore, the system loses
                                                                                 aging is most commonly utilized due to its speed, widespread availability,
accuracy when the cardiac surface of interest is 40 mm or more from
                                                                                 and high-resolution imaging with the obvious disadvantage of exposure
the catheter.562
                                                                                 to ionizing radiation.574 Magnetic resonance imaging provides better
   Electrographic flow mapping (Ablamap, Ablacon) utilizes a large bas­
                                                                                 soft tissue delineation albeit at a lower resolution, while eliminating radi­
ket catheter to record unipolar electrograms, which are then interpo­
                                                                                 ation risk.512 However, higher costs and longer scan times limit its applic­
lated and processed into a beat-by-beat electrical intensity map.563 As
                                                                                 ability. The recently developed imageless ECGI overcomes the need for
the electrical intensity changes beat-by-beat in AF, the Horn–Schunk it­
                                                                                 CT or MRI imaging by estimating the cardiac geometry and location inside
erative algorithm calculates the flow pattern seen during AF over time.
                                                                                 the patient’s thorax based on electrical, statistical, and thoracic geomet­
Regions with divergent flow patterns can be labelled as ‘sources’, which
                                                                                 rical information.575
can then be targeted for ablation. The recently announced FLOW-AF
                                                                                     The ECGI technique was first applied in a study of continuous biatrial
trial randomized persistent or long-standing persistent AF patients with
                                                                                 activation mapping validated against invasively generated electroanato­
recurrent, symptomatic AF despite at least one prior AF ablation pro­
                                                                                 mical maps.576 In this study, multiple concurrent wavelets were identi­
cedure to PVI plus electrographic flow-guided source ablation or to PVI
                                                                                 fied as the most common pattern of activation and ablation near
only. Adjunctive ablation of electrographic flow sources resulted in sig­
                                                                                 ECGI-identified critical sites resulted in restoration of SR. Using com­
nificant improvement in 1 year freedom from AF.564
                                                                                 mercially available mapping systems, unstable reentry circuits with vary­
                                                                                 ing spatiotemporal activity were described as the predominant
6.1.1.3. Spatiotemporal dispersion mapping                                       sustaining mechanism in persistent AF patients.577,578 In patients with
Mapping and ablation of regions exhibiting CFAEs was pioneered many              ablation-induced AF termination, arrhythmia-free survival was 85% at
years ago by the work of Nademanee et al.565 However, the STAR-AF II             1 year.577 In the AFACART study, an ablation strategy consisting of tar­
trial did not show an incremental benefit in rhythm outcome when                 geted ablation of AF drivers and PVI, followed by LA linear ablation if AF
CFAE ablation was performed in addition to PVI during AF ablation.566            persisted, resulted in 77% freedom from AF at 1 year in a cohort of
Catheter and surgical ablation of atrial fibrillation                                                                                                  33


persistent AF patients with continuous AF duration less than 1 year.579        the former resulted in significantly shorter time to achieve PVI, higher
Driver-only ablation resulted in AF termination in 64% of patients.579         freedom from arrhythmias at 12 months, and a trend towards in­
The TARGET-AF1 trial reported a 65% freedom from recurrent                     creased asymptomatic cerebral emboli.600 Furthermore, power-
AF/AT at 1 year in persistent AF patients undergoing PVI plus                  controlled ablation at 70 W over 5–7 s is associated with significantly
ECGI-guided ablation with a high rate of AF termination during driver          greater procedural efficiency, fewer AF recurrences, and a similar safety
ablation.580                                                                   profile to conventional power protocol (30–40 W for 20–40 s).601,602
    More recently, ECGI findings indicative of AF complexity, including        The absence of use of AI or LSI to standardize the lesion set in these
number, distribution, and density pattern of AF reentrant sites, have          latter studies may limit the reproducibility of the results. Care should
been associated with AF termination during ablation.581,582 The on­            be exercised using higher power at the posterior wall due to potential
going STRATIFY trial will further evaluate the role of ECGI-based as­          inadvertent overshoot and ‘heat stacking’ when applying consecutive le­
sessment of AF complexity for prediction of ablation efficacy                  sions in close proximity, although it is also possible that a high-power
(NCT04578275).                                                                 short-duration (HPSD) protocol may be safer over the esophagus
    Inherent limitations of ECGI relate to electrode density and mapping       due to less depth of penetration (Section 11.3.1.).599,603 Based on re­
resolution. Transformation of electrograms using phase-mapping is a            cent RCT findings, HPSD ablation may be associated with increased
complex process, and an obvious disadvantage is the limited ability            risk of asymptomatic cerebral emboli (Section 11.2.3.).
for raw signal analysis by the operator prior to transformation. In add­          The reduced accuracy of tissue temperature feedback during high-
ition, ECGI mapping is costly and time consuming. Finally, the lack of a       power irrigated ablation has led to the development of novel catheters
gold standard for validating the existence of rotors/drivers and conflict­     equipped with multiple thermocouples capable of accurate, real-time
ing results using ECGI vs. other phase-mapping approaches have fuelled         tissue temperature monitoring, allowing RF delivery in temperature-
scepticism about validity and reproducibility.571,577,578                      controlled mode using low irrigation flow rates (QDOT Micro,
    Nevertheless, ECGI remains the only modality capable of simultan­          Biosense Webster; DiamondTemp, Medtronic). The randomized
eous biatrial electrical characterization in AF. Further assessment in ran­    DIAMOND-AF study demonstrated similar safety and efficacy of the
domized trials as well as technological improvements to streamline             DiamondTemp ablation system compared with standard CF-guided ab­
workflows is needed before it can be incorporated as a valid tool in           lation with higher overall power delivery and reduced procedure times
the routine invasive management of AF patients.                                using temperature-controlled ablation.604 The CF-sensing QDOT cath­
                                                                               eter is capable of energy delivery of up to 50 W in ‘QMODE’ with a re­
6.1.2.2. Magnetic resonance imaging fibrosis guidance                          cent study supporting the safety and efficacy of this modality with a
                                                                               first-pass isolation rate of 92% and no esophageal injury on post
Magnetic resonance imaging has been used to identify areas of atrial fi­
                                                                               procedural endoscopy.605 Furthermore, this catheter is capable of
brosis in patients scheduled for AF catheter ablation.105,583,584
                                                                               very high power delivery at 90 W over 4 s (QMODE+). Several pre-
However, adequate spatial resolution remains problematic in the thin-
                                                                               clinical studies report a predominant resistive form of tissue heating
walled LA, and reproducibility of the different imaging techniques
                                                                               with 90 W/4 s ablation with a high rate of contiguity and transmural­
across centers remains low (Section 5.2.1.4.). Several RCTs have failed
                                                                               ity.592,606–608 In contrast, in a recent canine study, lesion size was smal­
to document that ablation of MRI-detected fibrotic areas provides in­
                                                                               lest with RF applications at 90 W/4 s, followed by 50 W/10 s and
cremental benefit in postablation rhythm outcome (Section 8.2.6.).
                                                                               greatest with 30 W/30 s.609 The QDOT-FAST study demonstrated
                                                                               the feasibility and safety of 90 W/4 s ablation in paroxysmal AF patients
6.2. Ablation tools                                                            undergoing PVI.610 The safety profile of this ablation workflow was fur­
6.2.1. Radiofrequency ablation                                                 ther supported in a study showing lack of esophageal injury.611 More
Radiofrequency catheter ablation is a widely employed thermal-based            recently, a small non-randomized study reported significantly reduced
technique with documented beneficial effect on rhythm outcome                  procedural times with 90 W/4 s vs conventional 25–40 W ablation
when compared with medical therapy in paroxysmal and persistent                with a similar safety profile.612 In contrast, a further comparative study
AF patients.236–238 Initial studies reported on PVI using non-irrigated        suggested an overall similar procedure time (with time being lost due to
catheters with RF delivery in temperature-controlled mode. Since the           a lower rate of first-pass isolation with 90 W/4 s ablation protocol).606
introduction of irrigated catheters, RF is most often delivered in power-      In the multicenter randomized POWER PLUS trial, first-time PVI with
controlled mode with conventional power settings between 20 and                very HPSD (90 W/4 s) RF ablation resulted in a significant but modest
40 W. The positive impact of CF measurement on procedural and                  reduction in procedure time with similar safety and 6-month arrhyth­
RF time and recurrence rates585–588 has resulted in the adoption and           mia recurrence rate when compared with 35/50 W AI-guided conven­
widespread use of irrigated CF-sensing catheters and additionally facili­      tional ablation.613 Furthermore, despite the potential of HPSD ablation
tated the development of algorithms aimed at real-time assessment of           to alleviate the issue of catheter instability, when it does occur it may
lesion quality including the force time integral (FTI),589 lesion size index   have a greater impact on lesion formation particularly in areas of in­
(LSI),590 and ablation index (AI)558,591 (Section 8.1.2.2.). Within the last   creased tissue thickness such as the carina.
years, the employment of point-by-point workflows using CF-sensing                In summary, contiguous, point-by-point RF ablation for PVI has
catheters and focusing on optimized and contiguous lesions has re­             evolved into a clinically safe and efficacious procedure. With high-power
sulted in improved outcomes for paroxysmal AF, with high first-pass            or very high-power ablation (in temperature-controlled or power-
isolation rates and 1 year success rates.554,555,558,559                       controlled mode), procedural times of close to or less than one hour
   More recently, focus has centered on enhanced lesion formation for          are achievable with similar safety and efficacy profiles.596,606 In the ab­
durable PVI, with increased power delivery proposed to improve lesion          sence of definite randomized data on long-term outcomes, the decision
quality and reduce procedure times. Experimental studies have demon­           to opt for novel higher power strategies may come down to operator
strated shallower and wider lesions with higher power and shorter dur­         preference or patient profile (shorter procedure times are preferable
ation lesions,592,593 and several clinical studies have underscored the        in awake patients, whereas low fluid delivery may be advantageous in pa­
enhanced procedural efficiency and preserved safety profile associated         tients with HF). Large-scale randomized trials are needed to determine
with 40–50 W ablation in power-controlled mode.594–599 In a recent             the long-term efficacy of such novel strategies.
small RCT comparing high-power (50 W) vs. standard power (30 W                    A multielectrode RF balloon catheter (HELIOSTAR, Biosense
anterior/25 W posterior wall) RF ablation in patients undergoing PVI,          Webster) has also been used for PVI.614 This single-shot ablation device
34                                                                                                                                              S. Tzeis et al.



is compatible with a 3D EAM system (CARTO) and is equipped with 10              arrhythmia recurrence at 12 months was similar in both groups, but
irrigated, flexible electrodes that independently deliver RF energy, thus       the use of the POLARx balloon resulted in significantly higher rate of
allowing customization of energy delivery in a focal, segmental, or cir­        PN palsies that did not recover within 24 h.627
cumferential approach. Furthermore, the use of an integrated,                      The FIRE AND ICE trial compared energy modalities for AF ablation
intraluminal, circular diagnostic catheter enables real-time recording          and randomized 762 patients with drug-refractory paroxysmal AF to
of PV electrograms. Observational studies have demonstrated that                treatment with either the second-generation cryoballoon or conven­
PVI with this multielectrode RF balloon catheter may have favourable            tional RF using a prospective multicenter design. The study showed
safety and effectiveness in paroxysmal AF patients.615–618                      cryoballoon ablation to be non-inferior to RF ablation with respect
    Another recent development in the field of RF ablation is a larger          to its primary endpoints of efficacy and safety and reported a possible
footprint, single-tip ablation device. Instead of a 3–4 mm, irrigated ter­      reduction in re-hospitalization or reablation in secondary ana­
minal tip, this catheter employs a lattice spherical structure, which is        lyses.294,628 Phrenic nerve injury was the most commonly reported
9 mm in diameter, and the surface of the sphere contains nine mini-             complication at discharge in the cryoballoon ablation group (2.7%).
electrodes (0.7 mm), which also contain thermocouples.619 The system            Permanent PN palsy was reported in 0.3% of patients. More recently,
delivers temperature-controlled, contact sensing–facilitated RF with sa­        the CIRCA-DOSE trial evaluated contemporary approaches to PVI
line irrigation sprayed from the center of the catheter, which does not         using latest generation technology in both the cryoballoon ablation as
impact temperature sensing at the surface of the catheter in contact            well as the RF ablation arms using an ICM for postablation rhythm mon­
with the tissue. The system delivers high-current RF to achieve a uni­          itoring.622 In this trial, no difference in 1 year efficacy (freedom from at­
form current cloud on the lattice spherical surface.619 In an initial pilot     rial tachyarrhythmia) was confirmed between the compared groups,
study, the system demonstrated a very high incidence of durable PVI             whereas continuous monitoring showed median AF burden reduction
and linear lesion block.619 The system has also incorporated PFA offer­         of >99% with both ablation technologies.
ing versatility in type of delivered energy.620
                                                                                6.2.2.2. Ultra-low temperature cryoablation
6.2.2. Cryoablation and ultra-low temperature                                   An innovative approach using highly compressed liquid nitrogen allows
cryoablation                                                                    a change from the liquid to the gaseous phase without the associated
6.2.2.1. Conventional cryoballoon technologies                                  volume expansion and thus without the associated problems of vapour
Cryotherapy, or the use of freezing temperatures to elicit a specific tis­      lock when using liquid nitrogen in closed circuit catheters.629 The impli­
sue response, has a long history of safe and effective use in medicine.         cations are that an ablation energy source with a far wider therapeutic
After open cardiac surgery applications had developed in the 1960s              margin can be used—liquid nitrogen boils at −189 °C—and that cryo­
and 70s, the first clinical experience using a focal tip cryoablation           catheter design is no longer constrained by the need for occlusion.
catheter—targeting the AV node—was described in 2001.621 Finally,                  Currently, a single platform using this technology is commercially
the development of a balloon-based cryothermy in the beginning of               available in the EU (iCLAS, Adagio Inc) and is undergoing clinical evalu­
the 21st century has led to a striking uptake in cryoablation for AF abla­      ation in the USA (IDE # G180263). The iCLAS system allows the use of
tion. A single-shot balloon design delivers significant benefits over a focal   variable shape catheters that enable rapid reconfiguration of the cath­
design. Firstly, it allows procedural simplification (no need for mapping       eter to the desired target tissue. The recently published first in man
systems, potential time gains), and secondly, it blocks antegrade flow          CRYOCURE-2 observational study reported promising acute proced­
from the targeted PV, thereby eliminating balloon heating by the blood          ural results and 12-month freedom from atrial arrhythmias in a mixed
pool and greatly enhancing cryoablation efficacy. However, a caveat re­         paroxysmal and persistent AF population.630 Potential synergies be­
lated to the absence of mapping system in the cryoballoon procedural            tween ultra-low temperature cryoballoon and PFA may exist, such as
workflow is the increased fluoroscopy exposure.622                              guaranteed tissue contact and elimination of microbubbles. Evidence
   All currently available cryoballoon catheters have an open inner lu­         for this strategy is currently limited, and a trial assessing its usefulness
men to allow insertion of a guidewire or a diagnostic catheter and              is underway (NCT05408754).
use N2O as a coolant, exploiting the Joule–Thomson gas expansion ef­
fect to achieve temperatures down to a theoretical minimum of −89°C.            6.2.3. Pulsed field ablation
The first-generation cryoballoon (Artic Front, Medtronic, Inc) showed           6.2.3.1. Biophysics and mechanisms
superiority over AADs in a randomized setting.239 However, over 80%             In contrast to RF or cryothermy, irreversible cardiac electroporation is
of patients with AF recurrence after first-generation cryoballoon abla­         considered a non-thermal energy source, meaning the cell death induc­
tion showed PV reconnection at the time of repeat ablation and over             tion is not dependent on thermal processes. Instead of exposing cells to
50% had reconnection of more than one PV.623 The second-generation              a thermal insult, electrical fields are applied to the cells leading to a dis­
cryoballoon (Arctic Front Advance, Medtronic, Inc.) was introduced in           ruption in cell membrane integrity and function.631 This short-term dis­
2012 and incorporates a modified refrigerant injection system charac­           ruption then leads eventually to cellular death and replacement fibrosis.
terized by eight injection jets in a more distal balloon position. Thus, a      Ablation using irreversible electroporation is more commonly referred
more homogeneous cooling of the complete distal balloon hemisphere,             to as PFA.
including the distal tip, is achieved.                                             The exact mechanism of PFA-induced cell death is not known.631
   More recently, the POLARx (Boston Scientific) cryoballoon catheter           Application of electrical fields of sufficient strength will lead to accumu­
received approval, and clinical experience has accumulated. A recent            lating charge on cell membranes, which can result in development of na­
multicenter registry has validated the procedural safety and efficacy           nopores in the membrane surface and increased membrane
of this cryoballoon for the treatment of patients with paroxysmal               permeability. This permeability disrupts the intracellular and extra
AF.624 Despite similarities in ablation technique and catheter design,          cellular concentration gradients required for cellular homeostasis. If
important differences exist when compared with other cryobal­                   the electrical field application is sufficiently long, alterations in cellular
loons.625,626 In the COMPARE-CRYO trial, 201 symptomatic paroxys­               pH, generation of reactive oxygen species, release of mitochondrial cy­
mal AF patients undergoing their first PVI procedure were randomized            tosome c, and other processes all result in a progression to cellular
to cryoballoon ablation using either the POLARx or the Arctic Front             apoptosis combined with some immediate cellular necrosis.632–634
catheter and were monitored with an ICM. The freedom from                       These processes occur over days to weeks and lead eventually to
Catheter and surgical ablation of atrial fibrillation                                                                                                   35


replacement fibrosis over 4–8 weeks. Unlike thermal ablation, PFA                PN palsy occurs, it typically recovers within a few hours.649 PFA also
does not permanently disrupt the local tissue extracellular matrix struc­        does not appear to cause PV stenosis.643,650 Skeletal muscle contrac­
ture or vascular supply,635 which is a critical element in why PFA may           tion was a problem with early versions of PFA, but with the implemen­
not result in as much collateral damage to non-cardiac tissues.631               tation of more optimized waveforms (biphasic especially), this risk is
   Electrical field ablation was pioneered in the 1980s when Scheinman           reduced, and most studies have shown that PFA can be safely per­
et al.636 delivered a full defibrillator shock through a catheter in the         formed without the use of paralytics.641,642,651
heart. The investigators achieved heart block, but the accompanying                 Microbubble formation has been observed with most PFA systems. It
heat and barotrauma sidelined direct current ablation and paved the              is unclear whether this is due to unwanted heat generation, an electro­
way for RF ablation. The key technological advance for today’s PFA is            lytic effect on water, or displacement of nitrogen gas.633 The size of the
that a ‘large charge’ can be broken up into a series of multiple applica­        bubbles appears to be small (<40 μm),652 and if gaseous, they should
tions of very brief duration. Since the cardiac cell is like a capacitor that    spontaneously resorb prior to causing significant cerebral ischemia.
can store charge, the intensity of the electrical field will depend on the       Early studies have suggested a low rate of silent cerebral emboli on
total duration of the exposure (number of repeated applications) in              cerebral MRI post-PFA ablation (3%), but further studies are required
addition to the actual voltage delivered.631                                     to confirm the potential risk of these bubbles.641,653 High Joule mono­
   Key parameters for PFA include voltage, pulse width, waveform (bi­            phasic pulse deliveries, e.g., can cause very large volumes of these bub­
phasic vs. monophasic), and polarity (bipolar vs. monopolar). Increasing         bles and have been associated with ST segment elevation and MRI
voltage will not only increase treatment effect but can also generate un­        lesions indicating embolic ischemia.654
wanted heating, gaseous microbubbles, and barotrauma.633,637 Most                   Coronary arterial spasm has been reported with PFA deliveries in
systems approved or in development today are utilizing voltages of               proximity to coronary vessels655,656 (Section 11.2.2.). The spasm per­
500–2000 V peak-to-peak for each application. Monopolar PFA deli­                sisted even after delivery was terminated and required injection of
vers energy from a single catheter to a return ground patch. Bipolar             intracoronary nitroglycerin to terminate the process. Cough has also
PFA delivers energy between adjacent electrodes and is more suited               been frequently reported even in anesthetized patients, which may
to larger, efficient, multipolar ablation catheters. Pulse width is also crit­   be due to field stimulation of the J receptors within the PVs or due
ical for treatment effect and minimization of gaseous emboli, muscle             to bronchial stimulation.631 In large cohorts of unselected patients,
contraction, and unwanted heat generation. Most systems are utilizing            the safety profile of PFA was consistent with preferential tissue
pulse widths in the microsecond range. Delivery of pulses (typically 10–         ablation.643,644
20) usually occurs in a series called a ‘packet’ or ‘train’ and then multiple
trains (1–7) may be delivered over several seconds.
   Although PFA is supposed to be non-thermal, the recipes used for              6.2.3.3. Efficacy of pulsed field ablation
ablation today encroach on the thermal threshold. For biphasic, bipolar          Pulsed field ablation can be delivered from a variety of different catheter
pulses, there can be 5–40°C rises in tissue surface tempera­                     shapes and styles. It can be delivered from larger, multipolar catheters
ture.631,638,639 However, these rises are for such brief duration (a             creating a ‘large footprint’ ablation. It can also be delivered from
few milliseconds) that significant thermal damage does not occur.                balloon-style devices. Finally, it can also be delivered from standard
Contact between the tissue and catheter is still required for optimal            point-by-point RF-style catheters (3.5 mm tip) and even larger tip ca­
PFA delivery.640 Whether CF is required for optimal PFA delivery is still        theters (like the 9 mm lattice sphere).657,658 Pulsed field ablation deliv­
an open question.                                                                eries can cause myocardial cell stunning and disappearance of electrical
                                                                                 signals. Therefore, acute disappearance of electrograms cannot neces­
                                                                                 sarily predict long-term success. Repetitive applications of PFA around
6.2.3.2. Efficiency and safety—key advantages                                    the veins may push the field penetration (and therefore lesion depth) to
Since PFA can be delivered over several milliseconds and several packets         achieve better results.642
can be delivered within seconds, procedural efficiency is one of the key            Early studies using a pentaspline multielectrode PFA catheter have
advantages of this energy source. Furthermore, PFA can be easily deliv­          shown that optimized biphasic, bipolar PFA deliveries can achieve
ered in large footprint (so-called ‘single shot’) devices, which can achieve     very high rates of durable PVI at a 3-month remapping procedure.641
large lesions around the PVs and on the posterior wall with ease. Even in        Few 1-year follow-up studies have been published to date. A pooled
the early evaluation studies, where operators were very early in their           analysis of three non-randomized prospective studies reported a
learning curve, LA dwell times were only 60–90 min or less.641,642 Now           78.5% freedom from any atrial arrhythmia at 1 year in paroxysmal AF
that some systems are available commercially, early registries report            patients.651 Multicenter registries (MANIFEST-PV and EU-PORIA)
average procedure times close to or even less than one hour for AF               using this pentaspline multielectrode PFA catheter reported 1-year
ablation.643,644                                                                 arrhythmia-free survival of 78.1 and 74%, respectively, in real-world
   The safety profile of PFA also makes it very promising for cardiac ab­        mixed paroxysmal and persistent AF populations undergoing PVI, with­
lation. With thermal ablation, there has always been a low, but detect­          out a standardized rhythm monitoring protocol.644,659
able, risk of collateral damage to the lung, esophagus, and PN.                     Recent evidence supports the efficacy and safety of other PFA sys­
Esophageal damage can lead to fatal complications such as an                     tems. In the large-scale, prospective, multicenter PULSED AF trial,
atrial-oesophageal fistula (AEF; Section 11.3.1.). Early preclinical data        PFA resulted in 100% acute PVI rate with a low rate of primary safety
have suggested that the field threshold for damaging cardiac cells is            adverse events (0.7% without PV, esophageal, or PN complications)
much lower than that required for smooth muscle (esophagus),645 vas­             and 12-month clinical success rates consistent with those reported in
cular (veins and arteries),635 and nerve cells.646 Adipose tissue is an ex­      thermal catheter ablation studies with similarly rigorous rhythm mon­
cellent insulator for electricity, and even thin fat layers separating           itoring (66.2% in paroxysmal AF and 55.1% in persistent AF).660 A bi­
esophageal tissue from the LA may have a significant protective ef­              phasic PFA system with a variable-loop circular catheter integrated
fect.631 Preclinical data have confirmed that clinical PFA systems ap­           with a 3D mapping system showed a 71% 1-year atrial arrhythmia free­
proved or under development do not cause long-term esophageal                    dom without device-related serious adverse events in a paroxysmal AF
damage.638,647,648 Esophageal temperature rises are not seen during ab­          patient population.661 A focal 9 mm lattice-tip catheter able to deliver
lation over the esophagus in humans.642 While acute PN capture can               both RF and PFA recently demonstrated 78% freedom from atrial ar­
occur during PFA applications, PN palsy is very rare.643 Even when               rhythmias at 12 months with primary safety endpoint rate of 0.6% in
36                                                                                                                                          S. Tzeis et al.



a mixed paroxysmal and persistent AF patient population. Invasive re­         6.4. Future developments
mapping demonstrated PVI durability in 97% of PVs and 91% of all de­          6.4.1. Mapping tools
ployed linear lesions using the optimized waveform.620
                                                                              Future mapping catheters are being developed, which will allow for ac­
   In the recent ADVENT trial, 607 patients with drug-refractory par­
                                                                              commodation of larger numbers and smaller electrodes to increase the
oxysmal AF were randomized either to PFA with the pentaspline cath­
                                                                              resolution of maps. Three-dimensional printing of electrodes is also al­
eter or to thermal ablation (either CF-sensing RF or cryoballoon
                                                                              lowing large numbers of electrodes to be placed on flexible surfaces.
ablation). After a 12-month follow-up, PFA was shown to be non-
                                                                              Already the Orion basket mapping catheter (Boston Scientific) exem­
inferior to thermal ablation in respect to efficacy (composite of acute
                                                                              plifies this technology. Future grid and basket designs will be developed.
procedural and chronic success) and safety (device-related and
                                                                                 The development of the ‘near’ unipole reference is a new advance,
procedure-related serious adverse events).662 Results of the SINGLE
                                                                              which will be expanded in multiple catheters. This was first seen on
SHOT CHAMPION (NCT05534581) and BEAT AF (NCT05159492)
                                                                              the Sphere 9 catheter where the indifferent electrode is placed on
RCTs will shed further light on the long-term efficacy and safety of
                                                                              the shaft of the catheter, close to the mapping elements, rather than
PFA for AF ablation when compared with RF and cryoballoon ablation.
                                                                              at Wilson’s Central Terminal. This produces a unipolar signal with
                                                                              less far-field artefact. Future basket designs will also feature algorithms,
6.2.4. Laser ablation                                                         which can measure far-field signals and subtract them from unipolar re­
A laser balloon ablation system transmits light energy through a balloon      cordings. This will allow for cleaner, localized unipolar recordings,
filled with deuterium oxide (‘heavy water’) to perform PVI. The lumen         which may enhance accuracy in defining propagation of wavefronts
of the 16 Fr catheter contains a fiber optic endoscope that allows PVI        and identifying local arrhythmia sources.
under direct visualization. The balloon is quite compliant, allowing a           Artificial intelligence will be further incorporated into mapping sys­
variable inflation diameter (25–32 mm), depending on PV size. Once in­        tem algorithms to help identify critical zones for arrhythmia initiation
flated, the operator can visualize the edge of the balloon and the PV an­     or perpetuation, particularly for complex arrhythmias like AF (Section
tra. The laser can then be delivered in a 30° arc around the antrum of        6.1.1.3.). The main limitation to this approach is the ‘black box’ nature
the vein. Energy can be titrated from 5.5 to 12 W for 20–30 s depend­         of artificial intelligence algorithms, which may limit operator
ing on the thickness of the tissue and the proximity to the esophagus.663     acceptance.
A newer development is the ability for the catheter to rotate the laser
arc 360° around the PV in a continuous sweep to avoid gaps and reduce         6.4.2. Ablation tools
procedure times compared with the segmental lesions delivered with
                                                                              Combined thermal/pulsed field modalities may overcome several lim­
the old system.663
                                                                              itations of the currently available PFA systems. Combined pulsed field
    Several studies sought to compare the safety and efficacy of laser bal­
                                                                              cryoablation using ultra-low cryothermy can create deeper lesions by
loon ablation with RF or cryoballoon ablation. In an early multicenter,
                                                                              delivering subtherapeutic cryoablation to create ice, which acts as an
prospective RCT, laser ablation resulted in similar 1-year freedom
                                                                              electrical insulator. Large voltages of PFA can then be delivered without
from AF when compared with wide-area circumferential RF ablation
                                                                              causing heating, bubbles, or muscle contraction because of the ice on
in persistent AF patients.664 Evidence from both comparative and ran­
                                                                              the catheter.671 Combined RF-PFA may allow for preconditioning of
domized trials and from a metaanalysis demonstrated similar efficacy
                                                                              the tissue with low-dose RF, dropping local impedance, and increasing
and safety of laser balloon compared with cryoballoon ablation.665–
667                                                                           intracellular fluid, which could allow for increased PFA efficacy.
     How laser will fit in a post-PFA world remains to be seen.
                                                                                  Even subtherapeutic doses of PFA can cause electrical stunning of
                                                                              cardiomyocytes such that signals disappear very quickly.
                                                                              Disappearance of signals, however, does not guarantee a fully devel­
6.3. Robotic and magnetic catheter                                            oped lesion. Repeated deliveries may be used to achieve durability,
navigation                                                                    but this is still empiric. Other electrogram characteristics or new lesion
The concept of remote catheter navigation was developed many years            assessment technologies (such as optical assessment of tissue birefrin­
ago and was quite promising for some time. The benefit was that op­           gence) may be required to acutely assess whether a fully transmural le­
erators could reduce radiation exposure for themselves (and possibly          sion has been developed with PFA.
the patient) and reduce the risk of occupational injury associated                Real-time guidance of ablation procedures with magnetic resonance
with wearing medical protective gear. The systems fell into two main          systems has been proposed for some time, and early feasibility studies
categories: (i) magnetically assisted catheter control, such as the           have been performed.672 However, the approach has been limited by
Niobe (Stereotaxis Inc., USA) and the Magnetecs system and (ii) robot­        the size of the MRI system, the current inability of an operator to func­
ic assisted catheter control, such as the Sensei robotic catheter system      tion comfortably in the environment, and the limited spatial resolution
(Hansen Medical, USA) and the Amigo remote catheter system                    of the various catheters within real-time, non-processed MRI imaging.
(Catheter Precision, USA). As AF ablation procedures have become              As the resolution of systems improve and the size of MRI machines de­
shorter (single-shot technologies) and radiation exposure has become          creases, this may eventually become a possible way to perform ablation
very low (electroanatomic mapping, ‘zero’ fluoroscopy techniques), the        without any risk of fluoroscopic exposure. Current mapping systems,
use of these remote navigation systems has become more niche and is           however, are already enabling near-zero fluoro procedures and could
not being widely adopted. Evidence from non-randomized trials and             slow down development of MRI-guided ablation systems.
metaanalyses demonstrates that AF ablation guided by remote magnet­               Carbon beam or other high-energy, heavy ion beams may be used to
ic navigation is associated with similar efficacy as manual navigation but    non-invasively beam radiation into specific cardiac structures to achieve
showed reduced periprocedural complications, reduced fluoroscopy              ablation. Preliminary preclinical data show that beams can be targeted
time, and prolonged procedure time.668–670 The high cost of installation      to the AV node, the PV–atrial junction, and the left ventricle.673 While
and disposables is a key barrier to wider adoption. In a post-PFA world       the non-invasive nature of the ablation is enticing, the complexity and
when procedural times will be further reduced, the advantage of such          cost of installing such systems (such as MRI guidance) is sure to be a lim­
systems for AF ablation will be further limited.                              iting factor.
Catheter and surgical ablation of atrial fibrillation                                                                                                 37


7. Procedural management and                                                      In addition to alleviating pain and anxiety, an important goal for anes­
                                                                               thesia during AF ablation is to minimize patient movement as this im­
techniques                                                                     proves catheter stability. Therefore, general anesthesia and deep
                                                                               sedation have frequently been preferred. A prior prospective study ran­
                                                                               domized 257 patients undergoing ablation for paroxysmal AF to either
                                                                               conscious sedation or general anesthesia and demonstrated significantly
                                                                               improved 17-month ablation efficacy with general anesthesia. General
  Procedural management and              Category of        Type of            anesthesia was also associated with shorter fluoroscopy and procedure
  techniques                               advice           evidence           times.697 Other retrospective studies and a metaanalysis have also ob­
  ..................................................................
                                                                               served better outcomes when general anesthesia is used compared
  Ultrasound guidance is beneficial
                                                                               with conscious sedation, and this finding was associated with improved
     for vascular access during AF                                             CF and greater first-pass isolation.697–700 General anesthesia has also
                                         Advice TO DO      OBS674–680
     catheter ablation to reduce the                                           been found to be as safe as conscious sedation in terms of total compli­
     risk of vascular complications                                            cations and serious adverse events.700 With the increasing use of cryoa­
  Heparin should be administered                                               blation for PVI, a number of studies have demonstrated the feasibility of
     during AF catheter ablation and                                           conscious sedation for this technique with similar efficacy and complica­
                                         Advice TO DO      OBS681–685          tion rates to general anesthesia, but with significantly reduced total pro­
     adjusted to achieve and maintain
                                                                               cedure duration due to reduced anesthetic time.701–703 With the
     an ACT of at least 300 s                                                  emergence of PFA, there may be a swing back towards the use of general
  Administration of initial heparin                                            anesthesia to reduce PFA-related pain and prevent discomfort due to
     bolus before transseptal                                                  contraction of the diaphragm.641–643,704–706 However, recent studies
                                             May be
     puncture is reasonable,                                                   have documented the safety and efficacy of deep sedation protocols dur­
                                         appropriate TO    OBS686–688          ing AF ablation with PFA.705,706 A survey of the writing group showed
     especially when performed
                                               DO                              that 52.8% of the writing group members use general anesthesia during
     under echocardiographic
                                                                               AF ablation procedures, 27.8% use deep sedation, and 19.4% use con­
     guidance
                                                                               scious sedation.
  Use of an esophageal temperature
     probe may be reasonable during
     thermal AF ablation procedures          Area of                           7.1.2. Ventilation
                                                          RAND689–694          Catheter–tissue CF and catheter stability are critically influenced by
     to monitor esophageal                 uncertainty
     temperature and help guide
                                                                               respiration. An early study demonstrated greater CF when ablation
                                                                               was performed during periods of apnoea with implications for ablation
     energy delivery
                                                                               time to achieve PVI and acute reconnection rates.707 Ventilation modu­
                                                                               lation has been employed in several studies to improve catheter stability
                                                                               and contact. Beyond using periods of apnoea, techniques have included
                                                                               high-frequency jet ventilation (HFJV) and high-frequency low tidal vol­
7.1. Anesthesia and ventilation during                                         ume (HFLTV) ventilation. High-frequency jet ventilation has been
                                                                               shown to improve catheter stability.708,709 A recent prospective regis­
atrial fibrillation ablation                                                   try indicated that use of HFJV in patients undergoing PVI for paroxysmal
An AF ablation procedure can be performed under general anesthesia,            AF using CF catheters was associated with decreased arrhythmia recur­
deep sedation, or conscious sedation based on patient and procedural           rence without appreciable increase in adverse procedural events.708
characteristics, physician experience, anesthesia availability, and institu­   High-frequency jet ventilation is most suitable for patients with normal
tional protocols. A multidisciplinary approach, involving electrophysiol­      pulmonary physiology and chest wall compliance. Hypotension requir­
ogists and anesthesiologists, is necessary to develop a safe and               ing administration of vasopressors is significantly more frequent during
effectively structured anesthesia protocol.                                    HFJV cases when compared with those using standard ventilation.708
                                                                               Complications that have been described with the use of HFJV have in­
7.1.1. General anesthesia vs. sedation                                         cluded airway dehydration, inadequate oxygenation and ventilation, re­
General anesthesia is the most commonly used anesthetic method in              spiratory acidosis, barotrauma, gastric distension, and aspiration.710,711
patients undergoing AF ablation. Under deep sedation, the anesthesia           Both due to these potential complications and lack of widespread avail­
depth approaches that of general anesthesia, and in most centers an            ability of dedicated ventilators, adoption of HFJV during PVI has been
anaesthesiologist, a second physician, or a specially trained nurse is re­     relatively limited.
quired to be present.695 For conscious sedation, patients are able to re­         A simpler alternative strategy that has recently been described is the
spond purposefully to verbal commands.                                         use of conventional ventilators to deliver HFLTV ventilation. Several
   An analysis of the National Anesthesia Clinical Outcomes Registry           studies demonstrated that HFLTV ventilation was associated with
that included 51 070 cases of AF ablations from 2013 to 2018 showed            improved catheter CF and stability, higher first-pass PVI rate, and short­
that 94% of cases were performed under general anesthesia in the               er total procedural and RF times without an increase in complica­
USA.696 In addition, the worldwide EHRA survey in 2021 showed                  tions.712–714 This technique has been more widely adopted due to its
that the most commonly used anesthetic technique was general anes­             ease of use. A recent large prospective multicenter registry enrolling
thesia (40.5%), followed by conscious sedation (32.0%) and deep sed­           paroxysmal AF patients undergoing catheter ablation demonstrated
ation (27.5%). However, this varied by continent, and in Europe,               that HFLTV ventilation improved freedom from atrial arrhythmia re­
conscious sedation was still the most commonly used technique                  currence, AF-related symptoms, and AF-related hospitalizations in
(38%). Between 2010 and 2019, the proportion of procedures per­                comparison with standard ventilation.715
formed under general anesthesia and deep sedation increased by 4.4                A survey of the writing group showed that 5.6% of the writing group
and 4.8%, respectively, whereas the use of conscious sedation de­              members routinely use HFJV and 29% routinely use HFLTV ventilation
creased by 9.2%.695                                                            during RF ablation procedures.
38                                                                                                                                        S. Tzeis et al.



7.2. Vascular access                                                         (OAC), heparin was not administered until after the second transseptal
Femoral venous access for AF ablation may be obtained using anatom­          crossing, the initial UFH bolus was at least 5000 units, and the target
ical markers or under ultrasound guidance. Significant vascular compli­      activated clotting time (ACT) was only 250–300. It remains unclear
cations that may occur include inadvertent arterial puncture,                whether a strategy of heparinized saline infusion of sheaths is important
arteriovenous fistula, pseudoaneurysm formation, access site hema­           in the context of a contemporary anticoagulation strategy. Nevertheless,
toma, and retroperitoneal bleed716,717 (Section 11.3.6.). When trad­         84% of the writing group members reported using heparinized sheath
itional anatomical marking is used for vascular access, an inferior          irrigation.
approach is associated with increased risk of femoral pseudoaneurysm             Most of the evidence regarding UFH administration during AF abla­
and arteriovenous fistula, while a superior approach may be associated       tion was derived from patients taking VKA. Studies that investigated the
with an increased risk of retroperitoneal bleeding. Evidence from ob­        use of UFH in patients on uninterrupted DOAC have shown that high­
servational studies and metaanalyses has indicated that use of               er amounts of intraprocedural UFH were needed to achieve target
ultrasound-guided vascular access significantly reduced the risks of vas­    ACT and not all DOACs interact with UFH in the same way.721–726
cular complications, postprocedural pain, and prolonged bruis­               Post hoc analysis of RE-CIRCUIT showed that patients on dabigatran re­
ing.675,678–680 A multicenter RCT comparing ultrasound-guided                quired similar amounts of UFH to achieve therapeutic ACTs compared
venipuncture vs. an anatomically guided approach was terminated early        with VKA, while other studies indicated that more UFH was needed in
due to substantially lower than expected complication rates.676              patients taking factor Xa antagonists.723–726 From literature review, a
Nevertheless, analysis of data collected demonstrated that first-pass        great amount of variability exists across different practices on intrapro­
success in gaining femoral vein access was higher in the ultrasound-         cedural UFH dosing protocols. Specific dosing regimens should be tai­
guided group, while puncture time, extra puncture attempts, inadvert­        lored to the patient population, medication use, and the last dose of
ent arterial puncture, and unsuccessful cannulation were all significantly   OAC as these factors impact the amount of UFH needed to achieve
lower in the ultrasound-guided group.676 In an era where AF ablations        therapeutic anticoagulation.726–728
are increasingly performed on uninterrupted anticoagulation, the risks           A metaanalysis of 19 studies involving 7150 patients concluded that
associated with vascular complications need to be minimized.                 patients with ACT > 300 s during AF catheter ablation had significantly
Therefore, preventive measures including ultrasound-guided venipunc­         reduced risk of thromboembolic complications without increased
ture should be implemented routinely.                                        risk of bleeding when compared with those with ACT < 300 s, irre­
    A survey of the writing group showed that 75.7% of the writing           spective of the type of oral anticoagulation used periprocedurally.683
group members routinely use ultrasound guidance for vascular access          A survey of the writing group showed that 61% of the members employ
during AF catheter ablation.                                                 a target ACT > 300 s during AF ablation, while 34% a value >350 s.
                                                                                 Evidence supports initial heparin bolus administration before trans­
                                                                             septal puncture. Observational studies in patients undergoing AF abla­
7.3. Continuous arterial blood pressure                                      tion have demonstrated that UFH administration before transseptal
                                                                             puncture is associated with a reduced incidence of ICE-detected
monitoring                                                                   thrombus when compared with those receiving UFH after transseptal
Continuous arterial BP monitoring via an intraarterial line is utilized in   puncture.686,687 A prospective observational study in 280 patients
many laboratories to monitor patients undergoing AF ablation (39.5%          undergoing AF ablation under VKA treatment reported that compli­
of the writing group members routinely use invasive arterial BP moni­        ance to a periprocedural anticoagulation protocol including UFH ad­
toring during AF catheter ablation). Limited data comparing outcomes         ministration before transseptal puncture, maintenance of therapeutic
with invasive vs. non-invasive BP monitoring exist. A retrospective multi    preprocedural INR, and consistent procedural ACT levels >300 s re­
centre study of 362 patients having AF ablation under general anesthe­       sulted in significantly reduced incidence of silent cerebral ischemia after
sia found no difference in complication rates between the invasive and       ablation.688 In addition, the increasing use of ICE significantly decreases
the non-invasive BP monitoring groups.718 In theory, an arterial line may    the risk of transseptal puncture associated bleeding. A survey of the
provide critical early indication to the presence of a major complication    writing group showed that 74% of the members administer initial
such as pericardial tamponade. Whether this justifies the routine use of     UFH bolus before transseptal puncture.
invasive hemodynamic monitoring or would indeed improve outcomes                 In the event when anticoagulation needs to be reversed due to intra­
is not established. In patients with impaired ventricular function, hemo­    procedural complications such as cardiac perforation and cardiac tam­
dynamic instability, and significant comorbidities, the use of invasive BP   ponade, UFH can be reversed with protamine administration. This was
monitoring may be reasonable on an individualized basis.                     validated by an RCT showing that protamine expedites vascular hemo­
                                                                             stasis after AF ablation.729 If bleeding stops, reversal of OAC is not sug­
                                                                             gested to protect against periprocedural thromboembolic risk. If
7.4. Anticoagulation during atrial                                           bleeding persists despite protamine administration, fresh frozen plasma
fibrillation ablation                                                        can be administered in warfarin-treated patients, idarucizumab to re­
Meticulous sheath handling and optimal intraprocedural anticoagula­          verse dabigatran, and andexanet for reversal of Factor Xa inhibi­
tion with unfractionated heparin (UFH) is critical to prevent                tors.730,731 If specific reversal agents are not available, prothrombin
thromboembolic complications and the development of silent cerebral          complex concentrates (Factors II, VII, IX, and X) can be administered
infarction.681,682,684,685,719 A single non-randomized study evaluated       to achieve immediate hemostasis and should be preferred over
the impact of flushing the transseptal sheath prior to vascular entry        recombinant activated Factor VIIa due to the latter’s prominent pro­
using 2 U/cc heparin concentration when compared with a flush con­           coagulant effect.732
taining 1000 U/cc heparin on the incidence of thrombus formation
on the transseptal sheath.720 Intracardiac echocardiography was used
to screen for thrombus. Patients having received a low-dose heparin          7.5. Transseptal puncture
flush prior to intravenous access had a significantly higher incidence       Transseptal puncture can now be performed with several different
of thrombus formation compared with the high-dose heparin group              technologies. In addition to the conventional needle, transseptal access
(9 vs. 1%) within 5–15 min of entering the LA. Notably however, the          can also be gained using an RF needle or a needle-free technique.
procedures were not performed on uninterrupted oral anticoagulant            Several RCTs have compared the RF needle with a standard approach.
Catheter and surgical ablation of atrial fibrillation                                                                                                    39


These studies found that transseptal puncture with an RF needle was              including 299 152 patients undergoing AF ablation over a 14-year per­
associated with significantly shorter time required for transseptal LA           iod reported that the use of ICE was significantly increased over the
access, shorter fluoroscopy requirement, lower rate of transseptal fail­         years and led to significant reduction in complication rate, in-hospital
ure, and fewer visible plastic shavings after needle advancement.                mortality, and length of hospital stay.749 A more recent propensity
Complication rates did not differ.733,734 However, one of these studies          score–matched analysis from a nationwide database validated the fa­
had a transseptal failure rate of 28% and an incidence of visible plastic        vourable impact of ICE use on in-hospital mortality, readmission rate,
shavings of 33%, which are not consistent with the actual very low in­           and length of stay without increase in healthcare-associated cost.750
cidence of these two events in clinical practice.733 Furthermore, the               Intracardiac echocardiography may also be used as an adjunct to AF
time savings of 20 s to several minutes seem insignificant in a clinical         ablation tools to guide safe and efficient energy delivery. Direct visual­
or lab usage context. Neither study addressed the additional cost asso­          ization of the LAPW and the adjacent esophagus may guide titration of
ciated with use of the RF needle. Indeed, uptake of the RF needle has            power and duration at these high-risk areas to reduce the risk of collat­
varied widely and in many countries is not in routine use. An observa­           eral damage during energy delivery.751 Intracardiac echocardiography
tional study also found that use of the RF transseptal needle was asso­          use allows real-time visualization of PV anatomy preventing inadvertent
ciated with a lower incidence of MRI-confirmed silent cerebral                   intra-PV RF energy delivery that increases the risk of PV stenosis.
lesions.735                                                                      Intracardiac echocardiography is also useful in validating proper PV oc­
   The needle-free transseptal approach can be achieved with the use of          clusion during cryoballoon ablation either with colour-flow Doppler as­
specific wires. A transseptal wire (Safesept, Pressure Products, San             sessment of PV leakage or with evaluation of microbubble backflow to
Pedro, CA, USA) is safe and effective in gaining LA access without a             the LA after saline injection in the internal lumen of the cryoballoon.752–
need for transseptal needle or exchange for a standard guidewire.736             754
                                                                                      The latter approach is feasible, safe, and useful in patients with
In a large, retrospective single-center analysis, it was shown to significant­   contraindication to iodinated contrast medium.755 Intracardiac echo­
ly reduce the risk of transseptal puncture-related cardiac tamponade.737         cardiography has been used to measure LA wall thickness in different
A newer technology is an RF wire that can be used to cross the septum            segments of the PV periphery and accordingly adjust target AI during
and provide support for the transseptal sheath (Versacross, Boston               RF energy delivery.756 Employment of a tailored AI protocol based
Scientific). The RF wire forms a pigtail end that can be advanced into           on ICE-measured LA wall thickness significantly increased acute pro­
the SVC to guide initial sheath placement. When pulled into the sheath,          cedural success and freedom from AF recurrence following PVI in par­
the wire straightens out, and upon ‘tenting’ of the septum, RF is applied        oxysmal AF patients compared with an FTI protocol.756
to the tip of the wire and the wire is advanced into the LA, reforming the          Factors limiting the adoption of ICE use in routine AF ablation work­
pigtail end that can be advanced into a PV and allow the sheath to be            flow include associated increase in procedural cost and the need for a
atraumatically advanced. This system can be useful in cases of redo abla­        second operator or multitasking by a single operator. A survey of the
tion or prior ASD closures to prevent the ‘jumping’ across the septum            writing group showed that 47.4% of the members routinely use ICE
that may occur with standard needles.                                            during AF ablation. Therefore, in practices familiar with ICE, it is reason­
   With circumferential RF ablation, both the single (two sheaths via            able to use ICE to exclude thrombi and enhance procedural safety and
one transseptal puncture site) and double transseptal (each sheath               efficiency during AF ablation.
via a separate transseptal puncture site) approaches have been used
(50% of the writing group members use single and 50% double
transseptal access). A prospective study comparing single vs. double             7.7. Fluoroless ablation
transseptal in patients undergoing AF ablation revealed no difference            Radiation exposure during catheter ablation of AF can cause potential
in procedure time, fluoroscopy time, complication rates, or AF recur­            delayed complications both in patients and operators that include acute
rence between the two approaches.738                                             and subacute skin injury, cataract, and malignancy.757 In addition, wear­
   The use of steerable sheaths during AF ablation facilitates catheter          ing of lead over time can lead to orthopaedic injuries (back pain, disc
navigation and manipulation and is associated with increased catheter            herniations) in operators and laboratory staff. Traditionally, many steps
stability.739 In an earlier prospective RCT, the use of steerable sheath         during an AF catheter ablation require fluoroscopy, including catheter
significantly reduced arrhythmia recurrences 6 months after AF abla­             positioning, transseptal puncture, PV angiography, and ablation.
tion and was the only independent predictor of rhythm outcome.740                Studies have shown that the lifetime risk of excess fatal malignancies
The introduction of steerable sheaths that can be visualized on 3D elec­         normalized to 60 min of fluoroscopy was 0.07% for female and 0.1%
troanatomical maps facilitates fluoroless understanding of their posi­           for male patients and that obese patients receive more than twice
tioning. Integration of visualizable steerable sheaths in AF ablation            the effective radiation dose of normal-weight ones during AF ablation
workflows has been shown to reduce fluoroscopy exposure when                     procedures.758,759
compared with the use of conventional steerable sheaths.741–744                     Fluoroscopy times were frequently in excess of 60 min in the initial
                                                                                 years of AF ablation. However, a single-center analysis of over 2300 AF
                                                                                 ablations indicated that fluoroscopy times and doses have dramatically
7.6. The use of intracardiac                                                     decreased over a 12 year period.760 Indeed, today, fluoroscopy times
echocardiography                                                                 and doses generally average fewer than 10 min and 1000 mGycm2
The use of ICE during AF ablation offers multiple benefits in different          for RF AF ablation procedures predominantly associated with position­
stages of the procedure. As already presented in detail (Section                 ing of diagnostic catheters and transseptal puncture.761 The use of ad­
5.3.2.2.), ICE is useful to screen for LA/LAA thrombus at the time of            vanced 3D mapping systems has largely obviated the need for
catheter ablation. Intracardiac echocardiography use has also a favour­          fluoroscopy after LA access has been achieved. When considering low-
able impact on procedural duration and safety. Observational studies             dose pulsed fluoroscopy of 2–5 min duration with collimation,762,763
and two metaanalyses indicated that ICE use in AF ablation was asso­             the effective radiation dose is as low as 1 mSv, equivalent to ∼4 months
ciated with significant reductions in fluoroscopy time, procedure                background radiation. Whether zero fluoroscopy meaningfully reduces
time, and complication rates compared with AF ablation without                   the risk associated with 3–5 min of fluoroscopy remains unproven.
ICE.745–748 In a propensity score–matched analysis, ICE was associated           Electrophysiologists should be familiar with measures that reduce radi­
with a significantly lower incidence of complications and repeat abla­           ation exposure of patients and cath lab personnel, which include, but
tion.747 A retrospective analysis of a national representative database          are not limited to, fluoroscopy system customization, workflow
40                                                                                                                                        S. Tzeis et al.



adaptations (frame rate, collimation, cine, projection angle, sensitive      the incidence of esophageal lesions.690 In a consecutive series of
areas), and shielding measures.764,765                                       120 patients undergoing high-power (50 W), short-duration RF abla­
    Nevertheless, in recent years, there has been an initiative to perform   tion, the endoscopic detection of ulceration was compared between
zero-fluoroscopy AF ablation. A number of studies have demonstrated          an initial group with use of a Circa esophageal temperature probe
that fluoroless transseptal puncture and AF ablation can be performed        (maximum allowable temperature of 39°C) and a second group with­
with TEE and/or ICE guidance with similar procedural duration, acute         out esophageal temperature monitoring.694 The overall incidence of
success rate, procedural complication rate, and 1-year AF recurrence         new endoscopically detected lesions was only 2.5% with no difference
rate to a minimal fluoroscopy approach.766–774 In up to 37% of patients      between the groups. The authors used a series of measures to avoid
in some series, complete fluoroless ablation could not be achieved, and      overheating the esophagus such as not performing contiguous lesions
minimal rescue fluoroscopy was needed to confirm catheter location           over the esophagus and allowing time between lesions for cooling,
and to assess for potential complications.767,769,770                        suggesting that this approach may be most important. Based on the
    The increasing use of cryoablation has again resulted in significantly   existing evidence, the use of esophageal temperature monitoring dur­
longer fluoroscopy times, when compared with RF ablation, with re­           ing AF ablation has not resulted in reduced risk of endoscopically de­
ported times of ∼20 min.294 Fluoroless cryoballoon ablation has not          tected esophageal lesions. Esophageal temperature probes with
been widely adopted both because of the need to identify balloon po­         varied numbers of temperature sensors and varied temporal respon­
sitioning at the PV ostium and to prove occlusion of the vein with con­      siveness are available for clinical use,778,779 but the esophagus is broad
trast injection. A single observational study of 50 patients found that      relative to the spatial resolution of even multisensor temperature
fluoroless cryoablation is achievable with similar outcomes to a fluoro-     probes, and severe esophageal temperature rise may remain un­
guided procedure, but this approach is not in wide clinical usage.775 A      detected when the sensor is >2 cm away from the ablation
survey of the writing group showed that 18.4% of the members rou­            catheter.780
tinely perform fluoroless RF ablation.                                          Mechanical esophageal deviation has been reported, but its use
                                                                             has been limited to a small number of patients at a limited number
                                                                             of centers.781 Significant esophageal deviation related trauma has
7.8. Esophageal temperature management                                       been reported when trying to achieve the extent of mechanical
Animal models and clinical series have documented that esophageal            esophageal deviation required to avoid esophageal heating, and it re­
perforation develops in the presence of underlying esophageal tissue in­     mains unclear whether the benefits of esophageal deviation exceed
jury.776,777 Therefore, because of the rarity of AEF occurrence, endo­       the risks.781
scopically detected esophageal lesions are considered as a surrogate            Esophageal cooling has also been evaluated for reducing the se­
indicator for potential development of AEF.                                  verity of esophageal heating. A systematic review of four RCTs
   Studies evaluating the relationship between measured esophageal           found that esophageal cooling reduced the risk of severe esopha­
heating during RF AF ablation and detection of esophageal ulceration         geal injury during AF catheter ablation.782 A single-center study
on postprocedural endoscopy have yielded divergent results. In a co­         randomized 188 patients undergoing RF ablation to either active
hort of patients undergoing their first RF ablation under continuous         esophageal cooling at 4 °C using the ensoETM device (Attune
esophageal temperature monitoring using an infrared thermography             Medical, USA) or standard practice with a single-sensor tempera­
system, peak esophageal temperature was predictive of thermal                ture probe. Esophageal endoscopy was performed in 120 patients
esophageal lesions detected by postablation endoscopy.691 A retro­           1 week following ablation and demonstrated significantly higher
spective study of 43 patients who underwent high-power (50 W)                occurrence of thermal injury in the control group when compared
short-duration (6–7 s) ablation found no difference in peak esophageal       with those receiving esophageal protection.783 The use of esopha­
temperatures measured on the multielectrode S-Cath probe (Circa              geal cooling has also been shown to improve postprocedural free­
Scientific, LLC, Englewood, CO, USA), between those patients who de­         dom from AF recurrences.784 The challenge with these studies is
veloped compared with those who did not develop esophageal abnor­            that the AEF is such a rare complication that it is unlikely any
malities (including small ulcers, non-bleeding erosions, erythema, and       RCT will show a true difference in that endpoint. In a retrospective
esophagitis). However, it was not determined whether the peak tem­           analysis of RF ablation cases from 30 US hospitals, the rate of AEF
peratures occurred in anatomic relationship to the esophagus.692 A           was significantly lower in the group of 14 224 patients who re­
metaanalysis of studies reporting prevalence and prevention of endo­         ceived active esophageal cooling when compared with the control
scopically detected esophageal lesions following AF ablation found a le­     cohort of 10 962 patients who underwent RF ablation without eso­
sion prevalence of 11% and no difference with or without the use of          phageal cooling but under esophageal temperature monitoring in
esophageal temperature monitoring.693                                        >90% of cases (0 vs. 0.146%).785
   Since then, a prospective randomized study of 86 patients has                Additional strategies that may be considered for limiting severe
found no difference in new endoscopically detected esophageal le­            esophageal heating include altering ablation lesion set to avoid ablation
sions when comparing ablation with vs. without luminal esophageal            of atrial tissue directly overlying the esophagus,786 avoiding higher CF
temperature monitoring (S-Cath, Circa Scientific, LLC, Englewood,            during LAPW ablation,787 and avoiding consecutive ablation lesions at
CO, USA), with an overall prevalence of 9%.689 However, ablation             sites with risk of esophageal injury.780 Use of PFA may also mitigate
was not terminated until the esophageal temperature reached 42°              this risk.
C. Achievement of an esophageal temperature of 42°C was predictive              A survey of the writing group showed that 50% of the members rou­
of esophageal lesions raising the possibility that an approach limiting      tinely use an esophageal temperature probe during catheter ablation
temperature rise to more conservative levels may potentially be ef­          procedures to monitor esophageal temperature during energy delivery.
fective in preventing esophageal lesion formation. In another pro­           Furthermore, as a strategy to avoid severe esophageal heating during RF
spective RCT, esophageal temperature monitoring using an                     catheter ablation, 84.2% of the members avoid high CF during energy
intraluminal probe (SensiTherm™, FIAB, Firenze, Italy) had no signifi­       delivery at the posterior wall, 76.3% reduce ablation power and/or dur­
cant impact on the incidence of endoscopically diagnosed esophageal          ation at the posterior wall, 63.2% avoid consecutive lesions at sites with
lesions. The total prevalence of esophageal lesions was 10%, and peak        risk of esophageal injury, 10.5% use mechanical esophageal deviation,
temperature measured by the thermoprobe did not correlate with               and 2.6% use esophageal cooling.
Catheter and surgical ablation of atrial fibrillation                                                                                                                          41


8. Ablation strategies


                                                                                                              Category of                   Type of evidence
     Ablation strategies
                                                                                                                advice
     ..............................................................................................................................................
     Pulmonary vein isolation
     Electrical isolation of the PVs is required during all AF ablation procedures                                                        META236,238,241,243–245,
                                                                                                             Advice TO DO                247,248,253,294,304,566,622,788


     Achievement of electrical isolation requires, at a minimum, assessment and demonstration                                               META236,238,241,243–
                                                                                                             Advice TO DO            245,247,248,253,294,304,566,622,788–792
       of entrance block into the PVs
     A waiting period (e.g. 20 min) following initial PVI may be reasonable to monitor for PV
                                                                                                            Area of uncertainty                 RAND793–800
       reconnection
     Administration of adenosine 20 min following initial PVI, with reablation if PV reconnection
                                                                                                            Area of uncertainty           RAND794,796–798,801–807
       occurs, may be reasonable to improve PVI durability
     Pace capture–guided approach following PVI using RF energy may be reasonable to improve
                                                                                                            Area of uncertainty                 RAND808–810
       PVI durability
     Adjunctive ablation targets beyond pulmonary vein isolation
     If linear ablation lesions are deployed, mapping and pacing maneuvers are required to
                                                                                                             Advice TO DO                        OBS811–818
       document conduction block
     If a reproducible focal trigger that initiates AF is identified outside the PV ostia at the time of
                                                                                                             Advice TO DO                        OBS819–823
       an AF ablation procedure, ablation of the focal trigger is beneficial
     Vein of Marshal ethanol infusion is reasonable to facilitate achieving block in the lateral mitral    May be appropriate
                                                                                                                                               OBS196,824–826
       isthmus in patients with mitral annular flutter                                                           TO DO
     Ablation of areas of abnormal myocardial tissue identified with voltage mapping during sinus
                                                                                                            Area of uncertainty                 META827–829
       rhythm may be reasonable during persistent AF ablation
     Vein of Marshal ethanol infusion may be reasonable during persistent AF ablation                       Area of uncertainty                 RAND830–834
     Mapping and ablation of non-PV triggers may be reasonable during persistent AF ablation                Area of uncertainty                OBS819–823,835
     Isolation of the left atrial posterior wall may be reasonable during repeat ablation of
                                                                                                            Area of uncertainty                 META836–847
       persistent AF
     Ablation of MRI-detected atrial delayed enhancement areas is not beneficial during                      Advice NOT TO                      META848,849
                               a
       persistent AF ablation                                                                                      DO

 a
  It is reasonable to enrol patients in prospective RCTs to assess the utility of newer technologies.




8.1. Pulmonary vein isolation                                                                    placement in adjacent structures, and gradual decrease of pacing output
8.1.1. Endpoint of pulmonary vein isolation                                                      to demonstrate loss of far-field capture have also been proposed to dif­
                                                                                                 ferentiate far-field from near-field capture.851 Following PVI, it may not
Pulmonary vein isolation is the cornerstone of AF ablation and is required
                                                                                                 be possible to demonstrate PV sleeve capture in up to 20% of patients.
during all AF ablation procedures. The endpoint of PVI is achievement of
                                                                                                 This finding correlated with PV entrance block and with adenosine-proof
electrical disconnection between the PVs and the LA. This disconnection                          isolation.852
can be verified by documenting the absence of wavefront propagation                                 Initial studies of segmental PVI using non-irrigated catheters reported
from the LA to the PV (entrance block) and/or from the PV to the LA                              persistent PV to LA conduction in almost 40% of cases in the presence
(exit block). Pulmonary vein entrance block is confirmed with disappear­                         of entrance block, stressing the need to include exit block documentation
ance or dissociation of PV potentials recorded usually with a multipolar                         in the PVI procedural endpoint.853 However, recent studies of circumfer­
catheter. Pulmonary vein exit block is verified in the presence of non-                          ential PVI using contemporary RF ablation technology have indicated that
conducted spontaneous PV activity (isolated PV ectopics, PV tachycardia,                         unidirectional exit conduction in the presence of documented entrance
or PV AF) or during non-conducted PV pacing. During pacing from the                              block is extremely infrequent.790 Duytschaever et al.791 reported a
vein to assess PV to LA conduction, it is important to verify local PV cap­                      0.6% prevalence of residual PV–LA conduction after proven entrance
ture (usually recorded on a multipolar catheter) and to avoid inadvertent                        block.
far-field capture of the LAA (when pacing anteriorly in the left PVs) or                            Few studies have also assessed the impact of bidirectional vs. unidir­
SVC (when pacing anteriorly in the RSPV) that could erroneously suggest                          ectional (entrance only) block on acute PV reconnection rate and
the presence of persistent electrical connection.850,851 Pacing the poster­                      long-term arrhythmia outcome after PVI. Chen et al.792 showed that
ior and proximal aspect of the PVs is a simple method to avoid far-field                         bidirectional block of the PV–LA junction is associated with reduced
capture of these structures. Differential pacing maneuvers, catheter                             intraprocedural reconnection incidence compared with unidirectional
42                                                                                                                                            S. Tzeis et al.



block. However, in a retrospective cohort analysis, inability to demon­         isolation rates and both low rates of acute PV reconnection and atrial
strate exit block was not associated with increased risk of PV reconnec­        tachyarrhthmia recurrence in prospective studies. In a pilot study, the
tion in redo procedures.790                                                     incidences of first-pass and adenosine-proof isolation were both 98%,
   The reported very low rates of persistent PV–LA conduction in the            and single-procedure success was 91.3% at 1 year.558 Strict application
presence of entrance block using contemporary ablation technology in­           of criteria for contiguity and AI in CLOSE-guided PVI was shown to im­
dicate that this finding alone is an adequate procedural endpoint during        prove procedural and 1-year outcome over conventional CF-guided
PVI. However, exit block documentation may prove useful when veri­              PVI.559,886,887 In the CLOSE to CURE study, PVI using the CLOSE
fication of entrance block is ambiguous.                                        protocol resulted in significant reduction in the atrial tachyarrhthmia
                                                                                burden (documented by implanted cardiac monitor), which was main­
8.1.2. Pulmonary vein isolation using radiofrequency energy                     tained during longer follow-up.555
8.1.2.1. Electrogram parameters and impedance change                               A recent randomized study indicated that the optimal interlesion dis­
Changes in electrogram morphology have been proposed as                         tance in AI-guided ablation may be less than the 5–6 mm incorporated
indicators of lesion transmurality during RF energy delivery to achieve         in the CLOSE protocol with an interlesion distance of 3–4 mm provid­
PVI.589,854–857 Elimination of the negative component of the atrial uni­        ing higher first-pass isolation with lower AI targets and shorter proced­
polar electrogram during PVI procedure following the contiguous                 ure duration.888 Optimal interlesion distance may also vary according
‘point-by-point’ approach was demonstrated to be a marker of trans­             to the anatomic region being ablated.889 High-power short-duration
mural lesion creation in both animal and human studies.858,859                  circumferential PVI (50 W at all sites) using a standard CLOSE protocol
However, electrogram morphology-guided ablation has yielded variable            approach has been shown to reduce both total procedural duration
long-term outcomes when compared with ablation guided by contem­                and RF time, without increasing the complication rate compared with
porary lesion quality indicators (Section 8.1.2.2.).860,861 In a recent study   lower power settings.595,596,694,890–892
using AI and CLOSE protocol-guided PVI, change in the unipolar electro­            The LSI is another proprietary multi-parametric index incorporating
gram was not found to correlate with RF markers of an adequate lesion.          time, power, CF, and impedance during ablation, which also predicts the
Changes in unipolar electrogram morphology indicative of transmurality          extent of myocardial tissue lesions. Further studies on the value of quality
are completed within 5–7 s of energy application, well before completion        lesion indications for PVI and ablation beyond the PVs are warranted.
of AI-guided delivery of high-quality lesion.862,863                               A survey of the writing group showed that 82% of the members rou­
   Electrode impedance has long been proposed as an indicator of elec­          tinely use lesion quality indicators to guide energy delivery during PVI
trode–tissue contact and lesion size.864 Insufficient impedance fall            with RF ablation.
(<10 Ω) has been associated with LA to PV conduction recovery.865
                                                                                8.1.2.3. Waiting phase
However, the quantitative relationship between real-time contact
and impedance drop is complex and varies according to parameters in­            In the non–CF-monitoring ablation era, early detection (within 30–60 min
cluding absolute force and catheter orientation.866–870 Local impedance         with or without adenosine challenge) of PV reconnection and adjuvant ab­
monitoring using an ablation catheter with microelectrodes incorpo­             lation of PV reconnection sites was reported to reduce AF recurrence
rated into the catheter tip (IntellaNav Mifi OI™, Boston Scientific)            rate after PVI.793,801,893–896 Others demonstrated that immediate abla­
may improve the utility of impedance monitoring for lesion predic­              tion of early detected reconnection may not improve the long-term out­
tion.871–873 Further work is needed to refine the precise roles of cath­        comes despite the association of acute PV reconnection with late AF
eter and generator-derived biophysical parameters to reliably predict           recurrence.797 More recently, the use of the aforementioned lesion qual­
lesion formation and the impact on clinical outcome.                            ity prediction tools has called into question the necessity of a waiting
                                                                                phase after initial PVI. It is now known that suboptimal tissue–catheter
                                                                                CF during RF delivery can be associated with spontaneous early reconnec­
8.1.2.2. Lesion quality indicators                                              tion or dormant conduction after PVI.897 In the CIRCA-DOSE study,
The advent of irrigated RF catheters with incorporated CF-sensing me­           using contemporary AF ablation technologies, spontaneous reconnection
chanisms has seen the parallel development of real-time lesion predic­          was elicited in 5.4% of PVs in 16.0% of patients and was significantly more
tion algorithms integrating biophysical data (power, temperature,               prevalent among patients treated with CF-RF ablation when compared
duration of RF delivery, and CF) to provide an estimate of critical lesion      with cryoballoon ablation (22.3 vs. 12.8%, P = 0.03).798 While CF cathe­
characteristics including area, depth, and continuity.874 Early experience      ters were used in this study, AI, interlesion distance and other key
of CF and its impact on electrical reconnection after PVI was reported          features of the CLOSE protocol were not. Interestingly, acute intraproce­
in multiple prospective studies including TOCCATA, EFFICAS I, and               dural PV reconnection, even when eliminated by adjuvant ablation, was
EFFICAS II, revealing a higher likelihood for reconnection with lower           associated with significantly higher arrhythmia recurrence rate only in
CF and FTI values achieved.875–878 In the EFFICAS II study, lesion con­         the cryoablation group and not in the RF group. The implications of these
tiguity was associated with more durable PVI.878 Although important             differences remain uncertain, and the overall recurrence rates between
first steps, these FTI-based studies did not incorporate RF power or re­        the two approaches did not differ.798
gional variation in LA wall thickness. In addition to these parameters,            Several studies have specifically evaluated whether the incorporation of
catheter stability, contact angle, and respiration are important determi­       a waiting period in the procedural workflow improves arrhythmia out­
nants of RF lesion formation.875,879–882                                        come among patients undergoing RF PVI using contemporary technology.
   The AI is a marker of lesion quality that incorporates CF, time, and         A multicenter randomized study assessing potential impact of a 30 min
power in a weighted formula. It has provided accurate estimation of le­         waiting period and/or adenosine triphosphate (ATP) testing after PVI
sion depth in animal studies883 and a strong correlation with impedance         on long-term 3 year outcome demonstrated no improvement in freedom
drop during LA ablation.884 Although attractive to standardize work­            from AF recurrence when using any of these strategies.799 Another pro­
flow, none of the available lesion prediction tools has yet incorporated        spective multicenter study randomized consecutive paroxysmal AF pa­
real-time measurement of atrial wall thickness to guide RF delivery and         tients to AI-guided PVI with vs. without a 20-min waiting period and
provide relatively crude estimates of transmurality.756,885                     also found similar rates of arrhythmia recurrence at 1-year follow-up.800
   The CLOSE protocol refers to PV encirclement using CF-sensing                   In the context of these data and taking into consideration that a wait­
catheter targeting an interlesion distance ≤6 mm and AI ≥400 at                 ing period considerably prolongs procedure duration without docu­
posterior/inferior walls and ≥550 at roof/anterior wall.558 The                 mented improvement in arrhythmia-free outcomes, its incorporation
proof-of-concept AI targets have been associated with high first-pass           in contemporary procedural workflows is no longer considered
Catheter and surgical ablation of atrial fibrillation                                                                                                     43


necessary. However, the value of a waiting phase after PVI with newly            8.1.2.6. Loss of pace capture along pulmonary vein isolation line
introduced ablation protocols or energy sources, including PFA, merits           The pace capture approach is an adjunctive technique to evaluate the
further assessment.                                                              integrity of a circumferential ablation lesion set.807–809,904–906 In this
   A survey of the writing group showed that 57% of the members em­              method, bipolar pacing at a high output (10 mA, 2 ms pulse width) is
ploy a waiting period of at least 20 min following initial PVI when per­         attempted along the ablation line.808,809,904 The sites of local LA capture
forming RF ablation with CF-sensing catheters.                                   during SR are identified and ablated further until local capture is lost.
                                                                                 The pertinent procedural endpoint is PVI with absence of pace capture
8.1.2.4. Adenosine testing                                                       along the entire circumferential PVI line.808,906
Intravenous adenosine (or ATP) can be used to unmask dormant con­                   An RCT including paroxysmal AF patients revealed that the rate of
duction across circumferential PV ablation lines.798,802,898,899 Adenosine       freedom from AF was higher with a pace-guided approach than the
dose and the time elapsed since initial PVI are determinants of                  conventional method at 12 months as well as after a 5-year follow-
adenosine-induced PV reconnection.896,900 Adenosine is given as a rapid          up.808 However, other studies have not reproduced these findings.809
bolus followed by saline bolus at a dose required to achieve at least one           A survey of the writing group showed that 31.6% of the members
blocked P-wave or a sinus pause >3 s798,803,901 with 12–18 mg of adeno­          routinely perform pace capture testing along the ablation line after ini­
sine being sufficient to achieve AV block in most patients.803                   tial PVI when performing RF ablation.
    Although some data suggest that use of adenosine to identify
dormant conduction and guide further ablation may improve out­
comes,802 contradictory results have also been reported.805,806 The rou­         8.1.2.7. Inducibility of atrial fibrillation after pulmonary vein isolation
tine use of adenosine has not been consistently associated with improved         Electrophysiological and pharmacological stimulation approaches are
outcomes when compared with a no-adenosine strategy.805 A recent                 sometimes performed to test for inducibility of AF following PVI.
study indicated that patients without spontaneous or adenosine-provoked          Generally, stimulation protocols consist of rapid atrial pacing and/or high-
PV reconnection had better outcomes than those with acute reconnec­              dose isoproterenol infusion, which can vary widely between centers.
tion despite undergoing further ablation. Although the authors suggested         Inducible AF has been defined as anything from 30 s to 10 min of AF
that efforts should be directed towards ensuring an ideal ablation lesion at     with no clear consensus on this. In the event of inducible AF, several stud­
the first attempt to achieve durable PVI, this finding may also point to ana­    ies have tested the value of additional ablation targeting atrial tissue dis­
tomic variations that render durable isolation more difficult to achieve.798     playing CFAE and low-voltage areas.223 However, AF meeting the above
    In the CIRCA-DOSE study using CF catheters and FTI but not AI or             definitions can be induced in up to 49.5% of patients with no history of
the CLOSE protocol, adenosine-mediated reconnection was observed                 clinical AF.907 Inducibility is dependent on the induction protocol, the
in 5.7% of PVs in 17.2% of patients and was significantly more common            number of induction attempts, and the definition of inducibility.
after CF-RF ablation when compared with cryoballoon ablation (31.3               Contradictory results have been reported regarding the prognostic value
vs. 10.2%, P < 0.001).798 Adenosine-mediated reconnection was asso­              of non-inducibility or change in inducibility status after AF catheter abla­
ciated with higher AF recurrence rates in the cryoballoon-treated pa­            tion on long-term freedom from recurrent arrhythmias.908–911
tients but not with use of RF when additional ablation was                          A survey of the writing group showed that 15.8% of the members
performed to achieve PVI. Studies using the CLOSE protocol have in­              routinely employ AF inducibility after initial PVI when performing RF
dicated significantly higher rates of adenosine-proof isolation compared         ablation.
with a standard approach to PVI (97 vs. 82%), and this translated into
improved outcomes.559 Furthermore, a multicenter randomized study                8.1.3. Pulmonary vein isolation with cryoballoon ablation
evaluating potential benefit derived from employment of ATP testing              The cryoballoon is a double layer balloon that is introduced into the LA via
and/or prolonged waiting periods after PVI reported no significant dif­          a steerable sheath (Section 6.2.2.1.). Navigation to the individual PV is
ferences in freedom from AF recurrence over standard care.799                    achieved by a circular mapping catheter advanced through the central cath­
    Taking into consideration (i) the high rate of adenosine-proof PVI with      eter lumen and can be used to map PV potentials and thereby document
contemporary RF ablation technology including the CLOSE protocol,                PVI. Exceptionally, a stiff guidewire may be used if balloon positioning is
(ii) the lack of documented benefit on long-term outcomes derived                difficult. To completely occlude the PV, the balloon is positioned in align­
from adenosine testing post-PVI when contemporary RF technology                  ment with the PV axis, and specific maneuvers with the steerable sheath
is used, (iii) the questionable value of adjunctive ablation at adenosine-       are performed (hockey stick, pull down). The degree of occlusion may
unmasked reconnection sites for long-term outcomes, and (iv) the incre­          be verified by injection of contrast agent through the central lumen.
ment in procedural time and cost when employing adenosine testing, the           Commonly, a four-step grading score is used to describe the degree of oc­
routine use of adenosine testing post-PVI is not a requirement.                  clusion912 although other imaging modalities such as TEE or ICE may be
    A survey of the writing group showed that 21.6% of the members               used to reduce fluoroscopy exposure to near zero (Section 7.6.).913
routinely employ adenosine testing after initial PVI when performing             Invasive pressure monitoring through the central lumen has been de­
RF ablation with CF-sensing catheters.                                           scribed as a reliable tool to assess PV occlusion.914 Very recently, wide
                                                                                 band dielectric imaging, a non-fluoroscopic imaging modality, was reported
8.1.2.5. First-pass isolation                                                    to accurately assess PV occlusion and guide cryoballoon-based PVI.915
First-pass isolation is defined as achievement of PVI upon completion of            Various dosing strategies have been proposed. In animal experi­
the encirclement of ipsilateral PVs. First-pass isolation is an indicator of     ments, single applications with 120, 180, and 240 s freezing times led
high-quality lesion set with favourable impact on procedural outcome.            to transmural lesions and a high rate of durable PVI.916,917 In the rando­
In a real-world setting, first-pass isolation is highly predictive of 12-month   mized FIRE and ICE trials, a bonus application was added to the 240 s
clinical success after CF-guided ablation in paroxysmal AF patients,902          index application.294 In a more recent randomized study, no differences
while the absence of first-pass isolation is associated with inferior PVI        in PVI durability nor in clinical outcome were observed after 2 × 120 vs.
durability and AF ablation outcomes.903 CLOSE protocol-guided PVI is             2 × 240 s cryolesions per PV.293,918 Other studies showed that an em­
associated with higher incidence of first-pass isolation of the PVs and          piric bonus application does not improve outcome, if PVI occurs within
higher single-procedure arrhythmia-free survival at 1 year when com­             75 s after starting the cryoapplication (time to isolation—TTI).919,920
pared with conventional CF-guided PVI.558,559,887 First-pass isolation is        Findings from a metaanalysis endorse the use of a single freeze applica­
associated with reduced likelihood of acute PV reconnection, and there­          tion approach, the latter resulting in shorter procedure times and a
fore whenever achieved, the waiting phase post-PVI may be obviated.              lower adverse event rate without compromising efficacy.921
44                                                                                                                                          S. Tzeis et al.



   The optimal freeze duration is subject to controversy. Since side ef­          The incremental benefit of linear ablation beyond PVI to prevent AF
fects at adjacent structures, such as the PN and the esophagus, usually       recurrence has not been demonstrated in prospective RCTs, although
occur beyond 180 s, shorter application times may be desirable to             it is indicated for the interventional management of macroreentrant
maximize safety.922 However, data from remapping studies indicate a           AT, which may be encountered either during an AF catheter ablation
higher rate of durable PVI after single 240 s freeze applications com­        procedure or during follow-up.811,812 Incomplete linear ablation, i.e. de­
pared with 180 s without associated increase in complication rates.923        livering lesions in a linear pattern without achieving block, has the po­
Alternatively, individualized dosing strategies are used, where the           tential to be proarrhythmic and create the substrate for left ATs and
cryoapplication duration consists of the TTI plus a fixed time interval.      therefore should be avoided.815,818
In two randomized comparisons of a single 180 s fixed cryoapplication             The STAR-AF II study reported no improvement in ablation efficacy
protocol compared with a TTI plus 60–90 s-guided approach, no differ­         with linear ablation (lateral mitral line and roof line) in addition to PVI
ences in freedom from atrial tachyarrhythmias were seen.924,925               over PVI alone in patients with persistent AF.566 It should be noted that
   Most commonly, the TTI is used as a marker of adequate lesion for­         in the subgroup of patients allocated to the PVI plus lines group, bidirec­
mation. In addition, the slope of the temperature curve, the minimal          tional block across both roof and mitral lines was achieved in 74% of pa­
temperature, and the thaw time have been reported to be associated            tients. In a STAR-AF II subanalysis, freedom from arrhythmia recurrence
with durable PVI.926–928 On the other hand, achievement of balloon            was similar among patients with as compared to those without complete
temperatures <−60°C (using the Artic Front device) may prompt ter­            linear block.814 These data indicate that empirical linear ablation does not
mination of energy delivery to avoid collateral damage. In clinical prac­     confer incremental benefit over PVI alone among persistent AF patients,
tice, the procedure is usually concluded after the last energy application    irrespective of the quality of the deployed linear lesion and the achieve­
and documentation of PVI. However, a waiting time of 20 min or                ment of bidirectional block.814 Evidence from metaanalyses also support
provocation maneuvers such as adenosine testing to assess LA to PV            this conclusion.936,937 Further prospective, multicenter studies of linear
reconduction has been evaluated (Sections 8.1.2.3. and 8.1.2.4.).             ablation with durable bidirectional conduction block may be warranted
   In patients with variant PV anatomy, e.g. common trunks, PVI using         to establish its role in selected patients with AF.938
the 28 mm cryoballoon may be more challenging. In patients with short             A survey of the writing group showed that 0% of the members rou­
common trunks, sequential treatment of the individual branches is usu­        tinely performs empiric linear ablation (other than to isolate the poster­
ally performed. In patients with long common trunks, a segmental ap­          ior wall) during ablation of paroxysmal AF and 13.2% of the members
proach with different balloon orientations (superior, inferior) may be        when performing ablation of persistent AF.
applied. In various studies, a similar clinical outcome was reported fol­
lowing cryoballoon ablation in patients with standard PV anatomy when         8.2.3. Complex fractionated atrial electrogram ablation
compared with those with common PV ostium.929–931 However,                    Complex fractionated atrial electrogram represent low-voltage (0.06–
contradictory results have also been reported.932                             0.25 mV peak-to-peak bipolar amplitude), fractionated, high-frequency
   A survey of the writing group showed that 55% of the writing group         electrograms recorded during AF and were proposed to represent
members employ cryoablation dosing algorithms to modify cryolesion            sites of potential drivers for AF thus serving as a potential target for
duration based on real-time monitoring of elimination of PV potentials        catheter ablation. This approach was widely adopted for both paroxys­
and 55% stop prematurely the deployment of cryolesion after the first         mal and persistent AF.939 However, the pathophysiologic mechanisms
60 s if elimination of PV potentials has not been achieved. In the absence    underpinning the creation and stability of CFAE and their contribution
of real-time recording of PV potentials during cryoballoon ablation,          to AF maintenance were never clarified.940 Furthermore, there was no
43.8% of the writing group members deliver a cryolesion of 180 s,             universally accepted definition allowing for standardization.
9.4% of 210 s, and 47% of 240 s duration.                                        The multicenter prospective STAR-AF II study randomized 589 pa­
                                                                              tients with persistent AF to PVI plus linear ablation (259 patients), PVI
                                                                              plus ablation of CFAE (identified by automated software in the mapping
8.2. Adjunctive ablation targets beyond                                       system, 263 patients), or PVI alone (67 patients) and demonstrated no
pulmonary vein isolation                                                      benefit of either of these approaches over PVI alone.566 The CHASE
8.2.1. Cavotricuspid isthmus                                                  AF study randomized 205 patients to PVI alone or PVI plus CFAE
                                                                              ablation. The latter group also underwent linear ablation if atrial
Catheter ablation is the recommended treatment for the management
                                                                              macroreentry occurred. There was no significant improvement in
of patients with CTI-dependent AFl due to the high success rates asso­
                                                                              arrhythmia-free survival with addition of CFAE ablation.941 A meta-
ciated with low risk of procedural complications.269 In the CF catheter
                                                                              analysis comprising 1415 patients from 13 studies concluded that despite
ablation era, lesion quality indices can be employed to standardize le­
                                                                              acceptable procedural safety, CFAE ablation did not improve arrhythmia-
sion deployment and procedural workflow during CTI ablation.933–935
                                                                              free survival in paroxysmal, persistent, or long-lasting persistent AF.942
   A survey of the writing group shows that 92.1% of the writing group
                                                                              In a recent, large meta-regression and trial sequential analysis, CFAE ab­
members perform CTI ablation in patients with prior history or
                                                                              lation was shown to be ineffective as an adjunctive strategy in persistent
intraprocedural induction of CTI-dependent AFl during AF catheter abla­
                                                                              AF ablation, and further study of this ablation approach was considered
tion. A suggested approach regarding CTI ablation in patients under­
                                                                              futile.936 The enthusiasm for CFAE ablation to treat AF has therefore
going AF ablation and pertinent supporting evidence are presented
                                                                              waned and should be avoided in most cases to avoid proarrhythmic
in Section 4.4.3.
                                                                              lesions.

8.2.2. Linear lesions                                                         8.2.4. Stepwise approach to atrial fibrillation ablation
The origins of linear ablation for AF lie in the Cox maze procedure and       The stepwise approach, which incorporated both linear ablation and
its subsequent iterations (Section 12). The most common sites for linear      defragmentation to target termination of persistent AF either directly
ablation are the LA roof joining the superior aspects of the PV encircling    or via intermediate AT, has gradually fallen out of favour. The proced­
lesion sets, the region of tissue between the anteroinferior aspect of the    ure demonstrated early promise in patients with persistent and long-
left PV encirclement and the lateral mitral annulus (the ‘mitral isthmus’),   standing persistent AF particularly when achievement of SR was used
and an anterior line between the anterior mitral valve annulus and ei­        as an endpoint.242,943 However, subsequent studies have not repro­
ther the right PV encirclement (most common) or to the roof line or           duced these initial results reporting poor 5-year clinical outcomes
to the left PV encirclement.                                                  (20.1% single procedure and 55.9% multiple procedure arrhythmia-free
Catheter and surgical ablation of atrial fibrillation                                                                                                     45


survival at 5 years).944 Recurrence rates of atrial tachyarrhythmias are      reconnection and elevated esophageal temperature during the index
high, reflecting the proarrhythmic effect of either incomplete linear ab­     procedure.960–962 Alternate explanations for lack of demonstrated
lation and/or iatrogenic islands of atrial scar caused by CFAE ablation,      benefit from PWI include the following: (i) PVI alone using a wide antral
which may serve as anchors or isthmus borders for macroreentry                isolation strategy already encompasses much of the LAPW, potentially
and localized reentry.944 In a recent metaanalysis, a stepwise strategy       leaving little additional benefit from roof and inferior lines; (ii) the con­
for persistent AF ablation had no significant impact on freedom from          tribution of the posterior LA to persistent AF mechanism is not univer­
atrial arrhythmia recurrences.936                                             sal, and a ‘one size fits all’ approach may be ineffective; or (iii) survival of
                                                                              epicardial LAPW tissue. This allows the possibility that posterior LA
8.2.5. Left atrial posterior wall isolation                                   isolation may have a role in a specific group of persistent AF patients.
The LAPW shares a common embryological origin with the PVs and                In a recent subgroup analysis of the CAPLA study, it was found that pa­
shares some of the PV arrhythmogenic properties.945,946 Extensive             tients with short cycle length posterior LA activity did derive a benefit
parasympathetic neural plexi located at the LAPW and extending to             from PWI, indicating that this may be a determinant of which patients
the PV antrum may also contribute to the initiation and maintenance           will have improved outcomes with this additional step.963
of AF.207,208,947 Therefore, electrical isolation of the LAPW as an ad­          Hybrid ablation has also been used to target LAPW as part of an ab­
junct to PVI seems to be a reasonable approach to increase the success        lation strategy in patients with persistent and long-standing persistent
rate of catheter ablation in AF patients.                                     AF (Section 12.3.3.2.).
    Several catheter ablation techniques have been proposed for                  A survey of the writing group showed that 15.8% of the members
achievement of PWI including: (i) posterior wall box isolation (circum­       perform PWI during first-time and 26.3% when performing redo
ferential PVI with deployment of roof and inferior lines connecting the       ablation of paroxysmal AF. Furthermore, 31.6% of the writing group
superior and inferior margins of PV rings, respectively), (ii) single ring    members perform PWI during first-time and 65.8% when performing
isolation (en-bloc encirclement of PVs and posterior wall),948,949 and        redo ablation of persistent AF.
(iii) posterior wall debulking (extensive focal ablation of the posterior
wall without linear lesion deployment).836 Cryoballoon ablation has           8.2.6. Substrate ablation
also been used for PWI, although adjuvant RF ablation may be needed           A range of conditions has been demonstrated to promote the develop­
in up to 45.5% of patients.950–953 Posterior wall ablation is also feasible   ment of abnormal atrial substrate.964 These include classically recog­
with a pentaspline PFA catheter.657,954,955 In the PersAFOne study, PFA       nized factors associated with AF such as hypertension, HF,965
ablation under ICE guidance resulted in low-voltage posterior wall            diabetes, and advanced age.966 Recently, other conditions have been
homogeneity with first pass in all 24 patients without primary safety         shown to drive atrial substrate development such as obesity,109,967
events. Interestingly, invasive remapping 2–3 months postablation de­         sleep disordered breathing,362 excess alcohol intake,459,968 and pro­
monstrated no evidence of conduction through the posterior wall in            longed high-intensity training in certain athletic sports.969 The patho­
100% of patients and partial voltage recovery of the PW-ablated area          physiologic mechanisms underlying areas of abnormal electrical
in 3 of 21 patients.657                                                       substrate include regional fibrosis, loss of cellular coupling due to loss
    Prior trials investigating PWI plus PVI in comparison with PVI alone in   of connexin, inflammation, and adipocyte infiltration into tissues.108,518
patients with AF have yielded conflicting results (Table 8). Although smal­   These changes promote AF initiation and maintenance (Section 2.4.—
ler non-randomized, retrospective trials showed promising results, more       Figure 1).
recent large prospective RCTs have demonstrated negative results. Yu             Electroanatomical mapping and cardiac MRI have both been utilized to
et al.956 randomized 113 patients to PVI alone or PVI plus posterior LA       define the atrial substrate, albeit using quite different surrogates of atrial
isolation and an anterior line and demonstrated no improvement in out­        fibrosis—bipolar voltage and late gadolinium signal intensity, respectively.
come. The POBI-AF trial randomized 217 patients with persistent AF to         Ablation guided by electroanatomical voltage mapping is a patient-tailored
PVI alone or PVI plus posterior wall box isolation, the latter defined as     approach targeting low-voltage areas, either by encirclement leading to
voltage abatement <0.1 mV, bidirectional block of the roof line, and docu­    isolation or direct ablation of the entire low-voltage area.829,970
mentation of both entrance and exit block. Sixty-nine percent of the pos­     Endpoints of this approach include local voltage reduction, elimination
terior LA isolation group also underwent an anterior line. Using              of fractionated electrograms, and regional isolation. Preliminary observa­
intermittent Holter monitoring, the reported freedom from any docu­           tional studies suggested the potential for favourable outcome.836,971–973
mented AF without AADs was similar in the PVI alone and the PVI plus          Several randomized trials have evaluated whether adjuvant ablation of
PWI groups.837 In the recent CAPLA study, 338 patients with symptom­          low-voltage areas may provide incremental benefit on rhythm outcome
atic persistent AF undergoing first-time RF ablation were randomized to       among paroxysmal or persistent AF patients. In the VOLCANO trial in­
either PVI (wide antral circumferential) plus PWI (roof and floor line de­    cluding 398 patients with paroxysmal AF and the STABLER-SR II trial in­
ployment plus ablation of earliest electrograms within the box if needed)     cluding 300 patients with persistent AF, low-voltage area ablation in
or PVI alone. Contact force–sensing catheters were used with specific le­     addition to PVI did not improve arrhythmia-free survival.827,974
sion quality targets, and the follow-up monitoring was intense (twice daily   However, the recent STABLE-SR-III trial randomized 438 older patients
ECG transmissions). There was no difference in the primary study end­         with paroxysmal AF to PVI plus low-voltage area ablation or PVI alone
point with 53.3% freedom from AF at 12 months in the PVI group as com­        and showed a significant incremental benefit derived by low-voltage
pared to 54.1% in the PVI + PWI group.838                                     area ablation in this patient population.975 In all trials, LA voltage mapping
    One explanation for the lack of incremental benefit from catheter         was performed during SR with a low-voltage cutoff <0.5 mV.
ablation of the LAPW could be the inability to achieve durable electrical        A recent prospective RCT presented evidence supporting the con­
isolation. Pertinent challenges stem from (i) the significant variation in    cept of substrate ablation in persistent AF patients.828 The ERASE AF
thickness of the septopulmonary bundle that is the dominant structure         study enrolled 324 patients who were randomized to PVI only (163 pa­
in the LAPW, (ii) difficulties in achieving transmural lesion at the LAPW     tients) or PVI plus substrate modification (161 patients). Substrate
roof due to insulation of the epicardial muscular bundle by fat inter-        modification was only performed in the subset of patients (34%) found
position,179 and (iii) a tendency to lower the power and duration of en­      to have low-voltage regions (voltage threshold 0.5 mV) during SR map­
ergy delivery during LAPW ablation to prevent thermal injury to the           ping. The primary study endpoint (first recurrence of an atrial arrhyth­
neighbouring esophagus.959,960 In fact, LAPW reconnection rates               mia >30 s after a single procedure) was reached in 50% of PVI only
have been reported to be as high as 40–100%, with predominantly pos­          patients and 35% of PVI plus substrate modification group at 12 months
terior location, while an association has been shown between LAPW             (HR = 0.62, 95% CI = 0.43–0.88, P = 0.006).828
                                                                                                                                                                                                                     46

Table 8 Clinical trials comparing left atrial posterior wall isolation plus PVI vs. PVI alone in AF patients undergoing catheter ablation

Study             Study design                   Number of patients                                       Ablation strategy                                                   Outcome
............................................................................................................................................................................................
Wong           RCT                     67 persistent AF patients (PVI + PWI: 39,       PVI vs. PVI + PWI                                               No difference in atrial arrhythmia recurrence rate
 et al.957                               PVI: 28)                                        PWI: box with additional ablation lesions within the box         between the PVI + PWI and PVI only groups at a
                                                                                         as needed                                                        median follow-up of 12.4 ± 3.0 months (25.6 vs. 28.6%;
                                                                                                                                                          P = 0.79)
Kistler        RCT                     338 symptomatic persistent AF patients          PVI (wide antral circumferential) plus PWI (roof and floor      No difference in the primary study endpoint at 12 months,
  et al.838                              (first ablation) (PVI + PWI: 170, PVI: 168)     lines deployment plus ablation of earliest electrograms          with 52.4% freedom from recurrent atrial arrhythmia
                                                                                         within the box if needed) or PVI alone                           after a single ablation procedure without AADs in the
                                                                                                                                                          PVI + PWI group as compared to 53.6% in the PVI
                                                                                                                                                          group (P = 0.98)
Jiang          Pooled analysis of 26   3287 paroxysmal and persistent AF               PWI: both box and non-box ablation lesions                      In persistent AF, adjunctive PWI was associated with
   et al.839     studies (9 RCTs)        patients receiving PVI + PWI                                                                                     substantially lower recurrence of all atrial arrhythmias
                                                                                                                                                          (risk ratio: 0.74; 95% CI: 0.62–0.90, P < 0.001) and AF
                                                                                                                                                          (risk ratio: 0.67; 95% CI: 0.50–0.91, P = 0.01),
                                                                                                                                                          particularly when only randomized data were examined
                                                                                                                                                       PVI + PWI using a non-box lesion was associated with
                                                                                                                                                          significantly less recurrence of AF (OR: 0.30; 95% CI:
                                                                                                                                                          0.22–0.41).
Jankelson      Consecutive series      321 paroxysmal AF patients (PVI: 214; PVI       PVI vs. PVI + PWI                                               Recurrence at 1 year:
   et al.958                             + PWI: 107)                                     PWI consisted of a roof line connecting the LSPV and          PVI group: 14% vs. PVI + PWI group: 15% (P = 0.96)
                                                                                         RSPV along with a low posterior line connecting the
                                                                                         inferior PVs
Ahn            RCT                     100 persistent AF patients undergoing first     PWI: additional cryoballoon ablation lesions at 9–13            Atrial tachyarrhythmia recurrence during a mean
  et al.953                              ablation (PVI only: 50 vs. PVI + PWI: 50)       different locations on the LAPW.                                follow-up of 457.9 ± 61.8 days:
                                         with cryoballoon                                                                                              PVI only: 46%
                                                                                                                                                       PVI + PWI: 24%, P = 0.035
Sirico         Consecutive series      73 persistent and long-standing persistent      PWI: roof line joining the 2 superior PVs and inferior line     PWI + PVI was able to reduce the mean atrial arrhythmic
   et al.840                             AF patients receiving PWI + PVI                linking the 2 inferior PVs                                       burden by more than 50% compared with preablation,
                                                                                                                                                         reporting very low levels (≤5%) over 2 years
Tokioka        Consecutive series      181 persistent AF patients (PVI only: 91 vs.    PWI: Pentaray was placed at the posterior wall to record        At a median follow-up of 19 months:
  et al.841                              PVI + PWI: 90)                                  electrical potentials                                         AF recurrence:
                                                                                       Endpoint was defined as the absence of electrical activity      PVI only: 47.3%
                                                                                         and inability to capture outside the posterior wall during    PVI + PWI: 31.1% (P = 0.35)
                                                                                         pacing with the Pentaray catheter with 5 mA output            Persistent AF recurrence:
                                                                                         from the posterior LA                                         PVI only: 20.9%
                                                                                                                                                       PVI + PWI: 5.6% (P = 0.002)
Pothineni      Consecutive series      196 paroxysmal (61%) and persistent             PVRI vs. PWI ± PVRI                                             Freedom from atrial arrhythmias off AADs at 1 year:
  et al.842                              (39%) AF patients undergoing repeat           PWI consisted of linear lesions across the LA roof and          PVRI: 69.9% vs. PWI ± PVRI: 43.7% (P = 0.5)
                                         ablation (PVRI: 93; PWI ± PVRI: 103)            floor connecting the previous circumferential lesion sets
                                                                                         that were used for left and right PVI, with additional
                                                                                         lesions at sites of earliest activation within the ‘box’ if
                                                                                         needed

                                                                                                                                                                                                         Continued
                                                                                                                                                                                                                     S. Tzeis et al.
Table 8 Continued

Study              Study design                     Number of patients                                       Ablation strategy                                                   Outcome
............................................................................................................................................................................................
Salih           Metaanalysis of 6        1334 persistent AF patients (PVI: 663; PVI      PVI vs. PVI + PWI                                              At 21.6 ± 13 months:
  et al.843      studies                   + PWI: 671)                                                                                                  AF recurrence rate:
                                                                                                                                                        PVI only: 29.1%
                                                                                                                                                        PVI + PWI: 19.8%, risk ratio: 0.64; 95% CI: 0.42–0.97, P <
                                                                                                                                                           0.04
                                                                                                                                                        Atrial arrhythmia recurrence rate:
                                                                                                                                                        PVI only: 41.1%
                                                                                                                                                        PVI + PWI: 30.8%, risk ratio: 0.75; 95% CI: 0.60–0.94, P <
                                                                                                                                                           0.01
Sutter          Retrospective study      558 persistent AF patients undergoing           PVI vs. PVI + PWI vs. PVI + lines                              Sinus rhythm at 6 months:
                                                                                                                                                                                                                         Catheter and surgical ablation of atrial fibrillation




  et al.844                                initial and repeat ablation (PVI: 255, PVI    PWI: linear ablation along the LA roof to connect LSPV         PVI: 73.9% vs. PVI + lines: 72.2% vs. PVI + PWI: 57.7%
                                           + PWI: 78, PVI + lines: 225)                     and RSPV and linear ablation along the LA floor to
                                                                                            connect inferior PVs
                                                                                         Lines: one or more of the following: mitral isthmus, LA
                                                                                            roof, or cavotricuspid isthmus line
Yamaji          RCT                      Persistent AF patients without LA               +PWI: PVI + PWI + SVCI + CTIA                                  AF/AT recurrence at median 62.7 weeks:
  et al.845                                 low-voltage area                             −PWI: PVI + SVCI + CTIA                                          +PWI: 25% vs. −PWI: 15% (P = 0.311)
                                         Electrophysiological test subgroup: 57          PWI: roof line joining the two superior PVs and inferior
                                            (+PWI: 24; −PWI: 33)                            line connecting the two inferior PVs
Lee et al.837   RCT                      207 persistent AF patients (PVI: 105; PVI +     PVI vs. PVI + PWI                                              Freedom from atrial arrhythmia without AAD at 1 year:
                                            PWI: 102)                                    PWI: roof line joining the two superior PVs and inferior       PVI: 50.5% vs. PVI + PWI: 55.9% (P = 0.522)
                                                                                            line connecting the two inferior PVs with touch-up
                                                                                            ablation at the PW if needed to achieve exit block
                                                                                            (additional anterior line at the physician’s discretion)
McLellan        Consecutive series       161 persistent AF patients undergoing           PWI: roof and inferior wall lines with the endpoint of         Adenosine-induced reconnection of the PW was
 et al.846                                 circumferential PVI followed by PWI              bidirectional block                                           demonstrated in 17%
                                           (no-adenosine challenge: 107, adenosine                                                                      Freedom from recurrent atrial arrhythmia at 19 ± 8
                                           challenge: 54)a                                                                                                months: adenosine challenge: 65% vs. no-adenosine
                                                                                                                                                          challenge: 40% (P < 0.01)
Bai et al.836   Prospective              52 persistent AF patients (PVI only: 20; PVI    PWI: PVI was extended to the CS and to the left side of the    Freedom from atrial arrhythmia without AADs at 1, 2, and
                  non-randomized            + PWI: 32)                                     interatrial septum, along with extensive ablations on the      3 year follow-ups:
                  trial                  All patients underwent a second procedure         LAPW                                                         PVI: 20, 15, and 10%, respectively
                                            3 months after the first procedure           At 3 months, electrophysiology study was performed in all      PVI + PWI: 65, 50, and 40%, respectively, P < 0.001
                                                                                           patients to confirm durability of the PWI and PVI
Kim             RCT                      120 persistent AF patients (PVI + lines: 60     Roof, anterior perimitral and CTI lines with conduction        Recurrence at 1 year:
  et al.847                                vs. PVI + lines + PWI: 60)                      block were performed in all patients                         PVI + lines: 36.7% vs. PVI + lines + PWI: 16.7%, P = 0.02
                                                                                         PWI: additional posterior inferior line connecting inferior
                                                                                           PVs

AAD, antiarrhythmic drug; AF, atrial fibrillation; CI, confidence interval; CS, coronary sinus; CTIA, cavotricuspid isthmus ablation; LA, left atrium; LAPW, left atrial posterior wall; LSPV, left superior pulmonary
vein; OR, odds ratio; PV, pulmonary vein; PVI, pulmonary vein isolation; PVRI, pulmonary vein reisolation; PWI, posterior wall isolation; RCTs, randomized controlled trials; RSPV, right superior pulmonary vein;
SVCI, superior vena cava isolation.
a
 Adenosine challenge to assess dormant conduction in the PVs and PW.
                                                                                                                                                                                                                         47
48                                                                                                                                                S. Tzeis et al.



   Despite recent encouraging results, methodologic challenges inher­             ablation procedure containing many components of the stepwise ap­
ent to the strategy of low voltage–guided substrate modification re­              proach. In this study, the majority of patients received mitral isthmus abla­
main. Voltage measurements are not only dependent on rhythm                       tion, LAPW isolation, and CFAE ablation. The study demonstrated that
status (AF vs. SR), size, and configuration of the recording electrodes           adjunctive VoM ethanol infusion significantly improved the off-AAD
and catheter–tissue contact but can also vary up to three-fold according          arrhythmia-free survival (49.2 vs. 38%, P = 0.04).830 Although these data
to atrial rate and wavefront directionality.976 Furthermore, voltage              are encouraging, the standard ablation procedure in this study was exten­
parameters indicative of abnormal substrate lack objective definition             sive, non-standardized, with significant differences between the compared
and low-voltage cutoffs vary considerably among different investigators.          groups and included, at the operator’s discretion, empiric linear ablation,
A one size fits all voltage cutoff does not consider regional variations in       CFAE ablation, and LAPW isolation most frequently in combination. In a
atrial wall thickness, nor again the nature of the recording electrodes.          VENUS substudy, the favourable impact of VoM ethanol infusion was po­
Ultimately, identification of substrate may require a more sophisticated          tentiated when performed in high-volume centers and when perimitral
analysis incorporating not only voltage but also electrogram morph­               block was achieved.833 The benefit of VoM ethanol infusion when added
ology and possibly measures of regional atrial conduction.                        to PVI has yet to be shown to improve outcomes over PVI alone.
   Cardiac MRI-LGE has been used to identify and localize cardiac fi­                In a recently published randomized trial, VoM ethanol infusion as the
brotic areas in a variety of cardiac diseases, including AF.92,105,512            first step in mitral isthmus linear ablation was shown to significantly reduce
Attempts to ‘calibrate’ electroanatomic voltage mapping using                     the number of RF applications needed to achieve mitral isthmus block.826
MRI-LGE have reported LA voltages between 0.2 and 0.45 mV as de­                  Pambrun et al.193 recently reported results of the ‘Marshall-PLAN’ pro­
marcating LA scar.977 Correlations of variable strength between LA                cedure for persistent AF. This procedure adds VoM ethanol infusion to
voltage mapping and atrial histology have been reported.105,512,978               a lesion set including PVI, linear lesions (posterior mitral line, roof line,
The DECAAF study reported that the severity of MRI-defined atrial fi­             and CTI line), LA ridge, ‘saddle’ (between the LSPV and the LAA), and ex­
brosis was a predictor of AF recurrence following AF catheter ablation,           tensive CS ablation. Implementation of this ablation strategy in an obser­
thereby supporting a role for MRI-LGE in the preprocedural evaluation             vational cohort of 75 consecutive patients with persistent AF (duration
of atrial substrate (Section 5.2.1.4.). This requires considerable experi­        9 ± 11 months) resulted in a 72% freedom from arrhythmia recurrence
ence of atrial LGE imaging, specific imaging sequences, and access to             at 12 months off-AAD after a single procedure.834 A randomized trial
a reproducible image processing workflow, which to date has limited               comparing the Marshall-PLAN ablation approach with PVI only in persist­
the widespread uptake of this technique.                                          ent AF patients is ongoing (NCT 04681872).
   In the ALICIA trial, 155 symptomatic, drug-refractory AF patients                 A survey of the writing group shows that 5.3% of the members em­
(54% paroxysmal AF) undergoing first or repeat ablation were rando­               ploy VoM ethanol infusion when performing first-time persistent AF
mized to either PVI or PVI plus MRI-guided ablation of fibrotic areas             ablation and 26.3% during redo ablation of persistent AF.
by either homogenization or isolation.848 Fibrotic areas outside the PV
antra were identified in only half of the patients, and their ablation did        8.2.8. Ablation of non-pulmonary vein triggers
not reduce arrhythmia recurrence rate at 1 year of follow-up.848 In               Pulmonary vein isolation is a highly effective procedure in patients with
the recent much larger DECAAF-II trial, 843 persistent AF patients                paroxysmal AF, in whom spontaneous PV firing is frequently the only
were randomized to either MRI-guided fibrosis ablation plus PVI or                trigger for AF paroxysms.981 However, recurrence of arrhythmia has
PVI alone. The primary composite of atrial arrhythmia recurrence or re­           been reported in up to 20% of paroxysmal AF patients in the presence
peat ablation did not differ between the two groups after a median                of isolated PVs.982,983 These observations have driven approaches to­
follow-up period of 273 days (43.0 vs. 46.1%; P = 0.63). Furthermore,             wards identification and targeting of non-PV triggers. Non-PV triggers
there was a significantly higher occurrence of the primary safety compos­         have been described originating from specific anatomic regions includ­
ite outcome in the fibrosis-guided ablation plus PVI group (2.2 vs. 0%, P =       ing the LAPW, SVC, CS, VoM, crista terminalis, interatrial septum, and
0.001), largely driven by higher ischemic stroke events.849 Therefore, one        LAA.984 In addition, persistent left SVC has also been reported as a site
should avoid additional ablation based on MRI-detected fibrosis pending           of AF triggers.985
development of better MRI resolution and future studies.                              Electrical LAA isolation has been proposed as a strategy to eliminate
   A survey of the writing group showed that 0% of the members per­               potential LAA triggers with varying reported success. In the prospective,
form ablation of MRI-detected or voltage mapping-detected abnormal                randomized BELIEF trial, 173 patients with long-standing persistent AF
atrial myocardial areas during first-time and 18.4% during redo ablation          were randomized to either empirical endocardial LAA electrical isolation
of paroxysmal AF. Furthermore, 13.2% of the writing group members                 plus extensive ablation (PVI plus ablation of PW, part of the LA septum,
perform ablation of MRI- or voltage mapping-detected abnormal atrial              non-PV triggers, and SVC) vs. extensive ablation alone at the index pro­
myocardial areas during first-time and 31.6% during redo ablation of              cedure. At 12-month follow-up, patients with LAA isolation had a higher
persistent AF.                                                                    freedom from atrial arrhythmias.986 A large propensity score–matched
                                                                                  study and a metaanalysis of nine studies in non-paroxysmal AF patients
8.2.7. Vein of Marshall ablation                                                  undergoing catheter ablation concluded that LAA isolation significantly in­
The VoM is an embryological remnant of the left upper caval system that           creased freedom from all atrial arrhythmia recurrence without increased
possesses arrhythmogenic potential and has been proposed as a target              risk of acute procedural complications.987,988 In a metaanalysis of seven
during AF catheter ablation979 (Section 3.5.). Ethanol infusion into the          studies assessing impact of LAA isolation on AF recurrence utilizing vari­
VoM has been proposed as an adjunctive ablation strategy in persistent            ous approaches, including ablation, surgery, and ligation by Lariat, LAA iso­
AF, acting not only by eliminating this arrhythmogenic structure but              lation was shown to be associated with a significantly lower rate of AF/AT
also providing collateral benefits including autonomic modulation and par­        recurrence.989 The authors concluded that further randomized studies
tial ablation of LA areas that are routinely targeted during circumferential      were nevertheless required to confirm safety and efficacy of this ap­
isolation of left PVs and lateral mitral isthmus line deployment.825 In a large   proach. However, the multicenter prospective randomized aMAZE trial
cohort of consecutive patients treated with ethanol infusion in the VoM,          in 610 patients with symptomatic persistent and long-standing persistent
the reported feasibility was almost 90% during the first attempt, with pre­       AF did not show a benefit in arrhythmia-free survival with addition of LAA
vious CS ablation reported as the only predictor of failure, while the re­        ligation with the Lariat epicardial suture device on top of PVI (404 pa­
ported complication rate was 2.0%.980                                             tients) vs. PVI alone (206 patients).990
   The VENUS trial was a prospective RCT that evaluated potential incre­              Several studies have reported a high incidence of LAA thrombus for­
mental benefit derived by VoM ethanol infusion in addition to an extensive        mation and increased risk of thromboembolism after endocardial LAA
Catheter and surgical ablation of atrial fibrillation                                                                                                             49


isolation using RF energy despite adequate OAC therapy.991–993                             A survey of the writing group showed that 31.6% of the writing
Intracardiac thrombus formation is identified in one-fifth of patients                  group members employ mapping and ablation of non-PV triggers during
undergoing wide area LAA isolation and the respective rate of                           first-time and 68.4% during redo ablation of paroxysmal AF, while
stroke/TIA is 6–9.8%.991,992 Interventional LAA occlusion may be                        34.2% during initial ablation of persistent AF and 73% during redo ab­
protective against thromboembolism in this clinical setting.991 In a non-               lation of persistent AF. Furthermore, 83.8% of writing group members
randomized study of 166 patients with durable LAA isolation, interven­                  employ mapping and ablation of non-PV triggers in redo AF ablation
tional LAA occlusion was associated with significant reduction in                       procedures when all PVs remain isolated. In addition, 0% of the writing
thromboembolic complications when compared with OAC therapy.994                         group members perform LAA isolation during first-time persistent AF
Randomized trials are needed to document the efficacy of this prevent­                  ablation and 5.3% when performing redo persistent AF ablation.
ive approach. Considering the modest evidence supporting the value of
LAA isolation as a stand-alone adjunct to PVI in persistent AF patients                 8.2.9. Ganglionated plexi ablation
and the associated increased risk of thrombus formation and thrombo­                    The cardiac ANS plays an important role in the initiation and mainten­
embolism, this ablation strategy may be only justified during redo abla­                ance of AF.123,126,208,210,211,998–1005 The GP, containing the cardiac
tion procedures in persistent AF patients and after informing the                       parasympathetic and sympathetic ganglia, are located on the epicardial
patient for the need of permanent thromboprophylaxis or mechanical                      aspect of the PV antra and are frequently ablated during PVI (Section
closure of the LAA.                                                                     3.7.). Their functional localization is possible with high-frequency stimu­
   Routine identification and ablation of non-PV triggers is limited by                 lation (cycle length 50 ms, 12–15 V, 10 ms pulse width), manifesting as
the absence of standardized induction protocols, differences in trigger                 sinus bradycardia or AV nodal conduction delay or block.999,1005
definition, and paucity of prospective randomized studies indicating a                  However, the sensitivity of endocardial high-frequency stimulation to
benefit of this approach either in denovo or repeat procedures.                         identify GP sites is not optimal.210
Induction protocols have used varying amounts of isoprenaline up to                        Ganglionated plexi ablation plus PVI has been variably reported to
20 μg/min or higher and burst pacing to induce AF followed by cardio­                   improve the outcome following AF ablation in some RCTs.1006,1007
version to initiate trigger activity. Variable trigger definitions have been            However, in the prospective randomized AFACT study, adjunctive epi­
proposed, including triggers resulting in AF paroxysms or repetitive                    cardial GP ablation during thoracoscopic AF surgery did not improve
focal activity even isolated atrial ectopics. In a randomized study of per­             freedom from AF recurrence but was associated with an increased
sistent AF patients, empiric ablation of common non-PV trigger sites in                 risk of major complications.1008 Due to the inconsistent RCT outcomes
addition to PVI did not improve outcome compared with PVI combined                      and the technical challenges associated with high-frequency stimulation,
with ablation of only documented non-PV triggers.835 Prevalence of                      the evidence in support of this approach is modest.
triggered ectopics has varied widely according to population and tech­                     A survey of the writing group showed that 2.7% of the members per­
nique used.995–997 More data are needed to establish a consensus on                     form GP ablation during first-time ablation of paroxysmal or persistent
the characterization and ablation of non-PV triggers.                                   AF ablation and 0% during redo ablation of paroxysmal or persistent AF.


9. Postprocedural management

     Postprocedural management                                                                                             Category of advice      Type of
                                                                                                                                                   evidence
     ..............................................................................................................................................
     Systemic anticoagulation is beneficial for at least 2 months following catheter ablation of AF                          Advice TO DO             OPN
     Postprocedural initiation of DOACs rather than VKAs is beneficial in patients not previously on anticoagulation
                                                                                                                             Advice TO DO         META1009–1013
       undergoing AF ablation
     Adherence to AF anticoagulation guidelines is beneficial for patients who have undergone an AF ablation
                                                                                                                             Advice TO DO             OPN
       procedure, regardless of the apparent success or failure of the procedure
     Administration of antiarrhythmic drugs following AF catheter ablation is reasonable in selected patients to prevent    May be appropriate
                                                                                                                                                  META1014–1021
       early postablation AF recurrence.                                                                                         TO DO
     In patients who have not been anticoagulated prior to AF catheter ablation or with interrupted anticoagulation         May be appropriate
                                                                                                                                                      OPN
       prior to ablation, administration of a DOAC 3–5 h after achievement of hemostasis is reasonable                           TO DO
     A same-day discharge protocol is reasonable in selected patients undergoing AF ablation                                May be appropriate
                                                                                                                                                  OBS1022–1030
                                                                                                                                 TO DO

     Administration of proton pump inhibitors for 2–4 weeks following catheter ablation may be reasonable to reduce
                                                                                                                            Area of uncertainty   OBS1031–1033
       the risk of esophageal lesions
     Discontinuation of anticoagulation may be reasonable 12 months following catheter ablation after shared
       decision-making in patients with CHA2DS2-VASc score 1 in males and 2 in females in the absence of clinical
                                                                                                                            Area of uncertainty       OPN
       symptoms or documented AF recurrence when patients and their physician are committed to long-term
                           a
       rhythm monitoring
     Patients in whom discontinuation of anticoagulation is being considered based on patient values and preferences
                                                                                                                            Area of uncertainty       OPN
       should undergo continuous or frequent ECG monitoring to screen for AF recurrence

 a
  Daily pulse or ECG monitoring, ECG-based wearables, or invasive rhythm monitoring.
50                                                                                                                                          S. Tzeis et al.



9.1. Sheath removal—hemostasis                                                9.3. Postprocedural pharmacological
achievement                                                                   management
After completion of the ablation procedure, ensuring adequate hemo­           9.3.1. Anticoagulants
stasis is of primary importance to reduce the risk of vascular complica­      9.3.1.1. Early postprocedural (the first 2 months)
tions. Sheaths can be removed after waning of heparin’s anticoagulant         Anticoagulation is recommended for at least 2 months following cath­
effect or while the patient is on full anticoagulation. In the former         eter ablation for all patients regardless of CHA2DS2-VASc score in
case, sheaths should be removed when the ACT is <200–250 s or after           prior guidelines and consensus documents.5,1041 This is due to endothe­
reversal of heparin effect with protamine infusion. Two RCTs and a re­        lial damage, an inflammatory state, and potential stunning of atrial myo­
cent metaanalysis of five studies have consistently shown that the use of     cardium following ablation and/or cardioversion. In patients not
protamine after catheter ablation significantly expedites vascular hemo­      previously on anticoagulation, initiation of DOACs rather than VKA
stasis and patient ambulation by about 3 h without associated increase        is preferred postablation because of the immediate effect that does
in vascular or thromboembolic complications.729,1034,1035 This favour­        not require bridging with UFH or LMWH.1009–1013 In patients who
able effect should be weighed against a 1.2% risk of adverse reaction         had not been anticoagulated or who did not take their last DOAC
to protamine often presented with profound hypotension.1036 A sur­            dose prior to the procedure, administration of the DOAC 3–5 h after
vey of the writing group showed that 57.9% of the members routinely           sheath removal is advisable, provided there is no evidence of mechanical
use protamine to reverse heparin anticoagulation effect after comple­         complications. In patients who require lifelong anticoagulation with
tion of AF ablation.                                                          VKA (e.g. mechanical heart valve or rheumatic heart disease), it is re­
   A figure-of-eight suture technique (with the use of either a knot or a     commended that ablation be performed on uninterrupted VKA.299
three-way stopcock to secure suture in place) has been proposed for
achieving hemostasis after catheter ablation obviating the need for man­
ual compression of the puncture site.1037–1039 This technique significantly   9.3.1.2. Late postprocedural (more than 2 months)
reduces the time required for hemostasis and patient’s post-procedure         The management of anticoagulation beyond the early postprocedural
time in the electrophysiological lab, without associated increase in bleed­   period after AF ablation remains controversial. Prior guidelines have re­
ing complications when compared with manual compression.1038,1039             commended continuing anticoagulation based on the patient’s stroke
Closure of venous access sites with specialized devices also shortens         risk profile rather than the presumed success or failure of the
time to postablation hemostasis and patient ambulation and reduces            ablation.5,1041
the need for pain medications, without significant difference in the inci­        In the absence of high-quality evidence, long-term anticoagulation
dence of minor or major access site complications.1040                        after AF ablation in patients with CHA2DS2-VASc score ≥2 for men
                                                                              or ≥3 for women is considered beneficial for a number of reasons:
                                                                              (i) recurrences of AF are common both early and late following AF ab­
                                                                              lation; (ii) asymptomatic AF is common and is even more common fol­
9.2. Duration of                                                              lowing than prior to AF ablation1042; (iii) there have been no large,
hospitalization—same-day discharge                                            randomized prospective trials that have assessed the safety of discon­
Catheter ablation for AF has typically been performed as an in-patient        tinuing anticoagulation in this patient population; (iv) while registry
procedure with at least one overnight stay. Given the increasing de­          data suggested a lower risk for stroke in patients undergoing AF abla­
mand for AF ablation, same-day discharge protocols have increasingly          tion compared with matched AF controls,1043,1044 the largest prospect­
been adopted to minimize health care resource utilization.1022–1024           ive randomized trial on AF ablation, the landmark CABANA trial, failed
Avoiding overnight hospital stay increases patient satisfaction and           to show a reduction in the risk of subsequent stroke in patients under­
may also have benefits for the patients such as reduced risk of infection.    going ablation.1045 This is in line with a metaanalysis of randomized con­
Metaanalyses of observational studies have shown that same-day dis­           trolled trials of AF ablation vs. AAD treatment, which also did not find a
charge was successful in >80% of the planned cases, and the reported          significant benefit of ablation over AAD treatment with regard to the
safety outcomes were favourable. No differences in 30-day complica­           subsequent risk of stroke258; (v) several studies have shown a temporal
tions or 30-day readmissions were identified between the patients             dissociation between ischemic stroke and episodes of AF,1046–1048
with same-day discharge compared with those with overnight hospital           which suggests that AF might be a marker of increased thrombo
stay.1025,1026,1029 Moderate quality evidence from a recent randomized        embolic risk rather than a causal factor; and (vi) stroke risk is a lifelong
trial supports the safety of same-day discharge after cryoballoon AF ab­      consideration and increases with age such that patients many years
lation.1027 Feasibility and safety of same-day discharge has been re­         from an apparently successful ablation will be at higher risk than
ported even when implemented as default management strategy in                when the decision to stop anticoagulation was made.
consecutive patient cohorts.1028 Overall, same-day discharge after AF             Arguments against the long-term management of postablation antic­
ablation appears to be a safe strategy in selected patients provided          oagulation based solely on stroke risk score include the following: (i) pa­
that appropriate institutional protocols and patient pathways are estab­      tients in SR without evidence of AF have generally no indication for
lished to identify suitable patients and ensure adequate follow-up.1030       anticoagulation and (ii) long-term and possibly lifelong continuation of
Eligibility criteria for same-day discharge include, but are not limited      anticoagulation has a small, yet significantly increased risk of severe
to, uncomplicated catheter ablation, at least 3–6 h of postprocedural         bleeding complications, which in some patients may outweigh the po­
monitoring, achievement of complete hemostasis, well-tolerated am­            tential benefits on stroke prevention.
bulation, normal vitals signs at discharge, and absence of symptoms               In the absence of RCTs comparing cessation vs. continuation of an­
or concerning comorbidities.1022 A standardized same-day discharge            ticoagulation after AF ablation, several metaanalysis have summarized
protocol based on specific eligibility criteria has been described, and       available data from non-randomized studies.1049–1051 In summary, a de­
its safety has been validated in a large multicenter prospective              creased thromboembolic risk and a favourable net clinical benefit from
registry.1029                                                                 continued anticoagulation were generally seen in patients with
   A survey of the writing group showed that 23.7% of the members             CHA2DS2-VASc ≥2, while no significant benefit was found from con­
implement a default strategy of same-day discharge, while 57.9% em­           tinued anticoagulation in patients with a CHA2DS2-VASc ≤1. This is im­
ploy a same-day discharge management protocol in selected patients            portant when interpreting individual studies that did not show an
following AF catheter ablation.                                               increased stroke risk with discontinuation of anticoagulation after AF
Catheter and surgical ablation of atrial fibrillation                                                                                               51


ablation. Many AF ablation cohorts are skewed towards enrolment of            and ICM. In addition to the binary detection of episodes of AF recur­
low-risk patients with CHA2DS2-VASc ≤1. Accordingly, the overall              rence, implantable devices can also quantify the burden and duration
background stroke risk in those cohorts is low, and the number of po­         of AF episodes, both of which correlate with stroke risk.1053,1054
tential high-risk patients with CHA2DS2-VASc ≥2 is often too small to         Most of the implantable cardiac devices have remote monitoring cap­
show a disadvantage of discontinuation of anticoagulation.                    abilities and could potentially be used to guide intermittent ‘on demand’
   The ongoing OCEAN trial (Optimal Anti-Coagulation for                      anticoagulation during periods of AF. This strategy could be attractive in
Enhanced-Risk Patients Post–Catheter Ablation for Atrial Fibrillation,        patients with paroxysmal AF, especially in younger, active ones who
NCT02168829) is enrolling subjects at risk for stroke as indicated by         may have a risk for bleeding complications related to everyday activities.
a CHA2DS2-VASc ≥1 and who have not had clinically apparent atrial                The first large, randomized trial, IMPACT, showed no benefit of such
arrhythmias for at least 12 months after their most recent AF abla­           an intermittent on demand anticoagulation strategy over standard con­
tion.1052 Eligible patients are randomized to anticoagulation with rivar­     tinued anticoagulation in 2718 ICD-patients with regard to thrombo­
oxaban 15 mg daily vs. aspirin 75–160 mg daily and followed for the           embolism and bleeding.1055 Among other factors, the use of VKA in
primary composite endpoint of clinically overt stroke, systemic embol­        the majority of patients, rather than DOACs, might have negatively af­
ism, and covert stroke based on brain MRI during 3 years of follow-up.        fected the results of this study given the delay in achieving therapeutic
The results of OCEAN will provide important data to inform                    anticoagulation. More recently, two small pilot studies have tested the
future management of anticoagulation after successful AF ablation.            strategy of an intermittent on demand anticoagulation with DOACs in
Additional clinical trials however will be needed to define the long-term     device recipients. Using single-arm designs in 48 patients and 59 pa­
stroke risk and the need for continued anticoagulation after AF ablation      tients, such an approach was feasible and decreased anticoagulation
overall as well as for selected patient subgroups, especially in those with   utilization by 75 and 94%, respectively.1056,1057 The studies were not
presumptive successful AF elimination after ablation.                         designed to assess the clinical outcomes of stroke or bleeding.
                                                                                 The concept of using continuous ECG monitoring by means of ICM
9.3.1.3. Candidates to discontinue anticoagulation                            or intensified non-invasive ECG monitoring using wearable devices is of
                                                                              potential interest as an adjunctive tool to guide anticoagulation after AF
Discontinuation of anticoagulation may be considered in several patient
                                                                              ablation. This strategy needs to be tested in prospective studies using
categories following AF catheter ablation.
                                                                              appropriate cutoffs for AF burden and AF duration before it could
    Low-risk patients (CHA2DS2-VASc 0 in men and 1 in females). In low-risk
                                                                              be recommended for routine clinical practice. Furthermore, the strat­
patients, anticoagulation should be discontinued 2 months after abla­
                                                                              egy of ‘on demand’ anticoagulation is limited by the reported temporal
tion regardless of the ablation outcome. Based on current guidelines,
                                                                              dissociation between AF and stroke, which casts doubt on the value of
risk-benefit assessment does not justify antithrombotic protection in
                                                                              guiding initiation and discontinuation of anticoagulation based on
these patients, irrespective of their rhythm status.522
                                                                              rhythm criteria.1046,1047 A prospective randomized study testing the
    Intermediate-risk patients (CHA2DS2-VASc 1 in men and 2 in females). In
                                                                              strategy of intermittent vs. continuous DOAC administration based
this patient category, discontinuation of anticoagulation may be consid­
                                                                              on symptoms and smartwatch-detected AF is currently underway
ered 12 months following catheter ablation in the absence of clinical
                                                                              (REACT-AF).
symptoms or electrocardiographically documented AF recurrence.
The writing group suggests deferral of OAC discontinuation until the          9.3.2. Antiarrhythmic drug treatment
completion of 12 months following catheter ablation in this patient cat­
                                                                              Several prospective RCTs assessed the value of routine AAD adminis­
egory, to increase the likelihood of selecting patients with truly success­
                                                                              tration in the immediate postablation period.1014–1019 EAST-AF was
ful AF elimination. A proposed prerequisite to maximize safety after
                                                                              the largest study and randomized 2038 AF patients (68% paroxysmal)
discontinuation of anticoagulation is that both patients and their physi­
                                                                              to 3 months of AAD treatment postablation or standard medical ther­
cians are committed to long-term rhythm monitoring (daily pulse or
                                                                              apy without AAD. While more patients remained free from atrial ar­
ECG monitoring, digital heart rhythm devices, or invasive monitoring)
                                                                              rhythmias during the 3-month blanking period in the AAD group
to screen for AF recurrence and guide accordingly the reinitiation of
                                                                              (59.0 vs. 52.1%, P = 0.01), no difference was observed 1 year after ab­
anticoagulant treatment.
                                                                              lation (69.5 vs. 67.8%, P = 0.38).1014 Aggregation of all studies in
    Higher risk patients (CHA2DS2-VASc ≥2 in men and ≥3 in women). In
                                                                              metaanalyses confirmed the effectiveness of short-term AAD therapy
higher risk patients, anticoagulation should not be discontinued for sev­
                                                                              in preventing early but not late relapses after discontinuation.1020,1021
eral reasons mentioned above. However, if discontinuation of anticoa­
                                                                              Given the psychological and financial burden of arrhythmia-related hos­
gulation is being considered based on strong patient values and
                                                                              pitalizations and cardioversions during the blanking period, short-term
preferences and despite prior clarification of pertinent exposure to in­
                                                                              continuation of AAD for several months after the ablation should be
creased thromboembolic risk, patients should be placed under regular
                                                                              considered in selected patients to prevent early AF recurrence, particu­
rhythm monitoring to screen for AF recurrence. As stated above, this
                                                                              larly those with persistent AF prior to ablation or who have tolerated
may include daily pulse or ECG monitoring, digital wearable heart
                                                                              antiarrhythmic medications prior to ablation. In others who experience
rhythm devices, or invasive monitoring, and selection of monitoring op­
                                                                              AAD-related side effects, discontinuation after ablation is reasonable.
tion should be individualized after detailed discussion with the patient.
                                                                                 A survey of the writing group showed that 57.8% of the writing
In case of documented AF recurrence, therapeutic anticoagulation
                                                                              group members administer AADs during the blanking period as a strat­
should be reinitiated. In addition, LAA occlusion may be discussed as
                                                                              egy to prevent early AF recurrences after paroxysmal AF ablation and
an alternative approach. The ongoing OPTION trial (NCT03795298)
                                                                              86.8% after persistent AF ablation.
is a prospective, randomized study to determine if LAA closure is a rea­
sonable alternative to OAC in patients after AF ablation.                     9.3.3. Proton pump inhibitors
                                                                              Damage of the esophagus is one of the most feared complications of AF
9.3.1.4. Targeted anticoagulation (on demand) postablation                    ablation. Esophageal lesions on routine endoscopy were found in 10–
When assessing the need for continued anticoagulation after AF abla­          15% and ulcerations in about 5% of patients after AF ablation.693
tion beyond the blanking period, the key question is whether the abla­        Atrioesophageal fistulae occur in 0.016–0.1% of AF ablation proce­
tion was successful in eliminating AF. Unfortunately, the answer to this      dures.1058–1067 It is hypothesized that AEF results from a double hit in­
question is difficult to ascertain in most patients. The exception is pa­     jury starting with a transmural ablation lesion extending through the
tients with implantable cardiac devices including pacemakers, ICDs,           atrial wall to the esophagus followed by subsequent ulcer erosion
52                                                                                                                                            S. Tzeis et al.



from gastroesophageal reflux (Section 11.3.1.).1068 Based on this pre­           correlation between symptoms and underlying rhythm following AF
sumed mechanism, administration of proton pump inhibitors (PPIs)                 catheter ablation, 53.8% of recorded AF episodes were asymptomatic,
to prevent ulceration has been widely adopted after LA ablation proce­           with an increase in asymptomatic episodes from the acute to the chron­
dures.1031 Evidence to support or disprove this practice is limited.             ic period after ablation.1080 In the DISCERN-AF study, continuous
A preclinical study found that progression of esophageal ulcer and               monitoring of symptomatic AF patients before and after catheter abla­
development of AEF after ablation were associated with reflux                    tion with an ICM demonstrated that the ratio of asymptomatic to
esophagitis.1032 A substudy of the MADE-PVI trial suggested a reduc­             symptomatic AF episodes significantly increased from 1.1 before to
tion in esophageal lesions as assessed by endoscopy in patients with             3.7 after ablation with 12% of patients having asymptomatic recur­
preprocedural use of PPI.1033 However, in a large-scale, retrospective,          rences only.1042 In the CIRCA-DOSE study, the 1-year arrhythmia-free
propensity score-matched analysis, the use of PPI before or on the day           survival based on the presence of documented recurrence of either
of ablation was not associated with reduced mortality or severe                  symptomatic or asymptomatic atrial tachyarrhythmia lasting >30 s on
esophageal injury within 30 days postablation.1069 Adequately powered            continuous cardiac monitoring was 52.6%, while the respective survival
clinical trials to establish the efficacy of pharmacological prophylaxis to      free from symptomatic only arrhythmia recurrences was 85.3%.7
reduce AEF are lacking and unlikely to be feasible given the low inci­           Consequently, symptoms are not well correlated with postablation
dence of AEF.                                                                    AF burden, stressing the need for postprocedural follow-up strategies
   Preclinical experience suggests a very low risk (if any) for esophageal       consisting of continuous or intermittent ambulatory rhythm monitor­
injury647 with PFA, and no AEF has been reported with early clinical use         ing in addition to symptom-driven rhythm assessments.
so far.643,644 Accordingly, the value of PPI postablation treatment in
PFA cases is less compelling.                                                    9.4.1. Continuous postablation rhythm monitoring
   A survey of the writing group showed that 79% of the members em­              Continuous rhythm monitoring includes ICM, pacemakers, or ICDs and
ploy short-term administration of PPI as a strategy to prevent esopha­           allows for continuous, remote, long-term monitoring in asymptomatic
geal lesions following catheter ablation when using non-PFA energy               and symptomatic individuals. Pacemakers and ICDs with an atrial lead
sources, while 54% when using PFA.                                               may record intracardiac atrial electrograms and detect atrial high-rate
                                                                                 episodes as an indicator of AF occurrence. The positive predictive value
9.3.4. Anti-inflammatory agents                                                  of recorded atrial high-rate episodes varies upon the programmed rate
Early AF recurrence in the first few weeks following AF ablation has             and duration thresholds, with false-positive rates of 17.3% for episodes
been linked to inflammation induced by the ablation procedure.                   lasting >6 min and 3.3% with threshold duration >6 h.1081 Long-term
Routine anti-inflammatory treatment may reduce the incidence of early            subcutaneous ICM can facilitate continuous AF monitoring based on
relapses of AF after ablation and potentially also long-term recurrence.         R–R interval analysis over a time period of up to 4.5 years.1082,1083
   Colchicine has been studied for this purpose in two prospective ran­          These continuous ECG monitoring devices have been used in several
domized trials. A 3-month course of treatment with colchicine 0.5 mg             studies to evaluate the results of catheter or surgical AF abla­
twice daily compared with placebo resulted in a reduction of AF recur­           tion.7,244,1084,1085 Although ICM hold promise for the determination
rences up to 90 days (16 vs. 34%, P = 0.01).1070 Interestingly, the              of AF burden in the long term, AF detection algorithms are primarily
3-month treatment with colchicine also improved long-term outcomes               based on R–R interval regularity, and pertinent limitations include re­
with reduced recurrence rates at 1 year (31 vs. 50%, P = 0.01).1071 The          duced specificity due to undersensing of beats, oversensing of myopo­
benefit in terms of AF recurrence also translated into benefits in QoL           tentials, and irregular atrial and ventricular premature beats, as well as
and psychological score. However, these data have not been repro­                limited memory resulting in electrograms not being retrievable to verify
duced and are limited by small sample size.                                      the correct rhythm diagnosis.1086,1087 Continuous rhythm monitoring
   Corticosteroids have also been used as a short-term treatment after           devices are more expensive, require implantation, and may not be avail­
AF ablation to reduce recurrences.1072–1076 Study designs were incon­            able in all healthcare settings. A continuous rhythm monitoring strategy,
sistent with regard to the duration of steroid treatments (single dose vs.       although invasive, overcomes many of the limitations of intermittent
several days). Most of the studies showed a decrease in early recur­             monitoring in assessing arrhythmia recurrence and offers the oppor­
rence rates until 3 months, but no difference with regard to late recur­         tunity to determine the most accurate estimate of AF ablation out­
rence. It is also possible that steroids may limit ablative lesion healing. In   comes.1086–1088 In those patients in whom the decision is made to
view of the potential side effects of steroids, when applied over weeks          continue long-term anticoagulation regardless of ablation outcome,
or even months, as well as the limited and inconclusive data available,          the cost and effort of continuous rhythm monitoring is likely not
steroids after ablation should only be used cautiously and for short             warranted.
durations.
                                                                                 9.4.2. Intermittent postablation rhythm monitoring
                                                                                 Intermittent rhythm monitoring includes standard 12-lead ECGs, am­
9.4. Rhythm monitoring following catheter                                        bulatory patch or electrode ECG monitors, transtelephonic monitoring
ablation                                                                         systems, and patient and automatically activated external recor­
Arrhythmia monitoring postablation is useful to detect asymptomatic              ders.1089,1090 The wide availability of direct-to-consumer mobile health
postprocedural arrhythmia recurrences and determine the etiology                 devices for heart rate and rhythm assessment equipped with either
of symptomatic palpitations. Palpitations may result from recurrent              ECG-based or photoplythesmography-based technology has increased
AF or other atrial tachyarrhythmia but may also result from atrial or            the availability of rhythm monitoring options in the postablation set­
ventricular premature beats and therefore are not an accurate predict­           ting.1091,1092 In a study conducted after AF ablation, a smartphone-
or of AF recurrence.1077 In the CIRCA-DOSE trial, only 45% of the                based single-lead system was compared with transtelephonic monitor
symptom-triggered activations were adjudicated as AFl or AF during               ECGs with 100% sensitivity and 97% specificity in detecting AF or
the postablation continuous monitoring of paroxysmal AF patients                 AFl.1090 A pilot randomized study demonstrated that the use of a self-
using an ICM.7                                                                   monitoring strategy with an ECG-based hand-held device for rhythm
   Multiple studies have demonstrated that asymptomatic AF common­               assessment in patients after AF ablation resulted in a similar rate of
ly occurs in patients following catheter ablation. Two studies reported          AF detection and less requirement for additional ECG monitoring
that the proportion of asymptomatic AF events was 11–35% prior to                when compared with the standard-of-care follow-up practice.1093
and 53–65% after ablation.1078,1079 In another study assessing the               Furthermore, long-term intermittent monitoring with an ECG-based
Catheter and surgical ablation of atrial fibrillation                                                                                                    53


hand-held device was shown to be significantly more effective in detect­         available, longer duration recordings with 7-day or 14-day continuous
ing AF recurrences after AF ablation when compared with short,                   monitoring are preferable.
continuous (Holter) heart rhythm monitoring.1094 The potential of in­
tegrating similar monitoring paradigms in the postablation care of AF            9.5. Early recurrences after
patients is being evaluated in a multicenter international project.1095
   Intermittent monitoring is limited by reduced sensitivity in detecting        ablation—postablation blanking period
sporadic arrhythmias, resulting in underdetection of recurrences, which          9.5.1. Incidence and pathophysiology of early recurrence
inflates estimates of arrhythmia-free survival. Such misclassification er­       after atrial fibrillation ablation
rors likely affect the accuracy and precision of comparative risk esti­          Recurrences of atrial tachyarrhythmia (AF or AFl or AT) may occur in the
mates. In a secondary analysis of the CIRCA-DOSE trial enrolling                 initial weeks to months after catheter ablation, leading to unplanned hos­
paroxysmal AF patients undergoing catheter ablation, the sensitivity             pitalizations or emergency department visits.1097 Some of these early re­
for detecting postablation arrhythmia recurrences was shown to in­               currences may resolve with time. Therefore, employment of an initial
crease with the intensity of intermittent rhythm monitoring.7                    blanking or blinding period is recommended when reporting efficacy out­
Commonly employed intermittent monitoring protocols (three short-                comes.1098 Recurrence of any type of atrial tachyarrhythmia during that
duration 24 and 48 h ambulatory Holter ECG monitors) failed to de­               period is not counted as treatment failure, and invasive treatment like re­
tect a considerable proportion of recurrences (sensitivity 15.8 and              peat ablation is usually not considered. However, the underlying patho­
24.5%, respectively) and demonstrated poor agreement with the true               physiological mechanisms responsible for early re-currence of AF,
AF burden.7 Based on computational simulation, an intermittent post­             without late AF occurrence, are not well understood.1099
ablation monitoring with a minimum cumulative duration of 28 days on                Short-term processes lasting hours to days and long-term processes
an annual basis, using serial longer term (7-day and 14-day) ambulatory          lasting weeks to months may be operative during the initial period after
ECG devices, provides a reasonable arrhythmia detection (sensitivity             AF ablation. These processes may be proarrhythmic or antiarrhythmic.
nearly 60%) and quantification of AF burden (nearly 80% agreement)               Short-term processes include ischemia, myocardial necrosis, oxidative
when compared with the gold standard of continuous monitoring                    stress, and myocardial edema.1100–1102 Long-term processes include lo­
with ICM.7 In a recent systematic review, intermittent monitoring                cal and systemic inflammation,1101–1105 nerve sprouting after neural
was associated with detection of significantly less atrial arrhythmia re­        damage,1106 proliferative tissue repair, and scar maturation.1102,1107–
currences than continuous monitoring in paroxysmal AF, but not in                1109
                                                                                       Better understanding of the underlying mechanisms for early recur­
persistent AF or paroxysmal-persistent combined arms.1096                        rence and delayed response to ablation will potentially lead to identifi­
                                                                                 cation of therapeutic targets for AF ablation. Furthermore, the duration
                                                                                 of blanking period can also be better defined.
9.4.3. Practical considerations on postablation rhythm                              The incidence of early recurrences after AF ablation is highly depend­
monitoring                                                                       ent on the type and intensity of implemented monitoring protocol
The suggested pattern and intensity of postablation rhythm monitoring            (Section 9.4.). As a result, there is remarkable variability in the reported
should be tailored based on whether patient management is part of rou­           incidence of early recurrences after AF ablation, which ranges from 16
tine clinical care or part of a clinical research trial. Monitoring strategies   to 67%.1110–1112 In a prespecified analysis of the CIRCA-DOSE study,
implemented during routine clinical care may be less strict and standar­         the rate of early postablation recurrences documented by continuous
dized than in clinical trials, since documentation of asymptomatic arrhyth­      rhythm monitoring was 61%, with a median interval of 12 days between
mia recurrences in everyday practice does not affect decision-making in          the index ablation procedure and the first early recurrence.1110 Several
postablation management except in patients where discontinuation of              studies have shown similar incidence of early recurrences between RF
anticoagulation is considered or in the presence of impaired ventricular         and cryoballoon ablation.1110,1113
function (Section 9.3.1.3.). In this context, as part of routine clinical           Multiple predictors for early recurrences after AF ablation have been
care, rhythm status should be assessed during regular follow-up within           identified, and many are also predictive of late recurrences and long-term
2–3 months after ablation with a minimum standard of a 12-lead ECG.              treatment failure.1114–1123 Baseline characteristics predictive of early re­
In the absence of symptoms, all patients should be evaluated on an annual        currences after AF ablation include older age, female gender, presence of
basis thereafter with a 12-lead ECG in every follow-up visit (Section 9.6.).     structural heart disease, longer AF duration prior to ablation, non-
In case of arrhythmia symptoms, some type of intermittent rhythm mon­            paroxysmal AF, higher CHA2DS2-VASc scores, larger LA size, impaired
itoring is suggested. Intensity and type of monitoring should be individua­      renal function, HF, and presence of LA epicardial adipose tis­
lized based on symptom severity, frequency, availability of monitoring           sue.518,1118–1124 Acute procedural predictors for early recurrences after
tools, associated cost, and patient preferences.                                 AF ablation include incomplete PVI and multiple AF foci.1125–1127 Other
   In the clinical trial setting, it is evident that continuous invasive mon­    predictors include markers of inflammation and increased levels of
itoring represents the gold standard of postablation monitoring and              C-reactive protein and homocystein.1128,1129
intermittent monitoring of prolonged duration with longer term ambu­
latory ECG devices stands as best alternative.7 However, their standar­          9.5.2. Duration of blanking period
dized employment in clinical trials would increase substantially the cost        The blanking period following catheter ablation has been introduced to
of trial conduction and would prevent consistency in trial reporting and         blind monitoring and efficacy assessment during the initial postablation
comparisons with historical controls. In addition, the availability of long­     phase during which detected recurrences do not necessarily indicate
er term ambulatory ECG devices is limited in several practices thus im­          treatment failure. It should be noted that the absence of early recur­
pairing widespread implementation of prolonged duration monitoring               rences during the blanking period is strongly predictive of freedom
regimens. Furthermore, prolonged duration intermittent rhythm mon­               from late recurrence. Calkins et al.1117 reported that patients free
itoring can be burdensome for patients and may result in reduced                 from AF recurrence during the 3-month blanking period have 90% like­
compliance.                                                                      lihood of remaining free from AF recurrence at a 12-month follow-up
   Based on the above considerations, the writing group suggests that,           or longer (89% negative predictive value for paroxysmal and 91% for
in the clinical trial setting and in the absence of invasive monitoring,         persistent AF). On the other hand, the predictive value of an early re­
a minimum of 24-hour continuous Holter type monitor should be con­               currence for a late recurrence is highly variable. Special characteristics
sidered every 3 months for the first year following catheter ablation,           of early recurrences after AF ablation have been identified to be more
preferably in combination with symptom-based monitoring. Where                   predictive of later recurrence and bear important implications for the
54                                                                                                                                            S. Tzeis et al.



optimal blanking period. Increasing number of early recurrences within          experienced recurrence during a mean follow-up of 15 months.1139 No
the blanking period is predictive of late recurrence. In a study involving      difference in outcome was observed for early (within 90 days of ablation
300 patients undergoing AF ablation with PVI and elimination of non-PV          procedure) or late (90–180 days following ablation procedure) cardiover­
triggers, patients experiencing multiple early recurrences spanning the         sion. In a retrospective study of 180 patients (60% persistent AF) who
initial 6 week postablation period had lower long-term ablation success         underwent electrical cardioversion due to early AF recurrence (within
compared with those with isolated or no early recurrences.1130 A                7 days) following RF AF ablation, successful electrical cardioversion
single-center study of 196 consecutive patients undergoing AF ablation          occurred in two-thirds of patients but had no impact on long-term
using continuous monitoring during follow-up demonstrated that the              rhythm outcome compared with unsuccessful cardioversion.1140
higher the burden of AF recurrences during the blanking period, the                In contrast, other studies reported beneficial effect of timely electric­
higher the likelihood of long-term AF recurrence.1131                           al cardioversion of early recurrence after AF ablation. In a large propen­
   Multiple studies have shown that the timing of early recurrences             sity score–matched cohort of patients with early recurrence following
within the blanking period is crucial in the prediction of long-term ab­        catheter ablation, successful electrical cardioversion was associated
lation failure. In a study involving 331 patients undergoing cryoballoon        with significant reduction in the 1-year AF recurrence rate.1141 In a pro­
ablation for AF, all patients who experienced early recurrence in the se­       spective cohort, early cardioversion of postablation recurrences was
cond half of the 3-month blinding period developed late recurrence of           associated with a favourable long-term rhythm outcome.1142 In a study
AF afterwards.1132 In a retrospective analysis of 3681 AF patients trea­        of patients undergoing surgical AF ablation, postoperative implementa­
ted with cryoballoon ablation, early recurrence within 1 month after            tion of an intensive rhythm control strategy, including systematic use of
ablation was shown to significantly predict the occurrence of long-term         cardioversion, led to a significantly higher proportion of patients main­
arrhythmia recurrences.1133 In the ADVICE trial, 401 patients with par­         tained in SR during follow-up.1143 Timely cardioversion of early
oxysmal AF undergoing PVI were followed for 12 months with transte­             recurrences after catheter ablation also impacts long-term rhythm out­
lephonic monitoring.1134 Early recurrence of atrial tachyarrhythmia             come. In a retrospective analysis of 384 consecutive patients with per­
occurred in 44.6% of patients, and the risk of late recurrence varied sig­      sistent arrhythmia following catheter ablation, early cardioversion
nificantly according to the timing of the early recurrence. One year            within 30 days of arrhythmia recurrence was an independent predictor
freedom from AF recurrence was 77.2% in patients without early re­              of SR maintenance.1144
currence compared with 62.6, 36.4 and 7.8% in patients with early re­              With the current evidence, it is reasonable to consider cardioversion
currence in the first, second, and third month after ablation,                  in patients with early recurrence after catheter ablation, especially with­
respectively.1134 In a prespecified substudy of the CIRCA-DOSE trial,           in 30 days of arrhythmia onset. If early AF recurs after cardioversion,
occurrences of early recurrence in the first, second, and third month           pharmacological pretreatment and waiting several weeks for inflamma­
of blanking period were associated with 4.9, 26.8, and 63.4 times higher        tion to subside before repeat cardioversion are reasonable.
likelihood of late recurrence of atrial tachyarrhythmia.1110 Early recur­
rences occurring later than 52 days following catheter ablation had a
95% specificity for predicting late recurrence.1110 Several studies have        9.5.3.2. Early reablation
also shown that the risk of late recurrence is inversely related to the         Early reablation is another possible treatment option for early recur­
timing of early recurrence within the blanking period.1135–1137                 rences after catheter ablation. Few studies have evaluated the impact
   With the current evidence, a consensus among the members of this             of early reablation on long-term rhythm outcome. In a retrospective
writing group has been reached to recommend an 8-week blanking period           study of 302 consecutive AF patients, early reablation within the first
after AF ablation. This cutoff was agreed while placing emphasis to minim­      month after the index procedure was shown to significantly reduce
ize misclassification of patients with early recurrences that are not indica­   the incidence of further recurrences with an associated increase in
tive of treatment failure and their pertinent exposure to an unnecessary        the total number of procedures over the entire follow-up.1145 In the
need for redo ablation procedure. The writing group supports the use of         STOP-AF trial, 245 patients with paroxysmal AF were randomized to
the revised 8-week blanking period in future clinical trial design.             either medical therapy or cryoballoon ablation. Early AF recurrence
                                                                                within the first 3 months after ablation occurred in 51.5% of patients
9.5.3. Management of early recurrences after catheter                           and was significantly associated with late recurrence. Early reablation
ablation                                                                        was independently associated with lower risk of late recurrence.
                                                                                However, patient allocation to reablation was non-randomized, and
Pharmacological management has been shown to prevent early ar­
                                                                                nearly half of patients with early recurrence not receiving early re
rhythmia recurrences following catheter ablation (Section 9.3.2.).
                                                                                ablation did not develop late recurrence.1146
Early postablation recurrences may be a transient finding in some pa­
                                                                                   Despite the efficacy of early reablation in reducing the incidence of
tients. Therefore, aggressive management may be unnecessary due to
                                                                                late recurrences, the rationale of implementing an invasive procedure
increased likelihood of spontaneous remission. However, a watchful
                                                                                with inherent risks and associated costs to treat a potentially transient
waiting approach with rate control medication allows persistence of
                                                                                arrhythmia is debated. Therefore, the writing group suggests that
AF facilitating the atrial remodelling process. Delayed implementation
                                                                                reablation of atrial tachyarrhythmia recurrences within the blanking
of rhythm control interventions contributes to long-term failure of
                                                                                period is not recommended unless they are recurrent, highly symptom­
SR maintenance.1138 Based on this concept, prompt management of
                                                                                atic, and resistant to AADs and cardioversion.
early recurrences is favoured to pursue SR maintenance.

9.5.3.1. Electrical cardioversion                                               9.6. Patient follow-up following catheter
Several studies have evaluated the impact of electrical cardioversion of        ablation
early recurrences after AF ablation on long-term arrhythmia-free sur­           After undergoing AF ablation, all patients should be seen in follow-up
vival, providing conflicting results. Reported inconsistency may be due         within 2–3 months. Thereafter, all patients should be assessed on an an­
to variance in AF type, timing of cardioversion in relation to recurrence       nual basis by physicians (family physicians, internists, cardiologists, or
onset, intensity of rhythm monitoring during follow-up, and definition          cardiac electrophysiologists) with a minimum standard of a 12-lead
of AF recurrence.                                                               ECG in the absence of symptoms. Patients experiencing arrhythmia-
   In a study of 55 patients who underwent AF catheter ablation and re­         related symptoms should undergo additional intermittent rhythm mon­
quired electrical cardioversion for persistent AF or AFl, 84% of patients       itoring (Section 9.4.3.). Comprehensive management of AF patients
Catheter and surgical ablation of atrial fibrillation                                                                                                55


based on the ‘Atrial Fibrillation Better Care’ (ABC) pathway is recom­        ablation of AT after AF ablation (difficulty in achieving transmurality,
mended.5 ‘A’ stands for Anticoagulation/Avoid stroke, ‘B’ stands for          epicardial-dependent tachycardias, and safety concerns in specific
Better symptom management, and ‘C’ stands for Cardiovascular and              areas), recent studies have shown very promising results in acute AT
Comorbidity optimization. The implementation of ABC pathway has               termination and long-term SR maintenance.1181,1182
been shown to reduce health-related costs, improve cardiovascular
outcome, and reduce cardiovascular and all-cause mortality when com­
pared with usual care.1147–1152 A similar integrated management of pa­        10. Ablation outcome and efficacy
tients following catheter ablation is suggested.
                                                                              10.1. Acute procedural success
9.7. Atrial tachycardia following atrial                                      Pulmonary vein isolation is the cornerstone of AF ablation. Electrical
                                                                              isolation of the PVs is recommended during all AF ablation procedures,
fibrillation ablation                                                         and isolation should be minimally confirmed by assessment of entry
9.7.1. Incidence—underlying mechanisms                                        block within the PVs (Section 8.1.1.).
The incidence of AT following AF ablation varies from less than 5                Due to the high recurrence rate observed in patients with persistent
to 40% and is associated with the strategy and extent of prior abla­          and long-standing persistent AF with PVI alone, efforts were made to
tion.343,811,815,1153–1161 Atrial tachycardias after AF ablation can be       identify additive strategies to improve the outcomes of AF ablation.
due to a focal (automatic or triggered activity) or reentrant mechanism       These strategies have included linear RF lesions in the LA and RA,
(macroreentrant or microreentrant). They are frequently associated            CFAE ablation, GP ablation, ablation of non-PV triggers, isolation of
with reconnection of previously isolated PVs1153,1162 and may be focal,       the LAA, ablation of fibrotic areas identified by voltage mapping
from the PV itself, or due to reentry between multiple sites of recon­        or MRI, PWI, ablation of rotational activity, and VoM alcohol
nection. In a recent multicenter study using high-resolution mapping,         ablation.566,830,838,843,848,849,986,988,1183–1185 Up to now, none of these
7% of AT after AF ablation were PV-gap reentrant ATs with distinct cir­       strategies have been broadly adopted. Therefore, in persistent AF, ab­
cuits and two critical isthmuses at the entrance and exit gaps of previ­      lation beyond PVI is of unclear benefit. However, if linear ablation le­
ous PVI lines.1163                                                            sions are deployed during AF ablation procedures, then confirmation
   Macroreentrant AT is the most common form and is seen with high­           of bidirectional block with mapping and pacing maneuvers is a required
er incidence after extensive LA ablation.811,1164,1165 Linear ablation        procedural endpoint (Section 8).
combined with PVI may result in reentrant AT because of conduction
gaps and non-transmural ablation lesions.172,174 Complex fractionated
atrial electrogram–based ablation is also associated with high AT             10.2. Atrial fibrillation recurrence
incidence.939,1166                                                            endpoints
   The incidence of AT after cryoballoon ablation is 3–11%, and more          Since the first AF ablation consensus statement published in 2007, AF
than half of these ATs are macroreentrant.1167–1172 Cryoballoon abla­         ablation success has been defined in a dichotomous manner by the ab­
tion may result in more antral and generous posterior LA debulking            sence of any atrial arrhythmia lasting >30 s off AADs. Overwhelming
during PVI compared with RF,1173,1174 narrowing the posterior wall            evidence indicates that this 30 s cutoff does not correlate with symp­
isthmus regions and potentially increasing the likelihood of                  tom severity, is not associated with cardiovascular outcomes, and re­
macroreentrant tachycardias.                                                  sults in marked underestimation of treatment efficacy.19 There is still
   Many patients present with recurrent AT after prior surgical abla­         uncertainty around the duration of AF leading to an increased risk of
tion, with macroreentry responsible for the majority of AT mechan­            stroke.19,1053,1186 A recent secondary analysis of the CIRCA-DOSE trial
isms; CTI flutter represents 24–32%, mitral flutter 18–32%, and               reported that a 1 h duration threshold of postablation AF recurrence is
roof-dependent flutter 12–16% of AT during follow-up catheter abla­           associated with subsequent patient clinical outcome, since longer AF
tion procedures.1175,1176                                                     recurrences resulted in significantly increased healthcare utilization
                                                                              and impaired disease-specific QoL.1187
9.7.2. Management
                                                                                 Until we have more data on duration thresholds of AF recurrence
Management of AT post-AF ablation depends on the pattern and timing           associated with patient clinical outcome, we continue to recommend
of occurrence, type of prior ablation, and intensity of symptoms. Atrial      reporting the 30 s threshold data to allow comparison with earlier lit­
tachycardias often occur during the blanking period after ablation with­      erature. Furthermore, it seems rational to move towards reporting AF
out necessarily predicting procedural failure.343 Atrioventricular nodal      burden to define ablation outcomes in a more granular fashion rather
agents should be maximized to achieve ventricular rate control. In            than necessarily considering a procedure as successful or unsuccessful
the case of severe symptoms, earlier intervention may be required.            based on any single cutoff value (Section 10.3.). It also remains important
Class III AADs may be preferred if pharmacologic treatment of posta­          to report all categories of recurrence transparently, such as freedom
blation AT is needed. Electrical cardioversion is generally the first step    from symptomatic atrial arrhythmias, AF recurrence separately from
for symptomatic persistent AT occurring early after AF ablation. If AT        other atrial arrhythmias, single and multiple procedure success rates,
recurs soon after an early cardioversion, it may be worth waiting at least    and success on and off antiarrhythmic therapy. Success rate should
2 weeks for ablation-related inflammation to subside before perform­          be reported at 1 year and after single and multiple procedures.
ing a repeat cardioversion. Up to a third of ATs have been reported to
resolve in the first 3 months after AF ablation.343,1164 However, after
this time frame, it is reasonable to pursue an ablation strategy if pharma­   10.3. Atrial fibrillation burden endpoints
cological control is ineffective or not desired.                              Given the challenges of achieving 100% AF freedom, AF burden has
   It is beyond the scope of this document to provide insights into inva­     emerged as an important endpoint of AF ablation. Although it is best
sive management of AT following AF catheter ablation. In general, a           measured with continuous monitoring (via ICM, pacemakers, or
multi-level strategy with assessment of tachycardia ECG characteristics,      ICDs), it can also be assessed with intermittent external monitoring.
CS, and biatrial activation pattern using multipolar diagnostic catheters     However, commonly employed short-duration (24 and 48 h) ambula­
and ultra-high-density atrial mapping complemented by entrainment             tory monitors may overestimate the true AF burden. Computational
maneuvers is suggested to unravel underlying AT mechanism, which              simulation of different monitoring strategies demonstrated that inter­
is the key to ablation success.1177–1180 Despite pertinent challenges in      mittent monitoring duration is inversely related to observed AF burden.
56                                                                                                                                           S. Tzeis et al.



A reasonable assessment of true AF burden is achieved by at least 28            10.6. Quality of life assessment
days of annual cumulative intermittent non-invasive monitoring using            Quality of life should remain an important endpoint for AF ablation
serial longer term (7-day and 14-day) ambulatory ECG devices.7                  studies, but not necessarily the primary endpoint. Quality of life is lim­
   Recent data have indicated the clinical relevance of reporting AF bur­       ited by treatment expectancy bias. Quality of life can be measured both
den as a procedural endpoint of catheter ablation. By studying AF bur­          using well-established scales like the SF-36 and EQ5D, but also using
den, a striking AF reduction is often observed following ablation despite       more specific scales such as the AFEQT, MAFSI, AFSS, or Symptom
AF recurrences being recorded.622 Reduced AF burden following AF                Severity Score.1041 Atrial fibrillation–specific scales are associated
ablation is also associated with improvement in QoL.1188 In                     with increased sensitivity and are more effective in discriminating be­
CASTLE-AF, a trial of patients with AF and HFrEF randomized to cath­            tween patients with successful and failed ablation.1041 Studies using
eter ablation or drug therapy, a 50% lower AF burden at 6 months                both general and specific scales showed improvement in QoL with
was associated with a decrease in the primary endpoint of all-cause mor­        catheter ablation over AAD.1192–1195 The CAPTAF trial, using QoL
tality and HF hospitalization and a reduction in all-cause mortality.           as primary endpoint, concluded that QoL improvement was greater
However, AF recurrence as a dichotomous variable (defined as a 30 s             with ablation compared with AAD, despite the fact that freedom
or more AF recording) was not predictive of the primary composite out­          from AF and number of cardioversions were similar in both groups;
come or mortality.1189 In a recent subanalysis of the CIRCA-DOSE study,         however, AF burden was reduced to a greater extent in the ablation
postablation burden >0.1% was associated with significantly increased           group compared with the AAD group.1188 In a CIRCA-DOSE subana­
risk of healthcare utilization (emergency room visit, all-cause hospitaliza­    lysis, significant impairment in AF-specific QoL following catheter abla­
tion, cardioversion, and repeat ablation).1187 It seems unlikely however        tion was demonstrated only in patients with postablation AF episode
that a single AF burden cutoff point accurately reflects each of the end­       durations >24 h or AF burdens >0.1% when compared with patients
points of symptom severity, health care utilization, and cardiovascular         without AF recurrence.1187
outcomes. It is probable that the relationship between AF burden and
these endpoints will vary between patients dependent on other factors
(e.g. CHAD2S2-VASc score for thromboembolic risk).
   Based on the above considerations, reporting AF burden as the out­           11. Complications
come of AF ablation trials is strongly advised especially in trials with pro­
longed cumulative intermittent or continuous postablation rhythm                11.1. General considerations
monitoring.                                                                     Catheter ablation for AF is a complex electrophysiology procedure.
                                                                                Due to its invasive nature requiring vascular access, catheter manipula­
                                                                                tion, and energy delivery in the LA, which is thin-walled and neighbours
10.4. Atrial fibrillation progression                                           organs potentially susceptible to thermal damage, AF ablation has a
endpoints                                                                       relevant complication rate. This is particularly important because in
Progression from paroxysmal to persistent and permanent AF occurs               most cases, the aim of the procedure is mainly symptomatic
in some patients, and achievement of rhythm control gets more difficult         improvement.
as AF progresses to the persistent stage and beyond (Section 2.3.). In the         Major complications are usually defined as complications that result
ATTEST study, AF ablation was superior to AADs in delaying progres­             in permanent injury or death, require intervention for treatment,
sion from paroxysmal to persistent AF.1190 In the CABANA trial, cath­           and prolong or require hospitalization. The rate of complications
eter ablation was shown to have a significant impact on the natural             after AF ablation lies, as consistently reported by administrative
history of AF and protect against AF progression to persistent and long-        databases, large registries and randomized trials, in the range of 2.5–
standing persistent types.1191 More recently, the EARLY-AF trial                8%.298,1045,1065,1066,1196–1199 In-hospital deaths are very rare.
provided longer term follow-up in 303 patients with paroxysmal AF               Contemporary in-hospital death rates (in experienced units) are usually
randomized to first-line rhythm control therapy with either cryobal­            in the range of 0.05–0.1%.1066,1196–1200 Although cumulative experience
loon ablation or antiarrhythmic medications.27 After 3 years, patients          and technical advances would be expected to lead to a significant de­
in the cryoablation group were less likely to progress to persistent            crease in the procedural complication rate, reports of time trends of
AF compared with patients treated with AADs (1.9 vs. 7.4%; HR                   the complication rates provide conflicting results.1045,1066,1196,1197,1199
0.25, 95% CI, 0.09–0.70)27 (Section 4.1.). Although not widely reported         A recent pooled analysis of adjudicated safety outcomes exclusively
in clinical trials, the reduction in AF progression with ablation is an im­     from RCTs demonstrated a significant decrease in the overall rate of
portant metric.                                                                 complications related to AF catheter ablation in the more recent period
                                                                                (2018–2022) when compared with the preceding 5-year period (3.8 vs.
                                                                                5.3%, respectively).1198 Importantly, some complications such as pericar­
10.5. Atrial fibrillation–related symptoms                                      dial tamponade, stroke, or esophageal perforation may be severe or im­
Although reported in trials, the endpoint of AF-related symptoms is dif­        mediately life-threatening and require urgent or emergent management.
ficult to clearly assess. Even in patients with highly symptomatic AF, as       For this reason, awareness of the different complications and knowledge
many as half of all episodes may occur without associated symptoms.             of their presentation pattern and management are mandatory.
The ratio of asymptomatic to symptomatic episodes increases up to                  Several studies have assessed sex-based differences in AF ablation ad­
four-fold postablation, perhaps due to shorter AF durations, slower             verse events. In an observational cohort study of 58 960 patients under­
ventricular rate, or autonomic modulation after the procedure1042               going AF ablation from 2016 to 2020, female gender was independently
(Section 9.4.). Double-blind treatment allocation is not easily feasible        associated with a higher risk of hospitalization >1 day and major and
in trials evaluating the effect of AF ablation, and therefore, improve­         any adverse events.1201 This gender disparity in AF complication rates
ment in symptoms can also partially be related to a placebo effect.             has been shown to persist over time and may be attributed to higher
Moreover, symptomatic and asymptomatic episodes often coexist in                burden of associated comorbidities, delayed referral for catheter abla­
the same patient. Nevertheless, since AF ablation partly serves as a            tion, higher rate of non-paroxysmal AF type among females as well as
treatment primarily for symptom amelioration, it is relevant to report          anatomical differences between genders.1202,1203
AF-related symptoms, keeping in perspective that symptoms should                   The main complications of catheter ablation for AF are listed in
not serve as a surrogate to assess AF burden nor other clinical end­            Table 9. In this section, the presentation, investigation, treatment as
points such as stroke, hospitalization, and mortality.                          well as methods to prevent these complications will be discussed.
Catheter and surgical ablation of atrial fibrillation                                                                                                  57


                                                                               power settings of 50 W up to 90 W with respective limitation of the
 Table 9 Main complications of catheter ablation of atrial                     maximal duration of energy application at each ablation site. Initial con­
 fibrillation                                                                  cerns of a potentially increased complication rate due to the higher en­
                                                                               ergy power were not confirmed. Indeed, existing data confirm the
     Complication type                             Complication rate, %
     ..................................................................        safety of this approach, albeit without indication of any considerable re­
     Periprocedural death                                0.05–0.1              duction in complication rates.601,1208–1210 In particular, there is no indi­
                                                                               cation for an increased rate of esophageal damage, although related
     Atrioesophageal fistula                             0.02–0.1
                                                                               impact, either positive or negative, would be difficult to detect given
     Periprocedural thromboembolic event                 0.15–0.5              the rarity of this complication.597 A recent RCT comparing higher
     Cardiac tamponade                                    0.4–1.3              power (40 W) short-duration vs. lower power (25 W) longer duration
     Severe pulmonary vein stenosis                       0–0.5                ablation on posterior wall with specific AI targets demonstrated an
                                                                               equivalent risk of esophageal thermal injury (4.5%) as documented by
     Permanent phrenic nerve palsy                       0.08–0.1
                                                                               postablation endoscopy.1211
     Vascular complications                                1–4a                   Recent trials suggest that the type of implemented RF ablation proto­
     Asymptomatic acute cerebral lesions                   5–30                col may have an impact on the rate of postablation asymptomatic cere­
                                                                               bral emboli. In a prospective randomized trial, HPSD (70 W for 9–10 s)
 a
  Without ultrasound-guided vascular puncture.                                 RF ablation for PVI was associated with significantly higher rate of
                                                                               MRI-detected subclinical strokes when compared with conventional
                                                                               AI-guided (25–40 W) ablation.602 Another smaller RCT comparing
                                                                               high vs. standard power RF ablation for PVI also demonstrated a trend
11.2. Factors associated with procedural                                       towards more asymptomatic cerebral emboli with HPSD ablation.1212
complication rate
11.2.1. Procedural volume                                                      11.2.4. Time course of complications and implications for
Reports consistently demonstrate a correlation between procedural              discharge practice
volume and safety outcomes in catheter ablation of AF. Overall compli­         With increasing experience and optimization of workflows, same-day
cation rates1196,1204,1205 and early mortality1200,1205 after catheter abla­   discharge of patients has been implemented for many different
tion of AF are higher in low-volume than in high-volume centers.               interventional cardiac procedures. Although traditionally patients
Although the annual center caseload cutoff for the definition of low-          stayed in the hospital for at least one night after AF catheter ablation,
volume and high-volume centers may vary between studies, the effect            several centers moved to same-day discharge, since the majority of
remains consistent. The magnitude of this effect is substantial.               relevant complications occurs in the first few hours after the proced­
Particularly for early mortality, high-volume centers are reported to          ure.1213 Indeed, several reports from different hospital settings demon­
have rates as low as one-third of those reported by low-volume                 strate the safety of same-day discharge.1024,1026,1214 Interestingly, these
centers.1196,1200,1204 Thus, operator experience appears to be the             reports pertain to both cryoablation and RF ablation.1026 Thus, with re­
most critical factor to decrease complications. Indeed, no other               spect to complications, same-day discharge after an uneventful AF ab­
technological or procedural aspect has been reported to be associated          lation appears safe provided that specific criteria are met (Section 9.2.).
with such a decisive reduction of complications. These data strongly
emphasize the need for structured education and training in the field
of AF ablation (see Section 13).                                               11.3. Presentation, treatment, and
                                                                               prevention of specific complications
11.2.2. Type of energy source                                                  11.3.1. Esophageal perforation
Radiofrequency and cryoenergy have been used in the last two decades           Esophageal injury is a rare but lethal complication of AF catheter
in the majority of AF ablations. Apart from these, PFA is a novel emer­        ablation.1063 It occurs with a time delay after the procedure with a re­
ging and promising energy source that is expected to gain a significant        ported incidence, which varies from 0.016 to 0.1%.1060–1067 The re­
role in the coming years. Other sources have been applied during the           spective incidence in large surveys enrolling more than 100 000 AF
last two decades for AF ablation but have not found a way into broad           ablations ranges from 0.016 to 0.026%.1060–1062 In the largest, multi
clinical application.                                                          national POTTER-AF registry enrolling a total of 553 729 catheter ab­
   Despite obvious differences between the main energy sources, the            lation procedures in 214 centers, the incidence of AEF was 0.025%.
complication rates between RF and cryoablation do not seem to differ           Also noteworthy is that the incidence of AEF varied markedly between
significantly, although the type of complications differ.293,294,1206,1207     centers (maximum of 0.4%, minimum 0.0066%; P < 0.01), implicating
Persistent PN palsy following PVI is observed almost exclusively after         some aspect of modifiable ablation technique in the occurrence. The
cryoablation, whereas esophageal perforation is, in the vast majority,         median time from catheter ablation to symptom onset and to AEF diag­
a consequence of RF ablation.1060 The respective data for PFA are still        nosis was 18 (range: 0–60) and 21 (range: 2–63) days, respectively.1060
limited, but the existing evidence indicates an overall complication rate         Three main types of esophageal injury are observed: AEF, atrial-
that is similar to the other two energy sources.643,644,651,662 Due to the     pericardial fistula, and esophageal hematoma. These types of complica­
specific effect of electroporation on cardiomyocytes, adverse extra            tions are caused by thermal damage to the esophagus that is in close
cardiac effects such as esophageal damage are expected to be signifi­          vicinity to the posterior LA wall.1215 It is observed almost exclusively
cantly limited, if not absent, after PFA (Section 11.3.1.).                    after RF ablation, but rare cases of esophageal perforation after cryoa­
                                                                               blation have been described.1059 In the POTTER-AF registry, the inci­
11.2.3. Role of ablation protocols                                             dence of AEF was significantly higher in RF as compared to
Radiofrequency ablation had been initially performed with power                cryoballoon ablation (0.038 vs. 0.0015%, P < 0.0001). Pulsed field abla­
settings of 30–35 W at the anterior LA wall and reduced power of               tion is described to have a specific effect on cardiac myocytes and is ex­
20–25 W at the posterior wall to reduce complications such as cardiac          pected to be associated with a substantially lower risk of esophageal
perforation and damage to the esophagus. In recent years, ablation pro­        injury. Initial clinical data with MRI imaging seem to corroborate this as­
tocols with increased power have been introduced. These are based on           sumption,1216 but definite conclusions cannot be drawn yet due to the
58                                                                                                                                           S. Tzeis et al.




                                                           Atrioesophageal fistula
           Definition: Connection between the atrium and the lumen of the esophagus                             Incidence: 0.02–0.1%


       How to prevent                                                                                  Clinical presentation
       Avoid consecutive RF lesions at                                                                  Fever
       posterior wall sites adjacent to the
       esophagus                                                                                        Chest pain, odynophagia

       Choice of energy source                                                                          Neurological events (stroke/TIA)
       Esophageal cooling                                                                               Esophageal bleeding,
                                                                                                        hematemesis
       Esophageal deviation

       Esophageal temperature monitoring                                                                Septic shock

       ICE-guided ablation                                                                              Systemic emboli

       PPI following ablation

       Reduce CF on posterior wall




       Investigations                                                                                  Management
       Chest CT scan                                                                                    Early recognition of related
                                                                                                        symptoms (patient awareness)
       Chest x-ray
                                                                                                        Urgent surgical repair (preferred)
       LGE-MRI
                                                                                                        Endoscopic treatment (selected
       Avoid endoscopy with air insufflation                                                            cases)




  Figure 10 Prevention, clinical presentation investigation, and management of atrio-oesophageal fistula. CF, contact force; CT, computed tomog­
  raphy; ICE, intracardiac echocardiography; LGE, late gadoliniun enhancement; MRI, magnetic resonance imaging; PPI, proton pump inhibitor; RF, radio­
  frequency; TIA, transient ischemic attack.




very low incidence of this complication and the limited number of pro­        fatal. Furthermore, endoscopy with air insufflation should be avoided in
cedures performed so far with PFA.                                            patients with symptoms suggestive of AEF, due to the risk of massive,
   Notably, esophageal lesions detected during routine endoscopy as           life-threatening air embolism. This is particularly important in a patient
potential precursors of perforation are common after ablation and lie         with acute gastrointestinal bleeding during the postablation period,
in the 10% range,690 but only a small minority will advance to esopha­        when endoscopy is often the first diagnostic test performed on an
geal perforation. The most common symptoms of esophageal perfor­              emergency basis. However, esophageal endoscopy with CO2 insuffla­
ation are fever, chest pain or odynophagia, and neurological events           tion may be performed with relative safety, usually in patients with
(septic emboli), but patients can present with esophageal bleeding,           high-risk features but negative initial chest CT scan, since CO2 is rap­
hematemesis, systemic emboli, septic shock, or death1060 (Figure 10).         idly absorbed into the blood with minimal risk of gaseous embolism.
   Chest CT with intravenous contrast is the preferred modality to            Early recognition of an AEF is critical, and thus, it is important to in­
document the diagnosis of AEF.1060 Typical findings include air in the        form patients of warning related symptoms and to advise them to
mediastinum or contrast extravasation to the pericardium, mediasti­           contact their AF ablation center directly in case of occurrence
num, or esophagus. However, a normal chest CT scan does not rule              (Figure 10).
out the presence of an AEF, and therefore in case of high clinical suspi­         Several approaches have been proposed for reducing the risk of this
cion, ongoing vigilance and repeat imaging are recommended to ensure          complication, including visualization of the course of the esophagus
prompt diagnosis and timely intervention. An LGE-MRI is also useful for       by integration of the CCT or CMR images in the 3D mapping
documentation of AEF diagnosis.1217 If AEF is suspected, a barium swal­       systems or by ICE, avoiding ablation or reducing CF and ablation power
low is contraindicated as entry of barium into the circulation could be       in the vicinity of the esophagus or at the LAPW or by employing
Catheter and surgical ablation of atrial fibrillation                                                                                                59


esophageal temperature monitoring, esophageal cooling, or devi­                11.3.2. Periprocedural thromboembolic events
ation.1215,1218,1219 However, the impact of these preventive measures          Thromboembolic events are one of the most significant complications
has not been clearly documented (Section 7.8.).690,782–785 A widely            of AF ablation (Figure 11). These manifest in almost all cases as strokes
used strategy is the routine use of PPIs for a limited period following        or TIA. In contemporary large series, the incidence of stroke or TIA
the procedure. Nevertheless, there is no substantial evidence for the          after catheter ablation lies in the range of 0.15–0.5%.1066,1196,1198,1199
benefit of this practice (Section 9.3.3.). Given the rarity of the complica­   Thromboembolic events typically occur within 24 h of the ablation
tion, conclusive evidence will be difficult to obtain.                         procedure, with the high-risk period extending for the first 2 weeks fol­
   Treatment of an AEF is a medical emergency that requires urgent             lowing ablation.1225,1226 Potential reasons of thromboembolic compli­
surgical repair.1060,1220,1221 Case series have reported an 83–100%            cations include the development of thrombi on or within sheaths and
mortality without surgical repair compared with a 34% mortality with           ablation catheters introduced into the LA, char formation at the tip
surgical repair.1220,1221 Several case reports have been published de­         of the ablation catheter, mobilization of a preexisting LA thrombus,
scribing favourable outcomes with esophageal stent placement for               and electrical cardioversion during the procedure. Therefore, a strict
treatment of an esophageal perforation or an esophageal pericardial fis­       anticoagulation protocol during the procedure with heparin adminis­
tula.1221–1224 In the POTTER-AF registry, overall mortality in patients        tration (even before transseptal puncture), regular ACT measure­
with AEF was 65.8% and was significantly lower following surgical              ments, and maintenance of an ACT of at least 300 s, as well as
(51.9%) or endoscopic treatment (56.5%) compared with conservative             meticulous attention to sheath management are recommended
management (89.5%).1060                                                        (Section 7.4.). Routine imaging screening for the presence of atrial
   In summary, esophageal perforation is a rare but unpredictable and          thrombus reduces the rate of thromboembolic complications
immediately life-threatening complication. Prompt diagnosis and surgi­         (Section 5.2.3.).
cal treatment are typically needed. Awareness of patients and physi­              Diagnosis of thromboembolic events is usually straightforward. The
cians is of paramount importance.                                              manifestations depend on the location of the occlusion within the




                                          Transient ischemic attack and stroke
            Definition: New focal or global neurological deficit preferably with positive neuroimaging
                                                                                                                     Incidence: 0.15–0.5%
                      study with (TIA) or without rapid (< 24 h) symptom resolution (stroke)



        How to prevent                                                                                   Clinical presentation
        ACT > 300 s during ablation                                                                      Neurologic signs/symptoms

        Avoid preablation OAC interruption

        Heparin bolus before TSP

        ICE monitoring for thrombus

        Preprocedural thrombus exclusion

        Sheath and catheter management




        Investigations                                                                                   Management
        Brain CT                                                                                         Thrombectomy

        Brain MRI                                                                                        Thrombolytic therapy




  Figure 11 Prevention, clinical presentation, investigation, and management of transient ischemic attack/stroke in the postablation setting. ACT, ac­
  tivated clotting time; CT, computed tomography; ICE, intracardiac echocardiography; MRI, magnetic resonance imaging; OAC, oral anticoagulant; TIA,
  transient ischemic attack; TSP, transseptal puncture.
60                                                                                                                                         S. Tzeis et al.



arterial tree. Treatment also varies according to the location of the em­   DOAC therapy with uninterrupted VKA anticoagulation demonstrated
bolus and, importantly for cerebral embolic events, the time interval be­   the safety of a periprocedural regimen with uninterrupted
tween symptom onset and diagnosis. Peripheral arterial embolization         DOACs386,388,1236; this anticoagulation regimen has become current
might be amenable to surgical thrombectomy, whereas cerebral embol­         standard in most high-volume centers (Section 5.2.).
ization has traditionally been managed conservatively. There is however         The impact of technical aspects of the ablation procedure to the risk
growing interest in aggressive early management of such events, using       of tamponade is not clear. A randomized study reported substantially
either thrombolytic drugs or percutaneous interventional techniques.        lower tamponade rates in procedures performed with cryoballoon ab­
The involvement of neurologists and interventional radiologists with        lation compared with RF energy,294 but observational data do not con­
experience in the interventional treatment of the cerebral arterial         firm this finding.1206 Although it was anticipated that the introduction of
tree is of major importance.                                                CF-sensing catheters would reduce the rate of tamponade, this was not
                                                                            confirmed in clinical trials.1237 The use of ICE is important for early diag­
11.3.3. Asymptomatic cerebral lesions                                       nosis but also prevention of cardiac tamponade. In a large nationwide
As recognized in recent years, catheter ablation for AF results in asymp­   cohort study including more than 100 000 patients who underwent
tomatic acute cerebral lesions that can be detected by high-resolution      AF ablation, the absence of intraprocedural ICE use was associated
diffusion-weighted brain MRI. Hyperintensity in T2-weighted fluid atte­     with 4.85-fold increased risk for cardiac perforation1238 (Section 7.6.).
nuated inverse recovery sequence (FLAIR positivity) is useful in differ­        Cardiac tamponade presents either as an abrupt or as a gradual BP
entiating acute from chronic cerebral ischemic lesions.1227 The             decrease (Figure 12). In the latter case, administration of fluid might re­
prevalence can be as high as 30% without difference between patients        turn BP to normal before further subsequent decline. It is vital that op­
on VKA and patients on DOACs.387,388,1228 These lesions are consid­         erators and staff be vigilant to the development of cardiac tamponade,
ered silent ischemic cerebral lesions since no grossly detectable symp­     as a delay in diagnosis can be fatal. Due to the immediately life-
toms are present. Recent data support that HPSD ablation protocols          threatening character of this complication, if not managed appropriate­
may increase the risk of asymptomatic cerebral emboli (Section              ly, the development of hypotension during an AF ablation procedure
11.2.3.).1212                                                               should be assumed to indicate tamponade until proven otherwise.
   Subtle cognitive dysfunction has been reported early (3 months)          An early sign of cardiac tamponade is a reduced or absent excursion
after AF ablation when compared with patients undergoing SVT abla­          of the cardiac silhouette on fluoroscopy with a simultaneous BP
tion or patients being treated medically.1229 In another study with long­   fall. The diagnosis is confirmed by immediate echocardiography.
er follow-up, early postablation cognitive dysfunction was transient        Importantly, the presentation of cardiac tamponade might be delayed
with complete recovery at 12 months of follow-up. Indeed, a higher          and can occur any time from an hour after the procedure to weeks la­
percentage of ablation treated patients demonstrated cognitive im­          ter.1239 The incidence of delayed tamponade was 0.2% in a worldwide
provement at 12 months compared with medically treated patients.1230        survey report.1239 Most, but not all, patients presented with warning
There are multiple potential mechanisms by which early post AF abla­        symptoms, and some presented with hypotension and shock.
tion cognitive dysfunction may occur, but several studies have found no         Early recognition and rapid appropriate treatment of cardiac tam­
relationship between asymptomatic cerebral lesions on MRI and cogni­        ponade is mandatory to prevent irreversible deterioration in perfusion
tive decline.1230–1232                                                      of the brain and other organs. In a dedicated worldwide survey, cardiac
                                                                            tamponade was reported to be the most frequent cause of peri
11.3.4. Cardiac tamponade                                                   procedural death, with 25% of all fatalities occurring in association
Cardiac tamponade remains the most frequent, potentially life-              with this complication.1240 Most cardiac tamponades can be managed
threatening complication of AF catheter ablation. In recent large sur­      successfully by immediate percutaneous drainage. Percutaneous drain­
veys, the reported incidence varies from 0.4 to 1.3%.1066,1196–1199         age is best achieved by subxiphoid Seldinger puncture of the pericardial
Women seem to have a higher risk for tamponade than men.1203,1233           sac and placement of an intra-pericardial catheter, such as a pigtail cath­
The substantially higher incidence of cardiac tamponade during AF ab­       eter. The puncture can be performed either with fluoroscopic guidance
lation compared with other cardiac electrophysiology procedures can         based on anatomic landmarks or with echocardiographic guidance.1241
be attributed to a number of procedural differences, including the          Usually, BP promptly increases after initial aspiration. Once the pericar­
need for transseptal puncture, extensive intracardiac catheter manipu­      dial space has been drained, the patient needs to be monitored for on­
lation and ablation, and the need for systemic anticoagulation during the   going bleeding with the drainage catheter left in place. Continuation of
procedure. The most common causes of cardiac perforation leading to         bleeding after aspiration of a substantial amount of blood indicates an
cardiac tamponade during AF ablation are (i) misdirected transseptal        extensive perforation that may need surgical repair. Although these
puncture with the puncture performed too posteriorly exiting the            are the minority of cases,1242,1243 it is for this reason that AF ablation
RA into the pericardium before entering the LA or with the puncture         procedures should only be performed in hospitals equipped or pre­
advanced too much and exiting the LA via the roof, LAA, or the lateral      pared to manage these types of emergencies with access to emergency
LA wall (Section 3.3.); (ii) direct LA mechanical trauma during catheter    surgical support. Several case series have reported the feasibility and
manipulation and ablation; and (iii) overheating during RF energy deliv­    safety of immediate direct autotransfusion of the blood aspirated
ery, with or without the development of a steam pop. Excessive power,       from the pericardial space through a femoral vein, without the use of
temperature, and force applied at the tip of the catheter might also        a cell saver system, to reduce the need for allotransfusion following
contribute.                                                                 emergency pericardiocentesis in patients undergoing cardiac electro­
   The need for periprocedural and intraprocedural anticoagulation          physiology procedures.1244,1245 Reversal of anticoagulation with pro­
with heparin infusion to achieve an ACT >300 s may increase the             tamine may be helpful to stop bleeding, but it may also lead to
volume of bleeding if perforation occurs. Concerns of increased bleed­      thrombus formation in the pigtail catheter if bleeding has not stopped.
ing risk related to uninterrupted anticoagulation have not been             Therefore, protamine should be administered once the rate of aspir­
confirmed. Previous studies showed that uninterrupted VKA anticoa­          ation decreases significantly. The drainage catheter is usually left in place
gulation did not result in higher incidence of tamponade compared           for at least 12 h following placement. However, observational studies
with interrupted VKA anticoagulation therapy with bridging hep­             have shown that early removal of the pericardial drain within the elec­
arin.381,382,819,997,1234,1235 Several RCTs comparing uninterrupted         trophysiology laboratory, after exclusion of blood reaccumulation, is
Catheter and surgical ablation of atrial fibrillation                                                                                                61




                                                          Cardiac tamponade
               Definition: Significant pericardial effusion (resulting in hemodynamic compromise or
                           requiring pericardiocentesis or ³1 cm in echo)
                                                                                                                     Incidence: 0.4–1.3%



         How to prevent                                                                                Clinical presentation
        ICE monitoring/transseptal guidance                                                              Hypotension

         Monitor contact force                                                                           Pulsus alternans

         Monitor ablation lesion indices

        Transseptal RF needle/wire




         Investigations                                                                                Management
         Echocardiography                                                                                Anticoagulant reversal
         (TTE or ICE or TEE)
                                                                                                         Pericardiocentesis
         Fluoroscopy (reduced excursion
         of the cardiac silhouette)                                                                      Surgical repair




  Figure 12 Prevention, clinical presentation, investigation, and management of periprocedural cardiac tamponade. ICE, intracardiac echocardiog­
  raphy; RF, radiofrequency; TEE, transesophageal echocardiography; TTE, transthoracic echocardiography.




safe and effective in reducing in-hospital stay and the need for analgesia     with RF ablation close to the PV orifices and/or within the PVs, with sig­
when compared with delayed drain removal.1244,1246 In patients antic­          nificantly higher incidence compared with antral ablation.789 Ablation
oagulated with warfarin, fresh frozen plasma may be administered.              within the PVs should be avoided but can occur due to shifts in the
Specific reversal agents for DOACs are available and provide the op­           3D electroanatomic map, respiratory motion, poor catheter stability,
portunity to immediately reverse the anticoagulant effect but do not           and/or operator inexperience.
seem to play any substantial role in clinical practice (Section 7.4.).            Symptoms usually occur weeks to months after the ablation proced­
                                                                               ure and include dyspnea, hemoptysis, cough, (recurrent) pulmonary in­
11.3.5. Pulmonary vein stenosis                                                fections or pneumonia, and chest pain.1250,1253–1255 These may lead to
Pulmonary vein stenosis is a well-recognized complication of AF abla­          misdiagnoses such as pneumonia, pulmonary embolism, or even lung
tion that results from thermal injury to the PVs. With the transition          cancer; therefore, patients should be informed about the importance
from ostial to antral ablation and the increased awareness that energy         of returning to the ablation center if such signs or symptoms develop.
delivery within the PVs should be avoided, the rate of this complication       According to the percentage reduction of the luminal diameter, the se­
has reduced significantly so that it is currently exceedingly rare. In large   verity of PV stenosis is generally defined as mild (<50%), moderate (50–
contemporary series of AF ablations, the reported incidence of severe          70%), or severe (>70%). Notably, patients with severe stenosis of a sin­
PV stenosis is 0–0.5%.1066,1198,1247 Nevertheless, cases of asymptomat­        gle PV may remain asymptomatic.1255
ic PV stenosis or moderate PV narrowing may not be taken into ac­                 Diagnosis is made by CT angiographic imaging, MRI, perfusion scans,
count. Pulmonary vein stenosis has been described for both                     TEE, or invasive PV angiography. The preferred imaging modality is MRI
point-by-point RF ablation as well as cryoballoon ablation.789,1248–1251       or CT angiography because they allow precise visualization of the loca­
There are limited data regarding the impact of RF power on the rate            tion and severity of PV narrowing. Additional advantage of MRI is the
of PV stenosis.597,610,1252 The highest risk for PV stenosis is associated     option of simultaneous assessment of pulmonary perfusion data.
62                                                                                                                                          S. Tzeis et al.



   Treatment of PV stenosis is difficult. Interventional treatment is indi­    balloon, the latter resulting in more proximal energy application.239,1248
cated in the presence of symptoms. Asymptomatic or mildly symptom­             The smaller balloon is potentially advanced further within the PV, caus­
atic PV stenoses should be managed conservatively with watchful                ing distortion of the anatomy, creating a higher susceptibility to PN
waiting, given that symptomatic amelioration has been observed after           thermal injury. Third, the use of additional freeze cycles can increase
PV stenosis or occlusion without treatment due to the formation of             the risk of dose-dependent nerve palsy.1169 Phrenic nerve palsy can
collateral vessels.1256 For symptomatic patients, PV angioplasty should        also occur during antral ablation using RF energy. This likely results
be considered. The dilation procedure is often complex, especially if the      from thermal injury to the PN as it courses anterior to the right PVs.
target PV is completely occluded as evidenced by lack of visualization         Another common scenario of PN palsy is during electrical isolation of
using either direct angiography via the LA or anterogradely via pulmon­        the SVC using point-by-point RF ablation (Section 3.9.).
ary artery angiography. Electroanatomic 3D mapping with registration              Phrenic nerve palsy can be asymptomatic but typically causes dys­
of the anatomy of the LA and the PVs, as well as fusion with the recon­        pnea, tachypnea, cough, hiccups, and thoracic pain (Figure 13). The diag­
structed LA from the imaging scan before the index procedure, enables          nosis is suggested when newly elevated hemidiaphragm with or without
a precise localization of the occluded PV.1257 Baseline CT angiography         atelectasis of the ipsilateral lung base is observed on postprocedural
or MRI is more helpful in defining the PV anatomy.                             chest x-ray. When suspected, diaphragm excursion should be evaluated
   Many PV stenoses are rigid and difficult to dilate. Even after acutely      using fluoroscopy (sniff test) or ultrasound to confirm the diagnosis.
successful angioplasty, PV restenosis occurs in up to 50% of                      A number of strategies have been employed to prevent PN palsy.
cases.1250,1254,1255,1258 Percutaneous treatment of PV stenosis with           These include limiting ablation to antral regions with various balloon
stenting is associated with reduced risk of restenosis when compared           maneuvers; preablation high-output pacing to establish whether the
with balloon angioplasty, particularly with the use of larger diameter         PN can be captured from the proposed ablation site before energy de­
and drug-eluting stents.1250,1254,1255,1258 Nevertheless, even after stent­    livery; PN mapping with anatomic tagging of its course using an EAM
ing, restenosis rates are high.1254,1255,1259 There are only limited data on   system to guide safe deployment of ablation lesions; and monitoring
the role of surgical treatment of PV stenosis. Connecting the patch to         of diaphragmatic excursion with abdominal palpation, fluoroscopy, or
the proximal end of the stenosis is challenging because this end is buried     intracardiac ultrasound while pacing the PN from the SVC or subclavian
in the lung parenchyma. Given this difficulty and the excessive risk, there    vein during ablation.1263 Monitoring the effects of right PN pacing is
is no evidence for recommending surgical treatment in patients with re­        now considered a standard part of cryoballoon ablation and should
current PV stenosis after AF ablation. Even for patients with recurrent        also be considered during RF energy delivery at the anterior part of
severe and persistent problems due to restenosis despite interventional        the rights PVs and during SVC isolation (Figure 6). Finally, diaphragmatic
treatment, recurrent infection and hemoptysis are uncommon and                 electromyography for direct monitoring of diaphragmatic compound
manageable, and the need for lobectomy or pneumonectomy is very                motor action potentials during ablation is a technique for early detec­
rare.1254 Therefore, repeat percutaneous intervention is the treatment         tion of PN palsy that has been reported to reduce incidence of
of choice for cases of PV restenosis after angioplasty.                        palsy.1264,1265 Compound motor action potentials are recorded using
                                                                               body surface electrodes, esophageal electrodes, or a diagnostic cath­
11.3.6. Phrenic nerve palsy                                                    eter positioned in the hepatic vein. A decrease in the amplitude of
Phrenic nerve palsy is a significant complication of AF ablation and re­       the myopotential by 30% is more sensitive than abdominal palpation
sults from direct PN injury. The right PN is most commonly affected            for predicting the subsequent reduction in diaphragmatic excursion
because it descends in close proximity to sites of ablation in the SVC         and PN palsy.1266 Energy delivery should be interrupted immediately
and both right-sided PVs. It courses slightly further from the right infer­    at the first sign of PN injury.
ior PV, so that injury during treatment of this vein is less common than          There is no active treatment known to facilitate PN healing. In highly
that occurring with RSPV ablation. Injury of the left PN may also occur        symptomatic patients, physical therapy of intercostal muscles and sca­
during ablation of the LAA due to its course anterior to the base of the       lenes can improve breathing. In patients with permanent nerve palsy,
LAA (Section 3.9.).                                                            surgical treatment with diaphragmatic plication can improve dyspnea
   Phrenic nerve palsy is observed with all technologies of thermal AF         and functional status.
ablation, but the vast majority of cases occurs after cryoabla­
tion.244,294,1206,1260 With cryoballoon ablation, most PN injuries are         11.3.7. Vascular complications
transient and resolve before the end of the procedure.1261 Based on re­        Vascular complications are the most common major complications of
cent PFA registries, the occurrence of PN palsy following ablation with        catheter ablation for AF and include groin hematoma, pseudoaneurysm
the pentaspline, multielectrode PFA catheter is exceedingly rare.643,644       of the femoral artery, arteriovenous fistula, and retroperitoneal bleed­
   In patients with persistent PN palsy, recovery of nerve function            ing. Current estimates of incidence range from 1 to 4%.1066,1196–1198
may occur within weeks and in the vast majority by 12 months, al­              The incidence of vascular complications that result from AF ablation
though 18–24 months might be required in some patients.1248,1262 In            is lower than those reported for ventricular tachycardia (VT) ablation,
a large multinational registry enrolling 17 356 patients undergoing            in which femoral arterial access is used in many cases.1267,1268
cryoballoon-based PVI, PN injury recovered in 97.0% of patients at                 Most groin hematomas can be managed conservatively or with
12 months, with only 0.1% of the overall population showing perman­            ultrasound-guided compression. However, complications such as fem­
ent PNI.1261 In recent large surveys, the reported incidence of perman­        oral pseudoaneurysm, arteriovenous fistula, and retroperitoneal bleed­
ent PN palsy ranges from 0.08 to 0.1%.1066,1198,1261                           ing might require blood transfusion and/or surgical or percutaneous
   Several mechanisms have been proposed to explain the increased in­          repair, which leads to increased morbidity and prolonged hospital
cidence of PN injury after balloon-based AF ablation. First, wedging or        stay.1269 Rarely, a large dense hematoma can lead to neurological
exerting force to direct the balloon into the RSPV for complete PV oc­         sequelae.
clusion can distort the anatomy and decrease the distance between the              The incidence of these complications may be related to the number
RSPV endocardium and the right PN.227 Second, a small balloon size             and size of the venous sheaths used, insertion of an arterial pressure
relative to PV diameter can increase the likelihood of distal ablation         line, and perhaps to the intensity of anticoagulation management be­
in the vein. Studies have shown a higher risk of PN injury associated          fore, during, and after the procedure. Recent randomized studies did
with the smaller 23 mm balloon compared with the larger 28 mm                  not provide any indication for increased risk of vascular complications
Catheter and surgical ablation of atrial fibrillation                                                                                             63




                                                        Phrenic nerve palsy
                 Definition: Absent phrenic nerve function as assessed by a sniff test                  Incidence: » 0.1% (permanent)



       How to prevent                                                                                Clinical presentation
        Avoid ablation distally within right PVs                                                      Dyspnea

        CMAP monitoring                                                                               Tachypnea

        Monitor diaphragmatic movement                                                                Cough
        during phrenic nerve pacing
                                                                                                      Hiccups
        Phrenic nerve mapping with
        high-output pacing                                                                            Thoracic pain




       Investigations                                                                                Management
        Chest X-ray (newly elevated                                                                   Supportive care
        hemidiaphragm w/wo atelectasis
        of the ipsilateral lung base)                                                                 Physical therapy

        Fluoroscopy                                                                                   Diaphragmatic plication

        Ultrasound




  Figure 13 Prevention, clinical presentation, investigation, and management of phrenic nerve palsy. CMAP, compound motor action potential; PV,
  pulmonary vein; w/wo, with or without.




under uninterrupted DOAC compared with uninterrupted VKA                     11.3.8.1. Air embolism
anticoagulation.387                                                          Air embolism may occur acutely during an AF ablation procedure. The
   The approach used for femoral venous access may affect the risk of        most common cause is introduction of air via the transseptal sheath, ei­
vascular complications. When an inferior approach to femoral vein ac­        ther through the infusion line or due to suction when catheters are re­
cess is used, small medial branches of the femoral artery, which can run     moved. Immediate diagnosis and treatment are based on clinical
across and superficial to the femoral vein, might be penetrated before       suspicion and depend on the site of embolization within the vascular
entry to the femoral vein, possibly leading to a femoral pseudoaneur­        tree. A common presentation of air embolism during AF ablation is
ysm and arteriovenous fistula. When a superior approach is used, there       acute inferior ischemia and/or complete AV block as a result of the
is an increased risk of retroperitoneal bleeding.                            preferential downstream migration of air emboli into the right coronary
   Several studies have consistently demonstrated the safety and the         artery. Supportive care usually results in complete resolution of symp­
beneficial effect of ultrasound-guided puncture for vascular access.         toms and signs within minutes. However, pacing and cardiopulmonary
This is an easy-to-learn technique that requires standard equipment          resuscitation might be needed if the hypotension and AV block persist,
and significantly reduces vascular complications in electrophysiology        but almost always patients recover completely.1270 Air embolism to the
procedures.674–677 For this reason, ultrasound guidance is recom­            cerebral vasculature can be associated with altered mental status, seiz­
mended for vascular access during AF catheter ablation to reduce the         ure, and focal neurological signs. Treatment should be initiated imme­
risk of vascular complications (Section 7.2.).                               diately if cerebral air embolism is suspected. The most important
                                                                             initial step is to maximize cerebral perfusion by the administration of
                                                                             fluids and supplemental oxygen, which increases the rate of nitrogen
                                                                             absorption from air bubbles. For large air emboli, it might be beneficial
11.3.8. Other complications of AF ablation                                   to briefly suspend the patient in a head-down position.1271
Apart from the aforementioned serious complications, catheter abla­             To prevent air embolism, it is imperative that all infusion lines are
tion for AF may lead to several other complications, some of which           monitored closely for bubbles. When catheters are removed, they
may be significant.                                                          should be withdrawn slowly to minimize suction effects, and the fluid
64                                                                                                                                          S. Tzeis et al.



column within the sheath should be aspirated simultaneously. Particular        Furthermore, extreme vigilance is warranted during catheter manipula­
care is advised when inserting and removing balloon catheters through          tion at the vicinity of mechanical mitral valves due to increased risk of
large sheaths.1272                                                             entrapment. In case of entrapment of a multispline catheter in a mech­
                                                                               anical mitral valve, extensive traction increases the risk of mechanical
11.3.8.2. Acute coronary artery stenosis and occlusion                         valve damage or shearing of catheter splines. Different techniques to re­
                                                                               lease entrapped multipolar catheters using the ablation catheter have
Injury to the coronary arteries during AF ablation is rare. The circum­
                                                                               been proposed.1285–1287
flex artery is in close proximity to the lateral LA and can potentially be
injured during ablation at sites adjacent to its course within the CS, the
lateral mitral isthmus, or the base of the LAA. Coronary artery injury         11.3.8.4. Stiff left atrial syndrome
can manifest as ventricular fibrillation or with features of acute myocar­
                                                                               First described after mitral valve surgery, stiff LA syndrome was later
dial infarction with ST segment changes occurring during abla­
                                                                               recognized as a rare complication of LA catheter ablation, typically after
tion.1273,1274 Immediate coronary angiography reveals the occlusion
                                                                               multiple ablations.1288–1291 Extensive LA ablation has been associated
site and facilitates revascularization (Section 11.2.2.).
                                                                               with worsening of echocardiographicaly measured LA stiffness.1292
   The sinus node artery originates from the proximal circumflex artery
                                                                               Symptoms include unexplained dyspnea and signs of right HF.
in one-third of cases and then courses along the anterior LA and then
                                                                               Diagnostic findings include new or worsening pulmonary hypertension,
the septal SVC and could therefore be susceptible to injury during ab­
                                                                               LA diastolic abnormalities, LA hypertension, and large V waves on LA
lation. Ablation at the anterior LA and septal RA has been reported to
                                                                               pressure or pulmonary capillary wedge pressure tracings.1291 The com­
result in injury of the sinus node artery presenting with sinus arrest dur­
                                                                               plication appears to be associated with extensive LA ablation particular­
ing or within 1 h of ablation without evidence of other ECG changes
                                                                               ly in patients with small LA size, high LA pressures, preexisting severe
associated with coronary occlusion.1273,1275 Permanent pacemaker in­
                                                                               LA scarring, and comorbidities such as diabetes and OSA.1289
sertion may be required to treat this complication.
                                                                                   Most patients show symptomatic improvement after diuretic ther­
   Emphasis should be placed on recent reports of severe coronary
                                                                               apy, which appears to be more effective for this syndrome than for
spasm during catheter ablation with the pentaspline PFA cath­
                                                                               other forms of pulmonary hypertension.1293 In contrast, another study
eter.644,656 This adverse event mostly occurs during PFA application ad­
                                                                               reported a case of stiff LA syndrome after AF catheter ablation that
jacent to a coronary artery (proximity-related). More rarely, a
                                                                               failed with furosemide and spironolactone, but which responded to
generalized coronary spasm has been described even when ablating re­
                                                                               sildenafil.1294
motely to a coronary artery. This adverse event can be mitigated by
nitroglycerin administration before PFA applications at high-risk areas.
However, it remains unclear whether nitroglycerine pretreatment will           11.3.8.5. Gastric hypomotility
eliminate any direct coronary artery injury from PFA.1276 In general,
                                                                               Gastric hypomotility may occur in the setting of AF ablation due to in­
these findings raise caution on the use of the pentaspline catheter for
                                                                               advertent injury of the anterior vagal esophageal plexus usually when RF
PFA delivery in proximity to a coronary artery, as during CTI or mitral
                                                                               energy is applied to the LAPW.1295–1297 Endoscopically detected gastric
isthmus ablation.655,656
                                                                               hypomotility has also been reported in 10–18% of patients undergoing
                                                                               cryoballoon AF ablation.1298–1300 Common symptoms include nausea,
11.3.8.3. Mitral valve trauma and curvilinear catheter entrapment              vomiting, bloating, and abdominal pain developing within a few hours to
Entrapment of a circular multielectrode mapping catheter by the mitral         a few weeks after the ablation procedure.1301–1303 Symptomatic but
valve apparatus is an uncommon but established complication of AF ab­          also asymptomatic gastric problems may be frequent after abla­
lation.1277–1281 It results from inadvertent positioning of a multi            tion.1302,1303 The time to recovery is variable, with some patients reco­
electrode catheter close to the mitral valve or into the left ventricle, of­   vering within 2 weeks, but others requiring a much more protracted
ten during attempts to position the catheter into the LIPV or when             time to recovery, occasionally >3 months.1295
using such catheters to create electroanatomic maps of the LA. This               Diagnostic evaluation can include endoscopy or a barium swallow to
complication should be suspected when attempts to reposition the               look for residual food after an overnight fast, abdominal CT scan that
catheter into another PV are met with resistance. When suspected,              shows marked gastric dilation, or real-time MRI to assess gastric motil­
it is important to confirm the diagnosis with echocardiography. One            ity and pyloric spasm.1304
option is to administer high-dose adenosine to cause AV block, thereby            Management of this complication depends on the severity of symp­
relieving tension in the mitral apparatus and freeing up the catheter          toms and whether gastric hypomotility or pylorospasm predomi­
tip.1282 Although successful freeing of the catheter has also been re­         nates. Dietary modification with small, low-fat, and low-fiber meals
ported with gentle clockwise catheter manipulation and advancing               may be adequate to alleviate symptoms. Pharmacological treatment
the sheath into the ventricle, there have also been a number of cases          can be used to relieve symptoms (antiemetics) and to promote gastric
reported in which the mitral valve apparatus and/or papillary muscles          contractility. In the latter category, several agents have been proposed
are torn during attempts to free the catheter.1278,1281,1283,1284 There        including erythromycin, domperidone, and metoclopramide.1305,1306
have also been several cases reported in which the distal tip of the cir­      Metoclopramide treatment should not extend beyond 12 weeks
cular catheter broke off during attempts at catheter removal and had to        due to associated risk of movement disorders. Domperidone has a
be subsequently removed either with a snare or with an open surgical           substantially lower risk of central nervous system side effects, but it
procedure.1279,1280,1283 In these cases, if gentle attempts to free the        has been associated with QT prolongation.1306 In patients with pre­
catheter fail, elective surgical removal of the catheter should be per­        dominant pylorospasm, intrapyloric injection of botulinum toxin or
formed. To prevent this complication, circular and multispline catheters       different types of surgical pyloric interventions have been proposed
should be manipulated with extreme caution near the mitral valve.              as treatment options.1307
Catheter and surgical ablation of atrial fibrillation                                                                                                             65


12. Surgical and hybrid atrial fibrillation ablation


  Surgical and hybrid AF ablation                                                                             Category of               Type of evidence
                                                                                                                advice
  ..............................................................................................................................................
  Concomitant surgical AF ablation is beneficial in patients with paroxysmal or persistent AF
    undergoing left atrial open cardiac surgery regardless of prior antiarrhythmic drug failure or           Advice TO DO                  META1308–1319
     intolerance
  Concomitant surgical AF ablation is beneficial in patients with paroxysmal or persistent AF
     intolerant or refractory to previous antiarrhythmic drug therapy, undergoing closed (non-left           Advice TO DO         META1308–1311,1313–1317,1320–1322
     atrial open) cardiac surgery
  Biatrial Cox maze procedure or a minimum of PVI plus left atrial posterior wall isolation is beneficial
                                                                                                             Advice TO DO         RAND1309,1311,1312,1320,1323–1328
     in patients undergoing surgical AF ablation concomitant to left atrial open cardiac surgery
  Documentation of exit and/or entrance block across pulmonary veins and completeness of
                                                                                                             Advice TO DO                       OPN
   deployed lines is beneficial during surgical AF ablation
  Exclusion of the left atrial appendage is beneficial as a part of surgical AF ablation procedures
                                                                                                             Advice TO DO                 RAND1329–1335
    (stand-alone or concomitant)
  Concomitant surgical AF ablation is reasonable in patients with paroxysmal or persistent AF prior
                                                                                                            May be appropriate          META1308–1318,1320–
    to initiation of Class I or III antiarrhythmic therapy, undergoing closed (non-left atrial open)                                      1322,1328,1336–1338
                                                                                                                 TO DO
     cardiac surgery
  Stand-alone surgical or hybrid ablation is reasonable in symptomatic patients with persistent AF
     with prior unsuccessful catheter ablation and also in those who are intolerant or refractory to        May be appropriate
                                                                                                                                           META1308–1318
     antiarrhythmic drug therapy and prefer a surgical/hybrid approach, after careful consideration of           TO DO
     relative safety and efficacy of treatment options
  Stand-alone surgical or hybrid ablation may be reasonable in symptomatic patients with paroxysmal
     AF with prior unsuccessful catheter ablations who prefer a surgical/hybrid approach, after careful     Area of uncertainty           RAND1339–1342
     consideration of relative safety and efficacy of treatment options




12.1. Technology and techniques                                                         12.1.1. Energy sources
Radiofrequency ablation and cryoablation are the two dominant tech­                     12.1.1.1. Radiofrequency energy
nologies used today due to their safety and efficacy profiles and will be               Radiofrequency energy can be delivered by either unipolar or bipolar
the only ones discussed in this section. While there have not been any                  electrodes, which can be either dry or irrigated. Irrigation helps to de­
RCTs to compare the efficacy of one ablation technology with another,                   liver RF energy uniformly and to prevent char formation by keeping
these technologies have had proven clinical efficiency over the last two                temperatures cooler at the tissue interface.1346 Unipolar RF ablation
decades.                                                                                works by delivering RF energy from the probe directly to the tissue.
   To date, a prospective, multicenter, non-RCT, AtriCure Bipolar                       The unipolar devices do not provide surgeons with transmurality indi­
Radiofrequency Ablation of Permanent Atrial Fibrillation, has resulted                  cators. In contrast, bipolar RF can be either directional or constrained,
in specific FDA approval for surgical treatment of AF.1343 This device                  and transmurality can be implied by the manufacturer’s dose–response
was used on patients with non-paroxysmal AF undergoing concomitant                      algorithms. The directional bipolar devices have two side-by-side elec­
coronary artery bypass graft (CABG) and/or valve procedures and Cox                     trodes that are applied to the tissue surface, with the energy passing
maze IV ablation and resulted in a 76% freedom from AF recurrence                       through the tissue between them. The constrained bipolar devices con­
off AADs at 6 months with a major peri-operative adverse event rate                     sist of a clamp with two jaws, which are applied on opposite sides of
of 9%.                                                                                  atrial tissue. The energy passes through the tissue between the two
   Surgical ablation procedures for AF can be grouped into three dif­                   jaws. When the conductance falls to a stable minimum, transmurality
ferent groups: (i) a full, biatrial Cox maze procedure; (ii) PVI or pos­                is inferred.
terior LA isolation alone, or (iii) PVI combined with an extended LA                        Unlike bipolar RF devices, unipolar ones have failed to consistently
lesion set. All surgical AF ablation approaches are combined with                       create transmural lesions and have a risk of forming endocardial char
LAA exclusion. At present, it is recommended that the term ‘Cox                         or thrombus.1347–1350 Both unipolar and directional bipolar RF energy
maze procedure’ is appropriately used only to refer to a biatrial lesion                sources have had difficulty creating transmural lesions when used from
set including specific transmural lesions that extend between non-                      the epicardial surface on the beating heart.1351 This difficulty is due to
conductive tissues (valve annulus or vena cava or another lesion;                       the circulating intracavitary blood flow, which produces convective
Figure 14).1344 The best late rhythm outcomes have been shown                           cooling. To overcome this problem, devices have employed suction
with the full biatrial Cox maze procedure, while a certain subgroup                     to pull the atrial tissue into apposition, thus partially ameliorating the
of patients, such as those with paroxysmal AF, have reasonable results                  circulating heat sink. Radiofrequency ablation with constrained bipolar
with more limited lesion sets.1345                                                      devices has allowed for faster and more efficient ablation due to direct
66                                                                                                                                         S. Tzeis et al.



contact with the tissue. Since the tissue is ablated between the jaws of a   single application, all lesions produced were transmural.1364
clamp, the energy delivery is focused and isolated from the surrounding      However, in clinical experience, multiple applications are needed to
circulating intracavitary blood reservoir, allowing for more effective       achieve exit block. In a recent human ex-vivo heart explant model, a sin­
creation of lesions on both the beating and arrested heart.                  gle application resulted in only 65% of lesions being transmural through­
   Factors that affect lesion size and depth are power, impedance, ab­       out their entire length. Inability to achieve transmurality was related to
lation duration, temperature, and CF.1352–1355 The generators of the ir­     the increased thickness of atrial tissue and the presence of epicardial fat.
rigated and non-irrigated bipolar RF clamps produce power                    Application of two successive ablations without unclamping resulted in
transmitted to the electrodes, and these data are used to predict the        100% lesion transmurality.1352 In comparison, irrigated bipolar RF
transmurality of the lesion. The generators of irrigated clamps do this      clamps, Cardioblate BP2 and LP (Medtronic Inc., Minneapolis, MN,
by measuring the impedance between electrodes, varying the power             USA), use a similar algorithm to provide real-time measurements of le­
according to the impedance, and terminating power delivery once              sion transmurality based on impedance. This device has also been stud­
the feedback programme detects a steady state plateau.1346 On the            ied in porcine models and showed a high rate of lesion transmurality.
other hand, the generators of non-irrigated clamps measure conduct­          Using the same ex-vivo human heart model, it has also been shown
ance and continue ablation until a stable low conductance is reached.        that a double application without unclamping results in significantly in­
Voltage is varied according to the conductance, resulting in a safe deliv­   creased rate of lesion transmurality compared with single application
ery of energy to the tissue.1352 Care should be taken to clean the elec­     (92 vs. 74%).1365 Most recently, another bipolar RF ablation device
trodes after every two to three ablations with the non-irrigated clamps      (Isolator Synergy EnCompass Clamp, AtriCure Inc., Mason, OH,
because char decreases conductance, which can result in non-                 USA) has been tested experimentally and has been shown to produce
transmural lesions. Importantly, in a human heart ex-vivo model, a dou­      reliable transmurality and isolation of the entire posterior LA wall and
ble ablation without unclamping improved lesion transmurality.               all four PVs with a single application in an in-vivo beating heart mod­
Epicardial fat and muscle thickness can also decrease conductance            el.1366 Further clinical trials will be needed to test its clinical
and limit ablation depth.1352 The ablation duration affects the tissue       performance.
temperature profile. Cardiac muscle exposed to temperature of                    Directional (non-clamp) devices. There are several directional unipolar
55°C or higher for more than a few seconds will show irreversible co­        and bipolar RF devices, with or without suction assistance, that can be
agulation necrosis.1356 Lastly, adequate but not excessive CF is needed      applied either on the epicardium or endocardium. The ablation times
to achieve a reliable transmural lesion.788,1357                             range from 10 to 40 s per the manufacturer’s instructions with the
                                                                             highest risk of ablation gaps at the end of the devices; thus, continuous
                                                                             lesions should be overlapped to increase transmurality. The two non–
12.1.1.2. Cryoenergy
                                                                             suction-assisted bipolar RF devices are the Isolator pen (AtriCure, Inc.)
Cryoablation has been used since the 1960s to ablate cardiac tissue. It is   and Coolrail device (AtriCure, Inc.). In both acute and chronic animal
the second most common ablation technology used for surgical abla­           models, the creation of transmural lesions has been inferior to bipolar
tion. In contrast to RF energy, cryothermy creates homogenous scars          RF clamps.1363,1367,1368 Furthermore, the Coolrail device should be
in a non-directional pattern. Cryoablation is safe because cold tem­         used with caution as it has been associated with a few case reports
peratures do not denature proteins and thus preserves fibrous tissue         of AEFs following AF ablation.1369 Rinsing the pericardium with saline
and the extracellular matrix, which makes it an ideal technology for         may be used to prevent AEF during ablation with the Coolrail device.
ablation around valvular tissue.1358,1359 Temperature, probe size, fre­          The two suction-assisted RF devices on the market are the Cobra
quency, duration of ablation, and the cryogen cooling agent are all fac­     Fusion 150 (AtriCure, Inc.) and EPi-Sense Coagulation System with
tors that determine the lesion’s volume and depth.1360 The                   VisiTrax (AtriCure, Inc.). The Cobra Fusion device has both unipolar
cryoablation probes deliver very low temperatures to cause irrevers­         and bipolar RF energy delivery capabilities. During ablation delivery, suc­
ible cell death and actively measure the probe–tissue interface tem­         tion should be maintained at −500 mmHg for 1–2 min depending on
perature through a thermocouple. The potential disadvantages are             the tissue thickness and desired temperature setting per the manufac­
the relatively longer time to create a lesion (2–3 min) and the difficulty   turer’s instructions. In an acute porcine beating heart model, delivery of
creating a lesion on the beating heart due to the heat sink effect cre­      two separate applications (initial bipolar followed by unipolar energy
ated from circulating intracavitary blood.1361,1362 Due to this, cryoa­      without disrupting the suction) from an epicardial approach resulted
blation should not be used to create epicardial lesions off                  in 68% rate of lesion transmurality.1348 The EPi-Sense device is a
cardiopulmonary bypass. To create a reliable uniform and continuous          3 cm long, suction-assisted, irrigated unipolar RF device. The lesion
cryolesion, a critical lethal temperature of <−30°C must be reached          transmurality of this device has been variable in multiple animal studies
during ablation.1360                                                         from 15 to 100%.1363,1370 However, its clinical performance has been
                                                                             validated in the treatment of patients with persistent and long-standing
12.1.2. Specific ablation tools                                              persistent AF in the setting of a minimally invasive hybrid approach
12.1.2.1. Radiofrequency ablation tools                                      (Section 12.3.3.2.).219
Unipolar devices. Unipolar RF devices come in varying lengths and can
measure the electrode interface temperature with or without a suction
stabilization device to enhance tissue contact. They can either be irri­     12.1.2.2. Cryoablation tools
gated or non-irrigated. Despite the variety of unipolar devices, as men­     There are two available cryogen sources on the market, nitrous oxide
tioned above, they have had limited success in creating transmural           and argon, which have been tested and shown to be efficacious in ani­
lesions consistently.1348,1349,1363 None have been FDA-approved for          mal and donor human transplant heart models.1358,1371,1372 Nitrous
surgical treatment of AF. The only FDA-approved unipolar device is           oxide has a higher heat absorption than argon. The argon device
for hybrid therapy of persistent and long-standing persistent AF             (Cardioblate CryoFlex, Medtronic Inc.) reaches a minimum tempera­
(EPi-Sense Guided Coagulation System with Visitrax, AtriCure, Inc.)          ture of −160°C. The two nitrous oxide devices (cryoFORM and
and is described below (Section 12.3.2.2.).                                  cryoICE, AtriCure, Inc.) reach minimal probe temperatures of −50
   Bipolar clamp devices. The only ablation device with FDA approval for     to −70°C. Both companies have designed long malleable disposable
the treatment of AF during concomitant cardiac procedures is the bi­         probes to adjust to the complex atrial anatomy. In a chronic ovine mod­
polar, non-irrigated RF clamp (Isolator Synergy clamp, AtriCure Inc.,        el using the cryoICE (AtriCure, Inc.) device, transmurality was achieved
Mason, OH, USA). In a chronic animal study using this device with a          in almost all atrial lesions (98%) performed endocardially.1373 Similarly,
Catheter and surgical ablation of atrial fibrillation                                                                                               67


in a chronic canine model, use of the CryoFlex clamp and probe                RA isthmus line and thus serves an important role in preventing late
(Medtronic Inc.) resulted in 93% tissue section transmurality of all          RA flutter. Documentation of completeness is beneficial in all deployed
LAA and PV lesions and 84% tissue section transmurality in all Cox            linear lesions during surgical AF ablation.
maze linear lesions.1374 There have been no surgical cryoablation de­
vices that have yet received an FDA indication for the treatment of
                                                                              12.1.3.4. Ganglionated plexi ablation
AF, but there are ongoing clinical trials with both the nitrous oxide
and argon devices.                                                            There has been interest in GP ablation in stand-alone surgical AF abla­
                                                                              tion procedures. An epicardial antral PVI and posterior box lesion in­
12.1.3. Procedural targets and lesion sets                                    cluding the ligament of Marshall results in collateral ablation of most
                                                                              atrial GP. Therefore, it is difficult to evaluate the additional role of
There are insufficient high-quality data on what should be the most im­
                                                                              GP ablation on top of epicardial PVI plus PWI using bipolar clamps.
portant targets during surgical ablation. This section will review what is
                                                                              The only randomized study examining the efficacy and safety of add­
known from retrospective case series and the few randomized trials
                                                                              itional GP ablation in patients undergoing thoracoscopic surgery
that have been performed.
                                                                              showed no incremental benefit in AF recurrence rate and a significantly
                                                                              higher rate of major procedural complications in patients randomized
12.1.3.1. Pulmonary vein isolation                                            to GP ablation.1008 Therefore, with the exception of a clinical trial set­
As with catheter ablation, PVI is a foundational part of all surgical AF      ting, GP ablation should not be performed during surgical AF ablation.
ablation procedures. Although documentation of exit and/or entrance
block across PVs is preferred, it is infrequently performed.                  12.1.3.5. Ligament of Marshall
Intraoperative mapping has documented complex activation patterns
                                                                              There are no data from the surgical literature to support the ligament
both in the LA and RA in patients with long-standing persistent AF
                                                                              of Marshall as a target for ablation. However, this structure is usually
undergoing surgery for AF and mitral valve disease, indicating that a sim­
                                                                              divided while isolating the left PVs during surgical ablation procedures.
plified approach with PVI alone may not be adequate during concomi­
tant surgical ablation.1375 Similar to catheter ablation of persistent AF,
surgical PVI alone has had disappointing late results. In a single-center     12.1.3.6. Left atrial appendage exclusion
cohort of consecutive patients with medically refractory symptomatic          Exclusion of the LAA is a standard part of all surgical AF ablation pro­
AF, a minimally invasive surgical approach employing PVI combined             cedures and is discussed in detail in Section 12.4.
only with ablation of autonomic ganglionated plexi and ligament of
Marshall resulted in a single-procedural success rate of 37.8% after a
5-year follow-up using ECG and transtelephonic monitoring.1376                12.2. Concomitant surgical ablation of
Retrospective observational data suggest that surgical ablation with          atrial fibrillation
PVI alone is inferior to the biatrial maze procedure in patients with per­    Patients undergoing cardiac surgery frequently have concomitant AF
sistent or long-standing persistent AF.1377 One randomized trial on           which if untreated has been shown to increase the risk of postoperative
non-paroxysmal AF patients undergoing mitral valve surgery reported           ischemic stroke and to negatively impact long-term sur­
similar rate of freedom from AF with PVI as compared to the biatrial          vival.1327,1336,1381 Surgical ablation of AF combined with LAA exclusion
maze procedure.1345 However, the study was underpowered to ad­                or excision restores SR and atrial contraction and reduces the risk of
equately answer the question of which lesion set was more efficacious.        thromboembolism. In this section, the efficacy, safety, and optimal le­
                                                                              sion set of concomitant AF ablation during cardiac surgical procedures
12.1.3.2. Isolation of the left atrial posterior wall                         are discussed. It is noteworthy that in patients eligible for cardiac sur­
Isolation of the entire LAPW and all four PVs is the most important part      gery and concomitant AF ablation, it is often challenging to differentiate
of surgical ablation procedures. In a large retrospective study of patients   whether patient reported symptoms are related to underlying cardiac
undergoing the Cox maze IV procedure, failure to isolate the entire           disease or coexistent AF.
posterior LA resulted in only 33% freedom from AF off AADs at
                                                                              12.2.1. Efficacy of concomitant atrial fibrillation surgery
5 years compared with a 66% freedom in patients who underwent pos­
terior LA isolation (P = 0.017).1326 An incomplete lesion set is even         Concomitant AF surgery has been shown to increase SR maintenance
more impactful in patients undergoing mitral valve surgery. In such pa­       rate in multiple randomized and non-randomized trials.1308–
                                                                              1310,1328,1336
tients, the failure to isolate the entire posterior LA during a Cox maze                     A metaanalysis of 23 RCTs demonstrated that AF ablation
procedure was the only independent predictor of procedural failure            concomitant to cardiac surgery results in increased freedom from AF at
and resulted in 6.7-fold increased risk of AF recurrence.1378 Due to an­      12 months.1382 Several trials have demonstrated a reduced incidence of
ticipated improvement in rhythm outcome with LA PWI, a minimum of             stroke at 5 years postoperatively.1311,1312,1320,1337,1338 Improvement of
PVI plus LA PWI should be performed in patients undergoing surgical           long-term survival after concomitant surgical AF ablation has not been
AF ablation.                                                                  proved by an RCT. However, an analysis of the US Society of Thoracic
                                                                              Surgeons AF database with propensity matching showed that concomi­
                                                                              tant surgical AF ablation was associated with a reduction in 30-day mor­
12.1.3.3. Right and left atrial linear lesions                                tality.1308 In addition, several retrospective and propensity-matched
Linear lesions interrupting the CTI in the RA and the mitral isthmus in       studies as well as large national registries have demonstrated that the
the LA aim to prevent macroreentrant tachycardias. Catheter ablation          performance of surgical AF ablation concomitant with other cardiac
data suggest that macroreentry is the predominant mechanism of ATs            procedures (particularly mitral valve surgery and CABG) was asso­
in patients with prior history of mitral valve surgery. In many cases         ciated with improved long-term survival.1313–1318,1321,1322 In a retro­
macroreentrant circuits are located in the RA, but left-sided circuits        spective propensity score–matched analysis of a nationwide registry,
may also occur particularly if a concomitant Maze procedure was per­          concomitant surgical ablation for AF in patients undergoing isolated
formed.1379 In a single-center analysis of consecutive persistent AF pa­      CABG was shown to significantly improve long-term survival rates.1322
tients undergoing thoracoscopic ablation, adjunctive CTI ablation             Improved QoL at a long-term postoperative follow-up period has also
significantly increased freedom from atrial tachyarrhythmia recur­            been demonstrated in patients who underwent AF surgery with SR
rence.1380 The superior-inferior vena cava ablation line anchors the          restoration.1383,1384
68                                                                                                                                                      S. Tzeis et al.



12.2.2. Safety of concomitant atrial fibrillation surgery                            AF conversion to SR and freedom from AF recurrence.1327,1385,1394
Several studies, including RCTs, have demonstrated that concomitant                  However, recognizing that surgical training and experience may vary
AF surgery is safe and does not increase operative mortal­                           across centers, the writing group suggests that biatrial Cox maze
ity.1313,1314,1327,1337,1385 Although a propensity score–matching study              procedure or a minimum of PVI plus LA PWI is required in patients
showed an increased incidence of acute kidney injury after AF surgery,               undergoing surgical ablation concomitant to LA open cardiac surgery.
the associated long-term risks were offset by the significant survival               The lesion set of the Cox maze IV procedure is shown in Figure 14.
benefit derived from the concomitant Cox maze procedure.1386
   Postoperative atrial tachyarrhythmias and new permanent pace­                     12.2.4. Optimal lesion set in patients undergoing non-left
maker implantation are the typical complications potentially related                 atrial open procedures
to AF surgery. Incomplete linear lesions with residual conduction and                Fewer patients undergoing non-LA open procedures, such as aortic valve
inappropriate surgical techniques are mainly responsible for post                    replacement or CABG, have undergone concomitant AF ablation com­
operative occurrence of predominantly macroreentrant ATs.1387                        pared with those with LA open procedures, because of the necessity of
Intraoperative verification of conduction block, particularly to ensure              adding an LA incision to perform ablation in the LA. Epicardial PVI alone
PVI, may reduce the incidence of AT due to incomplete ablation.1388                  has been performed more often than a biatrial maze procedure in AF pa­
   Increased incidence of new permanent pacemaker implantation after                 tients undergoing non-LA open procedures, and this might have led to
the Cox maze procedure has been demonstrated in many stud­                           biased analyses of the data.1395 A dilated LA has been shown to be asso­
ies.1308,1382,1389,1390 However, in a recent large European registry of pa­          ciated with worse AF-free and event-free survivals after PVI for patients
tients undergoing valve surgery, surgical AF ablation was not associated             with paroxysmal AF undergoing non-LA open cardiac surgery.1396
with increased need for permanent pacemaker implantation.1391 Sinus                  Several studies have shown that biatrial maze procedure is associated
node dysfunction requiring permanent pacemaker implantation can oc­                  with superior rhythm outcome and a lower risk of adverse events and
cur in up to 10% of patients after the Cox maze procedure for non-                   long-term overall mortality compared with LA lesion sets following surgi­
paroxysmal AF and may be a result of unmasking preexisting sick sinus                cal AF ablation concomitant to non-mitral valve surgery.1390,1397–1399
syndrome.1392 In addition, mechanical or thermal injury to the sinus or                 However, many surgeons are reluctant to increase procedural com­
AV node and interruption of the conduction system arterial supply are                plexity and risks by performing AF ablation through an atriotomy.1400
the main intraoperative reasons for postoperative bradycardia and                    Therefore, selection of PVI combined with PWI or other modified pro­
in-hospital permanent pacemaker implantation.1392 Multidisciplinary                  cedure should be individualized in patients undergoing surgical ablation
collaboration between cardiothoracic surgeons and electrophysiolo­                   concomitant to closed (non-LA open) cardiac surgery. Further clinical
gists, proper training on ablation techniques, and deployment of com­                studies are needed to clarify the optimal lesion set in these patients
plete linear lesions may reduce the incidence of postoperative atrial                and to further elucidate associated risks and benefits.
tachyarrhythmias and permanent pacemaker implantation and enhance
patient outcomes.1337,1393
                                                                                     12.3. Stand-alone surgical ablation of atrial
12.2.3. Optimal lesion set in patients undergoing left atrial                        fibrillation
open procedures                                                                      12.3.1. Stand-alone Cox maze procedure
The biatrial Cox maze procedure is the preferred procedure for surgi­                The largest series of stand-alone Cox maze IV procedures (236 con­
cal AF ablation during open LA procedures and achieves high rates of                 secutive patients, 59% prior failed catheter ablation, median duration




              A                                                                  B




  Figure 14 Lesion sets of the Cox maze IV procedure. (A) Left atrial lesion set including: (i) left atriotomy, (ii) ablation around the left-sided PVs, (iii)
  ablation around the right-sided PVs, (iv) posterior wall box lesion, (v) line connecting left PV lesion to excluded LAA, (vi) line connecting box lesion to
  mitral annulus, (vii) cryoablation to the epicardial ostial region of the coronary sinus (not shown). (B) Right atrial lesion set including: (i) right atriotomy
  extending over crista terminalis, (ii) line from the atriotomy to the superior and inferior vena cava posterior to the crista terminalis (to avoid injury to the
  sinoatrial node), (iii) line connecting the atriotomy to the tricuspid annulus (2 o’ clock relative to the valve), and (iv) line connecting the right atriotomy to
  the right atrial appendage. LAA, left atrial appendage; PV, pulmonary vein.
Catheter and surgical ablation of atrial fibrillation                                                                                                 69


of preoperative AF 6.2 years) demonstrated very high late efficacy in SR      ventilation. On the right side, a camera port is placed in the fifth inter
maintenance (89 and 77% freedom from recurrent atrial tachyarrhyth­           costal space midaxillary line, a 5 or 10 mm working port in the sixth
mias at 5 and 10 years, respectively), irrespective of AF type or surgical    or seventh intercostal space anterior axillary line, and a 5 mm working
approach (median sternotomy vs. minimally invasive approach), with­           port in the third intercostal space anterior axillary line. The pericardium
out 30-day mortality.1323 Lapenna et al.1324 reported on 59 patients          is opened anterior to the PN. Blunt dissection is used to open the trans­
undergoing stand-alone Cox maze procedure with similar excellent              verse and oblique sinuses. Antral isolation of the right PVs as a pair is
early and late outcomes with 84% of patients remaining in SR at 7 years,      performed with repetitive applications using a bipolar RF clamp
without 30-day mortality or late strokes. In 133 patients undergoing          (Section 12.1.2.). The same port incisions are made on the left side
minimally invasive, stand-alone Cox maze procedure (78% long-                 but placed more posteriorly. The pericardium is opened posterior to
standing persistent AF), Ad et al.1325 reported a 73% freedom from            the PN. In patients with severe chronic obstructive pulmonary disease,
atrial tachyarrhythmias off AADs at 5 years with only one late stroke         thoracoscopic epicardial isolation of the PVs can be performed only on
and no associated mortality. These case series demonstrate the low            the left, and the right PVs subsequently isolated from the endocardium
mortality and excellent late outcomes achieved by Cox maze proced­            to avoid bilateral sequential lung deflation. An alternative would also be
ure as stand-alone treatment in a challenging group of patients with the      a convergent procedure using subxiphoid access along with Lariat clos­
majority having long-standing persistent AF of long duration. It is im­       ure of the LAA. After PVI documentation, a roof line (connecting both
portant to point out that these procedures were done with cardiopul­          superior PVs) and an inferior line (connecting both inferior PVs) are
monary bypass, which may explain the safety of this procedure.                made epicardially using directional ablation devices (Section 12.1.2.) to
Unfortunately, there have been no prospective multicenter trials of           create box isolation of the LAPW (Figure 15). As an alternative, one epi­
the stand-alone treatment of AF with the Cox maze procedure.                  cardial box lesion including the posterior LA wall and the PVs can be
                                                                              created using only the irrigated bipolar biparietal Cardioblate
12.3.2. Minimally invasive surgical—hybrid atrial fibrillation                Gemini-S (Medtronic Inc.) RF ablation system by performing two clamp
ablation                                                                      lesions from the right and left sides that overlap in the middle of the
Minimally invasive techniques have been introduced in AF surgery aim­         posterior wall (Figure 15).
ing to reduce surgical invasiveness while maintaining efficacy in rhythm         Additional ablation lesions may be deployed, such as circular lesion of
outcome. These approaches combine sternotomy-sparing minimal sur­             the SVC, linear lesion connecting both caval veins and mitral isthmus
gical incisions with different access sites, endoscopic visualization, with   line. Endocardial touch-up ablation to achieve bidirectional block can
or without catheter ablation at the same or at a different stage (hybrid      be delivered in the same or subsequent stage with catheter ablation.
ablation). The reduced invasiveness of these techniques compared with         Furthermore, in patients with prior history or intraprocedural induc­
the surgical Cox maze procedure has rendered these approaches more            tion of CTI-dependent flutter, the CTI is ablated endocardially.
attractive to patients and surgeons. Evidence in different AF patient cat­       Left atrial appendage exclusion should also be performed in all patients
egories is accumulating to establish efficacy and safety. However, com­       during minimally invasive surgical AF ablation to reduce thromboembolic
parison of different study results is limited by non-uniformity in patient    risk (Section 12.4.). Through an incision at the third to fourth intercostal
populations and lack of standardized surgical technique, ablation tech­       space or via a completely thoracoscopic approach, the surgeon can easily
nology and deployed lesion sets.                                              reach the LAA and exclude it. Left atrial appendage exclusion must be
    During the last decade, the ‘hybrid’ approach, consisting of a com­       performed at the very base of the structure, as to avoid leaving behind
bined surgical-percutaneous catheter ablation strategy, has garnered in­      residual stump. Incomplete removal of the LAA is associated with in­
creasing acceptance in clinical practice, with promising rhythm               creased risk of local thrombus formation and embolization.
outcomes.221,1401–1408 A key aspect of this treatment strategy is that           Since the thoracoscopic surgical AF ablation lesions are exclusively
it harmonizes epicardial and endocardial ablation components to effect­       epicardial, one can perform the procedure without the need for antic­
ively target key drivers of AF, including the PVs and the LAPW. There         oagulation during and after the procedure. Therefore, stand-alone
are different surgical modalities to achieve the target of PVI and LA         thoracoscopic surgical AF ablation is the best option for patients
PWI. In this section, we discuss the two main techniques currently em­        who have bleeding diathesis (particularly central nervous system
ployed in clinical practice.                                                  bleeds) precluding the anticoagulation needed during and after endo­
    Hybrid ablation combines expertise from the surgical and electro­         cardial catheter ablation. Additional suitable patient subsets include
physiology teams to achieve an optimal result. Coordination and collab­       those without the ability to achieve LA access endocardially (large atrial
oration among the multidisciplinary team members are paramount to a           septal occlusion device, interrupted inferior vena cava) or those with
successful programme. The timing of the epicardial and endocardial stage      LAA thrombus.
of the hybrid ablation procedure varies based on institutional practice. In
the single-stage model, epicardial and endocardial procedures can occur
back-to-back in the same suite or separate suites or over sequential days.    12.3.2.2. Hybrid convergent procedure
Completion of both phases in the same session prolongs procedural             The hybrid convergent procedure was first described in 2009, and clin­
time, which may add additional risk in patients with comorbidities. For       ical outcomes were published in 2010 by Kiser et al.1409 Since then, the
dual-staged programs, the epicardial component typically occurs in the        employment of this technique has been reported in numerous studies,
cardiac operating room, and the endocardial component is scheduled            and subsequent modifications have been developed to maximize safety
∼2–4 months later in the electrophysiology laboratory, aiming to com­         and improve clinical outcomes.221,1401–1408,1410–1414 This is a minimally
plement the epicardial component with touch-up lesions, ensuring isola­       invasive, closed-chest procedure performed on the beating heart that
tion of PVs, LAPW, and completeness of epicardially deployed linear           combines epicardial RF ablation focused on the LAPW followed by
lesions. The impact of different procedural timing on patient outcomes        complementary endocardial catheter ablation. Epicardial ablation is
is unknown. The minimally invasive surgical part of the hybrid procedure      performed under endoscopic visualization using a closed-irrigation, uni­
is most frequently performed using a video-assisted thoracoscopic surgi­      polar RF catheter device (EPi-Sense Guided Coagulation System with
cal approach or with the ‘convergent’ approach.                               Visitrax, AtriCure, Inc.). The device is inserted via a small subxiphoid in­
                                                                              cision using a pericardioscopic cannula (Subtle, AtriCure, Inc.) to reach
12.3.2.1. Thoracoscopic surgical approach                                     the LAPW and is manoeuvred in the pericardial space using the cannula
The thoracoscopic approach is performed under general anesthesia              and endoscope. During ablation, epicardial tissue is suctioned by vac­
with double-lumen endotracheal tube placement for selective lung              uum onto the RF coil on one side of the device such that RF energy
70                                                                                                                                            S. Tzeis et al.




                       A                                                          B




                                                   C




  Figure 15 Posterior view of the left atrium showing epicardial lesion sets during thoracoscopic surgical AF ablation: pulmonary vein isolation with
  connecting roof and inferior lines (A), en-bloc pulmonary vein and posterior wall isolation using the Cardioblate Gemini-S (Medtronic Inc.) RF ablation
  system (B), and posterior wall ablation using the convergent approach (C ). AF, atrial fibrillation; RF, radiofrequency.




is only applied towards the heart and thus stabilizes the device on the         drugs).1416,1417 Timely diagnosis of pericardial effusion is facilitated by
atrium and optimizes energy delivery. Each lesion is created by a 90 s          patient education on symptoms and transthoracic echo surveillance
application of alternating current via an impedance-based power con­            at ∼2–4 weeks.1416 Complications can arise from both epicardial and
trol algorithm with a maximum output of 30 W. Lesions are overlapped            endocardial procedures, but greater experience has been associated
across the entire LAPW to promote contiguity and thus minimize gaps.            with reduced procedural complications.1414
The epicardial stage aims to debulk as much of the LAPW as can be ac­              Several energy sources and variant lesion sets (apart from PVI and
cessed and is limited at the superior margin of the lesion set by the ob­       LAPW ablation) have been incorporated in convergent endocardial ab­
lique sinus (Section 3.8.). Posterior segments of the PV ostia/antra may        lation workflows. One large study reported the use of endocardial
also be reached and ablated in most cases (Figure 15). The endocardial          cryoballoon in hybrid convergent procedures with favourable safety
component supplements the epicardial lesions around the pericardial             and efficacy.1418 The availability of PFA can improve safety and durabil­
reflections and any incompletely ablated posterior wall areas and ad­           ity of endocardial lesions delivered at the posterior wall and thus poten­
dresses any remaining gaps between the PV and the posterior wall le­            tially increase success rates. Given the likely role of LAA in persistent AF
sion set ensuring electrical isolation of the PVs. The endocardial              pathophysiology,819 limited studies have also combined the hybrid
component can also include a CTI line and additional substrate modifi­          convergent approach with epicardial placement of a clip or stapled ex­
cation. A key difference between thoracoscopic ablation and the hybrid          cision of the LAA reporting favourable initial results.1406,1419–1421
convergent procedure is that PVI is performed epicardially using bipolar
RF clamps in the former, while in the latter, it is achieved endocardially      12.3.3. Clinical evidence—comparison of catheter and
with catheter ablation.                                                         surgical ablation
   Single-center and multicenter studies have reported 66–95% free­             Several RCTs have compared efficacy and safety of surgical ablation
dom from atrial tachyarrhythmias at 1 year following the hybrid conver­         (minimally invasive or hybrid) with catheter ablation in mostly persist­
gent procedure,221,1401–1404,1406,1408,1415 with 52–81% arrhythmia-free         ent and long-standing persistent AF patients. Existing data and pertinent
survival without the use of AADs.1401,1403–1405,1415 Randomized                 advice are reported below.
controlled trial data are reported in detail in Section 12.3.3. Gained ex­
perience with hybrid convergent ablation has identified potential ad­
verse events that can be mitigated. Thermal injury to the esophagus             12.3.3.1. Paroxysmal atrial fibrillation
can be avoided by careful device orientation, esophageal temperature            Randomized controlled clinical trial data evaluating the efficacy of any
monitoring, and prophylactic irrigation of the pericardial space. Late          type of stand-alone surgical AF ablation in paroxysmal AF patients
pericardial effusion due to Dressler’s syndrome and cardiac tamponade           are limited. The FAST trial was a head-to-head randomized comparison
can be prevented by pericardial drains1403,1412 and prophylactic                of catheter ablation vs. epicardial thoracoscopic surgery (bipolar RF ab­
medications (colchicine, steroids, and/or nonsteroidal anti-inflammatory        lation without standardized procedural workflow) in a total of 124
Catheter and surgical ablation of atrial fibrillation                                                                                                   71


patients who had drug-refractory, symptomatic AF (66% paroxysmal               significantly higher costs and fewer quality-adjusted life-years than cath­
AF) with prior failed catheter ablation or at high risk for failure (dilated   eter ablation. Based on the study findings, the authors concluded that
LA).1339 The primary efficacy study endpoint (freedom from atrial ta­          they found no evidence to suggest stand-alone thoracoscopic surgical
chyarrhythmias >30 s off AADs at 12 month follow-up) was significant­          ablation as first-line invasive therapy in patients with symptomatic long-
ly higher in the surgical as compared to the catheter ablation group           standing persistent AF refractory to AADs.
(66 vs. 37%, P = 0.002). In the subgroup analysis, surgical ablation               In the CONVERGE trial, 153 patients with symptomatic persistent
showed superior efficacy in the paroxysmal but not in the persistent           or long-lasting persistent AF (mean duration 4.4 ± 4.7 years) were ran­
AF patient subgroup. The adverse event rate at 12 months was signifi­          domized 2:1 to undergo PVI plus PWI with a hybrid thoracoscopic/
cantly higher in the surgical ablation group mainly due to increased pro­      endocardial approach (99 patients) or PVI plus roof line (no PWI)
cedural complications. After a mean follow-up period of 7.0 years from         plus CTI line using a percutaneous, fully endocardial approach
randomization, atrial tachyarrhythmia recurrence was still significantly       (50 patients). There was a significantly higher 12-month freedom
lower with surgical ablation (56%) compared with catheter ablation             from AF in the absence of new or increased dosage of previously failed
(87%), without any difference in the primary clinical composite end­           or intolerant AADs (primary endpoint) in the hybrid arm compared
point (death, myocardial infarction, or cerebrovascular event).1340 In         with the endocardial arm (68 vs. 50%; P = 0.036).219 However,
a smaller RCT of 64 patients with previous failed catheter ablation            there was a higher major adverse event rate of 7.8% in the hybrid
(59% paroxysmal AF), minimally invasive surgical ablation (thoraco­            group compared with a 0% incidence in the endocardial group. The re­
scopic approach using bipolar RF clamp and targeting PVI, posterior            ported efficacy superiority of the hybrid as compared to the catheter
box isolation, and GP ablation) resulted in a significantly lower atrial ta­   ablation approach should be acknowledged in the context of relevant
chyarrhythmia recurrence rate at 12-months of follow-up as documen­            limitations such as the non-uniform ablation targets in compared
ted by ICM, with an associated significant increase in serious adverse         groups (no empirical PWI in the catheter ablation group) and compari­
events when compared with catheter ablation.1341                               son of a hybrid (epicardial/endocardial) double approach vs. a single
   Only one RCT has compared minimally invasive surgical ablation              catheter ablation.
(thoracoscopic approach using irrigated bipolar RF clamp and targeting             Recently, the HARTCAP-AF trial randomized 41 symptomatic,
PVI only with adjunctive LAA ligation) with catheter ablation as primary       ablation-naive patients with persistent or long-standing persistent AF
invasive AF treatment. The study included 52 patients with drug-               to an epicardial surgical ablation performed thoracoscopically (bipolar
refractory paroxysmal or early persistent (<3 months duration) AF              RF ablation) with occlusion/removal of the LAA combined with percu­
with ICM for rhythm assessment during follow-up. Single-procedure              taneous endocardial ablation (one stage) vs. percutaneous endocardial
arrhythmia-free survival off AADs after 2 years was similar in the cath­       catheter ablation, with optional repeated catheter ablation(s).1423
eter ablation when compared with the surgical ablation group (56 vs.           Hybrid ablation resulted in significantly more patients in SR off AADs
29%, respectively, P = 0.059), while a greater proportion of patients          at 12 months of follow-up compared with catheter ablation (89 vs.
in the catheter ablation group had a low AF burden (<0.5%) at 2 years.         41%, P = 0.002), without increasing the number of serious adverse
Procedure-related major complications occurred more often with the             events (21 vs. 14%, P = 0.685).
surgical than with the catheter ablation approach (20.8 vs. 0%, P =                The recent, multicenter CEASE-AF trial randomized a total of 154
0.029).1342                                                                    patients with drug-refractory, symptomatic persistent, or long-standing
   In paroxysmal AF patients, the primary therapeutic target for any           persistent AF in a 2:1 ratio to either a staged hybrid ablation or catheter
type of ablation strategy remains PVI. The following factors have              ablation with potential repeat ablation, which was not considered a pri­
been taken into account when determining the role of stand-alone sur­          mary effectiveness failure. The hybrid ablation procedure included
gical or hybrid ablation in symptomatic paroxysmal AF patients: (i) pau­       thoracoscopic RF ablation (PVI, PWI) and LAA exclusion with second-
city of RCT data in paroxysmal AF patients, (ii) discrepancy in reported       stage endocardial catheter ablation performed 3–6 months later. In the
rhythm outcome benefit when compared with catheter ablation, (iii)             catheter ablation arm, PVI was mandatory while additional ablation was
consistent reporting of higher complication rate with surgical ablation        left to physician’s discretion (only 40.2% received posterior wall abla­
compared with catheter ablation, (iv) lack of pathophysiological evi­          tion). Only 11.5% of patients in the endocardial ablation arm under­
dence to support ablation targets beyond PVI in paroxysmal AF pa­              went a second catheter ablation procedure. The primary efficacy
tients that may be achieved more efficiently with surgical approaches,         endpoint (freedom from AF/AFL/AT >30 s off all Class I/III AADs ex­
and (v) efficiency of catheter ablation in achieving durable PVI while en­     cept those at doses previously failed) was significantly higher in the hy­
suring reduced hospital stay and more rapid patient recovery.                  brid group as compared to the catheter ablation group (71.6 vs. 39.2%,
                                                                               P < 0.001) with similar major complication rates.1424
                                                                                   There is no RCT directly comparing minimally invasive epicardial sur­
12.3.3.2. Persistent and long-standing persistent atrial fibrillation          gical ablation alone vs. hybrid ablation. A systematic metaanalysis of 41
Several RCTs have evaluated the role of minimally invasive surgical or         studies (published until November 2016) reporting outcomes of these
hybrid ablation in comparison with catheter ablation in symptomatic            two types of ablation strategies in a total of 2737 patients concluded
patients with persistent or long-standing persistent AF as primary abla­       that single-procedure survival free from atrial tachyarrhythmias with­
tive therapy.                                                                  out AADs was similar between epicardial-alone and hybrid approaches
   In the CASA-AF trial, 120 patients with symptomatic long-standing           both at 12 months (epicardial alone 72 vs. hybrid 63%) and at 24
persistent AF without prior ablation were randomized to surgical abla­         months (69 and 57%, respectively). Interestingly, hybrid ablation was as­
tion (thoracoscopic approach using bipolar RF clamp and targeting PVI,         sociated with higher rate of major complications, while transdiaphrag­
posterior box isolation, and GP ablation) or catheter ablation (PVI, pos­      matic access and use of unipolar RF were associated with lower success
terior box isolation, CTI, and mitral isthmus line).1422 At 12 months,         rates when compared with thoracoscopic access and bipolar RF,
26% of patients in the surgical ablation arm and 28% of patients in            respectively.1425
the catheter ablation arm were free from atrial tachyarrhythmias, off              A limitation of hybrid AF ablation that restrains its wider applicability
AADs, after a single procedure as documented by invasive cardiac               is the higher rate of complications compared with percutaneous cath­
rhythm monitoring (P = 0.84). A similar percentage of patients experi­         eter ablation. This is not surprising given the added complexity and dur­
enced an arrhythmia burden reduction of ≥75% as well as                        ation of combining surgical and catheter-based procedures, particularly
procedure-related serious complications within 30 days of the inter­           when done at the same session. The reported rate of procedural-
vention in both compared arms. Surgical ablation was associated with           related serious adverse events in the abovementioned RCTs as well
72                                                                                                                                           S. Tzeis et al.



as in observational studies is usually in the range of 8–                     participants continuing their OAC treatment. At 3 years, there were
20%.1422,1423,1426,1427 These findings emphasize the importance of            significantly fewer strokes and systemic emboli in the occluded as com­
assembling an experienced multidisciplinary hybrid team consisting of         pared to the non-occluded cohort (4.8 vs. 7%, P = 0.001).
a cardiologist, electrophysiologist, and surgeon as discussed above.
Patients should be informed of the risks and benefits of a hybrid vs. a
percutaneous ablation approach prior to undergoing an AF ablation
procedure. Continued advances in ablation technologies and surgical           13. Training and institutional
and catheter-based approaches are anticipated to further improve pa­
tient outcome and reduce complications from hybrid ablation                   requirements for atrial fibrillation
procedures.                                                                   ablation
                                                                              For patients to have safe and effective AF ablation treatment, clinicians
12.4. Left atrial appendage exclusion                                         need to be adequately trained and work in an institution with appropri­
The LAA is the site of thrombus location in 90% of non-rheumatic AF           ate facilities and support. Before performing AF ablation, clinicians and
patients with stroke and is a well-documented target for stroke reduc­        institutions need to have formally assessed and recorded that they have
tion in patients with AF.1428 Multiple percutaneous and surgical techni­      the training, standard operating procedures, and facilities to:
ques have been proposed for LAA elimination. Recent evidence
supports the value of percutaneous LAA occlusion devices as an alter­         • select appropriate patients for treatment,
native to anticoagulants in AF patients.1429,1430 Surgical management of      • deliver the treatment in a safe and cost-effective way,
the LAA has an established role for stroke risk reduction in AF patients      • manage   common complications (e.g. postprocedural pain, hematoma),
as a part of surgical/hybrid AF ablation, as an adjunct to concomitant        • manage   or have arrangements to manage rare complications (e.g. car­
                                                                                diac perforation and tamponade, AEF, stroke),
cardiac surgery and, more rarely, as a stand-alone treatment. Early
evaluation of the Cox maze III procedure suggested a reduction in             • ensure  adequate patient follow-up,
late stroke after surgery.1431,1432 Other retrospective series subse­
                                                                              • record  and audit their results and outcomes, and

quently suggested a lower-than-expected incidence of late neurologic
                                                                              • respond   to incidents, errors, and complications and modify their prac­
                                                                                tice to reduce the probability of recurrence.
events after a Cox maze procedure, independent of the preoperative
CHA2DS2-VASc score or long-term warfarin use.1433,1434 The reduc­             The cost, efficiency, and access to catheter ablation are important con­
tion in stroke has been attributed to both SR restoration and LAA             siderations. It is therefore unrealistic to expect every clinician and insti­
elimination.                                                                  tution to provide the same level of facility and care. More complex
   Historically, the most common techniques for exclusion of the LAA          cases with higher risk should be treated by clinicians with a greater level
have been internal ligation, excision, or stapling at the base.1435–1438      of experience and training, in institutions with greater support.
Unfortunately, the efficacy of internal ligation and stapled excision or      Conversely, many lower risk patients undergoing simple PVI will not re­
exclusion have been poor in late follow-up.1439–1441 While surgical ex­       quire the same level of support. As long as centers and clinicians can
cision has been shown to be effective, there has been concern for             demonstrate that they are able to deliver all of these fundamental qual­
bleeding complications, especially in elderly patients with friable tissue.   ity metrics outlined above, then it is reasonable for them to perform
A more recent technique has been the use of external clips placed ei­         catheter ablation of AF.
ther under direct visualization or thoracoscopically at the base of the
appendage (AtriClip, AtriCure, Inc.).1442–1446 The first AtriClip exclu­
sion device was FDA approved in 2009 for the occlusion of the LAA             13.1. Training requirements
in patients undergoing other open cardiac surgical procedures. In a large     Atrial fibrillation ablation is not performed by a doctor or surgeon
prospective non-randomized trial, the EXCLUDE trial, 60 of 61 pa­             alone; it is a procedure involving a multidisciplinary team. Patients
tients had a successful LAA exclusion at the 3-month follow-up with           may interact with and depend on many of the clinicians in this team,
a first-generation AtriClip device.1447 Subsequently, the long-term re­       and therefore, training, competence, and access to facilities for all of
sults from a prospective device trial reported that all 36 patients           these team members need to be considered.
were without stroke, and there was 100% LAA occlusion confirmed
by imaging at 3 years without thrombi, reperfusion, or residual neck
stump of >1 cm.1448 In a recent larger series of 291 patients undergoing      13.1.1. Appropriate selection of patients
epicardial deployment of AtriClip device during open-heart surgery, the       Patients who are suitable for AF ablation are likely to be identified by
LAA was successfully excluded at 3 years in all patients.1449                 clinicians who do not perform AF ablation, including specialist nurses.
Furthermore, the subgroup of patients with LAA occlusion who dis­             However, before being scheduled for a procedure, patients should
continued OAC during follow-up had a 87.5% relative risk reduction            have had the opportunity to meet a doctor who is competent to per­
in ischemic stroke when compared with the expected rate in patients           form the procedure, with knowledge of the outcomes and other treat­
with similar CHA2DS2-VASc score.1449                                          ment options in order to allow the patient to make an informed
   Since then, several iterations have been made with the most recent         decision. Patients should also understand any limitations of the facilities
devices, Pro-V and FLEX-V AtriClip (AtriCure, Inc.), receiving FDA ap­        available to them, and physicians should be able to advise patients when
proval in 2016 and 2018, respectively. Several studies have established       a more complex level of care is needed. The treatment options for AF,
the safety and long-term efficacy of stand-alone minimally invasive or        AF ablation, and factors that influence outcomes are discussed in detail
thoracoscopic LAA occlusion with the AtriClip (AtriCure, Inc.) device         in previous sections. Trainees should have demonstrated similar knowl­
in patients who either cannot be anticoagulated or who are not candi­         edge and quality of consent as their supervisors before selecting and
dates for a transcatheter approach.1329–1334,1450,1451 The role of con­       consenting patients independently. Clinical staff involved in preparing
comitant surgical LAA occlusion, in addition to OAC use, is best              patients for their procedure should also be aware of clinical features
supported by a large RCT on LAA occlusion (LAAOS III).1335 Over               that may give them an increased risk or poorer outcome from an abla­
4800 patients with AF undergoing cardiac surgery were randomized              tion, and members of the team like specialist nurses performing pre-
to LAA occlusion (amputation, stapling, or suturing) or no treatment          admission assessment should be competent to identify such risk factors
and were followed for a mean period of 3.8 years, with 76.8% of the           and alert the rest of the team.
Catheter and surgical ablation of atrial fibrillation                                                                                                    73


13.1.2. Technical knowledge required                                               The writing group suggests that the minimum required practical ex­
The doctor performing the procedure should have a thorough under­                perience with active participation includes:
standing and appropriate training (with formal documentation of this if
appropriate) of:
                                                                                 • 50 AF ablation procedures,
                                                                                 • 20 CTI flutters, and
• current  indications for AF ablation (Section 4),                              • 10 non–CTI-dependent focal or reentrant tachycardias.
• relevant  anatomy (Section 3),                                                 These numbers are consistent with the 2015 ACC/AHA/HRS
• for
  advantages and disadvantages of different technologies and techniques
      AF ablation (Sections 6 and 8),
                                                                                 Advanced Training Statement on Clinical Cardiac Electrophysiology
                                                                                 and the Level 2 EHRA Certified Electrophysiology Specialist require­
• success  rates for ablation in different patient groups (Sections 8 and 10),
                                                                                 ments.1452 Further skills and knowledge may be required depending
• appropriate    postoperative management and follow-up of patients
  (Section 9), and                                                               on the practice of the trainee/physician.
• prevention,   clinical presentation, and management of procedural com­
  plications (Section 11).
                                                                                 13.1.5. Maintaining competence
Physicians should also have been through a formal and documented                 It is well recognized that both physician and institutional procedure vo­
training programme with their progress logged and signed off by an ap­           lumes are associated with improved patient outcomes. Even if physi­
propriate supervisor. They should have demonstrated a knowledge of               cians have received training for catheter ablation, it is important that
the areas required and competence to perform independently:                      they are performing these procedures regularly and continue a pro­
                                                                                 gramme of self-education to ensure that they are aware of the most
• achieve  venous access (including use of vascular ultrasound)
• perform    transseptal puncture                                                current evidence and thinking on AF and its management.
• identify  and isolate the PVs (including validating PVI on electrophysio­
  logical tracings and performing differential pacing maneuvers)
                                                                                     Actual procedure numbers continue to be difficult to define because
                                                                                 some clinicians will require longer training and more procedures to
• be  competent in using and interpreting 3D mapping systems                     maintain their performance than others. Analysis of early practice sug­
• understand    biophysics of RF, cryothermy and other energy sources, en­
  ergy selection, and application
                                                                                 gested that individual and institutional volumes of <25 and <50 AF ab­
                                                                                 lations per year, respectively, were associated with worse outcomes.298
• achieve     hemostasis post-procedure; this may include use of
  figure-of-eight sutures and/or vascular closure devices
                                                                                 More recent evidence suggests that procedure numbers are less im­
                                                                                 portant for institutions using cryoballoon ablation, with studies failing
• identify and drain a pericardial effusion                                      to show a significant difference between high-volume and low-volume
Atrial fibrillation ablation now comes in several forms, which range             centers.297,1453 The reality is probably more nuanced than simply a dis­
from PVI to complex AT ablation. It is recognized that some clinicians           tinction between high-volume and low-volume centers because, al­
may work in a service that just performs PVI with single-shot technolo­          though outcomes may not be statistically different, high-volume
gies and refers patients with rhythms other than AF to other electro­            centers will manage more complex, high-risk cases.1454 Therefore,
physiologists. The writing group suggests that all physicians involved           we would recommend that rather than using procedure numbers as
in AF ablation, even when focusing on single-shot PVI, should also               a crude assessment of competence, all centers performing AF ablation
have attained basic competence in mapping and ablation procedures                should be able to demonstrate their procedure outcomes and compli­
that are required for treatment of coexistent arrhythmias, e.g. typical          ance with the recommendations in this consensus document.
AFl, atypical AFl, or SVT. In case of non-availability of 3D mapping sys­            There is evidence of improved performance with team-based simu­
tems, patients with AT post-AF ablation should be referred to appro­             lations and loss of performance when this is discontinued.1455,1456 It is
priately equipped institutions.                                                  therefore strongly suggested that all members of the ablation team take
                                                                                 part in regular rehearsals or simulations to practice management of
                                                                                 emergencies and rarely seen complications like pericardial effusion.
13.1.3. Training of non-medical team members
                                                                                 This ensures that not only all team members are aware of the plan
The other members of the team performing ablation should have train­             and their role in it, but also that the necessary equipment is available.
ing appropriate to their roles. These roles may be varied but whatever
their role, their training and competence should be recorded and as­
sessed. Important roles fulfilled by non-medical members of the team             13.2. Institutional requirements
may include the following:                                                       13.2.1. Staff
                                                                                 Institutions should have sufficient trained staff to provide pre-admission
• selecting  patients—understanding indications and characteristics ad­
  versely affecting outcomes of AF ablation                                      counselling, AF ablation, and postoperative support and follow-up.
• managing    electrophysiology equipment                                        These roles should ideally not all be carried out by the physician per­
• managing    analgesia/sedation—appropriate and safe sedation training          forming the procedure, to ensure that other members of the team
• assisting in management of life-threatening complications (e.g. tampon­
  ade)—training and rehearsal of procedures and use of equipment
                                                                                 are appropriately trained to support patients in the absence of that
                                                                                 physician. If an institution is not able to offer 24/7 care to patients, pa­
• performing    patient follow-up                                                tients should be able to access care in the event of an emergency (even
• identification of complications or postablation arrhythmia recurrence          if it involves attending an emergency room) and know what those ar­
                                                                                 rangements are. Staff should be aware of common complications after
13.1.4. Completion of training                                                   AF ablation and to triage them appropriately.
Numbers of procedures required to achieve competence are very dif­
ficult to define because different clinicians will progress at different         13.2.2. Equipments and facilities
rates. It is recommended that trainees should have completed a training          Atrial fibrillation ablation in selected patients can be performed safely in
programme, and their supervisor/trainer should be able to take respon­           institutions without cardiothoracic surgical services.1214,1453 In a retro­
sibility for a trainee and confirm that the trainee is competent to per­         spective, non-randomized, propensity-matched analysis of Medicare
form the procedures they intend to undertake as an independent                   beneficiaries aged 65 years and older, the presence or absence of on-
practitioner.                                                                    site cardiothoracic surgery was not associated with 30-day rate of
74                                                                                                                                                                S. Tzeis et al.



cardiac perforation, cardiothoracic surgery, rehospitalization, and death                            The outcomes of physicians and their teams should be regularly re­
after AF ablation.1457 However, in this study, hospitals without cardio­                             viewed and arrangements in place to identify and manage poor per­
thoracic surgery accounted for just 2% of total ablations indicating that                            formance. Institutions should have a culture and system in place that
in the USA, this remains uncommon. When AF ablation is performed in                                  encourages reporting of poor outcomes and responding to this by
centers without cardiothoracic surgery services, it is recommended                                   avoiding individual blame, rather aiming to understand and correct
that transfer arrangements and checklists should be in place, and pa­                                the system failures that have led to poor performance and confirm
tients should be aware of the potential need to be transferred to a car­                             that appropriate changes have resulted in improved outcomes.
diothoracic center in case of emergency.                                                                If there is a regional or national audit database, centers should submit
   All institutions should have the following minimum equipment list to                              their data to those, including their complication rates.
perform AF ablation:
• ultrasound  for vascular access,
                                                                                                     14. Areas for future research
• echocardiography,   including TEE,
• fluoroscopic  X-ray imaging,                                                                       There has been significant progress in the safety and efficacy of AF ab­
• 3D  mapping or a single-shot PV ablation technology, and
                                                                                                     lation as well as significant advances in the technologies used to perform
• pericardial drainage equipment and anticoagulant reversal.                                         ablation. However, many critical questions remain unanswered, espe­
Institutions performing AT ablation should have access to a 3D map­                                  cially as we enter a new era in energy delivery with the advent of
ping technology.                                                                                     PFA (Table 10).

13.2.3. Follow-up and other requirements                                                             14.1. Basic translational science
Institutions should have arrangements for patient follow-up. Follow-up                               The importance of basic and translational research to better under­
intervals and duration are discussed in Section 9. Follow-up does not al­                            stand the mechanisms of AF should not be underestimated. It should
ways need to take place face-to-face. Digital ECG recording systems                                  be recognized that even after a century of research, the mechanisms
can facilitate remote phone or video consultation follow-up when                                     of AF have not been fully elucidated, hampering our ability to develop
the patient and the physician both feel this is appropriate. It is important                         better clinical tools for treating AF. The debate continues over the pri­
that this follow-up system should be used to record AF ablation out­                                 macy of the multiple wavelet hypothesis vs. focal sources of AF.1458
comes. These results should be audited, and the institution has formal                               While prior attempts to map with phase-mapping and other technolo­
arrangements for identifying and responding to serious complications.                                gies have not resulted in meaningful improvements in AF ablation,



 Table 10 Unanswered questions in AF ablation

  Topic                                                                                                          Questions
  ..............................................................................................................................................
  Basic/translational science                   • What are the mechanisms of AF?
                                                • What are the best preclinical models of AF for understanding human disease?
  Risk factor modification                      • Treatment of which risk factors (i.e. OSA, obesity, hypertension, physical inactivity) improve outcome after AF
                                                     ablation?
                                                • Does maintenance of risk factor modification reduce late AF recurrences?
                                                • Can pharmacologic prevention of remodelling/fibrosis improve long-term freedom from AF after ablation?
  Patient selection—personalized                • Can machine learning and artificial intelligence improve patient selection and downstream clinical outcomes?
    management                                  • Can we develop a personalized approach to AF ablation based on risk factors, AF duration, and atrial substrate?
                                                • Do asymptomatic individuals benefit from catheter ablation, including reductions in cardiovascular adverse events?
  Energy sources—ablation tools                 • What are the optimal settings for cryothermy and radiofrequency ablation in different LA regions?
                                                • What are the optimal PFA settings for AF ablation (delivery design, dose)?
                                                • Does PFA improve long-term outcomes when compared with radiofrequency or cryoballoon ablation?
                                                • Does PFA improve the safety and efficacy of additional substrate modification?
                                                • Are there unrecognized safety concerns if more extensive PFA leads to greater proportions of atrial myocardium
                                                     being ablated?
                                                • Can combined pulsed field and thermal ablation modalities improve AF ablation efficacy and safety?
  Ablation strategies                           • Can we prevent PV reconnection after PVI?
                                                • What is the optimal ablation approach of persistent AF?
                                                • Can ablation based upon computer simulations of the interactions between substrate and arrhythmia provide
                                                     personalized ablation strategies and lesion sets that result in safer, more effective, and more efficient procedures?
                                                •    Can we reproducibly map focal AF drivers and does ablation of these focal sources lead to improved outcomes?
                                                • Which patients benefit from hybrid ablation? Are outcomes and safety improved compared with catheter ablation?
  Endpoints and outcomes after                  • Can wearable technologies offer reliable monitoring of AF burden after AF ablation?
     ablation                                   • What is the optimal and most pragmatic efficacy endpoint for arrhythmia suppression after AF ablation?
 AF, atrial fibrillation; LA, left atrial; OSA, obstructive sleep apnoea; PFA, pulsed field ablation; PV, pulmonary vein; PVI, PV isolation.
Catheter and surgical ablation of atrial fibrillation                                                                                                     75


emerging technologies continue to offer promise. It is also possible that       that favour restrictive physiology,1180 but more data are needed, particu­
persistent AF has multiple mechanisms, which may vary in different              larly in patients undergoing extensive substrate modification.
patients and substrates. Investigation into more personalized AF treat­
ment strategies, based on clinical and electrophysiologic measurements,
that minimize tissue destruction should be encouraged. Whether we               14.5. Ablation strategies
can map AF in a way that leads to changes in ablation strategies with           While PVI remains the gold standard for the treatment of paroxysmal
an impact on short-term and long-term outcomes perhaps remains                  AF, PV reconnection after ablation remains a common problem and the
one of the largest unanswered questions in AF ablation.                         major reason for recurrence after ablation. Novel energy sources and
                                                                                approaches to minimize PV reconnection after ablation will be essential
14.2. Risk factor modification                                                  for determining the true effectiveness for durable PVI on freedom from
                                                                                AF. This is critical before other adjunctive strategies can be investigated.
Recent evidence has highlighted the importance of risk factor modifica­
                                                                                   Outcomes following ablation of persistent AF are suboptimal.
tion for improving the outcome after AF ablation and preventing long-
                                                                                Despite many clinical trials, no adjunctive ablation strategy has been
term AF recurrences (Section 5.1.). Optimal strategies for maintaining
                                                                                shown to be consistently superior to PVI alone. Delineation of optimal
weight loss and risk factor modification long term and its effect on
                                                                                method(s) for ablation of persistent AF beyond PVI remains a priority in
late AF recurrence should be investigated. Longer term (>10 year) out­
                                                                                future research in AF ablation. Advances in computational power and
come after ablation of AF should also be investigated to determine
                                                                                machine learning may also allow better characterization of the AF sub­
which patients benefit most from early intervention. It has also become
                                                                                strate and appropriate targets beyond PVI. Personalized computational
apparent that an underlying fibrotic atrial myopathy underlies AF pro­
                                                                                modelling has been evaluated to help ‘personalize’ ablation and pre-
gression in many patients. Pharmacologic approaches to minimize the
                                                                                determine ablation targets.1462 Future studies will need to prospective­
progression of atrial remodelling and fibrosis may be important for im­
                                                                                ly evaluate both clinical and machine learning risk stratification schemes,
proving long-term freedom from AF after ablation.
                                                                                and randomized studies will be needed to test personalized approaches
                                                                                to AF ablation. As with any new technology, reproducibility across
                                                                                centers will be essential.
14.3. Patient selection—personalized                                               The combined approach of hybrid ablation has shown some value for
management                                                                      improved outcomes in patients with persistent AF and more advanced
A key step in AF ablation is optimization of patient selection. Several         atrial substrates (Section 12). However, the morbidity of such proce­
variables are predictive of ablation outcome (Section 5.2.1.). There            dures is generally higher than catheter ablation, and outcomes depend
have been significant advances in our understanding of LA substrate             on surgical tools and experience. Studies to identify the best candidates,
and its relation to ablation outcomes. The DECAAF study highlighted             tools, and approach to hybrid ablation are needed. Future studies
the value of MRI-detected fibrosis for predicting outcomes after abla­          should also compare catheter ablation with hybrid approaches, ideally
tion.103 However, these findings have not been widely reproduced or             involving similar lesion sets and follow-up. Hybrid approaches that in­
employed. More recent studies have highlighted the promise of ma­               volve two procedures (surgical ablation followed by catheter ablation)
chine learning to predict outcomes following ablation.1459,1460                 should ideally be compared with two catheter ablations. Furthermore,
Development of a personalized approach to identify optimal AF abla­             the optimal timing between different stages of the hybrid procedure
tion candidates and predict procedural outcome is necessary to ad­              should be investigated.
vance precision medicine approach in the care of AF patients.                      While interventional catheter-based approaches to treat AF domin­
   To date, patient selection and indications for ablation of AF have fo­       ate our current approach, non-invasive methods for treating AF will un­
cused on those with symptoms and left ventricular systolic dysfunction.         doubtedly be developed in the future. Stereotactic body radiotherapy
However, recent data supporting improved outcomes with early                    has been demonstrated to be effective for refractory VT and is growing
rhythm control in asymptomatic persons raise the question as to                 in use.1463 Stereotactic body radiotherapy has also been used in a pilot
whether ablation may improve long-term outcomes in those without                study to treat AF in humans,1464 and such techniques will only improve
symptoms.332 Determining whether ablation can improve outcomes                  with safer targeting and radiation technology. Carbon and proton beam
in persons with asymptomatic AF will require relatively large RCTs.             ablation may allow more accurate targeting and lower radiation dose to
                                                                                surrounding tissues.1465 Further research into non-invasive ablation of
                                                                                AF should be encouraged.
14.4. Energy sources—ablation tools
In clinical practice across the world, cryothermy and RF remain the pre­        14.6. Endpoints and outcomes after
dominant modes of energy delivery for AF ablation. As both of these
technologies develop, the best approach to lesion delivery still remains        ablation
unclear. Pulsed field ablation has the potential to change that by providing    Testing different ablation strategies, evaluating the impact of new tech­
safer and more efficient lesion delivery. Utilization of PFA is rapidly grow­   nologies, and accurately understanding the impact of ablation require
ing, and larger multicenter experiences are reassuring.643,644 Additional       reporting and evaluation of standard, pragmatic, and meaningful mea­
investigation will be required to determine whether PFA results in similar      sures of arrhythmia suppression. While it is generally agreed that
or better long-term outcomes compared with cryoballoon and RF abla­             30 s of sustained atrial arrhythmia has limited value from a disease bur­
tion.662 While PFA may reduce the risk of significant PN palsy, esophageal      den and patient perspective, there still is no consensus on what the op­
injury, and PV stenosis, does it permanently impair GP? If not, what are        timal efficacy endpoint should be for AF ablation (Section 10.2.). While
the implications for longer term efficacy?1461 Does PFA perform as well         AF burden may be an ideal measure,7 at present, it requires either ex­
on non-PV targets with similar safety or are there additional safety con­       tended monitoring to provide periodic samples of AF burden or an im­
cerns as has been recently highlighted with coronary vasospasm?656              planted device to measure truly continuous AF burden (Section 10.3.).
Finally, if PFA does provide more reliable and facile ablation, will easier     However, this status quo may change as wearable technologies evolve
ablation result in more atrial myocardium being ablated and thus in­            (Section 9.4.).1466,1467 A key goal for the field should be the identification
creased risk for low-compliance complications of AF ablation such as stiff      of a universal, pragmatic, and meaningful efficacy endpoint for AF abla­
LA syndrome? Early data suggest that PFA does not engender changes              tion that impacts outcome.
76                                                                                                                                                                               S. Tzeis et al.



   Measuring outcomes is also challenging in asymptomatic patients;                                   Cardiology/American Heart Association task force on clinical practice guidelines and
while hard outcomes such as mortality and stroke would provide the                                    the Heart Rhythm Society. J Am Coll Cardiol 2019;74:104–32.
                                                                                                   9. Andrade JG, Aguilar M, Atzema C, Bell A, Cairns JA, Cheung CC, et al. The 2020
strongest support for ablation in asymptomatic patients, other out­
                                                                                                      Canadian Cardiovascular Society/Canadian Heart Rhythm Society comprehensive
comes such as exercise tolerance and QoL improvements would be im­                                    guidelines for the management of atrial fibrillation. Can J Cardiol 2020;36:1847–948.
portant to ascertain.                                                                             10. NHFA CSANZ Atrial Fibrillation Guideline Working Group; Brieger D, Amerena J,
                                                                                                      Attia J, Bajorek B, Chan KH, et al. National Heart Foundation of Australia and the
                                                                                                      Cardiac Society of Australia and New Zealand: Australian clinical guidelines for the
Supplementary material                                                                                diagnosis and management of atrial fibrillation 2018. Heart Lung Circ 2018;27:1209–66.
                                                                                                  11. Cheung CC, Nattel S, Macle L, Andrade JG. Management of atrial fibrillation in 2021: an
Supplementary material is available at Europace online.                                               updated comparison of the current CCS/CHRS, ESC, and AHA/ACC/HRS guidelines.
                                                                                                      Can J Cardiol 2021;37:1607–18.
Conflict of interest: All members provided disclosure statements                                  12. Wijffels MC, Kirchhof CJ, Dorland R, Allessie MA. Atrial fibrillation begets atrial fibril­
                                                                                                      lation. A study in awake chronically instrumented goats. Circulation 1995;92:1954–68.
to assess potential conflicts of interest. Details are available in the
                                                                                                  13. Fareh S, Villemaire C, Nattel S. Importance of refractoriness heterogeneity in the en­
Supplementary material.                                                                               hanced vulnerability to atrial fibrillation induction caused by tachycardia-induced atrial
                                                                                                      electrical remodeling. Circulation 1998;98:2202–9.
Data availability                                                                                 14. Crijns HJ, van Wijk LM, van Gilst WH, Kingma JH, van Gelder IC, Lie KI. Acute conver­
No new data were generated or analysed in support of this research.                                   sion of atrial fibrillation to sinus rhythm: clinical efficacy of flecainide acetate.
                                                                                                      Comparison of two regimens. Eur Heart J 1988;9:634–8.
                                                                                                  15. Suttorp MJ, Kingma JH, Jessurun ER, Lie AHL, van Hemel NM, Lie KI. The value of class
References                                                                                            IC antiarrhythmic drugs for acute conversion of paroxysmal atrial fibrillation or flutter
  1. Calkins H, Brugada J, Packer DL, Cappato R, Chen SA, Crijns HJ, et al. HRS/EHRA/                 to sinus rhythm. J Am Coll Cardiol 1990;16:1722–7.
     ECAS expert consensus statement on catheter and surgical ablation of atrial fibrilla­        16. Andrade JG, Deyell MW, Verma A, Macle L, Champagne J, Leong-Sit P, et al.
     tion: recommendations for personnel, policy, procedures and follow-up. A report                  Association of atrial fibrillation episode duration with arrhythmia recurrence following
     of the Heart Rhythm Society (HRS) task force on catheter and surgical ablation of atrial         ablation: a secondary analysis of a randomized clinical trial. JAMA Netw Open 2020;3:
     fibrillation developed in partnership with the European Heart Rhythm Association                 e208748.
     (EHRA) and the European Cardiac Arrhythmia Society (ECAS); in collaboration                  17. Boriani G, Botto GL, Padeletti L, Santini M, Capucci A, Gulizia M, et al. Improving stroke
     with the American College of Cardiology (ACC), American Heart Association                        risk stratification using the CHADS2 and CHA2DS2-VASc risk scores in patients with
     (AHA), and the Society of Thoracic Surgeons (STS). Endorsed and approved by the                  paroxysmal atrial fibrillation by continuous arrhythmia burden monitoring. Stroke
     governing bodies of the American College of Cardiology, the American Heart                       2011;42:1768–70.
     Association, the European Cardiac Arrhythmia Society, the European Heart                     18. Van Gelder IC, Healey JS, Crijns H, Wang J, Hohnloser SH, Gold MR, et al. Duration of
     Rhythm Association, the Society of Thoracic Surgeons, and the Heart Rhythm                       device-detected subclinical atrial fibrillation and occurrence of stroke in ASSERT. Eur
     Society. Europace 2007;9:335–79.                                                                 Heart J 2017;38:1339–44.
  2. Calkins H, Kuck KH, Cappato R, Brugada J, Camm AJ, Chen SA, et al. 2012 HRS/EHRA/            19. Chew DS, Li Z, Steinberg BA, O’Brien EC, Pritchard J, Bunch TJ, et al. Arrhythmic bur­
     ECAS expert consensus statement on catheter and surgical ablation of atrial fibrilla­            den and the risk of cardiovascular outcomes in patients with paroxysmal atrial fibrilla­
     tion: recommendations for patient selection, procedural techniques, patient manage­              tion and cardiac implanted electronic devices. Circ Arrhythm Electrophysiol 2022;15:
     ment and follow-up, definitions, endpoints, and research trial design: a report of the           e010304.
     Heart Rhythm Society (HRS) task force on catheter and surgical ablation of atrial fib­       20. Charitos EI, Purerfellner H, Glotzer TV, Ziegler PD. Clinical classifications of atrial fib­
     rillation. Developed in partnership with the European Heart Rhythm Association                   rillation poorly reflect its temporal persistence: insights from 1,195 patients continu­
     (EHRA), a registered branch of the European Society of Cardiology (ESC) and                      ously monitored with implantable devices. J Am Coll Cardiol 2014;63:2840–8.
     the European Cardiac Arrhythmia Society (ECAS); and in collaboration with the                21. Andrade JG, Yao RRJ, Deyell MW, Hawkins NM, Rizkallah J, Jolly U, et al. Clinical as­
     American College of Cardiology (ACC), American Heart Association (AHA), the                      sessment of AF pattern is poorly correlated with AF burden and post ablation out­
     Asia Pacific Heart Rhythm Society (APHRS), and the Society of Thoracic Surgeons                  comes: a CIRCA-DOSE sub-study. J Electrocardiol 2020;60:159–64.
     (STS). Endorsed by the governing bodies of the American College of Cardiology                22. De With RR, Erkuner O, Rienstra M, Nguyen BO, Korver FWJ, Linz D, et al. Temporal
     Foundation, the American Heart Association, the European Cardiac Arrhythmia                      patterns and short-term progression of paroxysmal atrial fibrillation: data from RACE
     Society, the European Heart Rhythm Association, the Society of Thoracic Surgeons,                V. Europace 2020;22:1162–72.
     the Asia Pacific Heart Rhythm Society, and the Heart Rhythm Society. Heart Rhythm            23. Blum S, Meyre P, Aeschbacher S, Berger S, Auberson C, Briel M, et al. Incidence and
     2012;9:632–96.e21.                                                                               predictors of atrial fibrillation progression: a systematic review and metaanalysis.
  3. Calkins H, Hindricks G, Cappato R, Kim Y-H, Saad EB, Aguinaga L, et al. 2017 HRS/
                                                                                                      Heart Rhythm 2019;16:502–10.
     EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical
                                                                                                  24. Kopecky SL, Gersh BJ, McGoon MD, Whisnant JP, Holmes DR, Ilstrup DM, et al. The
     ablation of atrial fibrillation: executive summary. J Arrhythm 2017;33:369–409.
                                                                                                      natural history of lone atrial fibrillation. A population-based study over three decades.
  4. January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC Jr, et al. 2019
                                                                                                      N Engl J Med 1987;317:669–74.
     AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the man­
                                                                                                  25. Pappone C, Radinovic A, Manguso F, Vicedomini G, Ciconte G, Sacchi S, et al. Atrial
     agement of patients with atrial fibrillation: a report of the American College of
                                                                                                      fibrillation progression and management: a 5-year prospective follow-up study.
     Cardiology/American Heart Association task force on clinical practice guidelines and
                                                                                                      Heart Rhythm 2008;5:1501–7.
     the Heart Rhythm Society in collaboration with the Society of Thoracic Surgeons.
                                                                                                  26. Simantirakis EN, Papakonstantinou PE, Kanoupakis E, Chlouverakis GI, Tzeis S, Vardas
     Circulation 2019;140:e125–51.
                                                                                                      PE. Recurrence rate of atrial fibrillation after the first clinical episode: a prospective
  5. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomstrom-Lundqvist C, et al. 2020
     ESC guidelines for the diagnosis and management of atrial fibrillation developed in col­         evaluation using continuous cardiac rhythm monitoring. Clin Cardiol 2018;41:594–600.
     laboration with the European Association for Cardio-Thoracic Surgery (EACTS): the            27. Andrade JG, Deyell MW, Macle L, Wells GA, Bennett M, Essebag V, et al. Progression
     task force for the diagnosis and management of atrial fibrillation of the European               of atrial fibrillation after cryoablation or drug therapy. N Engl J Med 2022;388:105–16.
     Society of Cardiology (ESC) developed with the special contribution of the                   28. Nguyen BO, Weberndorfer V, Crijns HJ, Geelhoed B, Ten Cate H, Spronk H, et al.
     European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 2021;42:                        Prevalence and determinants of atrial fibrillation progression in paroxysmal atrial fib­
     373–498.                                                                                         rillation. Heart 2022;109:186–94.
  6. Diederichsen SZ, Haugan KJ, Brandes A, Lanng MB, Graff C, Krieger D, et al. Natural          29. Potpara TS, Stankovic GR, Beleslin BD, Polovina MM, Marinkovic JM, Ostojic MC, et al.
     history of subclinical atrial fibrillation detected by implanted loop recorders. J Am Coll       A 12-year follow-up study of patients with newly diagnosed lone atrial fibrillation: im­
     Cardiol 2019;74:2771–81.                                                                         plications of arrhythmia progression on prognosis: the Belgrade atrial fibrillation study.
  7. Aguilar M, Macle L, Deyell MW, Yao R, Hawkins NM, Khairy P, et al. Influence of mon­             Chest 2012;141:339–47.
     itoring strategy on assessment of ablation success and postablation atrial fibrillation      30. Padfield GJ, Steinberg C, Swampillai J, Qian H, Connolly SJ, Dorian P, et al. Progression
     burden assessment: implications for practice and clinical trial design. Circulation              of paroxysmal to persistent atrial fibrillation: 10-year follow-up in the Canadian
     2022;145:21–30.                                                                                  Registry of Atrial Fibrillation. Heart Rhythm 2017;14:801–7.
  8. January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC Jr, et al. 2019           31. Piccini JP, Passman R, Turakhia M, Connolly AT, Nabutovsky Y, Varma N. Atrial fibril­
     AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the man­                        lation burden, progression, and the risk of death: a case-crossover analysis in patients
     agement of patients with atrial fibrillation: a report of the American College of                with cardiac implantable electronic devices. Europace 2019;21:404–13.
Catheter and surgical ablation of atrial fibrillation                                                                                                                                                77


 32. de Vos CB, Pisters R, Nieuwlaat R, Prins MH, Tieleman RG, Coelen RJ, et al.                         58. Low SK, Takahashi A, Ebana Y, Ozaki K, Christophersen IE, Ellinor PT, et al.
     Progression from paroxysmal to persistent atrial fibrillation clinical correlates and                   Identification of six new genetic loci associated with atrial fibrillation in the Japanese
     prognosis. J Am Coll Cardiol 2010;55:725–31.                                                            population. Nat Genet 2017;49:953–8.
 33. Kerr CR, Humphries KH, Talajic M, Klein GJ, Connolly SJ, Green M, et al. Progression                59. Weng LC, Choi SH, Klarin D, Smith JG, Loh PR, Chaffin M, et al. Heritability of atrial
     to chronic atrial fibrillation after the initial diagnosis of paroxysmal atrial fibrillation: re­       fibrillation. Circ Cardiovasc Genet 2017;10:e001838.
     sults from the Canadian Registry of Atrial Fibrillation. Am Heart J 2005;149:489–96.                60. Shoemaker MB, Shah RL, Roden DM, Perez MV. How will genetics inform the clinical
 34. Parkash R, Green MS, Kerr CR, Connolly SJ, Klein GJ, Sheldon R, et al. The association                  care of atrial fibrillation? Circ Res 2020;127:111–27.
     of left atrial size and occurrence of atrial fibrillation: a prospective cohort study from          61. Wilde AAM, Semsarian C, Márquez MF, Shamloo AS, Ackerman MJ, Ashley EA, et al.
     the Canadian Registry of Atrial Fibrillation. Am Heart J 2004;148:649–54.                               European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia
 35. Tsang TS, Barnes ME, Miyasaka Y, Cha SS, Bailey KR, Verzosa GC, et al. Obesity as a risk                Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society
     factor for the progression of paroxysmal to permanent atrial fibrillation: a longitudinal               (LAHRS) expert consensus statement on the state of genetic testing for cardiac dis­
     cohort study of 21 years. Eur Heart J 2008;29:2227–33.                                                  eases. Europace 2022;24:1307–67.
 36. Vitolo M, Proietti M, Imberti JF, Bonini N, Romiti GF, Mei DA, et al. Factors associated            62. Weiss JN, Garfinkel A, Karagueuzian HS, Chen PS, Qu Z. Early afterdepolarizations
     with progression of atrial fibrillation and impact on all-cause mortality in a cohort of                and cardiac arrhythmias. Heart Rhythm 2010;7:1891–9.
     European patients. J Clin Med 2023;12:768.                                                          63. Nattel S, Heijman J, Zhou L, Dobrev D. Molecular basis of atrial fibrillation pathophysi­
 37. De With RR, Marcos EG, Dudink E, Spronk HM, Crijns H, Rienstra M, et al. Atrial fib­                    ology and therapy: a translational perspective. Circ Res 2020;127:51–72.
     rillation progression risk factors and associated cardiovascular outcome in well-                   64. Andrade J, Khairy P, Dobrev D, Nattel S. The clinical profile and pathophysiology of
     phenotyped patients: data from the AF-RISK study. Europace 2020;22:352–60.                              atrial fibrillation: relationships among clinical features, epidemiology, and mechanisms.
 38. Ellinor PT, Yoerger DM, Ruskin JN, MacRae CA. Familial aggregation in lone atrial fib­                  Circ Res 2014;114:1453–68.
     rillation. Hum Genet 2005;118:179–84.                                                               65. Haïssaguerre M, Jaïs P, Shah DC, Takahashi A, Hocini M, Quiniou G, et al. Spontaneous
 39. Arnar DO, Thorvaldsson S, Manolio TA, Thorgeirsson G, Kristjansson K, Hakonarson                        initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl
     H, et al. Familial aggregation of atrial fibrillation in Iceland. Eur Heart J 2006;27:708–12.           J Med 1998;339:659–66.
 40. Lubitz SA, Yin X, Fontes JD, Magnani JW, Rienstra M, Pai M, et al. Association between              66. Ehrlich JR, Cha TJ, Zhang L, Chartier D, Melnyk P, Hohnloser SH, et al. Cellular elec­
     familial atrial fibrillation and risk of new-onset atrial fibrillation. JAMA 2010;304:                  trophysiology of canine pulmonary vein cardiomyocytes: action potential and ionic
     2263–9.                                                                                                 current properties. J Physiol 2003;551:801–13.
 41. Chen YH, Xu SJ, Bendahhou S, Wang XL, Wang Y, Xu WY, et al. KCNQ1                                   67. Teh AW, Kistler PM, Lee G, Medi C, Heck PM, Spence S, et al. Electroanatomic prop­
     gain-of-function mutation in familial atrial fibrillation. Science 2003;299:251–4.                      erties of the pulmonary veins: slowed conduction, low voltage and altered refractori­
 42. Olesen MS, Bentzen BH, Nielsen JB, Steffensen AB, David JP, Jabbari J, et al. Mutations                 ness in AF patients. J Cardiovasc Electrophysiol 2011;22:1083–91.
     in the potassium channel subunit KCNE1 are associated with early-onset familial atrial              68. Elbatran AI, Anderson RH, Mori S, Saba MM. The rationale for isolation of the left atrial
     fibrillation. BMC Med Genet 2012;13:24.                                                                 pulmonary venous component to control atrial fibrillation: a review article. Heart
 43. Yang Y, Xia M, Jin Q, Bendahhou S, Shi J, Chen Y, et al. Identification of a KCNE2                      Rhythm 2019;16:1392–8.
     gain-of-function mutation in patients with familial atrial fibrillation. Am J Hum Genet             69. Santangeli P, Marchlinski FE. Techniques for the provocation, localization, and ablation
     2004;75:899–905.                                                                                        of non-pulmonary vein triggers for atrial fibrillation. Heart Rhythm 2017;14:1087–96.
 44. Mann SA, Otway R, Guo G, Soka M, Karlsdotter L, Trivedi G, et al. Epistatic effects of              70. Mansour M, Mandapati R, Berenfeld O, Chen J, Samie FH, Jalife J. Left-to-right gradient
     potassium channel variation on cardiac repolarization and atrial fibrillation risk. J Am                of atrial frequencies during acute atrial fibrillation in the isolated sheep heart.
     Coll Cardiol 2012;59:1017–25.                                                                           Circulation 2001;103:2631–6.
 45. Sinner MF, Pfeufer A, Akyol M, Beckmann BM, Hinterseer M, Wacker A, et al. The non-                 71. Lazar S, Dixit S, Marchlinski FE, Callans DJ, Gerstenfeld EP. Presence of left-to-right
     synonymous coding IKr-channel variant KCNH2-K897T is associated with atrial fibril­                     atrial frequency gradient in paroxysmal but not persistent atrial fibrillation in humans.
     lation: results from a systematic candidate gene-based analysis of KCNH2 (HERG). Eur.                   Circulation 2004;110:3181–6.
     Heart J 2008;29:907–14.                                                                             72. Mandapati R, Skanes A, Chen J, Berenfeld O, Jalife J. Stable microreentrant sources as a
 46. Olesen MS, Refsgaard L, Holst AG, Larsen AP, Grubb S, Haunso S, et al. A novel                          mechanism of atrial fibrillation in the isolated sheep heart. Circulation 2000;101:194–9.
     KCND3 gain-of-function mutation associated with early-onset of persistent lone atrial               73. Davidenko JM, Pertsov AV, Salomonsz R, Baxter W, Jalife J. Stationary and drifting spir­
     fibrillation. Cardiovasc Res 2013;98:488–95.                                                            al waves of excitation in isolated cardiac muscle. Nature 1992;355:349–51.
 47. Christophersen IE, Olesen MS, Liang B, Andersen MN, Larsen AP, Nielsen JB, et al.                   74. Hansen BJ, Zhao J, Csepe TA, Moore BT, Li N, Jayne LA, et al. Atrial fibrillation driven by
     Genetic variation in KCNA5: impact on the atrial-specific potassium current IKur in                     micro-anatomic intramural reentry revealed by simultaneous sub-epicardial and sub-
     patients with lone atrial fibrillation. Eur Heart J 2013;34:1517–25.                                    endocardial optical mapping in explanted human hearts. Eur Heart J 2015;36:2390–401.
 48. Tsai CT, Hsieh CS, Chang SN, Chuang EY, Juang JM, Lin LY, et al. Next-generation se­                75. Narayan SM, Wright M, Derval N, Jadidi A, Forclaz A, Nault I, et al. Classifying fractio­
     quencing of nine atrial fibrillation candidate genes identified novel de novo mutations in              nated electrograms in human atrial fibrillation using monophasic action potentials and
     patients with extreme trait of atrial fibrillation. J Med Genet 2015;52:28–36.                          activation mapping: evidence for localized drivers, rate acceleration, and nonlocal signal
 49. Olesen MS, Yuan L, Liang B, Holst AG, Nielsen N, Nielsen JB, et al. High prevalence of                  etiologies. Heart Rhythm 2011;8:244–53.
     long QT syndrome-associated SCN5A variants in patients with early-onset lone atrial                 76. Zaman JAB, Sauer WH, Alhusseini MI, Baykaner T, Borne RT, Kowalewski CAB, et al.
     fibrillation. Circ Cardiovasc Genet 2012;5:450–9.                                                       Identification and characterization of sites where persistent atrial fibrillation is termi­
 50. Watanabe H, Darbar D, Kaiser DW, Jiramongkolchai K, Chopra S, Donahue BS, et al.                        nated by localized ablation. Circ Arrhythm Electrophysiol 2018;11:e005258.
     Mutations in sodium channel beta1- and beta2-subunits associated with atrial fibrilla­              77. Baykaner T, Rogers AJ, Meckler GL, Zaman J, Navara R, Rodrigo M, et al. Clinical im­
     tion. Circ Arrhythm Electrophysiol 2009;2:268–75.                                                       plications of ablation of drivers for atrial fibrillation: a systematic review and
 51. Li RG, Wang Q, Xu YJ, Zhang M, Qu XK, Liu X, et al. Mutations of the SCN4B-encoded                      metaanalysis. Circ Arrhythm Electrophysiol 2018;11:e006119.
     sodium channel beta4 subunit in familial atrial fibrillation. Int J Mol Med 2013;32:                78. Garrey WE. Auricular fibrillation. Physiol Rev 1924;4:215–50.
     144–50.                                                                                             79. Moe GK, Rheinboldt WC, Abildskov JA. A computer model of atrial fibrillation. Am
 52. Feghaly J, Zakka P, London B, MacRae CA, Refaat MM. Genetics of atrial fibrillation. J                  Heart J 1964;67:200–20.
     Am Heart Assoc 2018;7:e009884.                                                                      80. Kirchhof C, Chorro F, Scheffer GJ, Brugada J, Konings K, Zetelaki Z, et al. Regional en­
 53. Pessente GD, Sacilotto L, Calil ZO, Olivetti NQS, Wulkan F, de Oliveira TGM, et al.                     trainment of atrial fibrillation studied by high-resolution mapping in open-chest dogs.
     Effect of occurrence of Lamin A/C (LMNA) genetic variants in a cohort of 101 con­                       Circulation 1993;88:736–49.
     secutive apparent “Lone AF” patients: results and insights. Front Cardiovasc Med                    81. Lee S, Sahadevan J, Khrestian CM, Cakulev I, Markowitz A, Waldo AL. Simultaneous
     2022;9:823717.                                                                                          biatrial high-density (510-512 electrodes) epicardial mapping of persistent and long-
 54. Gudbjartsson DF, Arnar DO, Helgadottir A, Gretarsdottir S, Holm H, Sigurdsson A,                        standing persistent atrial fibrillation in patients: new insights into the mechanism of
     et al. Variants conferring risk of atrial fibrillation on chromosome 4q25. Nature                       its maintenance. Circulation 2015;132:2108–17.
     2007;448:353–7.                                                                                     82. Kamali R, Kump J, Ghafoori E, Lange M, Hu N, Bunch TJ, et al. Area available for atrial
 55. Roselli C, Chaffin MD, Weng LC, Aeschbacher S, Ahlberg G, Albert CM, et al.                             fibrillation to propagate is an important determinant of recurrence after ablation. JACC
     Multi-ethnic genome-wide association study for atrial fibrillation. Nat Genet 2018;                     Clin Electrophysiol 2021;7:896–908.
     50:1225–33.                                                                                         83. Eckstein J, Maesen B, Linz D, Zeemering S, van Hunnik A, Verheule S, et al. Time course
 56. Roselli C, Rienstra M, Ellinor PT. Genetics of atrial fibrillation in 2020: GWAS, genome                and mechanisms of endo-epicardial electrical dissociation during atrial fibrillation in the
     sequencing, polygenic risk, and beyond. Circ Res 2020;127:21–33.                                        goat. Cardiovasc Res 2011;89:816–24.
 57. Lee JY, Kim TH, Yang PS, Lim HE, Choi EK, Shim J, et al. Korean atrial fibrillation net­            84. Zhang L, van Schie MS, Knops P, Taverne Y, de Groot NMS. A novel diagnostic tool to
     work genome-wide association study for early-onset atrial fibrillation identifies novel                 identify atrial endo-epicardial asynchrony using signal fingerprinting. Hellenic J Cardiol
     susceptibility loci. Eur Heart J 2017;38:2586–94.                                                       2023:S1109-9666(23)00123-9.
78                                                                                                                                                                                   S. Tzeis et al.


 85. Lee G, Kumar S, Teh A, Madry A, Spence S, Larobina M, et al. Epicardial wave mapping           110. Wong CX, Ganesan AN, Selvanayagam JB. Epicardial fat and atrial fibrillation: current
     in human long-lasting persistent atrial fibrillation: transient rotational circuits, complex        evidence, potential mechanisms, clinical implications, and future directions. Eur Heart J
     wavefronts, and disorganized activity. Eur Heart J 2014;35:86–97.                                   2017;38:1294–302.
 86. Allessie MA, de Groot NM, Houben RP, Schotten U, Boersma E, Smeets JL, et al.                  111. Rocken C, Peters B, Juenemann G, Saeger W, Klein HU, Huth C, et al. Atrial amyloid­
     Electropathological substrate of long-standing persistent atrial fibrillation in patients           osis: an arrhythmogenic substrate for persistent atrial fibrillation. Circulation 2002;106:
     with structural heart disease: longitudinal dissociation. Circ Arrhythm Electrophysiol              2091–7.
     2010;3:606–15.                                                                                 112. Leone O, Boriani G, Chiappini B, Pacini D, Cenacchi G, Martin Suarez S, et al. Amyloid
 87. Parameswaran R, Teuwen CP, Watts T, Nalliah CJ, Royse A, Goldblatt J, et al.                        deposition as a cause of atrial remodelling in persistent valvular atrial fibrillation. Eur
     Functional atrial endocardial-epicardial dissociation in patients with structural heart             Heart J 2004;25:1237–41.
     disease undergoing cardiac surgery. JACC Clin Electrophysiol 2020;6:34–44.                     113. Steiner I, Hajkova P. Patterns of isolated atrial amyloid: a study of 100 hearts on aut­
 88. Parameswaran R, Kalman JM, Royse A, Goldblatt J, Larobina M, Watts T, et al.                        opsy. Cardiovasc Pathol 2006;15:287–90.
     Endocardial-epicardial phase mapping of prolonged persistent atrial fibrillation record­       114. Heijman J, Voigt N, Nattel S, Dobrev D. Cellular and molecular electrophysiology
     ings: high prevalence of dissociated activation patterns. Circ Arrhythm Electrophysiol              of atrial fibrillation initiation, maintenance, and progression. Circ Res 2014;114:
     2020;13:e008512.                                                                                    1483–99.
 89. Hong KL, Baley J, Baranchuk A, Bisleri G, Glover BM. Epicardial electrical activation          115. Nattel S, Burstein B, Dobrev D. Atrial remodeling and atrial fibrillation: mechanisms
     during atrial fibrillation: looking at the other side of the coin. JACC Case Rep 2019;1:            and implications. Circ Arrhythm Electrophysiol 2008;1:62–73.
     401–2.                                                                                         116. Caballero R, de la Fuente MG, Gomez R, Barana A, Amoros I, Dolz-Gaiton P, et al. In
 90. Jiang R, Buch E, Gima J, Upadhyay GA, Nayak HM, Beaser AD, et al. Feasibility of per­               humans, chronic atrial fibrillation decreases the transient outward current and ultra­
     cutaneous epicardial mapping and ablation for refractory atrial fibrillation: insights into         rapid component of the delayed rectifier current differentially on each atria and in­
     substrate and lesion transmurality. Heart Rhythm 2019;16:1151–9.                                    creases the slow component of the delayed rectifier current in both. J Am Coll
 91. Hoit BD. Left atrial size and function: role in prognosis. J Am Coll Cardiol 2014;63:               Cardiol 2010;55:2346–54.
     493–505.                                                                                       117. Voigt N, Trausch A, Knaut M, Matschke K, Varro A, Van Wagoner DR, et al.
 92. Mahnkopf C, Badger TJ, Burgon NS, Daccarett M, Haslam TS, Badger CT, et al.                         Left-to-right atrial inward rectifier potassium current gradients in patients with parox­
     Evaluation of the left atrial substrate in patients with lone atrial fibrillation using             ysmal versus chronic atrial fibrillation. Circ Arrhythm Electrophysiol 2010;3:472–80.
     delayed-enhanced MRI: implications for disease progression and response to catheter            118. Van Wagoner DR, Pond AL, Lamorgese M, Rossie SS, McCarthy PM, Nerbonne JM.
     ablation. Heart Rhythm 2010;7:1475–81.                                                              Atrial L-type Ca2+ currents and human atrial fibrillation. Circ Res 1999;85:428–36.
 93. Platonov PG, Mitrofanova LB, Orshanskaya V, Ho SY. Structural abnormalities in atrial          119. Martins RP, Kaur K, Hwang E, Ramirez RJ, Willis BC, Filgueiras-Rama D, et al. Dominant
     walls are associated with presence and persistency of atrial fibrillation but not with age.         frequency increase rate predicts transition from paroxysmal to long-term persistent
     J Am Coll Cardiol 2011;58:2225–32.                                                                  atrial fibrillation. Circulation 2014;129:1472–82.
 94. Kottkamp H. Fibrotic atrial cardiomyopathy: a specific disease/syndrome supplying              120. Deshmukh A, Barnard J, Sun H, Newton D, Castel L, Pettersson G, et al. Left atrial
     substrates for atrial fibrillation, atrial tachycardia, sinus node disease, AV node disease,        transcriptional changes associated with atrial fibrillation susceptibility and persistence.
     and thromboembolic complications. J Cardiovasc Electrophysiol 2012;23:797–9.                        Circ Arrhythm Electrophysiol 2015;8:32–41.
 95. Cochet H, Mouries A, Nivet H, Sacher F, Derval N, Denis A, et al. Age, atrial fibrillation,    121. Burstein B, Qi XY, Yeh YH, Calderone A, Nattel S. Atrial cardiomyocyte tachycardia
     and structural heart disease are the main determinants of left atrial fibrosis detected by          alters cardiac fibroblast function: a novel consideration in atrial remodeling. Cardiovasc
     delayed-enhanced magnetic resonance imaging in a general cardiology population. J                   Res 2007;76:442–52.
     Cardiovasc Electrophysiol 2015;26:484–92.                                                      122. Amar D, Zhang H, Miodownik S, Kadish AH. Competing autonomic mechanisms pre­
 96. Chrispin J, Ipek EG, Habibi M, Yang E, Spragg D, Marine JE, et al. Clinical predictors of           cedethe onset of postoperative atrial fibrillation. J Am Coll Cardiol 2003;42:1262–8.
     cardiac magnetic resonance late gadolinium enhancement in patients with atrial fibril­         123. Bettoni M, Zimmermann M. Autonomic tone variations before the onset of paroxys­
     lation. Europace 2017;19:371–7.                                                                     mal atrial fibrillation. Circulation 2002;105:2753–9.
 97. Ben Amar B, Bianca C. Towards a unified approach in the modeling of fibrosis: a review         124. Tomita T, Takei M, Saikawa Y, Hanaoka T, Uchikawa S, Tsutsui H, et al. Role of auto­
     with research perspectives. Phys Life Rev 2016;17:61–85.                                            nomic tone in the initiation and termination of paroxysmal atrial fibrillation in patients
 98. Jalife J. Mechanisms of persistent atrial fibrillation. Curr Opin Cardiol 2014;29:20–7.             without structural heart disease. J Cardiovasc Electrophysiol 2003;14:559–64.
 99. Xintarakou A, Tzeis S, Psarras S, Asvestas D, Vardas P. Atrial fibrosis as a dominant          125. Scherlag BJ, Yamanashi W, Patel U, Lazzara R, Jackman WM. Autonomically induced
     factor for the development of atrial fibrillation: facts and gaps. Europace 2020;22:                conversion of pulmonary vein focal firing into atrial fibrillation. J Am Coll Cardiol
     342–51.                                                                                             2005;45:1878–86.
100. Allessie M, Ausma J, Schotten U. Electrical, contractile and structural remodeling dur­        126. Patterson E, Po SS, Scherlag BJ, Lazzara R. Triggered firing in pulmonary veins initiated
     ing atrial fibrillation. Cardiovasc Res 2002;54:230–46.                                             by in vitro autonomic nerve stimulation. Heart Rhythm 2005;2:624–31.
101. Yue L, Xie J, Nattel S. Molecular determinants of cardiac fibroblast electrical function       127. Zhou J, Scherlag BJ, Edwards J, Jackman WM, Lazzara R, Po SS. Gradients of atrial re­
     and therapeutic implications for atrial fibrillation. Cardiovasc Res 2011;89:744–53.                fractoriness and inducibility of atrial fibrillation due to stimulation of ganglionated plexi.
102. Fedorov VV, Hansen BJ. A secret marriage between fibrosis and atrial fibrillation dri­              J Cardiovasc Electrophysiol 2007;18:83–90.
     vers. JACC Clin Electrophysiol 2018;4:30–2.                                                    128. Patterson E, Jackman WM, Beckman KJ, Lazzara R, Lockwood D, Scherlag BJ, et al.
103. Marrouche NF, Wilber D, Hindricks G, Jais P, Akoum N, Marchlinski F, et al.                         Spontaneous pulmonary vein firing in man: relationship to tachycardia-pause early
     Association of atrial tissue fibrosis identified by delayed enhancement MRI and atrial              afterdepolarizations and triggered arrhythmia in canine pulmonary veins in vitro. J
     fibrillation catheter ablation: the DECAAF study. JAMA 2014;311:498–506.                            Cardiovasc Electrophysiol 2007;18:1067–75.
104. Spragg DD, Khurram I, Zimmerman SL, Yarmohammadi H, Barcelon B, Needleman M,                   129. Jayachandran JV, Sih HJ, Winkle W, Zipes DP, Hutchins GD, Olgin JE. Atrial fibrillation
     et al. Initial experience with magnetic resonance imaging of atrial scar and                        produced by prolonged rapid atrial pacing is associated with heterogeneous changes in
     co-registration with electroanatomic voltage mapping during atrial fibrillation: success            atrial sympathetic innervation. Circulation 2000;101:1185–91.
     and limitations. Heart Rhythm 2012;9:2003–9.                                                   130. Lu Z, Scherlag BJ, Lin J, Niu G, Fung KM, Zhao L, et al. Atrial fibrillation begets atrial
105. Oakes RS, Badger TJ, Kholmovski EG, Akoum N, Burgon NS, Fish EN, et al. Detection                   fibrillation: autonomic mechanism for atrial electrical remodeling induced by short-
     and quantification of left atrial structural remodeling with delayed-enhancement magnet­            term rapid atrial pacing. Circ Arrhythm Electrophysiol 2008;1:184–92.
     ic resonance imaging in patients with atrial fibrillation. Circulation 2009;119:1758–67.       131. Stavrakis S, Stoner JA, Humphrey MB, Morris L, Filiberti A, Reynolds JC, et al. TREAT
106. Chen J, Arentz T, Cochet H, Müller-Edenborn B, Kim S, Moreno-Weidmann Z, et al.                     AF (transcutaneous electrical vagus nerve stimulation to suppress atrial fibrillation): a
     Extent and spatial distribution of left atrial arrhythmogenic sites, late gadolinium en­            randomized clinical trial. JACC Clin Electrophysiol 2020;6:282–91.
     hancement at magnetic resonance imaging, and low-voltage areas in patients with per­           132. Shen MJ, Hao-Che C, Park HW, George Akingba A, Chang PC, Zheng Z, et al.
     sistent atrial fibrillation: comparison of imaging vs. electrical parameters of fibrosis and        Low-level vagus nerve stimulation upregulates small conductance calcium-activated
     arrhythmogenesis. Europace 2019;21:1484–93.                                                         potassium channels in the stellate ganglion. Heart Rhythm 2013;10:910–5.
107. Haemers P, Hamdi H, Guedj K, Suffee N, Farahmand P, Popovic N, et al. Atrial fibril­           133. Bernstein SA, Wong B, Vasquez C, Rosenberg SP, Rooke R, Kuznekoff LM, et al. Spinal
     lation is associated with the fibrotic remodelling of adipose tissue in the subepicardium           cord stimulation protects against atrial fibrillation induced by tachypacing. Heart
     of human and sheep atria. Eur Heart J 2017;38:53–61.                                                Rhythm 2012;9:1426–33.e3.
108. Nalliah CJ, Bell JR, Raaijmakers AJA, Waddell HM, Wells SP, Bernasochi GB, et al.              134. Pokushalov E, Romanov A, Shugayev P, Artyomenko S, Shirokova N, Turov A, et al.
     Epicardial adipose tissue accumulation confers atrial conduction abnormality. J Am                  Selective ganglionated plexi ablation for paroxysmal atrial fibrillation. Heart Rhythm
     Coll Cardiol 2020;76:1197–211.                                                                      2009;6:1257–64.
109. Mahajan R, Lau DH, Brooks AG, Shipp NJ, Manavis J, Wood JP, et al.                             135. Katritsis D, Giazitzoglou E, Sougiannis D, Goumas N, Paxinos G, Camm AJ. Anatomic
     Electrophysiological, electroanatomical, and structural remodeling of the atria as con­             approach for ganglionic plexi ablation in patients with paroxysmal atrial fibrillation. Am J
     sequences of sustained obesity. J Am Coll Cardiol 2015;66:1–11.                                     Cardiol 2008;102:330–4.
Catheter and surgical ablation of atrial fibrillation                                                                                                                                               79


136. Katritsis DG, Giazitzoglou E, Zografos T, Pokushalov E, Po SS, Camm AJ. Rapid pul­               163. Benvenuti F, Meucci F, Vuolo L, Nistri R, Pracucci G, Picchioni A, et al. Relation
     monary vein isolation combined with autonomic ganglia modification: a randomized                      between the size of patent foramen ovale and the volume of acute cerebral
     study. Heart Rhythm 2011;8:672–8.                                                                     ischemic lesion in young patients with cryptogenic ischemic stroke. Neurol Sci 2022;
137. Nakagawa H, Scherlag BJ, Wu R, Po S, Lockwood D, Yokoyama K, et al. Addition of                       43:453–8.
     selective ablation of autonomic ganglia to pulmonary vein antrum isolation for treat­            164. Knecht S, Wright M, Lellouche N, Nault I, Matsuo S, O’Neill MD, et al. Impact of a pa­
     ment of paroxysmal and persistent atrial fibrillation. Circulation 2004;110:543.                      tent foramen ovale on paroxysmal atrial fibrillation ablation. J Cardiovasc Electrophysiol
138. Chen SA, Hsieh MH, Tai CT, Tsai CF, Prakash VS, Yu WC, et al. Initiation of atrial fib­               2008;19:1236–41.
     rillation by ectopic beats originating from the pulmonary veins: electrophysiological            165. Miyazaki S, Shah AJ, Nault I, Wright M, Jadidi AS, Forclaz A, et al. Impact of patent for­
     characteristics, pharmacological responses, and effects of radiofrequency ablation.                   amen ovale on left atrial linear lesions in the context of atrial fibrillation ablation.
     Circulation 1999;100:1879–86.                                                                         J Cardiovasc Electrophysiol 2011;22:846–50.
139. Jaïs P, Hocini M, Macle L, Choi KJ, Deisenhofer I, Weerasooriya R, et al. Distinctive elec­      166. Barrio-Lopez MT, Castellanos E, Betancur A, Zorita B, Medina J, Losada N, et al. The
     trophysiological properties of pulmonary veins in patients with atrial fibrillation.                  presence of a large patent foramen ovale reduces acute and chronic success in atrial
     Circulation 2002;106:2479–85.                                                                         fibrillation ablation. J Interv Card Electrophysiol 2022;64:705–13.
140. Cherry EM, Ehrlich JR, Nattel S, Fenton FH. Pulmonary vein reentry--properties and               167. Almendarez M, Alvarez-Velasco R, Pascual I, Alperi A, Moris C, Avanzas P. Transseptal
     size matter: insights from a computational analysis. Heart Rhythm 2007;4:1553–62.                     puncture: review of anatomy, techniques, complications and challenges, a critical view.
141. Bonczar M, Piątek-Koziej K, Wolska J, Tomala O, Stitou EA, Pękala J, et al. Variations in             Int J Cardiol 2022;351:32–38.
     human pulmonary vein ostia morphology: a systematic review with metaanalysis. Clin               168. De Ponti R, Cappato R, Curnis A, Della Bella P, Padeletti L, Raviele A, et al. Trans-septal
     Anat 2022;35:906–26.                                                                                  catheterization in the electrophysiology laboratory: data from a multicenter survey
142. Anselmino M, Blandino A, Beninati S, Rovera C, Boffano C, Belletti M, et al.                          spanning 12 years. J Am Coll Cardiol 2006;47:1037–42.
     Morphologic analysis of left atrial anatomy by magnetic resonance angiography in pa­             169. Li X, Wissner E, Kamioka M, Makimoto H, Rausch P, Metzner A, et al. Safety and feasi­
     tients with atrial fibrillation: a large single center experience. J Cardiovasc Electrophysiol        bility of transseptal puncture for atrial fibrillation ablation in patients with atrial septal
     2011;22:1–7.                                                                                          defect closure devices. Heart Rhythm 2014;11:330–5.
143. Cheruiyot I, Munguti J, Olabu B, Gichangi P. A metaanalysis of the relationship between          170. Santangeli P, Di Biase L, Burkhardt JD, Horton R, Sanchez J, Bailey S, et al. Transseptal
     anatomical variations of pulmonary veins and atrial fibrillation. Acta Cardiol 2020;75:1–9.           access and atrial fibrillation ablation guided by intracardiac echocardiography in pa­
144. Nathan H, Eliakim M. The junction between the left atrium and the pulmonary veins.                    tients with atrial septal closure devices. Heart Rhythm 2011;8:1669–75.
     An anatomic study of human hearts. Circulation 1966;34:412–22.                                   171. Wang K, Ho SY, Gibson DG, Anderson RH. Architecture of atrial musculature in hu­
145. Rivaud MR, Blok M, Jongbloed MRM, Boukens BJ. How Cardiac Embryology Translates                       mans. Br Heart J 1995;73:559–65.
     into Clinical Arrhythmias. J Cardiovasc Dev Dis 2021;8:70.                                       172. Jais P, Hocini M, Hsu LF, Sanders P, Scavee C, Weerasooriya R, et al. Technique and
146. Teres C, Soto-Iglesias D, Penela D, Jáuregui B, Ordoñez A, Chauca A, et al. Left atrial               results of linear ablation at the mitral isthmus. Circulation 2004;110:2996–3002.
     wall thickness of the pulmonary vein reconnection sites during atrial fibrillation redo          173. Derval N, Takigawa M, Frontera A, Mahida S, Konstantinos V, Denis A, et al.
     procedures. Pacing Clin Electrophysiol 2021;44:824–34.                                                Characterization of complex atrial tachycardia in patients with previous atrial interven­
147. Barrio-Lopez MT, Sanchez-Quintana D, Garcia-Martinez J, Betancur A, Castellanos E,                    tions using high-resolution mapping. JACC Clin Electrophysiol 2020;6:815–26.
     Arceluz M, et al. Epicardial connections involving pulmonary veins: the prevalence, pre­         174. Hocini M, Jais P, Sanders P, Takahashi Y, Rotter M, Rostock T, et al. Techniques, evalu­
     dictors, and implications for ablation outcome. Circ Arrhythm Electrophysiol 2020;13:                 ation, and consequences of linear block at the left atrial roof in paroxysmal atrial fib­
     e007544.                                                                                              rillation: a prospective randomized study. Circulation 2005;112:3688–96.
148. Perez-Castellano N, Villacastin J, Salinas J, Vega M, Moreno J, Doblado M, et al.                175. Ho SY. Normal and abnormal atrial anatomy relevant to atrial flutters: areas of physio­
     Epicardial connections between the pulmonary veins and left atrium: relevance for at­                 logical and acquired conduction blocks and delays predisposing to reentry. Card
     rial fibrillation ablation. J Cardiovasc Electrophysiol 2011;22:149–59.                               Electrophysiol Clin 2022;14:375–84.
149. Barrio-Lopez MT, Castellanos E, Ortiz M, Arceluz M, Lazaro C, Salas J, et al. Atrial map­        176. van Campenhout MJ, Yaksh A, Kik C, de Jaegere PP, Ho SY, Allessie MA, et al.
     ping during pulmonary vein pacing to detect conduction gaps in a second pulmonary                     Bachmann’s bundle: a key player in the development of atrial fibrillation? Circ
     vein isolation procedure. J Interv Card Electrophysiol 2018;53:195–205.                               Arrhythm Electrophysiol 2013;6:1041–6.
150. Yoshida K, Baba M, Shinoda Y, Harunari T, Tsumagari Y, Koda N, et al. Epicardial con­            177. Papez J. Heart musculature of the atria. Am J Anat 1920;27:255–85.
     nection between the right-sided pulmonary venous carina and the right atrium in pa­              178. Ho SY, Sanchez-Quintana D, Cabrera JA, Anderson RH. Anatomy of the left atrium:
     tients with atrial fibrillation: a possible mechanism for preclusion of pulmonary vein                implications for radiofrequency ablation of atrial fibrillation. J Cardiovasc
     isolation without carina ablation. Heart Rhythm 2019;16:671–8.                                        Electrophysiol 1999;10:1525–33.
151. Cabrera JA, Ho SY, Climent V, Fuertes B, Murillo M, Sanchez-Quintana D.                          179. Pambrun T, Duchateau J, Delgove A, Denis A, Constantin M, Ramirez FD, et al.
     Morphological evidence of muscular connections between contiguous pulmonary ven­                      Epicardial course of the septopulmonary bundle: anatomical considerations and clinical
     ous orifices: relevance of the interpulmonary isthmus for catheter ablation in atrial fib­            implications for roof line completion. Heart Rhythm 2021;18:349–57.
     rillation. Heart Rhythm 2009;6:1192–8.                                                           180. Chauvin M, Shah DC, Haissaguerre M, Marcellin L, Brechenmacher C. The anatomic
152. Cabrera JA, Ho SY, Climent V, Sanchez-Quintana D. The architecture of the left lateral                basis of connections between the coronary sinus musculature and the left atrium in
     atrial wall: a particular anatomic region with implications for ablation of atrial fibrilla­          humans. Circulation 2000;101:647–52.
     tion. Eur Heart J 2008;29:356–62.                                                                181. von Ludinghausen M, Ohmachi N, Besch S, Mettenleiter A. Atrial veins of the human
153. Ho SY, Cabrera JA, Sanchez-Quintana D. Left atrial anatomy revisited. Circ Arrhythm                   heart. Clin Anat 1995;8:169–89.
     Electrophysiol 2012;5:220–8.                                                                     182. Kim DT, Lai AC, Hwang C, Fan LT, Karagueuzian HS, Chen PS, et al. The ligament of
154. Ho SY, Anderson RH, Sanchez-Quintana D. Atrial structure and fibres: morphologic                      Marshall: a structural analysis in human hearts with implications for atrial arrhythmias.
     bases of atrial conduction. Cardiovasc Res 2002;54:325–36.                                            J Am Coll Cardiol 2000;36:1324–7.
155. Ho SY, Sanchez-Quintana D. The importance of atrial structure and fibers. Clin Anat              183. Makino M, Inoue S, Matsuyama TA, Ogawa G, Sakai T, Kobayashi Y, et al. Diverse myo­
     2009;22:52–63.                                                                                        cardial extension and autonomic innervation on ligament of Marshall in humans.
156. Patel PJ, D’Souza B, Saha P, Chik WW, Riley MP, Garcia FC. Electroanatomic mapping                    J Cardiovasc Electrophysiol 2006;17:594–9.
     of the intercaval bundle in atrial fibrillation. Circ Arrhythm Electrophysiol 2014;7:1262–7.     184. Von Lüdinghausen M, Ohmachi N, Boot C. Myocardial coverage of the coronary sinus
157. Anderson RH, Spicer DE, Brown NA, Mohun TJ. The development of septation in the                       and related veins. Clin Anat 1992;5:1–15.
     four-chambered heart. Anat Rec 2014;297:1414–29.                                                 185. xMarshall J. On the development of the great anterior veins in man and mammalia; in­
158. Klimek-Piotrowska W, Hołda MK, Koziej M, Piątek K, Hołda J. Anatomy of the true                       cluding an account of certain remnants of foetal structure found in the adult, a com­
     interatrial septum for transseptal access to the left atrium. Ann Anat 2016;205:60–4.                 parative view of these great veins in the different mammalia, and an analysis of their
159. Tzeis S, Andrikopoulos G, Deisenhofer I, Ho SY, Theodorakis G. Transseptal catheter­                  occasional peculiarities in the human subject. Philos Trans Roy Soc Lond 1850;140:
     ization: considerations and caveats. Pacing Clin Electrophysiol 2010;33:231–42.                       133–70.
160. Meier D, Antiochos P, Herrera-Siklody C, Eeckhout E, Delabays A, Tzimas G, et al.                186. DeSimone CV, Noheria A, Lachman N, Edwards WD, Gami AS, Maleszewski JJ, et al.
     Interatrial septum dissection and atrial wall hematoma following transseptal puncture:                Myocardium of the superior vena cava, coronary sinus, vein of Marshall, and the pul­
     a systematic review of the literature. Catheter Cardiovasc Interv 2020;96:424–31.                     monary vein ostia: gross anatomic studies in 620 hearts. J Cardiovasc Electrophysiol
161. Kerut EK, Norfleet WT, Plotnick GD, Giles TD. Patent foramen ovale: a review of as­                   2012;23:1304–9.
     sociated conditions and the impact of physiological size. J Am Coll Cardiol 2001;38:             187. Baez-Escudero JL, Keida T, Dave AS, Okishige K, Valderrabano M. Ethanol infusion in
     613–23.                                                                                               the vein of Marshall leads to parasympathetic denervation of the human left atrium:
162. Hagen PT, Scholz DG, Edwards WD. Incidence and size of patent foramen ovale dur­                      implications for atrial fibrillation. J Am Coll Cardiol 2014;63:1892–901.
     ing the first 10 decades of life: an autopsy study of 965 normal hearts. Mayo Clin Proc          188. Hwang C, Chen PS. Ligament of Marshall: why it is important for atrial fibrillation ab­
     1984;59:17–20.                                                                                        lation. Heart Rhythm 2009;6:S35–40.
80                                                                                                                                                                                       S. Tzeis et al.


189. Hwang C, Wu TJ, Doshi RN, Peter CT, Chen PS. Vein of Marshall cannulation for the                   215. Musikantow DR, Neuzil P, Petru J, Koruth JS, Kralovec S, Miller MA, et al. Pulsed field
     analysis of electrical activity in patients with focal atrial fibrillation. Circulation 2000;101:        ablation to treat atrial fibrillation: autonomic nervous system effects. JACC Clin
     1503–5.                                                                                                  Electrophysiol 2023;9:481–93.
190. Ulphani JS, Arora R, Cain JH, Villuendas R, Shen S, Gordon D, et al. The ligament of                216. von Olshausen G, Saluveer O, Schwieler J, Drca N, Bastani H, Tapanainen J, et al. Sinus
     Marshall as a parasympathetic conduit. Am J Physiol Heart Circ Physiol 2007;293:                         heart rate post pulmonary vein ablation and long-term risk of recurrences. Clin Res
     H1629–35.                                                                                                Cardiol 2021;110:851–60.
191. Hwang C, Karagueuzian HS, Chen PS. Idiopathic paroxysmal atrial fibrillation induced                217. Yu HT, Kim TH, Uhm JS, Kim JY, Joung B, Lee MH, et al. Prognosis of high sinus heart
     by a focal discharge mechanism in the left superior pulmonary vein: possible roles of                    rate after catheter ablation for atrial fibrillation. Europace 2017;19:1132–9.
     the ligament of Marshall. J Cardiovasc Electrophysiol 1999;10:636–48.                               218. Goff ZD, Laczay B, Yenokyan G, Sivasambu B, Sinha SK, Marine JE, et al. Heart rate in­
192. Wittkampf FH, van Oosterhout MF, Loh P, Derksen R, Vonken EJ, Slootweg PJ, et al.                        crease after pulmonary vein isolation predicts freedom from atrial fibrillation at 1 year.
     Where to draw the mitral isthmus line in catheter ablation of atrial fibrillation: histo­                J Cardiovasc Electrophysiol 2019;30:2818–22.
     logical analysis. Eur Heart J 2005;26:689–95.                                                       219. DeLurgio DB, Crossen KJ, Gill J, Blauth C, Oza SR, Magnano AR, et al. Hybrid conver­
193. Pambrun T, Denis A, Duchateau J, Sacher F, Hocini M, Jaïs P, et al. Marshall bundles                     gent procedure for the treatment of persistent and long-standing persistent atrial fib­
     elimination, pulmonary veins isolation and Lines completion for anatomical ablation                      rillation: results of CONVERGE clinical trial. Circ Arrhythm Electrophysiol 2020;13:
     of persistent atrial fibrillation: Marshall-PLAN case series. J Cardiovasc Electrophysiol                e009288.
     2019;30:7–15.                                                                                       220. Makati KJ, Sood N, Lee LS, Yang F, Shults CC, DeLurgio DB, et al. Combined epicardial
194. Becker AE. Left atrial isthmus: anatomic aspects relevant for linear catheter ablation                   and endocardial ablation for atrial fibrillation: best practices and guide to hybrid con­
     procedures in humans. J Cardiovasc Electrophysiol 2004;15:809–12.                                        vergent procedures. Heart Rhythm 2021;18:303–12.
195. Baez-Escudero JL, Morales PF, Dave AS, Sasaridis CM, Kim YH, Okishige K, et al.                     221. Kress DC, Erickson L, Choudhuri I, Zilinski J, Mengesha T, Krum D, et al. Comparative
     Ethanol infusion in the vein of Marshall facilitates mitral isthmus ablation. Heart                      effectiveness of hybrid ablation versus endocardial catheter ablation alone in patients
     Rhythm 2012;9:1207–15.                                                                                   with persistent atrial fibrillation. JACC Clin Electrophysiol 2017;3:341–9.
196. Takigawa M, Vlachos K, Martin CA, Bourier F, Denis A, Kitamura T, et al. Acute and                  222. Reddy VY, Neuzil P, D’Avila A, Ruskin JN. Isolating the posterior left atrium and pul­
     mid-term outcome of ethanol infusion of vein of Marshall for the treatment of perimi­                    monary veins with a “box” lesion set: use of epicardial ablation to complete electrical
     tral flutter. Europace 2020;22:1252–60.                                                                  isolation. J Cardiovasc Electrophysiol 2008;19:326–9.
197. Pambrun T, Derval N, Duchateau J, Denis A, Chauvel R, Tixier R, et al. Epicardial                   223. Piorkowski C, Kronborg M, Hourdain J, Piorkowski J, Kirstein B, Neudeck S, et al.
     course of the musculature related to the great cardiac vein: anatomical considerations                   Endo-/epicardial catheter ablation of atrial fibrillation: feasibility, outcome, and insights
                                                                                                              into arrhythmia mechanisms. Circ Arrhythm Electrophysiol 2018;11:e005748.
     and clinical implications for mitral isthmus block after vein of Marshall ethanol infusion.
                                                                                                         224. Tung R. Percutaneous epicardial ablation of atrial fibrillation. Card Electrophysiol Clin
     Heart Rhythm 2021;18:1951–8.
                                                                                                              2020;12:371–81.
198. Tsai CF, Tai CT, Hsieh MH, Lin WS, Yu WC, Ueng KC, et al. Initiation of atrial fibril­
                                                                                                         225. D’Avila A, Scanavacca M, Sosa E, Ruskin JN, Reddy VY. Pericardial anatomy for the
     lation by ectopic beats originating from the superior vena cava: electrophysiological
                                                                                                              interventional electrophysiologist. J Cardiovasc Electrophysiol 2003;14:422–30.
     characteristics and results of radiofrequency ablation. Circulation 2000;102:67–74.
                                                                                                         226. Smith NM, Segars L, Kauffman T, Olinger AB. Using anatomical landmark to avoid
199. Nyuta E, Takemoto M, Sakai T, Mito T, Masumoto A, Todoroki W, et al. Importance of
                                                                                                              phrenic nerve injury during balloon-based procedures in atrial fibrillation patients.
     the length of the myocardial sleeve in the superior vena cava in patients with atrial
                                                                                                              Surg Radiol Anat 2017;39:1369–75.
     fibrillation. J Arrhythm 2021;37:43–51.
                                                                                                         227. Okumura Y, Henz BD, Bunch TJ, Dalegrave C, Johnson SB, Packer DL. Distortion of
200. Depes D, Mennander A, Paavonen T, Kholová I. Autonomic nerves in myocardial
                                                                                                              right superior pulmonary vein anatomy by balloon catheters as a contributor to phren­
     sleeves around caval veins: potential role in cardiovascular mortality? Cardiovasc
                                                                                                              ic nerve injury. J Cardiovasc Electrophysiol 2009;20:1151–7.
     Pathol 2022;59:107426.
                                                                                                         228. Ströker E, de Asmundis C, Saitoh Y, Velagić V, Mugnai G, Irfan G, et al. Anatomic pre­
201. Miyazaki S, Taniguchi H, Kusa S, Ichihara N, Nakamura H, Hachiya H, et al. Factors pre­
                                                                                                              dictors of phrenic nerve injury in the setting of pulmonary vein isolation using the
     dicting an arrhythmogenic superior vena cava in atrial fibrillation ablation: insight into
                                                                                                              28-mm second-generation cryoballoon. Heart Rhythm 2016;13:342–51.
     the mechanism. Heart Rhythm 2014;11:1560–6.
                                                                                                         229. Romero J, Natale A, Lakkireddy D, Cerna L, Diaz JC, Alviz I, et al. Mapping and local­
202. Corradi D, Callegari S, Gelsomino S, Lorusso R, Macchi E. Morphology and patho­
                                                                                                              ization of the left phrenic nerve during left atrial appendage electrical isolation to avoid
     physiology of target anatomical sites for ablation procedures in patients with atrial fib­
                                                                                                              inadvertent injury in patients undergoing catheter ablation of atrial fibrillation. Heart
     rillation: part II: pulmonary veins, caval veins, ganglionated plexi, and ligament of                    Rhythm 2020;17:527–34.
     Marshall. Int J Cardiol 2013;168:1769–78.                                                           230. Gupta T, Cheema N, Randhawa A, Sahni D. Translational anatomy of the left atrium
203. Wickramasinghe SR, Patel VV. Local innervation and atrial fibrillation. Circulation 2013;                and esophagus as relevant to the pulmonary vein antral isolation for atrial fibrillation.
     128:1566–75.                                                                                             Surg Radiol Anat 2020;42:367–76.
204. Kusayama T, Wan J, Yuan Y, Chen PS. Neural mechanisms and therapeutic opportun­                     231. Bunch TJ, May HT, Crandall BG, Weiss JP, Bair TL, Osborn JS, et al. Intracardiac ultra­
     ities for atrial fibrillation. Methodist Debakey Cardiovasc J 2021;17:43–7.                              sound for esophageal anatomic assessment and localization during left atrial ablation
205. Kawashima T. The autonomic nervous system of the human heart with special refer­                         for atrial fibrillation. J Cardiovasc Electrophysiol 2013;24:33–9.
     ence to its origin, course, and peripheral distribution. Anat Embryol 2005;209:425–38.              232. Jang SW, Kwon BJ, Choi MS, Kim DB, Shin WS, Cho EJ, et al. Computed tomographic
206. Shen MJ, Zipes DP. Role of the autonomic nervous system in modulating cardiac ar­                        analysis of the esophagus, left atrium, and pulmonary veins: implications for catheter
     rhythmias. Circ Res 2014;114:1004–21.                                                                    ablation of atrial fibrillation. J Interv Card Electrophysiol 2011;32:1–6.
207. Hou Y, Zhou Q, Po SS. Neuromodulation for cardiac arrhythmia. Heart Rhythm 2016;                    233. Sarairah SY, Woodbury B, Methachittiphan N, Tregoning DM, Sridhar AR, Akoum N.
     13:584–92.                                                                                               Esophageal thermal injury following cryoballoon ablation for atrial fibrillation. JACC Clin
208. Armour JA, Murphy DA, Yuan BX, Macdonald S, Hopkins DA. Gross and microscopic                            Electrophysiol 2020;6:262–8.
     anatomy of the human intrinsic cardiac nervous system. Anat Rec 1997;247:289–98.                    234. Lemola K, Sneider M, Desjardins B, Case I, Han J, Good E, et al. Computed tomograph­
209. Kim MY, Sandler BC, Sikkel MB, Cantwell CD, Leong KM, Luther V, et al. Anatomical                        ic analysis of the anatomy of the left atrium and the esophagus: implications for left
     distribution of ectopy-triggering plexuses in patients with atrial fibrillation. Circ                    atrial catheter ablation. Circulation 2004;110:3655–60.
     Arrhythm Electrophysiol 2020;13:e008715.                                                            235. Good E, Oral H, Lemola K, Han J, Tamirisa K, Igic P, et al. Movement of the esophagus
210. Po SS, Nakagawa H, Jackman WM. Localization of left atrial ganglionated plexi in pa­                     during left atrial catheter ablation for atrial fibrillation. J Am Coll Cardiol 2005;46:
     tients with atrial fibrillation. J Cardiovasc Electrophysiol 2009;20:1186–9.                             2107–10.
211. Scherlag BJ, Nakagawa H, Jackman WM, Yamanashi WS, Patterson E, Po S, et al.                        236. Wilber DJ, Pappone C, Neuzil P, De Paola A, Marchlinski F, Natale A, et al. Comparison
     Electrical stimulation to identify neural elements on the heart: their role in atrial fibril­            of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with
     lation. J Interv Card Electrophysiol 2005;13:37–42.                                                      paroxysmal atrial fibrillation: a randomized controlled trial. JAMA 2010;303:333–40.
212. Lemery R, Birnie D, Tang AS, Green M, Gollob M. Feasibility study of endocardial map­               237. Calkins H, Reynolds MR, Spector P, Sondhi M, Xu Y, Martin A, et al. Treatment of atrial
     ping of ganglionated plexuses during catheter ablation of atrial fibrillation. Heart                     fibrillation with antiarrhythmic drugs or radiofrequency ablation: two systematic litera­
     Rhythm 2006;3:387–96.                                                                                    ture reviews and meta-analyses. Circ Arrhythm Electrophysiol 2009;2:349–61.
213. Stirrup J, Gregg S, Baavour R, Roth N, Breault C, Agostini D, et al. Hybrid solid-state             238. Jaïs P, Cauchemez B, Macle L, Daoud E, Khairy P, Subbiah R, et al. Catheter ablation
     SPECT/CT left atrial innervation imaging for identification of left atrial ganglionated                  versus antiarrhythmic drugs for atrial fibrillation: the A4 study. Circulation 2008;118:
     plexi: technique and validation in patients with atrial fibrillation. J Nucl Cardiol 2020;               2498–505.
     27:1939–50.                                                                                         239. Packer DL, Kowal RC, Wheelan KR, Irwin JM, Champagne J, Guerra PG, et al.
214. Lemoine MD, Mencke C, Nies M, Obergassel J, Scherschel K, Wieboldt H, et al.                             Cryoballoon ablation of pulmonary veins for paroxysmal atrial fibrillation: first results
     Pulmonary vein isolation by pulsed-field ablation induces less neurocardiac damage                       of the North American Arctic Front (STOP AF) pivotal trial. J Am Coll Cardiol 2013;61:
     than cryoballoon ablation. Circ Arrhythm Electrophysiol 2023;16:e011598.                                 1713–23.
Catheter and surgical ablation of atrial fibrillation                                                                                                                                            81


240. Poole JE, Bahnson TD, Monahan KH, Johnson G, Rostami H, Silverstein AP, et al.                 264. Torbey E, Karam B, Sleiman E, Tabet R, Kirk M, Donaldson D, et al. Incidence and risk
     Recurrence of atrial fibrillation after catheter ablation or antiarrhythmic drug therapy            factors for atrial fibrillation recurrence after ablation of nodal and atrioventricular re­
     in the CABANA trial. J Am Coll Cardiol 2020;75:3105–18.                                             entrant tachycardia: a metaanalysis. Cureus 2020;12:e7824.
241. Mont L, Bisbal F, Hernández-Madrid A, Pérez-Castellano N, Viñolas X, Arenal A, et al.          265. Inada K, Yamane T, Tokutake K, Yokoyama K, Mishima T, Hioki M, et al. The role of
     Catheter ablation vs. antiarrhythmic drug treatment of persistent atrial fibrillation: a            successful catheter ablation in patients with paroxysmal atrial fibrillation and pro­
     multicenter, randomized, controlled trial (SARA study). Eur Heart J 2014;35:501–7.                  longed sinus pauses: outcome during a 5-year follow-up. Europace 2014;16:208–13.
242. Scherr D, Khairy P, Miyazaki S, Aurillac-Lavignolle V, Pascale P, Wilton SB, et al.            266. Chen YW, Bai R, Lin T, Salim M, Sang CH, Long DY, et al. Pacing or ablation: which is
     Five-year outcome of catheter ablation of persistent atrial fibrillation using termination          better for paroxysmal atrial fibrillation-related tachycardia-bradycardia syndrome?
     of atrial fibrillation as a procedural endpoint. Circ Arrhythm Electrophysiol 2015;8:18–24.         Pacing Clin Electrophysiol 2014;37:403–11.
243. Wazni OM, Dandamudi G, Sood N, Hoyt R, Tyler J, Durrani S, et al. Cryoballoon ab­              267. Scharf C, Veerareddy S, Ozaydin M, Chugh A, Hall B, Cheung P, et al. Clinical signifi­
     lation as initial therapy for atrial fibrillation. N Engl J Med 2021;384:316–24.                    cance of inducible atrial flutter during pulmonary vein isolation in patients with atrial
244. Andrade JG, Wells GA, Deyell MW, Bennett M, Essebag V, Champagne J, et al.                          fibrillation. J Am Coll Cardiol 2004;43:2057–62.
     Cryoablation or drug therapy for initial treatment of atrial fibrillation. N Engl J Med        268. Wazni O, Marrouche NF, Martin DO, Gillinov AM, Saliba W, Saad E, et al. Randomized
     2021;384:305–15.                                                                                    study comparing combined pulmonary vein-left atrial junction disconnection and cavo­
245. Kuniss M, Pavlovic N, Velagic V, Hermida JS, Healey S, Arena G, et al. Cryoballoon                  tricuspid isthmus ablation versus pulmonary vein-left atrial junction disconnection
     ablation vs. antiarrhythmic drugs: first-line therapy for patients with paroxysmal atrial           alone in patients presenting with typical atrial flutter and atrial fibrillation. Circulation
     fibrillation. Europace 2021;23:1033–41.                                                             2003;108:2479–83.
246. Cosedis Nielsen C, Johannessen A, Raatikainen P, Hindricks G, Walfridsson H,                   269. Pérez FJ, Schubert CM, Parvez B, Pathak V, Ellenbogen KA, Wood MA. Long-term out­
     Kongstad O, et al. Radiofrequency ablation as initial therapy in paroxysmal atrial fibril­          comes after catheter ablation of cavo-tricuspid isthmus dependent atrial flutter: a
     lation. N Engl J Med 2012;367:1587–95.                                                              metaanalysis. Circ Arrhythm Electrophysiol 2009;2:393–401.
247. Morillo CA, Verma A, Connolly SJ, Kuck KH, Nair GM, Champagne J, et al.                        270. Prasitlumkum N, Tokavanich N, Trongtorsak A, Cheungpasitporn W, Kewcharoen J,
     Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of paroxysmal               Chokesuwattanaskul R, et al. Catheter ablation for atrial fibrillation in the elderly >75
     atrial fibrillation (RAAFT-2): a randomized trial. JAMA 2014;311:692–700.                           years old: systematic review and metaanalysis. J Cardiovasc Electrophysiol 2022;33:
248. Wazni OM, Marrouche NF, Martin DO, Verma A, Bhargava M, Saliba W, et al.                            1435–49.
     Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomat­          271. Kawamura I, Aikawa T, Yokoyama Y, Takagi H, Kuno T. Catheter ablation for atrial
     ic atrial fibrillation: a randomized trial. JAMA 2005;293:2634–40.                                  fibrillation in elderly patients: systematic review and a metaanalysis. Pacing Clin
249. Hakalahti A, Biancari F, Nielsen JC, Raatikainen MJ. Radiofrequency ablation vs. antiar­            Electrophysiol 2022;45:59–71.
     rhythmic drug therapy as first line treatment of symptomatic atrial fibrillation: system­      272. Nielsen J, Kragholm KH, Christensen SB, Johannessen A, Torp-Pedersen C, Kristiansen
     atic review and metaanalysis. Europace 2015;17:370–8.                                               SB, et al. Periprocedural complications and one-year outcomes after catheter ablation
250. Prabhu S, Taylor AJ, Costello BT, Kaye DM, McLellan AJA, Voskoboinik A, et al.                      for treatment of atrial fibrillation in elderly patients: a nationwide Danish cohort study.
     Catheter ablation versus medical rate control in atrial fibrillation and systolic dysfunc­          J Geriatr Cardiol 2021;18:897–907.
     tion: the CAMERA-MRI study. J Am Coll Cardiol 2017;70:1949–61.                                 273. Providencia R, Elliott P, Patel K, McCready J, Babu G, Srinivasan N, et al. Catheter ab­
251. Sugumar H, Prabhu S, Costello B, Chieng D, Azzopardi S, Voskoboinik A, et al.                       lation for atrial fibrillation in hypertrophic cardiomyopathy: a systematic review and
     Catheter ablation versus medication in atrial fibrillation and systolic dysfunction: late           metaanalysis. Heart 2016;102:1533–43.
     outcomes of CAMERA-MRI study. JACC Clin Electrophysiol 2020;6:1721–31.                         274. Zhao DS, Shen Y, Zhang Q, Lin G, Lu YH, Chen BT, et al. Outcomes of catheter ab­
252. Hunter RJ, Berriman TJ, Diab I, Kamdar R, Richmond L, Baker V, et al. A randomized                  lation of atrial fibrillation in patients with hypertrophic cardiomyopathy: a systematic
     controlled trial of catheter ablation versus medical treatment of atrial fibrillation in            review and metaanalysis. Europace 2016;18:508–20.
     heart failure (the CAMTAF trial). Circ Arrhythm Electrophysiol 2014;7:31–8.                    275. Dinshaw L, Münkler P, Schäffer B, Klatt N, Jungen C, Dickow J, et al. Ablation of atrial
253. Parkash R, Wells GA, Rouleau J, Talajic M, Essebag V, Skanes A, et al. Randomized                   fibrillation in patients with hypertrophic cardiomyopathy: treatment strategy, charac­
     ablation-based rhythm-control versus rate-control trial in patients with heart failure              teristics of consecutive atrial tachycardia and long-term outcome. J Am Heart Assoc
     and atrial fibrillation: results from the RAFT-AF trial. Circulation 2022;145:1693–704.             2021;10:e017451.
254. Romero J, Gabr M, Alviz I, Briceno D, Diaz JC, Rodriguez D, et al. Improved survival in        276. Creta A, Elliott P, Earley MJ, Dhinoja M, Finlay M, Sporton S, et al. Catheter ablation of
     patients with atrial fibrillation and heart failure undergoing catheter ablation compared           atrial fibrillation in patients with hypertrophic cardiomyopathy: a European observa­
     to medical treatment: a systematic review and metaanalysis of randomized controlled                 tional multicenter study. Europace 2021;23:1409–17.
     trials. J Cardiovasc Electrophysiol 2022;33:2356–66.                                           277. Santangeli P, Di Biase L, Themistoclakis S, Raviele A, Schweikert RA, Lakkireddy D, et al.
255. Di Biase L, Mohanty P, Mohanty S, Santangeli P, Trivedi C, Lakkireddy D, et al. Ablation            Catheter ablation of atrial fibrillation in hypertrophic cardiomyopathy: long-term out­
     versus amiodarone for treatment of persistent atrial fibrillation in patients with con­             comes and mechanisms of arrhythmia recurrence. Circ Arrhythm Electrophysiol 2013;6:
     gestive heart failure and an implanted device: results from the AATAC multicenter                   1089–94.
     randomized trial. Circulation 2016;133:1637–44.                                                278. Rozen G, Elbaz-Greener G, Marai I, Andria N, Hosseini SM, Biton Y, et al. Utilization
256. Sohns C, Zintl K, Zhao Y, Dagher L, Andresen D, Siebels J, et al. Impact of left ventricu­          and complications of catheter ablation for atrial fibrillation in patients with hyper­
     lar function and heart failure symptoms on outcomes post ablation of atrial fibrillation            trophic cardiomyopathy. J Am Heart Assoc 2020;9:e015721.
     in heart failure: CASTLE-AF trial. Circ Arrhythm Electrophysiol 2020;13:e008461.               279. Ezzeddine FM, Agboola KM, Hassett LC, Killu AM, Del-Carpio Munoz F, DeSimone
257. Packer DL, Piccini JP, Monahan KH, Al-Khalidi HR, Silverstein AP, Noseworthy PA,                    CV, et al. Catheter ablation of atrial fibrillation in patients with and without hyper­
     et al. Ablation versus drug therapy for atrial fibrillation in heart failure: results from          trophic cardiomyopathy: systematic review and metaanalysis. Europace 2023;25.
     the CABANA trial. Circulation 2021;143:1377–90.                                                280. Dorian P, Guerra PG, Kerr CR, O’Donnell SS, Crystal E, Gillis AM, et al. Validation of a
258. Asad ZUA, Yousif A, Khan MS, Al-Khatib SM, Stavrakis S. Catheter ablation versus                    new simple scale to measure symptoms in atrial fibrillation: the Canadian
     medical therapy for atrial fibrillation: a systematic review and metaanalysis of rando­             Cardiovascular Society Severity in Atrial Fibrillation scale. Circ Arrhythm Electrophysiol
     mized controlled trials. Circ Arrhythm Electrophysiol 2019;12:e007414.                              2009;2:218–24.
259. Briceño DF, Markman TM, Lupercio F, Romero J, Liang JJ, Villablanca PA, et al. Catheter        281. Kirchhof P, Auricchio A, Bax J, Crijns H, Camm J, Diener HC, et al. Outcome para­
     ablation versus conventional treatment of atrial fibrillation in patients with heart failure        meters for trials in atrial fibrillation: recommendations from a consensus conference
     with reduced ejection fraction: a systematic review and metaanalysis of randomized                  organized by the German Atrial Fibrillation Competence NETwork and the
     controlled trials. J Interv Card Electrophysiol 2018;53:19–29.                                      European Heart Rhythm Association. Europace 2007;9:1006–23.
260. Sohns C, Fox H, Marrouche NF, Crijns H, Costard-Jaeckle A, Bergau L, et al. Catheter           282. Rienstra M, Lubitz SA, Mahida S, Magnani JW, Fontes JD, Sinner MF, et al. Symptoms
     ablation in end-stage heart failure with atrial fibrillation. N Engl J Med 2023;389:                and functional status of patients with atrial fibrillation: state of the art and future re­
     1380–9.                                                                                             search opportunities. Circulation 2012;125:2933–43.
261. Sciarra L, Rebecchi M, De Ruvo E, De Luca L, Zuccaro LM, Fagagnini A, et al. How many          283. Sugishita K, Shiono E, Sugiyama T, Ashida T. Diabetes influences the cardiac symptoms
     atrial fibrillation ablation candidates have an underlying supraventricular tachycardia             related to atrial fibrillation. Circ J 2003;67:835–8.
     previously unknown? Efficacy of isolated triggering arrhythmia ablation. Europace              284. Hermans ANL, Gawalko M, Slegers DPJ, Andelfinger N, Pluymaekers N, Verhaert
     2010;12:1707–12.                                                                                    DVM, et al. Mobile app-based symptom-rhythm correlation assessment in patients
262. Katritsis DG, Giazitzoglou E, Wood MA, Shepard RK, Parvez B, Ellenbogen KA.                         with persistent atrial fibrillation. Int J Cardiol 2022;367:29–37.
     Inducible supraventricular tachycardias in patients referred for catheter ablation of at­      285. Kirchhof P, Camm AJ, Goette A, Brandes A, Eckardt L, Elvan A, et al. Early rhythm-
     rial fibrillation. Europace 2007;9:785–9.                                                           control therapy in patients with atrial fibrillation. N Engl J Med 2020;383:1305–16.
263. Delise P, Gianfranchi L, Paparella N, Brignole M, Menozzi C, Themistoclakis S, et al.          286. Freemantle N, Lafuente-Lafuente C, Mitchell S, Eckert L, Reynolds M. Mixed treatment
     Clinical usefulness of slow pathway ablation in patients with both paroxysmal atrioven­             comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone, for the
     tricular nodal reentrant tachycardia and atrial fibrillation. Am J Cardiol 1997;79:1421–3.          management of atrial fibrillation. Europace 2011;13:329–45.
82                                                                                                                                                                                      S. Tzeis et al.


287. Valembois L, Audureau E, Takeda A, Jarzebowski W, Belmin J, Lafuente-Lafuente C.                  311. Kirstein B, Neudeck S, Gaspar T, Piorkowski J, Wechselberger S, Kronborg MB, et al.
     Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation.               Left atrial fibrosis predicts left ventricular ejection fraction response after atrial fibril­
     Cochrane Database Syst Rev 2019;9:Cd005049.                                                            lation ablation in heart failure patients: the Fibrosis-HF study. Europace 2020;22:
288. Chew DS, Black-Maier E, Loring Z, Noseworthy PA, Packer DL, Exner DV, et al.                           1812–21.
     Diagnosis-to-ablation time and recurrence of atrial fibrillation following catheter abla­         312. Tsuji A, Masuda M, Asai M, Iida O, Okamoto S, Ishihara T, et al. Impact of the temporal
     tion: a systematic review and metaanalysis of observational studies. Circ Arrhythm                     relationship between atrial fibrillation and heart failure on prognosis after ablation. Circ
     Electrophysiol 2020;13:e008128.                                                                        J 2020;84:1467–74.
289. Kawaji T, Shizuta S, Yamagami S, Aizawa T, Komasa A, Yoshizawa T, et al. Early choice             313. Ishiguchi H, Yoshiga Y, Shimizu A, Ueyama T, Fukuda M, Kato T, et al. Long-term events
     for catheter ablation reduced readmission in management of atrial fibrillation: impact                 following catheter-ablation for atrial fibrillation in heart failure with preserved ejection
     of diagnosis-to-ablation time. Int J Cardiol 2019;291:69–76.                                           fraction. ESC Heart Fail 2022;9:3505–18.
290. Bisbal F, Alarcón F, Ferrero-De-Loma-Osorio A, González-Ferrer JJ, Alonso-Martín C,               314. Smit MD, Moes ML, Maass AH, Achekar ID, Van Geel PP, Hillege HL, et al. The import­
     Pachón M, et al. Diagnosis-to-ablation time in atrial fibrillation: a modifiable factor rele­          ance of whether atrial fibrillation or heart failure develops first. Eur J Heart Fail 2012;14:
     vant to clinical outcome. J Cardiovasc Electrophysiol 2019;30:1483–90.                                 1030–40.
291. Kalman JM, Al-Kaisey AM, Parameswaran R, Hawson J, Anderson RD, Lim M, et al.                     315. von Olshausen G, Benson L, Dahlström U, Lund LH, Savarese G, Braunschweig F.
     Impact of early vs. delayed atrial fibrillation catheter ablation on atrial arrhythmia re­             Catheter ablation for patients with atrial fibrillation and heart failure: insights from
     currences. Eur Heart J 2023;44:2447–54.                                                                the Swedish Heart Failure Registry. Eur J Heart Fail 2022;24:1636–46.
292. Andrade JG, Wazni OM, Kuniss M, Hawkins NM, Deyell MW, Chierchia GB, et al.                       316. Shiraishi Y, Kohsaka S, Ikemura N, Kimura T, Katsumata Y, Tanimoto K, et al. Catheter
     Cryoballoon ablation as initial treatment for atrial fibrillation: JACC state-of-the-art re­           ablation for patients with atrial fibrillation and heart failure with reduced and preserved
     view. J Am Coll Cardiol 2021;78:914–30.                                                                ejection fraction: insights from the KiCS-AF multicenter cohort study. Europace 2023;
293. Andrade JG, Champagne J, Dubuc M, Deyell MW, Verma A, Macle L, et al. Cryoballoon                      25:83–91.
     or radiofrequency ablation for atrial fibrillation assessed by continuous monitoring: a           317. Gu G, Wu J, Gao X, Liu M, Jin C, Xu Y. Catheter ablation of atrial fibrillation in patients
     randomized clinical trial. Circulation 2019;140:1779–88.                                               with heart failure and preserved ejection fraction: a metaanalysis. Clin Cardiol 2022;45:
294. Kuck KH, Brugada J, Fürnkranz A, Metzner A, Ouyang F, Chun KR, et al. Cryoballoon or                   786–93.
     radiofrequency ablation for paroxysmal atrial fibrillation. N Engl J Med 2016;374:                318. Yamauchi R, Morishima I, Okumura K, Kanzaki Y, Morita Y, Takagi K, et al. Catheter
     2235–45.                                                                                               ablation for non-paroxysmal atrial fibrillation accompanied by heart failure with pre­
295. Walters TE, Wick K, Tan G, Mearns M, Joseph SA, Morton JB, et al. Psychological dis­                   served ejection fraction: feasibility and benefits in functions and B-type natriuretic pep­
     tress and suicidal ideation in patients with atrial fibrillation: prevalence and response to           tide. Europace 2021;23:1252–61.
     management strategy. J Am Heart Assoc 2018;7:e005502.                                             319. Rordorf R, Scazzuso F, Chun KRJ, Khelae SK, Kueffer FJ, Braegelmann KM, et al.
296. Al-Kaisey AM, Parameswaran R, Bryant C, Anderson RD, Hawson J, Chieng D, et al.                        Cryoballoon ablation for the treatment of atrial fibrillation in patients with concomi­
     Atrial fibrillation catheter ablation vs medical therapy and psychological distress: a ran­            tant heart failure and either reduced or preserved left ventricular ejection fraction: re­
     domized clinical trial. JAMA 2023;330:925–33.                                                          sults from the Cryo AF Global Registry. J Am Heart Assoc 2021;10:e021323.
297. Providencia R, Defaye P, Lambiase PD, Pavin D, Cebron JP, Halimi F, et al. Results from           320. Aldaas OM, Lupercio F, Darden D, Mylavarapu PS, Malladi CL, Han FT, et al.
     a multicenter comparison of cryoballoon vs. radiofrequency ablation for paroxysmal                     Meta-analysis of the usefulness of catheter ablation of atrial fibrillation in patients
     atrial fibrillation: is cryoablation more reproducible? Europace 2017;19:48–57.                        with heart failure with preserved ejection fraction. Am J Cardiol 2021;142:66–73.
298. Deshmukh A, Patel NJ, Pant S, Shah N, Chothani A, Mehta K, et al. In-hospital compli­             321. Black-Maier E, Ren X, Steinberg BA, Green CL, Barnett AS, Rosa NS, et al. Catheter
     cations associated with catheter ablation of atrial fibrillation in the United States be­              ablation of atrial fibrillation in patients with heart failure and preserved ejection frac­
     tween 2000 and 2010: analysis of 93 801 procedures. Circulation 2013;128:2104–12.                      tion. Heart Rhythm 2018;15:651–7.
299. Calkins H, Hindricks G, Cappato R, Kim YH, Saad EB, Aguinaga L, et al. 2017 HRS/                  322. Chieng D, Sugumar H, Segan L, Tan C, Vizi D, Nanayakkara S, et al. Atrial fibrillation
     EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical                            ablation for heart failure with preserved ejection fraction. JACC Heart Fail 2023;11:
     ablation of atrial fibrillation. Heart Rhythm 2017;14:e275–444.                                        646–58.
300. Monahan KH, Bunch TJ, Mark DB, Poole JE, Bahnson TD, Al-Khalidi HR, et al. Influence              323. Ganapathy AV, Monjazeb S, Ganapathy KS, Shanoon F, Razavi M. “Asymptomatic” per­
     of atrial fibrillation type on outcomes of ablation vs. drug therapy: results from                     sistent or permanent atrial fibrillation: a misnomer in selected patients. Int J Cardiol
     CABANA. Europace 2022;24:1430–40.                                                                      2015;185:112–3.
301. Khan MN, Jaïs P, Cummings J, Di Biase L, Sanders P, Martin DO, et al. Pulmonary-vein              324. Shin DI, Jaekel K, Schley P, Sause A, Müller M, Fueth R, et al. Plasma levels of
     isolation for atrial fibrillation in patients with heart failure. N Engl J Med 2008;359:               NT-pro-BNP in patients with atrial fibrillation before and after electrical cardioversion.
     1778–85.                                                                                               Z Kardiol 2005;94:795–800.
302. MacDonald MR, Connelly DT, Hawkins NM, Steedman T, Payne J, Shaw M, et al.                        325. Stojadinović P, Deshraju A, Wichterle D, Fukunaga M, Peichl P, Kautzner J, et al. The
     Radiofrequency ablation for persistent atrial fibrillation in patients with advanced heart             hemodynamic effect of simulated atrial fibrillation on left ventricular function. J
     failure and severe left ventricular systolic dysfunction: a randomised controlled trial.               Cardiovasc Electrophysiol 2022;33:2569–77.
     Heart 2011;97:740–7.                                                                              326. Clark DM, Plumb VJ, Epstein AE, Kay GN. Hemodynamic effects of an irregular se­
303. Jones DG, Haldar SK, Hussain W, Sharma R, Francis DP, Rahman-Haley SL, et al. A ran­                   quence of ventricular cycle lengths during atrial fibrillation. J Am Coll Cardiol 1997;
     domized trial to assess catheter ablation versus rate control in the management of per­                30:1039–45.
     sistent atrial fibrillation in heart failure. J Am Coll Cardiol 2013;61:1894–903.                 327. Ganesan AN, Chew DP, Hartshorne T, Selvanayagam JB, Aylward PE, Sanders P, et al.
304. Kuck KH, Merkely B, Zahn R, Arentz T, Seidl K, Schlüter M, et al. Catheter ablation versus             The impact of atrial fibrillation type on the risk of thromboembolism, mortality, and
     best medical therapy in patients with persistent atrial fibrillation and congestive heart fail­        bleeding: a systematic review and metaanalysis. Eur Heart J 2016;37:1591–602.
     ure: the randomized AMICA trial. Circ Arrhythm Electrophysiol 2019;12:e007731.                    328. Link MS, Giugliano RP, Ruff CT, Scirica BM, Huikuri H, Oto A, et al. Stroke and mor­
305. Chen S, Pürerfellner H, Meyer C, Acou WJ, Schratter A, Ling Z, et al. Rhythm control                   tality risk in patients with various patterns of atrial fibrillation: results from the
     for patients with atrial fibrillation complicated with heart failure in the contemporary               ENGAGE AF-TIMI 48 trial (effective anticoagulation with factor Xa next generation
     era of catheter ablation: a stratified pooled analysis of randomized data. Eur Heart J                 in atrial fibrillation-thrombolysis in myocardial infarction 48). Circ Arrhythm
     2020;41:2863–73.                                                                                       Electrophysiol 2017;10:e004267.
306. Marrouche NF, Brachmann J, Andresen D, Siebels J, Boersma L, Jordaens L, et al.                   329. Kuck KH, Lebedev DS, Mikhaylov EN, Romanov A, Gellér L, Kalējs O, et al. Catheter
     Catheter ablation for atrial fibrillation with heart failure. N Engl J Med 2018;378:417–27.            ablation or medical therapy to delay progression of atrial fibrillation: the randomized
307. Bergonti M, Spera F, Tijskens M, Bonomi A, Saenen J, Huybrechts W, et al. A new pre­                   controlled atrial fibrillation progression trial (ATTEST). Europace 2021;23:362–9.
     diction model for left ventricular systolic function recovery after catheter ablation of          330. Mark DB, Anstrom KJ, Sheng S, Piccini JP, Baloch KN, Monahan KH, et al. Effect of cath­
     atrial fibrillation in patients with heart failure: the ANTWOORD Study. Int J Cardiol                  eter ablation vs medical therapy on quality of life among patients with atrial fibrillation:
     2022;358:45–50.                                                                                        the CABANA randomized clinical trial. JAMA 2019;321:1275–85.
308. Bergonti M, Ascione C, Marcon L, Pambrun T, Della Rocca DG, Ferrero TG, et al. Left               331. Bahnson TD, Giczewska A, Mark DB, Russo AM, Monahan KH, Al-Khalidi HR, et al.
     ventricular functional recovery after atrial fibrillation catheter ablation in heart failure:          Association between age and outcomes of catheter ablation versus medical therapy
     a prediction model. Eur Heart J 2023;44:3327–5.                                                        for atrial fibrillation: results from the CABANA trial. Circulation 2022;145:796–804.
309. Kawaji T, Shizuta S, Aizawa T, Yamagami S, Kato M, Yokomatsu T, et al. Impact of cath­            332. Willems S, Borof K, Brandes A, Breithardt G, Camm AJ, Crijns H, et al. Systematic, early
     eter ablation for atrial fibrillation on cardiac disorders in patients with coexisting heart           rhythm control strategy for atrial fibrillation in patients with or without symptoms: the
     failure. ESC Heart Fail 2021;8:670–9.                                                                  EAST-AFNET 4 trial. Eur Heart J 2022;43:1219–30.
310. Okada M, Tanaka N, Oka T, Tanaka K, Ninomiya Y, Hirao Y, et al. Clinical significance             333. Sauer WH, Alonso C, Zado E, Cooper JM, Lin D, Dixit S, et al. Atrioventricular nodal
     of left ventricular reverse remodeling after catheter ablation of atrial fibrillation in pa­           reentrant tachycardia in patients referred for atrial fibrillation ablation: response to ab­
     tients with left ventricular systolic dysfunction. J Cardiol 2021;77:500–8.                            lation that incorporates slow-pathway modification. Circulation 2006;114:191–5.
Catheter and surgical ablation of atrial fibrillation                                                                                                                                               83


334. Hamer ME, Wilkinson WE, Clair WK, Page RL, McCarthy EA, Pritchett EL. Incidence                       isolation: usefulness of type-3 portable monitor for sleep-disordered breathing.
     of symptomatic atrial fibrillation in patients with paroxysmal supraventricular tachycar­             J Interv Card Electrophysiol 2016;47:237–244.
     dia. J Am Coll Cardiol 1995;25:984–8.                                                            359. Ng CY, Liu T, Shehata M, Stevens S, Chugh SS, Wang X. Meta-analysis of obstructive
335. Dagres N, Clague JR, Lottkamp H, Hindricks G, Breithardt G, Borggrefe M. Impact of                    sleep apnea as predictor of atrial fibrillation recurrence after catheter ablation. Am J
     radiofrequency catheter ablation of accessory pathways on the frequency of atrial fib­                Cardiol 2011;108:47–51.
     rillation during long-term follow-up; high recurrence rate of atrial fibrillation in patients    360. Naruse Y, Tada H, Satoh M, Yanagihara M, Tsuneoka H, Hirata Y, et al. Concomitant
     older than 50 years of age. Eur Heart J 2001;22:423–7.                                                obstructive sleep apnea increases the recurrence of atrial fibrillation following radio­
336. Hocini M, Sanders P, Deisenhofer I, Jaïs P, Hsu LF, Scavée C, et al. Reverse remodeling               frequency catheter ablation of atrial fibrillation: clinical impact of continuous positive
     of sinus node function after catheter ablation of atrial fibrillation in patients with pro­           airway pressure therapy. Heart Rhythm 2013;10:331–7.
     longed sinus pauses. Circulation 2003;108:1172–5.                                                361. Li X, Zhou X, Xu X, Dai J, Chen C, Ma L, et al. Effects of continuous positive airway
337. Akoum N, McGann C, Vergara G, Badger T, Ranjan R, Mahnkopf C, et al. Atrial fibrosis                  pressure treatment in obstructive sleep apnea patients with atrial fibrillation: a
     quantified using late gadolinium enhancement MRI is associated with sinus node dys­                   metaanalysis. Medicine 2021;100:e25438.
     function requiring pacemaker implant. J Cardiovasc Electrophysiol 2012;23:44–50.                 362. Nalliah CJ, Wong GR, Lee G, Voskoboinik A, Kee K, Goldin J, et al. Impact of CPAP on
338. Calkins H. Should catheter ablation be the preferred approach for treatment of atrial                 the atrial fibrillation substrate in obstructive sleep apnea: the SLEEP-AF study. JACC Clin
     fibrillation related symptomatic sinus node dysfunction? Pacing Clin Electrophysiol 2014;             Electrophysiol 2022;8:869–77.
     37:401–2.                                                                                        363. Hunt TE, Traaen GM, Aakerøy L, Bendz C, Øverland B, Akre H, et al. Effect of continu­
339. Merino JL. Slow conduction and flutter following atrial fibrillation ablation: proarrhyth­            ous positive airway pressure therapy on recurrence of atrial fibrillation after pulmon­
     mia or unmasking effect of radiofrequency application? J Cardiovasc Electrophysiol 2006;              ary vein isolation in patients with obstructive sleep apnea: a randomized controlled
     17:516–9.                                                                                             trial. Heart Rhythm 2022;19:1433–41.
340. Hwang TH, Yu HT, Kim TH, Uhm JS, Kim JY, Joung B, et al. Permanent pacemaker im­                 364. Donnellan E, Aagaard P, Kanj M, Jaber W, Elshazly M, Hoosien M, et al. Association be­
     plantations after catheter ablation in patients with atrial fibrillation associated with              tween preablation glycemic control and outcomes among patients with diabetes
     underlying sinus node dysfunction. Korean Circ J 2020;50:346–57.                                      undergoing atrial fibrillation ablation. JACC Clin Electrophysiol 2019;5:897–903.
341. Waldo AL, Feld GK. Inter-relationships of atrial fibrillation and atrial flutter mechan­         365. Takahashi Y, Nitta J, Kobori A, Sakamoto Y, Nagata Y, Tanimoto K, et al. Alcohol con­
     isms and clinical implications. J Am Coll Cardiol 2008;51:779–86.                                     sumption reduction and clinical outcomes of catheter ablation for atrial fibrillation. Circ
342. Gupta D, Ding WY, Calvert P, Williams E, Das M, Tovmassian L, et al. Cryoballoon                      Arrhythm Electrophysiol 2021;14:e009770.
     pulmonary vein isolation as first-line treatment for typical atrial flutter. Heart 2023;         366. Cheng WH, Lo LW, Lin YJ, Chang SL, Hu YF, Hung Y, et al. Cigarette smoking causes a
     109:364–71.                                                                                           worse long-term outcome in persistent atrial fibrillation following catheter ablation.
343. Chugh A, Oral H, Lemola K, Hall B, Cheung P, Good E, et al. Prevalence, mechanisms,                   J Cardiovasc Electrophysiol 2018;29:699–706.
     and clinical significance of macroreentrant atrial tachycardia during and following left         367. Bertaglia E, Anselmino M, Zorzi A, Russo V, Toso E, Peruzza F, et al. NOACs and atrial
     atrial ablation for atrial fibrillation. Heart Rhythm 2005;2:464–71.                                  fibrillation: incidence and predictors of left atrial thrombus in the real world. Int J
344. Chen J, Hocini M, Larsen TB, Proclemer A, Sciaraffia E, Blomström-Lundqvist C.                        Cardiol 2017;249:179–83.
     Clinical management of arrhythmias in elderly patients: results of the European                  368. Lurie A, Wang J, Hinnegan KJ, McIntyre WF, Belley-Côté EP, Amit G, et al. Prevalence
     Heart Rhythm Association survey. Europace 2015;17:314–7.                                              of left atrial thrombus in anticoagulated patients with atrial fibrillation. J Am Coll Cardiol
345. Ikenouchi T, Nitta J, Nitta G, Kato S, Iwasaki T, Murata K, et al. Propensity-matched                 2021;77:2875–86.
     comparison of cryoballoon and radiofrequency ablation for atrial fibrillation in elderly         369. Lip GY, Frison L, Grind M. Stroke event rates in anticoagulated patients with paroxys­
     patients. Heart Rhythm 2019;16:838–45.                                                                mal atrial fibrillation. J Intern Med 2008;264:50–61.
346. Guttmann OP, Rahman MS, O’Mahony C, Anastasakis A, Elliott PM. Atrial fibrillation               370. Al-Khatib SM, Thomas L, Wallentin L, Lopes RD, Gersh B, Garcia D, et al. Outcomes of
     and thromboembolism in patients with hypertrophic cardiomyopathy: systematic re­                      apixaban vs. warfarin by type and duration of atrial fibrillation: results from the
     view. Heart 2014;100:465–72.                                                                          ARISTOTLE trial. Eur Heart J 2013;34:2464–71.
347. Rowin EJ, Orfanos A, Estes NAM, Wang W, Link MS, Maron MS, et al. Occurrence and                 371. Steinberg BA, Hellkamp AS, Lokhnygina Y, Patel MR, Breithardt G, Hankey GJ, et al.
     natural history of clinically silent episodes of atrial fibrillation in hypertrophic cardiomy­        Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibril­
     opathy. Am J Cardiol 2017;119:1862–5.                                                                 lation: results from the ROCKET-AF Trial. Eur Heart J 2015;36:288–96.
348. Rowin EJ, Hausvater A, Link MS, Abt P, Gionfriddo W, Wang W, et al. Clinical profile             372. Jung H, Sung JH, Yang PS, Jang E, Yu HT, Kim TH, et al. Stroke risk stratification for atrial
     and consequences of atrial fibrillation in hypertrophic cardiomyopathy. Circulation                   fibrillation patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2018;72:
     2017;136:2420–36.                                                                                     2409–11.
349. Asad Z, Abbas M, Javed I, Korantzopoulos P, Stavrakis S. Obesity is associated with              373. Manjunath CN, Srinivasa KH, Panneerselvam A, Prabhavathi B, Ravindranath KS,
     incident atrial fibrillation independent of gender: a metaanalysis. J Cardiovasc                      Rangan K, et al. Incidence and predictors of left atrial thrombus in patients with rheum­
     Electrophysiol 2018;29:725–32.                                                                        atic mitral stenosis and sinus rhythm: a transesophageal echocardiographic study.
350. Sivasambu B, Balouch MA, Zghaib T, Bajwa RJ, Chrispin J, Berger RD, et al. Increased                  Echocardiography 2011;28:457–60.
     rates of atrial fibrillation recurrence following pulmonary vein isolation in overweight         374. Saidi SJ, Motamedi MH. Incidence and factors influencing left atrial clot in patients with
     and obese patients. J Cardiovasc Electrophysiol 2018;29:239–45.                                       mitral stenosis and normal sinus rhythm. Heart 2004;90:1342–3.
351. Glover BM, Hong KL, Dagres N, Arbelo E, Laroche C, Riahi S, et al. Impact of body                375. Ahmed K, Rehman Memon A, Liaquat H Sr, Mujtaba M, Parkash C, Sultan FAT, et al.
     mass index on the outcome of catheter ablation of atrial fibrillation. Heart 2019;                    The frequency of left atrial thrombus on transthoracic echocardiogram in patients
     105:244–50.                                                                                           with mitral stenosis. Cureus 2020;12:e7453.
352. Shoemaker MB, Muhammad R, Farrell M, Parvez B, White BW, Streur M, et al. Relation               376. Feng D, Edwards WD, Oh JK, Chandrasekaran K, Grogan M, Martinez MW, et al.
     of morbid obesity and female gender to risk of procedural complications in patients                   Intracardiac thrombosis and embolism in patients with cardiac amyloidosis.
     undergoing atrial fibrillation ablation. Am J Cardiol 2013;111:368–73.                                Circulation 2007;116:2420–6.
353. Pathak RK, Middeldorp ME, Lau DH, Mehta AB, Mahajan R, Twomey D, et al.                          377. Feng D, Syed IS, Martinez M, Oh JK, Jaffe AS, Grogan M, et al. Intracardiac thrombosis
     Aggressive risk factor reduction study for atrial fibrillation and implications for the out­          and anticoagulation therapy in cardiac amyloidosis. Circulation 2009;119:2490–7.
     come of ablation: the ARREST-AF cohort study. J Am Coll Cardiol 2014;64:2222–31.                 378. El-Am EA, Dispenzieri A, Melduni RM, Ammash NM, White RD, Hodge DO, et al.
354. Pathak RK, Middeldorp ME, Meredith M, Mehta AB, Mahajan R, Wong CX, et al.                            Direct current cardioversion of atrial arrhythmias in adults with cardiac amyloidosis.
     Long-term effect of goal-directed weight management in an atrial fibrillation cohort:                 J Am Coll Cardiol 2019;73:589–97.
     a long-term follow-up study (LEGACY). J Am Coll Cardiol 2015;65:2159–69.                         379. Touboul O, Algalarrondo V, Oghina S, Elbaz N, Rouffiac S, Hamon D, et al. Electrical
355. Zhang D, Ma Y, Xu J, Yi F. Association between obstructive sleep apnea (OSA) and                      cardioversion of atrial arrhythmias with cardiac amyloidosis in the era of direct oral
     atrial fibrillation (AF): a dose-response metaanalysis. Medicine 2022;101:e29443.                     anticogulants. ESC Heart Fail 2022;9:3556–64.
356. Szymanski FM, Filipiak KJ, Platek AE, Hrynkiewicz-Szymanska A, Kotkowski M, Kozluk               380. Burczak DR, Julakanti RR, Kara Balla A, Scott CG, Geske JB, Ommen SR, et al. Risk of
     E, et al. Presence and severity of obstructive sleep apnea and remote outcomes of at­                 left atrial thrombus in patients with hypertrophic cardiomyopathy and atrial fibrillation.
     rial fibrillation ablations—a long-term prospective, cross-sectional cohort study. Sleep              J Am Coll Cardiol 2023;82:278–9.
     Breath 2015;19:849–56.                                                                           381. Di Biase L, Burkhardt JD, Mohanty P, Sanchez J, Horton R, Gallinghouse GJ, et al.
357. Li L, Wang ZW, Li J, Ge X, Guo LZ, Wang Y, et al. Efficacy of catheter ablation of atrial             Periprocedural stroke and management of major bleeding complications in patients
     fibrillation in patients with obstructive sleep apnoea with and without continuous posi­              undergoing catheter ablation of atrial fibrillation: the impact of periprocedural thera­
     tive airway pressure treatment: a metaanalysis of observational studies. Europace 2014;               peutic international normalized ratio. Circulation 2010;121:2550–6.
     16:1309–14.                                                                                      382. Santangeli P, Di Biase L, Horton R, Burkhardt JD, Sanchez J, Al-Ahmad A, et al. Ablation
358. Kawakami H, Nagai T, Fujii A, Uetani T, Nishimura K, Inoue K, et al. Apnea-hypopnea                   of atrial fibrillation under therapeutic warfarin reduces periprocedural complications:
     index as a predictor of atrial fibrillation recurrence following initial pulmonary vein               evidence from a metaanalysis. Circ Arrhythm Electrophysiol 2012;5:302–11.
84                                                                                                                                                                                     S. Tzeis et al.


383. Wazni OM, Beheiry S, Fahmy T, Barrett C, Hao S, Patel D, et al. Atrial fibrillation ab­              for atrial fibrillation: the Action-Ice I study. Circ Arrhythm Electrophysiol 2013;6:
     lation in patients with therapeutic international normalized ratio: comparison of strat­             1074–81.
     egies of anticoagulation management in the periprocedural period. Circulation 2007;             403. Tsyganov A, Shapieva A, Sandrikov V, Fedulova S, Mironovich S, Dzeranova A, et al.
     116:2531–4.                                                                                          Transesophageal vs. intracardiac echocardiographic screening in patients undergoing
384. Di Biase L, Burkhardt JD, Santangeli P, Mohanty P, Sanchez JE, Horton R, et al.                      atrial fibrillation ablation with uninterrupted rivaroxaban. BMC Cardiovasc Disord
     Periprocedural stroke and bleeding complications in patients undergoing catheter ab­                 2017;17:171.
     lation of atrial fibrillation with different anticoagulation management: results from the       404. Saksena S, Sra J, Jordaens L, Kusumoto F, Knight B, Natale A, et al. A prospective com­
     role of coumadin in preventing thromboembolism in atrial fibrillation (AF) patients                  parison of cardiac imaging using intracardiac echocardiography with transesophageal
     undergoing catheter ablation (COMPARE) randomized trial. Circulation 2014;129:                       echocardiography in patients with atrial fibrillation: the intracardiac echocardiography
     2638–44.                                                                                             guided cardioversion helps interventional procedures study. Circ Arrhythm
385. Cappato R, Marchlinski FE, Hohnloser SH, Naccarelli GV, Xiang J, Wilber DJ, et al.                   Electrophysiol 2010;3:571–7.
     Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter abla­            405. Sriram CS, Banchs JE, Moukabary T, Moradkhan R, Gonzalez MD. Detection of left
     tion in non-valvular atrial fibrillation. Eur Heart J 2015;36:1805–11.                               atrial thrombus by intracardiac echocardiography in patients undergoing ablation of
386. Calkins H, Willems S, Gerstenfeld EP, Verma A, Schilling R, Hohnloser SH, et al.                     atrial fibrillation. J Interv Card Electrophysiol 2015;43:227–36.
     Uninterrupted dabigatran versus warfarin for ablation in atrial fibrillation. N Engl J          406. Yu S, Zhang H, Li H. Cardiac computed tomography versus transesophageal echocar­
     Med 2017;376:1627–36.                                                                                diography for the detection of left atrial appendage thrombus: a systemic review and
387. Kirchhof P, Haeusler KG, Blank B, De Bono J, Callans D, Elvan A, et al. Apixaban in pa­              metaanalysis. J Am Heart Assoc 2021;10:e022505.
     tients at risk of stroke undergoing atrial fibrillation ablation. Eur Heart J 2018;39:          407. Vira T, Pechlivanoglou P, Connelly K, Wijeysundera HC, Roifman I. Cardiac computed
     2942–55.                                                                                             tomography and magnetic resonance imaging vs. transoesophageal echocardiography
388. Hohnloser SH, Camm J, Cappato R, Diener HC, Heidbüchel H, Mont L, et al.                             for diagnosing left atrial appendage thrombi. Europace 2019;21:e1–10.
     Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation:           408. Spagnolo P, Giglio M, Di Marco D, Cannaò PM, Agricola E, Della Bella PE, et al.
     the ELIMINATE-AF trial. Eur Heart J 2019;40:3013–21.                                                 Diagnosis of left atrial appendage thrombus in patients with atrial fibrillation: delayed
389. Cardoso R, Knijnik L, Bhonsale A, Miller J, Nasi G, Rivera M, et al. An updated                      contrast-enhanced cardiac CT. Eur Radiol 2021;31:1236–44.
     metaanalysis of novel oral anticoagulants versus vitamin K antagonists for uninterrupt­         409. Berruezo A, Tamborero D, Mont L, Benito B, Tolosana JM, Sitges M, et al.
     ed anticoagulation in atrial fibrillation catheter ablation. Heart Rhythm 2018;15:107–15.            Preprocedural predictors of atrial fibrillation recurrence after circumferential pulmon­
390. Romero J, Cerrud-Rodriguez RC, Alviz I, Diaz JC, Rodriguez D, Arshad S, et al.                       ary vein ablation. Eur Heart J 2007;28:836–41.
     Significant benefit of uninterrupted DOACs versus VKA during catheter ablation of               410. Wokhlu A, Hodge DO, Monahan KH, Asirvatham SJ, Friedman PA, Munger TM, et al.
     atrial fibrillation. JACC Clin Electrophysiol 2019;5:1396–405.                                       Long-term outcome of atrial fibrillation ablation: impact and predictors of very late re­
391. Di Biase L, Callans D, Haeusler KG, Hindricks G, Al-Khalidi H, Mont L, et al. Rationale              currence. J Cardiovasc Electrophysiol 2010;21:1071–8.
     and design of AXAFA-AFNET 5: an investigator-initiated, randomized, open, blinded               411. Arya A, Hindricks G, Sommer P, Huo Y, Bollmann A, Gaspar T, et al. Long-term results
     outcome assessment, multicentre trial to comparing continuous apixaban to vitamin                    and the predictors of outcome of catheter ablation of atrial fibrillation using steerable
     K antagonists in patients undergoing atrial fibrillation catheter ablation. Europace                 sheath catheter navigation after single procedure in 674 patients. Europace 2010;12:
     2017;19:132–8.                                                                                       173–80.
392. Romero J, Cerrud-Rodriguez RC, Diaz JC, Michaud GF, Taveras J, Alviz I, et al.                  412. Santoro F, Di Biase L, Trivedi C, Burkhardt JD, Paoletti Perini A, Sanchez J, et al. Impact
     Uninterrupted direct oral anticoagulants vs. uninterrupted vitamin K antagonists dur­                of uncontrolled hypertension on atrial fibrillation ablation outcome. JACC Clin
     ing catheter ablation of non-valvular atrial fibrillation: a systematic review and                   Electrophysiol 2015;1:164–73.
     metaanalysis of randomized controlled trials. Europace 2018;20:1612–20.                         413. Anselmino M, Matta M, D’Ascenzo F, Pappone C, Santinelli V, Bunch TJ, et al. Catheter
393. Di Biase L, Lakkireddy D, Trivedi C, Deneke T, Martinek M, Mohanty S, et al. Feasibility             ablation of atrial fibrillation in patients with diabetes mellitus: a systematic review and
     and safety of uninterrupted periprocedural apixaban administration in patients under­                metaanalysis. Europace 2015;17:1518–25.
     going radiofrequency catheter ablation for atrial fibrillation: results from a multicenter      414. Bogossian H, Frommeyer G, Brachmann J, Lewalter T, Hoffmann E, Kuck KH, et al.
     study. Heart Rhythm 2015;12:1162–8.                                                                  Catheter ablation of atrial fibrillation and atrial flutter in patients with diabetes mellitus:
394. Yu HT, Shim J, Park J, Kim TH, Uhm JS, Kim JY, et al. When is it appropriate to stop                 who benefits and who does not? Data from the German ablation registry. Int J Cardiol
     non-vitamin K antagonist oral anticoagulants before catheter ablation of atrial fibrilla­            2016;214:25–30.
     tion? A multicenter prospective randomized study. Eur Heart J 2019;40:1531–7.                   415. Creta A, Providencia R, Adragao P, de Asmundis C, Chun J, Chierchia G, et al. Impact of
395. Reynolds MR, Allison JS, Natale A, Weisberg IL, Ellenbogen KA, Richards M, et al. A                  type-2 diabetes mellitus on the outcomes of catheter ablation of atrial fibrillation
     Prospective randomized trial of apixaban dosing during atrial fibrillation ablation: the             (European observational multicenter study). Am J Cardiol 2020;125:901–6.
     AEIOU trial. JACC Clin Electrophysiol 2018;4:580–8.                                             416. Wang A, Truong T, Black-Maier E, Green C, Campbell KB, Barnett AS, et al. Catheter
396. Nakamura K, Naito S, Sasaki T, Take Y, Minami K, Kitagawa Y, et al. Uninterrupted vs.                ablation of atrial fibrillation in patients with diabetes mellitus. Heart Rhythm O2 2020;1:
     interrupted periprocedural direct oral anticoagulants for catheter ablation of atrial fib­           180–8.
     rillation: a prospective randomized single-center study on postablation thrombo                 417. Deshmukh A, Ghannam M, Liang J, Saeed M, Cunnane R, Ghanbari H, et al. Effect of
     embolic and haemorrhagic events. Europace 2019;21:259–67.                                            metformin on outcomes of catheter ablation for atrial fibrillation. J Cardiovasc
397. Ando M, Inden Y, Yoshida Y, Sairaku A, Yanagisawa S, Suzuki H, et al. Differences in                 Electrophysiol 2021;32:1232–9.
     prothrombotic response between the uninterrupted and interrupted apixaban ther­                 418. De Maat GE, Mulder BA, Berretty WL, Al-Jazairi MIH, Tan ES, Wiesfeld ACP, et al.
     apies in patients undergoing cryoballoon ablation for paroxysmal atrial fibrillation: a              Obesity is associated with impaired long-term success of pulmonary vein isolation: a
     randomized controlled study. Heart Vessels 2019;34:1533–41.                                          plea for risk factor management before ablation. Open Heart 2018;5:e000771.
398. Nagao T, Suzuki H, Matsunaga S, Nishikawa Y, Harada K, Mamiya K, et al. Impact of               419. Winkle RA, Mead RH, Engel G, Kong MH, Fleming W, Salcedo J, et al. Impact of obesity
     periprocedural anticoagulation therapy on the incidence of silent stroke after atrial fib­           on atrial fibrillation ablation: patient characteristics, long-term outcomes, and compli­
     rillation ablation in patients receiving direct oral anticoagulants: uninterrupted vs. inter­        cations. Heart Rhythm 2017;14:819–27.
     rupted by one dose strategy. Europace 2019;21:590–7.                                            420. Chang SL, Tuan TC, Tai CT, Lin YJ, Lo LW, Hu YF, et al. Comparison of outcome in
399. Patel K, Natale A, Yang R, Trivedi C, Romero J, Briceno D, et al. Is transesophageal                 catheter ablation of atrial fibrillation in patients with versus without the metabolic syn­
     echocardiography necessary in patients undergoing ablation of atrial fibrillation on                 drome. Am J Cardiol 2009;103:67–72.
     an uninterrupted direct oral anticoagulant regimen? Results from a prospective multi­           421. Tang RB, Dong JZ, Liu XP, Long DY, Yu RH, Kalifa J, et al. Metabolic syndrome and risk
     center registry. Heart Rhythm 2020;17:2093–9.                                                        of recurrence of atrial fibrillation after catheter ablation. Circ J 2009;73:438–43.
400. Wang Y, Zhao Y, Zhou K, Zei PC, Wang Y, Cheng H, et al. Intracardiac echocardiog­               422. Mohanty S, Mohanty P, Di Biase L, Bai R, Pump A, Santangeli P, et al. Impact of meta­
     raphy is a safe and effective alternative to transesophageal echocardiography for left               bolic syndrome on procedural outcomes in patients with atrial fibrillation undergoing
     atrial appendage thrombus evaluation at the time of atrial fibrillation ablation: the                catheter ablation. J Am Coll Cardiol 2012;59:1295–301.
     ICE-TEE study. Pacing Clin Electrophysiol 2023;46:3–10.                                         423. Donnellan E, Wazni OM, Harb S, Kanj M, Saliba WI, Jaber WA. Higher baseline cardio­
401. Morton JB, Sanders P, Sparks PB, Morgan J, Kalman JM. Usefulness of phased-array in­                 respiratory fitness is associated with lower arrhythmia recurrence and death after at­
     tracardiac echocardiography for the assessment of left atrial mechanical “stunning” in               rial fibrillation ablation. Heart Rhythm 2020;17:1687–93.
     atrial flutter and comparison with multiplane transesophageal echocardiography(*).              424. Mandsager KT, Phelan DM, Diab M, Baranowski B, Saliba WI, Tarakji KG, et al.
     Am J Cardiol 2002;90:741–6.                                                                          Outcomes of pulmonary vein isolation in athletes. JACC Clin Electrophysiol 2020;6:
402. Baran J, Stec S, Pilichowska-Paszkiet E, Zaborska B, Sikora-Frąc M, Kryński T, et al.                1265–74.
     Intracardiac echocardiography for detection of thrombus in the left atrial appendage:           425. Liu MB, Lee JZ, Klooster L, Petty SA, Scott LR. Influence of endurance sports on atrial
     comparison with transesophageal echocardiography in patients undergoing ablation                     fibrillation ablation outcomes. J Arrhythm 2022;38:1–16.
Catheter and surgical ablation of atrial fibrillation                                                                                                                                                 85


426. Koopman P, Nuyens D, Garweg C, La Gerche A, De Buck S, Van Casteren L, et al.                    451. Donnellan E, Wazni OM, Kanj M, Baranowski B, Cremer P, Harb S, et al. Association
     Efficacy of radiofrequency catheter ablation in athletes with atrial fibrillation.                    between preablation bariatric surgery and atrial fibrillation recurrence in morbidly ob­
     Europace 2011;13:1386–93.                                                                             ese patients undergoing atrial fibrillation ablation. Europace 2019;21:1476–83.
427. Kato M, Ogano M, Mori Y, Kochi K, Morimoto D, Kito K, et al. Exercise-based cardiac              452. Youssef I, Kamran H, Yacoub M, Patel N, Goulbourne C, Kumar S, et al. Obstructive
     rehabilitation for patients with catheter ablation for persistent atrial fibrillation: a ran­         sleep apnea as a risk factor for atrial fibrillation: a metaanalysis. J Sleep Disord Ther 2018;
     domized controlled clinical trial. Eur J Prev Cardiol 2019;26:1931–40.                                7:282.
428. Congrete S, Bintvihok M, Thongprayoon C, Bathini T, Boonpheng B, Sharma K, et al.                453. Linz D, Schotten U, Neuberger HR, Bohm M, Wirth K. Negative tracheal pressure dur­
     Effect of obstructive sleep apnea and its treatment of atrial fibrillation recurrence after           ing obstructive respiratory events promotes atrial fibrillation by vagal activation. Heart
     radiofrequency catheter ablation: a metaanalysis. J Evid Based Med 2018;11:145–51.                    Rhythm 2011;8:1436–43.
429. Matiello M, Nadal M, Tamborero D, Berruezo A, Montserrat J, Embid C, et al. Low ef­              454. Holtstrand Hjalm H, Fu M, Hansson PO, Zhong Y, Caidahl K, Mandalenakis Z, et al.
     ficacy of atrial fibrillation ablation in severe obstructive sleep apnoea patients. Europace          Association between left atrial enlargement and obstructive sleep apnea in a general
     2010;12:1084–9.                                                                                       population of 71-year-old men. J Sleep Res 2018;27:252–8.
430. Takigawa M, Takahashi A, Kuwahara T, Takahashi Y, Okubo K, Nakashima E, et al.                   455. Iwasaki YK, Kato T, Xiong F, Shi YF, Naud P, Maguy A, et al. Atrial fibrillation promotion
     Impact of alcohol consumption on the outcome of catheter ablation in patients                         with long-term repetitive obstructive sleep apnea in a rat model. J Am Coll Cardiol 2014;
     with paroxysmal atrial fibrillation. J Am Heart Assoc 2016;5:e004149.                                 64:2013–23.
431. Qiao Y, Shi R, Hou B, Wu L, Zheng L, Ding L, et al. Impact of alcohol consumption on             456. Qureshi WT, Nasir UB, Alqalyoobi S, O’Neal WT, Mawri S, Sabbagh S, et al.
     substrate remodeling and ablation outcome of paroxysmal atrial fibrillation. J Am Heart               Meta-analysis of continuous positive airway pressure as a therapy of atrial fibrillation
     Assoc 2015;4:e002349.                                                                                 in obstructive sleep apnea. Am J Cardiol 2015;116:1767–73.
432. Fukamizu S, Sakurada H, Takano M, Hojo R, Nakai M, Yuba T, et al. Effect of cigarette            457. Linz D, McEvoy RD, Cowie MR, Somers VK, Nattel S, Lévy P, et al. Associations of ob­
     smoking on the risk of atrial fibrillation recurrence after pulmonary vein isolation.                 structive sleep apnea with atrial fibrillation and continuous positive airway pressure
     J Arrhythm 2010;26:21–9.                                                                              treatment: a review. JAMA Cardiol 2018;3:532–40.
433. Elliott AD, Middeldorp ME, Van Gelder IC, Albert CM, Sanders P. Author correction:               458. Gallagher C, Hendriks JML, Elliott AD, Wong CX, Rangnekar G, Middeldorp ME, et al.
     epidemiology and modifiable risk factors for atrial fibrillation. Nat Rev Cardiol 2023;20:            Alcohol and incident atrial fibrillation—a systematic review and metaanalysis. Int J
     429.                                                                                                  Cardiol 2017;246:46–52.
434. Benjamin EJ, Levy D, Vaziri SM, D’Agostino RB, Belanger AJ, Wolf PA. Independent risk            459. Voskoboinik A, Wong G, Lee G, Nalliah C, Hawson J, Prabhu S, et al. Moderate alcohol
     factors for atrial fibrillation in a population-based cohort. The Framingham Heart                    consumption is associated with atrial electrical and structural changes: insights from
     Study. JAMA 1994;271:840–4.                                                                           high-density left atrial electroanatomic mapping. Heart Rhythm 2019;16:251–9.
435. Kim D, Yang PS, Kim TH, Jang E, Shin H, Kim HY, et al. Ideal blood pressure in patients          460. Mandyam MC, Vedantham V, Scheinman MM, Tseng ZH, Badhwar N, Lee BK, et al.
     with atrial fibrillation. J Am Coll Cardiol 2018;72:1233–45.                                          Alcohol and vagal tone as triggers for paroxysmal atrial fibrillation. Am J Cardiol
436. Okin PM, Hille DA, Larstorp AC, Wachtell K, Kjeldsen SE, Dahlof B, et al. Effect of low­
                                                                                                           2012;110:364–8.
     er on-treatment systolic blood pressure on the risk of atrial fibrillation in hypertensive
                                                                                                      461. Khawaja O, Bartz TM, Ix JH, Heckbert SR, Kizer JR, Zieman SJ, et al. Plasma free fatty
     patients. Hypertension 2015;66:368–73.
                                                                                                           acids and risk of atrial fibrillation (from the cardiovascular health study). Am J Cardiol
437. Verdecchia P, Angeli F, Reboldi G. Hypertension and atrial fibrillation: doubts and cer­
                                                                                                           2012;110:212–6.
     tainties from basic and clinical studies. Circ Res 2018;122:352–68.
                                                                                                      462. McManus DD, Yin X, Gladstone R, Vittinghoff E, Vasan RS, Larson MG, et al. Alcohol
438. Zylla MM, Hochadel M, Andresen D, Brachmann J, Eckardt L, Hoffmann E, et al.
                                                                                                           consumption, left atrial diameter, and atrial fibrillation. J Am Heart Assoc 2016;5:
     Ablation of atrial fibrillation in patients with hypertension-an analysis from the
                                                                                                           e004060.
     German Ablation Registry. J Clin Med 2020;9:2402.
                                                                                                      463. Sagawa Y, Nagata Y, Miwa N, Yamaguchi T, Watanabe K, Kaneko M, et al. Alcohol con­
439. Parkash R, Wells GA, Sapp JL, Healey JS, Tardif JC, Greiss I, et al. Effect of aggressive
                                                                                                           sumption is associated with postablation recurrence but not changes in atrial substrate
     blood pressure control on the recurrence of atrial fibrillation after catheter ablation:
                                                                                                           in patients with atrial fibrillation: insight from a high-density mapping study. J Am Heart
     a randomized, open-label clinical trial (SMAC-AF [substrate modification with aggres­
                                                                                                           Assoc 2022;11:e025697.
     sive blood pressure control]). Circulation 2017;135:1788–98.
                                                                                                      464. Barmano N, Charitakis E, Kronstrand R, Walfridsson U, Karlsson JE, Walfridsson H,
440. Pokushalov E, Romanov A, Corbucci G, Artyomenko S, Baranova V, Turov A, et al. A
                                                                                                           et al. The association between alcohol consumption, cardiac biomarkers, left atrial
     randomized comparison of pulmonary vein isolation with versus without concomitant
                                                                                                           size and reablation in patients with atrial fibrillation referred for catheter ablation.
     renal artery denervation in patients with refractory symptomatic atrial fibrillation and
                                                                                                           PLoS One 2019;14:e0215121.
     resistant hypertension. J Am Coll Cardiol 2012;60:1163–70.
441. Steinberg JS, Shabanov V, Ponomarev D, Losik D, Ivanickiy E, Kropotkin E, et al. Effect          465. Mohanty S, Mohanty P, Tamaki M, Natale V, Gianni C, Trivedi C, et al. Differential as­
     of renal denervation and catheter ablation vs catheter ablation alone on atrial fibrilla­             sociation of exercise intensity with risk of atrial fibrillation in men and women: evi­
     tion recurrence among patients with paroxysmal atrial fibrillation and hypertension:                  dence from a metaanalysis. J Cardiovasc Electrophysiol 2016;27:1021–9.
     the ERADICATE-AF randomized clinical trial. JAMA 2020;323:248–55.                                466. Mozaffarian D, Furberg CD, Psaty BM, Siscovick D. Physical activity and incidence of
442. Hohl M, Selejan SR, Wintrich J, Lehnert U, Speer T, Schneider C, et al. Renal denerv­                 atrial fibrillation in older adults: the cardiovascular health study. Circulation 2008;
     ation prevents atrial arrhythmogenic substrate development in CKD. Circ Res 2022;                     118:800–7.
     130:814–28.                                                                                      467. Jin MN, Yang PS, Song C, Yu HT, Kim TH, Uhm JS, et al. Physical activity and risk of atrial
443. Al-Kaisey AM, Kalman JM. Obesity and atrial fibrillation: epidemiology, pathogenesis                  fibrillation: a nationwide cohort study in general population. Sci Rep 2019;9:13270.
     and effect of weight loss. Arrhythm Electrophysiol Rev 2021;10:159–64.                           468. Morseth B, Graff-Iversen S, Jacobsen BK, Jørgensen L, Nyrnes A, Thelle DS, et al.
444. Wong CX, Sullivan T, Sun MT, Mahajan R, Pathak RK, Middeldorp M, et al. Obesity and                   Physical activity, resting heart rate, and atrial fibrillation: the Tromsø study. Eur
     the risk of incident, postoperative, and postablation atrial fibrillation: a metaanalysis of          Heart J 2016;37:2307–13.
     626,603 individuals in 51 studies. JACC Clin Electrophysiol 2015;1:139–52.                       469. Pathak RK, Elliott A, Middeldorp ME, Meredith M, Mehta AB, Mahajan R, et al. Impact of
445. Abed HS, Samuel CS, Lau DH, Kelly DJ, Royce SG, Alasady M, et al. Obesity results in                  CARDIOrespiratory FITness on arrhythmia recurrence in obese individuals with atrial
     progressive atrial structural and electrical remodeling: implications for atrial fibrillation.        fibrillation: the CARDIO-FIT study. J Am Coll Cardiol 2015;66:985–96.
     Heart Rhythm 2013;10:90–100.                                                                     470. Elliott AD, Verdicchio CV, Mahajan R, Middeldorp ME, Gallagher C, Mishima RS, et al.
446. Munger TM, Dong YX, Masaki M, Oh JK, Mankad SV, Borlaug BA, et al.                                    An exercise and physical activity program in patients with atrial fibrillation: the
     Electrophysiological and hemodynamic characteristics associated with obesity in pa­                   ACTIVE-AF randomized controlled trial. JACC Clin Electrophysiol 2023;9:455–65.
     tients with atrial fibrillation. J Am Coll Cardiol 2012;60:851–60.                               471. Calvo N, Mont L, Tamborero D, Berruezo A, Viola G, Guasch E, et al. Efficacy of cir­
447. Wong CX, Abed HS, Molaee P, Nelson AJ, Brooks AG, Sharma G, et al. Pericardial fat                    cumferential pulmonary vein ablation of atrial fibrillation in endurance athletes.
     is associated with atrial fibrillation severity and ablation outcome. J Am Coll Cardiol               Europace 2010;12:30–6.
     2011;57:1745–51.                                                                                 472. Decroocq M, Ninni S, Klein C, Machuron F, Verbrugge E, Klug D, et al. No impact of
448. Hatem SN, Sanders P. Epicardial adipose tissue and atrial fibrillation. Cardiovasc Res                sports practice before or after atrial fibrillation ablation on procedure efficacy in ath­
     2014;102:205–13.                                                                                      letes: a case-control study. Europace 2019;21:1833–42.
449. Mohanty S, Mohanty P, Natale V, Trivedi C, Gianni C, Burkhardt JD, et al. Impact of              473. Aune D, Feng T, Schlesinger S, Janszky I, Norat T, Riboli E. Diabetes mellitus, blood
     weight loss on ablation outcome in obese patients with longstanding persistent atrial                 glucose and the risk of atrial fibrillation: a systematic review and metaanalysis of cohort
     fibrillation. J Cardiovasc Electrophysiol 2018;29:246–53.                                             studies. J Diabetes Complicat 2018;32:501–11.
450. Gessler N, Willems S, Steven D, Aberle J, Akbulak RO, Gosau N, et al. Supervised                 474. Liu C, Fu H, Li J, Yang W, Cheng L, Liu T, et al. Hyperglycemia aggravates atrial inter­
     obesity reduction trial for AF ablation patients: results from the SORT-AF trial.                     stitial fibrosis, ionic remodeling and vulnerability to atrial fibrillation in diabetic rabbits.
     Europace 2021;23:1548–58.                                                                             Anadolu Kardiyol Derg 2012;12:543–50.
86                                                                                                                                                                                       S. Tzeis et al.


475. Chamberlain AM, Agarwal SK, Folsom AR, Duval S, Soliman EZ, Ambrose M, et al.                         isolation: a systematic review and metaanalysis of observational studies. Europace
     Smoking and incidence of atrial fibrillation: results from the atherosclerosis risk in com­           2012;14:638–45.
     munities (ARIC) study. Heart Rhythm 2011;8:1160–6.                                               499. Blanche C, Tran N, Rigamonti F, Burri H, Zimmermann M. Value of P-wave signal aver­
476. Smith JG, Platonov PG, Hedblad B, Engstrom G, Melander O. Atrial fibrillation in the                  aging to predict atrial fibrillation recurrences after pulmonary vein isolation. Europace
     Malmo diet and cancer study: a study of occurrence, risk factors and diagnostic validity.             2013;15:198–204.
     Eur J Epidemiol 2010;25:95–102.                                                                  500. Yugo D, Kuo MJ, Hu YF, Liu CM, Lin YJ, Chang SL, et al. Dynamic changes in
477. Zhu W, Yuan P, Shen Y, Wan R, Hong K. Association of smoking with the risk of in­                     signal-averaged P wave after catheter ablation of atrial fibrillation. J Chin Med Assoc
     cident atrial fibrillation: a metaanalysis of prospective studies. Int J Cardiol 2016;218:            2022;85:549–53.
     259–66.                                                                                          501. Salah A, Zhou S, Liu Q, Yan H. P wave indices to predict atrial fibrillation recurrences
478. Albertsen IE, Rasmussen LH, Lane DA, Overvad TF, Skjoth F, Overvad K, et al. The                      post pulmonary vein isolation. Arq Bras Cardiol 2013;101:519–27.
     impact of smoking on thromboembolism and mortality in patients with incident atrial              502. Pranata R, Yonas E, Vania R. Prolonged P-wave duration in sinus rhythm preablation is
     fibrillation: insights from the Danish diet, cancer, and health study. Chest 2014;145:                associated with atrial fibrillation recurrence after pulmonary vein isolation-a systematic
     559–66.                                                                                               review and metaanalysis. Ann Noninvasive Electrocardiol 2019;24:e12653.
479. Kwon S, Kim TJ, Choi EK, Ahn HJ, Lee E, Lee SR, et al. Predictors of ischemic stroke for         503. Nakatani Y, Sakamoto T, Yamaguchi Y, Tsujino Y, Kataoka N, Kinugawa K. P-wave vec­
     low-risk patients with atrial fibrillation: a matched case-control study. Heart Rhythm                tor magnitude predicts recurrence of atrial fibrillation after catheter ablation in pa­
     2021;18:702–8.                                                                                        tients with persistent atrial fibrillation. Ann Noninvasive Electrocardiol 2019;24:e12646.
480. Pathak RK, Middeldorp ME, Stolcman S, Willoughby S, Mahajan R, Lau D, et al.                     504. Müller-Edenborn B, Chen J, Allgeier J, Didenko M, Moreno-Weidmann Z, Neumann FJ,
     Aggressive risk factor REduction STudy: implications for the substrate for atrial fibril­             et al. Amplified sinus-P-wave reveals localization and extent of left atrial low-voltage
     lation (ARREST-AF substrate study). Circ J 2015;132:S115–6.                                           substrate: implications for arrhythmia freedom following pulmonary vein isolation.
481. John B, Stiles MK, Kuklik P, Brooks AG, Chandy ST, Kalman JM, et al. Reverse remod­                   Europace 2020;22:240–9.
     eling of the atria after treatment of chronic stretch in humans: implications for the at­        505. Moreno-Weidmann Z, Müller-Edenborn B, Jadidi AS, Bazan-Gelizo V, Chen J, Park CI,
     rial fibrillation substrate. J Am Coll Cardiol 2010;55:1217–26.                                       et al. Easily available ECG and echocardiographic parameters for prediction of left atrial
482. Rienstra M, Hobbelt AH, Alings M, Tijssen JGP, Smit MD, Brügemann J, et al. Targeted                  remodeling and atrial fibrillation recurrence after pulmonary vein isolation: a multicen­
     therapy of underlying conditions improves sinus rhythm maintenance in patients with                   ter study. J Cardiovasc Electrophysiol 2021;32:1584–93.
     persistent atrial fibrillation: results of the RACE 3 trial. Eur Heart J 2018;39:2987–96.        506. Liu P, Lv T, Yang Y, Gao Q, Zhang P. Use of P wave indices to evaluate efficacy of cath­
483. Pandey AK, Okaj I, Kaur H, Belley-Cote EP, Wang J, Oraii A, et al. Sodium-glucose co-                 eter ablation and atrial fibrillation recurrence: a systematic review and metaanalysis.
     transporter inhibitors and atrial fibrillation: a systematic review and metaanalysis of               J Interv Card Electrophysiol 2022;65:827–40.
     randomized controlled trials. J Am Heart Assoc 2021;10:e022222.                                  507. Jadidi A, Müller-Edenborn B, Chen J, Keyl C, Weber R, Allgeier J, et al. The duration of
484. Olsson LG, Swedberg K, Ducharme A, Granger CB, Michelson EL, McMurray JJ, et al.                      the amplified sinus-P-wave identifies presence of left atrial low voltage substrate and
     Atrial fibrillation and risk of clinical events in chronic heart failure with and without left        predicts outcome after pulmonary vein isolation in patients with persistent atrial fib­
     ventricular systolic dysfunction: results from the Candesartan in heart
                                                                                                           rillation. JACC Clin Electrophysiol 2018;4:531–43.
     failure-assessment of reduction in mortality and morbidity (CHARM) program. J Am                 508. Koutalas E, Kallergis E, Nedios S, Kochiadakis G, Kanoupakis E. P-wave duration as a
     Coll Cardiol 2006;47:1997–2004.                                                                       marker of atrial remodeling in patients referred to ablation for atrial fibrillation: a
485. Cheng WH, Lo LW, Lin YJ, Chang SL, Hu YF, Hung Y, et al. Ten-year ablation out­
                                                                                                           new stratification tool emerging? Hellenic J Cardiol 2023.
     comes of patients with paroxysmal atrial fibrillation undergoing pulmonary vein isola­
                                                                                                      509. Okumura Y, Watanabe I, Ohkubo K, Ashino S, Kofune M, Hashimoto K, et al.
     tion. Heart Rhythm 2019;16:1327–33.
                                                                                                           Prediction of the efficacy of pulmonary vein isolation for the treatment of atrial fibril­
486. Sawhney N, Anousheh R, Chen WC, Narayan S, Feld GK. Five-year outcomes after
                                                                                                           lation by the signal-averaged P-wave duration. Pacing Clin Electrophysiol 2007;30:
     segmental pulmonary vein isolation for paroxysmal atrial fibrillation. Am J Cardiol
                                                                                                           304–13.
     2009;104:366–72.
                                                                                                      510. Kuppahally SS, Akoum N, Badger TJ, Burgon NS, Haslam T, Kholmovski E, et al.
487. Uchiyama T, Miyazaki S, Taniguchi H, Komatsu Y, Kusa S, Nakamura H, et al. Six-year
                                                                                                           Echocardiographic left atrial reverse remodeling after catheter ablation of atrial fibril­
     follow-up of catheter ablation in paroxysmal atrial fibrillation. Circ J 2013;77:2722–7.
                                                                                                           lation is predicted by preablation delayed enhancement of left atrium by magnetic res­
488. Gokoglan Y, Mohanty S, Gunes MF, Trivedi C, Santangeli P, Gianni C, et al. Pulmonary
                                                                                                           onance imaging. Am Heart J 2010;160:877–84.
     vein antrum isolation in patients with paroxysmal atrial fibrillation: more than a decade
                                                                                                      511. Akkaya M, Higuchi K, Koopmann M, Burgon N, Erdogan E, Damal K, et al. Relationship
     of follow-up. Circ Arrhythm Electrophysiol 2016;9:e003660.
                                                                                                           between left atrial tissue structural remodelling detected using late gadolinium en­
489. Hung Y, Lo LW, Lin YJ, Chang SL, Hu YF, Chung FP, et al. Characteristics and long-term
                                                                                                           hancement MRI and left ventricular hypertrophy in patients with atrial fibrillation.
     catheter ablation outcome in long-standing persistent atrial fibrillation patients with
                                                                                                           Europace 2013;15:1725–32.
     non-pulmonary vein triggers. Int J Cardiol 2017;241:205–11.
                                                                                                      512. McGann C, Akoum N, Patel A, Kholmovski E, Revelo P, Damal K, et al. Atrial fibrillation
490. Wynn GJ, El-Kadri M, Haq I, Das M, Modi S, Snowdon R, et al. Long-term outcomes
     after ablation of persistent atrial fibrillation: an observational study over 6 years.                ablation outcome is predicted by left atrial remodeling on MRI. Circ Arrhythm
     Open Heart 2016;3:e000394.                                                                            Electrophysiol 2014;7:23–30.
491. Chew DS, Jones KA, Loring Z, Black-Maier E, Noseworthy PA, Exner DV, et al.                      513. Ambale-Venkatesh B, Lima JA. Cardiac MRI: a central prognostic tool in myocardial fi­
     Diagnosis-to-ablation time predicts recurrent atrial fibrillation and rehospitalization               brosis. Nat Rev Cardiol 2015;12:18–29.
     following catheter ablation. Heart Rhythm O2 2022;3:23–31.                                       514. Nairn D, Eichenlaub M, Müller-Edenborn B, Huang T, Lehrmann H, Nagel C, et al.
492. De Greef Y, Schwagten B, Chierchia GB, de Asmundis C, Stockman D, Buysschaert I.                      Differences in atrial substrate localization using late gadolinium enhancement-magnetic
     Diagnosis-to-ablation time as a predictor of success: early choice for pulmonary vein                 resonance imaging, electrogram voltage, and conduction velocity: a cohort study using
     isolation and long-term outcome in atrial fibrillation: results from the Middelheim-PVI               a consistent anatomical reference frame in patients with persistent atrial fibrillation.
     Registry. Europace 2018;20:589–95.                                                                    Europace 2023;25:euad278.
493. Baysal E, Okşul M, Burak C, Yalin K, Soysal AU, Yalman H, et al. Decreasing time be­             515. Nakahara S, Hori Y, Kobayashi S, Sakai Y, Taguchi I, Takayanagi K, et al. Epicardial adi­
     tween first diagnosis of paroxysmal atrial fibrillation and cryoballoon ablation positively           pose tissue-based defragmentation approach to persistent atrial fibrillation: its impact
     affects long-term consequences. J Interv Card Electrophysiol 2022;65:365–72.                          on complex fractionated electrograms and ablation outcome. Heart Rhythm 2014;11:
494. Takamiya T, Nitta J, Inaba O, Sato A, Inamura Y, Murata K, et al. Impact of                           1343–51.
     diagnosis-to-ablation time on non-pulmonary vein triggers and ablation outcomes in               516. Chao TF, Hung CL, Tsao HM, Lin YJ, Yun CH, Lai YH, et al. Epicardial adipose tissue
     persistent atrial fibrillation. J Cardiovasc Electrophysiol 2021;32:1251–8.                           thickness and ablation outcome of atrial fibrillation. PLoS One 2013;8:e74926.
495. D’Ascenzo F, Corleto A, Biondi-Zoccai G, Anselmino M, Ferraris F, di Biase L, et al.             517. Masuda M, Mizuno H, Enchi Y, Minamiguchi H, Konishi S, Ohtani T, et al. Abundant
     Which are the most reliable predictors of recurrence of atrial fibrillation after trans­              epicardial adipose tissue surrounding the left atrium predicts early rather than late re­
     catheter ablation?: a metaanalysis. Int J Cardiol 2013;167:1984–9.                                    currence of atrial fibrillation after catheter ablation. J Interv Card Electrophysiol 2015;44:
496. Njoku A, Kannabhiran M, Arora R, Reddy P, Gopinathannair R, Lakkireddy D, et al. Left                 31–7.
     atrial volume predicts atrial fibrillation recurrence after radiofrequency ablation: a           518. Sepehri Shamloo A, Dagres N, Dinov B, Sommer P, Husser-Bollmann D, Bollmann A,
     metaanalysis. Europace 2018;20:33–42.                                                                 et al. Is epicardial fat tissue associated with atrial fibrillation recurrence after ablation? A
497. Costa FM, Ferreira AM, Oliveira S, Santos PG, Durazzo A, Carmo P, et al. Left atrial                  systematic review and metaanalysis. Int J Cardiol Heart Vasc 2019;22:132–8.
     volume is more important than the type of atrial fibrillation in predicting the long-term        519. Nagashima K, Okumura Y, Watanabe I, Nakai T, Ohkubo K, Kofune T, et al.
     success of catheter ablation. Int J Cardiol 2015;184:56–61.                                           Association between epicardial adipose tissue volumes on 3-dimensional recon­
498. Zhuang J, Wang Y, Tang K, Li X, Peng W, Liang C, et al. Association between left atrial               structed CT images and recurrence of atrial fibrillation after catheter ablation. Circ J
     size and atrial fibrillation recurrence after single circumferential pulmonary vein                   2011;75:2559–65.
Catheter and surgical ablation of atrial fibrillation                                                                                                                                            87


520. Vroomen M, Olsthoorn JR, Maesen B, L’Espoir V, La Meir M, Das M, et al.                         540. Di Biase L, Zou F, Lin AN, Grupposo V, Marazzato J, Tarantino N, et al. Feasibility of
     Quantification of epicardial adipose tissue in patients undergoing hybrid ablation for               three-dimensional artificial intelligence algorithm integration with intracardiac echo­
     atrial fibrillation. Eur J Cardiothorac Surg 2019;56:79–86.                                          cardiography for left atrial imaging during atrial fibrillation catheter ablation.
521. El Mahdiui M, Simon J, Smit JM, Kuneman JH, van Rosendael AR, Steyerberg EW, et al.                  Europace 2023;25:euad211.
     Posterior left atrial adipose tissue attenuation assessed by computed tomography and            541. Vicera JJB, Lin YJ, Lee PT, Chang SL, Lo LW, Hu YF, et al. Identification of critical isth­
     recurrence of atrial fibrillation after catheter ablation. Circ Arrhythm Electrophysiol 2021;        mus using coherent mapping in patients with scar-related atrial tachycardia.
     14:e009135.                                                                                          J Cardiovasc Electrophysiol 2020;31:1436–7.
522. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, et al. 2020          542. Deno DC, Bhaskaran A, Morgan DJ, Goksu F, Batman K, Olson GK, et al.
     ESC guidelines for the diagnosis and management of atrial fibrillation developed in col­             High-resolution, live, directional mapping. Heart Rhythm 2020;17:1621–8.
     laboration with the European Association for Cardio-Thoracic Surgery (EACTS): the               543. Unland R, Bergau L, El Hamriti M, Guckel D, Piran M, Fink T, et al. Find me if you can:
     task force for the diagnosis and management of atrial fibrillation of the European                   first clinical experience using the novel CARTOFINDER algorithm in a routine work­
     Society of Cardiology (ESC) developed with the special contribution of the                           flow for atrial fibrillation ablation. J Clin Med 2021;10:2979.
     European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 2021;42:                       544. Honarbakhsh S, Schilling RJ, Dhillon G, Ullah W, Keating E, Providencia R, et al. A novel
     373–498.                                                                                             mapping system for panoramic mapping of the left atrium: application to detect and
523. van Vugt SPG, Westra SW, Volleberg R, Hannink G, Nakamura R, de Asmundis C, et al.                   characterize localized sources maintaining atrial fibrillation. JACC Clin Electrophysiol
     Meta-analysis of controlled studies on minimally interrupted vs. continuous use of non-
                                                                                                          2018;4:124–34.
     vitamin K antagonist oral anticoagulants in catheter ablation for atrial fibrillation.
                                                                                                     545. Chang TY, Lin CY, Lin YJ, Wu CI, Chang SL, Lo LW, et al. Long-term outcome of pa­
     Europace 2021;23:1961–9.
                                                                                                          tients with long-standing persistent atrial fibrillation undergoing ablation guided by a
524. Yadav R, Brilliant J, Akhtar T, Milstein J, Sampognaro JR, Marine J, et al. Relationship be­
                                                                                                          novel high-density panoramic mapping system: a propensity score matching study.
     tween amiodarone response prior to ablation and 1-year outcomes of catheter abla­
                                                                                                          Heart Rhythm O2 2022;3:269–78.
     tion for atrial fibrillation. J Cardiovasc Electrophysiol 2023;34:860–8.
                                                                                                     546. Sporton SC, Earley MJ, Nathan AW, Schilling RJ. Electroanatomic versus fluoroscopic
525. Dukes JW, Chilukuri K, Scherr D, Marine JE, Berger RD, Nazarian S, et al. The effect of
                                                                                                          mapping for catheter ablation procedures: a prospective randomized study.
     antiarrhythmic medication management on atrial fibrillation ablation outcomes.
                                                                                                          J Cardiovasc Electrophysiol 2004;15:310–5.
     J Cardiovasc Electrophysiol 2013;24:882–7.
                                                                                                     547. Estner HL, Deisenhofer I, Luik A, Ndrepepa G, von Bary C, Zrenner B, et al. Electrical
526. Miwa Y, Minamiguchi H, Bhandari AK, Cannom DS, Ho IC. Amiodarone reduces the
     amount of ablation during catheter ablation for persistent atrial fibrillation. Europace             isolation of pulmonary veins in patients with atrial fibrillation: reduction of fluoroscopy
     2014;16:1007–14.                                                                                     exposure and procedure duration by the use of a non-fluoroscopic navigation system
527. Mohanty S, Di Biase L, Mohanty P, Trivedi C, Santangeli P, Bai R, et al. Effect of peri­             (NavX). Europace 2006;8:583–7.
     procedural amiodarone on procedure outcome in patients with longstanding persist­               548. Scaglione M, Biasco L, Caponi D, Anselmino M, Negro A, Di Donna P, et al.
     ent atrial fibrillation undergoing extended pulmonary vein antrum isolation: results                 Visualization of multiple catheters with electroanatomical mapping reduces X-ray ex­
     from a randomized study (SPECULATE). Heart Rhythm 2015;12:477–83.                                    posure during atrial fibrillation ablation. Europace 2011;13:955–62.
528. Efremidis M, Bazoukis G, Vlachos K, Prappa E, Megarisiotou A, Dragasis S, et al. Safety         549. Martinek M, Nesser HJ, Aichinger J, Boehm G, Purerfellner H. Impact of integration of
     of catheter ablation of atrial fibrillation without pre- or periprocedural imaging for the           multislice computed tomography imaging into three-dimensional electroanatomic
     detection of left atrial thrombus in the era of uninterrupted anticoagulation. J Arrhythm            mapping on clinical outcomes, safety, and efficacy using radiofrequency ablation for at­
     2021;37:28–32.                                                                                       rial fibrillation. Pacing Clin Electrophysiol 2007;30:1215–23.
529. Diab M, Wazni OM, Saliba WI, Tarakji KG, Ballout JA, Hutt E, et al. Ablation of atrial          550. Caponi D, Corleto A, Scaglione M, Blandino A, Biasco L, Cristoforetti Y, et al. Ablation
     fibrillation without left atrial appendage imaging in patients treated with direct oral an­          of atrial fibrillation: does the addition of three-dimensional magnetic resonance im­
     ticoagulants. Circ Arrhythm Electrophysiol 2020;13:e008301.                                          aging of the left atrium to electroanatomic mapping improve the clinical outcome?:
530. Puwanant S, Varr BC, Shrestha K, Hussain SK, Tang WH, Gabriel RS, et al. Role of the                 a randomized comparison of Carto-Merge vs. Carto-XP three-dimensional mapping
     CHADS2 score in the evaluation of thromboembolic risk in patients with atrial fibril­                ablation in patients with paroxysmal and persistent atrial fibrillation. Europace 2010;
     lation undergoing transesophageal echocardiography before pulmonary vein isolation.                  12:1098–104.
     J Am Coll Cardiol 2009;54:2032–9.                                                               551. Bertaglia E, Bella PD, Tondo C, Proclemer A, Bottoni N, De Ponti R, et al. Image inte­
531. Manning WJ, Weintraub RM, Waksmonski CA, Haering JM, Rooney PS, Maslow AD,                           gration increases efficacy of paroxysmal atrial fibrillation catheter ablation: results from
     et al. Accuracy of transesophageal echocardiography for identifying left atrial thrombi.             the CartoMerge Italian Registry. Europace 2009;11:1004–10.
     A prospective, intraoperative study. Ann Intern Med 1995;123:817–22.                            552. Della Bella P, Fassini G, Cireddu M, Riva S, Carbucicchio C, Giraldi F, et al. Image
532. Hahn RT, Abraham T, Adams MS, Bruce CJ, Glas KE, Lang RM, et al. Guidelines for                      integration-guided catheter ablation of atrial fibrillation: a prospective randomized
     performing a comprehensive transesophageal echocardiographic examination: recom­                     study. J Cardiovasc Electrophysiol 2009;20:258–65.
     mendations from the American Society of Echocardiography and the Society of                     553. Kistler PM, Rajappan K, Harris S, Earley MJ, Richmond L, Sporton SC, et al. The impact
     Cardiovascular Anesthesiologists. J Am Soc Echocardiogr 2013;26:921–64.                              of image integration on catheter ablation of atrial fibrillation using electroanatomic
533. Daniel WG, Erbel R, Kasper W, Visser CA, Engberding R, Sutherland GR, et al. Safety                  mapping: a prospective randomized study. Eur Heart J 2008;29:3029–36.
     of transesophageal echocardiography. A multicenter survey of 10,419 examinations.               554. Duytschaever M, Vijgen J, De Potter T, Scherr D, Van Herendael H, Knecht S, et al.
     Circulation 1991;83:817–21.                                                                          Standardized pulmonary vein isolation workflow to enclose veins with contiguous le­
534. Davenport MS, Perazella MA, Yee J, Dillman JR, Fine D, McDonald RJ, et al. Use of intra­
                                                                                                          sions: the multicenter VISTAX trial. Europace 2020;22:1645–52.
     venous iodinated contrast media in patients with kidney disease: consensus statements
                                                                                                     555. Duytschaever M, De Pooter J, Demolder A, El Haddad M, Phlips T, Strisciuglio T, et al.
     from the American College of Radiology and the National Kidney Foundation. Kidney
                                                                                                          Long-term impact of catheter ablation on arrhythmia burden in low-risk patients with
     Med 2020;2:85–93.
                                                                                                          paroxysmal atrial fibrillation: the CLOSE to CURE study. Heart Rhythm 2020;17:
535. Stocker TJ, Deseive S, Leipsic J, Hadamitzky M, Chen MY, Rubinshtein R, et al.
                                                                                                          535–43.
     Reduction in radiation exposure in cardiovascular computed tomography imaging:
                                                                                                     556. De Pooter J, Strisciuglio T, El Haddad M, Wolf M, Phlips T, Vandekerckhove Y, et al.
     results from the PROspective multicenter registry on radiaTion dose Estimates of car­
                                                                                                          Pulmonary vein reconnection no longer occurs in the majority of patients after a single
     diac CT angIOgraphy iN daily practice in 2017 (PROTECTION VI). Eur Heart J 2018;
                                                                                                          pulmonary vein isolation procedure. JACC Clin Electrophysiol 2019;5:295–305.
     39:3715–23.
                                                                                                     557. Hussein A, Das M, Riva S, Morgan M, Ronayne C, Sahni A, et al. Use of ablation index-
536. Kitkungvan D, Nabi F, Ghosn MG, Dave AS, Quinones M, Zoghbi WA, et al. Detection
     of LA and LAA thrombus by CMR in patients referred for pulmonary vein isolation.                     guided ablation results in high rates of durable pulmonary vein isolation and freedom
     JACC Cardiovasc Imaging 2016;9:809–18.                                                               from arrhythmia in persistent atrial fibrillation patients: the PRAISE study results. Circ
537. Rathi VK, Reddy ST, Anreddy S, Belden W, Yamrozik JA, Williams RB, et al.                            Arrhythm Electrophysiol 2018;11:e006576.
     Contrast-enhanced CMR is equally effective as TEE in the evaluation of left atrial ap­          558. Taghji P, El Haddad M, Phlips T, Wolf M, Knecht S, Vandekerckhove Y, et al. Evaluation
     pendage thrombus in patients with atrial fibrillation undergoing pulmonary vein isola­               of a strategy aiming to enclose the pulmonary veins with contiguous and optimized
     tion procedure. Heart Rhythm 2013;10:1021–7.                                                         radiofrequency lesions in paroxysmal atrial fibrillation: a pilot study. JACC Clin
538. Ohyama H, Hosomi N, Takahashi T, Mizushige K, Osaka K, Kohno M, et al.                               Electrophysiol 2018;4:99–108.
     Comparison of magnetic resonance imaging and transesophageal echocardiography                   559. Phlips T, Taghji P, El Haddad M, Wolf M, Knecht S, Vandekerckhove Y, et al. Improving
     in detection of thrombus in the left atrial appendage. Stroke 2003;34:2436–9.                        procedural and one-year outcome after contact force-guided pulmonary vein isola­
539. Brooks AG, Wilson L, Chia NH, Lau DH, Alasady M, Leong DP, et al. Accuracy and                       tion: the role of interlesion distance, ablation index, and contact force variability in
     clinical outcomes of CT image integration with Carto-Sound compared to electro-                      the ‘CLOSE’-protocol. Europace 2018;20:f419–27.
     anatomical mapping for atrial fibrillation ablation: a randomized controlled study. Int         560. Grace A, Willems S, Meyer C, Verma A, Heck P, Zhu M, et al. High-resolution noncon­
     J Cardiol 2013;168:2774–82.                                                                          tact charge-density mapping of endocardial activation. JCI Insight 2019;4:e126422.
88                                                                                                                                                                               S. Tzeis et al.


561. Willems S, Verma A, Betts TR, Murray S, Neuzil P, Ince H, et al. Targeting nonpulmon­               treatment: results from the EFFICAS I study. Circ Arrhythm Electrophysiol 2013;6:
     ary vein sources in persistent atrial fibrillation identified by noncontact charge density          327–33.
     mapping: UNCOVER AF trial. Circ Arrhythm Electrophysiol 2019;12:e007233.                       587. Kautzner J, Neuzil P, Lambert H, Peichl P, Petru J, Cihak R, et al. EFFICAS II: optimiza­
562. Shi R, Parikh P, Chen Z, Angel N, Norman M, Hussain W, et al. Validation of dipole                  tion of catheter contact force improves outcome of pulmonary vein isolation for par­
     density mapping during atrial fibrillation and sinus rhythm in human left atrium. JACC              oxysmal atrial fibrillation. Europace 2015;17:1229–35.
     Clin Electrophysiol 2020;6:171–81.                                                             588. Andrade JG, Monir G, Pollak SJ, Khairy P, Dubuc M, Roy D, et al. Pulmonary vein iso­
563. Haines DE, Kong MH, Ruppersberg P, Haeusser P, Avitall B, Szili Torok T, et al.                     lation using “contact force” ablation: the effect on dormant conduction and long-term
     Electrographic flow mapping for atrial fibrillation: theoretical basis and preliminary ob­          freedom from recurrent atrial fibrillation—a prospective study. Heart Rhythm 2014;
     servations. J Interv Card Electrophysiol 2022;66:1015–28.                                           11:1919–24.
564. Reddy VY, Neuzil P, Langbein A, Petru J, Funasako M, Dinshaw L, et al. AB-453070-2             589. Squara F, Latcu DG, Massaad Y, Mahjoub M, Bun SS, Saoudi N. Contact force and
     FLOW-AF: a randomized controlled trial of electrographic flow-guided ablation in                    force-time integral in atrial radiofrequency ablation predict transmurality of lesions.
     redo patients with non-paroxysmal atrial fibrillation. Heart Rhythm 2023;20:S1–2.                   Europace 2014;16:660–7.
565. Nademanee K, Schwab MC, Kosar EM, Karwecki M, Moran MD, Visessook N, et al.                    590. Whitaker J, Fish J, Harrison J, Chubb H, Williams SE, Fastl T, et al. Lesion index-guided
     Clinical outcomes of catheter substrate ablation for high-risk patients with atrial fibril­         ablation facilitates continuous, transmural, and durable lesions in a porcine recovery
     lation. J Am Coll Cardiol 2008;51:843–9.                                                            model. Circ Arrhythm Electrophysiol 2018;11:e005892.
566. Verma A, Jiang CY, Betts TR, Chen J, Deisenhofer I, Mantovan R, et al. Approaches to           591. Das M, Loveday JJ, Wynn GJ, Gomes S, Saeed Y, Bonnett LJ, et al. Ablation index, a
     catheter ablation for persistent atrial fibrillation. N Engl J Med 2015;372:1812–22.                novel marker of ablation lesion quality: prediction of pulmonary vein reconnection
567. Seitz J, Bars C, Theodore G, Beurtheret S, Lellouche N, Bremondy M, et al. AF ablation              at repeat electrophysiology study and regional differences in target values. Europace
     guided by spatiotemporal electrogram dispersion without pulmonary vein isolation: a                 2017;19:775–83.
     wholly patient-tailored approach. J Am Coll Cardiol 2017;69:303–21.                            592. Bourier F, Duchateau J, Vlachos K, Lam A, Martin CA, Takigawa M, et al. High-power
568. Lin R, Zeng C, Xu K, Wu S, Qin M, Liu X. Dispersion-guided ablation in conjunction                  short-duration versus standard radiofrequency ablation: insights on lesion metrics.
     with circumferential pulmonary vein isolation is superior to stepwise ablation ap­                  J Cardiovasc Electrophysiol 2018;29:1570–5.
     proach for persistent atrial fibrillation. Int J Cardiol 2019;278:97–103.                      593. Borne RT, Sauer WH, Zipse MM, Zheng L, Tzou W, Nguyen DT. Longer duration ver­
569. Jadidi AS, Lehrmann H, Keyl C, Sorrel J, Markstein V, Minners J, et al. Ablation of per­            sus increasing power during radiofrequency ablation yields different ablation lesion
     sistent atrial fibrillation targeting low-voltage areas with selective activation character­        characteristics. JACC Clin Electrophysiol 2018;4:902–8.
     istics. Circ Arrhythm Electrophysiol 2016;9:e002962.                                           594. Kyriakopoulou M, Wielandts JY, Strisciuglio T, El Haddad M, Pooter J, Almorad A, et al.
570. Seitz J, Durdez TM, Albenque JP, Pisapia A, Gitenay E, Durand C, et al. Artificial intel­           Evaluation of higher power delivery during RF pulmonary vein isolation using opti­
     ligence software standardizes electrogram-based ablation outcome for persistent at­                 mized and contiguous lesions. J Cardiovasc Electrophysiol 2020;31:1091–8.
     rial fibrillation. J Cardiovasc Electrophysiol 2022;33:2250–60.                                595. Berte B, Hilfiker G, Russi I, Moccetti F, Cuculi F, Toggweiler S, et al. Pulmonary vein
571. Narayan SM, Krummen DE, Shivkumar K, Clopton P, Rappel WJ, Miller JM. Treatment                     isolation using a higher power shorter duration CLOSE protocol with a surround
     of atrial fibrillation by the ablation of localized sources: CONFIRM (conventional abla­            flow ablation catheter. J Cardiovasc Electrophysiol 2019;30:2199–204.
     tion for atrial fibrillation with or without focal impulse and rotor modulation) trial. J Am   596. Chen S, Schmidt B, Bordignon S, Urbanek L, Tohoku S, Bologna F, et al. Ablation index-
     Coll Cardiol 2012;60:628–36.                                                                        guided 50 W ablation for pulmonary vein isolation in patients with atrial fibrillation:
572. Gray RA, Jalife J, Panfilov AV, Baxter WT, Cabo C, Davidenko JM, et al. Mechanisms of               procedural data, lesion analysis, and initial results from the FAFA AI high power study.
     cardiac fibrillation. Science 1995;270:1222–3; author reply 1224–5.                                 J Cardiovasc Electrophysiol 2019;30:2724–31.
573. Salinet J, Molero R, Schlindwein FS, Karel J, Rodrigo M, Rojo-Alvarez JL, et al.               597. Winkle RA, Mohanty S, Patrawala RA, Mead RH, Kong MH, Engel G, et al. Low com­
     Electrocardiographic imaging for atrial fibrillation: a perspective from computer mod­              plication rates using high power (45–50 W) for short duration for atrial fibrillation ab­
     els and animal experiments to clinical value. Front Physiol 2021;12:653013.                         lations. Heart Rhythm 2019;16:165–9.
574. Ramanathan C, Ghanem RN, Jia P, Ryu K, Rudy Y. Noninvasive electrocardiographic                598. Winkle RA, Moskovitz R, Hardwin Mead R, Engel G, Kong MH, Fleming W, et al. Atrial
     imaging for cardiac electrophysiology and arrhythmia. Nat Med 2004;10:422–8.                        fibrillation ablation using very short duration 50 W ablations and contact force sensing
575. Molero R, González-Ascaso A, Climent AM, Guillem MS. Robustness of imageless elec­                  catheters. J Interv Card Electrophysiol 2018;52:1–8.
     trocardiographic imaging against uncertainty in atrial morphology and location.                599. Wielandts JY, Kyriakopoulou M, Almorad A, Hilfiker G, Strisciuglio T, Phlips T, et al.
     J Electrocardiol 2023;77:58–61.                                                                     Prospective randomized evaluation of high power during CLOSE-guided pulmonary
576. Cuculich PS, Wang Y, Lindsay BD, Faddis MN, Schuessler RB, Damiano RJ Jr, et al.                    vein isolation: the POWER-AF study. Circ Arrhythm Electrophysiol 2021;14:e009112.
     Noninvasive characterization of epicardial activation in humans with diverse atrial fib­       600. Lee AC, Voskoboinik A, Cheung CC, Yogi S, Tseng ZH, Moss JD, et al. A randomized
     rillation patterns. Circulation 2010;122:1364–72.                                                   trial of high vs standard power radiofrequency ablation for pulmonary vein isolation:
577. Haissaguerre M, Hocini M, Denis A, Shah AJ, Komatsu Y, Yamashita S, et al. Driver do­               SHORT-AF. JACC Clin Electrophysiol 2023;9:1038–47.
     mains in persistent atrial fibrillation. Circulation 2014;130:530–8.                           601. Kottmaier M, Popa M, Bourier F, Reents T, Cifuentes J, Semmler V, et al. Safety and
578. Lim HS, Hocini M, Dubois R, Denis A, Derval N, Zellerhoff S, et al. Complexity and                  outcome of very high-power short-duration ablation using 70 W for pulmonary
     distribution of drivers in relation to duration of persistent atrial fibrillation. J Am Coll        vein isolation in patients with paroxysmal atrial fibrillation. Europace 2020;22:388–93.
     Cardiol 2017;69:1257–69.                                                                       602. Castrejón-Castrejón S, Martínez Cossiani M, Jáuregui-Abularach M, Basterra Sola N,
579. Knecht S, Sohal M, Deisenhofer I, Albenque JP, Arentz T, Neumann T, et al. Multicentre              Ibáñez Criado JL, Osca Asensi J, et al. POWER FAST III trial investigators.
     evaluation of non-invasive biatrial mapping for persistent atrial fibrillation ablation: the        Multicenter prospective comparison of conventional and high-power short duration
     AFACART study. Europace 2017;19:1302–9.                                                             radiofrequency application for pulmonary vein isolation: the high-power short-
580. Honarbakhsh S, Dhillon G, Abbass H, Waddingham PH, Dennis A, Ahluwalia N, et al.                    duration radiofrequency application for faster and safer pulmonary vein ablation
     Noninvasive electrocardiographic imaging-guided targeting of drivers of persistent at­              (POWER FAST III) trial. J Interv Card Electrophysiol 2023;66:1889–99.
     rial fibrillation: the TARGET-AF1 trial. Heart Rhythm 2022;19:875–84.                          603. Leung LWM, Akhtar Z, Sheppard MN, Louis-Auguste J, Hayat J, Gallagher MM.
581. Gao X, Lam AG, Bilchick KC, Darby A, Mehta N, Mason PK, et al. The use of non-                      Preventing esophageal complications from atrial fibrillation ablation: a review. Heart
     invasive mapping in persistent AF to predict acute procedural outcome.                              Rhythm O2 2021;2:651–64.
     J Electrocardiol 2019;57S:S21–6.                                                               604. Kautzner J, Albenque JP, Natale A, Maddox W, Cuoco F, Neuzil P, et al. A novel
582. Rodrigo M, Climent AM, Hernandez-Romero I, Liberos A, Baykaner T, Rogers AJ, et al.                 temperature-controlled radiofrequency catheter ablation system used to treat pa­
     Noninvasive assessment of complexity of atrial fibrillation: correlation with contact               tients with paroxysmal atrial fibrillation. JACC Clin Electrophysiol 2021;7:352–63.
     mapping and impact of ablation. Circ Arrhythm Electrophysiol 2020;13:e007700.                  605. Almorad A, Wielandts JY, El Haddad M, Knecht S, Tavernier R, Kobza R, et al.
583. Badger TJ, Adjei-Poku YA, Marrouche NF. MRI in cardiac electrophysiology: the emer­                 Performance and safety of temperature- and flow-controlled radiofrequency ablation
     ging role of delayed-enhancement MRI in atrial fibrillation ablation. Future Cardiol 2009;          in ablation index-guided pulmonary vein isolation. JACC Clin Electrophysiol 2021;7:
     5:63–70.                                                                                            408–9.
584. Bisbal F, Calvo M, Trucco E, Arbelo E, Berruezo A, Mont L. Left atrial tachycardia after       606. Bortone A, Albenque JP, Ramirez FD, Haïssaguerre M, Combes S, Constantin M, et al.
     atrial fibrillation ablation: can magnetic resonance imaging assist the ablation? Can J             90 vs 50-watt radiofrequency applications for pulmonary vein isolation: experimental
     Cardiol 2015;31:104.e1–3.                                                                           and clinical findings. Circ Arrhythm Electrophysiol 2022;15:e010663.
585. Reddy VY, Shah D, Kautzner J, Schmidt B, Saoudi N, Herrera C, et al. The relationship          607. Leshem E, Zilberman I, Tschabrunn CM, Barkagan M, Contreras-Valdes FM, Govari A,
     between contact force and clinical outcome during radiofrequency catheter ablation                  et al. High-power and short-duration ablation for pulmonary vein isolation: biophysical
     of atrial fibrillation in the TOCCATA study. Heart Rhythm 2012;9:1789–95.                           characterization. JACC Clin Electrophysiol 2018;4:467–79.
586. Neuzil P, Reddy VY, Kautzner J, Petru J, Wichterle D, Shah D, et al. Electrical recon­         608. Takigawa M, Kitamura T, Martin CA, Fuimaono K, Datta K, Joshi H, et al. Temperature-
     nection after pulmonary vein isolation is contingent on contact force during initial                and flow-controlled ablation/very-high-power short-duration ablation vs conventional
Catheter and surgical ablation of atrial fibrillation                                                                                                                                       89


     power-controlled ablation: comparison of focal and linear lesion characteristics. Heart       630. De Potter T, Klaver M, Babkin A, Iliodromitis K, Hocini M, Cox J, et al. Ultra-low tem­
     Rhythm 2021;18:553–61.                                                                             perature cryoablation for atrial fibrillation: primary outcomes for efficacy and safety:
609. Nakagawa H, Ikeda A, Sharma T, Govari A, Ashton J, Maffre J, et al. Comparison of in               the cryocure-2 study. JACC Clin Electrophysiol 2022;8:1034–9.
     vivo tissue temperature profile and lesion geometry for radiofrequency ablation with          631. Verma A, Asivatham SJ, Deneke T, Castellvi Q, Neal RE 2nd. Primer on pulsed elec­
     high power-short duration and moderate power-moderate duration: effects of ther­                   trical field ablation: understanding the benefits and limitations. Circ Arrhythm
     mal latency and contact force on lesion formation. Circ Arrhythm Electrophysiol 2021;14:           Electrophysiol 2021;14:e010086.
     e009899.                                                                                      632. Ruzgys P, Novickij V, Novickij J, Satkauskas S. Influence of the electrode material on
610. Reddy VY, Grimaldi M, De Potter T, Vijgen JM, Bulava A, Duytschaever MF, et al.                    ROS generation and electroporation efficiency in low and high frequency nanosecond
     Pulmonary vein isolation with very high power, short duration, temperature-                        pulse range. Bioelectrochemistry 2019;127:87–93.
     controlled lesions: the QDOT-FAST trial. JACC Clin Electrophysiol 2019;5:778–86.              633. Rubinsky L, Guenther E, Mikus P, Stehling M, Rubinsky B. Electrolytic effects during tis­
611. Halbfass P, Wielandts JY, Knecht S, Le Polain de Waroux JB, Tavernier R, De Wilde V,               sue ablation by electroporation. Technol Cancer Res Treat 2016;15:NP95–103.
     et al. Safety of very high-power short-duration radiofrequency ablation for pulmonary         634. Xie F, Varghese F, Pakhomov AG, Semenov I, Xiao S, Philpott J, et al. Ablation of myo­
     vein isolation: a two-centre report with emphasis on silent esophageal injury. Europace            cardial tissue with nanosecond pulsed electric fields. PLoS One 2015;10:e0144833.
     2022;24:400–5.                                                                                635. Maor E, Ivorra A, Leor J, Rubinsky B. The effect of irreversible electroporation on
612. Richard Tilz R, Sano M, Vogler J, Fink T, Saraei R, Sciacca V, et al. Very high-power              blood vessels. Technol Cancer Res Treat 2007;6:307–12.
     short-duration temperature-controlled ablation versus conventional power-                     636. Scheinman MM, Morady F, Hess DS, Gonzalez R. Catheter-induced ablation of the
     controlled ablation for pulmonary vein isolation: the fast and furious – AF study. Int
                                                                                                        atrioventricular junction to control refractory supraventricular arrhythmias. JAMA
     J Cardiol Heart Vasc 2021;35:100847.
                                                                                                        1982;248:851–5.
613. O’Neill L, El Haddad M, Berte B, Kobza R, Hilfiker G, Scherr D, et al. Very high-power
                                                                                                   637. van den Bos W, Scheffer HJ, Vogel JA, Wagstaff PG, de Bruin DM, de Jong MC, et al.
     ablation for contiguous pulmonary vein isolation: results from the randomized
                                                                                                        Thermal energy during irreversible electroporation and the influence of different ab­
     POWER PLUS trial. JACC Clin Electrophysiol 2022;9:511–22.
                                                                                                        lation parameters. J Vasc Interv Radiol 2016;27:433–43.
614. Reddy VY, Schilling R, Grimaldi M, Horton R, Natale A, Riva S, et al. Pulmonary vein
                                                                                                   638. Stewart MT, Haines DE, Miklavcic D, Kos B, Kirchhof N, Barka N, et al. Safety and
     isolation with a novel multielectrode radiofrequency balloon catheter that allows dir­
                                                                                                        chronic lesion characterization of pulsed field ablation in a porcine model.
     ectionally tailored energy delivery: short-term outcomes from a multicenter
     first-in-human study (RADIANCE). Circ Arrhythm Electrophysiol 2019;12:e007541.                     J Cardiovasc Electrophysiol 2021;32:958–69.
615. Dhillon GS, Honarbakhsh S, Di Monaco A, Coling AE, Lenka K, Pizzamiglio F, et al. Use         639. Meckes D, Emami M, Fong I, Lau DH, Sanders P. Pulsed-field ablation: computational
     of a multielectrode radiofrequency balloon catheter to achieve pulmonary vein isola­               modeling of electric fields for lesion depth analysis. Heart Rhythm O2 2022;3:433–440.
     tion in patients with paroxysmal atrial fibrillation: 12-month outcomes of the                640. Verma A, Howard BT, Tzou WT, Mattison LM, Kos B, Miklavcic D, et al. Effects of tis­
     RADIANCE study. J Cardiovasc Electrophysiol 2020;31:1259–69.                                       sue proximity on cardiac lesion formation using pulsed field ablation. Heart Rhythm
616. Almorad A, Del Monte A, Della Rocca DG, Pannone L, Ramak R, Overeinder I, et al.                   2022;19:S228.
     Outcomes of pulmonary vein isolation with radiofrequency balloon vs. cryoballoon ab­          641. Reddy VY, Neuzil P, Koruth JS, Petru J, Funosako M, Cochet H, et al. Pulsed field ab­
     lation: a multi-centric study. Europace 2023;25:euad252.                                           lation for pulmonary vein isolation in atrial fibrillation. J Am Coll Cardiol 2019;74:
617. Schilling R, Dhillon GS, Tondo C, Riva S, Grimaldi M, Quadrini F, et al. Safety, effective­        315–26.
     ness, and quality of life following pulmonary vein isolation with a multielectrode radio­     642. Verma A, Boersma L, Haines DE, Natale A, Marchlinski FE, Sanders P, et al.
     frequency balloon catheter in paroxysmal atrial fibrillation: 1-year outcomes from                 First-in-human experience and acute procedural outcomes using a novel pulsed field
     SHINE. Europace 2021;23:851–60.                                                                    ablation system: the PULSED AF pilot trial. Circ Arrhythm Electrophysiol 2022;15:
618. Del Monte A, Almorad A, Pannone L, Della Rocca DG, Bisignani A, Monaco C, et al.                   e010168.
     Pulmonary vein isolation with the radiofrequency balloon catheter: a single center pro­       643. Ekanem E, Reddy VY, Schmidt B, Reichlin T, Neven K, Metzner A, et al. Multi-national
     spective study. Europace 2023;25:896–904.                                                          survey on the methods, efficacy, and safety on the post-approval clinical use of pulsed
619. Reddy VY, Anter E, Rackauskas G, Peichl P, Koruth JS, Petru J, et al. Lattice-tip focal            field ablation (MANIFEST-PF). Europace 2022;24:1256–66.
     ablation catheter that toggles between radiofrequency and pulsed field energy to treat        644. Schmidt B, Bordignon S, Neven K, Reichlin T, Blaauw Y, Hansen J, et al. EUropean real-
     atrial fibrillation: a first-in-human trial. Circ Arrhythm Electrophysiol 2020;13:e008718.         world outcomes with pulsed field ablatiOn in patients with symptomatic atRIAl fibril­
620. Reddy VY, Peichl P, Anter E, Rackauskas G, Petru J, Funasako M, et al. A focal ablation            lation: lessons from the multicentre EU-PORIA registry. Europace 2023;25:euad185.
     catheter toggling between radiofrequency and pulsed field energy to treat atrial fibril­      645. Maor E, Ivorra A, Rubinsky B. Non thermal irreversible electroporation: novel technol­
     lation. JACC Clin Electrophysiol 2023;9:1786–801.                                                  ogy for vascular smooth muscle cells ablation. PLoS One 2009;4:e4757.
621. Dubuc M, Khairy P, Rodriguez-Santiago A, Talajic M, Tardif JC, Thibault B, et al.             646. Li W, Fan Q, Ji Z, Qiu X, Li Z. The effects of irreversible electroporation (IRE) on
     Catheter cryoablation of the atrioventricular node in patients with atrial fibrillation:           nerves. PLoS One 2011;6:e18831.
     a novel technology for ablation of cardiac arrhythmias. J Cardiovasc Electrophysiol           647. Koruth JS, Kuroki K, Kawamura I, Brose R, Viswanathan R, Buck ED, et al. Pulsed field
     2001;12:439–44.                                                                                    ablation versus radiofrequency ablation: esophageal injury in a novel porcine model.
622. Andrade JG, Champagne J, Dubuc M, Deyell MW, Verma A, Macle L, et al. Cryoballoon                  Circ Arrhythm Electrophysiol 2020;13:e008303.
     or radiofrequency ablation for atrial fibrillation assessed by continuous monitoring: a       648. Stewart MT, Haines DE, Verma A, Kirchhof N, Barka N, Grassl E, et al. Intracardiac
     randomized clinical trial. Circulation 2019;140:1779–88.                                           pulsed field ablation: proof of feasibility in a chronic porcine model. Heart Rhythm
623. Furnkranz A, Chun KR, Nuyens D, Metzner A, Koster I, Schmidt B, et al.
                                                                                                        2019;16:754–64.
     Characterization of conduction recovery after pulmonary vein isolation using the “sin­
                                                                                                   649. Howard B, Haines DE, Verma A, Kirchhof N, Barka N, Onal B, et al. Characterization of
     gle big cryoballoon” technique. Heart Rhythm 2010;7:184–90.
                                                                                                        phrenic nerve response to pulsed field ablation. Circ Arrhythm Electrophysiol 2022;15:
624. Martin CA, Tilz RRR, Anic A, Defaye P, Luik A, de Asmundis C, et al. Acute procedural
                                                                                                        e010127.
     efficacy and safety of a novel cryoballoon for the treatment of paroxysmal atrial fibril­
                                                                                                   650. Howard B, Haines DE, Verma A, Packer D, Kirchhof N, Barka N, et al. Reduction in
     lation: results from the POLAR ICE study. J Cardiovasc Electrophysiol 2023;34:833–40.
                                                                                                        pulmonary vein stenosis and collateral damage with pulsed field ablation compared
625. Tilz RR, Meyer-Saraei R, Eitel C, Fink T, Sciacca V, Lopez LD, et al. Novel cryoballoon
                                                                                                        with radiofrequency ablation in a canine model. Circ Arrhythm Electrophysiol 2020;13:
     ablation system for single shot pulmonary vein isolation- the prospective ICE-AGE-X
     study. Circ J 2021;85:1296–304.                                                                    e008337.
626. Assaf A, Bhagwandien R, Szili-Torok T, Yap SC. Comparison of procedural efficacy,             651. Reddy VY, Dukkipati SR, Neuzil P, Anic A, Petru J, Funasako M, et al. Pulsed field ab­
     balloon nadir temperature, and incidence of phrenic nerve palsy between two cryobal­               lation of paroxysmal atrial fibrillation: 1-year outcomes of IMPULSE, PEFCAT, and
     loon technologies for pulmonary vein isolation: a systematic review and metaanalysis.              PEFCAT II. JACC Clin Electrophysiol 2021;7:614–27.
     J Cardiovasc Electrophysiol 2021;32:2424–31.                                                  652. Chung EM, Banahan C, Patel N, Janus J, Marshall D, Horsfield MA, et al. Size distribution
627. Reichlin T, Kaueffer T, Knecht S, Madaffari A, Badertscher P, Maurhofer J, et al.                  of air bubbles entering the brain during cardiac surgery. PLoS One 2015;10:e0122166.
     Comparison of the PolarX and the Arctic Front cryoballoon for pulmonary vein iso­             653. Reinsch N, Füting A, Höwel D, Bell J, Lin Y, Neven K. Cerebral safety after pulsed field
     lation in patients with paroxysmal atrial fibrillation (COMPARE CRYO). Presented at                ablation for paroxysmal atrial fibrillation. Heart Rhythm 2022;19:1813–8.
     ESC Congress 2023, Late Breaking Sciences in Atrial Fibrillation Session 2023.                654. Loh P, van Es R, Groen MHA, Neven K, Kassenberg W, Wittkampf FHM, et al.
628. Kuck KH, Furnkranz A, Chun KR, Metzner A, Ouyang F, Schluter M, et al. Cryoballoon                 Pulmonary vein isolation with single pulse irreversible electroporation: a first in human
     or radiofrequency ablation for symptomatic paroxysmal atrial fibrillation: reinterven­             study in 10 patients with atrial fibrillation. Circ Arrhythm Electrophysiol 2020;13:
     tion, rehospitalization, and quality-of-life outcomes in the FIRE AND ICE trial. Eur               e008192.
     Heart J 2016;37:2858–65.                                                                      655. Gunawardene Melanie A, Schaeffer Benjamin N, Jularic M, Eickholt C, Maurer T,
629. Bredikis A, Wilber DJ. Cryoablation of Cardiac Arrhythmias. 1st ed. Philadelphia, PA:              Akbulak Ruken Ö, et al. Coronary spasm during pulsed field ablation of the mitral isth­
     Elsevier/Saunders; 2011.                                                                           mus line. JACC Clin Electrophysiol 2021;7:1618–20.
90                                                                                                                                                                                    S. Tzeis et al.


656. Reddy VY, Petru J, Funasako M, Kopriva K, Hala P, Chovanec M, et al. Coronary arterial           679. Sobolev M, Shiloh AL, Di Biase L, Slovut DP. Ultrasound-guided cannulation of the
     spasm during pulsed field ablation to treat atrial fibrillation. Circulation 2022;146:                femoral vein in electrophysiological procedures: a systematic review and metaanalysis.
     1808–19.                                                                                              Europace 2017;19:850–5.
657. Reddy VY, Anic A, Koruth J, Petru J, Funasako M, Minami K, et al. Pulsed field ablation in       680. Wang TKM, Wang MTM, Martin A. Meta-analysis of ultrasound-guided vs convention­
     patients with persistent atrial fibrillation. J Am Coll Cardiol 2020;76:1068–80.                      al vascular access for cardiac electrophysiology procedures. J Arrhythm 2019;35:
658. Anić A, Phlips T, Brešković T, Koopman P, Girouard S, Mediratta V, et al. Pulsed field                858–62.
     ablation using focal contact force-sensing catheters for treatment of atrial fibrillation:       681. Verma A, Debruyne P, Nardi S, Deneke T, DeGreef Y, Spitzer S, et al. Evaluation and
     acute and 90-day invasive remapping results. Europace 2023;25:euad147.                                reduction of asymptomatic cerebral embolism in ablation of atrial fibrillation, but high
659. Turagam MK, Neuzil P, Schmidt B, Reichlin T, Neven K, Metzner A, et al. Safety and                    prevalence of chronic silent infarction: results of the evaluation of reduction of asymp­
     effectiveness of pulsed field ablation to treat atrial fibrillation: one-year outcomes                tomatic cerebral embolism trial. Circ Arrhythm Electrophysiol 2013;6:835–42.
     from the MANIFEST-PF registry. Circulation 2023;148:35–46.                                       682. Yu Y, Wang X, Li X, Zhou X, Liao S, Yang W, et al. Higher incidence of asymptomatic
660. Verma A, Haines DE, Boersma LV, Sood N, Natale A, Marchlinski FE, et al. Pulsed field                 cerebral emboli after atrial fibrillation ablation found with high-resolution diffusion-
     ablation for the treatment of atrial fibrillation: PULSED AF pivotal trial. Circulation               weighted magnetic resonance imaging. Circ Arrhythm Electrophysiol 2020;13:e007548.
     2023;147:1422–32.                                                                                683. Briceno DF, Villablanca PA, Lupercio F, Kargoli F, Jagannath A, Londono A, et al. Clinical
661. Duytschaever M, De Potter T, Grimaldi M, Anic A, Vijgen J, Neuzil P, et al. Paroxysmal
                                                                                                           impact of heparin kinetics during catheter ablation of atrial fibrillation: metaanalysis and
     atrial fibrillation ablation using a novel variable-loop biphasic pulsed field ablation cath­
                                                                                                           meta-regression. J Cardiovasc Electrophysiol 2016;27:683–93.
     eter integrated with a 3-dimensional mapping system: 1-year outcomes of the multi­
                                                                                                      684. Maleki K, Mohammadi R, Hart D, Cotiga D, Farhat N, Steinberg JS. Intracardiac ultra­
     center inspIRE study. Circ Arrhythm Electrophysiol 2023;16:e011780.
                                                                                                           sound detection of thrombus on transseptal sheath: incidence, treatment, and preven­
662. Reddy VY, Gerstenfeld EP, Natale A, Whang W, Cuoco FA, Patel C, et al. Pulsed field
                                                                                                           tion. J Cardiovasc Electrophysiol 2005;16:561–5.
     or conventional thermal ablation for paroxysmal atrial fibrillation. N Engl J Med 2023;
                                                                                                      685. Ren JF, Marchlinski FE, Callans DJ, Gerstenfeld EP, Dixit S, Lin D, et al. Increased inten­
     389:1660–71.
                                                                                                           sity of anticoagulation may reduce risk of thrombus during atrial fibrillation ablation
663. Rovaris G, Ciconte G, Schiavone M, Mitacchione G, Gasperetti A, Piazzi E, et al.
                                                                                                           procedures in patients with spontaneous echo contrast. J Cardiovasc Electrophysiol
     Second-generation laser balloon ablation for the treatment of atrial fibrillation as­
     sessed by continuous rhythm monitoring: the LIGHT-AF study. Europace 2021;23:                         2005;16:474–7.
                                                                                                      686. Bruce CJ, Friedman PA, Narayan O, Munger TM, Hammill SC, Packer DL, et al. Early
     1380–90.
664. Schmidt B, Neuzil P, Luik A, Osca Asensi J, Schrickel JW, Deneke T, et al. Laser balloon              heparinization decreases the incidence of left atrial thrombi detected by intracardiac
     or wide-area circumferential irrigated radiofrequency ablation for persistent atrial fib­             echocardiography during radiofrequency ablation for atrial fibrillation. J Interv Card
     rillation: a multicenter prospective randomized study. Circ Arrhythm Electrophysiol 2017;             Electrophysiol 2008;22:211–9.
     10:e005767.                                                                                      687. Asbach S, Biermann J, Bode C, Faber TS. Early heparin administration reduces risk for
665. Chun JKR, Bordignon S, Last J, Mayer L, Tohoku S, Zanchi S, et al. Cryoballoon versus                 left atrial thrombus formation during atrial fibrillation ablation procedures. Cardiol Res
     laserballoon: insights from the first prospective randomized balloon trial in catheter                Pract 2011;2011:615087.
     ablation of atrial fibrillation. Circ Arrhythm Electrophysiol 2021;14:e009294.                   688. Di Biase L, Gaita F, Toso E, Santangeli P, Mohanty P, Rutledge N, et al. Does peripro­
666. Ye W, Chen Q, Fan G, Zhou X, Wang X, Mao W, et al. Efficacy and safety of visually                    cedural anticoagulation management of atrial fibrillation affect the prevalence of silent
     guided laser balloon versus cryoballoon ablation for paroxysmal atrial fibrillation: a sys­           thromboembolic lesion detected by diffusion cerebral magnetic resonance imaging in
     tematic review and metaanalysis. Front Cardiovasc Med 2023;10:1229223.                                patients undergoing radiofrequency atrial fibrillation ablation with open irrigated ca­
667. Schiavone M, Gasperetti A, Montemerlo E, Pozzi M, Sabato F, Piazzi E, et al. Long-term                theters? Results from a prospective multicenter study. Heart Rhythm 2014;11:791–8.
     comparisons of atrial fibrillation ablation outcomes with a cryoballoon or laser-                689. Meininghaus DG, Blembel K, Waniek C, Kruells-Muench J, Ernst H, Kleemann T, et al.
     balloon: a propensity-matched analysis based on continuous rhythm monitoring.                         Temperature monitoring and temperature-driven irrigated radiofrequency energy ti­
     Hellenic J Cardiol 2022;65:1–7.                                                                       tration do not prevent thermally induced esophageal lesions in pulmonary vein isola­
668. Proietti R, Pecoraro V, Di Biase L, Natale A, Santangeli P, Viecca M, et al. Remote mag­              tion: a randomized study controlled by esophagoscopy before and after catheter
     netic with open-irrigated catheter vs. manual navigation for ablation of atrial fibrillation:         ablation. Heart Rhythm 2021;18:926–34.
     a systematic review and metaanalysis. Europace 2013;15:1241–8.                                   690. Schoene K, Arya A, Grashoff F, Knopp H, Weber A, Lerche M, et al. Oesophageal
669. Jia K, Jin Q, Liu A, Wu L. Remote magnetic navigation versus manual control navigation                probe evaluation in radiofrequency ablation of atrial fibrillation (OPERA): results
     for atrial fibrillation ablation: a systematic review and metaanalysis. J Electrocardiol 2019;        from a prospective randomized trial. Europace 2020;22:1487–94.
     55:78–86.                                                                                        691. Deneke T, Nentwich K, Berkovitz A, Sonne K, Ene E, Pavlov B, et al. High-resolution
670. Li X, Bao Y, Jia K, Zhang N, Lin C, Wei Y, et al. Comparison of the mid-term outcomes                 infrared thermal imaging of the esophagus during atrial fibrillation ablation as a predict­
     of robotic magnetic navigation-guided radiofrequency ablation versus cryoballoon ab­                  or of endoscopically detected thermal lesions. Circ Arrhythm Electrophysiol 2018;11:
     lation for persistent atrial fibrillation. J Cardiovasc Dev Dis 2022;9:88.                            e006681.
671. Verma A, Feld GK, Cox JL, Dewland TA, Babkin A, De Potter T, et al. Combined pulsed              692. Ayoub T, El Hajjar AH, Singh Sidhu GD, Bhatnagar A, Zhang Y, Mekhael M, et al.
     field ablation with ultra-low temperature cryoablation: a pre-clinical experience.                    Esophageal temperature during atrial fibrillation ablation poorly predicts esophageal
     J Cardiovasc Electrophysiol 2022;34:2124–33.
                                                                                                           injury: an observational study. Heart Rhythm O2 2021;2:570–7.
672. Hilbert S, Sommer P, Gutberlet M, Gaspar T, Foldyna B, Piorkowski C, et al. Real-time
                                                                                                      693. Ha FJ, Han HC, Sanders P, Teh AW, O’Donnell D, Farouque O, et al. Prevalence and
     magnetic resonance-guided ablation of typical right atrial flutter using a combination of
                                                                                                           prevention of esophageal injury during atrial fibrillation ablation: a systematic review
     active catheter tracking and passive catheter visualization in man: initial results from a
                                                                                                           and metaanalysis. Europace 2019;21:80–90.
     consecutive patient series. Europace 2016;18:572–7.
                                                                                                      694. Chen S, Schmidt B, Seeger A, Bordignon S, Tohoku S, Willems F, et al. Catheter abla­
673. Lehmann HI, Graeff C, Simoniello P, Constantinescu A, Takami M, Lugenbiel P, et al.
                                                                                                           tion of atrial fibrillation using ablation index-guided high power (50 W) for pulmonary
     Feasibility study on cardiac arrhythmia ablation using high-energy heavy ion beams.
                                                                                                           vein isolation with or without esophageal temperature probe (the AI-HP ESO II).
     Sci Rep 2016;6:38895.
                                                                                                           Heart Rhythm 2020;17:1833–40.
674. Ströker E, de Asmundis C, Kupics K, Takarada K, Mugnai G, De Cocker J, et al. Value of
                                                                                                      695. Garcia R, Waldmann V, Vanduynhoven P, Nesti M, Jansen de Oliveira Figueiredo M,
     ultrasound for access guidance and detection of subclinical vascular complications in
     the setting of atrial fibrillation cryoballoon ablation. Europace 2019;21:434–9.                      Narayanan K, et al. Worldwide sedation strategies for atrial fibrillation ablation: cur­
675. Wynn GJ, Haq I, Hung J, Bonnett LJ, Lewis G, Webber M, et al. Improving safety in cath­               rent status and evolution over the last decade. Europace 2021;23:2039–45.
     eter ablation for atrial fibrillation: a prospective study of the use of ultrasound to guide     696. Dada RS, Hayanga JWA, Woods K, Schwartzman D, Thibault D, Ellison M, et al.
     vascular access. J Cardiovasc Electrophysiol 2014;25:680–5.                                           Anesthetic choice for atrial fibrillation ablation: a national anesthesia clinical outcomes
676. Yamagata K, Wichterle D, Roubicek T, Jarkovsky P, Sato Y, Kogure T, et al.                            registry analysis. J Cardiothorac Vasc Anesth 2021;35:2600–6.
     Ultrasound-guided versus conventional femoral venipuncture for catheter ablation                 697. Di Biase L, Conti S, Mohanty P, Bai R, Sanchez J, Walton D, et al. General anesthesia
     of atrial fibrillation: a multicenter randomized efficacy and safety trial (ULTRA-FAST                reduces the prevalence of pulmonary vein reconnection during repeat ablation when
     trial). Europace 2018;20:1107–14.                                                                     compared with conscious sedation: results from a randomized study. Heart Rhythm
677. Sharma PS, Padala SK, Gunda S, Koneru JN, Ellenbogen KA. Vascular complications                       2011;8:368–72.
     during catheter ablation of cardiac arrhythmias: a comparison between vascular ultra­            698. Chikata A, Kato T, Yaegashi T, Sakagami S, Kato C, Saeki T, et al. General anesthesia
     sound guided access and conventional vascular access. J Cardiovasc Electrophysiol 2016;               improves contact force and reduces gap formation in pulmonary vein isolation: a com­
     27:1160–6.                                                                                            parison with conscious sedation. Heart Vessels 2017;32:997–1005.
678. Pellegrino PL, Di Monaco A, Santoro F, Grimaldi M, D’Arienzo G, Casavecchia G, et al.            699. Martin CA, Curtain JP, Gajendragadkar PR, Begley DA, Fynn SP, Grace AA, et al.
     Near zero vascular complications using echo-guided puncture during catheter ablation                  Improved outcome and cost effectiveness in ablation of persistent atrial fibrillation un­
     of arrhythmias: a retrospective study and literature review. J Arrhythm 2022;38:395–9.                der general anesthetic. Europace 2018;20:935–42.
Catheter and surgical ablation of atrial fibrillation                                                                                                                                              91


700. Pang N, Gao J, Zhang N, Zhang B, Wang R. Comparison of the different anesthesia                 723. Hohnloser SH, Camm AJ, Cappato R, Diener HC, Heidbuchel H, Mont L, et al.
     strategies for atrial fibrillation catheter ablation: a systematic review and metaanalysis.          Periprocedural anticoagulation in the uninterrupted edoxaban vs. vitamin K antago­
     Cardiol Res Pract 2022;2022;1124372.                                                                 nists for ablation of atrial fibrillation (ELIMINATE-AF) trial. Europace 2021;23:65–72.
701. Weinmann K, Heudorfer R, Lenz A, Aktolga D, Rattka M, Bothner C, et al. Safety of               724. Calkins H, Willems S, Verma A, Schilling R, Hohnloser SH, Okumura K, et al. Heparin
     conscious sedation in electroanatomical mapping procedures and cryoballoon pul­                      dosing in uninterrupted anticoagulation with dabigatran vs. warfarin in atrial fibrillation
     monary vein isolation. Heart Vessels 2021;36:561–7.                                                  ablation: RE-CIRCUIT study. Europace 2019;21:879–85.
702. Wasserlauf J, Knight BP, Li Z, Andrei AC, Arora R, Chicos AB, et al. Moderate sedation          725. Payne JE, Koerber SM, Bickel T, Ghadban R, Flaker G, Gautam S. Higher initial weight-
     reduces lab time compared to general anesthesia during cryoballoon ablation for AF                   based heparin dosing is required with direct oral anticoagulants during catheter abla­
     without compromising safety or long-term efficacy. Pacing Clin Electrophysiol 2016;                  tion for atrial fibrillation. J Interv Card Electrophysiol 2020;58:185–91.
     39:1359–65.                                                                                     726. Martin AC, Kyheng M, Foissaud V, Duhamel A, Marijon E, Susen S, et al. Activated clot­
703. Tohoku S, Schmidt B, Bordignon S, Chen S, Bologna F, Chun JK. Initial clinical experi­               ting time monitoring during atrial fibrillation catheter ablation: does the anticoagulant
     ence of pulmonary vein isolation using the ultra-low temperature cryoablation cath­                  matter? J Clin Med 2020;9:350.
     eter for patients with atrial fibrillation. J Cardiovasc Electrophysiol 2022;33:1371–9.         727. Songqun H, Chunling W, Zhifu G, Xinmiao H, Jiang C. Effects of rivaroxaban on acti­
704. Schmidt B, Bordignon S, Tohoku S, Chen S, Bologna F, Urbanek L, et al. 5S study: safe                vated clotting time in catheter ablation for atrial fibrillation in Chinese patients. J Interv
                                                                                                          Card Electrophysiol 2020;59:509–16.
     and simple single shot pulmonary vein isolation with pulsed field ablation using sed­
                                                                                                     728. Safani M, Tobias S, Shandling AH, Redmond K, Lee MY. Comprehensive intraproce­
     ation. Circ Arrhythm Electrophysiol 2022;15:e010817.
                                                                                                          dural unfractionated heparin protocol during catheter ablation of atrial fibrillation in
705. Iacopino S, Colella J, Dini D, Mantovani L, Sorrenti PF, Malacrida M, et al. Sedation strat­
                                                                                                          the presence of direct oral anticoagulants and wide spectrum of body mass index.
     egies for pulsed-field ablation of atrial fibrillation: focus on deep sedation with intraven­
                                                                                                          J Cardiovasc Pharmacol Ther 2021;26:349–58.
     ous ketamine in spontaneous respiration. Europace 2023;25:euad230.
                                                                                                     729. Ghannam M, Chugh A, Dillon P, Alyesh D, Kossidas K, Sharma S, et al. Protamine to
706. Grimaldi M, Quadrini F, Caporusso N, Troisi F, Vitulano N, Delmonte V, et al. Deep
                                                                                                          expedite vascular hemostasis after catheter ablation of atrial fibrillation: a randomized
     sedation protocol during atrial fibrillation ablation using a novel variable-loop biphasic
                                                                                                          controlled trial. Heart Rhythm 2018;15:1642–7.
     pulsed field ablation catheter. Europace 2023;25:euad222.
                                                                                                     730. Pollack CV Jr, Reilly PA, van Ryn J, Eikelboom JW, Glund S, Bernstein RA, et al.
707. Kumar S, Morton JB, Halloran K, Spence SJ, Lee G, Wong MC, et al. Effect of respir­
                                                                                                          Idarucizumab for dabigatran reversal. N Engl J Med 2015;373:511–20.
     ation on catheter-tissue contact force during ablation of atrial arrhythmias. Heart             731. Siegal DM, Curnutte JT, Connolly SJ, Lu G, Conley PB, Wiens BL, et al. Andexanet alfa
     Rhythm 2012;9:1041–7.e1.                                                                             for the reversal of factor Xa inhibitor activity. N Engl J Med 2015;373:2413–24.
708. Sivasambu B, Hakim JB, Barodka V, Chrispin J, Berger RD, Ashikaga H, et al. Initiation of       732. Steffel J, Collins R, Antz M, Cornu P, Desteghe L, Haeusler KG, et al. 2021 European
     a high-frequency jet ventilation strategy for catheter ablation for atrial fibrillation:             heart rhythm association practical guide on the use of non-vitamin K antagonist oral
     safety and outcomes data. JACC Clin Electrophysiol 2018;4:1519–25.                                   anticoagulants in patients with atrial fibrillation. Europace 2021;23:1612–76.
709. Aizer A, Qiu JK, Cheng AV, Wu PB, Barbhaiya CR, Jankelson L, et al. Rapid pacing and            733. Hsu JC, Badhwar N, Gerstenfeld EP, Lee RJ, Mandyam MC, Dewland TA, et al.
     high-frequency jet ventilation additively improve catheter stability during atrial fibrilla­         Randomized trial of conventional transseptal needle versus radiofrequency energy
     tion ablation. J Cardiovasc Electrophysiol 2020;31:1678–86.                                          needle puncture for left atrial access (the TRAVERSE-LA study). J Am Heart Assoc
710. Fernandez-Bustamante A, Ibañez V, Alfaro JJ, de Miguel E, Germán MJ, Mayo A, et al.                  2013;2:e000428.
     High-frequency jet ventilation in interventional bronchoscopy: factors with predictive          734. Andrade JG, Macle L, Bennett MT, Hawkins NM, Essebag V, Champagne J, et al.
     value on high-frequency jet ventilation complications. J Clin Anesth 2006;18:349–56.                 Randomized trial of conventional versus radiofrequency needle transseptal puncture
711. Babapoor-Farrokhran S, Alzubi J, Port Z, Khraisha O, Mainigi SK. Utility of high-                    for cryoballoon ablation: the CRYO-LATS trial. J Interv Card Electrophysiol 2022;65:
     frequency jet ventilation in atrial fibrillation ablation. J Innov Card Rhythm Manag                 481–9.
     2021;12:4590–3.                                                                                 735. Tokuda M, Yamashita S, Matsuo S, Kato M, Sato H, Oseto H, et al. Radiofrequency nee­
712. Osorio J, Varley A, Kreidieh O, Godfrey B, Schrappe G, Rajendra A, et al.                            dle for transseptal puncture is associated with lower incidence of thromboembolism
     High-frequency, low-tidal-volume mechanical ventilation safely improves catheter sta­                during catheter ablation of atrial fibrillation: propensity score-matched analysis. Heart
     bility and procedural efficiency during radiofrequency ablation of atrial fibrillation. Circ         Vessels 2018;33:1238–44.
     Arrhythm Electrophysiol 2022;15:e010722.                                                        736. Chow AWC, Cobb V, Sepahpour A, McCready JW. Transseptal puncture performed
713. Gabriels J, Donnelly J, Khan M, Anca D, Beldner S, Willner J, et al. High-frequency, low             with the new needle-free ‘SafeSept’ guidewire: a multicenter experience. J Interv Card
     tidal volume ventilation to improve catheter stability during atrial fibrillation ablation.          Electrophysiol 2020;59:29–34.
     JACC Clin Electrophysiol 2019;5:1224–6.                                                         737. Maclean E, Mahtani K, Roelas M, Vyas R, Butcher C, Ahluwalia N, et al. Transseptal
714. Kadado AJ, Gobeil K, Fakhoury F, Pervaiz A, Chalhoub F. Very low tidal volume, high-                 puncture for left atrial ablation: risk factors for cardiac tamponade and a proposed
     frequency ventilation in atrial fibrillation ablation: a systematic review. J Interv Card            causative classification system. J Cardiovasc Electrophysiol 2022;33:1747–55.
     Electrophysiol 2022;64:539–43.                                                                  738. Stauber A, Kornej J, Sepehri Shamloo A, Dinov B, Bacevicius J, Dagres N, et al. Impact
715. Osorio J, Zei PC, Díaz JC, Varley AL, Morales GX, Silverstein JR, et al. High-frequency              of single versus double transseptal puncture on outcome and complications in pul­
     low-tidal-volume ventilation improves long-term outcomes in atrial fibrillation abla­                monary vein isolation procedures. Cardiol J 2021;28:671–7.
     tion: a multicenter prospective study. JACC Clin Electrophysiol 2023;9:1543–54.                 739. Deyell MW, Wen G, Laksman Z, Bennett MT, Chakrabarti S, Yeung-Lai-Wah JA, et al.
716. Hoyt H, Bhonsale A, Chilukuri K, Alhumaid F, Needleman M, Edwards D, et al.                          The impact of steerable sheaths on unblinded contact force during catheter ablation
                                                                                                          for atrial fibrillation. J Interv Card Electrophysiol 2020;57:417–24.
     Complications arising from catheter ablation of atrial fibrillation: temporal trends
                                                                                                     740. Piorkowski C, Eitel C, Rolf S, Bode K, Sommer P, Gaspar T, et al. Steerable versus non­
     and predictors. Heart Rhythm 2011;8:1869–74.
                                                                                                          steerable sheath technology in atrial fibrillation ablation: a prospective, randomized
717. Deshmukh A, Patel NJ, Pant S, Shah N, Chothani A, Mehta K, et al. In-hospital compli­
                                                                                                          study. Circ Arrhythm Electrophysiol 2011;4:157–65.
     cations associated with catheter ablation of atrial fibrillation in the United States be­
                                                                                                     741. Janosi K, Debreceni D, Janosa B, Bocz B, Simor T, Kupo P. Visualizable vs. standard,
     tween 2000 and 2010: analysis of 93 801 procedures. Circulation 2013;128:2104–12.
                                                                                                          non-visualizable steerable sheath for pulmonary vein isolation procedures: rando­
718. Iqbal AM, Li KY, Aznaurov SG, Lugo RM, Venkataraman R, Gautam S. Catheter abla­
                                                                                                          mized, single-center trial. Front Cardiovasc Med 2022;9:1033755.
     tion for atrial fibrillation can be safely performed without invasive hemodynamic mon­
                                                                                                     742. Rajendra A, Hunter TD, Morales GX, Zei P, Boo LM, Varley A, et al. Steerable sheath
     itoring: a multi-center study. J Interv Card Electrophysiol 2022;64:743–9.
                                                                                                          visualizable under 3D electroanatomical mapping facilitates paroxysmal atrial fibrilla­
719. Deneke T, Shin DI, Balta O, Bünz K, Fassbender F, Mügge A, et al. Postablation asymp­
                                                                                                          tion ablation with minimal fluoroscopy. J Interv Card Electrophysiol 2023;66:381–8.
     tomatic cerebral lesions: long-term follow-up using magnetic resonance imaging. Heart           743. Fitzpatrick N, Mittal A, Galvin J, Jauvert G, Keaney J, Keelan E, et al. The impact of steer­
     Rhythm 2011;8:1705–11.                                                                               able sheath visualization during catheter ablation for atrial fibrillation. Europace 2023.
720. Maleki K, Mohammadi R, Hart D, Cotiga D, Farhat N, Steinberg JS. Intracardiac ultra­            744. Khalaph M, Sommer P, Lucas P, Guckel D, Fink T, Sciacca V, et al. First clinical experi­
     sound detection of thrombus on transseptal sheath: incidence, treatment, and preven­                 ence using a visualized sheath for atrial fibrillation ablation. Pacing Clin Electrophysiol
     tion. J Cardiovasc Electrophysiol 2005;16:561–5.                                                     2022;45:922–9.
721. Zhang RF, Ma CM, Wang N, Yang MH, Li WW, Yin XM, et al. Appropriate intrapro­                   745. Goya M, Frame D, Gache L, Ichishima Y, Tayar DO, Goldstein L, et al. The use of in­
     cedural initial heparin dosing in patients undergoing catheter ablation for atrial fibrilla­         tracardiac echocardiography catheters in endocardial ablation of cardiac arrhythmia:
     tion receiving uninterrupted non-vitamin-K antagonist oral anticoagulant treatment.                  metaanalysis of efficiency, effectiveness, and safety outcomes. J Cardiovasc
     BMC Cardiovasc Disord 2021;21:214.                                                                   Electrophysiol 2020;31:664–73.
722. Benali K, Verain J, Hammache N, Guenancia C, Hooks D, Magnin-Poull I, et al. Running            746. Xu J, Gao Y, Liu C, Wang Y. Radiofrequency ablation for treatment of atrial fibrillation
     after activated clotting time values in patients receiving direct oral anticoagulants: a po­         with the use of intracardiac echocardiography versus without intracardiac echocardi­
     tentially dangerous race. Results from a prospective study in atrial fibrillation catheter           ography: a metaanalysis of observational and randomized studies. J Cardiovasc
     ablation procedures. J Clin Med 2021;10:4240.                                                        Electrophysiol 2022;33:897–907.
92                                                                                                                                                                                  S. Tzeis et al.


747. Pimentel RC, Rahai N, Maccioni S, Khanna R. Differences in outcomes among patients             770. Bulava A, Hanis J, Eisenberger M. Catheter ablation of atrial fibrillation using zero-
     with atrial fibrillation undergoing catheter ablation with versus without intracardiac              fluoroscopy technique: a randomized trial. Pacing Clin Electrophysiol 2015;38:797–806.
     echocardiography. J Cardiovasc Electrophysiol 2022;33:2015–47.                                 771. Lurie A, Amit G, Divakaramenon S, Acosta JG, Healey JS, Wong JA. Outcomes and
748. La Greca C, Cirasa A, Di Modica D, Sorgato A, Simoncelli U, Pecora D. Advantages of                 safety of fluoroless catheter ablation for atrial fibrillation. CJC Open 2021;3:303–10.
     the integration of ICE and 3D electroanatomical mapping and ultrasound-guided fem­             772. Sommer P, Bertagnolli L, Kircher S, Arya A, Bollmann A, Richter S, et al. Safety profile of
     oral venipuncture in catheter ablation of atrial fibrillation. J Interv Card Electrophysiol         near-zero fluoroscopy atrial fibrillation ablation with non-fluoroscopic catheter visualiza­
     2021;61:559–66.                                                                                     tion: experience from 1000 consecutive procedures. Europace 2018;20:1952–8.
749. Isath A, Padmanabhan D, Haider SW, Siroky G, Perimbeti S, Correa A, et al. Does the            773. Enriquez A, Velasco A, Diaz JC, Sadek M, Osorio J, Zei P, et al. Fluoroless catheter ab­
     use of intracardiac echocardiography during atrial fibrillation catheter ablation improve           lation of atrial fibrillation: a step-by-step workflow. J Interv Card Electrophysiol 2023;66:
     outcomes and cost? A nationwide 14-year analysis from 2001 to 2014. J Interv Card                   1291–301.
     Electrophysiol 2021;61:461–8.                                                                  774. Ahn J, Shin DG, Han S-J, Lim HE. Safety and efficacy of intracardiac echocardiography–
750. Deshpande S, Sawatari H, Ahmed R, Nair RG, Khan H, Khanji MY, et al. Impact of in­                  guided zero-fluoroscopic cryoballoon ablation for atrial fibrillation: a prospective ran­
     tracardiac echocardiography on readmission morbidity and mortality following atrial                 domized controlled trial. Europace 2023;25:euad086.
     fibrillation ablation. J Cardiovasc Electrophysiol 2022;33:2496–503.                           775. Alyesh D, Venkataraman G, Stucky A, Joyner J, Choe W, Sundaram S. Acute safety and
751. Ren JF, Chen S, Callans DJ, Jiang C, Marchlinski FE. Role of intracardiac echocardiog­              efficacy of fluoroless cryoballoon ablation for atrial fibrillation. J Innov Card Rhythm
     raphy for catheter ablation of atrial fibrillation: reduction of complications and mortal­          Manag 2021;12:4413–20.
     ity. J Am Coll Cardiol 2020;75:1244–5.                                                         776. Halbfass P, Pavlov B, Müller P, Nentwich K, Sonne K, Barth S, et al. Progression from
752. Catanzariti D, Maines M, Angheben C, Centonze M, Cemin C, Vergara G. Usefulness of                  esophageal thermal asymptomatic lesion to perforation complicating atrial fibrillation
     contrast intracardiac echocardiography in performing pulmonary vein balloon occlusion               ablation: a single-center registry. Circ Arrhythm Electrophysiol 2017;10:e005233.
     during cryo-ablation for atrial fibrillation. Indian Pacing Electrophysiol J 2012;12:237–49.   777. Ripley KL, Gage AA, Olsen DB, Van Vleet JF, Lau CP, Tse HF. Time course of esopha­
753. Makino Y, Mizutani Y, Yamashita D, Yonekawa J, Satake A, Kurobe M, et al.                           geal lesions after catheter ablation with cryothermal and radiofrequency ablation: im­
     Cryoballoon ablation for atrial fibrillation without the use of a contrast medium: a                plication for atrio-esophageal fistula formation after catheter ablation for atrial
     combination of the intracardiac echocardiography and pressure wave monitoring                       fibrillation. J Cardiovasc Electrophysiol 2007;18:642–6.
     guided approach. Heart Vessels 2022;37:765–74.                                                 778. Tschabrunn CM, Silverstein J, Berzin T, Ellis E, Buxton AE, Josephson ME, et al.
754. Suzuki A, Fujiwara R, Asada H, Iwasa K, Miyata T, Song WH, et al. Peri-balloon leak flow            Comparison between single- and multisensor esophageal temperature probes during
     velocity assessed by intracardiac echography predicts pulmonary vein electrical                     atrial fibrillation ablation: thermodynamic characteristics. Europace 2015;17:891–7.
     gap-intracardiac echography-guided contrast-free cryoballoon ablation. Circ J 2022;            779. Turagam MK, Miller S, Sharma SP, Prakash P, Gopinathannair R, Lakkireddy P, et al.
     86:256–65.                                                                                          Differences in transient thermal response of commercial esophageal temperature
755. Kanda T, Masuda M, Kurata N, Asai M, Iida O, Okamoto S, et al. A saline                             probes: insights from an experimental study. JACC Clin Electrophysiol 2019;5:1280–8.
     contrast-enhanced echocardiography-guided approach to cryoballoon ablation.                    780. Barbhaiya CR, Kogan EV, Jankelson L, Knotts RJ, Spinelli M, Bernstein S, et al.
     Pacing Clin Electrophysiol 2020;43:664–70.                                                          Esophageal temperature dynamics during high-power short-duration posterior wall
756. Motoike Y, Harada M, Ito T, Nomura Y, Nishimura A, Koshikawa M, et al. Wall                         ablation. Heart Rhythm 2020;17:721–7.
     thickness-based adjustment of ablation index improves efficacy of pulmonary vein iso­          781. Bhardwaj R, Naniwadekar A, Whang W, Mittnacht AJ, Palaniswamy C, Koruth JS, et al.
     lation in atrial fibrillation: real-time assessment by intracardiac echocardiography.               Esophageal deviation during atrial fibrillation ablation: clinical experience with a dedi­
     J Cardiovasc Electrophysiol 2021;32:1620–30.                                                        cated esophageal balloon retractor. JACC Clin Electrophysiol 2018;4:1020–30.
757. Chen J, Einstein AJ, Fazel R, Krumholz HM, Wang Y, Ross JS, et al. Cumulative exposure         782. Hamed M, Elseidy SA, Abdelazeem M, Morcos R, Abdallah A, Sammour Y, et al. Role of
     to ionizing radiation from diagnostic and therapeutic cardiac imaging procedures: a                 esophageal cooling in the prevention of esophageal injury in atrial fibrillation catheter
     population-based analysis. J Am Coll Cardiol 2010;56:702–11.                                        ablation: a systematic review and metaanalysis of randomized controlled trials.
758. Lickfett L, Mahesh M, Vasamreddy C, Bradley D, Jayam V, Eldadah Z, et al. Radiation                 Europace 2023;25:euad080.
     exposure during catheter ablation of atrial fibrillation. Circulation 2004;110:3003–10.        783. Leung LWM, Bajpai A, Zuberi Z, Li A, Norman M, Kaba RA, et al. Randomized com­
759. Ector J, Dragusin O, Adriaenssens B, Huybrechts W, Willems R, Ector H, et al. Obesity               parison of esophageal protection with a temperature control device: results of the
     is a major determinant of radiation dose in patients undergoing pulmonary vein isola­               IMPACT study. Europace 2021;23:205–15.
     tion for atrial fibrillation. J Am Coll Cardiol 2007;50:234–42.                                784. Joseph C, Nazari J, Zagrodzky J, Brumback B, Sherman J, Zagrodzky W, et al. Improved
760. Voskoboinik A, Kalman ES, Savicky Y, Sparks PB, Morton JB, Lee G, et al. Reduction in               1-year outcomes after active cooling during left atrial radiofrequency ablation. J Interv
     radiation dose for atrial fibrillation ablation over time: a 12-year single-center experi­          Card Electrophysiol 2023;66:1621–9.
     ence of 2344 patients. Heart Rhythm 2017;14:810–16.                                            785. Sanchez J, Woods C, Zagrodzky J, Nazari J, Singleton MJ, Schricker A, et al.
761. Lee G, Hunter RJ, Lovell MJ, Finlay M, Ullah W, Baker V, et al. Use of a contact force-             Atrioesophageal fistula rates before and after adoption of active esophageal cooling
     sensing ablation catheter with advanced catheter location significantly reduces fluoros­            during atrial fibrillation ablation. JACC Clin Electrophysiol 2023;9:2558–70.
     copy time and radiation dose in catheter ablation of atrial fibrillation. Europace 2016;       786. Teres C, Soto-Iglesias D, Penela D, Falasconi G, Viveros D, Meca-Santamaria J, et al.
     18:211–8.                                                                                           Relationship between the posterior atrial wall and the esophagus: esophageal position
762. Walters TE, Kistler PM, Morton JB, Sparks PB, Halloran K, Kalman JM. Impact of col­                 and temperature measurement during atrial fibrillation ablation (AWESOME-AF).
     limation on radiation exposure during interventional electrophysiology. Europace                    A randomized controlled trial. J Interv Card Electrophysiol 2022;65:651–61.
     2012;14:1670–3.                                                                                787. Zhang X, Kuang X, Gao X, Xiang H, Wei F, Liu T, et al. RESCUE-AF in patients under­
763. Schneider R, Lauschke J, Schneider C, Tischer T, Glass A, Bänsch D. Reduction of ra­                going atrial fibrillation ablation: the RESCUE-AF trial. Circ Arrhythm Electrophysiol 2019;
     diation exposure during ablation of atrial fibrillation. Herz 2015;40:883–91.                       12:e007044.
764. Heidbuchel H, Wittkampf FH, Vano E, Ernst S, Schilling R, Picano E, et al. Practical ways      788. Reddy VY, Dukkipati SR, Neuzil P, Natale A, Albenque J-P, Kautzner J, et al.
     to reduce radiation dose for patients and staff during device implantations and electro­            Randomized, controlled trial of the safety and effectiveness of a contact force-sensing
     physiological procedures. Europace 2014;16:946–64.                                                  irrigated catheter for ablation of paroxysmal atrial fibrillation: results of the TactiCath
765. Sommer P, Sciacca V, Anselmino M, Tilz R, Bourier F, Lehrmann H, et al. Practical guid­             contact force ablation catheter study for atrial fibrillation (TOCCASTAR) study.
     ance to reduce radiation exposure in electrophysiology applying ultra low-dose pro­                 Circulation 2015;132:907–15.
     tocols: a European heart rhythm association review. Europace 2023;25:euad191.                  789. Arentz T, Jander N, von Rosenthal J, Blum T, Fürmaier R, Görnandt L, et al. Incidence of
766. Zei PC, Quadros KK, Clopton P, Thosani A, Ferguson J, Brodt C, et al. Safety and efficacy           pulmonary vein stenosis 2 years after radiofrequency catheter ablation of refractory
     of minimal- versus zero-fluoroscopy radiofrequency catheter ablation for atrial fibrilla­           atrial fibrillation. Eur Heart J 2003;24:963–9.
     tion: a multicenter, prospective study. J Innov Card Rhythm Manag 2020;11:4281–91.             790. Mochizuki A, Nagahara D, Kamiyama N, Fujito T, Miura T. Revaluation of the signifi­
767. Tahin T, Riba A, Nemeth B, Arvai F, Lupkovics G, Szeplaki G, et al. Implementation of a             cance of demonstrable exit block after radiofrequency pulmonary vein isolation. Circ
     zero fluoroscopic workflow using a simplified intracardiac echocardiography guided                  Rep 2020;2:218–25.
     method for catheter ablation of atrial fibrillation, including repeat procedures. BMC          791. Duytschaever M, De Meyer G, Acena M, El-Haddad M, De Greef Y, Van Heuverswyn F,
     Cardiovasc Disord 2021;21:407.                                                                      et al. Lessons from dissociated pulmonary vein potentials: entry block implies exit
768. Lyan E, Tsyganov A, Abdrahmanov A, Morozov A, Bakytzhanuly A, Tursunbekov A,                        block. Europace 2013;15:805–12.
     et al. Nonfluoroscopic catheter ablation of paroxysmal atrial fibrillation. Pacing Clin        792. Chen S, Meng W, Sheng He D, Chen G, Zhang F, Yan Y, et al. Blocking the pulmonary
     Electrophysiol 2018;41:611–9.                                                                       vein to left atrium conduction in addition to the entrance block enhances clinical effi­
769. Falasconi G, Penela D, Soto-Iglesias D, Jauregui B, Chauca A, Antonio RS, et al. A stan­            cacy in atrial fibrillation ablation. Pacing Clin Electrophysiol 2012;35:524–31.
     dardized stepwise zero-fluoroscopy approach with transesophageal echocardiog­                  793. Wang X-h, Liu X, Sun Y-m, Gu J-n, Shi H-f, Zhou L, et al. Early identification and treat­
     raphy guidance for atrial fibrillation ablation. J Interv Card Electrophysiol 2022;64:              ment of PV re-connections: role of observation time and impact on clinical results of
     629–39.                                                                                             atrial fibrillation ablation. Europace 2007;9:481–6.
Catheter and surgical ablation of atrial fibrillation                                                                                                                                              93


794. Jiang CY, Jiang RH, Matsuo S, Liu Q, Fan YQ, Zhang ZW, et al. Early detection of pul­                results of catheter ablation, and risk factors for recurrence. J Am Coll Cardiol 2007;
     monary vein reconnection after isolation in patients with paroxysmal atrial fibrillation:            50:1781–7.
     a comparison of ATP-induction and reassessment at 30 minutes postisolation.                     816. Tzeis S, Luik A, Jilek C, Schmitt C, Estner HL, Wu J, et al. The modified anterior line: an
     J Cardiovasc Electrophysiol 2009;20:1382–7.                                                          alternative linear lesion in perimitral flutter. J Cardiovasc Electrophysiol 2010;21:665–70.
795. Cheema A, Dong J, Dalal D, Marine JE, Henrikson CA, Spragg D, et al. Incidence and              817. Pappone C, Manguso F, Vicedomini G, Gugliotta F, Santinelli O, Ferro A, et al.
     time course of early recovery of pulmonary vein conduction after catheter ablation                   Prevention of iatrogenic atrial tachycardia after ablation of atrial fibrillation: a prospect­
     of atrial fibrillation. J Cardiovasc Electrophysiol 2007;18:387–91.                                  ive randomized study comparing circumferential pulmonary vein ablation with a modi­
796. Brunelli M, Raffa S, Große A, Hanazawa K, Sammut M, Roos M, et al. Residual conduc­                  fied approach. Circulation 2004;110:3036–42.
     tion after pulmonary vein isolation with a circular multielectrode radiofrequency abla­         818. Takagi T, Derval N, Duchateau J, Chauvel R, Tixier R, Marchand H, et al. Gaps after
     tion catheter: the role of adenosine and orciprenalin during a prolonged observation                 linear ablation of persistent atrial fibrillation (Marshall-PLAN): clinical implication.
     time. Int J Cardiol 2013;168:4122–31.                                                                Heart Rhythm 2023;20:14–21.
797. Efremidis M, Letsas K, Giannopoulos G, Lioni L, Vlachos K, Asvestas D, et al. Early pul­        819. Di Biase L, Burkhardt JD, Mohanty P, Sanchez J, Mohanty S, Horton R, et al. Left atrial
     monary vein reconnection as a predictor of left atrial ablation outcomes for paroxys­                appendage: an underrecognized trigger site of atrial fibrillation. Circulation 2010;122:
     mal atrial fibrillation. Europace 2015;17:741–6.                                                     109–18.
798. Andrade JG, Deyell MW, Nattel S, Khairy P, Dubuc M, Champagne J, et al. Prevalence              820. Ikenouchi T, Nitta J, Inaba O, Kono T, Murata K, Takamiya T, et al. Effect of isolation
     and clinical impact of spontaneous and adenosine-induced pulmonary vein reconduc­                    feasibility of non-pulmonary vein foci on efficacy of ablation for atrial fibrillation: com­
     tion in the contact-force vs. cryoballoon atrial fibrillation ablation (CIRCA-DOSE)                  parison of the isolation and focal ablation methods. J Interv Card Electrophysiol 2022;65:
     study. Heart Rhythm 2020;17:897–904.                                                                 441–51.
799. Jiang R, Chen M, Yang B, Liu Q, Zhang Z, Zhang F, et al. Intraprocedural endpoints to           821. Della Rocca DG, Di Biase L, Mohanty S, Trivedi C, Gianni C, Romero J, et al. Targeting
     predict durable pulmonary vein isolation: a randomized trial of four postablation tech­              non-pulmonary vein triggers in persistent atrial fibrillation: results from a prospective,
     niques. Europace 2020;22:567–75.                                                                     multicenter, observational registry. Europace 2021;23:1939–49.
800. Sousa PA, Barra S, Adão L, Primo J, Khoueiry Z, Puga L, et al. Assessment of the need of        822. Takamiya T, Nitta J, Inaba O, Sato A, Ikenouchi T, Murata K, et al. One-year outcomes
     a waiting period after pulmonary vein isolation with the ablation index software.                    after pulmonary vein isolation plus posterior wall isolation and additional non-
     J Cardiovasc Electrophysiol 2022;33:1725–33.                                                         pulmonary vein trigger ablation for persistent atrial fibrillation with or without contact
801. Miller MA, d’Avila A, Dukkipati SR, Koruth JS, Viles-Gonzalez J, Napolitano C, et al.                force sensing: a propensity score-matched comparison. J Interv Card Electrophysiol
     Acute electrical isolation is a necessary but insufficient endpoint for achieving durable            2020;59:585–93.
     PV isolation: the importance of closing the visual gap. Europace 2012;14:653–60.                823. Zhao Y, Di Biase L, Trivedi C, Mohanty S, Bai R, Mohanty P, et al. Importance of non-
802. Macle L, Khairy P, Weerasooriya R, Novak P, Verma A, Willems S, et al.                               pulmonary vein triggers ablation to achieve long-term freedom from paroxysmal atrial
     Adenosine-guided pulmonary vein isolation for the treatment of paroxysmal atrial fib­                fibrillation in patients with low ejection fraction. Heart Rhythm 2016;13:141–9.
                                                                                                     824. Nakashima T, Pambrun T, Vlachos K, Goujeau C, André C, Krisai P, et al. Impact of vein
     rillation: an international, multicenter, randomised superiority trial. Lancet 2015;386:
                                                                                                          of Marshall ethanol infusion on mitral isthmus block: efficacy and durability. Circ
     672–9.
                                                                                                          Arrhythm Electrophysiol 2020;13:e008884.
803. Kapa S, Killu A, Deshmukh A, Mulpuru SK, Asirvatham SJ. Dose-dependent pulmonary
                                                                                                     825. Valderrábano M, Liu X, Sasaridis C, Sidhu J, Little S, Khoury DS. Ethanol infusion in the
     vein reconnection in response to adenosine: relevance of atrioventricular block during
                                                                                                          vein of Marshall: adjunctive effects during ablation of atrial fibrillation. Heart Rhythm
     infusion. J Interv Card Electrophysiol 2016;47:117–23.
                                                                                                          2009;6:1552–8.
804. Teunissen C, Clappers N, Kassenberg W, Hassink RJ, van der Heijden JF, Loh P. Time
                                                                                                     826. Gillis K, O’Neill L, Wielandts JY, Hilfiker G, Almorad A, Lycke M, et al. Vein of Marshall
     matters: adenosine testing immediately after pulmonary vein isolation does not substi­
                                                                                                          ethanol infusion as first step for mitral isthmus linear ablation. JACC Clin Electrophysiol
     tute a waiting period. Europace 2017;19:1140–5.
                                                                                                          2022;8:367–76.
805. McLellan AJA, Kumar S, Smith C, Ling LH, Prabhu S, Kalman JM, et al. The role of ad­
                                                                                                     827. Yang G, Zheng L, Jiang C, Fan J, Liu X, Zhan X, et al. Circumferential pulmonary vein
     enosine challenge in catheter ablation for atrial fibrillation: a systematic review and
                                                                                                          isolation plus low-voltage area modification in persistent atrial fibrillation: the
     metaanalysis. Int J Cardiol 2017;236:253–61.
                                                                                                          STABLE-SR-II trial. JACC Clin Electrophysiol 2022;8:882–91.
806. Kobori A, Shizuta S, Inoue K, Kaitani K, Morimoto T, Nakazawa Y, et al. Adenosine
                                                                                                     828. Huo Y, Gaspar T, Schönbauer R, Wójcik M, Fiedler L, Roithinger Franz X, et al.
     triphosphate-guided pulmonary vein isolation for atrial fibrillation: the unmasking dor­
                                                                                                          Low-voltage myocardium-guided ablation trial of persistent atrial fibrillation. NEJM
     mant electrical reconduction by adenosine triphosphate (UNDER-ATP) trial. Eur
                                                                                                          Evidence 2022;1:EVIDoa2200141.
     Heart J 2015;36:3276–87.
                                                                                                     829. Kottkamp H, Berg J, Bender R, Rieger A, Schreiber D. Box isolation of fibrotic areas
807. Zeng LJ, Shi L, Tian Y, Wang YJ, Yin XD, Liu XQ, et al. Pace capture and adenosine
                                                                                                          (BIFA): a patient-tailored substrate modification approach for ablation of atrial fibrilla­
     triphosphate provocation are complementary rather than mutually exclusive methods                    tion. J Cardiovasc Electrophysiol 2016;27:22–30.
     to ensure durable pulmonary vein isolation. J Cardiovasc Electrophysiol 2019;30:815–23.         830. Valderrábano M, Peterson LE, Swarup V, Schurmann PA, Makkar A, Doshi RN, et al.
808. Moser J, Sultan A, Luker J, Servatius H, Salzbrunn T, Altenburg M, et al. 5-Year outcome             Effect of catheter ablation with vein of Marshall ethanol infusion vs catheter ablation
     of pulmonary vein isolation by loss of pace capture on the ablation line versus electrical           alone on persistent atrial fibrillation: the VENUS randomized clinical trial. JAMA
     circumferential pulmonary vein isolation. JACC Clin Electrophysiol 2017;3:1262–71.                   2020;324:1620–8.
809. Masuda M, Fujita M, Iida O, Okamoto S, Ishihara T, Nanto K, et al. Pace-capture-guided          831. Huang L, Gao M, Lai Y, Guo Q, Li S, Li C, et al. The adjunctive effect for left pulmonary
     ablation after contact-force-guided pulmonary vein isolation: results of the rando­                  vein isolation of vein of Marshall ethanol infusion in persistent atrial fibrillation.
     mized controlled DRAGON trial. Europace 2018;20:1451–8.                                              Europace 2023;25:441–9.
810. Steven D, Sultan A, Reddy V, Luker J, Altenburg M, Hoffmann B, et al. Benefit of pul­           832. Nakashima T, Pambrun T, Vlachos K, Goujeau C, André C, Krisai P, et al. Strategy
     monary vein isolation guided by loss of pace capture on the ablation line: results from a            for repeat procedures in patients with persistent atrial fibrillation: systematic linear
     prospective 2-center randomized trial. J Am Coll Cardiol 2013;62:44–50.                              ablation with adjunctive ethanol infusion into the vein of Marshall versus
811. Sawhney N, Anousheh R, Chen W, Feld GK. Circumferential pulmonary vein ablation                      electrophysiology-guided ablation. J Cardiovasc Electrophysiol 2022;33:1116–24.
     with additional linear ablation results in an increased incidence of left atrial flutter com­   833. Lador A, Peterson LE, Swarup V, Schurmann PA, Makkar A, Doshi RN, et al.
     pared with segmental pulmonary vein isolation as an initial approach to ablation of par­             Determinants of outcome impact of vein of Marshall ethanol infusion when added
     oxysmal atrial fibrillation. Circ Arrhythm Electrophysiol 2010;3:243–8.                              to catheter ablation of persistent atrial fibrillation: a secondary analysis of the
812. Ouyang F, Ernst S, Vogtmann T, Goya M, Volkmer M, Schaumann A, et al.                                VENUS randomized clinical trial. Heart Rhythm 2021;18:1045–54.
     Characterization of reentrant circuits in left atrial macroreentrant tachycardia: critical      834. Derval N, Duchateau J, Denis A, Ramirez FD, Mahida S, André C, et al. Marshall bundle
     isthmus block can prevent atrial tachycardia recurrence. Circulation 2002;105:                       elimination, pulmonary vein isolation, and line completion for ANATOmical ablation
     1934–42.                                                                                             of persistent atrial fibrillation (Marshall-PLAN): prospective, single-center study.
813. Mujović N, Marinković M, Marković N, Stanković G, Lip GYH, Blomstrom-Lundqvist C,                    Heart Rhythm 2021;18:529–37.
     et al. Persistency of left atrial linear lesions after radiofrequency catheter ablation for     835. Dixit S, Marchlinski FE, Lin D, Callans DJ, Bala R, Riley MP, et al. Randomized ablation
     atrial fibrillation: data from an invasive follow-up electrophysiology study. J Cardiovasc           strategies for the treatment of persistent atrial fibrillation: RASTA study. Circ Arrhythm
     Electrophysiol 2017;28:1403–14.                                                                      Electrophysiol 2012;5:287–94.
814. Sanchez-Somonte P, Jiang CY, Betts TR, Chen J, Mantovan R, Macle L, et al.                      836. Bai R, Di Biase L, Mohanty P, Trivedi C, Dello Russo A, Themistoclakis S, et al. Proven
     Completeness of linear or fractionated electrogram ablation in addition to pulmonary                 isolation of the pulmonary vein antrum with or without left atrial posterior wall isola­
     vein isolation on ablation outcome: a substudy of the STAR AF II trial. Circ Arrhythm                tion in patients with persistent atrial fibrillation. Heart Rhythm 2016;13:132–40.
     Electrophysiol 2021;14:e010146.                                                                 837. Lee JM, Shim J, Park J, Yu HT, Kim TH, Park JK, et al. The electrical isolation of the left
815. Chae S, Oral H, Good E, Dey S, Wimmer A, Crawford T, et al. Atrial tachycardia after                 atrial posterior wall in catheter ablation of persistent atrial fibrillation. JACC Clin
     circumferential pulmonary vein ablation of atrial fibrillation: mechanistic insights,                Electrophysiol 2019;5:1253–61.
94                                                                                                                                                                                    S. Tzeis et al.


838. Kistler PM, Chieng D, Sugumar H, Ling LH, Segan L, Azzopardi S, et al. Effect of cath­            860. Ejima K, Kato K, Okada A, Wakisaka O, Kimura R, Ishizawa M, et al. Comparison be­
     eter ablation using pulmonary vein isolation with vs without posterior left atrial wall                tween contact force monitoring and unipolar signal modification as a guide for cath­
     isolation on atrial arrhythmia recurrence in patients with persistent atrial fibrillation:             eter ablation of atrial fibrillation: prospective multi-center randomized study. Circ
     the CAPLA randomized clinical trial. JAMA 2023;329:127–35.                                             Arrhythm Electrophysiol 2019;12:e007311.
839. Jiang X, Liao J, Ling Z, Meyer C, Sommer P, Futyma P, et al. Adjunctive left atrial pos­          861. Fu G, He B, Wang B, Feng M, Du X, Liu J, et al. Unipolar electrogram-guided versus
     terior wall isolation in treating atrial fibrillation: insight from a large secondary analysis.        lesion size index-guided catheter ablation in patients with paroxysmal atrial fibrillation.
     JACC Clin Electrophysiol 2022;8:605–18.                                                                J Cardiovasc Dev Dis 2022;9:229.
840. Sirico G, Sirico D, Montisci A, Cerrato E, Morosato M, Panigada S, et al. Contact-Force           862. Coeman M, Haddad ME, Wol M, Choudhury R, Vandekerckhove Y, Choudhury R,
     guided posterior wall isolation as an adjunctive ablation strategy for persistent atrial               et al. ‘CLOSE’-guided pulmonary vein isolation and changes in local bipolar and uni­
     fibrillation. J Atr Fibrillation 2021;14:20200475.                                                     polar atrial electrograms: observations from the EP lab. J Atr Fibrillation 2018;10:1794.
841. Tokioka S, Fukamizu S, Kimura T, Takahashi M, Kitamura T, Hojo R. The effect of pos­              863. Tomlinson DR, Myles M, Stevens KN, Streeter AJ. Transmural unipolar electrogram
     terior wall isolation for persistent atrial fibrillation on recurrent arrhythmia.                      change occurs within 7 s at the left atrial posterior wall during pulmonary vein isolation.
     J Cardiovasc Electrophysiol 2021;32:597–604.                                                           Pacing Clin Electrophysiol 2019;42:922–9.
842. Pothineni NVK, Lin A, Frankel DS, Supple GE, Garcia FC, Lin D, et al. Impact of left              864. Zheng X, Walcott GP, Hall JA, Rollins DL, Smith WM, Kay GN, et al. Electrode imped­
     atrial posterior wall isolation on arrhythmia outcomes in patients with atrial fibrillation            ance: an indicator of electrode-tissue contact and lesion dimensions during linear ab­
     undergoing repeat ablation. Heart Rhythm O2 2021;2:489–97.                                             lation. J Interv Card Electrophysiol 2000;4:645–54.
843. Salih M, Darrat Y, Ibrahim AM, Al-Akchar M, Bhattarai M, Koester C, et al. Clinical out­          865. Chinitz JS, Kapur S, Barbhaiya C, Kumar S, John R, Epstein LM, et al. Sites with small
     comes of adjunctive posterior wall isolation in persistent atrial fibrillation: a                      impedance decrease during catheter ablation for atrial fibrillation are associated
     metaanalysis. J Cardiovasc Electrophysiol 2020;31:1394–402.                                            with recovery of pulmonary vein conduction. J Cardiovasc Electrophysiol 2016;27:
844. Sutter JS, Lokhnygina Y, Daubert JP, Bahnson T, Jackson K, Koontz JI, et al. Safety and                1390–8.
     efficacy outcomes of left atrial posterior wall isolation compared to pulmonary vein              866. Reichlin T, Knecht S, Lane C, Kuhne M, Nof E, Chopra N, et al. Initial impedance de­
     isolation and pulmonary vein isolation with linear ablation for the treatment of persist­              crease as an indicator of good catheter contact: insights from radiofrequency ablation
     ent atrial fibrillation. Am Heart J 2020;220:89–96.                                                    with force sensing catheters. Heart Rhythm 2014;11:194–201.
845. Yamaji H, Higashiya S, Murakami T, Hina K, Kawamura H, Murakami M, et al. Efficacy of             867. Wakili R, Clauss S, Schmidt V, Ulbrich M, Hahnefeld A, Schüssler F, et al. Impact of real-
     an adjunctive electrophysiological test-guided left atrial posterior wall isolation in per­            time contact force and impedance measurement in pulmonary vein isolation proce­
     sistent atrial fibrillation without a left atrial low-voltage area. Circ Arrhythm                      dures for treatment of atrial fibrillation. Clin Res Cardiol 2014;103:97–106.
     Electrophysiol 2020;13:e008191.                                                                   868. Park HS, Kim IC, Cho YK, Yoon HJ, Kim H, Nam CW, et al. Comparison of the efficacy
846. McLellan AJA, Prabhu S, Voskoboinik A, Wong MCG, Walters TE, Pathik B, et al.                          between impedance-guided and contact force-guided atrial fibrillation ablation using
     Isolation of the posterior left atrium for patients with persistent atrial fibrillation: rou­          an automated annotation system. J Arrhythm 2018;34:239–46.
                                                                                                       869. Knecht S, Reichlin T, Pavlovic N, Schaer B, Osswald S, Sticherling C, et al. Contact force
     tine adenosine challenge for dormant posterior left atrial conduction improves long-
                                                                                                            and impedance decrease during ablation depends on catheter location and orientation:
     term outcome. Europace 2017;19:1958–66.
                                                                                                            insights from pulmonary vein isolation using a contact force-sensing catheter. J Interv
847. Kim JS, Shin SY, Na JO, Choi CU, Kim SH, Kim JW, et al. Does isolation of the left atrial
                                                                                                            Card Electrophysiol 2015;43:297–306.
     posterior wall improve clinical outcomes after radiofrequency catheter ablation for
                                                                                                       870. Yasumoto K, Egami Y, Kawanami S, Sugae H, Ukita K, Kawamura A, et al. The correl­
     persistent atrial fibrillation?: a prospective randomized clinical trial. Int J Cardiol 2015;
                                                                                                            ation between local impedance drop and catheter contact in clinical pulmonary vein
     181:277–83.
                                                                                                            isolation use. Pacing Clin Electrophysiol 2022;45:984–92.
848. Bisbal F, Benito E, Teis A, Alarcón F, Sarrias A, Caixal G, et al. Magnetic resonance
                                                                                                       871. Segreti L, De Simone A, Schillaci V, Bongiorni MG, Pelargonio G, Pandozi C, et al. A
     imaging-guided fibrosis ablation for the treatment of atrial fibrillation: the ALICIA trial.
                                                                                                            novel local impedance algorithm to guide effective pulmonary vein isolation in atrial
     Circ Arrhythm Electrophysiol 2020;13:e008707.
                                                                                                            fibrillation patients: preliminary experience across different ablation sites from the
849. Marrouche NF, Wazni O, McGann C, Greene T, Dean JM, Dagher L, et al. Effect of
                                                                                                            CHARISMA pilot study. J Cardiovasc Electrophysiol 2020;31:2319–27.
     MRI-guided fibrosis ablation vs conventional catheter ablation on atrial arrhythmia re­
                                                                                                       872. Hashimoto K, Tsuzuki I, Seki Y, Ibe S, Yamashita T, Miyama H, et al. Change in the local
     currence in patients with persistent atrial fibrillation: the DECAAF II randomized clin­
                                                                                                            impedance and electrograms recorded by a micro-electrode tip catheter during initial
     ical trial. JAMA 2022;327:2296–305.
                                                                                                            atrial fibrillation ablation. Journal of Arrhythmia 2021;37:566–73.
850. Ip JE, Markowitz SM, Cheung JW, Liu CF, Thomas G, Lessner SJ, et al. Method for dif­
                                                                                                       873. Solimene F, Giannotti Santoro M, De Simone A, Malacrida M, Stabile G, Pandozi C,
     ferentiating left superior pulmonary vein exit conduction from pseudo-exit conduc­
                                                                                                            et al. Pulmonary vein isolation in atrial fibrillation patients guided by a novel local im­
     tion. Pacing Clin Electrophysiol 2013;36:299–308.
                                                                                                            pedance algorithm: 1-year outcome from the CHARISMA study. J Cardiovasc
851. Vijayaraman P, Dandamudi G, Naperkowski A, Oren J, Storm R, Ellenbogen KA.
                                                                                                            Electrophysiol 2021;32:1540–8.
     Assessment of exit block following pulmonary vein isolation: far-field capture mas­               874. Yokoyama K, Nakagawa H, Shah DC, Lambert H, Leo G, Aeby N, et al. Novel contact
     querading as entrance without exit block. Heart Rhythm 2012;9:1653–9.                                  force sensor incorporated in irrigated radiofrequency ablation catheter predicts lesion
852. Squara F, Liuba I, Chik W, Santangeli P, Zado ES, Callans DJ, et al. Loss of local capture             size and incidence of steam pop and thrombus. Circ Arrhythm Electrophysiol 2008;1:
     of the pulmonary vein myocardium after antral isolation: prevalence and clinical signifi­              354–62.
     cance. J Cardiovasc Electrophysiol 2015;26:242–50.                                                875. Kumar S, Morton JB, Lee J, Halloran K, Spence SJ, Gorelik A, et al. Prospective charac­
853. Gerstenfeld EP, Dixit S, Callans D, Rho R, Rajawat Y, Zado E, et al. Utility of exit block             terization of catheter-tissue contact force at different anatomic sites during antral pul­
     for identifying electrical isolation of the pulmonary veins. J Cardiovasc Electrophysiol               monary vein isolation. Circ Arrhythm Electrophysiol 2012;5:1124–9.
     2002;13:971–9.                                                                                    876. Reddy VY, Shah D, Kautzner J, Schmidt B, Saoudi N, Herrera C, et al. The relationship
854. Tada H, Oral H, Wasmer K, Greenstein R, Pelosi F, Knight BP, et al. Pulmonary vein                     between contact force and clinical outcome during radiofrequency catheter ablation
     isolation: comparison of bipolar and unipolar electrograms at successful and unsuc­                    of atrial fibrillation in the TOCCATA study. Heart Rhythm 2012;9:1789–95.
     cessful ostial ablation sites. J Cardiovasc Electrophysiol 2002;13:13–19.                         877. Neuzil P, Reddy VY, Kautzner J, Petru J, Wichterle D, Shah D, et al. Electrical recon­
855. Tada H, Oral H, Knight BP, Ozaydin M, Chugh A, Scharf C, et al. Randomized compari­                    nection after pulmonary vein isolation is contingent on contact force during initial
     son of bipolar versus unipolar plus bipolar recordings during segmental ostial ablation                treatment: results from the EFFICAS I study. Circ Arrhythm Electrophysiol 2013;6:
     of pulmonary veins. J Cardiovasc Electrophysiol 2002;13:851–6.                                         327–33.
856. Michowitz Y, Buch E, Bourke T, Tung R, Bradfield J, Mathuria N, et al. Unipolar and               878. Kautzner J, Neuzil P, Lambert H, Peichl P, Petru J, Cihak R, et al. EFFICAS II: optimiza­
     bipolar electrogram characteristics predict exit block during pulmonary vein antral iso­               tion of catheter contact force improves outcome of pulmonary vein isolation for par­
     lation. Pacing Clin Electrophysiol 2012;35:1294–301.                                                   oxysmal atrial fibrillation. Europace 2015;17:1229–35.
857. Bortone A, Appetiti A, Bouzeman A, Maupas E, Ciobotaru V, Boulenc JM, et al.                      879. Shah DC, Lambert H, Nakagawa H, Langenkamp A, Aeby N, Leo G. Area under the
     Unipolar signal modification as a guide for lesion creation during radiofrequency appli­               real-time contact force curve (force-time integral) predicts radiofrequency lesion
     cation in the left atrium: prospective study in humans in the setting of paroxysmal atrial             size in an in vitro contractile model. J Cardiovasc Electrophysiol 2010;21:1038–43.
     fibrillation catheter ablation. Circ Arrhythm Electrophysiol 2013;6:1095–102.                     880. Kuck K-H, Reddy VY, Schmidt B, Natale A, Neuzil P, Saoudi N, et al. A novel radiofre­
858. Bortone A, Brault-Noble G, Appetiti A, Marijon E. Elimination of the negative compo­                   quency ablation catheter using contact force sensing: Toccata study. Heart Rhythm
     nent of the unipolar atrial electrogram as an in vivo marker of transmural lesion cre­                 2012;9:18–23.
     ation: acute study in canines. Circ Arrhythm Electrophysiol 2015;8:905–11.                        881. Kumar S, Morton JB, Halloran K, Spence SJ, Lee G, Wong MCG, et al. Effect of respir­
859. Bortone A, Lagrange P, Cauchemez B, Durand C, Dieuzaide P, Prévot S, et al.                            ation on catheter-tissue contact force during ablation of atrial arrhythmias. Heart
     Elimination of the negative component of the unipolar electrogram as a local proced­                   Rhythm 2012;9:1041–47.e1.
     ural endpoint during paroxysmal atrial fibrillation catheter ablation using contact-force         882. El Haddad E, Taghji P, Phlips T, Wolf M, Demolder A, Choudhury R, et al.
     sensing: the UNIFORCE study. J Interv Card Electrophysiol 2017;49:299–306.                             Determinants of acute and late pulmonary vein reconnection in contact force-guided
Catheter and surgical ablation of atrial fibrillation                                                                                                                                              95


     pulmonary vein isolation: identifying the weakest link in the ablation chain. Circ             904. Barbhaiya CR, Aizer A, Knotts R, Bernstein S, Park D, Holmes D, et al. Simultaneous
     Arrhythm Electrophysiol 2017;10:e004867.                                                            pace-ablate during CARTO-guided pulmonary vein isolation with a contact-force
883. Nakagawa H, Ikeda A, Govari A, Papaioannou T, Constantine G, Bar-Tal M, et al.                      sensing radiofrequency ablation catheter. J Interv Card Electrophysiol 2019;54:119–24.
     Abstract 12104: prospective study using a new formula incorporating contact force,             905. Kogawa R, Okumura Y, Watanabe I, Sonoda K, Sasaki N, Takahashi K, et al. Difference
     radiofrequency power and application time (force-power-time index) for quantifying                  between dormant conduction sites revealed by adenosine triphosphate provocation
     lesion formation to guide long continuous atrial lesions in the beating canine heart.               and unipolar pace-capture sites along the ablation line after pulmonary vein isolation.
     Circulation 2013;128:A12104–A12104.                                                                 Int Heart J 2016;57:25–9.
884. Ullah W, Hunter RJ, Finlay MC, McLean A, Dhinoja MB, Sporton S, et al. Ablation index          906. Okumura Y, Watanabe I, Nagashima K, Sonoda K, Mano H, Sasaki N, et al. The effects
     and surround flow catheter irrigation: impedance-based appraisal in clinical ablation.              of standard electrical PV isolation vs. “pace and ablate” on ATP-provoked PV recon­
     JACC Clin Electrophysiol 2017;3:1080–8.                                                             nections. J Interv Card Electrophysiol 2014;40:39–45.
885. Teres C, Soto-Iglesias D, Penela D, Jáuregui B, Ordoñez A, Chauca A, et al.                    907. Kumar S, Kalman JM, Sutherland F, Spence SJ, Finch S, Sparks PB. Atrial fibrillation in­
     Personalized paroxysmal atrial fibrillation ablation by tailoring ablation index to the             ducibility in the absence of structural heart disease or clinical atrial fibrillation: critical
     left atrial wall thickness: the ‘ablate by-LAW’ single-center study-a pilot study.                  dependence on induction protocol, inducibility definition, and number of inductions.
     Europace 2022;24:390–9.                                                                             Circ Arrhythm Electrophysiol 2012;5:531–6.
886. Kyriakopoulou M, Strisciuglio T, El Haddad M, De Pooter J, Almorad A, Van Beeumen              908. Darma A, Daneschnejad SS, Gaspar T, Huo Y, Wetzel U, Dagres N, et al. Role of in­
     K, et al. Evaluation of a simple technique aiming at optimizing point-by-point isolation            ducibility and its dynamic change in the outcome of catheter ablation of atrial fibrilla­
     of the left pulmonary veins: a randomized study. Europace 2019;21:1185–92.                          tion: a single center prospective study. J Cardiovasc Electrophysiol 2020;31:705–11.
887. Berte B, Hilfiker G, Moccetti F, Schefer T, Weberndörfer V, Cuculi F, et al. Pulmonary         909. Santangeli P, Zado ES, Garcia FC, Riley MP, Lin D, Frankel DS, et al. Lack of prognostic
     vein isolation using ablation index vs. CLOSE protocol with a surround flow ablation                value of atrial arrhythmia inducibility and change in inducibility status after catheter ab­
     catheter. Europace 2020;22:84–9.                                                                    lation of atrial fibrillation. Heart Rhythm 2018;15:660–5.
888. Hoffmann P, Diaz Ramirez I, Baldenhofer G, Stangl K, Mont L, Althoff TF. Randomized            910. Leong-Sit P, Robinson M, Zado ES, Callans DJ, Garcia F, Lin D, et al. Inducibility of atrial
     study defining the optimum target interlesion distance in ablation index-guided atrial              fibrillation and flutter following pulmonary vein ablation. J Cardiovasc Electrophysiol
     fibrillation ablation. Europace 2020;22:1480–6.                                                     2013;24:617–23.
889. Kobayashi S, Fukaya H, Oikawa J, Saito D, Sato T, Matsuura G, et al. Optimal interlesion       911. Millenaar D, Becker N, Pavlicek V, Wintrich J, Böhm M, Mahfoud F, et al. Inducibility of
     distance in ablation index-guided pulmonary vein isolation for atrial fibrillation. J Interv        atrial fibrillation after catheter ablation predicts recurrences of atrial fibrillation: a
     Card Electrophysiol 2021;62:123–31.                                                                 metaanalysis. Pacing Clin Electrophysiol 2021;44:667–76.
890. Francke A, Taha NS, Scharfe F, Schoen S, Wunderlich C, Christoph M. Procedural ef­             912. Neumann T, Vogt J, Schumacher B, Dorszewski A, Kuniss M, Neuser H, et al.
     ficacy and safety of standardized, ablation index guided fixed 50 W high-power short-               Circumferential pulmonary vein isolation with the cryoballoon technique results
     duration pulmonary vein isolation and substrate modification using the CLOSE proto­                 from a prospective 3-center study. J Am Coll Cardiol 2008;52:273–8.
                                                                                                    913. Alyesh D, Frederick J, Choe W, Sundaram S. Step by step: how to perform a fluoroless
     col. J Cardiovasc Electrophysiol 2021;32:2408–17.
                                                                                                         cryoballoon ablation for atrial fibrillation. J Cardiovasc Electrophysiol 2022;33:2351–5.
891. Francke A, Scharfe F, Schoen S, Wunderlich C, Christoph M. Reconnection patterns
                                                                                                    914. Siklódy CH, Minners J, Allgeier M, Allgeier HJ, Jander N, Keyl C, et al. Pressure-guided
     after CLOSE-guided 50 W high-power-short-duration circumferential pulmonary
                                                                                                         cryoballoon isolation of the pulmonary veins for the treatment of paroxysmal atrial
     vein isolation and substrate modification-PV reconnection might no longer be an issue.
                                                                                                         fibrillation. J Cardiovasc Electrophysiol 2010;21:120–5.
     J Cardiovasc Electrophysiol 2022;33:1136–45.
                                                                                                    915. Rottner L, Sinning C, Reissmann B, Schleberger R, Dinshaw L, Münkler P, et al.
892. Chen S, Schmidt B, Bordignon S, Tohoku S, Urban VC, Schulte-Hahn B, et al. Catheter
                                                                                                         Wide-band dielectric imaging and the novel cryoballoon-occlusion tool to guide
     ablation of atrial fibrillation using ablation index-guided high-power technique:
                                                                                                         cryoballoon-based pulmonary vein isolation. Circ Arrhythm Electrophysiol 2020;13:
     Frankfurt AI high-power 15-month follow-up. J Cardiovasc Electrophysiol 2021;32:
                                                                                                         e008507.
     616–24.
                                                                                                    916. Takami M, Lehmann HI, Misiri J, Parker KD, Sarmiento RI, Johnson SB, et al. Impact of
893. Jiang C-Y, Jiang R-H, Matsuo S, Liu Q, Fan Y-Q, Zhang Z-W, et al. Early detection of
                                                                                                         freezing time and balloon size on the thermodynamics and isolation efficacy during pul­
     pulmonary vein reconnection after isolation in patients with paroxysmal atrial fibrilla­
                                                                                                         monary vein isolation using the second generation cryoballoon. Circ Arrhythm
     tion: a comparison of ATP-induction and reassessment at 30 minutes postisolation.
                                                                                                         Electrophysiol 2015;8:836–45.
     J Cardiovasc Electrophysiol 2009;20:1382–7.
                                                                                                    917. Andrade JG, Dubuc M, Guerra PG, Landry E, Coulombe N, Leduc H, et al. Pulmonary
894. Cheema A, Dong J, Dalal D, Marine JE, Henrikson CA, Spragg D, et al. Incidence and
                                                                                                         vein isolation using a second-generation cryoballoon catheter: a randomized comparison
     time course of early recovery of pulmonary vein conduction after catheter ablation
                                                                                                         of ablation duration and method of deflation. J Cardiovasc Electrophysiol 2013;24:692–8.
     of atrial fibrillation. J Cardiovasc Electrophysiol 2007;18:387–91.                            918. Cheung CC, Deyell MW, Macle L, Verma A, Champagne J, Leong-Sit P, et al. Repeat
895. Brunelli M, Raffa S, Große A, Hanazawa K, Sammut M, Roos M, et al. Residual conduc­                 atrial fibrillation ablation procedures in the CIRCA-DOSE study. Circ Arrhythm
     tion after pulmonary vein isolation with a circular multielectrode radiofrequency abla­             Electrophysiol 2020;13:e008480.
     tion catheter: the role of adenosine and orciprenalin during a prolonged observation           919. Chun KR, Stich M, Fürnkranz A, Bordignon S, Perrotta L, Dugo D, et al. Individualized
     time. Int J Cardiol 2013;168:4122–31.                                                               cryoballoon energy pulmonary vein isolation guided by real-time pulmonary vein re­
896. Dallaglio PD, Betts TR, Ginks M, Bashir Y, Anguera I, Rajappan K. The role of adenosine             cordings, the randomized ICE-T trial. Heart Rhythm 2017;14:495–500.
     in pulmonary vein isolation: a critical review. Cardiol Res Pract 2016;2016:8632509.           920. Wissner E, Heeger CH, Grahn H, Reissmann B, Wohlmuth P, Lemes C, et al. One-year
897. le Polain de Waroux J-B, Weerasooriya R, Anvardeen K, Barbraud C, Marchandise S,                    clinical success of a ‘no-bonus’ freeze protocol using the second-generation 28 mm
     De Meester C, et al. Low contact force and force-time integral predict early recovery               cryoballoon for pulmonary vein isolation. Europace 2015;17:1236–40.
     and dormant conduction revealed by adenosine after pulmonary vein isolation.                   921. Farkowski MM, Karlinski M, Barra S, Providencia R, Golicki D, Pytkowski M, et al.
     Europace 2015;17:877–83.                                                                            Effectiveness and safety of a single freeze strategy of cryoballoon ablation of atrial fib­
898. Datino T, Macle L, Qi XY, Maguy A, Comtois P, Chartier D, et al. Mechanisms by which                rillation: an EHRA systematic review and metaanalysis. Europace 2022;24:58–69.
     adenosine restores conduction in dormant canine pulmonary veins. Circulation 2010;             922. Bordignon S, Chen S, Bologna F, Thohoku S, Urbanek L, Willems F, et al. Optimizing
     121:963–72.                                                                                         cryoballoon pulmonary vein isolation: lessons from >1000 procedures- the Frankfurt
899. Tokuda M, Matsuo S, Isogai R, Uno G, Tokutake K, Yokoyama K, et al. Adenosine test­                 approach. Europace 2021;23:868–77.
     ing during cryoballoon ablation and radiofrequency ablation of atrial fibrillation: a pro­     923. Chen S, Schmidt B, Bordignon S, Perrotta L, Bologna F, Chun KRJ. Impact of cryobal­
     pensity score-matched analysis. Heart Rhythm 2016;13:2128–34.                                       loon freeze duration on long-term durability of pulmonary vein isolation: ICE re-map
900. Ghanbari H, Jani R, Hussain-Amin A, Al-Assad W, Huether E, Ansari S, et al. Role of                 study. JACC Clin Electrophysiol 2019;5:551–9.
     adenosine after antral pulmonary vein isolation of paroxysmal atrial fibrillation: a ran­      924. Heeger CH, Popescu SS, Saraei R, Kirstein B, Hatahet S, Samara O, et al. Individualized
     domized controlled trial. Heart Rhythm 2016;13:407–15.                                              or fixed approach to pulmonary vein isolation utilizing the fourth-generation cryobal­
901. Prabhu S, Mackin V, McLellan AJ, Phan T, McGlade D, Ling LH, et al. Determining the                 loon in patients with paroxysmal atrial fibrillation: the randomized INDI-FREEZE trial.
     optimal dose of adenosine for unmasking dormant pulmonary vein conduction follow­                   Europace 2022;24:921–7.
     ing atrial fibrillation ablation: electrophysiological and hemodynamic assessment.             925. Ferrero-de-Loma-Osorio Á, García-Fernández A, Castillo-Castillo J, Izquierdo-de-
     DORMANT-AF study. J Cardiovasc Electrophysiol 2017;28:13–22.                                        Francisco M, Ibáñez-Críado A, Moreno-Arribas J, et al. Time-to-effect-based dosing
902. Osorio J, Hunter TD, Rajendra A, Zei P, Silverstein J, Morales G. Predictors of clinical            strategy for cryoballoon ablation in patients with paroxysmal atrial fibrillation: results
     success after paroxysmal atrial fibrillation catheter ablation. J Cardiovasc Electrophysiol         of the plusONE multicenter randomized controlled noninferiority trial. Circ Arrhythm
     2021;32:1814–21.                                                                                    Electrophysiol 2017;10:e005318.
903. Ninomiya Y, Inoue K, Tanaka N, Okada M, Tanaka K, Onishi T, et al. Absence of first-           926. Ciconte G, Mugnai G, Sieira J, Velagić V, Saitoh Y, Irfan G, et al. On the quest for the
     pass isolation is associated with poor pulmonary vein isolation durability and atrial fib­          best freeze: predictors of late pulmonary vein reconnections after second-generation
     rillation ablation outcomes. J Arrhythm 2021;37:1468–76.                                            cryoballoon ablation. Circ Arrhythm Electrophysiol 2015;8:1359–65.
96                                                                                                                                                                                       S. Tzeis et al.


927. Aryana A, Mugnai G, Singh SM, Pujara DK, de Asmundis C, Singh SK, et al. Procedural                951. Aryana A, Baker JH, Espinosa Ginic MA, Pujara DK, Bowers MR, O’Neill PG, et al.
     and biophysical indicators of durable pulmonary vein isolation during cryoballoon ab­                   Posterior wall isolation using the cryoballoon in conjunction with pulmonary vein ab­
     lation of atrial fibrillation. Heart Rhythm 2016;13:424–32.                                             lation is superior to pulmonary vein isolation alone in patients with persistent atrial fib­
928. Ghosh J, Martin A, Keech AC, Chan KH, Gomes S, Singarayar S, et al. Balloon warming                     rillation: a multicenter experience. Heart Rhythm 2018;15:1121–9.
     time is the strongest predictor of late pulmonary vein electrical reconnection following           952. Aryana A, Allen SL, Pujara DK, Bowers MR, O’Neill PG, Yamauchi Y, et al. Concomitant
     cryoballoon ablation for atrial fibrillation. Heart Rhythm 2013;10:1311–7.                              pulmonary vein and posterior wall isolation using cryoballoon with adjunct radiofre­
929. Bose A, Chevli PA, Berberian G, Januszkiewicz J, Ahmad G, Hashmath Z, et al. Presence                   quency in persistent atrial fibrillation. JACC Clin Electrophysiol 2021;7:187–96.
     of a left common pulmonary vein and pulmonary vein anatomical characteristics as                   953. Ahn J, Shin DG, Han SJ, Lim HE. Does isolation of the left atrial posterior wall using
     predictors of outcome following cryoballoon ablation for paroxysmal atrial fibrillation.                cryoballoon ablation improve clinical outcomes in patients with persistent atrial fibril­
     J Interv Card Electrophysiol 2021;62:409–17.                                                            lation? A prospective randomized controlled trial. Europace 2022;24:1093–101.
930. Coutiño HE, Ströker E, Takarada K, Mugnai G, Abugattas JP, Sieira J, et al.                        954. Gunawardene MA, Frommeyer G, Ellermann C, Jularic M, Leitz P, Hartmann J, et al.
     Radiofrequency versus cryoballoon ablation for atrial fibrillation in the setting of left               Left atrial posterior wall isolation with pulsed field ablation in persistent atrial fibrilla­
     common pulmonary veins. Pacing Clin Electrophysiol 2019;42:1456–62.                                     tion. J Clin Med 2023;12:6304.
931. Yamaguchi M, Miyazaki S, Kajiyama T, Hada M, Nakamura H, Hachiya H, et al.                         955. Sohns C, Fink T, Braun M, Sciacca V, Piran M, Khalaph M, et al. Lesion formation fol­
     Pulmonary vein isolation in patients with a left common pulmonary vein: comparison                      lowing pulsed field ablation for pulmonary vein and posterior wall isolation. Pacing
     between second-generation cryoballoon and radiofrequency ablation. J Cardiol 2019;                      Clin Electrophysiol 2023;46:714–6.
     73:292–8.                                                                                          956. Yu HT, Shim J, Park J, Kim IS, Kim TH, Uhm JS, et al. Pulmonary vein isolation alone
932. Shigeta T, Okishige K, Yamauchi Y, Aoyagi H, Nakamura T, Yamashita M, et al. Clinical                   versus additional linear ablation in patients with persistent atrial fibrillation converted
     assessment of cryoballoon ablation in cases with atrial fibrillation and a left common                  to paroxysmal type with antiarrhythmic drug therapy: a multicenter, prospective, ran­
     pulmonary vein. J Cardiovasc Electrophysiol 2017;28:1021–7.                                             domized study. Circ Arrhythm Electrophysiol 2017;10:e004915.
933. Asvestas D, Sousonis V, Kotsovolis G, Karanikas S, Xintarakou A, Sakadakis E, et al.               957. Wong K, Schricker AA, Nerlekar R, Feng Z, Sudat S, Cook K, et al. The posterior wall
     Cavotricuspid isthmus ablation guided by force-time integral – a randomized study.                      isolation for persistent atrial fibrillation high-power short duration (PEF-HOT) trial.
     Clin Cardiol 2022;45:503–8.                                                                             JACC Clin Electrophysiol 2023;9:2166–8.
934. Sakama S, Yagishita A, Sakai T, Morise M, Ayabe K, Amino M, et al. Ablation index-                 958. Jankelson L, Garber L, Shulman E, Cohen RB, Peterson C, Wadhwani L, et al.
     guided cavotricuspid isthmus ablation with contiguous lesions using fluoroscopy inte­                   Outcomes of posterior wall isolation with pulmonary vein isolation for paroxysmal at­
     grated 3D mapping in atrial flutter. J Interv Card Electrophysiol 2022;64:217–22.                       rial fibrillation. J Cardiovasc Electrophysiol 2022;33:209–17.
935. Sasaki T, Nakamura K, Inoue M, Minami K, Miki Y, Goto K, et al. Optimal local imped­               959. Sugumar H, Thomas SP, Prabhu S, Voskoboinik A, Kistler PM. How to perform pos­
     ance drops for an effective radiofrequency ablation during cavo-tricuspid isthmus ab­                   terior wall isolation in catheter ablation for atrial fibrillation. J Cardiovasc
     lation. J Arrhythm 2020;36:905–11.                                                                      Electrophysiol 2018;29:345–52.
936. Sau A, Kapadia S, Al-Aidarous S, Howard J, Sohaib A, Sikkel MB, et al. Temporal trends             960. Tran VN, Kusa S, Smietana J, Tsai WC, Bhasin K, Teh A, et al. The relationship between
     and lesion sets for persistent atrial fibrillation ablation: a metaanalysis with trial sequen­          esophageal heating during left atrial posterior wall ablation and the durability of pul­
     tial analysis and meta-regression. Circ Arrhythm Electrophysiol 2023;16:e011861.                        monary vein isolation. Europace 2017;19:1664–9.
937. Clarnette JA, Brooks AG, Mahajan R, Elliott AD, Twomey DJ, Pathak RK, et al.                       961. Markman TM, Hyman MC, Kumareswaran R, Arkles JS, Santangeli P, Schaller RD, et al.
     Outcomes of persistent and long-standing persistent atrial fibrillation ablation: a sys­                Durability of posterior wall isolation after catheter ablation among patients with recur­
     tematic review and metaanalysis. Europace 2018;20:f366–76.                                              rent atrial fibrillation. Heart Rhythm 2020;17:1740–4.
938. Bergonti M, Spera FR, Ferrero TG, Nsahlai M, Bonomi A, Boris W, et al. Anterior mitral             962. Kumar P, Bamimore AM, Schwartz JD, Chung EH, Gehi AK, Kiser AC, et al. Challenges
     line in patients with persistent atrial fibrillation and anterior scar: a multicenter                   and outcomes of posterior wall isolation for ablation of atrial fibrillation. J Am Heart
     matched comparison-The MiLine study. Heart Rhythm 2023;20:658–65.                                       Assoc 2016;5:e003885.
939. Nademanee K, McKenzie J, Kosar E, Schwab M, Sunsaneewitayakul B, Vasavakul T, et al.               963. Segan L, Chieng D, Prabhu S, Hunt A, Watts T, Klys B, et al. Posterior wall isolation
     A new approach for catheter ablation of atrial fibrillation: mapping of the electrophy­                 improves outcomes for persistent AF with rapid posterior wall activity: a CAPLA sub­
     siologic substrate. J Am Coll Cardiol 2004;43:2044–53.                                                  study. Clin Electrophysiol 2023;9:2536–46.
940. Lau DH, Maesen B, Zeemering S, Verheule S, Crijns HJ, Schotten U. Stability of com­                964. Al-Kaisey AM, Parameswaran R, Kalman JM. Atrial fibrillation structural substrates: eti­
     plex fractionated atrial electrograms: a systematic review. J Cardiovasc Electrophysiol                 ology, identification and implications. Arrhythm Electrophysiol Rev 2020;9:113–20.
     2012;23:980–7.                                                                                     965. Prabhu S, Voskoboinik A, McLellan AJA, Peck KY, Pathik B, Nalliah CJ, et al. Biatrial
941. Vogler J, Willems S, Sultan A, Schreiber D, Lüker J, Servatius H, et al. Pulmonary vein                 electrical and structural atrial changes in heart failure: electroanatomic mapping in per­
     isolation versus defragmentation: the CHASE-AF clinical trial. J Am Coll Cardiol 2015;66:               sistent atrial fibrillation in humans. JACC Clin Electrophysiol 2018;4:87–96.
     2743–52.                                                                                           966. Kistler PM, Sanders P, Fynn SP, Stevenson IH, Spence SJ, Vohra JK, et al.
942. Providência R, Lambiase PD, Srinivasan N, Ganesh Babu G, Bronis K, Ahsan S, et al. Is                   Electrophysiologic and electroanatomic changes in the human atrium associated
     there still a role for complex fractionated atrial electrogram ablation in addition to pul­             with age. J Am Coll Cardiol 2004;44:109–16.
     monary vein isolation in patients with paroxysmal and persistent atrial fibrillation?              967. Mahajan R, Lau DH, Brooks AG, Shipp NJ, Wood JPM, Manavis J, et al. Atrial fibrillation
     Meta-analysis of 1415 patients. Circ Arrhythm Electrophysiol 2015;8:1017–29.                            and obesity: reverse remodeling of atrial substrate with weight reduction. JACC Clin
943. O’Neill MD, Wright M, Knecht S, Jaïs P, Hocini M, Takahashi Y, et al. Long-term follow-                 Electrophysiol 2021;7:630–41.
     up of persistent atrial fibrillation ablation using termination as a procedural endpoint.          968. Voskoboinik A, Kalman JM, De Silva A, Nicholls T, Costello B, Nanayakkara S, et al.
     Eur Heart J 2009;30:1105–12.                                                                            Alcohol abstinence in drinkers with atrial fibrillation. N Engl J Med 2020;382:20–8.
944. Schreiber D, Rostock T, Fröhlich M, Sultan A, Servatius H, Hoffmann BA, et al.                     969. Trivedi SJ, Claessen G, Stefani L, Flannery MD, Brown P, Janssens K, et al. Differing me­
     Five-year follow-up after catheter ablation of persistent atrial fibrillation using the step­           chanisms of atrial fibrillation in athletes and non-athletes: alterations in atrial structure
     wise approach and prognostic factors for success. Circ Arrhythm Electrophysiol 2015;8:                  and function. Eur Heart J Cardiovasc Imaging 2020;21:1374–83.
     308–17.                                                                                            970. Kottkamp H, Bender R, Berg J. Catheter ablation of atrial fibrillation: how to modify the
945. Suenari K, Chen YC, Kao YH, Cheng CC, Lin YK, Chen YJ, et al. Discrepant electro­                       substrate? J Am Coll Cardiol 2015;65:196–206.
     physiological characteristics and calcium homeostasis of left atrial anterior and poster­          971. Rolf S, Kircher S, Arya A, Eitel C, Sommer P, Richter S, et al. Tailored atrial substrate
     ior myocytes. Basic Res Cardiol 2011;106:65–74.                                                         modification based on low-voltage areas in catheter ablation of atrial fibrillation. Circ
946. Markides V, Schilling RJ, Ho SY, Chow AW, Davies DW, Peters NS. Characterization                        Arrhythm Electrophysiol 2014;7:825–33.
     of left atrial activation in the intact human heart. Circulation 2003;107:733–9.                   972. Cutler MJ, Johnson J, Abozguia K, Rowan S, Lewis W, Costantini O, et al. Impact of
947. Pauza DH, Skripka V, Pauziene N. Morphology of the intrinsic cardiac nervous system                     voltage mapping to guide whether to perform ablation of the posterior wall in patients
     in the dog: a whole-mount study employing histochemical staining with acetylcholines­                   with persistent atrial fibrillation. J Cardiovasc Electrophysiol 2016;27:13–21.
     terase. Cells Tissues Organs 2002;172:297–320.                                                     973. Yang G, Yang B, Wei Y, Zhang F, Ju W, Chen H, et al. Catheter ablation of nonparox­
948. Thiyagarajah A, Mahajan R, Iwai S, Griffin A, Mishima RS, Linz D, et al. Single ring iso­               ysmal atrial fibrillation using electrophysiologically guided substrate modification dur­
     lation with inferior line sparing for atrial fibrillation: a proof-of-concept study. Circ               ing sinus rhythm after pulmonary vein isolation. Circ Arrhythm Electrophysiol 2016;9:
     Arrhythm Electrophysiol 2021;14:e009552.                                                                e003382.
949. Thomas SP, Lim TW, McCall R, Seow SC, Ross DL. Electrical isolation of the posterior               974. Masuda M, Asai M, Iida O, Okamoto S, Ishihara T, Nanto K, et al. Additional
     left atrial wall and pulmonary veins for atrial fibrillation: feasibility of and rationale for a        low-voltage-area ablation in patients with paroxysmal atrial fibrillation: results of the
     single-ring approach. Heart Rhythm 2007;4:722–30.                                                       randomized controlled VOLCANO trial. J Am Heart Assoc 2020;9:e015927.
950. Bisignani A, Pannone L, Miraglia V, Sieira J, Iacopino S, Bala G, et al. Feasibility and safety    975. Chen H, Li C, Han B, Xiao F, Yi F, Wei Y, et al. Circumferential pulmonary vein isolation
     of left atrial posterior wall isolation with a new Cryoballoon technology in patients                   with vs without additional low-voltage-area ablation in older patients with paroxysmal
     with persistent atrial fibrillation. Pacing Clin Electrophysiol 2022;45:605–11.                         atrial fibrillation: a randomized clinical trial. JAMA Cardiol 2023;8:765–72.
Catheter and surgical ablation of atrial fibrillation                                                                                                                                              97


976. Wong GR, Nalliah CJ, Lee G, Voskoboinik A, Prabhu S, Parameswaran R, et al.                      999. Nakagawa H, Scherlag BJ, Patterson E, Ikeda A, Lockwood D, Jackman WM.
     Dynamic atrial substrate during high-density mapping of paroxysmal and persistent                     Pathophysiologic basis of autonomic ganglionated plexus ablation in patients with atrial
     AF: implications for substrate ablation. JACC Clin Electrophysiol 2019;5:1265–77.                     fibrillation. Heart Rhythm 2009;6:S26–34.
977. Kapa S, Desjardins B, Callans DJ, Marchlinski FE, Dixit S. Contact electroanatomic map­          1000. Pauza DH, Skripka V, Pauziene N, Stropus R. Morphology, distribution, and variability
     ping derived voltage criteria for characterizing left atrial scar in patients undergoing ab­            of the epicardiac neural ganglionated subplexuses in the human heart. Anat Rec 2000;
     lation for atrial fibrillation. J Cardiovasc Electrophysiol 2014;25:1044–52.                            259:353–82.
978. Takahashi Y, Yamaguchi T, Otsubo T, Nakashima K, Shinzato K, Osako R, et al.                     1001. Patterson E, Lazzara R, Szabo B, Liu H, Tang D, Li YH, et al. Sodium-calcium exchange
     Histological validation of atrial structural remodelling in patients with atrial fibrillation.          initiated by the Ca2+ transient: an arrhythmia trigger within pulmonary veins. J Am
     Eur Heart J 2023;44:3339–53.                                                                            Coll Cardiol 2006;47:1196–206.
979. Vlachos K, Derval N, Pambrun T, Duchateau J, Martin CA, Bazoukis G, et al. Ligament              1002. Lemola K, Chartier D, Yeh YH, Dubuc M, Cartier R, Armour A, et al. Pulmonary vein
     of Marshall ablation for persistent atrial fibrillation. Pacing Clin Electrophysiol 2021;44:            region ablation in experimental vagal atrial fibrillation: role of pulmonary veins versus
     782–91.                                                                                                 autonomic ganglia. Circulation 2008;117:470–7.
980. Kamakura T, Derval N, Duchateau J, Denis A, Nakashima T, Takagi T, et al. Vein of                1003. Nishida K, Maguy A, Sakabe M, Comtois P, Inoue H, Nattel S. The role of pulmonary
     Marshall ethanol infusion: feasibility, pitfalls, and complications in over 700 patients.               veins vs. autonomic ganglia in different experimental substrates of canine atrial fibril­
     Circ Arrhythm Electrophysiol 2021;14:e010001.                                                           lation. Cardiovasc Res 2011;89:825–33.
981. Gianni C, Mohanty S, Trivedi C, Di Biase L, Natale A. Novel concepts and approaches              1004. Nishida K, Datino T, Macle L, Nattel S. Atrial fibrillation ablation: translating basic
     in ablation of atrial fibrillation: the role of non-pulmonary vein triggers. Europace 2018;             mechanistic insights to the patient. J Am Coll Cardiol 2014;64:823–31.
     20:1566–76.                                                                                      1005. Stavrakis S, Nakagawa H, Po SS, Scherlag BJ, Lazzara R, Jackman WM. The role of the
982. Mohanty S, Trivedi C, Horton P, Della Rocca DG, Gianni C, MacDonald B, et al.                           autonomic ganglia in atrial fibrillation. JACC Clin Electrophysiol 2015;1:1–13.
     Natural history of arrhythmia after successful isolation of pulmonary veins, left atrial         1006. Katritsis DG, Pokushalov E, Romanov A, Giazitzoglou E, Siontis GC, Po SS, et al.
     posterior wall, and superior vena cava in patients with paroxysmal atrial fibrillation:                 Autonomic denervation added to pulmonary vein isolation for paroxysmal atrial fib­
     a multi-center experience. J Am Heart Assoc 2021;10:e020563.                                            rillation: a randomized clinical trial. J Am Coll Cardiol 2013;62:2318–25.
983. Sørensen SK, Johannessen A, Worck R, Hansen ML, Hansen J. Radiofrequency versus                  1007. Pokushalov E, Romanov A, Katritsis DG, Artyomenko S, Shirokova N, Karaskov A,
     cryoballoon catheter ablation for paroxysmal atrial fibrillation: durability of pulmonary               et al. Ganglionated plexus ablation vs linear ablation in patients undergoing pulmonary
     vein isolation and effect on atrial fibrillation burden: the RACE-AF randomized con­                    vein isolation for persistent/long-standing persistent atrial fibrillation: a randomized
     trolled trial. Circ Arrhythm Electrophysiol 2021;14:e009573.                                            comparison. Heart Rhythm 2013;10:1280–6.
984. Della Rocca DG, Tarantino N, Trivedi C, Mohanty S, Anannab A, Salwan AS, et al.                  1008. Driessen AHG, Berger WR, Krul SPJ, van den Berg NWE, Neefs J, Piersma FR, et al.
                                                                                                             Ganglion plexus ablation in advanced atrial fibrillation: the AFACT study. J Am Coll
     Non-pulmonary vein triggers in nonparoxysmal atrial fibrillation: implications of patho­
                                                                                                             Cardiol 2016;68:1155–65.
     physiology for catheter ablation. J Cardiovasc Electrophysiol 2020;31:2154–67.
                                                                                                      1009. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al.
985. Hsu LF, Jaïs P, Keane D, Wharton JM, Deisenhofer I, Hocini M, et al. Atrial fibrillation
                                                                                                             Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;
     originating from persistent left superior vena cava. Circulation 2004;109:828–32.
                                                                                                             361:1139–51.
986. Di Biase L, Burkhardt JD, Mohanty P, Mohanty S, Sanchez JE, Trivedi C, et al. Left atrial
                                                                                                      1010. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus
     appendage isolation in patients with longstanding persistent AF undergoing catheter
                                                                                                             warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883–91.
     ablation: BELIEF trial. J Am Coll Cardiol 2016;68:1929–40.
                                                                                                      1011. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al.
987. Romero J, Di Biase L, Mohanty S, Trivedi C, Patel K, Parides M, et al. Long-term out­
                                                                                                             Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:
     comes of left atrial appendage electrical isolation in patients with nonparoxysmal atrial
                                                                                                             981–92.
     fibrillation: a propensity score-matched analysis. Circ Arrhythm Electrophysiol 2020;13:
                                                                                                      1012. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al.
     e008390.
                                                                                                             Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013;369:
988. Romero J, Gabr M, Patel K, Briceno D, Diaz JC, Alviz I, et al. Efficacy and safety of left
                                                                                                             2093–104.
     atrial appendage electrical isolation during catheter ablation of atrial fibrillation: an up­
                                                                                                      1013. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD,
     dated metaanalysis. Europace 2021;23:226–37.
                                                                                                             et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin
989. Friedman DJ, Black-Maier EW, Barnett AS, Pokorney SD, Al-Khatib SM, Jackson KP,
                                                                                                             in patients with atrial fibrillation: a metaanalysis of randomised trials. Lancet 2014;
     et al. Left atrial appendage electrical isolation for treatment of recurrent atrial fibrilla­
                                                                                                             383:955–62.
     tion: a metaanalysis. JACC Clin Electrophysiol 2018;4:112–20.                                    1014. Kaitani K, Inoue K, Kobori A, Nakazawa Y, Ozawa T, Kurotobi T, et al. Efficacy of anti­
990. Bavry A. Outcomes of adjunctive left atrial appendage ligation utilizing the LARIAT
                                                                                                             arrhythmic drugs short-term use after catheter ablation for atrial fibrillation
     compared to pulmonary vein antral isolation alone - aMAZE. Presented by Dr.
                                                                                                             (EAST-AF) trial. Eur Heart J 2016;37:610–8.
     David J. Wilber at the american heart association virtual annual scientific sessions             1015. Darkner S, Chen X, Hansen J, Pehrson S, Johannessen A, Nielsen JB, et al. Recurrence
     (AHA 2021), 2021.                                                                                       of arrhythmia following short-term oral amiodarone after catheter ablation for atrial
991. Fink T, Vogler J, Heeger CH, Sano M, Sciacca V, Reissmann B, et al. Impact of left atrial               fibrillation: a double-blind, randomized, placebo-controlled study (AMIO-CAT trial).
     appendage closure on LAA thrombus formation and thromboembolism after LAA iso­                          Eur Heart J 2014;35:3356–64.
     lation. JACC Clin Electrophysiol 2020;6:1687–97.                                                 1016. Hayashi M, Miyauchi Y, Iwasaki YK, Yodogawa K, Tsuboi I, Uetake S, et al. Three-
992. Rillig A, Tilz RR, Lin T, Fink T, Heeger CH, Arya A, et al. Unexpectedly high incidence of              month lower-dose flecainide after catheter ablation of atrial fibrillation. Europace
     stroke and left atrial appendage thrombus formation after electrical isolation of the left              2014;16:1160–7.
     atrial appendage for the treatment of atrial tachyarrhythmias. Circ Arrhythm                     1017. Roux JF, Zado E, Callans DJ, Garcia F, Lin D, Marchlinski FE, et al. Antiarrhythmics
     Electrophysiol 2016;9:e003461.                                                                          after ablation of atrial fibrillation (5A study). Circulation 2009;120:1036–40.
993. Kim YG, Shim J, Oh SK, Lee KN, Choi JI, Kim YH. Electrical isolation of the left atrial          1018. Leong-Sit P, Roux JF, Zado E, Callans DJ, Garcia F, Lin D, et al. Antiarrhythmics after
     appendage increases the risk of ischemic stroke and transient ischemic attack regard­                   ablation of atrial fibrillation (5A Study): six-month follow-up study. Circ Arrhythm
     less of postisolation flow velocity. Heart Rhythm 2018;15:1746–53.                                      Electrophysiol 2011;4:11–4.
994. Zender N, Weise FK, Bordignon S, Herrmann E, Konstantinou A, Bologna F, et al.                   1019. Gu J, Liu X, Tan H, Zhou L, Gu J, Jiang W, et al. Extensive antiarrhythmic drugs after
     Thromboembolism after electrical isolation of the left atrial appendage: a new indica­                  catheter ablation of persistent atrial fibrillation. Acta Cardiol 2012;67:407–14.
     tion for interventional closure? Europace 2019;21:1502–8.                                        1020. Chen W, Liu H, Ling Z, Xu Y, Fan J, Du H, et al. Efficacy of short-term antiarrhythmic
995. Dixit S, Lin D, Frankel DS, Marchlinski FE. Catheter ablation for persistent atrial fibril­             drugs use after catheter ablation of atrial fibrillation-a systematic review with
     lation: antral pulmonary vein isolation and elimination of nonpulmonary vein triggers                   meta-analyses and trial sequential analyses of randomized controlled trials. PLoS
     are sufficient. Circ Arrhythm Electrophysiol 2012;5:1216–23; discussion 1223.                           One 2016;11:e0156121.
996. Inoue K, Kurotobi T, Kimura R, Toyoshima Y, Itoh N, Masuda M, et al. Trigger-based               1021. Goldenberg GR, Burd D, Lodzinski P, Stabile G, Udell JA, Newman D, et al.
     mechanism of the persistence of atrial fibrillation and its impact on the efficacy of cath­             Antiarrhythmic therapy as an adjuvant to promote post pulmonary vein isolation suc­
     eter ablation. Circ Arrhythm Electrophysiol 2012;5:295–301.                                             cess—a metaanalysis. J Interv Card Electrophysiol 2016;47:171–6.
997. Santangeli P, Di Biase L, Mohanty P, Burkhardt JD, Horton R, Bai R, et al. Catheter ab­          1022. Deyell MW, Leather RA, Macle L, Forman J, Khairy P, Zhang R, et al. Efficacy and
     lation of atrial fibrillation in octogenarians: safety and outcomes. J Cardiovasc                       safety of same-day discharge for atrial fibrillation ablation. JACC Clin Electrophysiol
     Electrophysiol 2012;23:687–93.                                                                          2020;6:609–19.
998. Choi EK, Shen MJ, Han S, Kim D, Hwang S, Sayfo S, et al. Intrinsic cardiac nerve activity        1023. Creta A, Ventrella N, Providência R, Earley MJ, Sporton S, Dhillon G, et al. Same-day
     and paroxysmal atrial tachyarrhythmia in ambulatory dogs. Circulation 2010;121:                         discharge following catheter ablation of atrial fibrillation: a safe and cost-effective ap­
     2615–23.                                                                                                proach. J Cardiovasc Electrophysiol 2020;31:3097–103.
98                                                                                                                                                                                 S. Tzeis et al.


1024. Kowalski M, Parikh V, Salcido JR, Chalfoun N, Albano A, O’Neill PG, et al. Same-day                systemic emboli based on stored device data: a subgroup analysis of TRENDS.
      discharge after cryoballoon ablation of atrial fibrillation: a multicenter experience.             Heart Rhythm 2011;8:1416–23.
      J Cardiovasc Electrophysiol 2021;32:183–90.                                                  1047. Brambatti M, Connolly SJ, Gold MR, Morillo CA, Capucci A, Muto C, et al. Temporal
1025. Tang PT, Davies M, Bashir Y, Betts TR, Pedersen M, Rajappan K, et al. Efficacy and                 relationship between subclinical atrial fibrillation and embolic events. Circulation 2014;
      safety of same-day discharge after atrial fibrillation ablation compared with post                 129:2094–9.
      procedural overnight stay: a systematic review and metaanalysis. Europace 2022;              1048. Camen S, Ojeda FM, Niiranen T, Gianfagna F, Vishram-Nielsen JK, Costanzo S, et al.
      24:1569–84.                                                                                        Temporal relations between atrial fibrillation and ischemic stroke and their prognos­
1026. Jafry AH, Akhtar KH, Khan JA, Clifton S, Reese J, Sami KN, et al. Safety and feasibility           tic impact on mortality. Europace 2020;22:522–9.
      of same-day discharge for catheter ablation of atrial fibrillation: a systematic review      1049. Romero J, Cerrud-Rodriguez RC, Diaz JC, Rodriguez D, Arshad S, Alviz I, et al. Oral
      and metaanalysis. J Interv Card Electrophysiol 2022;65:803–11.                                     anticoagulation after catheter ablation of atrial fibrillation and the associated risk of
1027. Sangrigoli R, Harding J, Venkataraman G, Tomaiko-Clark E, Bai R, Su W. Randomized                  thromboembolic events and intracranial hemorrhage: a systematic review and
      prospective evaluation of same-day discharge after cryoballoon ablation of atrial fib­             metaanalysis. J Cardiovasc Electrophysiol 2019;30:1250–7.
      rillation: results of the EASY PVI study. J Interv Card Electrophysiol 2023;66:1601–7.       1050. Proietti R, AlTurki A, Di Biase L, China P, Forleo G, Corrado A, et al. Anticoagulation
1028. Deyell MW, Hoskin K, Forman J, Laksman ZW, Hawkins NM, Bennett MT, et al.                          after catheter ablation of atrial fibrillation: an unnecessary evil? A systematic review
      Same-day discharge for atrial fibrillation ablation: outcomes and impact of ablation               and metaanalysis. J Cardiovasc Electrophysiol 2019;30:468–78.
      modality. Europace 2023;25:400–7.                                                            1051. Liang JJ, Elafros MA, Mullen MT, Muser D, Hayashi T, Enriquez A, et al.
1029. Rajendra A, Osorio J, Diaz JC, Hoyos C, Rivera E, Matos CD, et al. Performance of the              Anticoagulation use and clinical outcomes after catheter ablation in patients with per­
      REAL-AF same-day discharge protocol in patients undergoing catheter ablation of at­                sistent and longstanding persistent atrial fibrillation. J Cardiovasc Electrophysiol 2018;
      rial fibrillation. JACC Clin Electrophysiol 2023;9:1515–26.                                        29:823–32.
1030. Jimenez-Candil J, Hernandez Hernandez J, Cruz Galban A, Blanco F, Moriñigo JL,               1052. Verma A, Ha ACT, Kirchhof P, Hindricks G, Healey JS, Hill MD, et al. The optimal
      Sanchez García M, et al. Clinical and economic outcomes of a systematic same-day                   anti-coagulation for enhanced-risk patients post-catheter ablation for atrial fibrilla­
      discharge programme after pulmonary vein isolation: comparison between cryobal­                    tion (OCEAN) trial. Am Heart J 2018;197:124–32.
      loon vs. radiofrequency ablation. Europace 2023;25:euad265.                                  1053. Healey JS, Connolly SJ, Gold MR, Israel CW, Van Gelder IC, Capucci A, et al.
1031. Zellerhoff S, Lenze F, Eckardt L. Prophylactic proton pump inhibition after atrial fib­            Subclinical atrial fibrillation and the risk of stroke. N Engl J Med 2012;366:120–9.
      rillation ablation: is there any evidence? Europace 2011;13:1219–21.                         1054. Glotzer TV, Daoud EG, Wyse DG, Singer DE, Ezekowitz MD, Hilker C, et al. The re­
1032. Yokoyama K, Nakagawa H, Seres KA, Jung E, Merino J, Zou Y, et al. Canine model of                  lationship between daily atrial tachyarrhythmia burden from implantable device diag­
      esophageal injury and atrial-esophageal fistula after applications of forward-firing               nostics and stroke risk: the TRENDS study. Circ Arrhythm Electrophysiol 2009;2:
      high-intensity focused ultrasound and side-firing unfocused ultrasound in the left at­             474–80.
      rium and inside the pulmonary vein. Circ Arrhythm Electrophysiol 2009;2:41–9.                1055. Martin DT, Bersohn MM, Waldo AL, Wathen MS, Choucair WK, Lip GY, et al.
1033. Cordes F, Ellermann C, Dechering DG, Frommeyer G, Kochhäuser S, Lange PS, et al.                   Randomized trial of atrial arrhythmia monitoring to guide anticoagulation in patients
      Preprocedural proton pump inhibition is associated with fewer peri-oesophageal le­                 with implanted defibrillator and cardiac resynchronization devices. Eur Heart J 2015;
      sions after cryoballoon pulmonary vein isolation. Sci Rep 2021;11:4728.                            36:1660–8.
1034. Rolantova L, Bulava A, Eisenberger M, Chloubova I, Tothova V, Hanis J.                       1056. Waks JW, Passman RS, Matos J, Reynolds M, Thosani A, Mela T, et al. Intermittent
      Nurse-performed venous sheath removal in patients undergoing radiofrequency                        anticoagulation guided by continuous atrial fibrillation burden monitoring using dual-
      catheter ablation for atrial fibrillation: a randomised study. Eur J Cardiovasc Nurs               chamber pacemakers and implantable cardioverter-defibrillators: results from the tai­
      2019;18:332–9.                                                                                     lored anticoagulation for non-continuous atrial fibrillation (TACTIC-AF) pilot study.
1035. Kewcharoen J, Shah K, Bhardwaj R, Contractor T, Turagam MK, Mandapati R, et al.                    Heart Rhythm 2018;15:1601–7.
      Periprocedural outcomes of protamine administration after catheter ablation of at­           1057. Passman R, Leong-Sit P, Andrei AC, Huskin A, Tomson TT, Bernstein R, et al.
      rial fibrillation. Rev Cardiovasc Med 2022;23:34.                                                  Targeted anticoagulation for atrial fibrillation guided by continuous rhythm assess­
1036. Chilukuri K, Henrikson CA, Dalal D, Scherr D, MacPherson EC, Cheng A, et al.                       ment with an insertable cardiac monitor: the rhythm evaluation for anticoagulation
      Incidence and outcomes of protamine reactions in patients undergoing catheter ab­                  with continuous monitoring (REACT.COM) pilot study. J Cardiovasc Electrophysiol
      lation of atrial fibrillation. J Interv Card Electrophysiol 2009;25:175–81.                        2016;27:264–70.
1037. Traullé S, Kubala M, Doucy A, Quenum S, Hermida JS. Feasibility and safety of tem­           1058. Barbhaiya CR, Kumar S, John RM, Tedrow UB, Koplan BA, Epstein LM, et al. Global
      porary subcutaneous venous figure-of-eight suture to achieve hemostasis after abla­                survey of esophageal and gastric injury in atrial fibrillation ablation: incidence, time to
      tion of atrial fibrillation. Europace 2016;18:815–9.                                               presentation, and outcomes. J Am Coll Cardiol 2015;65:1377–8.
1038. Kumar V, Wish M, Venkataraman G, Bliden K, Jindal M, Strickberger A. A randomized            1059. Piccini JP, Braegelmann KM, Simma S, Koneru JN, Ellenbogen KA. Risk of atrioesopha­
      comparison of manual pressure versus figure-of-eight suture for hemostasis after                   geal fistula with cryoballoon ablation of atrial fibrillation. Heart Rhythm O2 2020;1:
      cryoballoon ablation for atrial fibrillation. J Cardiovasc Electrophysiol 2019;30:2806–10.         173–9.
1039. Aytemir K, Canpolat U, Yorgun H, Evranos B, Kaya EB, Şahiner ML, et al. Usefulness           1060. Tilz RR, Schmidt V, Pürerfellner H, Maury P, Chun KJ, Martinek M, et al. A worldwide
      of ‘figure-of-eight’ suture to achieve hemostasis after removal of 15-French calibre               survey on incidence, management and prognosis of esophageal fistula formation fol­
      femoral venous sheath in patients undergoing cryoablation. Europace 2016;18:                       lowing atrial fibrillation catheter ablation: the POTTER-AF study. Eur Heart J 2023;44:
      1545–50.                                                                                           2458–69.
1040. Natale A, Mohanty S, Liu PY, Mittal S, Al-Ahmad A, De Lurgio David B, et al. Venous          1061. Barbhaiya Chirag R, Kumar S, Guo Y, Zhong J, John Roy M, Tedrow Usha B, et al.
      vascular closure system versus manual compression following multiple access elec­                  Global survey of esophageal injury in atrial fibrillation ablation. JACC Clin
      trophysiology procedures. JACC Clin Electrophysiol 2020;6:111–24.                                  Electrophysiol 2016;2:143–50.
1041. Calkins H, Hindricks G, Cappato R, Kim YH, Saad EB, Aguinaga L, et al. 2017 HRS/             1062. Gandjbakhch E, Mandel F, Dagher Y, Hidden-Lucet F, Rollin A, Maury P. Incidence,
      EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgi­                          epidemiology, diagnosis and prognosis of atrio-oesophageal fistula following percu­
      cal ablation of atrial fibrillation. Europace 2018;20:e1–160.                                      taneous catheter ablation: a French nationwide survey. Europace 2021;23:557–64.
1042. Verma A, Champagne J, Sapp J, Essebag V, Novak P, Skanes A, et al. Discerning the            1063. Della Rocca DG, Magnocavallo M, Natale VN, Gianni C, Mohanty S, Trivedi C, et al.
      incidence of symptomatic and asymptomatic episodes of atrial fibrillation before                   Clinical presentation, diagnosis, and treatment of atrioesophageal fistula resulting
      and after catheter ablation (DISCERN AF): a prospective, multicenter study. JAMA                   from atrial fibrillation ablation. J Cardiovasc Electrophysiol 2021;32:2441–50.
      Intern Med 2013;173:149–56.                                                                  1064. Dagres N, Kottkamp H, Piorkowski C, Doll N, Mohr F, Horlitz M, et al. Rapid detec­
1043. Bunch TJ, May HT, Bair TL, Weiss JP, Crandall BG, Osborn JS, et al. Atrial fibrillation            tion and successful treatment of esophageal perforation after radiofrequency abla­
      ablation patients have long-term stroke rates similar to patients without atrial fibril­           tion of atrial fibrillation: lessons from five cases. J Cardiovasc Electrophysiol 2006;17:
      lation regardless of CHADS2 score. Heart Rhythm 2013;10:1272–7.                                    1213–5.
1044. Friberg L, Tabrizi F, Englund A. Catheter ablation for atrial fibrillation is associated     1065. Dagres N, Hindricks G, Kottkamp H, Sommer P, Gaspar T, Bode K, et al.
      with lower incidence of stroke and death: data from Swedish health registries. Eur                 Complications of atrial fibrillation ablation in a high-volume center in 1,000 proce­
      Heart J 2016;37:2478–87.                                                                           dures: still cause for concern? J Cardiovasc Electrophysiol 2009;20:1014–9.
1045. Packer DL, Mark DB, Robb RA, Monahan KH, Bahnson TD, Poole JE, et al. Effect of              1066. Arbelo E, Brugada J, Blomström-Lundqvist C, Laroche C, Kautzner J, Pokushalov E,
      catheter ablation vs antiarrhythmic drug therapy on mortality, stroke, bleeding, and               et al. Contemporary management of patients undergoing atrial fibrillation ablation:
      cardiac arrest among patients with atrial fibrillation: the CABANA randomized clin­                in-hospital and 1-year follow-up findings from the ESC-EHRA atrial fibrillation abla­
      ical trial. JAMA 2019;321:1261–74.                                                                 tion long-term registry. Eur Heart J 2017;38:1303–16.
1046. Daoud EG, Glotzer TV, Wyse DG, Ezekowitz MD, Hilker C, Koehler J, et al.                     1067. Markar SR, Koehler R, Low DE, Ross A. Novel multimodality endoscopic closure of
      Temporal relationship of atrial tachyarrhythmias, cerebrovascular events, and                      postoperative esophageal fistula. Int J Surg Case Rep 2012;3:577–9.
Catheter and surgical ablation of atrial fibrillation                                                                                                                                                99


1068. Kapur S, Barbhaiya C, Deneke T, Michaud GF. Esophageal injury and atrioesophageal             1091. Rizas KD, Freyer L, Sappler N, von Stülpnagel L, Spielbichler P, Krasniqi A, et al.
      fistula caused by ablation for atrial fibrillation. Circulation 2017;136:1247–55.                   Smartphone-based screening for atrial fibrillation: a pragmatic randomized clinical
1069. Ugata Y, Michihata N, Matsui H, Fushimi K, Yasunaga H. Impact of proton pump in­                    trial. Nat Med 2022;28:1823–30.
      hibitors on mortality and severe esophageal injury after catheter ablation for atrial         1092. Svennberg E, Tjong F, Goette A, Akoum N, Di Biase L, Bordachar P, et al. How to use
      fibrillation: a nationwide retrospective study using propensity score matching.                     digital devices to detect and manage arrhythmias: an EHRA practical guide. Europace
      Heart Vessels 2021;36:1730–8.                                                                       2022;24:979–1005.
1070. Deftereos S, Giannopoulos G, Kossyvakis C, Efremidis M, Panagopoulou V, Kaoukis               1093. Lambert CT, Patel D, Bumgarner JM, Kanj M, Cantillon D, Saliba W, et al. Atrial fib­
      A, et al. Colchicine for prevention of early atrial fibrillation recurrence after pulmon­           rillation future clinic. Novel platform to integrate smart device electrocardiogram
      ary vein isolation: a randomized controlled study. J Am Coll Cardiol 2012;60:1790–6.                into clinical practice. Cardiovasc Digit Health J 2021;2:92–100.
1071. Deftereos S, Giannopoulos G, Efremidis M, Kossyvakis C, Katsivas A, Panagopoulou              1094. Hermans ANL, Gawalko M, Pluymaekers N, Dinh T, Weijs B, van Mourik MJW, et al.
      V, et al. Colchicine for prevention of atrial fibrillation recurrence after pulmonary vein          Long-term intermittent versus short continuous heart rhythm monitoring for the de­
      isolation: mid-term efficacy and effect on quality of life. Heart Rhythm 2014;11:620–8.             tection of atrial fibrillation recurrences after catheter ablation. Int J Cardiol 2021;329:
1072. Koyama T, Tada H, Sekiguchi Y, Arimoto T, Yamasaki H, Kuroki K, et al. Prevention of                105–12.
      atrial fibrillation recurrence with corticosteroids after radiofrequency catheter abla­       1095. Gawałko M, Duncker D, Manninger M, van der Velden RMJ, Hermans ANL, Verhaert
      tion: a randomized controlled trial. J Am Coll Cardiol 2010;56:1463–72.                             DVM, et al. The European TeleCheck-AF project on remote app-based management
1073. Kim YR, Nam GB, Han S, Kim SH, Kim KH, Lee S, et al. Effect of short-term steroid                   of atrial fibrillation during the COVID-19 pandemic: center and patient experiences.
      therapy on early recurrence during the blanking period after catheter ablation of at­               Europace 2021;23:1003–15.
      rial fibrillation. Circ Arrhythm Electrophysiol 2015;8:1366–72.                               1096. Unni RR, Prager RT, Odabashian R, Zhang JJ, Fat Hing NN, Nery PB, et al. Rhythm-
1074. Iskandar S, Reddy M, Afzal MR, Rajasingh J, Atoui M, Lavu M, et al. Use of oral steroid             monitoring strategy and arrhythmia recurrence in atrial fibrillation ablation trials: a
      and its effects on atrial fibrillation recurrence and inflammatory cytokines post abla­             systematic review. CJC Open 2022;4:488–96.
      tion – the steroid AF study. J Atr Fibrillation 2017;9:1604.                                  1097. Andrade JG, Khairy P, Verma A, Guerra PG, Dubuc M, Rivard L, et al. Early recurrence
1075. Kim DR, Won H, Uhm JS, Kim JY, Sung JH, Pak HN, et al. Comparison of two different                  of atrial tachyarrhythmias following radiofrequency catheter ablation of atrial fibrilla­
      doses of single bolus steroid injection to prevent atrial fibrillation recurrence after             tion. Pacing Clin Electrophysiol 2012;35:106–16.
      radiofrequency catheter ablation. Yonsei Med J 2015;56:324–31.                                1098. Calkins H, Hindricks G, Cappato R, Kim YH, Saad EB, Aguinaga L, et al. 2017 HRS/
1076. Won H, Kim JY, Shim J, Uhm JS, Pak HN, Lee MH, et al. Effect of a single bolus injec­               EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgi­
      tion of low-dose hydrocortisone for prevention of atrial fibrillation recurrence after              cal ablation of atrial fibrillation: executive summary. Europace 2018;20:157–208.
      radiofrequency catheter ablation. Circ J 2013;77:53–9.                                        1099. Gottlieb LA, Dekker LRC, Coronel R. The blinding period following ablation therapy
1077. Vasamreddy CR, Dalal D, Dong J, Cheng A, Spragg D, Lamiy SZ, et al. Symptomatic                     for atrial fibrillation: proarrhythmic and antiarrhythmic pathophysiological mechan­
      and asymptomatic atrial fibrillation in patients undergoing radiofrequency catheter                 isms. JACC Clin Electrophysiol 2021;7:416–30.
                                                                                                    1100. Opacic D, van Bragt KA, Nasrallah HM, Schotten U, Verheule S. Atrial metabolism
      ablation. J Cardiovasc Electrophysiol 2006;17:134–9.
1078. Janse PA, van Belle YL, Theuns DA, Rivero-Ayerza M, Scholten MF, Jordaens LJ.                       and tissue perfusion as determinants of electrical and structural remodelling in atrial
                                                                                                          fibrillation. Cardiovasc Res 2016;109:527–41.
      Symptoms versus objective rhythm monitoring in patients with paroxysmal atrial fib­
                                                                                                    1101. Lim HS, Schultz C, Dang J, Alasady M, Lau DH, Brooks AG, et al. Time course of in­
      rillation undergoing pulmonary vein isolation. Eur J Cardiovasc Nurs 2008;7:147–51.
                                                                                                          flammation, myocardial injury, and prothrombotic response after radiofrequency
1079. Piorkowski C, Kottkamp H, Tanner H, Kobza R, Nielsen JC, Arya A, et al. Value of
                                                                                                          catheter ablation for atrial fibrillation. Circ Arrhythm Electrophysiol 2014;7:83–9.
      different follow-up strategies to assess the efficacy of circumferential pulmonary
                                                                                                    1102. Richter B, Gwechenberger M, Socas A, Zorn G, Albinni S, Marx M, et al. Markers of
      vein ablation for the curative treatment of atrial fibrillation. J Cardiovasc
                                                                                                          oxidative stress after ablation of atrial fibrillation are associated with inflammation,
      Electrophysiol 2005;16:1286–92.
                                                                                                          delivered radiofrequency energy and early recurrence of atrial fibrillation. Clin Res
1080. Klemm HU, Ventura R, Rostock T, Brandstrup B, Risius T, Meinertz T, et al.
                                                                                                          Cardiol 2012;101:217–25.
      Correlation of symptoms to ECG diagnosis following atrial fibrillation ablation.
                                                                                                    1103. Sepehri Shamloo A, Bollmann A, Dagres N, Hindricks G, Arya A. Natriuretic pep­
      J Cardiovasc Electrophysiol 2006;17:146–50.
                                                                                                          tides: biomarkers for atrial fibrillation management. Clin Res Cardiol 2020;109:
1081. Kaufman ES, Israel CW, Nair GM, Armaganijan L, Divakaramenon S, Mairesse GH,
                                                                                                          957–66.
      et al. Positive predictive value of device-detected atrial high-rate episodes at different
                                                                                                    1104. Liang JJ, Dixit S, Santangeli P. Mechanisms and clinical significance of early recurrences
      rates and durations: an analysis from ASSERT. Heart Rhythm 2012;9:1241–6.
                                                                                                          of atrial arrhythmias after catheter ablation for atrial fibrillation. World J Cardiol 2016;
1082. Hindricks G, Pokushalov E, Urban L, Taborsky M, Kuck KH, Lebedev D, et al.
                                                                                                          8:638–46.
      Performance of a new leadless implantable cardiac monitor in detecting and quanti­
                                                                                                    1105. Grégoire JM, Gilon C, Carlier S, Bersini H. Role of the autonomic nervous system and
      fying atrial fibrillation: results of the XPECT trial. Circ Arrhythm Electrophysiol 2010;3:
                                                                                                          premature atrial contractions in short-term paroxysmal atrial fibrillation forecasting:
      141–7.                                                                                              insights from machine learning models. Arch Cardiovasc Dis 2022;115:377–87.
1083. Xing LY, Diederichsen SZ, Højberg S, Krieger DW, Graff C, Olesen MS, et al.                   1106. Scherschel K, Hedenus K, Jungen C, Lemoine MD, Rübsamen N, Veldkamp MW, et al.
      Electrocardiographic markers of subclinical atrial fibrillation detected by implantable             Cardiac glial cells release neurotrophic S100B upon catheter-based treatment of at­
      loop recorder: insights from the LOOP Study. Europace 2023;25:euad014.                              rial fibrillation. Sci Transl Med 2019;11:eaav7770.
1084. Charitos EI, Ziegler PD, Stierle U, Graf B, Sievers HH, Hanke T. Long-term outcomes           1107. Sasaki N, Okumura Y, Watanabe I, Nagashima K, Sonoda K, Kogawa R, et al.
      after surgical ablation for atrial fibrillation in patients with continuous heart rhythm            Transthoracic echocardiographic backscatter-based assessment of left atrial remod­
      monitoring devices. Interact Cardiovasc Thorac Surg 2015;21:712–21.                                 eling involving left atrial and ventricular fibrosis in patients with atrial fibrillation. Int J
1085. Perez-Castellano N, Fernandez-Cavazos R, Moreno J, Canadas V, Conde A,                              Cardiol 2014;176:1064–6.
      Gonzalez-Ferrer JJ, et al. The COR trial: a randomized study with continuous rhythm           1108. McGann C, Kholmovski E, Blauer J, Vijayakumar S, Haslam T, Cates J, et al. Dark re­
      monitoring to compare the efficacy of cryoenergy and radiofrequency for pulmonary                   gions of no-reflow on late gadolinium enhancement magnetic resonance imaging re­
      vein isolation. Heart Rhythm 2014;11:8–14.                                                          sult in scar formation after atrial fibrillation ablation. J Am Coll Cardiol 2011;58:177–85.
1086. Kapa S, Epstein AE, Callans DJ, Garcia FC, Lin D, Bala R, et al. Assessing arrhythmia         1109. Peters DC, Wylie JV, Hauser TH, Nezafat R, Han Y, Woo JJ, et al. Recurrence of atrial
      burden after catheter ablation of atrial fibrillation using an implantable loop recorder:           fibrillation correlates with the extent of postprocedural late gadolinium enhance­
      the ABACUS study. J Cardiovasc Electrophysiol 2013;24:875–81.                                       ment: a pilot study. JACC Cardiovasc Imaging 2009;2:308–16.
1087. Damiano RJ Jr, Lawrance CP, Saint LL, Henn MC, Sinn LA, Kruse J, et al. Detection of          1110. Steinberg C, Champagne J, Deyell MW, Dubuc M, Leong-Sit P, Calkins H, et al.
      atrial fibrillation after surgical ablation: conventional versus continuous monitoring.             Prevalence and outcome of early recurrence of atrial tachyarrhythmias in the cryo­
      Ann Thorac Surg 2016;101:42–7; discussion 47–8.                                                     balloon vs irrigated radiofrequency catheter ablation (CIRCA-DOSE) study. Heart
1088. Andrade JG, Wells GA, Deyell MW, Bennett M, Essebag V, Champagne J, et al.                          Rhythm 2021;18:1463–70.
      Cryoablation or drug therapy for initial treatment of atrial fibrillation. N Engl J Med       1111. Charitakis E, Metelli S, Karlsson LO, Antoniadis AP, Rizas KD, Liuba I, et al. Comparing
      2021;384:305–15.                                                                                    efficacy and safety in catheter ablation strategies for atrial fibrillation: a network
1089. Goldenthal IL, Sciacca RR, Riga T, Bakken S, Baumeister M, Biviano AB, et al.                       metaanalysis. BMC Med 2022;20:193.
      Recurrent atrial fibrillation/flutter detection after ablation or cardioversion using         1112. Andrade JG, Khairy P, Verma A, Guerra PG, Dubuc M, Rivard L, et al. Early recurrence
      the AliveCor KardiaMobile device: iHEART results. J Cardiovasc Electrophysiol 2019;                 of atrial tachyarrhythmias following radiofrequency catheter ablation of atrial fibrilla­
      30:2220–8.                                                                                          tion. Pacing Clin Electrophysiol 2012;35:106–16.
1090. Tarakji KG, Wazni OM, Callahan T, Kanj M, Hakim AH, Wolski K, et al. Using a novel            1113. Baimbetov AK, Bizhanov KA, Jukenova AM, Aubakirova AT, Ualiyeva AY, Sagatov IY.
      wireless system for monitoring patients after the atrial fibrillation ablation procedure:           Comparative effectiveness and safety of cryoablation versus radiofrequency ablation
      the iTransmit study. Heart Rhythm 2015;12:554–9.                                                    treatments for persistent atrial fibrillation. Am J Cardiol 2022;184:22–30.
100                                                                                                                                                                                  S. Tzeis et al.


1114. Choi J-H, Kwon H-J, Kim HR, Park S-J, Kim JS, On YK, et al. Electrocardiographic pre­          1136. Themistoclakis S, Schweikert RA, Saliba WI, Bonso A, Rossillo A, Bader G, et al.
      dictors of early recurrence of atrial fibrillation. Ann Noninvasive Electrocardiol 2021;26:          Clinical predictors and relationship between early and late atrial tachyarrhythmias
      e12884.                                                                                              after pulmonary vein antrum isolation. Heart Rhythm 2008;5:679–85.
1115. Ribeiro Da Silva M, Santos Silva G, Ribeiro Queiros P, Teixeira R, Almeida J, Fonseca          1137. Noujaim C, Lim C, Mekhael M, Feng H, Chouman N, Younes H, et al. Identifying the
      P, et al. Predictors of early and late recurrence of atrial fibrillation after catheter ab­          prognostic significance of early arrhythmia recurrence during the blanking period and
      lation: two sides of the same coin? Eur Heart J 2021;42:ehab724.                                     the optimal blanking period duration: insights from the DECAAF II study. Europace
1116. Kim Yun G, Boo Ki Y, Choi J-I, Choi Yun Y, Choi Ha Y, Roh S-Y, et al. Early recurrence               2023;25:euad173.
      is reliable predictor of late recurrence after radiofrequency catheter ablation of atrial      1138. Cosio FG, Aliot E, Botto GL, Heidbüchel H, Geller CJ, Kirchhof P, et al. Delayed
      fibrillation. JACC Clin Electrophysiol 2021;7:343–51.                                                rhythm control of atrial fibrillation may be a cause of failure to prevent recurrences:
1117. Calkins H, Gache L, Frame D, Boo LM, Ghaly N, Schilling R, et al. Predictive value of                reasons for change to active antiarrhythmic treatment at the time of the first de­
      atrial fibrillation during the postradiofrequency ablation blanking period. Heart                    tected episode. Europace 2007;10:21–7.
      Rhythm 2021;18:366–73.                                                                         1139. Chilukuri K, Dukes J, Dalal D, Marine JE, Henrikson CA, Scherr D, et al. Outcomes in
1118. Filipovic K, Dittrich S, Scheurlen C, Arica Z, Erlhoefer S, Woermann J, et al. Validation            patients requiring cardioversion following catheter ablation of atrial fibrillation.
      of seven risk scores in a prospective and independent cohort: the challenge of pre­                  J Cardiovasc Electrophysiol 2010;21:27–32.
      dicting recurrence after atrial fibrillation ablation. Europace 2022;24:euac053.191.           1140. Ebert M, Stegmann C, Kosiuk J, Dinov B, Richter S, Arya A, et al. Predictors, manage­
1119. Dretzke J, Chuchu N, Agarwal R, Herd C, Chua W, Fabritz L, et al. Predicting recur­                  ment, and outcome of cardioversion failure early after atrial fibrillation ablation.
      rent atrial fibrillation after catheter ablation: a systematic review of prognostic mod­             Europace 2018;20:1428–34.
      els. Europace 2020;22:748–60.                                                                  1141. Dong Z, Du X, Hou XX, He L, Dong JZ, Ma CS. Effect of electrical cardioversion on
1120. Winkle RA, Jarman JW, Mead RH, Engel G, Kong MH, Fleming W, et al. Predicting                        1-year outcomes in patients with early recurrence after catheter ablation for atrial
      atrial fibrillation ablation outcome: the CAAP-AF score. Heart Rhythm 2016;13:                       fibrillation. Clin Cardiol 2021;44:1128–38.
      2119–25.                                                                                       1142. Malasana G, Day JD, Weiss JP, Crandall BG, Bair TL, May HT, et al. A strategy of rapid
1121. Kornej J, Hindricks G, Arya A, Sommer P, Husser D, Bollmann A. The APPLE score –                     cardioversion minimizes the significance of early recurrent atrial tachyarrhythmias
      a novel score for the prediction of rhythm outcomes after repeat catheter ablation of                after ablation for atrial fibrillation. J Cardiovasc Electrophysiol 2011;22:761–6.
      atrial fibrillation. PLOS ONE 2017;12:e0169933.                                                1143. Sponga S, Leoni L, Buja G, Nalli C, Voisine P, Gerosa G. Role of an aggressive rhythm
1122. Jud FN, Obeid S, Duru F, Haegeli LM. A novel score in the prediction of rhythm out­                  control strategy on sinus rhythm maintenance following intraoperative radiofre­
      come after ablation of atrial fibrillation: the SUCCESS score. Anatol J Cardiol 2019;21:             quency ablation of atrial fibrillation in patients undergoing surgical correction of valvu­
      142–9.
                                                                                                           lar disease. J Cardiol 2012;60:316–20.
1123. Mesquita J, Ferreira AM, Cavaco D, Moscoso Costa F, Carmo P, Marques H, et al.
                                                                                                     1144. Baman TS, Gupta SK, Billakanty SR, Ilg KJ, Good E, Crawford T, et al. Time to cardi­
      Development and validation of a risk score for predicting atrial fibrillation recurrence
                                                                                                           oversion of recurrent atrial arrhythmias after catheter ablation of atrial fibrillation and
      after a first catheter ablation procedure – ATLAS score. Europace 2018;20:f428–35.
                                                                                                           long-term clinical outcome. J Cardiovasc Electrophysiol 2009;20:1321–5.
1124. Nielsen JC, Lin Y-J, de Oliveira Figueiredo MJ, Sepehri Shamloo A, Alfie A, Boveda S,
                                                                                                     1145. Lellouche N, Jaïs P, Nault I, Wright M, Bevilacqua M, Knecht S, et al. Early recurrences
      et al. European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia
                                                                                                           after atrial fibrillation ablation: prognostic value and effect of early reablation.
      Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society
                                                                                                           J Cardiovasc Electrophysiol 2008;19:599–605.
      (LAHRS) expert consensus on risk assessment in cardiac arrhythmias: use the right
                                                                                                     1146. Andrade JG, Khairy P, Macle L, Packer DL, Lehmann JW, Holcomb RG, et al. Incidence
      tool for the right outcome, in the right population. Europace 2020;22:1147–8.
                                                                                                           and significance of early recurrences of atrial fibrillation after cryoballoon ablation: in­
1125. Lee S-H, Tai C-T, Hsieh M-H, Tsai C-F, Lin Y-K, Tsao H-M, et al. Predictors of early
                                                                                                           sights from the multicenter sustained treatment of paroxysmal atrial fibrillation
      and late recurrence of atrial fibrillation after catheter ablation of paroxysmal atrial fib­
                                                                                                           (STOP AF) Trial. Circ Arrhythm Electrophysiol 2014;7:69–75.
      rillation. J Interv Card Electrophysiol 2004;10:221–6.
                                                                                                     1147. Proietti M, Romiti GF, Olshansky B, Lane DA, Lip GYH. Improved outcomes by in­
1126. Kuck K-H, Hoffmann BA, Ernst S, Wegscheider K, Treszl A, Metzner A, et al. Impact
                                                                                                           tegrated care of anticoagulated patients with atrial fibrillation using the simple ABC
      of complete versus incomplete circumferential lines around the pulmonary veins dur­
                                                                                                           (atrial fibrillation better care) pathway. Am J Med 2018;131:1359–66.e6.
      ing catheter ablation of paroxysmal atrial fibrillation: results from the gap-atrial fibril­
                                                                                                     1148. Rivera-Caravaca JM, Roldán V, Martínez-Montesinos L, Vicente V, Lip GYH, Marín F.
      lation–German atrial fibrillation competence network 1 trial. Circ Arrhythm
                                                                                                           The atrial fibrillation better care (ABC) pathway and clinical outcomes in patients
      Electrophysiol 2016;9:e003337.
                                                                                                           with atrial fibrillation: the prospective murcia AF project phase II cohort. J Gen
1127. Liu H, Yuan P, Zhu X, Fu L, Hong K, Hu J. Is atrial fibrillation noninducibility by burst
                                                                                                           Intern Med 2023;38:315–23.
      pacing after catheter ablation associated with reduced clinical recurrence? A system­
                                                                                                     1149. Kotalczyk A, Guo Y, Stefil M, Wang Y, Lip GYH. Effects of the atrial fibrillation better
      atic review and metaanalysis. J Am Heart Assoc 2020;9:e015260.
1128. Okada M, Inoue K, Tanaka N, Masuda M, Furukawa Y, Hirata A, et al. Reappraising the                  care pathway on outcomes among clinically complex Chinese patients with atrial fib­
      role of baseline plasma C-reactive protein levels on recurrence after catheter abla­                 rillation with multimorbidity and polypharmacy: a report from the ChiOTEAF regis­
      tion of persistent atrial fibrillation: insight from EARNEST-PVI trial. Eur Heart J                  try. J Am Heart Assoc 2022;11:e024319.
      2021;42:ehab724. 0507.                                                                         1150. Patel SM, Palazzolo MG, Murphy SA, Antman EM, Braunwald E, Lanz HJ, et al.
1129. Charalampidis P, Teperikidis E, Boulmpou A, Papadopoulos CE, Potoupni V, Tsioni K,                   Evaluation of the atrial fibrillation better care pathway in the ENGAGE AF-TIMI 48
      et al. Homocysteine as a predictor of paroxysmal atrial fibrillation-related events: a               trial. Europace 2022;24:1730–8.
      scoping review of the literature. Diagnostics 2022;12:2192.                                    1151. Stevens D, Harrison SL, Kolamunnage-Dona R, Lip GYH, Lane DA. The atrial fibril­
1130. Liang JJ, Elafros MA, Chik WW, Santangeli P, Zado ES, Frankel DS, et al. Early recur­                lation better care pathway for managing atrial fibrillation: a review. Europace 2021;23:
      rence of atrial arrhythmias following pulmonary vein antral isolation: timing and fre­               1511–27.
      quency of early recurrences predicts long-term ablation success. Heart Rhythm 2015;            1152. Proietti M, Lip GYH, Laroche C, Fauchier L, Marin F, Nabauer M, et al. Relation of
      12:2461–8.                                                                                           outcomes to ABC (atrial fibrillation better care) pathway adherent care in
1131. Amankwah NA, Pothineni NVK, Guandalini G, Santangeli P, Schaller R, Supple GE,                       European patients with atrial fibrillation: an analysis from the ESC-EHRA EORP
      et al. Impact of atrial fibrillation recurrences during the blanking period following cath­          Atrial Fibrillation General Long-Term (AFGen LT) registry. Europace 2021;23:
      eter ablation on long-term arrhythmia-free survival: a prospective study with con­                   174–83.
      tinuous monitoring. J Interv Card Electrophysiol 2022;65:519–25.                               1153. Gerstenfeld EP, Callans DJ, Dixit S, Russo AM, Nayak H, Lin D, et al. Mechanisms of
1132. Mugnai G, de Asmundis C, Hünük B, Ströker E, Velagic V, Moran D, et al.                              organized left atrial tachycardias occurring after pulmonary vein isolation. Circulation
      Second-generation cryoballoon ablation for paroxysmal atrial fibrillation: predictive                2004;110:1351–7.
      role of atrial arrhythmias occurring in the blanking period on the incidence of late re­       1154. Chugh A, Oral H, Good E, Han J, Tamirisa K, Lemola K, et al. Catheter ablation of
      currences. Heart Rhythm 2016;13:845–51.                                                              atypical atrial flutter and atrial tachycardia within the coronary sinus after left atrial
1133. Stabile G, Iacopino S, Verlato R, Arena G, Pieragnoli P, Molon G, et al. Predictive role             ablation for atrial fibrillation. J Am Coll Cardiol 2005;46:83–91.
      of early recurrence of atrial fibrillation after cryoballoon ablation. Europace 2020;22:       1155. Deisenhofer I, Estner H, Zrenner B, Schreieck J, Weyerbrock S, Hessling G, et al. Left
      1798–804.                                                                                            atrial tachycardia after circumferential pulmonary vein ablation for atrial fibrillation:
1134. Willems S, Khairy P, Andrade JG, Hoffmann BA, Levesque S, Verma A, et al.                            incidence, electrophysiological characteristics, and results of radiofrequency ablation.
      Redefining the blanking period after catheter ablation for paroxysmal atrial fibrilla­               Europace 2006;8:573–82.
      tion: insights from the ADVICE (adenosine following pulmonary vein isolation to tar­           1156. Gerstenfeld EP, Callans DJ, Sauer W, Jacobson J, Marchlinski FE. Reentrant and non­
      get dormant conduction elimination) trial. Circ Arrhythm Electrophysiol 2016;9:                      reentrant focal left atrial tachycardias occur after pulmonary vein isolation. Heart
      e003909.                                                                                             Rhythm 2005;2:1195–202.
1135. Alipour P, Azizi Z, Pirbaglou M, Ritvo P, Pantano A, Verma A, et al. Defining blanking         1157. Gerstenfeld EP, Marchlinski FE. Mapping and ablation of left atrial tachycardias occur­
      period post-pulmonary vein antrum isolation. JACC Clin Electrophysiol 2017;3:568–76.                 ring after atrial fibrillation ablation. Heart Rhythm 2007;4:S65–72.
Catheter and surgical ablation of atrial fibrillation                                                                                                                                             101


1158. Lim TW, Koay CH, McCall R, See VA, Ross DL, Thomas SP. Atrial arrhythmias after                     delineate gap-related atrial tachycardias post atrial fibrillation ablation. Europace
      single-ring isolation of the posterior left atrium and pulmonary veins for atrial fibril­           2021;23:1052–62.
      lation: mechanisms and management. Circ Arrhythm Electrophysiol 2008;1:120–6.                 1181. Sundaram S, Choe W, Ryan Jordan J, Mullins N, Boorman C, Kessler EJ, et al. Catheter
1159. Anousheh R, Sawhney NS, Panutich M, Tate C, Chen WC, Feld GK. Effect of mitral                      ablation of atypical atrial flutter: a novel 3D anatomic mapping approach to quickly
      isthmus block on development of atrial tachycardia following ablation for atrial fibril­            localize and terminate atypical atrial flutter. J Interv Card Electrophysiol 2017;49:
      lation. Pacing Clin Electrophysiol 2010;33:460–8.                                                   307–18.
1160. Wasmer K, Monnig G, Bittner A, Dechering D, Zellerhoff S, Milberg P, et al. Incidence,        1182. Luik A, Schmidt K, Haas A, Unger L, Tzamalis P, Brüggenjürgen B. Ablation of left atrial
      characteristics, and outcome of left atrial tachycardias after circumferential antral ab­           tachycardia following catheter ablation of atrial fibrillation: 12-month success rates.
      lation of atrial fibrillation. Heart Rhythm 2012;9:1660–6.                                          J Clin Med 2022;11:1047.
1161. Karch MR, Zrenner B, Deisenhofer I, Schreieck J, Ndrepepa G, Dong J, et al. Freedom           1183. Lupercio F, Lin AY, Aldaas OM, Romero J, Briceno D, Hoffmayer KS, et al. Role of
      from atrial tachyarrhythmias after catheter ablation of atrial fibrillation: a randomized           adjunctive posterior wall isolation in patients undergoing atrial fibrillation ablation:
      comparison between 2 current ablation strategies. Circulation 2005;111:2875–80.                     a systematic review and metaanalysis. J Interv Card Electrophysiol 2020;58:77–86.
1162. Ouyang F, Antz M, Ernst S, Hachiya H, Mavrakis H, Deger FT, et al. Recovered pul­             1184. Kim MY, Coyle C, Tomlinson DR, Sikkel MB, Sohaib A, Luther V, et al.
      monary vein conduction as a dominant factor for recurrent atrial tachyarrhythmias                   Ectopy-triggering ganglionated plexuses ablation to prevent atrial fibrillation:
      after complete circular isolation of the pulmonary veins: lessons from double                       GANGLIA-AF study. Heart Rhythm 2022;19:516–24.
      Lasso technique. Circulation 2005;111:127–35.                                                 1185. Gianni C, Mohanty S, Di Biase L, Metz T, Trivedi C, Gokoglan Y, et al. Acute and early
1163. Yamashita S, Takigawa M, Denis A, Derval N, Sakamoto Y, Masuda M, et al.                            outcomes of focal impulse and rotor modulation (FIRM)-guided rotors-only ablation
      Pulmonary vein-gap reentrant atrial tachycardia following atrial fibrillation ablation:             in patients with nonparoxysmal atrial fibrillation. Heart Rhythm 2016;13:830–5.
      an electrophysiological insight with high-resolution mapping. Europace 2019;21:               1186. Perera KS, Sharma M, Connolly SJ, Wang J, Gold MR, Hohnloser SH, et al. Stroke type
      1039–47.                                                                                            and severity in patients with subclinical atrial fibrillation: an analysis from the asymp­
1164. Wojcik M, Berkowitsch A, Zaltsberg S, Hamm CW, Pitschner HF, Kuniss M, et al.                       tomatic atrial fibrillation and stroke evaluation in pacemaker patients and the atrial
      Predictors of early and late left atrial tachycardia and left atrial flutter after catheter         fibrillation reduction atrial pacing trial (ASSERT). Am Heart J 2018;201:160–3.
      ablation of atrial fibrillation: long-term follow-up. Cardiol J 2015;22:557–66.               1187. Andrade JG, Deyell MW, Macle L, Steinberg JS, Glotzer TV, Hawkins NM, et al.
1165. Mesas CE, Pappone C, Lang CC, Gugliotta F, Tomita T, Vicedomini G, et al. Left atrial               Healthcare utilization and quality of life for atrial fibrillation burden: the
      tachycardia after circumferential pulmonary vein ablation for atrial fibrillation: elec­            CIRCA-DOSE study. Eur Heart J 2023;44:765–76.
      troanatomic characterization and treatment. J Am Coll Cardiol 2004;44:1071–9.                 1188. Blomstrom-Lundqvist C, Gizurarson S, Schwieler J, Jensen SM, Bergfeldt L,
1166. Oral H, Chugh A, Good E, Wimmer A, Dey S, Gadeela N, et al. Radiofrequency cath­                    Kenneback G, et al. Effect of catheter ablation vs antiarrhythmic medication on quality
      eter ablation of chronic atrial fibrillation guided by complex electrograms. Circulation
                                                                                                          of life in patients with atrial fibrillation: the CAPTAF randomized clinical trial. JAMA
      2007;115:2606–12.
                                                                                                          2019;321:1059–68.
1167. Mikhaylov EN, Bhagwandien R, Janse PA, Theuns DA, Szili-Torok T. Regular atrial ta­
                                                                                                    1189. Brachmann J, Sohns C, Andresen D, Siebels J, Sehner S, Boersma L, et al. Atrial fibril­
      chycardias developing after cryoballoon pulmonary vein isolation: incidence, charac­
                                                                                                          lation burden and clinical outcomes in heart failure: the CASTLE-AF trial. JACC Clin
      teristics, and predictors. Europace 2013;15:1710–7.
                                                                                                          Electrophysiol 2021;7:594–603.
1168. Hermida A, Kubala M, Traulle S, Buiciuc O, Quenum S, Hermida JS. Prevalence and
                                                                                                    1190. Kuck KH, Lebedev DS, Mikhaylov EN, Romanov A, Geller L, Kalejs O, et al. Catheter
      predictive factors of left atrial tachycardia occurring after second-generation cryobal­
                                                                                                          ablation or medical therapy to delay progression of atrial fibrillation: the randomized
      loon ablation of atrial fibrillation. J Cardiovasc Electrophysiol 2018;29:46–54.
                                                                                                          controlled atrial fibrillation progression trial (ATTEST). Europace 2021;23:362–9.
1169. Guhl EN, Siddoway D, Adelstein E, Voigt A, Saba S, Jain SK. Efficacy of cryoballoon
                                                                                                    1191. Packer D, Monahan K, Piccini J, Al-Khalidi H, Silverstein A, Poole J, et al. Impact of
      pulmonary vein isolation in patients with persistent atrial fibrillation. J Cardiovasc
                                                                                                          treatment strategies for AF on the progression and regression of AF type in the
      Electrophysiol 2016;27:423–7.
                                                                                                          CABANA trial. European Heart Journal 2020;41:ehaa946.0680.
1170. Lyan E, Yalin K, Abdin A, Sawan N, Liosis S, Lange SA, et al. Mechanism, underlying
                                                                                                    1192. Gupta D, Vijgen J, Potter T, Scherr D, Van Herendael H, Knecht S, et al. Quality of life
      substrate and predictors of atrial tachycardia following atrial fibrillation ablation using
                                                                                                          and healthcare utilisation improvements after atrial fibrillation ablation. Heart 2021;
      the second-generation cryoballoon. J Cardiol 2019;73:497–506.
                                                                                                          107:1296–302.
1171. Julia J, Chierchia GB, de Asmundis C, Mugnai G, Sieira J, Ciconte G, et al. Regular atrial
                                                                                                    1193. Mark DB, Anstrom KJ, Sheng S, Piccini JP, Baloch KN, Monahan KH, et al. Effect of
      tachycardias following pulmonary vein isolation for paroxysmal atrial fibrillation: a
                                                                                                          catheter ablation vs medical therapy on quality of life among patients with atrial fib­
      retrospective comparison between the cryoballoon and conventional focal tip radio­
                                                                                                          rillation: the CABANA randomized clinical trial. JAMA 2019;321:1275–85.
      frequency techniques. J Interv Card Electrophysiol 2015;42:161–9.
                                                                                                    1194. Samuel M, Khairy P, Champagne J, Deyell MW, Macle L, Leong-Sit P, et al. Association
1172. Akerstrom F, Bastani H, Insulander P, Schwieler J, Arias MA, Jensen-Urstad M.
                                                                                                          of atrial fibrillation burden with health-related quality of life after atrial fibrillation ab­
      Comparison of regular atrial tachycardia incidence after circumferential radiofre­
      quency versus cryoballoon pulmonary vein isolation in real-life practice.                           lation: substudy of the cryoballoon vs contact-force atrial fibrillation ablation
      J Cardiovasc Electrophysiol 2014;25:948–52.                                                         (CIRCA-DOSE) randomized clinical trial. JAMA Cardiol 2021;6:1324–8.
1173. Van Belle Y, Knops P, Janse P, Rivero-Ayerza M, Jessurun E, Szili-Torok T, et al.             1195. Wazni O, Dandamudi G, Sood N, Hoyt R, Tyler J, Durrani S, et al. Quality of life after
      Electro-anatomical mapping of the left atrium before and after cryothermal balloon                  the initial treatment of atrial fibrillation with cryoablation versus drug therapy. Heart
      isolation of the pulmonary veins. J Interv Card Electrophysiol 2009;25:59–65.                       Rhythm 2022;19:197–205.
1174. Kenigsberg DN, Martin N, Lim HW, Kowalski M, Ellenbogen KA. Quantification of                 1196. Wu L, Narasimhan B, Ho KS, Zheng Y, Shah AN, Kantharia BK. Safety and complica­
      the cryoablation zone demarcated by pre- and postprocedural electroanatomic map­                    tions of catheter ablation for atrial fibrillation: predictors of complications from an
      ping in patients with atrial fibrillation using the 28-mm second-generation cryobal­                updated analysis the national inpatient database. J Cardiovasc Electrophysiol 2021;32:
      loon. Heart Rhythm 2015;12:283–90.                                                                  1024–34.
1175. Gopinathannair R, Mar PL, Afzal MR, Di Biase L, Tu Y, Lakkireddy T, et al. Atrial ta­         1197. Ngo L, Ali A, Ganesan A, Woodman R, Adams R, Ranasinghe I. Ten-year trends in
      chycardias after surgical atrial fibrillation ablation: clinical characteristics, electro­          mortality and complications following catheter ablation of atrial fibrillation. Eur
      physiological mechanisms, and ablation outcomes from a large, multicenter study.                    Heart J Qual Care Clin Outcomes 2022;8:398–408.
      JACC Clin Electrophysiol 2017;3:865–74.                                                       1198. Benali K, Khairy P, Hammache N, Petzl A, Da Costa A, Verma A, et al.
1176. Huo Y, Schoenbauer R, Richter S, Rolf S, Sommer P, Arya A, et al. Atrial arrhythmias                Procedure-related complications of catheter ablation for atrial fibrillation. J Am Coll
      following surgical AF ablation: electrophysiological findings, ablation strategies, and             Cardiol 2023;81:2089–99.
      clinical outcome. J Cardiovasc Electrophysiol 2014;25:725–38.                                 1199. Hsu JC, Darden D, Du C, Marine JE, Nichols S, Marcus GM, et al. Initial findings from
1177. Takigawa M, Derval N, Frontera A, Martin R, Yamashita S, Cheniti G, et al. Revisiting               the national cardiovascular data registry of atrial fibrillation ablation procedures. J Am
      anatomic macroreentrant tachycardia after atrial fibrillation ablation using ultrahigh-             Coll Cardiol 2023;81:867–78.
      resolution mapping: implications for ablation. Heart Rhythm 2018;15:326–33.                   1200. König S, Ueberham L, Schuler E, Wiedemann M, Reithmann C, Seyfarth M, et al.
1178. Pascale P, Shah AJ, Roten L, Scherr D, Komatsu Y, Jadidi AS, et al. Pattern and timing              In-hospital mortality of patients with atrial arrhythmias: insights from the
      of the coronary sinus activation to guide rapid diagnosis of atrial tachycardia after at­           German-wide Helios hospital network of 161 502 patients and 34 025 arrhythmia-
      rial fibrillation ablation. Circ Arrhythm Electrophysiol 2013;6:481–90.                             related procedures. Eur Heart J 2018;39:3947–57.
1179. Arroyo R C, Latcu DG, Maeda S, Kubala M, Santangeli P, Garcia FC, et al. Coronary             1201. Mszar R, Friedman DJ, Ong E, Du C, Wang Y, Zeitler EP, et al. Sex-based differences
      sinus activation and ECG characteristics of roof-dependent left atrial flutter after pul­           in atrial fibrillation ablation adverse events. Heart 2023;109:595–605.
      monary vein isolation. Circ Arrhythm Electrophysiol 2018;11:e005948.                          1202. Forleo GB, Tondo C, De Luca L, Dello Russo A, Casella M, De Sanctis V, et al.
1180. Vlachos K, Efremidis M, Derval N, Martin CA, Takigawa M, Bazoukis G, et al. Use of                  Gender-related differences in catheter ablation of atrial fibrillation. Europace 2007;
      high-density activation and voltage mapping in combination with entrainment to                      9:613–20.
102                                                                                                                                                                                  S. Tzeis et al.


1203. Ngo L, Ali A, Ganesan A, Woodman R, Adams R, Ranasinghe I. Gender differences in               1225. Liu Y, Zhan X, Xue Y, Deng H, Fang X, Liao H, et al. Incidence and outcomes of cere­
      complications following catheter ablation of atrial fibrillation. Eur Heart J Qual Care              brovascular events complicating catheter ablation for atrial fibrillation. Europace 2016;
      Clin Outcomes 2021;7:458–67.                                                                         18:1357–65.
1204. Tonchev IR, Nam MCY, Gorelik A, Kumar S, Haqqani H, Sanders P, et al. Relationship             1226. Kosiuk J, Kornej J, Bollmann A, Piorkowski C, Myrda K, Arya A, et al. Early cerebral
      between procedural volume and complication rates for catheter ablation of atrial fib­                thromboembolic complications after radiofrequency catheter ablation of atrial fibril­
      rillation: a systematic review and metaanalysis. Europace 2021;23:1024–32.                           lation: incidence, characteristics, and risk factors. Heart Rhythm 2014;11:1934–40.
1205. Cheung JW, Yeo I, Cheng EP, Ip JE, Thomas G, Liu CF, et al. Inpatient hospital pro­            1227. Deneke T, Jais P, Scaglione M, Schmitt R LDIB, Christopoulos G, Schade A, et al. Silent
      cedural volume and outcomes following catheter ablation of atrial fibrillation.                      cerebral events/lesions related to atrial fibrillation ablation: a clinical review.
      J Cardiovasc Electrophysiol 2020;31:1908–19.                                                         J Cardiovasc Electrophysiol 2015;26:455–63.
1206. Mörtsell D, Arbelo E, Dagres N, Brugada J, Laroche C, Trines SA, et al. Cryoballoon            1228. Kimura T, Kashimura S, Nishiyama T, Katsumata Y, Inagawa K, Ikegami Y, et al.
      vs. radiofrequency ablation for atrial fibrillation: a study of outcome and safety based             Asymptomatic cerebral infarction during catheter ablation for atrial fibrillation: com­
      on the ESC-EHRA atrial fibrillation ablation long-term registry and the Swedish cath­                paring uninterrupted rivaroxaban and warfarin (ASCERTAIN). JACC Clin
      eter ablation registry. Europace 2019;21:581–9.                                                      Electrophysiol 2018;4:1598–609.
1207. Buiatti A, von Olshausen G, Barthel P, Schneider S, Luik A, Kaess B, et al. Cryoballoon        1229. Medi C, Evered L, Silbert B, Teh A, Halloran K, Morton J, et al. Subtle postprocedural
      vs. radiofrequency ablation for paroxysmal atrial fibrillation: an updated metaanalysis              cognitive dysfunction after atrial fibrillation ablation. J Am Coll Cardiol 2013;62:531–9.
      of randomized and observational studies. Europace 2017;19:378–84.                              1230. Al-Kaisey AM, Parameswaran R, Bryant C, Anderson RD, Hawson J, Chieng D, et al.
1208. Ravi V, Poudyal A, Abid QU, Larsen T, Krishnan K, Sharma PS, et al. High-power short                 Impact of catheter ablation on cognitive function in atrial fibrillation: a randomized
      duration vs. conventional radiofrequency ablation of atrial fibrillation: a systematic re­           control trial. JACC Clin Electrophysiol 2023;9:1024–34.
      view and metaanalysis. Europace 2021;23:710–21.                                                1231. Kato N, Muraga K, Hirata Y, Shindo A, Matsuura K, Ii Y, et al. Brain magnetic reson­
1209. Hansom SP, Alqarawi W, Birnie DH, Golian M, Nery PB, Redpath CJ, et al.                              ance imaging and cognitive alterations after ablation in patients with atrial fibrillation.
      High-power, short-duration atrial fibrillation ablation compared with a conventional                 Sci Rep 2021;11:18995.
      approach: outcomes and reconnection patterns. J Cardiovasc Electrophysiol 2021;32:             1232. Haeusler KG, Eichner FA, Heuschmann PU, Fiebach JB, Engelhorn T, Blank B, et al.
      1219–28.                                                                                             MRI-detected brain lesions and cognitive function in patients with atrial fibrillation
1210. Mueller J, Halbfass P, Sonne K, Nentwich K, Ene E, Berkovitz A, et al. Safety aspects of             undergoing left atrial catheter ablation in the randomized AXAFA-AFNET 5 trial.
      very high power very short duration atrial fibrillation ablation using a modified radio­             Circulation 2022;145:906–15.
      frequency RF-generator: single-center experience. J Cardiovasc Electrophysiol 2022;            1233. Grecu M, Blomström-Lundqvist C, Kautzner J, Laroche C, Van Gelder IC, Jordaens L,
      33:920–7.                                                                                            et al. In-hospital and 12-month follow-up outcome from the ESC-EORP EHRA atrial
1211. Chieng D, Segan L, Sugumar H, Al-Kaisey A, Hawson J, Moore BM, et al. Higher                         fibrillation ablation long-term registry: sex differences. Europace 2020;22:66–73.
                                                                                                     1234. Santangeli P, Di Biase L, Al-Ahmad A, Horton R, Burkhardt JD, Sanchez JE, et al.
      power short duration vs. lower power longer duration posterior wall ablation for at­
                                                                                                           Ablation for atrial fibrillation: termination of atrial fibrillation is not the end point.
      rial fibrillation and esophageal injury outcomes: a prospective multicentre rando­
                                                                                                           Card Electrophysiol Clin 2012;4:343–52.
      mized controlled study (Hi-Lo HEAT trial). Europace 2023;25:417–24.
                                                                                                     1235. Nairooz R, Sardar P, Payne J, Aronow WS, Paydak H. Meta-analysis of major bleeding
1212. Lee AC, Voskoboinik A, Cheung CC, Yogi S, Tseng ZH, Moss JD, et al. A randomized
                                                                                                           with uninterrupted warfarin compared to interrupted warfarin and heparin bridging
      trial of high vs standard power radiofrequency ablation for pulmonary vein isolation.
                                                                                                           in ablation of atrial fibrillation. Int J Cardiol 2015;187:426–9.
      JACC Clin Electrophysiol 2023;9:1038–47.
                                                                                                     1236. Ezekowitz MD, Pollack CV Jr, Halperin JL, England RD, VanPelt Nguyen S, Spahr J,
1213. Paul Nordin A, Drca N, Insulander P, Bastani H, Bourke T, Braunschweig F, et al. Low
                                                                                                           et al. Apixaban compared to heparin/vitamin K antagonist in patients with atrial fib­
      incidence of major complications after the first six hours post atrial fibrillation abla­
                                                                                                           rillation scheduled for cardioversion: the EMANATE trial. Eur Heart J 2018;39:
      tion: is same-day discharge safe and feasible in most patients? J Cardiovasc
                                                                                                           2959–71.
      Electrophysiol 2021;32:2953–60.
                                                                                                     1237. Lin H, Chen YH, Hou JW, Lu ZY, Xiang Y, Li YG. Role of contact force-guided radio­
1214. Opel A, Mansell J, Butler A, Schwartz R, Fannon M, Finlay M, et al. Comparison of a
                                                                                                           frequency catheter ablation for treatment of atrial fibrillation: a systematic review and
      high throughput day case atrial fibrillation ablation service in a local hospital with
                                                                                                           metaanalysis. J Cardiovasc Electrophysiol 2017;28:994–1005.
      standard regional tertiary cardiac center care. Europace 2019;21:440–4.
                                                                                                     1238. Friedman DJ, Pokorney SD, Ghanem A, Marcello S, Kalsekar I, Yadalam S, et al.
1215. Dagres N, Anastasiou-Nana M. Prevention of atrial-esophageal fistula after catheter
                                                                                                           Predictors of cardiac perforation with catheter ablation of atrial fibrillation. JACC
      ablation of atrial fibrillation. Curr Opin Cardiol 2011;26:1–5.
                                                                                                           Clin Electrophysiol 2020;6:636–45.
1216. Cochet H, Nakatani Y, Sridi-Cheniti S, Cheniti G, Ramirez FD, Nakashima T, et al.
                                                                                                     1239. Cappato R, Calkins H, Chen SA, Davies W, Iesaka Y, Kalman J, et al. Delayed cardiac
      Pulsed field ablation selectively spares the esophagus during pulmonary vein isolation
                                                                                                           tamponade after radiofrequency catheter ablation of atrial fibrillation: a worldwide
      for atrial fibrillation. Europace 2021;23:1391–9.                                                    report. J Am Coll Cardiol 2011;58:2696–7.
1217. Marashly Q, Gopinath C, Baher A, Acharya M, Kheirkhahan M, Hardisty B, et al. Late             1240. Cappato R, Calkins H, Chen SA, Davies W, Iesaka Y, Kalman J, et al. Prevalence and
      gadolinium enhancement magnetic resonance imaging evaluation of post-atrial fibril­                  causes of fatal outcome in catheter ablation of atrial fibrillation. J Am Coll Cardiol 2009;
      lation ablation esophageal thermal injury across the spectrum of severity. J Am Heart                53:1798–803.
      Assoc 2021;10:e018924.                                                                         1241. Tsang TS, Enriquez-Sarano M, Freeman WK, Barnes ME, Sinak LJ, Gersh BJ, et al.
1218. Di Biase L, Saenz LC, Burkhardt DJ, Vacca M, Elayi CS, Barrett CD, et al. Esophageal                 Consecutive 1127 therapeutic echocardiographically guided pericardiocenteses: clin­
      capsule endoscopy after radiofrequency catheter ablation for atrial fibrillation: docu­              ical profile, practice patterns, and outcomes spanning 21 years. Mayo Clin Proc 2002;
      mented higher risk of luminal esophageal damage with general anesthesia as com­                      77:429–36.
      pared with conscious sedation. Circ Arrhythm Electrophysiol 2009;2:108–12.                     1242. Bunch TJ, Asirvatham SJ, Friedman PA, Monahan KH, Munger TM, Rea RF, et al.
1219. Martinek M, Meyer C, Hassanein S, Aichinger J, Bencsik G, Schoefl R, et al.                          Outcomes after cardiac perforation during radiofrequency ablation of the atrium.
      Identification of a high-risk population for esophageal injury during radiofrequency                 J Cardiovasc Electrophysiol 2005;16:1172–9.
      catheter ablation of atrial fibrillation: procedural and anatomical considerations.            1243. Michowitz Y, Rahkovich M, Oral H, Zado ES, Tilz R, John S, et al. Effects of sex on the
      Heart Rhythm 2010;7:1224–30.                                                                         incidence of cardiac tamponade after catheter ablation of atrial fibrillation: results
1220. Singh SM, d’Avila A, Singh SK, Stelzer P, Saad EB, Skanes A, et al. Clinical outcomes                from a worldwide survey in 34 943 atrial fibrillation ablation procedures. Circ
      after repair of left atrial esophageal fistulas occurring after atrial fibrillation ablation         Arrhythm Electrophysiol 2014;7:274–80.
      procedures. Heart Rhythm 2013;10:1591–7.                                                       1244. Zhao Q, Li L, Liu N, Zhang M, Wu K, Ruan Y, et al. Early versus delayed removal of the
1221. Mohanty S, Santangeli P, Mohanty P, Di Biase L, Trivedi C, Bai R, et al. Outcomes of                 pericardial drain in patients with cardiac tamponade complicating radiofrequency ab­
      atrioesophageal fistula following catheter ablation of atrial fibrillation treated with              lation of atrial fibrillation. J Cardiovasc Electrophysiol 2020;31:597–603.
      surgical repair versus esophageal stenting. J Cardiovasc Electrophysiol 2014;25:579–84.        1245. Zhao X, Liu JF, Su X, Long DY, Sang CH, Tang RB, et al. Direct autotransfusion in the
1222. Mohanty S, Santangeli P, Mohanty P, Di Biase L, Holcomb S, Trivedi C, et al. Catheter                management of acute pericardial tamponade during catheter ablation for atrial fibril­
      ablation of asymptomatic longstanding persistent atrial fibrillation: impact on quality              lation: an imperfect but practical method. Front Cardiovasc Med 2022;9:984251.
      of life, exercise performance, arrhythmia perception, and arrhythmia-free survival.            1246. Pedersen MEF, Leo M, Kalla M, Malhotra A, Stone M, Wong K, et al. Management of
      J Cardiovasc Electrophysiol 2014;25:1057–64.                                                         tamponade complicating catheter ablation for atrial fibrillation: early removal of peri­
1223. Eitel C, Rolf S, Zachäus M, John S, Sommer P, Bollmann A, et al. Successful nonsurgical              cardial drains is safe and effective and reduces analgesic requirements and hospital
      treatment of esophagopericardial fistulas after atrial fibrillation catheter ablation: a             stay compared to conventional delayed removal. JACC Clin Electrophysiol 2017;3:
      case series. Circ Arrhythm Electrophysiol 2013;6:675–81.                                             367–73.
1224. Bunch TJ, Nelson J, Foley T, Allison S, Crandall BG, Osborn JS, et al. Temporary               1247. Raeisi-Giglou P, Wazni OM, Saliba WI, Barakat A, Tarakji KG, Rickard J, et al.
      esophageal stenting allows healing of esophageal perforations following atrial fibrilla­             Outcomes and management of patients with severe pulmonary vein stenosis from
      tion ablation procedures. J Cardiovasc Electrophysiol 2006;17:435–9.                                 prior atrial fibrillation ablation. Circ Arrhythm Electrophysiol 2018;11:e006001.
Catheter and surgical ablation of atrial fibrillation                                                                                                                                            103


1248. Andrade JG, Khairy P, Guerra PG, Deyell MW, Rivard L, Macle L, et al. Efficacy and            1272. Franzen OW, Klemm H, Hamann F, Koschyk D, von Kodolitsch Y, Weil J, et al.
      safety of cryoballoon ablation for atrial fibrillation: a systematic review of published            Mechanisms underlying air aspiration in patients undergoing left atrial catheterization.
      studies. Heart Rhythm 2011;8:1444–51.                                                               Catheter Cardiovasc Interv 2008;71:553–8.
1249. Fender EA, Packer DL, Holmes DR Jr. Pulmonary vein stenosis after atrial fibrillation         1273. Chugh A, Makkar A, Yen Ho S, Yokokawa M, Sundaram B, Pelosi F, et al.
      ablation. EuroIntervention 2016;12:X31–4.                                                           Manifestations of coronary arterial injury during catheter ablation of atrial fibrillation
1250. Saad EB, Marrouche NF, Saad CP, Ha E, Bash D, White RD, et al. Pulmonary vein                       and related arrhythmias. Heart Rhythm 2013;10:1638–45.
      stenosis after catheter ablation of atrial fibrillation: emergence of a new clinical syn­     1274. Takahashi Y, Jaïs P, Hocini M, Sanders P, Rotter M, Rostock T, et al. Acute occlusion of
      drome. Ann Intern Med 2003;138:634–8.                                                               the left circumflex coronary artery during mitral isthmus linear ablation. J Cardiovasc
1251. Tokutake K, Tokuda M, Yamashita S, Sato H, Ikewaki H, Okajima E, et al. Anatomical                  Electrophysiol 2005;16:1104–7.
      and procedural factors of severe pulmonary vein stenosis after cryoballoon pulmon­            1275. Kitamura T, Fukamizu S, Arai K, Hojo R, Aoyama Y, Komiyama K, et al. Transient sinus
      ary vein ablation. JACC Clin Electrophysiol 2019;5:1303–15.                                         node dysfunction following sinus node artery occlusion due to radiofrequency cath­
1252. Kim J, Kim D, Yu HT, Kim TH, Joung B, Lee MH, et al. Revisiting symptomatic pulmon­                 eter ablation of the septal superior vena cava-right atrium junction. J Electrocardiol
      ary vein stenosis after high-power short-duration radiofrequency ablation in patients               2016;49:18–22.
      with atrial fibrillation. Europace 2023;25:euad296.                                           1276. Higuchi S, Im SI, Stillson C, Buck ED, Jerrell S, Schneider CW, et al. Effect of epicardial
1253. Katz ES, Tsiamtsiouris T, Applebaum RM, Schwartzbard A, Tunick PA, Kronzon I.                       pulsed field ablation directly on coronary arteries. JACC Clin Electrophysiol 2022;8:
                                                                                                          1486–96.
      Surgical left atrial appendage ligation is frequently incomplete: a transesophageal
                                                                                                    1277. Kesek M, Englund A, Jensen SM, Jensen-Urstad M. Entrapment of circular mapping
      echocardiograhic study. J Am Coll Cardiol 2000;36:468–71.
                                                                                                          catheter in the mitral valve. Heart Rhythm 2007;4:17–9.
1254. Fender EA, Widmer RJ, Hodge DO, Cooper GM, Monahan KH, Peterson LA, et al.
                                                                                                    1278. Grove R, Kranig W, Coppoolse R, Lüdorff G, Wolff E, Warnecke H, et al. Demand for
      Severe pulmonary vein stenosis resulting from ablation for atrial fibrillation: presen­
                                                                                                          open heart surgery due to entrapment of a circular mapping catheter in the mitral
      tation, management, and clinical outcomes. Circulation 2016;134:1812–21.
                                                                                                          valve in a patient undergoing atrial fibrillation ablation. Clin Res Cardiol 2008;97:628–9.
1255. Fender EA, Widmer RJ, Hodge DO, Packer DL, Holmes DR Jr. Assessment and man­
                                                                                                    1279. Lakkireddy D, Nagarajan D, Di Biase L, Vanga SR, Mahapatra S, Jared Bunch T, et al.
      agement of pulmonary vein occlusion after atrial fibrillation ablation. JACC Cardiovasc
                                                                                                          Radiofrequency ablation of atrial fibrillation in patients with mitral or aortic mechan­
      Interv 2018;11:1633–9.
                                                                                                          ical prosthetic valves: a feasibility, safety, and efficacy study. Heart Rhythm 2011;8:
1256. Hilbert S, Paetsch I, Bollmann A, Jahnke C. Pulmonary vein collateral formation as a
                                                                                                          975–80.
      long-term result of post-interventional pulmonary vein stenosis. Eur Heart J 2016;37:         1280. Zeljko HM, Mont L, Sitges M, Tolosana JM, Nadal M, Castella M, et al. Entrapment of
      2474.                                                                                               the circular mapping catheter in the mitral valve in two patients undergoing atrial fib­
1257. Hilbert S, Sommer P, Bollmann A. Pulmonary vein dilatation in a case of total pulmon­               rillation ablation. Europace 2011;13:132–3.
      ary vein occlusion: contemporary approach using a combination of 3D-mapping sys­              1281. Wu RC, Brinker JA, Yuh DD, Berger RD, Calkins HG. Circular mapping catheter en­
      tem and image integration. Catheter Cardiovasc Interv 2016;88:E227–32.                              trapment in the mitral valve apparatus: a previously unrecognized complication of fo­
1258. Holmes DR Jr, Monahan KH, Packer D. Pulmonary vein stenosis complicating ablation                   cal atrial fibrillation ablation. J Cardiovasc Electrophysiol 2002;13:819–21.
      for atrial fibrillation: clinical spectrum and interventional considerations. JACC            1282. Kim EJ, Gerstenfeld EP, Pellegrini CN. Use of adenosine to release an entrapped cath­
      Cardiovasc Interv 2009;2:267–76.                                                                    eter during ablation of premature ventricular complexes. JACC Case Rep 2021;3:
1259. Fender EA, Widmer RJ, Mahowald MK, Hodge DO, Packer DL, Holmes DR Jr.                               610–13.
      Recurrent pulmonary vein stenosis after successful intervention: prognosis and man­           1283. Tavernier R, Duytschaever M, Taeymans Y. Fracture of a circular mapping catheter
      agement of restenosis. Catheter Cardiovasc Interv 2020;95:954–8.                                    after entrapment in the mitral valve apparatus during segmental pulmonary vein iso­
1260. Mol D, Renskers L, Balt JC, Bhagwandien RE, Blaauw Y, van Driel V, et al. Persistent                lation. Pacing Clin Electrophysiol 2003;26:1774–5.
      phrenic nerve palsy after atrial fibrillation ablation: follow-up data from The               1284. Gurbuz O, Ercan A, Ozkan H, Kumtepe G, Karal IH, Ener S. Case report: paravalvular
      Netherlands Heart Registration. J Cardiovasc Electrophysiol 2022;33:559–64.                         leak as a complication of percutaneous catheter ablation for atrial fibrillation.
1261. Heeger CH, Sohns C, Pott A, Metzner A, Inaba O, Straube F, et al. Phrenic nerve in­                 J Cardiothorac Surg 2014;9:187.
      jury during cryoballoon-based pulmonary vein isolation: results of the worldwide              1285. Kawaji T, Kato M, Yokomatsu T. How to release PentaRay catheter entrapped in the
      YETI registry. Circ Arrhythm Electrophysiol 2022;15:e010516.                                        hinge point of mechanical mitral valve? Europace 2020;22:204.
1262. Sacher F, Monahan KH, Thomas SP, Davidson N, Adragao P, Sanders P, et al. Phrenic             1286. Yagishita A, Ayabe K, Sakama S, Morise M, Amino M, Ikari Y, et al. A novel technique
      nerve injury after atrial fibrillation catheter ablation: characterization and outcome in           to release a PentaRay entrapped in a mechanical mitral valve using an ablation cath­
      a multicenter study. J Am Coll Cardiol 2006;47:2498–503.                                            eter. JACC Clin Electrophysiol 2020;6:1597–8.
1263. Yong Ji S, Dewire J, Barcelon B, Philips B, Catanzaro J, Nazarian S, et al. Phrenic nerve     1287. Lopes J, Sousa PA, Elvas L, Gonçalves L. Successful retrieval of a broken PentaRay
      injury: an underrecognized and potentially preventable complication of pulmonary                    catheter spine in a patient with mechanic mitral valve prosthesis. J Interv Card
      vein isolation using a wide-area circumferential ablation approach. J Cardiovasc                    Electrophysiol 2021;61:625–6.
      Electrophysiol 2013;24:1086–91.                                                               1288. Cochet H, Scherr D, Zellerhoff S, Sacher F, Derval N, Denis A, et al. Atrial structure
1264. Franceschi F, Dubuc M, Guerra PG, Khairy P. Phrenic nerve monitoring with dia­                      and function 5 years after successful ablation for persistent atrial fibrillation: an MRI
      phragmatic electromyography during cryoballoon ablation for atrial fibrillation: the                study. J Cardiovasc Electrophysiol 2014;25:671–9.
                                                                                                    1289. Gibson DN, Di Biase L, Mohanty P, Patel JD, Bai R, Sanchez J, et al. Stiff left atrial syn­
      first human application. Heart Rhythm 2011;8:1068–71.
1265. Miyazaki S, Hachiya H, Taniguchi H, Nakamura H, Ichihara N, Usui E, et al. Prospective              drome after catheter ablation for atrial fibrillation: clinical characterization, preva­
                                                                                                          lence, and predictors. Heart Rhythm 2011;8:1364–71.
      evaluation of bilateral diaphragmatic electromyograms during cryoballoon ablation of
                                                                                                    1290. Shoemaker MB, Hemnes AR, Robbins IM, Langberg JJ, Ellis CR, Aznaurov SG, et al.
      atrial fibrillation. J Cardiovasc Electrophysiol 2015;26:622–8.
                                                                                                          Left atrial hypertension after repeated catheter ablations for atrial fibrillation. J Am
1266. Mondésert B, Andrade JG, Khairy P, Guerra PG, Dyrda K, Macle L, et al. Clinical ex­
                                                                                                          Coll Cardiol 2011;57:1918–9.
      perience with a novel electromyographic approach to preventing phrenic nerve in­
                                                                                                    1291. Welch TD, Coylewright M, Powell BD, Asirvatham SJ, Gersh BJ, Dearani JA, et al.
      jury during cryoballoon ablation in atrial fibrillation. Circ Arrhythm Electrophysiol
                                                                                                          Symptomatic pulmonary hypertension with giant left atrial v waves after surgical
      2014;7:605–11.
                                                                                                          maze procedures: evaluation by comprehensive hemodynamic catheterization.
1267. Palaniswamy C, Kolte D, Harikrishnan P, Khera S, Aronow WS, Mujib M, et al.
                                                                                                          Heart Rhythm 2013;10:1839–42.
      Catheter ablation of postinfarction ventricular tachycardia: ten-year trends in utiliza­      1292. Moon I, Lee SY, Lee E, Lee SR, Cha MJ, Choi EK, et al. Extensive left atrial ablation was
      tion, in-hospital complications, and in-hospital mortality in the United States. Heart              associated with exacerbation of left atrial stiffness and dyspnea. J Cardiovasc
      Rhythm 2014;11:2056–63.                                                                             Electrophysiol 2019;30:2782–9.
1268. Peichl P, Wichterle D, Pavlu L, Cihak R, Aldhoon B, Kautzner J. Complications of cath­        1293. Witt C, Powell B, Holmes D, Alli O. Recurrent dyspnea following multiple ablations
      eter ablation of ventricular tachycardia: a single-center experience. Circ Arrhythm                 for atrial fibrillation explained by the “stiff left atrial syndrome”. Catheter Cardiovasc
      Electrophysiol 2014;7:684–90.                                                                       Interv 2013;82:E747–9.
1269. Waigand J, Uhlich F, Gross CM, Thalhammer C, Dietz R. Percutaneous treatment of               1294. Wong GR, Lau DH, Baillie TJ, Middeldorp ME, Steele PM, Sanders P. Novel use of
      pseudoaneurysms and arteriovenous fistulas after invasive vascular procedures.                      sildenafil in the management of pulmonary hypertension due to post-catheter abla­
      Catheter Cardiovasc Interv 1999;47:157–64.                                                          tion ‘stiff left atrial syndrome’. Int J Cardiol 2015;181:55–6.
1270. Kuwahara T, Takahashi A, Takahashi Y, Kobori A, Miyazaki S, Takei A, et al. Clinical          1295. Lakkireddy D, Reddy YM, Atkins D, Rajasingh J, Kanmanthareddy A, Olyaee M, et al.
      characteristics of massive air embolism complicating left atrial ablation of atrial fibril­         Effect of atrial fibrillation ablation on gastric motility: the atrial fibrillation gut study.
      lation: lessons from five cases. Europace 2012;14:204–8.                                            Circ Arrhythm Electrophysiol 2015;8:531–6.
1271. Krivonyak GS, Warren SG. Cerebral arterial air embolism treated by a vertical head-           1296. Kuwahara T, Takahashi A, Takahashi Y, Kobori A, Miyazaki S, Takei A, et al. Clinical
      down maneuver. Catheter Cardiovasc Interv 2000;49:185–7.                                            characteristics and management of periesophageal vagal nerve injury complicating left
104                                                                                                                                                                                      S. Tzeis et al.


      atrial ablation of atrial fibrillation: lessons from eleven cases. J Cardiovasc Electrophysiol   1320. Reston JT, Shuhaiber JH. Meta-analysis of clinical outcomes of maze-related surgical
      2013;24:847–51.                                                                                        procedures for medically refractory atrial fibrillation. Eur J Cardiothorac Surg 2005;28:
1297. Knopp H, Halm U, Lamberts R, Knigge I, Zachäus M, Sommer P, et al. Incidental and                      724–30.
      ablation-induced findings during upper gastrointestinal endoscopy in patients after              1321. Rankin JS, Lerner DJ, Braid-Forbes MJ, McCrea MM, Badhwar V. Surgical ablation of
      ablation of atrial fibrillation: a retrospective study of 425 patients. Heart Rhythm                   atrial fibrillation concomitant to coronary-artery bypass grafting provides cost-
      2014;11:574–8.                                                                                         effective mortality reduction. J Thorac Cardiovasc Surg 2020;160:675–86.e13.
1298. Miyazaki S, Nakamura H, Taniguchi H, Hachiya H, Takagi T, Igarashi M, et al. Gastric             1322. Suwalski P, Kowalewski M, Jasiński M, Staromłyński J, Zembala M, Widenka K, et al.
      hypomotility after second-generation cryoballoon ablation-unrecognized silent nerve                    Surgical ablation for atrial fibrillation during isolated coronary artery bypass surgery.
      injury after cryoballoon ablation. Heart Rhythm 2017;14:670–7.                                         Eur J Cardiothorac Surg 2020;57:691–700.
1299. Aksu T, Golcuk S, Guler TE, Yalin K, Erden I. Gastroparesis as a complication of atrial          1323. MacGregor RM, Bakir NH, Pedamallu H, Sinn LA, Maniar HS, Melby SJ, et al. Late re­
      fibrillation ablation. Am J Cardiol 2015;116:92–7.                                                     sults after stand-alone surgical ablation for atrial fibrillation. J Thorac Cardiovasc Surg
1300. Shigeta T, Okishige K, Aoyagi H, Nishimura T, Nakamura RA, Ito N, et al. Clinical in­                  2022;164:1515–28.e8.
      vestigation of esophageal injury from cryoballoon ablation of persistent atrial fibrilla­        1324. Lapenna E, De Bonis M, Giambuzzi I, Del Forno B, Ruggeri S, Cireddu M, et al.
      tion. Pacing Clin Electrophysiol 2019;42:230–7.                                                        Long-term outcomes of stand-alone maze IV for persistent or long-standing persist­
1301. Bunch TJ, Ellenbogen KA, Packer DL, Asirvatham SJ. Vagus nerve injury after poster­                    ent atrial fibrillation. Ann Thorac Surg 2020;109:124–31.
                                                                                                       1325. Ad N, Holmes SD, Friehling T. Minimally invasive stand-alone cox maze procedure for
      ior atrial radiofrequency ablation. Heart Rhythm 2008;5:1327–30.
                                                                                                             persistent and long-standing persistent atrial fibrillation: perioperative safety and
1302. Miyazaki S, Taniguchi H, Kusa S, Komatsu Y, Ichihara N, Takagi T, et al. Factors asso­
                                                                                                             5-year outcomes. Circ Arrhythm Electrophysiol 2017;10:e005352.
      ciated with periesophageal vagal nerve injury after pulmonary vein antrum isolation.
                                                                                                       1326. Henn MC, Lancaster TS, Miller JR, Sinn LA, Schuessler RB, Moon MR, et al. Late out­
      J Am Heart Assoc 2014;3:e001209.
                                                                                                             comes after the Cox maze IV procedure for atrial fibrillation. J Thorac Cardiovasc Surg
1303. Pisani CF, Hachul D, Sosa E, Scanavacca M. Gastric hypomotility following epicardial
                                                                                                             2015;150:1168–76, 1178.e1-2.
      vagal denervation ablation to treat atrial fibrillation. J Cardiovasc Electrophysiol 2008;
                                                                                                       1327. Gammie JS, Haddad M, Milford-Beland S, Welke KF, Ferguson TB Jr, O’Brien SM, et al.
      19:211–3.
                                                                                                             Atrial fibrillation correction surgery: lessons from the Society of Thoracic Surgeons
1304. Schwartz TW, Rehfeld JF, Stadil F, Larson LI, Chance RE, Moon N. Pancreatic-
                                                                                                             National Cardiac Database. Ann Thorac Surg 2008;85:909–14.
      polypeptide response to food in duodenal-ulcer patients before and after vagotomy.
                                                                                                       1328. Gillinov AM, Gelijns AC, Parides MK, DeRose JJ Jr, Moskowitz AJ, Voisine P, et al.
      Lancet 1976;307:1102–5.                                                                                Surgical ablation of atrial fibrillation during mitral-valve surgery. N Engl J Med 2015;
1305. Janssens J, Peeters TL, Vantrappen G, Tack J, Urbain JL, De Roo M, et al. Improvement                  372:1399–409.
      of gastric emptying in diabetic gastroparesis by erythromycin. Preliminary studies. N            1329. Mokracek A, Kurfirst V, Bulava A, Hanis J, Tesarik R, Pesl L. Thoracoscopic occlusion
      Engl J Med 1990;322:1028–31.                                                                           of the left atrial appendage. Innovations 2015;10:179–82.
1306. Camilleri M, Atieh J. New developments in prokinetic therapy for gastric motility dis­           1330. Wang J-L, Zhou K, Qin Z, Cheng W-J, Zhang L-Z, Zhou Y-J. Minimally invasive thor­
      orders. Front Pharmacol 2021;12:711500.                                                                acoscopic left atrial appendage occlusion compared with transcatheter left atrial ap­
1307. Zheng T, Camilleri M. Management of gastroparesis. Gastroenterol Hepatol (N Y) 2021;                   pendage closure for stroke prevention in recurrent nonvalvular atrial fibrillation
      17:515–25.                                                                                             patients after radiofrequency ablation: a prospective cohort study. J Geriatr Cardiol
1308. Badhwar V, Rankin JS, Ad N, Grau-Sepulveda M, Damiano RJ, Gillinov AM, et al.                          2021;18:877–85.
      Surgical ablation of atrial fibrillation in the United States: trends and propensity             1331. Fu M, Qin Z, Zheng S, Li Y, Yang S, Zhao Y, et al. Thoracoscopic left atrial appendage
      matched outcomes. Ann Thorac Surg 2017;104:493–500.                                                    occlusion for stroke prevention compared with long-term warfarin therapy in pa­
1309. Budera P, Straka Z, Osmančík P, Vaněk T, Jelínek Š, Hlavička J, et al. Comparison of                   tients with nonvalvular atrial fibrillation. Am J Cardiol 2019;123:50–6.
      cardiac surgery with left atrial surgical ablation vs. cardiac surgery without atrial ab­        1332. Kim JY, Jeong DS, Park S-J, Park K-M, Kim JS, On YK. Long-term efficacy and antic­
      lation in patients with coronary and/or valvular heart disease plus atrial fibrillation: fi­           oagulation strategy of left atrial appendage occlusion during total thoracoscopic ab­
      nal results of the PRAGUE-12 randomized multicenter study. Eur Heart J 2012;33:                        lation of atrial fibrillation to prevent ischemic stroke. Front Cardiovasc Med 2022;9:
      2644–52.                                                                                               853299.
1310. Nashef SAM, Fynn S, Abu-Omar Y, Spyt TJ, Mills C, Everett CC, et al. Amaze: a ran­               1333. Branzoli S, Marini M, Guarracini F, Pederzolli C, Pomarolli C, D’Onghia G, et al.
      domized controlled trial of adjunct surgery for atrial fibrillation. Eur J Cardiothorac Surg           Epicardial standalone left atrial appendage clipping for prevention of ischemic stroke
      2018;54:729–37.                                                                                        in patients with atrial fibrillation contraindicated for oral anticaogulation. J Cardiovasc
1311. Osmancik P, Budera P, Talavera D, Hlavicka J, Herman D, Holy J, et al. Five-year out­                  Electrophysiol 2020;31:2187–91.
      comes in cardiac surgery patients with atrial fibrillation undergoing concomitant sur­           1334. Cartledge R, Suwalski G, Witkowska A, Gottlieb G, Cioci A, Chidiac G, et al.
      gical ablation versus no ablation. The long-term follow-up of the PRAGUE-12 study.                     Standalone epicardial left atrial appendage exclusion for thromboembolism preven­
      Heart Rhythm 2019;16:1334–40.                                                                          tion in atrial fibrillation. Interact Cardiovasc Thorac Surg 2022;34:548–55.
1312. Wong JW, Mak KH. Impact of maze and concomitant mitral valve surgery on clinical                 1335. Whitlock RP, Belley-Cote EP, Paparella D, Healey JS, Brady K, Sharma M, et al. Left
      outcomes. Ann Thorac Surg 2006;82:1938–47.                                                             atrial appendage occlusion during cardiac surgery to prevent stroke. N Engl J Med
1313. Lee R, McCarthy PM, Wang EC, Vaduganathan M, Kruse J, Malaisrie SC Jr, et al.                          2021;384:2081–91.
      Midterm survival in patients treated for atrial fibrillation: a propensity-matched com­          1336. Quader MA, McCarthy PM, Gillinov AM, Alster JM, Cosgrove DM 3rd, Lytle BW,
      parison to patients without a history of atrial fibrillation. J Thorac Cardiovasc Surg 2012;           et al. Does preoperative atrial fibrillation reduce survival after coronary artery bypass
                                                                                                             grafting? Ann Thorac Surg 2004;77:1514–22; discussion 1522–4.
      143:1341–51; discussion 1350–1.
                                                                                                       1337. Ad N, Damiano RJ Jr, Badhwar V, Calkins H, La Meir M, Nitta T, et al. Expert consen­
1314. Musharbash FN, Schill MR, Sinn LA, Schuessler RB, Maniar HS, Moon MR, et al.
                                                                                                             sus guidelines: examining surgical ablation for atrial fibrillation. J Thorac Cardiovasc Surg
      Performance of the Cox-maze IV procedure is associated with improved long-term
                                                                                                             2017;153:1330–54.e1.
      survival in patients with atrial fibrillation undergoing cardiac surgery. J Thorac
                                                                                                       1338. Cox JL, Ad N, Palazzo T. Impact of the maze procedure on the stroke rate in patients
      Cardiovasc Surg 2018;155:159–70.
                                                                                                             with atrial fibrillation. J Thorac Cardiovasc Surg 1999;118:833–40.
1315. Iribarne A, DiScipio AW, McCullough JN, Quinn R, Leavitt BJ, Westbrook BM, et al.
                                                                                                       1339. Boersma LV, Castella M, van Boven W, Berruezo A, Yilmaz A, Nadal M, et al. Atrial
      Surgical atrial fibrillation ablation improves long-term survival: a multicenter analysis.
                                                                                                             fibrillation catheter ablation versus surgical ablation treatment (FAST): a 2-center
      Ann Thorac Surg 2019;107:135–42.                                                                       randomized clinical trial. Circulation 2012;125:23–30.
1316. Kowalewski M, Pasierski M, Kołodziejczak M, Litwinowicz R, Kowalówka A, Wańha                    1340. Castellá M, Kotecha D, van Laar C, Wintgens L, Castillo Y, Kelder J, et al.
      W, et al. Atrial fibrillation ablation improves late survival after concomitant cardiac                Thoracoscopic vs. catheter ablation for atrial fibrillation: long-term follow-up of
      surgery. J Thorac Cardiovasc Surg 2023;166:1656–68.e8.                                                 the FAST randomized trial. Europace 2019;21:746–53.
1317. Kim HJ, Kim YJ, Kim M, Yoo JS, Kim DH, Park DW, et al. Surgical ablation for atrial              1341. Pokushalov E, Romanov A, Elesin D, Bogachev-Prokophiev A, Losik D, Bairamova S,
      fibrillation during aortic and mitral valve surgery: a nationwide population-based co­                 et al. Catheter versus surgical ablation of atrial fibrillation after a failed initial pulmon­
      hort study. J Thorac Cardiovasc Surg 2022.                                                             ary vein isolation procedure: a randomized controlled trial. J Cardiovasc Electrophysiol
1318. Suwalski P, Kowalewski M, Jasiński M, Staromłyński J, Zembala M, Widenka K, et al.                     2013;24:1338–43.
      Survival after surgical ablation for atrial fibrillation in mitral valve surgery: analysis       1342. Adiyaman A, Buist TJ, Beukema RJ, Smit JJJ, Delnoy P, Hemels MEW, et al.
      from the polish national registry of cardiac surgery procedures (KROK). J Thorac                       Randomized controlled trial of surgical versus catheter ablation for paroxysmal
      Cardiovasc Surg 2019;157:1007–18.e4.                                                                   and early persistent atrial fibrillation. Circ Arrhythm Electrophysiol 2018;11:e006182.
1319. Gemelli M, Gallo M, Addonizio M, Van den Eynde J, Pradegan N, Danesi TH, et al.                  1343. Philpott JM, Zemlin CW, Cox JL, Stirling M, Mack M, Hooker RL, et al. The ABLATE
      Surgical ablation for atrial fibrillation during mitral valve surgery: a systematic review             trial: safety and efficacy of Cox maze-IV using a bipolar radiofrequency ablation sys­
      and metaanalysis of randomized controlled trials. Am J Cardiol 2023;209:104–113.                       tem. Ann Thorac Surg 2015;100:1541–6; discussion 1547–8.
Catheter and surgical ablation of atrial fibrillation                                                                                                                                               105


1344. McGilvray MMO, Barron L, Yates TE, Zemlin CW, Damiano RJ Jr. The Cox-maze                      1370. Kiser AC, Nifong LW, Raman J, Kasirajan V, Campbell N, Chitwood WR Jr. Evaluation
      procedure: what lesions and why. JTCVS Tech 2023;17:84–93.                                           of a novel epicardial atrial fibrillation treatment system. Ann Thorac Surg 2008;85:
1345. Gillinov AM, Gelijns AC, Parides MK, DeRose JJ Jr, Moskowitz AJ, Voisine P, et al.                   300–3.
      Surgical ablation of atrial fibrillation during mitral-valve surgery. N Engl J Med 2015;       1371. Weimar T, Lee AM, Ray S, Schuessler RB, Damiano RJ Jr. Evaluation of a novel cryoa­
      372:1399–409.                                                                                        blation system: in vivo testing in a chronic porcine model. Innovations (Phila) 2012;7:
1346. Hamner CE, Potter DD Jr, Cho KR, Lutterman A, Francischelli D, Sundt TM 3rd, et al.                  410–6.
      Irrigated radiofrequency ablation with transmurality feedback reliably produces Cox            1372. El Arid J-M, Sénage T, Toquet C, Al Habash O, Mugniot A, Baron O, et al. Human
      maze lesions in vivo. Ann Thorac Surg 2005;80:2263–70.                                               comparative experimental study of surgical treatment of atrial fibrillation by epicar­
1347. Schuessler RB, Lee AM, Melby SJ, Voeller RK, Gaynor SL, Sakamoto S-I, et al. Animal                  dial techniques. J Cardiothorac Surg 2013;8:140.
      studies of epicardial atrial ablation. Heart Rhythm 2009;6:S41–5.                              1373. Schill MR, Melby SJ, Speltz M, Breitbach M, Schuessler RB, Damiano RJ Jr. Evaluation of
1348. Saint LL, Lawrance CP, Okada S, Kazui T, Robertson JO, Schuessler RB, et al.                         a novel cryoprobe for atrial ablation in a chronic ovine model. Ann Thorac Surg 2017;
      Performance of a novel bipolar/monopolar radiofrequency ablation device on the                       104:1069–73.
      beating heart in an acute porcine model. Innovations 2013;8:276–83.                            1374. Milla F, Skubas N, Briggs WM, Girardi LN, Lee LY, Ko W, et al. Epicardial beating heart
1349. Bugge E, Nicholson IA, Thomas SP. Comparison of bipolar and unipolar radiofre­                       cryoablation using a novel argon-based cryoclamp and linear probe. J Thorac
      quency ablation in an in vivo experimental model. Eur J Cardiothorac Surg 2005;28:                   Cardiovasc Surg 2006;131:403–11.
      76–80; discussion 80–2.                                                                        1375. Nitta T, Ishii Y, Miyagi Y, Ohmori H, Sakamoto S-I, Tanaka S. Concurrent multiple left
1350. Thomas SP, Guy DJR, Boyd AC, Eipper VE, Ross DL, Chard RB. Comparison of epi­                        atrial focal activations with fibrillatory conduction and right atrial focal or reentrant
      cardial and endocardial linear ablation using handheld probes. Ann Thorac Surg 2003;                 activation as the mechanism in atrial fibrillation. J Thorac Cardiovasc Surg 2004;127:
      75:543–8.                                                                                            770–8.
1351. La Meir M. Surgical options for treatment of atrial fibrillation. Ann Cardiothorac Surg        1376. Saini A, Hu YL, Kasirajan V, Han FT, Khan MZ, Wolfe L, et al. Long-term outcomes of
      2014;3:30–7.                                                                                         minimally invasive surgical ablation for atrial fibrillation: a single-center experience.
1352. Khiabani AJ, MacGregor RM, Manghelli JL, Ruaengsri C, Carter DI, Melby SJ, et al.                    Heart Rhythm 2017;14:1281–8.
      Bipolar radiofrequency ablation on explanted human hearts: how to ensure trans­                1377. Gillinov AM, Bhavani S, Blackstone EH, Rajeswaran J, Svensson LG, Navia JL, et al.
      mural lesions. Ann Thorac Surg 2020;110:1933–9.                                                      Surgery for permanent atrial fibrillation: impact of patient factors and lesion set.
1353. Jaïs P, Haïssaguerre M, Shah DC, Takahashi A, Hocini M, Lavergne T, et al. Successful                Ann Thorac Surg 2006;82:502–13; discussion 513–4.
      irrigated-tip catheter ablation of atrial flutter resistant to conventional radiofre­          1378. Saint LL, Bailey MS, Prasad S, Guthrie TJ, Bell J, Moon MR, et al. Cox-maze IV results
      quency ablation. Circulation 1998;98:835–8.                                                          for patients with lone atrial fibrillation versus concomitant mitral disease. Ann Thorac
1354. Haines DE. The biophysics and pathophysiology of lesion formation during radiofre­                   Surg 2012;93:789–94; discussion 794–5.
      quency catheter ablation. In Zipes DP, Jalife J, Stevenson WG (eds.), Cardiac                  1379. Enriquez A, Santangeli P, Zado ES, Liang J, Castro S, Garcia FC, et al. Postoperative
                                                                                                           atrial tachycardias after mitral valve surgery: mechanisms and outcomes of catheter
      Electrophysiology: From Cell to Bedside. 4th ed. Philadelphia: WB Saunders Co; 2005;
                                                                                                           ablation. Heart Rhythm 2017;14:520–6.
      1018–27.
                                                                                                     1380. Gwag HB, Jeong DS, Hwang JK, Park S-J, Park K-M, Kim JS, et al. Additional cavotri­
1355. Melby SJ, Zierer A, Voeller RK, Lall SC, Bailey MS, Moon MR, et al. Wide variations in
                                                                                                           cuspid isthmus ablation may reduce recurrent atrial tachyarrhythmia after total thor­
      energy delivery using an impedance-controlled algorithm in bipolar radiofrequency
                                                                                                           acoscopic ablation for persistent atrial fibrillation. Interact Cardiovasc Thorac Surg
      ablation: evidence against fixed time ablation. Innovations 2007;2:67–72.
                                                                                                           2019;28:177–82.
1356. Dewhirst MW, Viglianti BL, Lora-Michiels M, Hanson M, Hoopes PJ. Basic principles
                                                                                                     1381. Ngaage DL, Schaff HV, Mullany CJ, Sundt TM 3rd, Dearani JA, Barnes S, et al. Does
      of thermal dosimetry and thermal thresholds for tissue damage from hyperthermia.
                                                                                                           preoperative atrial fibrillation influence early and late outcomes of coronary artery
      Int J Hyperthermia 2003;19:267–94.
                                                                                                           bypass grafting? J Thorac Cardiovasc Surg 2007;133:182–9.
1357. Varzaly JA, Chapman D, Lau DH, Edwards S, Louise J, Edwards J, et al. Contact force
                                                                                                     1382. McClure GR, Belley-Cote EP, Jaffer IH, Dvirnik N, An KR, Fortin G, et al. Surgical ab­
      and ablation assessment of surgical bipolar radiofrequency clamps in the treatment of
                                                                                                           lation of atrial fibrillation: a systematic review and metaanalysis of randomized con­
      atrial fibrillation. Interact Cardiovasc Thorac Surg 2019;28:85–93.
                                                                                                           trolled trials. Europace 2018;20:1442–50.
1358. Schill MR, Melby SJ, Speltz M, Breitbach M, Schuessler RB, Damiano RJ. Evaluation of a
                                                                                                     1383. Johansson B, Houltz B, Berglin E, Brandrup-Wognsen G, Karlsson T, Edvardsson N.
      novel cryoprobe for atrial ablation in a chronic ovine model. Ann Thorac Surg 2017;
                                                                                                           Short-term sinus rhythm predicts long-term sinus rhythm and clinical improvement
      104:1069–73.
                                                                                                           after intraoperative ablation of atrial fibrillation. Europace 2008;10:610–7.
1359. Weimar T, Lee AM, Ray S, Schuessler RB, Damiano RJ. Evaluation of a novel cryoa­
                                                                                                     1384. Grubitzsch H, Dushe S, Beholz S, Dohmen PM, Konertz W. Surgical ablation of atrial
      blation system: in vivo testing in a chronic porcine model. Innovations (Phila) 2012;7:
                                                                                                           fibrillation in patients with congestive heart failure. J Card Fail 2007;13:509–16.
      410–6.                                                                                         1385. Saint LL, Damiano RJ Jr, Cuculich PS, Guthrie TJ, Moon MR, Munfakh NA, et al.
1360. Cox JL, Malaisrie SC, Churyla A, Mehta C, Kruse J, Kislitsina ON, et al. Cryosurgery                 Incremental risk of the Cox-maze IV procedure for patients with atrial fibrillation
      for atrial fibrillation: physiologic basis for creating optimal cryolesions. Ann Thorac Surg         undergoing mitral valve surgery. J Thorac Cardiovasc Surg 2013;146:1072–7.
      2021;112:354–62.                                                                               1386. Bakir NH, Khiabani AJ, MacGregor RM, Kelly MO, Sinn LA, Schuessler RB, et al.
1361. Masroor S, Jahnke M-E, Carlisle A, Cartier C, LaLonde J-P, MacNeil T, et al.                         Concomitant surgical ablation for atrial fibrillation is associated with increased risk
      Endocardial hypothermia and pulmonary vein isolation with epicardial cryoablation                    of acute kidney injury but improved late survival. J Thorac Cardiovasc Surg 2022;
      in a porcine beating-heart model. J Thorac Cardiovasc Surg 2008;135:1327–33.e5.                      164:1847–57.e3.
1362. Aupperle H, Doll N, Walther T, Ullmann C, Schoon HA, Wilhelm Mohr F.                           1387. Takahashi K, Miyauchi Y, Hayashi M, Iwasaki YK, Yodogawa K, Tsuboi I, et al.
      Histological findings induced by different energy sources in experimental atrial abla­               Mechanisms of postoperative atrial tachycardia following biatrial surgical ablation
      tion in sheep. Interact Cardiovasc Thorac Surg 2005;4:450–5.                                         of atrial fibrillation in relation to the surgical lesion sets. Heart Rhythm 2016;13:
1363. Schuessler RB, Lee AM, Melby SJ, Voeller RK, Gaynor SL, Sakamoto S, et al. Animal                    1059–65.
      studies of epicardial atrial ablation. Heart Rhythm 2009;6:S41–5.                              1388. Ishii Y, Nitta T, Kambe M, Kurita J, Ochi M, Miyauchi Y, et al. Intraoperative verifica­
1364. MacGregor RM, Melby SJ, Schuessler RB, Damiano RJ. Energy sources for the surgical                   tion of conduction block in atrial fibrillation surgery. J Thorac Cardiovasc Surg 2008;
      treatment of atrial fibrillation. Innovations (Phila) 2019;14:503–8.                                 136:998–1004.
1365. Yates TA, McGilvray M, Schill MR, Barron L, Razo N, Roberts HG Jr, et al.                      1389. Phan K, Xie A, Tsai YC, Kumar N, La Meir M, Yan TD. Biatrial ablation vs. left atrial
      Performance of an irrigated bipolar radiofrequency ablation clamp on explanted hu­                   concomitant surgical ablation for treatment of atrial fibrillation: a metaanalysis.
      man hearts. Ann Thorac Surg 2023;116:307–13.                                                         Europace 2015;17:38–47.
1366. Yates T-A, McGilvray M, Razo N, McElligott S, Melby SJ, Zemlin C, et al. Efficacy of a         1390. Bogachev-Prokophiev AV, Afanasyev AV, Pivkin AN, Ovcharov MA, Zheleznev SI,
      novel bipolar radiofrequency clamp: an acute porcine model. Innovations (Phila) 2022;                Sharifulin RM, et al. A left atrial versus a biatrial lesion set for persistent atrial fibrilla­
      17:409–15.                                                                                           tion ablation during open heart surgery. Eur J Cardiothorac Surg 2018;54:738–44.
1367. Watanabe Y, Weimar T, Kazui T, Lee U, Schuessler RB, Damiano RJ Jr. Epicardial ab­             1391. Kowalewski M, Pasierski M, Finke J, Kołodziejczak M, Staromłyński J, Litwinowicz R,
      lation performance of a novel radiofrequency device on the beating heart in pigs. Ann                et al. Permanent pacemaker implantation after valve and arrhythmia surgery in pa­
      Thorac Surg 2014;97:673–8.                                                                           tients with preoperative atrial fibrillation. Heart Rhythm 2022;19:1442–9.
1368. Lee AM, Aziz A, Clark KL, Schuessler RB, Damiano RJ Jr. Chronic performance of a               1392. Cox JL, Ad N, Churyla A, Malaisrie SC, Pham DT, Kruse J, et al. The maze procedure
      novel radiofrequency ablation device on the beating heart: limitations of conduction                 and postoperative pacemakers. Ann Thorac Surg 2018;106:1561–9.
      delay to assess transmurality. J Thorac Cardiovasc Surg 2012;144:859–65.                       1393. Badhwar V, Rankin JS, Damiano RJ Jr, Gillinov AM, Bakaeen FG, Edgerton JR, et al. The
1369. Bringmans T, Verrijcken A, La Meir M, Rega F. Atrioesophageal fistula after epicardial               Society of Thoracic Surgeons 2017 clinical practice guidelines for the surgical treat­
      ablation for atrial fibrillation. J Thorac Cardiovasc Surg 2018;155:e19–21.                          ment of atrial fibrillation. Ann Thorac Surg 2017;103:329–41.
106                                                                                                                                                                                  S. Tzeis et al.


1394. Raanani E, Albage A, David TE, Yau TM, Armstrong S. The efficacy of the Cox/maze              1418. Makati K, Davoudi R, Giedrimas A, Irwin J, Sherman A, Gerogiannis I, et al. Safety and
      procedure combined with mitral valve surgery: a matched control study. Eur J                        efficacy of a convergent hybrid procedure using cryo as endocardial energy source for
      Cardiothorac Surg 2001;19:438–42.                                                                   the treatment of persistent and longstanding persistent atrial fibrillation. J Am Coll
1395. Li H, Lin X, Ma X, Tao J, Zou R, Yang S, Liu H, Hua P. Biatrial versus isolated left atrial         Cardiol 2020;75:424.
      ablation in atrial fibrillation: a systematic review and metaanalysis. Biomed Res Int         1419. Starck CT, Steffel J, Emmert MY, Plass A, Mahapatra S, Falk V, et al. Epicardial left atrial
      2018;2018:3651212.                                                                                  appendage clip occlusion also provides the electrical isolation of the left atrial append­
1396. Kainuma S, Mitsuno M, Toda K, Funatsu T, Nakamura T, Miyagawa S, et al. Dilated left                age. Interact Cardiovasc Thorac Surg 2012;15:416–8.
      atrium as a predictor of late outcome after pulmonary vein isolation concomitant              1420. Lee LS. Subxiphoid minimally invasive epicardial ablation (convergent procedure)
      with aortic valve replacement and/or coronary artery bypass grafting†. Eur J                        with left thoracoscopic closure of the left atrial appendage. Oper Tech Thorac
      Cardiothorac Surg 2015;48:765–77; discussion 777.                                                   Cardiovasc Surg 2018;23:152–65.
1397. Barnett SD, Ad N. Surgical ablation as treatment for the elimination of atrial fibrilla­      1421. Gegochkori N, Yang F, Miller A, Kulbak G, Jacobwitz I, Greenberg Y. Comparison of
      tion: a metaanalysis. J Thorac Cardiovasc Surg 2006;131:1029–35.                                    hybrid ablation for persistent atrial fibrillation with and without left atrial appendage
1398. Kim HJ, Kim JB, Kim SO, Cho MS, Kim JK, Kim WK, et al. Long-term outcomes of                        closure: report of 1 year follow up. Presented at Venice Arrhythmias, Venice, Italy,
      surgical ablation for atrial fibrillation: impact of ablation lesion sets. JACC Asia 2021;          2019. J Interv Card Electrophysiol 2020;57:164.
      1:203–14.                                                                                     1422. Haldar S, Khan HR, Boyalla V, Kralj-Hans I, Jones S, Lord J, et al. Catheter ablation vs.
1399. Kainuma S, Mitsuno M, Toda K, Miyagawa S, Yoshikawa Y, Hata H, et al. Surgical ab­                  thoracoscopic surgical ablation in long-standing persistent atrial fibrillation: CASA-AF
      lation concomitant with nonmitral valve surgery for persistent atrial fibrillation. Ann             randomized controlled trial. Eur Heart J 2020;41:4471–80.
      Thorac Surg 2021;112:1909–20.                                                                 1423. van der Heijden CAJ, Weberndörfer V, Vroomen M, Luermans JG, Chaldoupi S-M,
1400. La Meir M, Gelsomino S, Nonneman B. The problem with concomitant atrial fibrilla­                   Bidar E, et al. Hybrid ablation versus repeated catheter ablation in persistent atrial
      tion in non-mitral valve surgery. Ann Cardiothorac Surg 2014;3:124–9.                               fibrillation. JACC Clin Electrophysiol 2023;9:1013–23.
1401. Civello K, Smith C, Boedefeld W. Combined endocardial and epicardial ablation for             1424. Doll N, Weimar T, Kosior DA, Bulava A, Mokracek A, Mönnig G, et al. Efficacy and
      symptomatic atrial fibrillation: single center experience in 100+ consecutive patients.             safety of hybrid epicardial and endocardial ablation versus endocardial ablation in pa­
      J Innov Card Rhythm Manag 2013;4:1–7.                                                               tients with persistent and longstanding persistent atrial fibrillation: a randomised, con­
1402. Gehi AK, Mounsey JP, Pursell I, Landers M, Boyce K, Chung EH, et al. Hybrid                         trolled trial. EClinicalMedicine 2023;61:102052.
      epicardial-endocardial ablation using a pericardioscopic technique for the treatment          1425. Pearman CM, Poon SS, Bonnett LJ, Haldar S, Wong T, Mediratta N, et al. Minimally
      of atrial fibrillation. Heart Rhythm 2013;10:22–8.                                                  invasive epicardial surgical ablation alone versus hybrid ablation for atrial fibrillation: a
1403. Gersak B, Jan M. Long-term success for the convergent atrial fibrillation procedure:                systematic review and metaanalysis. Arrhythm Electrophysiol Rev 2017;6:202–9.
      4-year outcomes. Ann Thorac Surg 2016;102:1550–7.                                             1426. Bhatia NK, Shah RL, Deb B, Pong T, Kapoor R, Rogers AJ, et al. Mapping atrial fibril­
1404. Gersak B, Zembala MO, Muller D, Folliguet T, Jan M, Kowalski O, et al. European ex­                 lation after surgical therapy to guide endocardial ablation. Circ Arrhythm Electrophysiol
      perience of the convergent atrial fibrillation procedure: multicenter outcomes in con­              2022;15:e010502.
                                                                                                    1427. de Asmundis C, Chierchia GB, Mugnai G, Van Loo I, Nijs J, Czapla J, et al. Midterm
      secutive patients. J Thorac Cardiovasc Surg 2014;147:1411–6.
1405. Gilligan D, Joyner C, Bundy G. Multidisciplinary collaboration for the treatment of at­             clinical outcomes of concomitant thoracoscopic epicardial and transcatheter endo­
                                                                                                          cardial ablation for persistent and long-standing persistent atrial fibrillation: a single-
      rial fibrillation: convergent procedure outcomes from a single center. J Innov Card
                                                                                                          center experience. Europace 2017;19:58–65.
      Rhythm Manag 2013;4:1396–403.
                                                                                                    1428. Blackshear JL, Odell JA. Appendage obliteration to reduce stroke in cardiac surgical
1406. Tonks R, Lantz G, Mahlow J, Hirsh J, Lee LS. Short and intermediate term outcomes
                                                                                                          patients with atrial fibrillation. Ann Thorac Surg 1996;61:755–9.
      of the convergent procedure: initial experience in a tertiary referral center. Ann
                                                                                                    1429. Osmancik P, Herman D, Neuzil P, Hala P, Taborsky M, Kala P, et al. Left atrial append­
      Thorac Cardiovasc Surg 2020;26:13–21.
                                                                                                          age closure versus direct oral anticoagulants in high-risk patients with atrial fibrilla­
1407. Toplisek J, Pernat A, Ruzic N, Robic B, Sinkovec M, Cvijic M, et al. Improvement of
                                                                                                          tion. J Am Coll Cardiol 2020;75:3122–35.
      atrial and ventricular remodeling with low atrial fibrillation burden after hybrid abla­
                                                                                                    1430. Brouwer TF, Whang W, Kuroki K, Halperin JL, Reddy VY. Net clinical benefit of left
      tion of persistent atrial fibrillation. Pacing Clin Electrophysiol 2016;39:216–24.
                                                                                                          atrial appendage closure versus warfarin in patients with atrial fibrillation: a pooled
1408. Zembala M, Filipiak K, Kowalski O, Buchta P, Niklewski T, Nadziakiewicz P, et al.
                                                                                                          analysis of the randomized PROTECT-AF and PREVAIL studies. J Am Heart Assoc
      Staged hybrid ablation for persistent and longstanding persistent atrial fibrillation ef­
                                                                                                          2019;8:e013525.
      fectively restores sinus rhythm in long-term observation. Arch Med Sci 2017;13:
                                                                                                    1431. Albåge A, Sartipy U, Kennebäck G, Johansson B, Scherstén H, Jidéus L; Swedish
      109–17.
                                                                                                          Arrhythmia Surgery Group. Long-term risk of ischemic stroke after the Cox-maze
1409. Kiser AC, Landers M, Horton R, Hume A, Natale A, Gersak B. The convergent pro­
                                                                                                          III procedure for atrial fibrillation. Ann Thorac Surg 2017;104:523–9.
      cedure: a multidisciplinary atrial fibrillation treatment. Heart Surg Forum 2010;13:
                                                                                                    1432. Wang H, Han J, Wang Z, Yin Z, Liu Z, Jin Y, et al. A prospective randomized trial of the
      E317–21.
                                                                                                          cut-and-sew maze procedure in patients undergoing surgery for rheumatic mitral
1410. Edgerton Z, Perini AP, Horton R, Trivedi C, Santangeli P, Bai R, et al. Hybrid proced­
                                                                                                          valve disease. J Thorac Cardiovasc Surg 2018;155:608–17.
      ure (endo/epicardial) versus standard manual ablation in patients undergoing ablation         1433. Ad N, Holmes SD, Massimiano PS, Rongione AJ, Fornaresio LM. Long-term outcome
      of longstanding persistent atrial fibrillation: results from a single center. J Cardiovasc          following concomitant mitral valve surgery and Cox maze procedure for atrial fibril­
      Electrophysiol 2016;27:524–30.                                                                      lation. J Thorac Cardiovasc Surg 2018;155:983–94.
1411. Jan M, Zizek D, Gersak ZM, Gersak B. Comparison of treatment outcomes between                 1434. Pet M, Robertson JO, Bailey M, Guthrie TJ, Moon MR, Lawton JS, et al. The impact of
      convergent procedure and catheter ablation for paroxysmal atrial fibrillation evalu­                CHADS2 score on late stroke after the Cox maze procedure. J Thorac Cardiovasc Surg
      ated with implantable loop recorder monitoring. J Cardiovasc Electrophysiol 2018;                   2013;146:85–9.
      29:1073–80.                                                                                   1435. Alqaqa A, Martin S, Hamdan A, Shamoon F, Asgarian KT. Concomitant left atrial ap­
1412. Gersak B, Pernat A, Robic B, Sinkovec M. Low rate of atrial fibrillation recurrence                 pendage clipping during minimally invasive mitral valve surgery: technically feasible and
      verified by implantable loop recorder monitoring following a convergent epicardial                  safe. J Atr Fibrillation 2016;9:1407.
      and endocardial ablation of atrial fibrillation. J Cardiovasc Electrophysiol 2012;23:         1436. Suwalski P, Witkowska A, Drobiński D, Rozbicka J, Sypuła S, Liszka I, et al. Stand-alone
      1059–66.                                                                                            totally thoracoscopic left atrial appendage exclusion using a novel clipping system in
1413. Zannis K, Alam W, Sebag FA, Folliguet T, Bars C, Fahed M, et al. The convergent pro­                patients with high risk of stroke – initial experience and literature review. Kardiochir
      cedure: a hybrid approach for long lasting persistent atrial fibrillation ablation, the             Torakochirurgia Pol 2015;12:298–303.
      French experience. J Cardiovasc Surg (Torino) 2020;61:369–75.                                 1437. Osmancik P, Budera P, Zdarska J, Herman D, Petr R, Fojt R, et al. Residual echocar­
1414. Maclean E, Yap J, Saberwal B, Kolvekar S, Lim W, Wijesuriya N, et al. The convergent                diographic and computed tomography findings after thoracoscopic occlusion of the
      procedure versus catheter ablation alone in longstanding persistent atrial fibrillation: a          left atrial appendage using the AtriClip PRO device. Interact Cardiovasc Thorac Surg
      single center, propensity-matched cohort study. Int J Cardiol 2020;303:49–53.                       2018;26:919–25.
1415. Kiser AC, Landers MD, Boyce K, Sinkovec M, Pernat A, Gersak B. Simultaneous cath­             1438. Bedeir K, Warriner S, Kofsky E, Gullett C, Ramlawi B. Left atrial appendage epicardial clip
      eter and epicardial ablations enable a comprehensive atrial fibrillation procedure.                 (AtriClip): essentials and post-procedure management. J Atr Fibrillation 2019;11:2087.
      Innovations (Phila) 2011;6:243–7.                                                             1439. Lee R, Vassallo P, Kruse J, Malaisrie SC, Rigolin V, Andrei A-C, et al. A randomized,
1416. Lee LS. Subxiphoid minimally invasive epicardial ablation (convergent procedure)                    prospective pilot comparison of 3 atrial appendage elimination techniques: internal
      with left thoracoscopic closure of the left atrial appendage. Oper Tech Thorac                      ligation, stapled excision, and surgical excision. J Thorac Cardiovasc Surg 2016;152:
      Cardiovasc Surg 2019;23:152–65.                                                                     1075–80.
1417. Thosani AJ, Gerczuk P, Liu E, Belden W, Moraca R. Closed chest convergent                     1440. Kanderian AS, Gillinov AM, Pettersson GB, Blackstone E, Klein AL. Success of surgical
      epicardial-endocardial ablation of non-paroxysmal atrial fibrillation – a case series               left atrial appendage closure: assessment by transesophageal echocardiography. J Am
      and literature review. Arrhythm Electrophysiol Rev 2013;2:65–8.                                     Coll Cardiol 2008;52:924–9.
Catheter and surgical ablation of atrial fibrillation                                                                                                                                          107


1441. Vainrib AF, Harb SC, Jaber W, Benenstein RJ, Aizer A, Chinitz LA, et al. Left atrial ap­       1454. Vassilikos VP, Pagourelias ED, Laroche C, Blomström-Lundqvist C, Kautzner J,
      pendage occlusion/exclusion: procedural image guidance with transesophageal echo­                    Maggioni AP, et al. Impact of center volume on atrial fibrillation ablation outcomes
      cardiography. J Am Soc Echocardiogr 2018;31:454–74.                                                  in Europe: a report from the ESC EHRA EORP Atrial Fibrillation Ablation
1442. van Laar C, Verberkmoes NJ, van Es HW, Lewalter T, Dunnington G, Stark S, et al.                     Long-Term (AFA LT) registry. Europace 2021;23:49–58.
      Thoracoscopic left atrial appendage clipping: a multicenter cohort analysis. JACC Clin         1455. Steinemann S, Berg B, Skinner A, DiTulio A, Anzelon K, Terada K, et al. In situ, multi­
      Electrophysiol 2018;4:893–901.                                                                       disciplinary, simulation-based teamwork training improves early trauma care. J Surg
1443. Smith NE, Joseph J, Morgan J, Masroor S. Initial experience with minimally invasive                  Educ 2011;68:472–7.
      surgical exclusion of the left atrial appendage with an epicardial clip. Innovations           1456. Miller D, Crandall C, Washington C 3rd, McLaughlin S. Improving teamwork and
      2017;12:28–32.                                                                                       communication in trauma care through in situ simulations. Acad Emerg Med 2012;
1444. Ad N, Massimiano PS, Shuman DJ, Pritchard G, Holmes SD. New approach to ex­                          19:608–12.
      clude the left atrial appendage during minimally invasive cryothermic surgical ablation.       1457. Friedman DJ, Pokorney SD, Khanna R, Goldstein L, Atwater BD, Bahnson TD, et al.
      Innovations 2015;10:323–7.                                                                           Catheter ablation of atrial fibrillation with and without on-site cardiothoracic surgery.
1445. Starck CT, Steffel J, Emmert MY, Plass A, Mahapatra S, Falk V, et al. Epicardial left atrial         J Am Coll Cardiol 2019;73:2487–9.
      appendage clip occlusion also provides the electrical isolation of the left atrial append­     1458. Pope MTB, Kuklik P, Briosa EGA, Leo M, Mahmoudi M, Paisey J, et al. Impact of adeno­
      age. Interact Cardiovasc Thorac Surg 2012;15:416–8.                                                  sine on wavefront propagation in persistent atrial fibrillation: insights from global non­
1446. Toale C, Fitzmaurice GJ, Eaton D, Lyne J, Redmond KC. Outcomes of left atrial ap­                    contact charge density mapping of the left atrium. J Am Heart Assoc 2022;11:e021166.
      pendage occlusion using the AtriClip device: a systematic review. Interact Cardiovasc          1459. Tang S, Razeghi O, Kapoor R, Alhusseini MI, Fazal M, Rogers AJ, et al. Machine
      Thorac Surg 2019;29:655–62.                                                                          learning-enabled multimodal fusion of intra-atrial and body surface signals in predic­
1447. Ailawadi G, Gerdisch MW, Harvey RL, Hooker RL, Damiano RJ Jr, Salamon T, et al.                      tion of atrial fibrillation ablation outcomes. Circ Arrhythm Electrophysiol 2022;15:
      Exclusion of the left atrial appendage with a novel device: early results of a multicenter           e010850.
      trial. J Thorac Cardiovasc Surg 2011;142:1002–9, 1009.e1.                                      1460. Saglietto A, Gaita F, Blomstrom-Lundqvist C, Arbelo E, Dagres N, Brugada J, et al.
1448. Emmert MY, Puippe G, Baumüller S, Alkadhi H, Landmesser U, Plass A, et al. Safe,                     AFA-Recur: an ESC EORP AFA-LT registry machine-learning web calculator predict­
      effective and durable epicardial left atrial appendage clip occlusion in patients with at­           ing atrial fibrillation recurrence after ablation. Europace 2023;25:92–100.
      rial fibrillation undergoing cardiac surgery: first long-term results from a prospective       1461. Stojadinovic P, Wichterle D, Peichl P, Nakagawa H, Cihak R, Haskova J, et al.
      device trial. Eur J Cardiothorac Surg 2014;45:126–31.                                                Autonomic changes are more durable after radiofrequency than pulsed electric field
1449. Caliskan E, Sahin A, Yilmaz M, Seifert B, Hinzpeter R, Alkadhi H, et al. Epicardial left             pulmonary vein ablation. JACC Clin Electrophysiol 2022;8:895–904.
      atrial appendage AtriClip occlusion reduces the incidence of stroke in patients with           1462. Boyle PM, Zghaib T, Zahid S, Ali RL, Deng D, Franceschi WH, et al. Computationally
      atrial fibrillation undergoing cardiac surgery. Europace 2018;20:e105–14.                            guided personalized targeted ablation of persistent atrial fibrillation. Nat Biomed Eng
1450. Zhang S, Cui Y, Li J, Tian H, Yun Y, Zhou X, et al. Concomitant transcatheter occlu­                 2019;3:870–9.
      sion versus thoracoscopic surgical clipping for left atrial appendage in patients under­       1463. Cuculich PS, Schill MR, Kashani R, Mutic S, Lang A, Cooper D, et al. Noninvasive car­
      going ablation for atrial fibrillation: a metaanalysis. Front Cardiovasc Med 2022;9:                 diac radiation for ablation of ventricular tachycardia. N Engl J Med 2017;377:2325–36.
      970847.                                                                                        1464. Qian PC, Azpiri JR, Assad J, Gonzales Aceves EN, Cardona Ibarra CE, de la Pena C,
1451. Branzoli S, Guarracini F, Marini M, D’Onghia G, Catanzariti D, Merola E, et al. Heart                et al. Noninvasive stereotactic radioablation for the treatment of atrial fibrillation:
      team for left appendage occlusion without the use of antithrombotic therapy: the epi­                first-in-man experience. J Arrhythm 2020;36:67–74.
      cardial perspective. J Clin Med 2022;11:6492.                                                  1465. Hohmann S, Deisher AJ, Konishi H, Rettmann ME, Suzuki A, Merrell KW, et al.
1452. Zipes DP, Calkins H, Daubert JP, Ellenbogen KA, Field ME, Fisher JD, et al. 2015 ACC/                Catheter-free ablation of infarct scar through proton beam therapy: tissue effects
      AHA/HRS advanced training statement on clinical cardiac electrophysiology (a revi­                   in a porcine model. Heart Rhythm 2020;17:2190–9.
      sion of the ACC/AHA 2006 update of the clinical competence statement on invasive               1466. Avram R, Ramsis M, Cristal AD, Nathan V, Zhu L, Kim J, et al. Validation of an algo­
      electrophysiology studies, catheter ablation, and cardioversion). Circ Arrhythm                      rithm for continuous monitoring of atrial fibrillation using a consumer smartwatch.
      Electrophysiol 2015;8:1522–51.                                                                       Heart Rhythm 2021;18:1482–90.
1453. Hoffmann R, Parade U, Bauerle H, Winter KD, Rauschenbach U, Mischke K, et al.                  1467. Zhu L, Nathan V, Kuang J, Kim J, Avram R, Olgin J, et al. Atrial fibrillation detection and
      Safety and acute efficacy of cryoballoon ablation for atrial fibrillation at community               atrial fibrillation burden estimation via wearables. IEEE J Biomed Health Inform 2022;
      hospitals. Europace 2021;23:1744–50.                                                                 26:2063–74.
